RowID,Outcome,Comparator,Intervention,Answer,Reasoning,xml_offsets,XML,PMID,Location
59610,Recurrent venous thromboembolism,Low-molecular-weight heparins: Tinzaparin (175 IU/kg),Unfractionated heparin  5000 IU followed by 30 000 IU,No significant difference,A nonsignificant reduction in the incidence of recurrent venous thromboembolism (6.9% in the standard heparin-treated group versus 2.8% in the LMWH-treated group),8657:8819,59610,11714421,Unavailable
59610,Major bleeding,Low-molecular-weight heparins: Tinzaparin (175 IU/kg),Unfractionated heparin  5000 IU followed by 30 000 IU,Significantly decreased,a significant reduction in the rate of major bleeding (5.0% versus 0.5%) and a significant reduction in the rate of deaths (9.6% versus 4.7%) in favour of the LMWH were observed.,8820:8999,59610,11714421,Unavailable
59610,Mortality,Low-molecular-weight heparins: Tinzaparin (175 IU/kg),Unfractionated heparin  5000 IU followed by 30 000 IU,Significantly decreased,a significant reduction in the rate of major bleeding (5.0% versus 0.5%) and a significant reduction in the rate of deaths (9.6% versus 4.7%) in favour of the LMWH were observed.,8820:8999,59610,11714421,Unavailable
59610,Recurrent venous thromboembolism,Low-molecular-weight heparins: Nadroparin (weight-adjusted) ,Unfractionated heparin  100 IU/kg followed by infusion of 35 000 IU,No significant difference,in the LMWH group there was a nonsignificant reduction in the rate of recurrent venous thromboembolism (14% in the standard heparin-treated group versus 7% in the LMWH-treated group),9519:9701,59610,11714421,Unavailable
59610,Major bleeding ,Low-molecular-weight heparins: Nadroparin (weight-adjusted) ,Unfractionated heparin  100 IU/kg followed by infusion of 35 000 IU,No significant difference,a nonsignificant reduction in major bleeding (3.5% versus 1%) and a nonsignificant reduction in deaths after 6 months of follow up (14% versus 7%).,9702:9850,59610,11714421,Unavailable
59610,6-month mortality,Low-molecular-weight heparins: Nadroparin (weight-adjusted) ,Unfractionated heparin  100 IU/kg followed by infusion of 35 000 IU,No significant difference,a nonsignificant reduction in major bleeding (3.5% versus 1%) and a nonsignificant reduction in deaths after 6 months of follow up (14% versus 7%).,9702:9850,59610,11714421,Unavailable
59610,Recurrent venous thromboembolism,Low-molecular-weight heparins: Nadroparin (weight-adjusted) ,Intravenous unfractionated heparin ,No significant difference,"The rate of events was comparable in the two groups with regard to recurrent venous thromboembolism (8.6 and 6.9%, respectively), major bleeding (2.0 and 0.5%, respectively) and death (8.1 and 6.9%, respectively).",12068:12281,59610,11714421,Unavailable
59610,Major bleeding,Low-molecular-weight heparins: Nadroparin (weight-adjusted) ,Intravenous unfractionated heparin ,No significant difference,"The rate of events was comparable in the two groups with regard to recurrent venous thromboembolism (8.6 and 6.9%, respectively), major bleeding (2.0 and 0.5%, respectively) and death (8.1 and 6.9%, respectively).",12068:12281,59610,11714421,Unavailable
59610,Mortality,Low-molecular-weight heparins: Nadroparin (weight-adjusted) ,Intravenous unfractionated heparin ,No significant difference,"The rate of events was comparable in the two groups with regard to recurrent venous thromboembolism (8.6 and 6.9%, respectively), major bleeding (2.0 and 0.5%, respectively) and death (8.1 and 6.9%, respectively).",12068:12281,59610,11714421,Unavailable
59610,Duration of hospitalization ,Low-molecular-weight heparins: Nadroparin (weight-adjusted) ,Intravenous unfractionated heparin ,Significantly decreased,"Importantly, the duration of hospitalization was reduced by 67% from 8.1 days in the unfractionated heparin group to 2.7 days in the LMWH group.",12282:12426,59610,11714421,Unavailable
59610,Recurrent venous thromboembolism,Low-molecular-weight heparins: Enoxaparin ,Intravenous unfractionated heparin ,No significant difference,The event rates of recurrent venous thromboembolism and major bleeding did not reach statistical significance and therefore it was concluded that the LMWH enoxaparine was not inferior to unfractionated heparin in the treatment of deep venous thrombosis.,12933:13186,59610,11714421,Unavailable
59610,Major bleeding,Low-molecular-weight heparins: Enoxaparin ,Intravenous unfractionated heparin ,No significant difference,The event rates of recurrent venous thromboembolism and major bleeding did not reach statistical significance and therefore it was concluded that the LMWH enoxaparine was not inferior to unfractionated heparin in the treatment of deep venous thrombosis.,12933:13186,59610,11714421,Unavailable
59610,Duration of hospitalization ,Low-molecular-weight heparins: Enoxaparin ,Intravenous unfractionated heparin ,Significantly decreased,". As in the previous study, the time spent in the hospital was remarkably reduced, from 6.5 days to 1.1 days, and 120 out of the 247 patients randomized to the LMWH were never admitted to the hospital.",13185:13386,59610,11714421,Unavailable
59610,Pulmonary embolism recurrence ,Low-molecular-weight heparins: reviparin ,Intravenous unfractionated heparin 5000 IU bolus followed by a dose of 1250 IU/h,No significant difference,was also similar in the two treatment groups (5.8% in the reviparin group versus 6.0% in the unfractionated heparin group).,16850:16974,59610,11714421,Unavailable
59610,Pulmonary embolism recurrence (8 days),Low-molecular-weight heparins: tinzaparin  175 anti-Xa units/kg,Unfractionated heparin IV bolus of 50 IU/kg + initial dose of 500 IU/kg,No significant difference,"After 8 days, the occurrence of events included in the primary outcome (recurrent venous thromboembolism, major bleeding or death) was similar in the two treatment groups: 2.9% in the unfractionated heparin group and 3.0% in the tinzaparin group.",17705:17951,59610,11714421,Unavailable
59610,Major bleeding (8 days),Low-molecular-weight heparins: tinzaparin  175 anti-Xa units/kg,Unfractionated heparin IV bolus of 50 IU/kg + initial dose of 500 IU/kg,No significant difference,"After 8 days, the occurrence of events included in the primary outcome (recurrent venous thromboembolism, major bleeding or death) was similar in the two treatment groups: 2.9% in the unfractionated heparin group and 3.0% in the tinzaparin group.",17705:17951,59610,11714421,Unavailable
59610,Mortality (8 days),Low-molecular-weight heparins: tinzaparin  175 anti-Xa units/kg,Unfractionated heparin IV bolus of 50 IU/kg + initial dose of 500 IU/kg,No significant difference,"After 8 days, the occurrence of events included in the primary outcome (recurrent venous thromboembolism, major bleeding or death) was similar in the two treatment groups: 2.9% in the unfractionated heparin group and 3.0% in the tinzaparin group.",17705:17951,59610,11714421,Unavailable
59610,Pulmonary embolism recurrence (90 days),Low-molecular-weight heparins: tinzaparin  175 anti-Xa units/kg,Unfractionated heparin IV bolus of 50 IU/kg + initial dose of 500 IU/kg,No significant difference,"After 90 days this similarity remained, with a 7.1% and 5.9% incidence in the unfractionated heparin and tinzaparin groups, respectively.",17952:18090,59610,11714421,Unavailable
59610,Major bleeding (90 days),Low-molecular-weight heparins: tinzaparin  175 anti-Xa units/kg,Unfractionated heparin IV bolus of 50 IU/kg + initial dose of 500 IU/kg,No significant difference,"After 90 days this similarity remained, with a 7.1% and 5.9% incidence in the unfractionated heparin and tinzaparin groups, respectively.",17952:18090,59610,11714421,Unavailable
59610,Mortality (90 days),Low-molecular-weight heparins: tinzaparin  175 anti-Xa units/kg,Unfractionated heparin IV bolus of 50 IU/kg + initial dose of 500 IU/kg,No significant difference,"After 90 days this similarity remained, with a 7.1% and 5.9% incidence in the unfractionated heparin and tinzaparin groups, respectively.",17952:18090,59610,11714421,Unavailable
59610,Fatal pulmonary embolism,Low-molecular-weight heparins: tinzaparin  175 anti-Xa units/kg,Unfractionated heparin IV bolus of 50 IU/kg + initial dose of 500 IU/kg,No significant difference,There was a 1.0% rate of fatal pulmonary emboli in both groups.,18090:18153,59610,11714421,Unavailable
59610,Recurrent pulmonary embolism,Low-molecular-weight heparins: Tinzaparin (175 IU/kg),Unfractionated heparin  5000 IU followed by 40320 IU,Significantly decreased,"There were no recurrent episodes of venous thromboembolism in the group of patients treated with tinzaparin, and seven new episodes (four pulmonary embolisms) in the unfractionated heparin group (95% confidence interval for the difference 1.9% to 11.7%; P = 0.01).",19121:19402,59610,11714421,Unavailable
30713,Mean VO2 (ml/min),Manual turning,Manual turning + percussion and postural drainage,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VO2 (ml/min),Manual turning,Continuous rotation,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VO2 (ml/min),Manual turning,Continuous rotation  + percussion and postural drainage,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VO2 (ml/min),Manual turning + percussion and postural drainage,Continuous rotation,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VO2 (ml/min),Manual turning + percussion and postural drainage,Continuous rotation + percussion and postural drainage,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VO2 (ml/min),Continuous rotation,Continuous rotation + percussion and postural drainage,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VCO2 (ml/min),Manual turning,Manual turning + percussion and postural drainage,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VCO2 (ml/min),Manual turning,Continuous rotation,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VCO2 (ml/min),Manual turning,Continuous rotation  + percussion and postural drainage,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VCO2 (ml/min),Manual turning + percussion and postural drainage,Continuous rotation,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VCO2 (ml/min),Manual turning + percussion and postural drainage,Continuous rotation + percussion and postural drainage,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Mean VCO2 (ml/min),Continuous rotation,Continuous rotation + percussion and postural drainage,No significant difference,"VO2 and VCO2 tended to be higher during the periods of P&amp;PD than without, although this difference was similarly not statistically significant.",17171:17336,30713,11299066,Unavailable
30713,Kirby index,Manual turning,Manual turning + percussion and postural drainage,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16603:16962,30713,11299066,Unavailable
30713,Kirby index,Manual turning,Continuous rotation,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16603:16963,30713,11299066,Unavailable
30713,Kirby index,Manual turning,Continuous rotation  + percussion and postural drainage,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16602:16963,30713,11299066,Unavailable
30713,Kirby index,Manual turning + percussion and postural drainage,Continuous rotation,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16603:16962,30713,11299066,Unavailable
30713,Kirby index,Manual turning + percussion and postural drainage,Continuous rotation + percussion and postural drainage,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16602:16962,30713,11299066,Unavailable
30713,Kirby index,Continuous rotation,Continuous rotation + percussion and postural drainage,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16602:16962,30713,11299066,Unavailable
30713,Dead-space fraction,Manual turning,Manual turning + percussion and postural drainage,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16602:16962,30713,11299066,Unavailable
30713,Dead-space fraction,Manual turning,Continuous rotation,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16602:16962,30713,11299066,Unavailable
30713,Dead-space fraction,Manual turning,Continuous rotation  + percussion and postural drainage,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16602:16962,30713,11299066,Unavailable
30713,Dead-space fraction,Manual turning + percussion and postural drainage,Continuous rotation,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16602:16962,30713,11299066,Unavailable
30713,Dead-space fraction,Manual turning + percussion and postural drainage,Continuous rotation + percussion and postural drainage,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16602:16962,30713,11299066,Unavailable
30713,Dead-space fraction,Continuous rotation,Continuous rotation + percussion and postural drainage,No significant difference,"There was a tendency for PaO2/FIO2 to increase (174 ± 31 versus 188 ± 36; P = 0.068) and Vd/Vt to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",16602:16962,30713,11299066,Unavailable
30713,Airway pressure,Manual turning,Manual turning + percussion and postural drainage,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17080:17170,30713,11299066,Unavailable
30713,Airway pressure,Manual turning,Continuous rotation,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17080:17170,30713,11299066,Unavailable
30713,Airway pressure,Manual turning,Continuous rotation  + percussion and postural drainage,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17080:17171,30713,11299066,Unavailable
30713,Airway pressure,Manual turning + percussion and postural drainage,Continuous rotation,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17079:17170,30713,11299066,Unavailable
30713,Airway pressure,Manual turning + percussion and postural drainage,Continuous rotation + percussion and postural drainage,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17079:17170,30713,11299066,Unavailable
30713,Airway pressure,Continuous rotation,Continuous rotation + percussion and postural drainage,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17079:17170,30713,11299066,Unavailable
30713,Cardiac output ,Manual turning,Manual turning + percussion and postural drainage,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17079:17170,30713,11299066,Unavailable
30713,Cardiac output,Manual turning,Continuous rotation,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17079:17170,30713,11299066,Unavailable
30713,Cardiac output,Manual turning,Continuous rotation  + percussion and postural drainage,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17079:17170,30713,11299066,Unavailable
30713,Cardiac output,Manual turning + percussion and postural drainage,Continuous rotation,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17079:17170,30713,11299066,Unavailable
30713,Cardiac output,Manual turning + percussion and postural drainage,Continuous rotation + percussion and postural drainage,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17079:17170,30713,11299066,Unavailable
30713,Cardiac output,Continuous rotation,Continuous rotation + percussion and postural drainage,No significant difference,Airway pressures were unchanged during the study period and cardiac output was unaffected.,17079:17170,30713,11299066,Unavailable
30713,Partial pressure of carbon dioxide,Manual turning,Manual turning + percussion and postural drainage,No significant difference,There were no changes in PaCO2 during the study (Fig. 1),16963:17078,30713,11299066,Unavailable
30713,Partial pressure of carbon dioxide,Manual turning,Continuous rotation,No significant difference,There were no changes in PaCO2 during the study (Fig. 1),16962:17078,30713,11299066,Unavailable
30713,Partial pressure of carbon dioxide,Manual turning,Continuous rotation  + percussion and postural drainage,No significant difference,There were no changes in PaCO2 during the study (Fig. 1),16963:17078,30713,11299066,Unavailable
30713,Partial pressure of carbon dioxide,Manual turning + percussion and postural drainage,Continuous rotation,No significant difference,There were no changes in PaCO2 during the study (Fig. 1),16963:17078,30713,11299066,Unavailable
30713,Partial pressure of carbon dioxide,Manual turning + percussion and postural drainage,Continuous rotation + percussion and postural drainage,No significant difference,There were no changes in PaCO2 during the study (Fig. 1),16963:17078,30713,11299066,Unavailable
30713,Partial pressure of carbon dioxide,Continuous rotation,Continuous rotation + percussion and postural drainage,No significant difference,There were no changes in PaCO2 during the study (Fig. 1),16962:17078,30713,11299066,Unavailable
30713,Sputum production,Manual turning,Manual turning + percussion and postural drainage,No significant difference,There were statistically significant increases in sputum volume during the periods of CLR (Table 3). The addition of P&amp;PD did not increase sputum volume for the group as a whole.,17455:17672,30713,11299066,Unavailable
30713,Sputum production,Manual turning,Continuous rotation,Significantly decreased,There were statistically significant increases in sputum volume during the periods of CLR (Table 3). The addition of P&amp;PD did not increase sputum volume for the group as a whole.,17455:17672,30713,11299066,Unavailable
30713,Sputum production,Manual turning,Continuous rotation  + percussion and postural drainage,Significantly decreased,There were statistically significant increases in sputum volume during the periods of CLR (Table 3). The addition of P&amp;PD did not increase sputum volume for the group as a whole.,17455:17672,30713,11299066,Unavailable
30713,Sputum production,Manual turning + percussion and postural drainage,Continuous rotation,Significantly decreased,There were statistically significant increases in sputum volume during the periods of CLR (Table 3). The addition of P&amp;PD did not increase sputum volume for the group as a whole.,17455:17672,30713,11299066,Unavailable
30713,Sputum production,Manual turning + percussion and postural drainage,Continuous rotation + percussion and postural drainage,Significantly decreased,There were statistically significant increases in sputum volume during the periods of CLR (Table 3). The addition of P&amp;PD did not increase sputum volume for the group as a whole.,17455:17672,30713,11299066,Unavailable
30713,Sputum production,Continuous rotation,Continuous rotation + percussion and postural drainage,No significant difference,There were statistically significant increases in sputum volume during the periods of CLR (Table 3). The addition of P&amp;PD did not increase sputum volume for the group as a whole.,17455:17672,30713,11299066,Unavailable
30713,Sputum volume when production was over 40 ml,Continuous rotation,Continuous rotation + percussion and postural drainage,Significantly decreased,"However, in the four patients producing more than 40 ml of sputum per day, P&amp;PD increased sputum volume significantly (Table 3)",17672:17847,30713,11299066,Unavailable
32174,Satisfaction with the recovery,Implementation of patient-held record,Control,Significantly increased,"PHR group patients were more satisfied with the recovery they had made (79% vs. 59%, p=0.04), but felt less able to talk to staff about their problems (61% vs. 82%, p=0.02).",4736:4909,32174,11257719,Unavailable
32174,Feeling of being able to discuss problems with staff ,Implementation of patient-held record,Control,Significantly decreased,"PHR group patients were more satisfied with the recovery they had made (79% vs. 59%, p=0.04), but felt less able to talk to staff about their problems (61% vs. 82%, p=0.02).",4736:4909,32174,11257719,Unavailable
32174,Explanations about patient condition received ,Implementation of patient-held record,Control,No significant difference,"PHR group patients reported receiving fewer explanations about their condition (18% vs. 33%, p=0.12) and treatment (26% vs. 45%, p=0.07)",4910:5046,32174,11257719,Unavailable
32174,Explanations about treatment received ,Implementation of patient-held record,Control,No significant difference,"PHR group patients reported receiving fewer explanations about their condition (18% vs. 33%, p=0.12) and treatment (26% vs. 45%, p=0.07)",4910:5046,32174,11257719,Unavailable
32174,Fear of asking questions to the doctor,Implementation of patient-held record,Control,Significantly increased,"and were more afraid of asking doctors questions (21% vs. 4%, p=0.01) than controls.",5048:5133,32174,11257719,Unavailable
32174,Preparation for discharge,Implementation of patient-held record,Control,No significant difference,PHR group patients were no better prepared for hospital discharge than control group patients,5133:5226,32174,11257719,Unavailable
32174,Information level about services and benefits ,Implementation of patient-held record,Control,No significant difference,and both groups were ill-informed about services and benefits that might have helped after discharge from hospital.,5228:5343,32174,11257719,Unavailable
32174,Patient involvement in discussions about their treatment with staff,Implementation of patient-held record,Control,No significant difference,"Most patients (68% PHR vs. 61% control, p=0.39) were not involved in discussions about their treatment with doctors or therapists",23274:23403,32174,11257719,Unavailable
32174,Fear of asking questions to therapists and social workers,Implementation of patient-held record,Control,No significant difference,The vast majority of patients in both groups felt able to ask questions of therapists and social workers.,23567:23672,32174,11257719,Unavailable
32174,Readiness to go home when discharged ,Implementation of patient-held record,Control,No significant difference,"More PHR than control group patients felt ready to go home at the point of discharge (82% vs. 60%, p=0.14)",23970:24076,32174,11257719,Unavailable
32174,Being instructed in how to cope at home,Implementation of patient-held record,Control,No significant difference,"but control group patients were more likely to have been instructed in how to cope at home (49% vs. 33%, p=0.11).",17725:17809,32174,11257719,Unavailable
32174,Feeling of being fully recovered ,Implementation of patient-held record,Control,Significantly increased,"Significantly more PHR than control group patients felt that they had made a complete recovery from the stroke (38% vs. 14%, p=0.01)",24385:24517,32174,11257719,Unavailable
32174,Feeling of having their lives back together,Implementation of patient-held record,Control,No significant difference,"and a higher proportion felt that they had ""got their lives back together again"" (48% VS. 31%, P=0.08)",24519:24621,32174,11257719,Unavailable
32174,Need for help with everyday activities,Implementation of patient-held record,Control,No significant difference,"Despite this, two-thirds of patients in both groups needed help with everyday activities.",24622:24712,32174,11257719,Unavailable
32174,Satisfaction with community services received,Implementation of patient-held record,Control,No significant difference,Both groups reported high levels of disatisfaction with community services received.,17725:17809,32174,11257719,Unavailable
32174,Having a poor notion of what was happening to them,Implementation of patient-held record,Control,No significant difference,Slightly more (61%) PHR group patients than control patients (49%) reported that they had had little idea what was happening to them while they were in hospital.,23404:23566,32174,11257719,Unavailable
60660,Serum folate level 30 min after the first UVA exposure,UVA irradiation ,Control,No significant difference,"At all times of blood collection the differences between serum folate levels were insignificant for UV exposed as well as non-exposed volunteers (P &gt; 0.05), except of the non-exposed controls at T2 (P &lt; 0.05). However, this was certainly not of clinical relevance.",10261:10546,60660,11737876,Unavailable
60660,Serum folate level 24 h after the sixth UV exposure,UVA irradiation ,Control,No significant difference,At all times of blood collection the differences between serum folate levels were insignificant for UV exposed as well as non-exposed volunteers (P &gt; 0.05),10262:10417,60660,11737876,Unavailable
65045,Score on critical appraisal ,Evidence Based Medicine workshop,Control,No significant difference,The students mean scores were similar in Group A (14.8) and Group B (15.0) after Group A had received the intervention and Group B had received the control (p = 0.75),4157:4323,65045,11818036,Unavailable
65045,Confidence in reading research papers,Evidence Based Medicine workshop,Control,No significant difference,"Student self-perception of confidence tended to increase slightly during the trial, although not to a level that was statistically significant",18503:18647,65045,11818036,Unavailable
79000,Low density lipoprotein levels after 12 weeks,Simvastatin 20 mg,Baseline,Significantly decreased,"Plasma low density lipoprotein-cholesterol concentration fell 7%, 39% (p &lt; 0.01 vs baseline) and 47% (p &lt; 0.01 vs baseline) after 12 weeks of treatment with placebo, simvastatin 20 mg and 40 mg, respectively.",3584:3792,79000,11879528,Unavailable
79000,Low density lipoprotein levels after 12 weeks,Simvastatin 40 mg,Baseline,Significantly decreased,"Plasma low density lipoprotein-cholesterol concentration fell 7%, 39% (p &lt; 0.01 vs baseline) and 47% (p &lt; 0.01 vs baseline) after 12 weeks of treatment with placebo, simvastatin 20 mg and 40 mg, respectively.",3584:3792,79000,11879528,Unavailable
79000,Low density lipoprotein levels after 12 weeks,Placebo,Baseline,No significant difference,"Plasma low density lipoprotein-cholesterol concentration fell 7%, 39% (p &lt; 0.01 vs baseline) and 47% (p &lt; 0.01 vs baseline) after 12 weeks of treatment with placebo, simvastatin 20 mg and 40 mg, respectively.",3584:3792,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 6 weeks,Simvastatin 20 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 12 weeks,Simvastatin 20 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 6 weeks,Simvastatin 40 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 12 weeks,Simvastatin 40 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 6 weeks,Placebo,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 12 weeks,Placebo,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,N-telopeptide levels after 6 weeks,Simvastatin 20 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,N-telopeptide levels after 12 weeks,Simvastatin 20 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,N-telopeptide levels after 6 weeks,Simvastatin 40 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,N-telopeptide levels after 12 weeks,Simvastatin 40 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,N-telopeptide levels after 6 weeks,Placebo,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,N-telopeptide levels after 12 weeks,Placebo,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen after 6 weeks,Simvastatin 20 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen after 12 weeks,Simvastatin 20 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen after 6 weeks,Simvastatin 40 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen after 12 weeks,Simvastatin 40 mg,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen after 6 weeks,Placebo,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen after 12 weeks,Placebo,Baseline,No significant difference,"At 6 and 12 weeks, bone marker concentrations were not different from baseline",3876:3955,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 6 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 6 weeks,Simvastatin 20 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 6 weeks,Simvastatin 40 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 12 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 12 weeks,Simvastatin 20 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 12 weeks,Simvastatin 40 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,N-telopeptide levels after 6 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,N-telopeptide levels after 6 weeks,Simvastatin 20 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,N-telopeptide levels after 6 weeks,Simvastatin 40 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,N-telopeptide levels after 12 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,N-telopeptide levels after 12 weeks,Simvastatin 20 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,N-telopeptide levels after 12 weeks,Simvastatin 40 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 6 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 6 weeks,Simvastatin 20 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 6 weeks,Simvastatin 40 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 12 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 12 weeks,Simvastatin 20 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 12 weeks,Simvastatin 40 mg,Placebo,No significant difference,no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.,3961:4081,79000,11879528,Unavailable
79000,Total cholesterol after 12 weeks,Simvastatin 20 mg,Baseline,Significantly decreased,"After 12 weeks, total cholesterol fell 2%, 25% (p &lt; 0.01 vs. baseline) and 26% (p &lt; 0.01 vs baseline) on placebo, simvastatin 20 mg and 40 mg, respectively.",13104:13260,79000,11879528,Unavailable
79000,Total cholesterol after 12 weeks,Simvastatin 40 mg,Baseline,Significantly decreased,"After 12 weeks, total cholesterol fell 2%, 25% (p &lt; 0.01 vs. baseline) and 26% (p &lt; 0.01 vs baseline) on placebo, simvastatin 20 mg and 40 mg, respectively.",13104:13260,79000,11879528,Unavailable
79000,Total cholesterol after 12 weeks,Placebo,Baseline,No significant difference,"After 12 weeks, total cholesterol fell 2%, 25% (p &lt; 0.01 vs. baseline) and 26% (p &lt; 0.01 vs baseline) on placebo, simvastatin 20 mg and 40 mg, respectively.",13104:13260,79000,11879528,Unavailable
79000,Low density lipoprotein levels after 12 weeks,Simvastatin 20 mg,Baseline,Significantly decreased,"Low density lipoprotein (LDL)-cholesterol was reduced by 7%, 39% (p &lt; 0.01 vs. baseline) and 47% (p &lt; 0.01 vs baseline), respectively",13260:13394,79000,11879528,Unavailable
79000,Low density lipoprotein levels after 12 weeks,Simvastatin 40 mg,Baseline,Significantly decreased,"Low density lipoprotein (LDL)-cholesterol was reduced by 7%, 39% (p &lt; 0.01 vs. baseline) and 47% (p &lt; 0.01 vs baseline), respectively.",13261:13395,79000,11879528,Unavailable
79000,Low density lipoprotein levels after 12 weeks,Placebo,Baseline,No significant difference,"Low density lipoprotein (LDL)-cholesterol was reduced by 7%, 39% (p &lt; 0.01 vs. baseline) and 47% (p &lt; 0.01 vs baseline),",13260:13381,79000,11879528,Unavailable
79000,Triglycerides levels after 12 weeks,Simvastatin 20 mg,Baseline,No significant difference,No significant changes from baseline to 12 weeks were observed for triglycerides or high density lipoprotein-cholesterol within treatment groups.,13396:13541,79000,11879528,Unavailable
79000,Triglycerides levels after 12 weeks,Simvastatin 40 mg,Baseline,No significant difference,No significant changes from baseline to 12 weeks were observed for triglycerides or high density lipoprotein-cholesterol within treatment groups.,13396:13541,79000,11879528,Unavailable
79000,Triglycerides levels after 12 weeks,Placebo,Baseline,No significant difference,No significant changes from baseline to 12 weeks were observed for triglycerides or high density lipoprotein-cholesterol within treatment groups.,13396:13541,79000,11879528,Unavailable
79000,HDL levels after 12 weeks,Simvastatin 20 mg,Baseline,No significant difference,No significant changes from baseline to 12 weeks were observed for triglycerides or high density lipoprotein-cholesterol within treatment groups.,13396:13541,79000,11879528,Unavailable
79000,HDL levels after 12 weeks,Simvastatin 40 mg,Baseline,No significant difference,No significant changes from baseline to 12 weeks were observed for triglycerides or high density lipoprotein-cholesterol within treatment groups.,13396:13541,79000,11879528,Unavailable
79000,HDL levels after 12 weeks,Placebo,Baseline,No significant difference,No significant changes from baseline to 12 weeks were observed for triglycerides or high density lipoprotein-cholesterol within treatment groups.,13396:13541,79000,11879528,Unavailable
79000,Total cholesterol levels after 12 weeks,Simvastatin 40 mg,Placebo,Significantly decreased,"When treatment groups were compared, total and LDL-cholesterol were significantly lower at 12 weeks in women randomized to simvastatin 40 mg compared with those assigned to placebo (p &lt; 0.01 for both).",13542:13743,79000,11879528,Unavailable
79000,LDL levels after 12 weeks,Simvastatin 40 mg,Placebo,Significantly decreased,"When treatment groups were compared, total and LDL-cholesterol were significantly lower at 12 weeks in women randomized to simvastatin 40 mg compared with those assigned to placebo (p &lt; 0.01 for both).",13542:13743,79000,11879528,Unavailable
79000,LDL levels after 12 weeks,Simvastatin 40 mg,Simvastatin 20 mg,Significantly decreased,LDL-cholesterol was also lower among women in the simvastatin 40 mg group compared with the simvastatin 20 mg group (p &lt; 0.05).,13743:13871,79000,11879528,Unavailable
79000,AST levels after 12 weeks,Simvastatin 20 mg,Baseline,No significant difference,All subjects' serum asparate aminotransferase levels remained normal at 12 weeks.,13872:13953,79000,11879528,Unavailable
79000,AST levels after 12 weeks,Simvastatin 40 mg,Baseline,No significant difference,All subjects' serum asparate aminotransferase levels remained normal at 12 weeks.,13872:13953,79000,11879528,Unavailable
79000,AST levels after 12 weeks,Placebo,Baseline,No significant difference,All subjects' serum asparate aminotransferase levels remained normal at 12 weeks.,13872:13953,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 6 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15932:16013,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 6 weeks,Simvastatin 20 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15932:16013,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 6 weeks,Simvastatin 40 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 12 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15932:16013,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 12 weeks,Simvastatin 20 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15932:16013,79000,11879528,Unavailable
79000,Bone-specific alkaline phosphatase after 12 weeks,Simvastatin 40 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
79000,N-telopeptide levels after 6 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15932:16013,79000,11879528,Unavailable
79000,N-telopeptide levels after 6 weeks,Simvastatin 20 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
79000,N-telopeptide levels after 6 weeks,Simvastatin 40 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
79000,N-telopeptide levels after 12 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
79000,N-telopeptide levels after 12 weeks,Simvastatin 20 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
79000,N-telopeptide levels after 12 weeks,Simvastatin 40 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15932:16013,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 6 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15932:16013,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 6 weeks,Simvastatin 20 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 6 weeks,Simvastatin 40 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 12 weeks,Simvastatin 20 mg,Simvastatin 40 mg,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 12 weeks,Simvastatin 20 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
79000,C-terminal propeptide of type 1 collagen levels after 12 weeks,Simvastatin 40 mg,Placebo,No significant difference,"At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups.",15931:16013,79000,11879528,Unavailable
554761,Exhaled carbon monoxide between 0 and 1 hour,Smoking,Not smoking,Significantly increased,"Significant findings were: Smoking increased exhaled carbon monoxide between 0 and 1 hour, and induced a greater decrease in blood eosinophils and sputum lymphocytes between 0 and 3 hours compared to non-smoking.",5517:5729,554761,15740629,Unavailable
554761,Blood eosinophils between 0 and 3 hours,Smoking,Not smoking,Significantly decreased,"Significant findings were: Smoking increased exhaled carbon monoxide between 0 and 1 hour, and induced a greater decrease in blood eosinophils and sputum lymphocytes between 0 and 3 hours compared to non-smoking.",5517:5730,554761,15740629,Unavailable
554761,Sputum lymphocytes between 0 and 3 hours,Smoking,Not smoking,Significantly decreased,"Significant findings were: Smoking increased exhaled carbon monoxide between 0 and 1 hour, and induced a greater decrease in blood eosinophils and sputum lymphocytes between 0 and 3 hours compared to non-smoking.",5517:5730,554761,15740629,Unavailable
554761,Interleukin-8 release from stimulated blood cells between 0 and 3 hours,Smoking,Not smoking,Significantly increased,"Compared to non-smoking, smoking induced a greater interleukin-8 release from stimulated blood cells between 0 and 3 hours",5730:5852,554761,15740629,Unavailable
554761,Sputum lymphocytes between 3 and 12 hours,Smoking,Not smoking,Significantly increased,and a greater increase in sputum lymphocytes and neutrophils between 3 and 12 hours.,5854:5938,554761,15740629,Unavailable
554761,Sputum neutrophils between 3 and 12 hours,Smoking,Not smoking,Significantly increased,and a greater increase in sputum lymphocytes and neutrophils between 3 and 12 hours.,5854:5938,554761,15740629,Unavailable
554761,Exhaled carbon monoxide between 0 and 1 hour,Smoking,Not smoking,Significantly increased,Exhaled CO increased significantly more with smoking than without between 0 and 1 hour,18058:18144,554761,15740629,Unavailable
554761,Exhaled carbon monoxide between 1 and 12 hours,Smoking,Not smoking,Significantly decreased,Exhaled CO increased significantly more with smoking than without between 0 and 1 hour and subsequently decreased significantly more between 1 and 12 hours,18058:18214,554761,15740629,Unavailable
554761,Exhaled Nitric oxide,Smoking,Not smoking,No significant difference,Smoking had no significant effect on exhaled NO (data not shown) or FEV1,18311:18388,554761,15740629,Unavailable
554761,FEV-1,Smoking,Not smoking,No significant difference,Smoking had no significant effect on exhaled NO (data not shown) or FEV1,18311:18388,554761,15740629,Unavailable
554761,Blood eosinophils between 0 and 3 hours,Smoking,Not smoking,Significantly decreased,The number of blood eosinophils decreased more with smoking than without between 0 and 3 hours,20293:20387,554761,15740629,Unavailable
554761,Interleukin-8 release from stimulated blood cells between 0 and 3 hours,Smoking,Not smoking,Significantly increased,IL-8 release from LPS stimulated blood cells increased more with smoking than without between 0 and 3 hours,20732:20840,554761,15740629,Unavailable
554761,TNF-α release in blood between 0 and 3 hours,Smoking,Not smoking,No significant difference,"Smoking had no significant effect on TNF-α, IL-10 and IL-1β release compared with no smoking",24730:24975,554761,15740629,Unavailable
554761,IL-10 release in blood ,Smoking,Not smoking,No significant difference,"Smoking had no significant effect on TNF-α, IL-10 and IL-1β release compared with no smoking",24730:24975,554761,15740629,Unavailable
554761,IL-1β release in blood ,Smoking,Not smoking,No significant difference,"Smoking had no significant effect on TNF-α, IL-10 and IL-1β release compared with no smoking",24730:24975,554761,15740629,Unavailable
554761,Expression of CD11b on CD14-high blood cells,Smoking,Not smoking,No significant difference,"There was no significant difference in the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells between smoking and no smoking",24730:24975,554761,15740629,Unavailable
554761,Expression of CD11b on CD14-low blood cells,Smoking,Not smoking,No significant difference,"There was no significant difference in the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells between smoking and no smoking",24730:24975,554761,15740629,Unavailable
554761,Expression of CD63 on CD14-high blood cells,Smoking,Not smoking,No significant difference,"There was no significant difference in the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells between smoking and no smoking",24730:24975,554761,15740629,Unavailable
554761,Expression of CD63 on CD14-low blood cells,Smoking,Not smoking,No significant difference,"There was no significant difference in the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells between smoking and no smoking",24730:24975,554761,15740629,Unavailable
554761,Expression of  HLA-DR on CD14-high blood cells,Smoking,Not smoking,No significant difference,"There was no significant difference in the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells between smoking and no smoking",24730:24975,554761,15740629,Unavailable
554761,Expression of  HLA-DR on CD14-low blood cells,Smoking,Not smoking,No significant difference,"There was no significant difference in the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells between smoking and no smoking",24730:24975,554761,15740629,Unavailable
554761,Blood neutrophils between 0 and 12 hours,Smoking,Not smoking,No significant difference,Smoking had no significant effect on the number of other blood cells,20487:20556,554761,15740629,Unavailable
554761,Blood monocytes between 0 and 1 hour,Smoking,Not smoking,No significant difference,Smoking had no significant effect on the number of other blood cells,20487:20556,554761,15740629,Unavailable
554761,Blood lymphocytes between 0 and 12 hours,Smoking,Not smoking,No significant difference,Smoking had no significant effect on the number of other blood cells,20487:20556,554761,15740629,Unavailable
554761,Number of sputum neutrophils between 3 and 12 hours,Smoking,Not smoking,Significantly increased,The number of neutrophils increased significantly more with smoking than without between 3 and 12 hours,24730:24975,554761,15740629,Unavailable
554761,Number of sputum lymphocytes between 0 and 3 hours,Smoking,Not smoking,Significantly decreased,The number of sputum lymphocytes decreased more with smoking than without between 0 and 3 hours,24730:24975,554761,15740629,Unavailable
554761,Number of sputum lymphocytes between 3 and 12 hours,Smoking,Not smoking,Significantly increased,"Subsequently, however, the percentage and number of sputum lymphocytes increased more with smoking than without between 3 and 12 hours",24730:24975,554761,15740629,Unavailable
554761,Percentage of sputum lymphocytes between 3 and 12 hours,Smoking,Not smoking,Significantly increased,"Subsequently, however, the percentage and number of sputum lymphocytes increased more with smoking than without between 3 and 12 hours",24730:24975,554761,15740629,Unavailable
554761,Number of sputum eosinophils ,Smoking,Not smoking,No significant difference,"Smoking had no significant effect on the percentage and number of sputum eosinophils (table 5, figure 5) and macrophages (table 5)",24730:24975,554761,15740629,Unavailable
554761,Number of sputum macrophages ,Smoking,Not smoking,No significant difference,"Smoking had no significant effect on the percentage and number of sputum eosinophils (table 5, figure 5) and macrophages (table 5)",24730:24975,554761,15740629,Unavailable
554761,Percentage of sputum eosinophils ,Smoking,Not smoking,No significant difference,"Smoking had no significant effect on the percentage and number of sputum eosinophils (table 5, figure 5) and macrophages (table 5)",24730:24975,554761,15740629,Unavailable
554761,Percentage of sputum macrophages ,Smoking,Not smoking,No significant difference,"Smoking had no significant effect on the percentage and number of sputum eosinophils (table 5, figure 5) and macrophages (table 5)",24730:24975,554761,15740629,Unavailable
554761,Interleukin-8 release in sputum,Smoking,Not smoking,No significant difference,Smoking had also no significant effect on the levels of inflammatory mediators in sputum,24977:25065,554761,15740629,Unavailable
554761,TNF-α release in sputum ,Smoking,Not smoking,No significant difference,Smoking had also no significant effect on the levels of inflammatory mediators in sputum,24977:25065,554761,15740629,Unavailable
554761,IL-10 release in sputum ,Smoking,Not smoking,No significant difference,Smoking had also no significant effect on the levels of inflammatory mediators in sputum,24977:25065,554761,15740629,Unavailable
554761,IL-1β release in sputum ,Smoking,Not smoking,No significant difference,Smoking had also no significant effect on the levels of inflammatory mediators in sputum,24977:25065,554761,15740629,Unavailable
554761,Expression of CD11b on CD14-high sputum cells,Smoking,Not smoking,No significant difference,"Smoking had also no significant effect on the levels of inflammatory mediators in sputum (additional file 1, table 3) and the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells and the number of iNOS positive macrophages",24976:25310,554761,15740629,Unavailable
554761,Expression of CD11b on CD14-low sputum cells,Smoking,Not smoking,No significant difference,"Smoking had also no significant effect on the levels of inflammatory mediators in sputum (additional file 1, table 3) and the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells and the number of iNOS positive macrophages",24977:25310,554761,15740629,Unavailable
554761,Expression of CD63 on CD14-high sputum cells,Smoking,Not smoking,No significant difference,"Smoking had also no significant effect on the levels of inflammatory mediators in sputum (additional file 1, table 3) and the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells and the number of iNOS positive macrophages",24977:25311,554761,15740629,Unavailable
554761,Expression of CD63 on CD14-low sputum cells,Smoking,Not smoking,No significant difference,"Smoking had also no significant effect on the levels of inflammatory mediators in sputum (additional file 1, table 3) and the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells and the number of iNOS positive macrophages",24977:25310,554761,15740629,Unavailable
554761,Expression of  HLA-DR on CD14-high sputum cells,Smoking,Not smoking,No significant difference,"Smoking had also no significant effect on the levels of inflammatory mediators in sputum (additional file 1, table 3) and the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells and the number of iNOS positive macrophages",24977:25310,554761,15740629,Unavailable
554761,Expression of  HLA-DR on CD14-low sputum cells,Smoking,Not smoking,No significant difference,"Smoking had also no significant effect on the levels of inflammatory mediators in sputum (additional file 1, table 3) and the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells and the number of iNOS positive macrophages",24977:25310,554761,15740629,Unavailable
554761,Number of inducible nitric oxide synthase- postive macrophages ,Smoking,Not smoking,No significant difference,"Smoking had also no significant effect on the levels of inflammatory mediators in sputum (additional file 1, table 3) and the expression of CD11b, CD63 and HLA-DR on CD14 high and CD14 low cells and the number of iNOS positive macrophages",24977:25310,554761,15740629,Unavailable
554761,Leukotriene E4 levels in urine,Smoking,Not smoking,No significant difference,Smoking had no significant effect on leukotriene E4 levels in urine compared to no smoking,33496:33586,554761,15740629,Unavailable
546286,C-terminal telopeptide fragments of type I collagen (CTX-I) serum levels,Calcium + vitamin D + hormone replacement therapy,Calcium + vitamin D alone,Significantly decreased,"Treatment with HRT resulted in decrease in CTX-I (P &lt; 0.001), ICTP (P &lt; 0.001), PICP (P &lt; 0.05), COMP (P &lt; 0.01), and CTX-II (P &lt; 0.05) at 2 years.",5025:5270,546286,15380045,Unavailable
546286,C-terminal telopeptide of type I collagen (ICTP) serum levels,Calcium + vitamin D + hormone replacement therapy,Calcium + vitamin D alone,Significantly decreased,"Treatment with HRT resulted in decrease in CTX-I (P &lt; 0.001), ICTP (P &lt; 0.001), PICP (P &lt; 0.05), COMP (P &lt; 0.01), and CTX-II (P &lt; 0.05) at 2 years.",5025:5270,546286,15380045,Unavailable
546286,C-terminal propeptide of type I procollagen (PICP) serum levels,Calcium + vitamin D + hormone replacement therapy,Calcium + vitamin D alone,Significantly decreased,"Treatment with HRT resulted in decrease in CTX-I (P &lt; 0.001), ICTP (P &lt; 0.001), PICP (P &lt; 0.05), COMP (P &lt; 0.01), and CTX-II (P &lt; 0.05) at 2 years.",5025:5270,546286,15380045,Unavailable
546286,Cartilage oligomeric matrix protein (COMP) serum levels,Calcium + vitamin D + hormone replacement therapy,Calcium + vitamin D alone,Significantly decreased,"Treatment with HRT resulted in decrease in CTX-I (P &lt; 0.001), ICTP (P &lt; 0.001), PICP (P &lt; 0.05), COMP (P &lt; 0.01), and CTX-II (P &lt; 0.05) at 2 years.",5025:5270,546286,15380045,Unavailable
546286,Collagen type II C-telopeptide degradation fragments (CTX-II) urinary levels,Calcium + vitamin D + hormone replacement therapy,Baseline,Significantly decreased,"Treatment with HRT resulted in decrease in CTX-I (P &lt; 0.001), ICTP (P &lt; 0.001), PICP (P &lt; 0.05), COMP (P &lt; 0.01), and CTX-II (P &lt; 0.05) at 2 years.",25185:25374,546286,15380045,Unavailable
546286,C-terminal telopeptide fragments of type I collagen (CTX-I) serum levels,Calcium + vitamin D + hormone replacement therapy,Calcium + vitamin D alone,Significantly decreased,"HRT caused a pronounced decrease in the collagen type I degradation marker, CTX-I, both when the HRT and control groups were compared (P &lt; 0.001) and within the HRT group (P &lt; 0.001)",23528:23747,546286,15380045,Unavailable
546286,C-terminal telopeptide fragments of type I collagen (CTX-I) serum levels after 12 months,Calcium + vitamin D + hormone replacement therapy,Baseline,Significantly decreased,"HRT caused a pronounced decrease in the collagen type I degradation marker, CTX-I, both when the HRT and control groups were compared (P &lt; 0.001) and within the HRT group (P &lt; 0.001) (Fig. 1a). CTX-I in the HRT group was reduced by 62 ± 5% (mean ± SEM) after 12 months and 53 ± 6% after 24 months",23528:23901,546286,15380045,Unavailable
546286,C-terminal telopeptide fragments of type I collagen (CTX-I) serum levels after 24 months,Calcium + vitamin D + hormone replacement therapy,Baseline,Significantly decreased,"HRT caused a pronounced decrease in the collagen type I degradation marker, CTX-I, both when the HRT and control groups were compared (P &lt; 0.001) and within the HRT group (P &lt; 0.001) (Fig. 1a). CTX-I in the HRT group was reduced by 62 ± 5% (mean ± SEM) after 12 months and 53 ± 6% after 24 months.",23528:23902,546286,15380045,Unavailable
546286,C-terminal telopeptide fragments of type I collagen (CTX-I) serum levels after 12 months,Calcium + vitamin D,Baseline,No significant difference,"In the control group a decrease of 3 ± 13% and an increase of 12 ± 13% was observed after 12 and 24 months, respectively.",23902:24024,546286,15380045,Unavailable
546286,C-terminal telopeptide fragments of type I collagen (CTX-I) serum levels after 24 months,Calcium + vitamin D  ,Baseline,No significant difference,"In the control group a decrease of 3 ± 13% and an increase of 12 ± 13% was observed after 12 and 24 months, respectively.",23903:24024,546286,15380045,Unavailable
546286,C-terminal telopeptide of type I collagen (ICTP) serum levels,Calcium + vitamin D + hormone replacement therapy,Calcium + vitamin D alone,Significantly decreased,"HRT resulted also in a significant (P = 0.035) but less pronounced reduction in the other collagen type I degradation product, ICTP.",24031:24180,546286,15380045,Unavailable
546286,C-terminal telopeptide of type I collagen (ICTP) serum levels after 12 months,Calcium + vitamin D + hormone replacement therapy,Baseline,No significant difference,The average percentage reduction of this marker was 5 ± 7% after 12 months and 5 ± 5% after 24 months in the HRT group.,24181:24300,546286,15380045,Unavailable
546286,C-terminal telopeptide of type I collagen (ICTP) serum levels after 24 months,Calcium + vitamin D + hormone replacement therapy,Baseline,No significant difference,The average percentage reduction of this marker was 5 ± 7% after 12 months and 5 ± 5% after 24 months in the HRT group.,24181:24300,546286,15380045,Unavailable
546286,C-terminal telopeptide of type I collagen (ICTP) serum levels after 12 moths,Calcium + vitamin D ,Baseline,Significantly increased,"A significant increase (P = 0.002) of ICTP was found in the controls, by an average of 21 ± 6% after 12 months and 31 ± 10% after 24 months.",24181:24300,546286,15380045,Unavailable
546286,C-terminal telopeptide of type I collagen (ICTP) serum levels after 24 moths,Calcium + vitamin D ,Baseline,Significantly increased,"A significant increase (P = 0.002) of ICTP was found in the controls, by an average of 21 ± 6% after 12 months and 31 ± 10% after 24 months.",24181:24300,546286,15380045,Unavailable
546286,BSP levels ,Calcium + vitamin D + hormone replacement therapy,Baseline,No significant difference,"BSP, which is a bone-specific protein enriched in the cartilage–bone interface, increased significantly (P = 0.023) in the control group but remained unchanged in the HRT group.",24465:24659,546286,15380045,Unavailable
546286,BSP levels ,Calcium + vitamin D ,Baseline,Significantly increased,"BSP, which is a bone-specific protein enriched in the cartilage–bone interface, increased significantly (P = 0.023) in the control group but remained unchanged in the HRT group.",24465:24659,546286,15380045,Unavailable
546286,C-terminal propeptide of type I procollagen (PICP) serum levels,Calcium + vitamin D + hormone replacement therapy,Calcium + vitamin D alone,Significantly decreased,"The marker of bone formation, PICP, decreased significantly in comparison with the controls (P = 0.005)",24666:24786,546286,15380045,Unavailable
546286,C-terminal propeptide of type I procollagen (PICP) serum levels after 12 months,Calcium + vitamin D + hormone replacement therapy,Baseline,Significantly decreased,"The marker of bone formation, PICP, decreased significantly in comparison with the controls (P = 0.005) as well as within the HRT group (P &lt; 0.001) by the end of the first year.",24666:24877,546286,15380045,Unavailable
546286,C-terminal propeptide of type I procollagen (PICP) serum levels after 24 months,Calcium + vitamin D + hormone replacement therapy,Baseline,Significantly decreased,"After the second year, a significant decrease was found within the HRT group (P = 0.021) in comparison with baseline values.",24878:25022,546286,15380045,Unavailable
546286,Cartilage oligomeric matrix protein (COMP) serum levels,Calcium + vitamin D + hormone replacement therapy,Calcium + vitamin D alone,Significantly decreased,"The HRT group presented a marked decrease in serum levels of COMP, both between the HRT and control group (P = 0.003)",25185:25319,546286,15380045,Unavailable
546286,Cartilage oligomeric matrix protein (COMP) serum levels,Calcium + vitamin D + hormone replacement therapy,Baseline,Significantly decreased,"The HRT group presented a marked decrease in serum levels of COMP, both between the HRT and control group (P = 0.003) and within the HRT group (P = 0.003).",25185:25374,546286,15380045,Unavailable
546286,Collagen type II C-telopeptide degradation fragments (CTX-II) urinary levels,Calcium + vitamin D + hormone replacement therapy,Baseline,Significantly decreased,"The urinary marker of cartilage degradation, CTX-II, had decreased significantly at 2 years within the HRT group (P = 0.023) in comparison with baseline values.",25546:25723,546286,15380045,Unavailable
547907,OCD improvement,SRI + Quetiapine,SRI + Placebo,No significant difference,Quetiapine did not demonstrate a significant benefit over placebo at the end of the six-week treatment period (p = .636).,4899:5009,547907,15667657,Unavailable
547907,Tic improvement in patients with co-morbid tics,SRI + Quetiapine,SRI + Placebo,No significant difference,Similarly quetiapine failed to separate from placebo in the subgroup of subjects (n = 10) with co-morbid tics.,34493:34567,547907,15667657,Unavailable
547907,OCD improvement,SRI + Quetiapine,SRI + Placebo,No significant difference,However quetiapine did not demonstrate significant benefit over placebo at the end of the six-week treatment period (F = .19; p = .636),18506:18642,547907,15667657,Unavailable
547907,Yale-Brown Obsessive Compulsive Scale score reduction after 6 weeks,SRI + Quetiapine,SRI + Placebo,No significant difference,YBOCS (change at week 6) -7.1(SD7.2) -7.2(SD8.4),34362:34460,547907,15667657,Unavailable
547907,Yale-Brown Obsessive Compulsive Scale score percentage reduction ,SRI + Quetiapine,SRI + Placebo,No significant difference,"YBOCS % change	-26.9%	-26%",33242:33314,547907,15667657,Unavailable
547907,Clinical Global Impression score for Severity after 6 weeks,SRI + Quetiapine,SRI + Placebo,No significant difference,CGI-Severity (week 6) 4.1 (SD1.4) 4.1(SD1.5),33792:33888,547907,15667657,Unavailable
547907,Montgomery-Asberg Depression Rating Scale score reduction after 6 weeks,SRI + Quetiapine,SRI + Placebo,No significant difference,"MADRS (change at week 6)	-2.6 (SD 6.5)	-3 (SD 8.3)",33792:33888,547907,15667657,Unavailable
547907,Sheehan Disability Scale score reduction after 6 weeks,SRI + Quetiapine,SRI + Placebo,No significant difference,"SDS (change at week 6)	-5.3(SD5.6)	-6.1 (SD4.8)",34076:34169,547907,15667657,Unavailable
547907,Yale Global Tic Severity Scale score reduction after 6 weeks,SRI + Quetiapine,SRI + Placebo,No significant difference,YGTSS (change at week 6) -4.5(SD 5.1) -9.4 (SD 14.6),34362:34460,547907,15667657,Unavailable
547907,Yale Global Tic Severity Scale score percentage reduction,SRI + Quetiapine,SRI + Placebo,No significant difference,"YGTSS % change	-18.2%	-41.6%",34493:34567,547907,15667657,Unavailable
547907,Tic improvement in patients with co-morbid tics,SRI + Quetiapine,SRI + Placebo,No significant difference,"The reduction in the YGTSS did not differ significantly between treatment groups with tics (quetiapine -4.5, placebo -9.4; F = 2.8, p = .46).",34855:34996,547907,15667657,Unavailable
547907,Montgomery-Asberg Depression Rating Scale (for Severity) after 6 weeks,SRI + Quetiapine,SRI + Placebo,No significant difference,"Severity ratings for depressive symptoms (MADRS) were low at baseline (mean 10.6, SD 4.8), showed little change over the study period, and at week 6 remained similar for both groups (quetiapine = 8.2, SD 4.8; placebo = 7.7, SD 6.1).",35003:35235,547907,15667657,Unavailable
547907,Sedation,SRI + Quetiapine,SRI + Placebo,No significant difference,"Sedation	75% (15)	33.3%(7)",36821:36889,547907,15667657,Unavailable
547907,Dry mouth,SRI + Quetiapine,SRI + Placebo,No significant difference,"Dry mouth	15% (3)	0",36920:36981,547907,15667657,Unavailable
547907,Headache,SRI + Quetiapine,SRI + Placebo,No significant difference,"Headache	15% (3)	38% (8)",37012:37078,547907,15667657,Unavailable
547907,Fatigue,SRI + Quetiapine,SRI + Placebo,No significant difference,"Fatigue	15% (3)	19% (4)",37109:37174,547907,15667657,Unavailable
547907,Irritability,SRI + Quetiapine,SRI + Placebo,No significant difference,"Irritability	10% (2)	4.7% (1)",37205:37276,547907,15667657,Unavailable
547907,Impaired concentration,SRI + Quetiapine,SRI + Placebo,No significant difference,"Impaired concentration	10% (2)	0",37307:37381,547907,15667657,Unavailable
547907,Dizziness,SRI + Quetiapine,SRI + Placebo,No significant difference,"Dizziness	5% (1)	14.3% (3)",37412:37480,547907,15667657,Unavailable
547907,Nausea,SRI + Quetiapine,SRI + Placebo,No significant difference,"Nausea	5% (1)	9.5% (2)",37511:37575,547907,15667657,Unavailable
547907,Increased appetite,SRI + Quetiapine,SRI + Placebo,No significant difference,"Increased appetite	5% (1)	9.5% (2)",37606:37682,547907,15667657,Unavailable
547907,Delayed ejaculation,SRI + Quetiapine,SRI + Placebo,No significant difference,"Delayed ejaculation	5% (1)	0",37713:37783,547907,15667657,Unavailable
547907,Weight gain,SRI + Quetiapine,SRI + Placebo,No significant difference,"Weight gain	5% (1)	0",37814:37876,547907,15667657,Unavailable
547907,Worsening of mood,SRI + Quetiapine,SRI + Placebo,No significant difference,"Worsening mood	5%(1)	4.7%(1)",37907:37977,547907,15667657,Unavailable
547907,Difficulties with memory,SRI + Quetiapine,SRI + Placebo,No significant difference,"Memory difficulties	5%(1)	0",38008:38077,547907,15667657,Unavailable
547907,Muscle aches,SRI + Quetiapine,SRI + Placebo,No significant difference,"Muscle aches	5%(1)	0",38108:38170,547907,15667657,Unavailable
547907,Abdominal tenderness,SRI + Quetiapine,SRI + Placebo,No significant difference,"Abdominal tenderness	5%(1)	0",38201:38271,547907,15667657,Unavailable
547907,Slurred speech,SRI + Quetiapine,SRI + Placebo,No significant difference,"Slurred speech	5%(1)	0",38302:38366,547907,15667657,Unavailable
2010104,Overall survival,Chemotherapy + Bacille Calmette-Guérin vaccine,Chemotherapy alone,Significantly increased,The overall survival of the C+I group was significantly increased (P less than 0.05).,1595:1680,2010104,389265,Unavailable
2010104,Duration of first remission,Chemotherapy + Bacille Calmette-Guérin vaccine,Chemotherapy alone,No significant difference,There was no significant increase in the duration of first remission in the C+I group (0.05 less than P less than 0.1) nor in the time from first relapse to death (0.05 less than P less than 0.1),1681:1876,2010104,389265,Unavailable
2010104,Time from first relapse to death ,Chemotherapy + Bacille Calmette-Guérin vaccine,Chemotherapy alone,No significant difference,There was no significant increase in the duration of first remission in the C+I group (0.05 less than P less than 0.1) nor in the time from first relapse to death (0.05 less than P less than 0.1),1681:1876,2010104,389265,Unavailable
2010104,Incidence of first remision,Chemotherapy + Bacille Calmette-Guérin vaccine,Chemotherapy alone,No significant difference,There was no significant difference in the incidence of first or second remissions,1878:1960,2010104,389265,Unavailable
2010104,Incidence of second remision,Chemotherapy + Bacille Calmette-Guérin vaccine,Chemotherapy alone,No significant difference,There was no significant difference in the incidence of first or second remissions,1878:1960,2010104,389265,Unavailable
2010104,Time taken to enter remission,Chemotherapy + Bacille Calmette-Guérin vaccine,Chemotherapy alone,No significant difference,the time taken to enter remission did not differ significantly between the two groups.,1965:2052,2010104,389265,Unavailable
5755681,Exercise endurance time after 12 weeks,Umeclidinium/Vilanterol,Placebo,No significant difference,UMEC/VI treatment did not result in a statistically significant improvement in EET change from baseline at week 12 versus placebo (p=0.790).,4807:4964,5755681,29322050,Unavailable
5755681,FEV1 improvement after 12 weeks,Umeclidinium/Vilanterol,Placebo,Significantly increased,"However, improvements were observed in trough FEV1 (206 mL, 95% CI 167–246), 3-h post-dose FRC (−346 mL, 95% CI −487 to −204) and CAT score (−1.07 units, 95% CI −2.09 to −0.05) versus placebo at week 12.",29421:29561,5755681,29322050,Unavailable
5755681,3-h post-dose functional residual capacity after 12 weeks,Umeclidinium/Vilanterol,Placebo,Significantly increased,"However, improvements were observed in trough FEV1 (206 mL, 95% CI 167–246), 3-h post-dose FRC (−346 mL, 95% CI −487 to −204) and CAT score (−1.07 units, 95% CI −2.09 to −0.05) versus placebo at week 12.",29421:29561,5755681,29322050,Unavailable
5755681,COPD Assessment Test improvement after 12 weeks,Umeclidinium/Vilanterol,Placebo,Significantly increased,"However, improvements were observed in trough FEV1 (206 mL, 95% CI 167–246), 3-h post-dose FRC (−346 mL, 95% CI −487 to −204) and CAT score (−1.07 units, 95% CI −2.09 to −0.05) versus placebo at week 12.",29421:29561,5755681,29322050,Unavailable
5755681,Exercise endurance time after 12 weeks,Umeclidinium/Vilanterol,Placebo,No significant difference,"For the primary end-point, UMEC/VI did not result in a statistically significant improvement in EET change from baseline at week 12 compared with placebo (3.3 s, 95% CI −21.1–27.7; p=0.790)",22291:22481,5755681,29322050,Unavailable
5755681,Exercise endurance time after 6 weeks,Umeclidinium/Vilanterol,Placebo,Significantly increased,"Difference from placebo (95% CI)		27.6 (3.3–52.0)	0.026",26179:26375,5755681,29322050,Unavailable
5755681,Exercise endurance time after 2 days,Umeclidinium/Vilanterol,Placebo,Significantly increased,"Difference from placebo (95% CI)		27.2 (8.2–46.2)	0.005",25447:25643,5755681,29322050,Unavailable
5755681,FEV1 improvement after 12 weeks,Umeclidinium/Vilanterol,Placebo,Significantly increased,". For trough FEV1, treatment with UMEC/VI resulted in improvements compared with placebo at week 12 (206 mL, 95% CI 167–246)",29421:29561,5755681,29322050,Unavailable
5755681,3-h post-dose functional residual capacity after 12 weeks,Umeclidinium/Vilanterol,Placebo,Significantly increased,"Treatment with UMEC/VI resulted in improvements in 3-h post-dose FRC (−346 mL, 95% CI −487 to −204) (figure 3b) and 3-h post-dose inspiratory capacity (259 mL, 95% CI 194–324) (figure 3c) compared with placebo at week 12. Similar results were observed at day 2",28972:29306,5755681,29322050,Unavailable
5755681,3-h post-dose inspiratory capacity after 12 weeks,Umeclidinium/Vilanterol,Placebo,Significantly increased,"Treatment with UMEC/VI resulted in improvements in 3-h post-dose FRC (−346 mL, 95% CI −487 to −204) (figure 3b) and 3-h post-dose inspiratory capacity (259 mL, 95% CI 194–324) (figure 3c) compared with placebo at week 12. Similar results were observed at day 2",28972:29306,5755681,29322050,Unavailable
5755681,3-h post-dose functional residual capacity after 2 days,Umeclidinium/Vilanterol,Placebo,Significantly increased,"Treatment with UMEC/VI resulted in improvements in 3-h post-dose FRC (−346 mL, 95% CI −487 to −204) (figure 3b) and 3-h post-dose inspiratory capacity (259 mL, 95% CI 194–324) (figure 3c) compared with placebo at week 12. Similar results were observed at day 2",28972:29306,5755681,29322050,Unavailable
5755681,3-h post-dose inspiratory capacity after 2 days,Umeclidinium/Vilanterol,Placebo,Significantly increased,"Treatment with UMEC/VI resulted in improvements in 3-h post-dose FRC (−346 mL, 95% CI −487 to −204) (figure 3b) and 3-h post-dose inspiratory capacity (259 mL, 95% CI 194–324) (figure 3c) compared with placebo at week 12. Similar results were observed at day 2",28972:29306,5755681,29322050,Unavailable
5755681,COPD Assessment Test improvement after 12 weeks,Umeclidinium/Vilanterol,Placebo,Significantly increased,"Treatment with UMEC/VI also resulted in improvements in the CAT score compared with placebo at week 12 (−1.07 units, 95% CI −2.09 to −0.05).",29421:29561,5755681,29322050,Unavailable
5755681,Adverse events,Umeclidinium/Vilanterol,Placebo,No significant difference,The incidence of adverse events was similar between the UMEC/VI group (21%) and the placebo group (23%).,30169:30273,5755681,29322050,Unavailable
3636802,Number of visits to the Quit-smoking website,Content with a prescriptive tone,Content with a motivational tone ,No significant difference,"Adjusting for baseline readiness to quit, persons who received content written in a prescriptive tone made the same number of visits to the website as persons receiving content in a motivational tone,",7701:7901,3636802,23529377,Unavailable
3636802,Content areas viewed on the website,Content with a prescriptive tone,Content with a motivational tone ,Significantly increased,but viewed 1.17 times as many content areas (95% CI 1.08-1.28; P&lt;.001) and 1.15 times as many pages (95% CI 1.04-1.28; P=.009).,7902:8066,3636802,23529377,Unavailable
3636802,Pages viewed on the website,Content with a prescriptive tone,Content with a motivational tone ,Significantly increased,but viewed 1.17 times as many content areas (95% CI 1.08-1.28; P&lt;.001) and 1.15 times as many pages (95% CI 1.04-1.28; P=.009).,7902:8066,3636802,23529377,Unavailable
3636802,Time spent viewing materials on the website,Content with a prescriptive tone,Content with a motivational tone ,No significant difference,Time spent viewing materials did not differ among groups (P=.06).,8067:8149,3636802,23529377,Unavailable
3636802,Number of visits to the Quit-smoking website,Dictated order to view content,Freely navigating the site,No significant difference,Persons required to view content in a dictated order based on their initial readiness to quit made the same number of visits as people able to freely navigate the site,7902:8066,3636802,23529377,Unavailable
3636802,Content areas viewed on the website,Dictated order to view content,Freely navigating the site,Significantly decreased,"but viewed fewer content areas (ratio of means 0.80, 95% CI 0.74-0.87; P&lt;.001), 1.17 times as many pages (95% CI 1.06-1.31; P=.003), and spent 1.37 times more minutes online (95% CI 1.17-1.59; P&lt;.001).",8319:8575,3636802,23529377,Unavailable
3636802,Pages viewed on the website,Dictated order to view content,Freely navigating the site,Significantly increased,"but viewed fewer content areas (ratio of means 0.80, 95% CI 0.74-0.87; P&lt;.001), 1.17 times as many pages (95% CI 1.06-1.31; P=.003), and spent 1.37 times more minutes online (95% CI 1.17-1.59; P&lt;.001).",8319:8574,3636802,23529377,Unavailable
3636802,Time spent viewing materials on the website,Dictated order to view content,Freely navigating the site,Significantly increased,"but viewed fewer content areas (ratio of means 0.80, 95% CI 0.74-0.87; P&lt;.001), 1.17 times as many pages (95% CI 1.06-1.31; P=.003), and spent 1.37 times more minutes online (95% CI 1.17-1.59; P&lt;.001).",8319:8575,3636802,23529377,Unavailable
3636802,Number of visits to the Quit-smoking website,Receiving proactive email reminders,No reminders,Significantly increased,"Persons receiving proactive email reminders made 1.20 times as many visits (95% CI 1.09-1.33; P&lt;.001),",8575:8697,3636802,23529377,Unavailable
3636802,Content areas viewed on the website,Receiving proactive email reminders,No reminders,No significant difference,viewed a similar number of content areas as persons receiving no reminders,8698:8772,3636802,23529377,Unavailable
3636802,Pages viewed on the website,Receiving proactive email reminders,No reminders,Significantly increased,viewed 1.58 times as many pages (95% CI 1.48-1.68; P&lt;.001),8773:8852,3636802,23529377,Unavailable
3636802,Time spent viewing materials on the website,Receiving proactive email reminders,No reminders,Significantly increased,and spent 1.51 times as many minutes online (95% CI 1.29-1.77; P&lt;.001) as those who did not receive proactive emails.,8854:8991,3636802,23529377,Unavailable
3636802,Number of visits to the Quit-smoking website,Inclusion of personally tailored testimonials,No testimonials,No significant difference,Tailored testimonials did not significantly affect engagement.,8992:9054,3636802,23529377,Unavailable
3636802,Content areas viewed on the website,Inclusion of personally tailored testimonials,No testimonials,No significant difference,Tailored testimonials did not significantly affect engagement.,8992:9054,3636802,23529377,Unavailable
3636802,Pages viewed on the website,Inclusion of personally tailored testimonials,No testimonials,Significantly increased,Tailored testimonials did not significantly affect engagement.,8991:9054,3636802,23529377,Unavailable
3636802,Time spent viewing materials on the website,Inclusion of personally tailored testimonials,No testimonials,Significantly increased,Tailored testimonials did not significantly affect engagement.,8991:9054,3636802,23529377,Unavailable
3636802,Number of visits to the Quit-smoking website,Content with a prescriptive tone,Content with a motivational tone ,No significant difference,"For example, after adjustment for baseline readiness to quit, the average number of website visits among those who received content written in a prescriptive tone was approximately the same as the average number of visits among those whose content was written in a motivational tone, yielding a ratio of means of 1.00 (95% CI 0.90-1.10; P=.93)",39582:39943,3636802,23529377,Unavailable
3636802,Content areas viewed on the website,Content with a prescriptive tone,Content with a motivational tone ,Significantly increased,"However, those viewing content in a prescriptive tone viewed an average of 1.17 times more content areas (95% CI 1.08-1.28; P&lt;.001), and 1.15 times more content pages (95% CI 1.04-1.28; P=.009) than those whose content was written in a motivational tone.",39945:40237,3636802,23529377,Unavailable
3636802,Pages viewed on the website,Content with a prescriptive tone,Content with a motivational tone ,Significantly increased,"However, those viewing content in a prescriptive tone viewed an average of 1.17 times more content areas (95% CI 1.08-1.28; P&lt;.001), and 1.15 times more content pages (95% CI 1.04-1.28; P=.009) than those whose content was written in a motivational tone.",39945:40236,3636802,23529377,Unavailable
3636802,Time spent viewing materials on the website,Content with a prescriptive tone,Content with a motivational tone ,No significant difference,"Duration of time spent viewing materials did not differ statistically between the 2 levels of the tone factor (ratio of means 0.87, 95% CI 0.75-1.01; P=.06).",40237:40411,3636802,23529377,Unavailable
3636802,Number of visits to the Quit-smoking website,Dictated order to view content,Freely navigating the site,No significant difference,Persons required to view content in a dictated order based on their initial readiness to quit made approximately the same average number of visits as people able to freely navigate the site,40884:41073,3636802,23529377,Unavailable
3636802,Content areas viewed on the website,Dictated order to view content,Freely navigating the site,Significantly decreased,"but viewed fewer content areas on average (ratio of means 0.80, 95% CI 0.74-0.87; P&lt;.001),",41075:41185,3636802,23529377,Unavailable
3636802,Pages viewed on the website,Dictated order to view content,Freely navigating the site,Significantly increased,"viewed 1.17 times as many pages (95% CI 1.06-1.31; P=.003),",41186:41265,3636802,23529377,Unavailable
3636802,Time spent viewing materials on the website,Dictated order to view content,Freely navigating the site,Significantly increased,and spent 1.37 times as many minutes online (95% CI 1.17-1.59; P&lt;.001).,41266:41355,3636802,23529377,Unavailable
3636802,Number of visits to the Quit-smoking website,Receiving proactive email reminders,No reminders,Significantly increased,Persons receiving proactive email reminders had an average of 1.20 times as many website visits resulting in content views (95% CI 1.09-1.33; P&lt;.001),40412:40578,3636802,23529377,Unavailable
3636802,Content areas viewed on the website,Receiving proactive email reminders,No reminders,No significant difference,but visited a similar number of content areas as persons receiving no reminders.,40580:40660,3636802,23529377,Unavailable
3636802,Pages viewed on the website,Receiving proactive email reminders,No reminders,Significantly increased,"Individuals with proactive email reminders viewed 1.58 times as many content pages (95% CI 1.48-1.68; P&lt;.001), and spent 1.51 times as many minutes online (95% CI 1.29-1.77; P&lt;.001).",40660:40883,3636802,23529377,Unavailable
3636802,Time spent viewing materials on the website,Receiving proactive email reminders,No reminders,Significantly increased,"Individuals with proactive email reminders viewed 1.58 times as many content pages (95% CI 1.48-1.68; P&lt;.001), and spent 1.51 times as many minutes online (95% CI 1.29-1.77; P&lt;.001).",40661:40883,3636802,23529377,Unavailable
3636802,Number of visits to the Quit-smoking website,Inclusion of personally tailored testimonials,No testimonials,No significant difference,There were no significant differences in the average number of visits to the website or content areas viewed between participants who did and did not receive the personally tailored testimonials.,41355:41550,3636802,23529377,Unavailable
3636802,Content areas viewed on the website,Inclusion of personally tailored testimonials,No testimonials,No significant difference,There were no significant differences in the average number of visits to the website or content areas viewed between participants who did and did not receive the personally tailored testimonials.,41355:41550,3636802,23529377,Unavailable
3636802,Pages viewed on the website,Inclusion of personally tailored testimonials,No testimonials,Significantly increased,There were no significant differences in the average number of visits to the website or content areas viewed between participants who did and did not receive the personally tailored testimonials.,41355:41550,3636802,23529377,Unavailable
3636802,Time spent viewing materials on the website,Inclusion of personally tailored testimonials,No testimonials,Significantly increased,There were no significant differences in the average number of visits to the website or content areas viewed between participants who did and did not receive the personally tailored testimonials.,41355:41550,3636802,23529377,Unavailable
5844531,HIV treatement retention,Family Clinic Day intervention,No intervention,No significant difference,"The FCD did not improve retention (aOR 1.11; 90% CI 0.63–1.97, p = 0.75), but was associated with improved adherence to last appointment schedule (aOR 1.64; 90% CI 1.27–2.11, p&lt;0.001).",17541:17726,5844531,29522530,Unavailable
5844531,Adherence to last appointment schedule,Family Clinic Day intervention,No intervention,Significantly increased,"The FCD did not improve retention (aOR 1.11; 90% CI 0.63–1.97, p = 0.75), but was associated with improved adherence to last appointment schedule (aOR 1.64; 90% CI 1.27–2.11, p&lt;0.001).",17541:17726,5844531,29522530,Unavailable
5844531,HIV treatement retention,Family Clinic Day intervention,No intervention,No significant difference,"patients enrolled in care at an intervention facility had an 11% higher odds of being retained in care as compared to that of control facilities (Table 5, Model 2), but the difference was not significant (90% CI 0.63 − 1.97, p value 0.75)",80398:80690,5844531,29522530,Unavailable
5844531,Adherence to last appointment schedule,Family Clinic Day intervention,No intervention,Significantly increased,"patients receiving care from intervention were 67% more likely to be adherent to their appointment that participants from control facilities (90% CI 1.27−2.11, p value &lt;0.001)",81657:81832,5844531,29522530,Unavailable
3757794,Difficulty of intubation scale score,Trueview laryngoscope,Macintosh laryngoscope,No significant difference,The IDS score was low and comparable between the two laryngoscopes.,3860:3927,3757794,24015124,Unavailable
3757794,Ease for laryngeal view,Trueview laryngoscope,Macintosh laryngoscope,No significant difference,Modified Cormack Lehane (MCL) grade 2a or less in 98.14% of the cases with the Truview laryngoscope compared to 78.7% of the cases with the Macintosh laryngoscope.,15916:16066,3757794,24015124,Unavailable
3757794,Duration of intubation,Trueview laryngoscope,Macintosh laryngoscope,No significant difference,The duration of intubation was comparable between Truview and Macintosh laryngoscopes (12.1±3.8 s vs. 10.9±2.1 s),3957:4120,3757794,24015124,Unavailable
3757794,Difficulty of intubation scale score,Trueview laryngoscope,Macintosh laryngoscope,No significant difference,"IDS score of 0 in the Truview group (98.1%) was comparable to the Macintosh group (92.5%), which suggested easy intubation with both the laryngoscopes",15916:16066,3757794,24015124,Unavailable
3757794,Ease for laryngeal view,Trueview laryngoscope,Macintosh laryngoscope,No significant difference,The laryngeal view was easy (MCL grade 2a or less) in 98.14% of the cases with the Truview laryngoscope compared to 78.7% of the cases with the Macintosh laryngoscope.,16117:16284,3757794,24015124,Unavailable
3757794,Difficulty percentage of glottic opening,Trueview laryngoscope,Macintosh laryngoscope,No significant difference,The POGO score was comparable in both the groups.,16431:16480,3757794,24015124,Unavailable
3757794,Duration of intubation,Trueview laryngoscope,Macintosh laryngoscope,No significant difference,"The average time of intubation was slightly more with the Truview laryngoscope (12.1±3.8s) compared to the Macintosh laryngoscope (10.9±2.1s); however, the difference was not statistically significant.",16481:16682,3757794,24015124,Unavailable
3757794,Ease of use of the laryngoscope,Trueview laryngoscope,Macintosh laryngoscope,No significant difference,The Visual analogue scale VAS score used to assess the ease of use of the laryngoscope showed no statistically significant difference between both the laryngoscopes.,16683:16848,3757794,24015124,Unavailable
3682318,Colonization of insertion sites,Honey + standard care in cathether site,Standard care,No significant difference,"Colonization of insertion sites was not affected by the use of medical-grade honey, as 44 (34%) of 129 and 36 (34%) of 106 patients in the honey and standard care groups, respectively, had a positive skin culture (P = 0.98).",6406:6611,3682318,23111148,Unavailable
3682318,Level of skin colonization,Honey + standard care in cathether site,Standard care,No significant difference,"Median levels of skin colonization at the last sampling were 1 (0 to 2.84) and 1 (0 to 2.70) log colony-forming units (CFUs)/swab for the honey and control groups, respectively (P = 0.94)",6406:6611,3682318,23111148,Unavailable
3682318,Colonization of insertion sites,Honey + standard care in cathether site,Standard care,No significant difference,"In both the honey-treated group and the control group, 34% of the patients had a positive skin culture (defined as &gt;100 CFUs) at the last sampling point",21632:21785,3682318,23111148,Unavailable
3682318,Level of skin colonization,Honey + standard care in cathether site,Standard care,No significant difference,"Median (IQR) levels of skin colonization at the last sampling were 1 (0 to 2.84) and 1 (0 to 2.70) log CFU/swab for the honey and control groups, respectively (P = 0.94).",21839:22026,3682318,23111148,Unavailable
3682318,Length of stay in UCI,Honey + standard care in cathether site,Standard care,No significant difference,"Median ICU length of stay was 9 (4 to 18) and 9 (5 to 16) days for patients in the honey-treated and control groups, respectively (P = 0.67).",24690:24848,3682318,23111148,Unavailable
3682318,Duration of catheter use,Honey + standard care in cathether site,Standard care,No significant difference,Median duration of catheter use was 5 (3 to 7) days for both study groups (P = 0.32).,24849:24951,3682318,23111148,Unavailable
3682318,ICU mortality ,Honey + standard care in cathether site,Standard care,No significant difference,"ICU mortality was 24% and 23% in the honey and control groups, respectively (P = 0.88),",24951:25056,3682318,23111148,Unavailable
3682318,Total mortality ,Honey + standard care in cathether site,Standard care,No significant difference,and total hospital mortality was 36% and 34% for the respective groups (P = 0.89).,25056:25156,3682318,23111148,Unavailable
3682318,Removing cathether due to suspected infection,Honey + standard care in cathether site,Standard care,No significant difference,"Suspected infection, n (%)	20 (16)	15 (14)	0.77",25819:25946,3682318,23111148,Unavailable
3682318,Removing cathether due to dysfunction,Honey + standard care in cathether site,Standard care,No significant difference,"Dysfunction, n (%)	5 (4)	4 (4)	0.97",25977:26092,3682318,23111148,Unavailable
3682318,Removing cathether due to death of patient,Honey + standard care in cathether site,Standard care,No significant difference,"Patient died, n (%)	19 (15)	18 (17)	0.64",26123:26243,3682318,23111148,Unavailable
3682318,Removing cathether due to death of patient's discharge,Honey + standard care in cathether site,Standard care,No significant difference,"Patient discharged, n (%)	31 (24)	30 (28)	0.46",26274:26400,3682318,23111148,Unavailable
3682318,Coagulase-negative staphylococci isolation,Honey + standard care in cathether site,Standard care,No significant difference,"Coagulase-negative staphylococci (CoNSs) were the most frequently isolated bacteria at insertion sites, accounting for 62% and 60% of all isolated microorganisms in the honey and control groups, respectively.",28006:28214,3682318,23111148,Unavailable
3682318,Enterococci isolation,Honey + standard care in cathether site,Standard care,No significant difference,Enterococci were isolated in 30% of positive skin cultures for both study groups.,28215:28296,3682318,23111148,Unavailable
3682318,Microbial growth in blood,Honey + standard care in cathether site,Standard care,No significant difference,"Eleven (16%) of 70 and six (13%) of 48 (P = 0.79) blood samples from patients in the honey-treated and control groups, respectively, were positive for microbial growth.",28450:28636,3682318,23111148,Unavailable
1543618,CAPS-scores improvement,Cognitive behavioral treatment,Control,Significantly increased,CAPS-scores showed significantly greater improvement in the CBT condition as compared to the wait list condition,4468:4580,1543618,16824221,Unavailable
1543618,Reduction in co-morbid major depression,Cognitive behavioral treatment,Control,Significantly increased,"Additionally, patients of the CBT condition showed significantly greater reductions in co-morbid major depression than the control condition.",4815:4956,1543618,16824221,Unavailable
1543618,Posttraumatic stress disorder symptoms reduction,Cognitive behavioral treatment,Control,Significantly increased,"A between group comparison at post-test by ANCOVA (controlled for pre-values) revealed that the CBT condition showed greater PTSD symptom reduction than WLC (F [1, 39] = 23.47, p &lt; 0.001, d = 1.55).",25197:25395,1543618,16824221,Unavailable
1543618,Post-treatment full recovery in non-PTSD patients,Cognitive behavioral treatment,Control,Significantly increased,"CBT was superior to Wait List (Chi2 [1, N = 21] = 3.70, p &lt; 0.05) post-treatment.",28353:28445,1543618,16824221,Unavailable
1543618,Recovery rate in major depressive disorder patients,Cognitive behavioral treatment,Control,Significantly increased,"Chi squares test revealed, for those with MDD (49% of the sample), that CBT led to a significantly higher rate of recovery than Wait List (Chi2 [1, N = 21] = 5.74, p &lt; 0.05).",29048:29233,1543618,16824221,Unavailable
1543618,Intrusive symptoms improvement,Cognitive behavioral treatment,Control,Significantly increased,"IESR-Intrusion	Pre	21.7a	20.0a	F = 28.5, p &lt; 0.001	F = 28.8, p &lt; 0.001,",30679:30888,1543618,16824221,Unavailable
1543618,Avoidance symptoms improvement,Cognitive behavioral treatment,Control,Significantly increased,"IESR-Avoidance	Pre	19.0a	16.5a	F = 10.7, p &lt; 0.01	F = 10.4, p &lt; 0.01",31233:31439,1543618,16824221,Unavailable
1543618,Hyperarousal improvement,Cognitive behavioral treatment,Control,Significantly increased,"IESR-Hyperarousal	Pre	20.1a	20.7a	F = 11.9 p &lt; 0.001	F = 8.9, p &lt; 0.01",31785:31993,1543618,16824221,Unavailable
1543618,Depressive symptoms improvement,Cognitive behavioral treatment,Control,No significant difference,"BDI Pre 17.9a 16.0a F = 4.9 p &lt; 0.05 F = 6.6, p = 0.14",32338:32530,1543618,16824221,Unavailable
1543618,State-Trait Anxiety Inventory improvement,Cognitive behavioral treatment,Control,Significantly increased,"STAI	Pre	50.5a	49.1a	F = 6.4 p &lt; 0.01	F = 6.5, p &lt; 0.01",32873:33066,1543618,16824221,Unavailable
1543618,Posttraumatic Cognitions Inventory improvement,Cognitive behavioral treatment,Control,Significantly increased,"PTCI	Pre	123.3a	107.9a	F = 20.2 p &lt; 0.001	F = 16.7, p &lt; 0.001",33413:33612,1543618,16824221,Unavailable
4707160,Number of cigarettes smoked,FNP intervention,Control,No significant difference,"Reported number of cigarettes smoked per day at late pregnancy did not differ between groups for women (n=610) classified at baseline as smokers (adjusted difference in means 0·12 cigarettes, 97·5% CI −0·73 to 0·97; table 2).",32261:32527,4707160,26474809,Unavailable
4707160,Mean birthweights of babies,FNP intervention,Control,No significant difference,"Mean birthweights of babies were 3217·4 g (SD 618·0 g) for babies of women assigned to FNP and 3197·5 g (581·5 g) for those of women assigned to usual care, an adjusted difference of 20·75 g (97·5% CI −47·73 to 89·23).",32528:32746,4707160,26474809,Unavailable
4707160,Having a second pregnancy within 24 months,FNP intervention,Control,No significant difference,The proportion of women with a second pregnancy within 24 months of their first child's birth did not differ between the FNP (66%) and usual care (66%) groups,32747:32905,4707160,26474809,Unavailable
4707160,Emergency attendances or hospital admissions within 24 months of birth,FNP intervention,Control,No significant difference,"Rates of emergency attendances or hospital admissions within 24 months of birth included in the analysis were 81% for FNP and 77% usual care group (OR 1·32, 97·5% CI 0·99–1·76).",33109:33286,4707160,26474809,Unavailable
4707160,Having at least one serious adverse event,FNP intervention,Control,No significant difference,The proportion of participants with at least one serious adverse event (mainly clinical events associated with pregnancy and infancy period) was similar (310 [38%] of 808 mother–child dyads in the usual care group vs 357 [44%] of 810 participants in the FNP group),35893:36174,4707160,26474809,Unavailable
1829425,Making a case assessment,Computer intervention,Control,Significantly increased,"Intervention physicians exceeded controls on “Assess” (OR 5.06; 95% CI 3.22, 7.95)",4517:4599,1829425,17372796,Unavailable
1829425,Advising patients,Computer intervention,Control,Significantly increased,"“Advise” (OR 2.79; 95% CI 1.70, 4.59)",4601:4638,1829425,17372796,Unavailable
1829425,Setting goals,Computer intervention,Control,Significantly increased,"“Assist–set goals” (OR 4.31; 95% CI 2.59, 7.16)",4640:4687,1829425,17372796,Unavailable
1829425,Providing written materials,Computer intervention,Control,Significantly increased,"“Assist–set goals” (OR 4.31; 95% CI 2.59, 7.16)",4640:4687,1829425,17372796,Unavailable
1829425,Making referrals,Computer intervention,Control,Significantly increased,"“Assist–provide referral” (OR 6.48; 95% CI 3.11, 13.49)",4754:4810,1829425,17372796,Unavailable
1829425,Discussing medications,Computer intervention,Control,Significantly increased,"“Assist–discuss medication” (OR 4.72;95% CI 2.90, 7.68)",4812:4867,1829425,17372796,Unavailable
1829425,Arranging follow-ups,Computer intervention,Control,Significantly increased,"and “Arrange” (OR 8.14; 95% CI 3.98, 16.68), all p values being &lt; 0.0001.",4869:4959,1829425,17372796,Unavailable
1829425,Being abstinent ,Computer intervention,Control,No significant difference,"Intervention patients were 1.77 (CI 0.94, 3.34,p = 0.078) times more likely than controls to be abstinent (12 versus 8%), a difference that approached, but did not reach statistical significance",5176:5302,1829425,17372796,Unavailable
1829425,Longest quit attempt (in days),Computer intervention,Control,Significantly increased,"and surpassed controls on number of days quit (18.4 versus 12.2, p &lt; .05) but not on number of quit attempts.",25094:25182,1829425,17372796,Unavailable
1829425,Number of quit attempts,Computer intervention,Control,No significant difference,"and surpassed controls on number of days quit (18.4 versus 12.2, p &lt; .05) but not on number of quit attempts.",5176:5302,1829425,17372796,Unavailable
1829425,Making a case assessment,Computer intervention,Control,Significantly increased,"GEE generalized linear modeling indicated that intervention physicians exceeded controls on “Assess”, “Advise”, “Assist”, and “Arrange” (p &lt; 0.0001)",22713:22879,1829425,17372796,Unavailable
1829425,Advising patients,Computer intervention,Control,Significantly increased,"GEE generalized linear modeling indicated that intervention physicians exceeded controls on “Assess”, “Advise”, “Assist”, and “Arrange” (p &lt; 0.0001)",22713:22879,1829425,17372796,Unavailable
1829425,General assistance,Computer intervention,Control,Significantly increased,"GEE generalized linear modeling indicated that intervention physicians exceeded controls on “Assess”, “Advise”, “Assist”, and “Arrange” (p &lt; 0.0001)",22713:22879,1829425,17372796,Unavailable
1829425,Arranging follow-ups,Computer intervention,Control,Significantly increased,"GEE generalized linear modeling indicated that intervention physicians exceeded controls on “Assess”, “Advise”, “Assist”, and “Arrange” (p &lt; 0.0001)",22713:22878,1829425,17372796,Unavailable
1829425,Making a case assessment,Computer intervention,Control,Significantly increased,"twice as many intervention as control physicians assessed patients’ readiness to quit smoking (OR 5.06; 95% CI 3.22, 7.95)",22955:23077,1829425,17372796,Unavailable
1829425,Advising patients,Computer intervention,Control,Significantly increased,"More intervention than control physicians advised their patients to quit smoking (OR 2.79; 95% CI 1.70, 4.59).",23079:23189,1829425,17372796,Unavailable
1829425,Setting goals,Computer intervention,Control,Significantly increased,"Two-to-four times as many intervention as control physicians provided quit-smoking assistance including: set goals (OR 4.31; 95% CI 2.59, 7.16)",23190:23333,1829425,17372796,Unavailable
1829425,Providing written materials,Computer intervention,Control,Significantly increased,"provided written materials (OR 5.14; 95% CI 2.60, 10.14)",23334:23391,1829425,17372796,Unavailable
1829425,Making referrals,Computer intervention,Control,Significantly increased,"and referred to a quit-smoking program (OR 6.48; 95% CI 3.11, 13.49)",23462:23530,1829425,17372796,Unavailable
1829425,Discussing medications,Computer intervention,Control,Significantly increased,"discussed smoking cessation medication (OR 4.72; 95% CI 2.90, 7.68)",23393:23460,1829425,17372796,Unavailable
1829425,Arranging follow-ups,Computer intervention,Control,Significantly increased,"Finally, intervention physicians arranged a follow-up to discuss smoking at 5 times the rate of control physicians (OR 8.14; 95% CI 3.98, 16.68).",23532:23677,1829425,17372796,Unavailable
1829425,Being abstinent ,Computer intervention,Control,No significant difference,"Seven-day point-prevalence abstinence was higher in the intervention group (12%) than the control group (8%), a difference that approached, but did not reach significance (OR 1.77; 95% CI 0.94, 3.34, p = .078)",24216:24442,1829425,17372796,Unavailable
1829425,Longest quit attempt (in days),Computer intervention,Control,Significantly increased,Longest quit attempt in days: M (SD) 18.4 (36.7) 12.4 (29.6) 0.05,25094:25182,1829425,17372796,Unavailable
1829425,Number of quit attempts,Computer intervention,Control,No significant difference,"Number of 24-hour quit attempts: M (SD)	2.1 (3.4)	2.1 (3.5)	0.91",25094:25182,1829425,17372796,Unavailable
3531527,Hemodynamic variables,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"Significant differences were not observed between the two groups in terms of hemodynamic variables, respiratory variables, and inspiratory and expiratory desflurane concentrations.",4931:5111,3531527,23277809,Unavailable
3531527,Respiratory variables,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"Significant differences were not observed between the two groups in terms of hemodynamic variables, respiratory variables, and inspiratory and expiratory desflurane concentrations.",4931:5111,3531527,23277809,Unavailable
3531527,Inspiratory desflurane concentration,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"Significant differences were not observed between the two groups in terms of hemodynamic variables, respiratory variables, and inspiratory and expiratory desflurane concentrations.",4931:5111,3531527,23277809,Unavailable
3531527,Expiratory desflurane concentration,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"Significant differences were not observed between the two groups in terms of hemodynamic variables, respiratory variables, and inspiratory and expiratory desflurane concentrations.",4931:5111,3531527,23277809,Unavailable
3531527, Inspiratory O2 concentration,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,Significantly decreased,Inspiratory O2 concentration was maintained lower in the MF group than in the HF group (43-53% vs. 53-59%; P &lt; 0.05).,5111:5240,3531527,23277809,Unavailable
3531527,Carboxyhemoglobin,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,Significantly increased,"Compared with the HF group, COHb concentrations was higher (P &lt; 0.05)",5240:5310,3531527,23277809,Unavailable
3531527,Aspartate transaminase,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"Serum AST, ALT, BUN, and creatinine were not significantly different between the two groups.",5370:5463,3531527,23277809,Unavailable
3531527,Alanine Aminotransferase,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"Serum AST, ALT, BUN, and creatinine were not significantly different between the two groups.",5370:5463,3531527,23277809,Unavailable
3531527,Blood Urea Nitrogen,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"Serum AST, ALT, BUN, and creatinine were not significantly different between the two groups.",5370:5463,3531527,23277809,Unavailable
3531527,Creatinine,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"Serum AST, ALT, BUN, and creatinine were not significantly different between the two groups.",5370:5463,3531527,23277809,Unavailable
3531527,Heart rate,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"The changes in heart rate, systolic blood pressure, and diastolic blood pressure during laparoscopic surgery are shown in Fig. 1. These hemodynamic parameters were maintained within ± 20% of baseline and were not significantly different between the groups during the study period.",11962:12279,3531527,23277809,Unavailable
3531527,Systolic blood pressure,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"The changes in heart rate, systolic blood pressure, and diastolic blood pressure during laparoscopic surgery are shown in Fig. 1. These hemodynamic parameters were maintained within ± 20% of baseline and were not significantly different between the groups during the study period.",11962:12279,3531527,23277809,Unavailable
3531527,Diastolic blood pressure,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"The changes in heart rate, systolic blood pressure, and diastolic blood pressure during laparoscopic surgery are shown in Fig. 1. These hemodynamic parameters were maintained within ± 20% of baseline and were not significantly different between the groups during the study period.",11962:12279,3531527,23277809,Unavailable
3531527,Inspiratory desflurane concentration,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,Inspiratory and expiratory desflurane concentration did not differ significantly between the groups during the study period.,12617:12742,3531527,23277809,Unavailable
3531527,Expiratory desflurane concentration,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,Inspiratory and expiratory desflurane concentration did not differ significantly between the groups during the study period.,12618:12742,3531527,23277809,Unavailable
3531527,PaO2 at 2 hours,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,Significantly decreased,"Inspiratory O2 concentration was maintained at 53-59% in the HF group and at 43-53% in the MF group. At 2, 4, and 6 hours after induction, PaO2 was significantly lower in the MF group than in the HF group (P &lt; 0.05).",12855:12966,3531527,23277809,Unavailable
3531527,PaO2 at 4 hours,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,Significantly decreased,"Inspiratory O2 concentration was maintained at 53-59% in the HF group and at 43-53% in the MF group. At 2, 4, and 6 hours after induction, PaO2 was significantly lower in the MF group than in the HF group (P &lt; 0.05).",12855:12966,3531527,23277809,Unavailable
3531527, PaO2 at 6 hours,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,Significantly decreased,"Inspiratory O2 concentration was maintained at 53-59% in the HF group and at 43-53% in the MF group. At 2, 4, and 6 hours after induction, PaO2 was significantly lower in the MF group than in the HF group (P &lt; 0.05).",12855:12966,3531527,23277809,Unavailable
3531527, Inspiratory O2 concentration,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,Significantly decreased,Inspiratory O2 concentration was maintained at 53-59% in the HF group and at 43-53% in the MF group,12855:12966,3531527,23277809,Unavailable
3531527,Blood pH,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"In contrast, pH, PaCO2 and HCO3- were not different between the groups",13094:13201,3531527,23277809,Unavailable
3531527,PaCO2,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"In contrast, pH, PaCO2 and HCO3- were not different between the groups",12855:12966,3531527,23277809,Unavailable
3531527,HCO3-,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"In contrast, pH, PaCO2 and HCO3- were not different between the groups",12855:12966,3531527,23277809,Unavailable
3531527,Carboxyhemoglobin,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,Significantly increased,The COHb concentration was significantly higher in the MF group than in the HF group (P &lt; 0.05).,13258:13354,3531527,23277809,Unavailable
3531527,Aspartate transaminase,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"However, significant differences were not observed in AST, ALT, BUN, and creatinine between the two groups throughout the study period.",13984:14119,3531527,23277809,Unavailable
3531527,Alanine Aminotransferase,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"However, significant differences were not observed in AST, ALT, BUN, and creatinine between the two groups throughout the study period.",13983:14119,3531527,23277809,Unavailable
3531527,Blood Urea Nitrogen,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"However, significant differences were not observed in AST, ALT, BUN, and creatinine between the two groups throughout the study period.",13984:14119,3531527,23277809,Unavailable
3531527,Creatinine,Minimal-flow desflurane anesthesia,Conventional high-flow desflurane anesthesia,No significant difference,"However, significant differences were not observed in AST, ALT, BUN, and creatinine between the two groups throughout the study period.",13984:14119,3531527,23277809,Unavailable
3805553,non-REM Slow-wave activity in the frontal derivation,2590 meter altitude ,490 meter altitude ,Significantly decreased,"SWA in non-REM sleep was reduced in an altitude-dependent manner, by 4.4% (p&lt;0.05) in the first night at 1630 m in derivation F3A2 only and 16% (N1) and 13% (N2) in F3A2 as well as 15% (N1) and 14% (N2) in C3A2 (p&lt;0.0001) at 2590 m compared to 490 m.",54838:54901,3805553,24167552,Unavailable
3805553,non-REM Slow-wave activity in the central derivation,2590 meter altitude ,490 meter altitude ,Significantly decreased,"SWA in non-REM sleep was reduced in an altitude-dependent manner, by 4.4% (p&lt;0.05) in the first night at 1630 m in derivation F3A2 only and 16% (N1) and 13% (N2) in F3A2 as well as 15% (N1) and 14% (N2) in C3A2 (p&lt;0.0001) at 2590 m compared to 490 m.",54838:54901,3805553,24167552,Unavailable
3805553,REM Slow-wave activity in the central derivation,2590 meter altitude ,490 meter altitude ,Significantly decreased,SWA was reduced by 9% (N1) and 11% (N2) in C3A2 only (p&lt;0.01),54838:54901,3805553,24167552,Unavailable
3805553,REM theta activity in the frontal derivation,2590 meter altitude ,490 meter altitude ,Significantly decreased,and theta activity by 13% (N1) and 10% (N2) in F3A2 and 14% (N1) and 13% (N2) in C3A2 compared to 490 m.,54900:55005,3805553,24167552,Unavailable
3805553,REM theta activity in the central derivation,2590 meter altitude ,490 meter altitude ,Significantly decreased,and theta activity by 13% (N1) and 10% (N2) in F3A2 and 14% (N1) and 13% (N2) in C3A2 compared to 490 m.,54900:55005,3805553,24167552,Unavailable
3805553,Frequency range of sleep spindles,2590 meter altitude ,490 meter altitude ,No significant difference,"Although the mixed model ANOVA revealed an altitude effect in the frequency range of sleep spindles, post-hoc analysis did not show altitude related changes",55072:55246,3805553,24167552,Unavailable
5735451,Surgical field quality,Dexmedetomidine,Magnesium Sulfate,Significantly increased,The quality of the surgical field intraoperatively was significantly better in dexmedetomidine group as well as the blood loss was significantly less in D group,18348:18509,5735451,29284876,Unavailable
5735451,Blood loss ,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,The quality of the surgical field intraoperatively was significantly better in dexmedetomidine group as well as the blood loss was significantly less in D group,18348:18509,5735451,29284876,Unavailable
5735451,Intraoperative fentanyl consumption,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,"As regards fentanyl consumption, total dose of the fentanyl used intraoperatively was lower in D group than M group",18840:18955,5735451,29284876,Unavailable
5735451,FLACC scale score,Dexmedetomidine,Magnesium Sulfate,No significant difference,"As regards FLACC score, it was lower in D group than M group with no significant differences",19214:19307,5735451,29284876,Unavailable
5735451,Recovery time,Dexmedetomidine,Magnesium Sulfate,No significant difference,"Regarding recovery (modified Aldrete score), it was slightly longer in D group than in Mg group (P &gt; 0.05) with no significant difference",19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after intubation,Dexmedetomidine,Magnesium Sulfate,No significant difference,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 10 min,Dexmedetomidine,Magnesium Sulfate,No significant difference,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 20 min,Dexmedetomidine,Magnesium Sulfate,No significant difference,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 30 min,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 40 min,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 50 min,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 60 min,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 70 min,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 80 min,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 90 min,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate in PACU,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 15 min in PACU,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Heart rate after 30 min in PACU,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,HR was significantly lower in all times except the initial stage till 30 min intraoperative in D group as compared to M group. P &lt; 0.05,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after intubation,Dexmedetomidine,Magnesium Sulfate,No significant difference,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 10 min into surgery,Dexmedetomidine,Magnesium Sulfate,No significant difference,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 20 min into surgery,Dexmedetomidine,Magnesium Sulfate,No significant difference,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 30 min into surgery,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 40 min into surgery,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 50 min into surgery,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 60 min into surgery,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 70 min into surgery,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 80 min into surgery,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 90 min into surgery,Dexmedetomidine,Magnesium Sulfate,Significantly decreased,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure in PACU,Dexmedetomidine,Magnesium Sulfate,No significant difference,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 15 min in PACU,Dexmedetomidine,Magnesium Sulfate,No significant difference,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
5735451,Mean arterial pressure after 30 min in PACU,Dexmedetomidine,Magnesium Sulfate,No significant difference,MAP values were significantly lower in all times (P &lt; 0.001) except the initial stages till 30 min intraoperatively and in PACU in D group as compared to M group,19586:19741,5735451,29284876,Unavailable
3562170,Blood glucose,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,Significantly increased,Blood glucose was higher (p &lt;  0.05) after 50 min of submaximal cycling just prior to the WAnT for CE (6.1 ± 1.7 mmol/L) compared to W (4.9 ± 1.5 mmol/L) and NCE (4.6 ± 1.2 mmol/L).,5314:5462,3562170,23347391,Unavailable
3562170,Blood glucose,Flavored carbohydrate-electrolyte drink,Water,Significantly increased,Blood glucose was higher (p &lt;  0.05) after 50 min of submaximal cycling just prior to the WAnT for CE (6.1 ± 1.7 mmol/L) compared to W (4.9 ± 1.5 mmol/L) and NCE (4.6 ± 1.2 mmol/L).,5118:5313,3562170,23347391,Unavailable
3562170,Peak power on first Wingate anaerobic tests,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,No significant difference,"Nonetheless, there were no differences among treatments in peak (642 ± 153, 635 ± 143, 650 ± 141 watts for W, NCE, and CE, respectively; p  =  0.44)",5463:5587,3562170,23347391,Unavailable
3562170,Peak power on first Wingate anaerobic tests,Flavored carbohydrate-electrolyte drink,Water,No significant difference,"Nonetheless, there were no differences among treatments in peak (642 ± 153, 635 ± 143, 650 ± 141 watts for W, NCE, and CE, respectively; p  =  0.44)",5463:5587,3562170,23347391,Unavailable
3562170,Peak power on first Wingate anaerobic tests,Non-caloric electrolyte drink,Water,No significant difference,"Nonetheless, there were no differences among treatments in peak (642 ± 153, 635 ± 143, 650 ± 141 watts for W, NCE, and CE, respectively; p  =  0.44)",5463:5587,3562170,23347391,Unavailable
3562170,Mean power on first Wingate anaerobic tests,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,No significant difference,"or mean (455 ± 100, 458 ± 95, 454 ± 95 watts for W, NCE, and CE, respectively; p = 0.62) power for the first WAnT",5463:5587,3562170,23347391,Unavailable
3562170,Mean power on first Wingate anaerobic tests,Flavored carbohydrate-electrolyte drink,Water,No significant difference,"or mean (455 ± 100, 458 ± 95, 454 ± 95 watts for W, NCE, and CE, respectively; p = 0.62) power for the first WAnT",5463:5587,3562170,23347391,Unavailable
3562170,Mean power on first Wingate anaerobic tests,Non-caloric electrolyte drink,Water,No significant difference,"or mean (455 ± 100, 458 ± 95, 454 ± 95 watts for W, NCE, and CE, respectively; p = 0.62) power for the first WAnT",5463:5587,3562170,23347391,Unavailable
3562170,Average power on all Wingate anaerobic tests,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,No significant difference,"or mean (414 ± 92, 425 ± 85, 423 ± 82 watts, respectively; p = 0.13) power output averaged across all 3 WAnT",5588:5707,3562170,23347391,Unavailable
3562170,Average power on all Wingate anaerobic tests,Flavored carbohydrate-electrolyte drink,Water,No significant difference,"or mean (414 ± 92, 425 ± 85, 423 ± 82 watts, respectively; p = 0.13) power output averaged across all 3 WAnT",5588:5707,3562170,23347391,Unavailable
3562170,Average power on all Wingate anaerobic tests,Non-caloric electrolyte drink,Water,No significant difference,"or mean (414 ± 92, 425 ± 85, 423 ± 82 watts, respectively; p = 0.13) power output averaged across all 3 WAnT",5588:5707,3562170,23347391,Unavailable
3562170,Rating of perceived exertion during submaximal exercise,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Rating of perceived exertion during submaximal exercise,Flavored carbohydrate-electrolyte drink,Water,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Rating of perceived exertion during submaximal exercise,Non-caloric electrolyte drink,Water,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Session rating of perceived exertion ,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Session rating of perceived exertion ,Flavored carbohydrate-electrolyte drink,Water,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Session rating of perceived exertion ,Non-caloric electrolyte drink,Water,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Fatigue,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Fatigue,Flavored carbohydrate-electrolyte drink,Water,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Fatigue,Non-caloric electrolyte drink,Water,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Vigor ,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Vigor ,Flavored carbohydrate-electrolyte drink,Water,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Vigor ,Non-caloric electrolyte drink,Water,No significant difference,"Likewise, RPE during submaximal exercise, session RPE, and fatigue and vigor assessed by POMS did not differ among beverage treatments (p &gt; 0.05).",5708:5855,3562170,23347391,Unavailable
3562170,Blood glucose,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,Significantly increased,"because of the provision of 49 ± 22 g of carbohydrates in the CE trial, blood glucose was ~ 25% and ~ 32% higher than the W and NCE treatments, respectively",31751:31907,3562170,23347391,Unavailable
3562170,Blood glucose,Flavored carbohydrate-electrolyte drink,Water,Significantly increased,"because of the provision of 49 ± 22 g of carbohydrates in the CE trial, blood glucose was ~ 25% and ~ 32% higher than the W and NCE treatments, respectively",31751:31907,3562170,23347391,Unavailable
3562170,Rating of perceived exertion during submaximal exercise,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,No significant difference,Ratings of perceived exertion by time point and beverage (mean ± SD). †  =  (p  &lt;  0.001) between RPE for all other time points during 50 min of sub-maximal cycling. No main effect exhibited for beverage type during sub-maximal cycling (p  =  0.72) or for S (p  =  0.88).,33683:33961,3562170,23347391,Unavailable
3562170,Rating of perceived exertion during submaximal exercise,Flavored carbohydrate-electrolyte drink,Water,No significant difference,Ratings of perceived exertion by time point and beverage (mean ± SD). †  =  (p  &lt;  0.001) between RPE for all other time points during 50 min of sub-maximal cycling. No main effect exhibited for beverage type during sub-maximal cycling (p  =  0.72) or for S (p  =  0.88).,33683:33961,3562170,23347391,Unavailable
3562170,Rating of perceived exertion during submaximal exercise,Non-caloric electrolyte drink,Water,No significant difference,Ratings of perceived exertion by time point and beverage (mean ± SD). †  =  (p  &lt;  0.001) between RPE for all other time points during 50 min of sub-maximal cycling. No main effect exhibited for beverage type during sub-maximal cycling (p  =  0.72) or for S (p  =  0.88).,33683:33961,3562170,23347391,Unavailable
3562170,Session rating of perceived exertion ,Flavored carbohydrate-electrolyte drink,Non-caloric electrolyte drink,No significant difference,Ratings of perceived exertion by time point and beverage (mean ± SD). †  =  (p  &lt;  0.001) between RPE for all other time points during 50 min of sub-maximal cycling. No main effect exhibited for beverage type during sub-maximal cycling (p  =  0.72) or for S (p  =  0.88).,33683:33961,3562170,23347391,Unavailable
3562170,Session rating of perceived exertion ,Flavored carbohydrate-electrolyte drink,Water,No significant difference,Ratings of perceived exertion by time point and beverage (mean ± SD). †  =  (p  &lt;  0.001) between RPE for all other time points during 50 min of sub-maximal cycling. No main effect exhibited for beverage type during sub-maximal cycling (p  =  0.72) or for S (p  =  0.88).,33683:33961,3562170,23347391,Unavailable
3562170,Session rating of perceived exertion ,Non-caloric electrolyte drink,Water,No significant difference,Ratings of perceived exertion by time point and beverage (mean ± SD). †  =  (p  &lt;  0.001) between RPE for all other time points during 50 min of sub-maximal cycling. No main effect exhibited for beverage type during sub-maximal cycling (p  =  0.72) or for S (p  =  0.88).,33683:33961,3562170,23347391,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness after 2 years of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Two years after randomisation, the proportion of patients with abnormal ET was significantly lower in the exemestane compared with tamoxifen arm (36% versus 62%, respectively; P = 0.004).",6066:6310,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness after 6 months of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,"This difference emerged within 6 months of switching treatment (43.5% versus 65.2%, respectively; P = 0.01) and disappeared within 12 months of treatment completion (30.8% versus 34.7%, respectively; P = 0.67).",6066:6310,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness 12 months after end of treatment,Change to exemestane,Continue with tamoxifen,No significant difference,"This difference emerged within 6 months of switching treatment (43.5% versus 65.2%, respectively; P = 0.01) and disappeared within 12 months of treatment completion (30.8% versus 34.7%, respectively; P = 0.67).",6066:6310,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness after 2 years of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,ET ≥5 mm was found in 35.5% [95% confidence interval (CI) 23.6% to 47.4%] of patients switched to exemestane and in 61.8% (95% CI 49.0% to 74.7%) of those continuing tamoxifen (P = 0.004,36269:36473,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness after 6 months of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,The difference in the proportion of patients with abnormal ET had emerged by 6 months after randomisation (43.5% exemestane versus 65.2% tamoxifen; P = 0.01) and persisted throughout the protocol treatment period.,36526:36756,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness 12 months after end of treatment,Change to exemestane,Continue with tamoxifen,No significant difference,"Within 12 months of treatment completion, there were no differences in the proportion of patients with abnormal ET (30.8% exemestane versus 34.7% tamoxifen; P = 0.67).",36757:36941,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness after 6 months of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,"6 months	69	30 (43.5)	69	45 (65.2)	0.01",37947:38256,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness after 12 months of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,"12 months	61	19 (31.2)	61	35 (57.4)	0.004",38298:38609,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness after 2 years of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,"24 months	62	22 (35.5)	55	34 (61.8)	0.004a",38657:39080,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness by the end of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,"EoT	54	15 (27.8)	53	33 (62.3)	&lt;0.001",39129:39435,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness 12 months after end of treatment,Change to exemestane,Continue with tamoxifen,No significant difference,"EoT + 12 months	52	16 (30.8)	49	17 (34.7)	0.67",39480:39796,2826098,19717534,Unavailable
2826098,Proportion of patients with abnormal ET endometrial thickness 24 months after end of treatment,Change to exemestane,Continue with tamoxifen,No significant difference,"EoT + 24 months	46	16 (34.8)	38	13 (34.2)	0.96",39838:40154,2826098,19717534,Unavailable
2826098,Uterine volume after 6 months of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,"In consequence, 6 months after randomisation, the difference in mean change between the two treatment groups (−13.5 cm3; 95% CI −21.7 to −5.2) was highly significant (P = 0.002).",44363:44570,2826098,19717534,Unavailable
2826098,Uterine volume after 12 months of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Again, the observed difference was maintained after 12 and 24 months, with difference in mean changes of −22.1 cm3 (95% CI −32.8 to −11.4; P = 0.0001) and −18.9 cm3 (95% CI −30.4 to −7.5; P = 0.001), respectively.",44570:44839,2826098,19717534,Unavailable
2826098,Uterine volume after 24 months of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Again, the observed difference was maintained after 12 and 24 months, with difference in mean changes of −22.1 cm3 (95% CI −32.8 to −11.4; P = 0.0001) and −18.9 cm3 (95% CI −30.4 to −7.5; P = 0.001), respectively.",44570:44839,2826098,19717534,Unavailable
2826098,Uterine volume 12 months after end of treatment,Change to exemestane,Continue with tamoxifen,Significantly decreased,Mean change from baseline in uterine volume continued to differ between the treatment groups at 12 months after EoT (−16 cm3; 95% CI −28.7 to −3.3; P = 0.01) but no significant difference was seen 24 months after EoT.,44840:45085,2826098,19717534,Unavailable
2826098,Uterine volume 24 months after end of treatment,Change to exemestane,Continue with tamoxifen,No significant difference,Mean change from baseline in uterine volume continued to differ between the treatment groups at 12 months after EoT (−16 cm3; 95% CI −28.7 to −3.3; P = 0.01) but no significant difference was seen 24 months after EoT.,44840:45085,2826098,19717534,Unavailable
2826098,Gynaecological symptoms,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Gynaecological symptoms	128	128	256	11.0	156	210	366	15.7	&lt;0.001",46979:47529,2826098,19717534,Unavailable
2826098,Serious  gynaecological symptoms,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Serious gynaecological symptoms	70	55	125	5.4	90	103	193	8.3	&lt;0.001",47578:48131,2826098,19717534,Unavailable
2826098,Endometrial hyperplasia,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Endometrial hyperplasia	0	1	1	0.0	1	19	20	0.9	&lt;0.001",48176:48714,2826098,19717534,Unavailable
2826098,Genital pruritis,Change to exemestane,Continue with tamoxifen,No significant difference,"Genital pruritis female	19	0	19	0.8	21	7	28	1.2	0.2",48759:49296,2826098,19717534,Unavailable
2826098,Hot flashes,Change to exemestane,Continue with tamoxifen,No significant difference,"Hot flashes	955	2	957	41.3	901	2	903	38.6	0.07",49338:49870,2826098,19717534,Unavailable
2826098,Hysterectomy,Change to exemestane,Continue with tamoxifen,No significant difference,"Hysterectomy	0	17	17	0.7	0	25	25	1.1	0.22",49912:50439,2826098,19717534,Unavailable
2826098,Uterine dilation and curettage,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Uterine D&amp;C	0	12	12	0.5	0	29	29	1.2	0.01",50481:51011,2826098,19717534,Unavailable
2826098,Uterine polyps/fibroids,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Uterine polyps/fibroids	1	23	24	1.0	1	64	65	2.8	&lt;0.001",51053:51593,2826098,19717534,Unavailable
2826098,Vaginal discharge,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Vaginal discharge	53	12	65	2.8	79	12	91	3.9	0.04",51638:52172,2826098,19717534,Unavailable
2826098,Vulvovaginal dryness,Change to exemestane,Continue with tamoxifen,No significant difference,"Vulvovaginal dryness	53	2	55	2.4	47	4	51	2.2	0.67",52214:52749,2826098,19717534,Unavailable
2826098,Metrorrhagia/vaginal bleeding,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Metrorrhagia/vaginal bleeding	80	23	103	4.4	116	42	158	6.8	0.002",52791:53341,2826098,19717534,Unavailable
2826098,Vaginal prolapse/uterine prolapse,Change to exemestane,Continue with tamoxifen,Significantly decreased,"Vaginal prolapse/uterine prolapse	4	23	27	1.2	2	11	13	0.6	0.02",53383:53931,2826098,19717534,Unavailable
2826098,Vaginal infections,Change to exemestane,Continue with tamoxifen,No significant difference,"Vaginitis/vaginitis atrophic/vaginal candidiasis/vaginal infection	13	27	40	1.7	12	28	40	1.7	0.97",53973:54556,2826098,19717534,Unavailable
5557574,Maintaining MAP &gt;60 mmHg,Selepressin 2.5 ng/kg/minute ,Selepressin 1.25 ng/kg/minute,Significantly increased,"A higher proportion of the patients receiving 2.5 ng/kg/minute selepressin maintained MAP &gt;60 mmHg without norepinephrine (about 50% and 70% at 12 and 24 h, respectively) vs. 1.25 ng/kg/minute selepressin and placebo (p &lt; 0.01).",8995:9153,5557574,28807037,Unavailable
5557574,Maintaining MAP &gt;60 mmHg,Selepressin 2.5 ng/kg/minute ,Placebo,Significantly increased,"A higher proportion of the patients receiving 2.5 ng/kg/minute selepressin maintained MAP &gt;60 mmHg without norepinephrine (about 50% and 70% at 12 and 24 h, respectively) vs. 1.25 ng/kg/minute selepressin and placebo (p &lt; 0.01).",8995:9153,5557574,28807037,Unavailable
5557574,7-day cumulative doses of norepinephrine,Selepressin 2.5 ng/kg/minute,Placebo,Significantly decreased,"The 7-day cumulative doses of norepinephrine were 761, 659, and 249 μg/kg (placebo 1.25 ng/kg/minute and 2.5 ng/kg/minute, respectively; 2.5 ng/kg/minute vs. placebo; p &lt; 0.01).",8995:9153,5557574,28807037,Unavailable
5557574, Reducing speed of norepinephrine infusion ,Selepressin 2.5 ng/kg/minute,Placebo,Significantly increased,"Norepinephrine infusion was weaned more rapidly in selepressin 2.5 ng/kg/minute vs. placebo (0.04 vs. 0.18 μg/kg/minute at 24 h, p &lt; 0.001), successfully maintaining target MAP and reducing norepinephrine dose vs. placebo (first 24 h, p &lt; 0.001).",29703:30011,5557574,28807037,Unavailable
5557574,Norepinephrine dose,Selepressin 2.5 ng/kg/minute,Placebo,Significantly decreased,"Norepinephrine infusion was weaned more rapidly in selepressin 2.5 ng/kg/minute vs. placebo (0.04 vs. 0.18 μg/kg/minute at 24 h, p &lt; 0.001), successfully maintaining target MAP and reducing norepinephrine dose vs. placebo (first 24 h, p &lt; 0.001).",8995:9153,5557574,28807037,Unavailable
5557574,Cumulative net fluid balance,Selepressin 2.5 ng/kg/minute,Placebo,Significantly decreased,Cumulative net fluid balance was lower from day 5 onward in the selepressin 2.5 ng/kg/minute group vs. placebo (p &lt; 0.05).,8995:9153,5557574,28807037,Unavailable
5557574,Proportion of days alive and free of ventilation,Selepressin 2.5 ng/kg/minute,Placebo,Significantly increased,The selepressin 2.5 ng/kg/minute group had a greater proportion of days alive and free of ventilation vs. placebo (p &lt; 0.02).,8995:9153,5557574,28807037,Unavailable
5557574,Treatment-emergent adverse events,Selepressin 2.5 ng/kg/minute,Placebo,No significant difference,"Selepressin (2.5 ng/kg/minute) was well tolerated, with a similar frequency of treatment-emergent adverse events for selepressin 2.5 ng/kg/minute and placebo.",8995:9153,5557574,28807037,Unavailable
5557574,Maintaining MAP  &gt;60 mmHg,Selepressin 2.5 ng/kg/minute ,Selepressin 1.25 ng/kg/minute,Significantly increased,"The swift onset of action of selepressin was illustrated by the high proportion of patients receiving 2.5 ng/kg/minute selepressin who early on maintained MAP &gt;60 mmHg without norepinephrine (about 50% at 12 h and 70% at 24 h) (Fig. 2). In contrast, in the placebo and 1.25 ng/kg/minute selepressin groups, no patient was free of norepinephrine at 12 h and ≤20% were free of norepinephrine at 24 h (p &lt; 0.01).",28683:29151,5557574,28807037,Unavailable
5557574,Maintaining MAP  &gt;60 mmHg,Selepressin 2.5 ng/kg/minute ,Placebo,Significantly increased,"The swift onset of action of selepressin was illustrated by the high proportion of patients receiving 2.5 ng/kg/minute selepressin who early on maintained MAP &gt;60 mmHg without norepinephrine (about 50% at 12 h and 70% at 24 h) (Fig. 2). In contrast, in the placebo and 1.25 ng/kg/minute selepressin groups, no patient was free of norepinephrine at 12 h and ≤20% were free of norepinephrine at 24 h (p &lt; 0.01).",28683:29151,5557574,28807037,Unavailable
5557574,7-day cumulative doses of norepinephrine,Selepressin 2.5 ng/kg/minute,Placebo,Significantly decreased,"The 7-day baseline adjusted mean cumulative doses of open-label norepinephrine were 761, 659, and 249 μg/kg for the placebo, 1.25 ng/kg/minute, and 2.5 ng/kg/minute groups, respectively (p &lt; 0.001 for 2.5 ng/kg/minute vs. placebo groups) (Fig. 3a).",29703:30011,5557574,28807037,Unavailable
5557574, Reducing speed of norepinephrine infusion ,Selepressin 2.5 ng/kg/minute,Placebo,Significantly increased,"Furthermore, the norepinephrine mean infusion rate was initially reduced more rapidly in the selepressin 2.5 ng/kg/minute group than in the placebo group; at 24 h, the infusion rates were 0.04 vs. 0.18 μg/kg/minute (p &lt; 0.005)",30011:30254,5557574,28807037,Unavailable
5557574,Recovery speed,Selepressin 2.5 ng/kg/minute,Selepressin 1.25 ng/kg/minute,No significant difference,"Selepressin at 2.5 ng/kg/minute appeared to result in a faster recovery from shock (off vasopressors, including selepressin) than 1.25 ng/kg/minute and placebo, but without statistical significance (58% vs. 29%, p = 0.11, at 48 h)",31243:31491,5557574,28807037,Unavailable
5557574,Recovery speed,Selepressin 2.5 ng/kg/minute,Placebo,No significant difference,"Selepressin at 2.5 ng/kg/minute appeared to result in a faster recovery from shock (off vasopressors, including selepressin) than 1.25 ng/kg/minute and placebo, but without statistical significance (58% vs. 29%, p = 0.11, at 48 h)",31243:31491,5557574,28807037,Unavailable
5557574,28-day mortality rate,Selepressin 2.5 ng/kg/minute,Selepressin 1.25 ng/kg/minute,No significant difference,"There was no significant difference between groups in 28-day mortality rates (placebo 4 [21%] of 19, selepressin 1.25 ng/kg/minute 5 [50%] of 10, selepressin 2.5 ng/kg/minute 1 [5%] of 19).",31575:31764,5557574,28807037,Unavailable
5557574,28-day mortality rate,Selepressin 2.5 ng/kg/minute,Placebo,No significant difference,"There was no significant difference between groups in 28-day mortality rates (placebo 4 [21%] of 19, selepressin 1.25 ng/kg/minute 5 [50%] of 10, selepressin 2.5 ng/kg/minute 1 [5%] of 19).",31575:31764,5557574,28807037,Unavailable
5557574,28-day mortality rate,Selepressin 1.25 ng/kg/minute,Placebo,No significant difference,"There was no significant difference between groups in 28-day mortality rates (placebo 4 [21%] of 19, selepressin 1.25 ng/kg/minute 5 [50%] of 10, selepressin 2.5 ng/kg/minute 1 [5%] of 19).",31575:31764,5557574,28807037,Unavailable
5557574,Proportion of days alive and free of ventilation,Selepressin 2.5 ng/kg/minute,Placebo,Significantly increased,"The proportion of days alive and free of ventilation was greater in the selepressin 2.5 ng/kg/minute group than in the placebo group (54% vs. 23%, p &lt; 0.02) over the 7-day treatment period.",31902:32108,5557574,28807037,Unavailable
5557574,Proportion of days alive and free of ventilation,Selepressin 1.25 ng/kg/minute,Placebo,No significant difference,There was no difference between the 1.25 ng/kg/minute (31%) and placebo groups,32109:32187,5557574,28807037,Unavailable
5557574,Cumulative net fluid balance,Selepressin 2.5 ng/kg/minute,Placebo,Significantly decreased,"Selepressin at 2.5 ng/kg/minute decreased the cumulative net fluid balance over the treatment period compared with the 1.25 ng/kg/minute and placebo groups (from about 9 L to 6.5 L, p = 0.1) (Fig. 4), and compared with placebo, the difference was significant (p &lt; 0.05)",32283:32625,5557574,28807037,Unavailable
5557574,UCI length of stay,Selepressin 2.5 ng/kg/minute,Selepressin 1.25 ng/kg/minute,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,UCI length of stay,Selepressin 2.5 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,UCI length of stay,Selepressin 1.25 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma C-reactive protein,Selepressin 2.5 ng/kg/minute,Selepressin 1.25 ng/kg/minute,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma C-reactive protein,Selepressin 2.5 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma C-reactive protein,Selepressin 1.25 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma TNF-α,Selepressin 2.5 ng/kg/minute,Selepressin 1.25 ng/kg/minute,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma TNF-α,Selepressin 2.5 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma TNF-α,Selepressin 1.25 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma IL-6,Selepressin 2.5 ng/kg/minute,Selepressin 1.25 ng/kg/minute,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma IL-6,Selepressin 2.5 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma IL-6,Selepressin 1.25 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma IL-10,Selepressin 2.5 ng/kg/minute,Selepressin 1.25 ng/kg/minute,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma IL-10,Selepressin 2.5 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma IL-10,Selepressin 1.25 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma IL-1 receptor antagonist,Selepressin 2.5 ng/kg/minute,Selepressin 1.25 ng/kg/minute,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma IL-1 receptor antagonist,Selepressin 2.5 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Plasma IL-1 receptor antagonist,Selepressin 1.25 ng/kg/minute,Placebo,No significant difference,"There were no significant differences between groups in length of stay in the ICU or hospital up to 28 days; in plasma CRP, TNF-α, IL-6, IL-10, or IL-1ra levels; or in any other secondary morbidity endpoint.",33362:33569,5557574,28807037,Unavailable
5557574,Treatment-emergent adverse events,Selepressin 2.5 ng/kg/minute,Placebo,No significant difference,"Selepressin was well tolerated, with no difference between selepressin dose groups and placebo in terms of treatment-emergent adverse events.",34389:34530,5557574,28807037,Unavailable
5557574,Treatment-emergent adverse events,Selepressin 1.25 ng/kg/minute,Placebo,No significant difference,"Selepressin was well tolerated, with no difference between selepressin dose groups and placebo in terms of treatment-emergent adverse events.",34389:34530,5557574,28807037,Unavailable
3544598,Adequate Clinical and Parasitological Response,Artesunate/amodiaquine (AS+AQ),Artemether/lumefantrine (AL),No significant difference,"ACRP in ITT after PCR correction did not show any statistical difference between the two groups with 97.6% for AS+AQ versus 94.8% for AL. In the PP analysis, the corrected ACRP were respectively 98.7% and 96.9% for the two regimens.",6643:6876,3544598,23270636,Unavailable
3544598,Clinical tolerance,Artesunate/amodiaquine (AS+AQ),Artemether/lumefantrine (AL),No significant difference,The clinical tolerance was good without significant difference.,6877:6940,3544598,23270636,Unavailable
3544598,Adequate Clinical and Parasitological Response,Artesunate/amodiaquine (AS+AQ),Artemether/lumefantrine (AL),No significant difference,"The ACRP at D28 after PCR correction in ITT analysis was 97.6% for AS+AQ versus 94.8% for AL (difference 0.027 95% CI [-0.006; 0.062]) (p= 0.11). In PP analysis, it was 98.7% in AS+AQ arm versus 96.9% in AL arm (difference 0.18 95% CI [-0.007; 0.044] (p= 0.16).",23971:24233,3544598,23270636,Unavailable
3544598,Incidence of failure rate,Artesunate/amodiaquine (AS+AQ),Artemether/lumefantrine (AL),No significant difference,The Kaplan Meier analysis didn’t show any significant difference between the two group in terms of incidence of failure rate (log rank test: p= 0.12),24664:24814,3544598,23270636,Unavailable
3544598,Crude parasitological failure,Artesunate/amodiaquine (AS+AQ),Artemether/lumefantrine (AL),No significant difference,"Crude parasitological failure at day 28	05/246 (2%)	10/227 (4.4%)	0.14",27199:27407,3544598,23270636,Unavailable
3544598,Incidence of failure rate,Artesunate/amodiaquine (AS+AQ),Artemether/lumefantrine (AL),No significant difference,"PCR adjusted failure rate at day 28	04/246 (1.6%)	09/227 (3.9%)	0.12",27463:27669,3544598,23270636,Unavailable
3544598,Adequate Clinical and Parasitological Response,Artesunate/amodiaquine (AS+AQ),Artemether/lumefantrine (AL),No significant difference,"PCR adjusted ACPR at day 28	242/246 (98.7%)	218/227 (96.9%)	0.16",27725:27927,3544598,23270636,Unavailable
3364678,Heparin consumption,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,Significantly decreased,The amount of heparin consumed by the second group was higher (P &lt;0.001),5874:5963,3364678,22666720,Unavailable
3364678,Pain level after 30 hours,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,Significantly decreased,the difference in the pain level between the 2 groups evaluated 30 hours post-operation was significant (P=0.016),6178:6291,3364678,22666720,Unavailable
3364678,Time of ICU stay,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,The mean time of intensive care unit stay was longer in the second group but it was not statistically significant.,6292:6407,3364678,22666720,Unavailable
3364678,Respiratory rate 12 hours after surgery,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"The respiration rate, evaluated 12, 24 and 48 hours after the surgery, was not different between the groups.",16436:16544,3364678,22666720,Unavailable
3364678,Respiratory rate 24 hours after surgery,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"The respiration rate, evaluated 12, 24 and 48 hours after the surgery, was not different between the groups.",16436:16544,3364678,22666720,Unavailable
3364678,Respiratory rate 48 hours after surgery,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"The respiration rate, evaluated 12, 24 and 48 hours after the surgery, was not different between the groups.",16436:16544,3364678,22666720,Unavailable
3364678,Oxygen saturation 12 hours after surgery,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,Significantly increased,"Oxygen saturation was measured 12, 24 and 48 hours after the surgery, and was higher in the first group during all post-operation evaluations. This difference was statistically significant in the evaluations that were performed during the first 24 hours after the surgery (P =.047)",16545:16846,3364678,22666720,Unavailable
3364678,Oxygen saturation 24 hours after surgery,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,Significantly increased,"Oxygen saturation was measured 12, 24 and 48 hours after the surgery, and was higher in the first group during all post-operation evaluations. This difference was statistically significant in the evaluations that were performed during the first 24 hours after the surgery (P =.047)",16545:16846,3364678,22666720,Unavailable
3364678,Oxygen saturation 48 hours after surgery,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"Oxygen saturation was measured 12, 24 and 48 hours after the surgery, and was higher in the first group during all post-operation evaluations. This difference was statistically significant in the evaluations that were performed during the first 24 hours after the surgery (P =.047)",16545:16846,3364678,22666720,Unavailable
3364678,Pain level after 6 hours,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"Pain level according to VAS was evaluated 6, 12, 18, 24, 30, 36, 42 and 48 hours after the surgery. The pain level evaluated 30 hours post-operation was significantly different between the 2 groups (P =.016), but was not significantly different at any other time point",16848:17133,3364678,22666720,Unavailable
3364678,Pain level after 12 hours,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"Pain level according to VAS was evaluated 6, 12, 18, 24, 30, 36, 42 and 48 hours after the surgery. The pain level evaluated 30 hours post-operation was significantly different between the 2 groups (P =.016), but was not significantly different at any other time point",16848:17133,3364678,22666720,Unavailable
3364678,Pain level after 18 hours,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"Pain level according to VAS was evaluated 6, 12, 18, 24, 30, 36, 42 and 48 hours after the surgery. The pain level evaluated 30 hours post-operation was significantly different between the 2 groups (P =.016), but was not significantly different at any other time point",16848:17133,3364678,22666720,Unavailable
3364678,Pain level after 24 hours,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"Pain level according to VAS was evaluated 6, 12, 18, 24, 30, 36, 42 and 48 hours after the surgery. The pain level evaluated 30 hours post-operation was significantly different between the 2 groups (P =.016), but was not significantly different at any other time point",16848:17133,3364678,22666720,Unavailable
3364678,Pain level after 30 hours,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,Significantly decreased,"Pain level according to VAS was evaluated 6, 12, 18, 24, 30, 36, 42 and 48 hours after the surgery. The pain level evaluated 30 hours post-operation was significantly different between the 2 groups (P =.016), but was not significantly different at any other time point",16848:17133,3364678,22666720,Unavailable
3364678,Pain level after 36 hours,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"Pain level according to VAS was evaluated 6, 12, 18, 24, 30, 36, 42 and 48 hours after the surgery. The pain level evaluated 30 hours post-operation was significantly different between the 2 groups (P =.016), but was not significantly different at any other time point",16848:17133,3364678,22666720,Unavailable
3364678,Pain level after 42 hours,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"Pain level according to VAS was evaluated 6, 12, 18, 24, 30, 36, 42 and 48 hours after the surgery. The pain level evaluated 30 hours post-operation was significantly different between the 2 groups (P =.016), but was not significantly different at any other time point",16848:17133,3364678,22666720,Unavailable
3364678,Pain level after 48 hours,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"Pain level according to VAS was evaluated 6, 12, 18, 24, 30, 36, 42 and 48 hours after the surgery. The pain level evaluated 30 hours post-operation was significantly different between the 2 groups (P =.016), but was not significantly different at any other time point",16848:17133,3364678,22666720,Unavailable
3364678,Time of ICU stay,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,No significant difference,"The mean time of ICU stay was longer in the second group, but it was not significantly different between the groups",17223:17338,3364678,22666720,Unavailable
3364678,Heparin consumption,Tube removal within the first 24 hours after surgery,Tube removal within the second 24 hours after surgery,Significantly decreased,"However, the amount of heparin consumed by the second group was higher (P &lt;.001)",16251:16348,3364678,22666720,Unavailable
5830038,Cerebral metabolic rate of glucose in cortical grey matter,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly decreased,"During acute hyperketonemia CMRglu was reduced 14% in cortical grey matter; KET (19.6±0.8 mmol/100g/min) compared with CTR (22.8±1.3 mmol/100g/min), p = 0.02 (t-test)",32384:32561,5830038,29489818,Unavailable
5830038,Cerebral metabolic rate of glucose in frontal region,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly decreased,"The same was found in frontal, temporal, parietal, and occipital regions, with the largest reduction in the frontal region",32624:32746,5830038,29489818,Unavailable
5830038,Cerebral metabolic rate of glucose in temporal region,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly decreased,"The same was found in frontal, temporal, parietal, and occipital regions, with the largest reduction in the frontal region",32624:32746,5830038,29489818,Unavailable
5830038,Cerebral metabolic rate of glucose in parietal region,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly decreased,"The same was found in frontal, temporal, parietal, and occipital regions, with the largest reduction in the frontal region",32624:32746,5830038,29489818,Unavailable
5830038,Cerebral metabolic rate of glucose in occipital region,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly decreased,"The same was found in frontal, temporal, parietal, and occipital regions, with the largest reduction in the frontal region",32624:32746,5830038,29489818,Unavailable
5830038,Plasma glucose concentrations,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly decreased,"plasma glucose concentrations remained slightly lower during KET compared with CTR, p&lt;0.001",32953:33045,5830038,29489818,Unavailable
5830038, Lactate concentration,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly increased,"Lactate concentration was higher (p = 0.02 (main effect, ANOVA)) during KET compared with CTR",33177:33270,5830038,29489818,Unavailable
5830038,Cerebral blood flow in cortical grey matter,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly increased,"CBF increased 30% during acute hyperketonemia in cortical grey matter during KET (52.0±2.0 ml/100 g/min) compared with CTR (40.9±2.1 ml/100 g/min), p&lt;0.001(t-test)",40931:41094,5830038,29489818,Unavailable
5830038,Cerebral blood flow in frontal region,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly increased,"CBF increased 30% during acute hyperketonemia in cortical grey matter during KET (52.0±2.0 ml/100 g/min) compared with CTR (40.9±2.1 ml/100 g/min), p&lt;0.001(t-test) (Fig 3B), the same pattern being observed in the frontal, temporal, parietal and occipital regions",40931:41248,5830038,29489818,Unavailable
5830038,Cerebral blood flow in temporal region,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly increased,"CBF increased 30% during acute hyperketonemia in cortical grey matter during KET (52.0±2.0 ml/100 g/min) compared with CTR (40.9±2.1 ml/100 g/min), p&lt;0.001(t-test) (Fig 3B), the same pattern being observed in the frontal, temporal, parietal and occipital regions",40931:41248,5830038,29489818,Unavailable
5830038,Cerebral blood flow in parietal region,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly increased,"CBF increased 30% during acute hyperketonemia in cortical grey matter during KET (52.0±2.0 ml/100 g/min) compared with CTR (40.9±2.1 ml/100 g/min), p&lt;0.001(t-test) (Fig 3B), the same pattern being observed in the frontal, temporal, parietal and occipital regions",40931:41248,5830038,29489818,Unavailable
5830038,Cerebral blood flow in occipital region,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly increased,"CBF increased 30% during acute hyperketonemia in cortical grey matter during KET (52.0±2.0 ml/100 g/min) compared with CTR (40.9±2.1 ml/100 g/min), p&lt;0.001(t-test) (Fig 3B), the same pattern being observed in the frontal, temporal, parietal and occipital regions",40931:41248,5830038,29489818,Unavailable
5830038,Heart rate,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly increased,"Heart rate increased during KET (14±2 beats per minute) compared with CTR (2±1 beats per minute), p&lt;0.001 (t-test).",41369:41484,5830038,29489818,Unavailable
5830038,Mean arterial pressure,Ketone body infusion with 3-hydroxybutyrate,Control,No significant difference,"We found no difference in mean arterial pressure 100±3 mmHg(CTR) vs 97 mmHg(KET), p = 0.24 (t-test).",41485:41585,5830038,29489818,Unavailable
5830038,Arterial carbondioxide concentration,Ketone body infusion with 3-hydroxybutyrate,Control,No significant difference,Arterial carbondioxide concentration and pH was unchanged in the two conditions,41586:41665,5830038,29489818,Unavailable
5830038,pH,Ketone body infusion with 3-hydroxybutyrate,Control,No significant difference,Arterial carbondioxide concentration and pH was unchanged in the two conditions,41586:41665,5830038,29489818,Unavailable
5830038,Arterial oxygen partial pressure,Ketone body infusion with 3-hydroxybutyrate,Control,Significantly decreased,"arterial oxygen partial pressure was slightly and significantly higher during CTR (10.5±1.1 kPa) compared with KET (9.5±1.2 kPa), p = 0.01 (t-test).",41670:41818,5830038,29489818,Unavailable
5830038,Cerebral metabolic rate of oxigen in cortical grey matter,Ketone body infusion with 3-hydroxybutyrate,Control,No significant difference,"CMRo2 was unaltered during 3-OHB infusion CTR (128.1±4.4 umol/100 ml/min) vs KET (126.0±3.6 umol/100 ml/min), p = 0.71",41929:42058,5830038,29489818,Unavailable
5830038,Cerebral metabolic rate of oxigen in frontal region,Ketone body infusion with 3-hydroxybutyrate,Control,No significant difference,"Frontal	127.6±5.0	125.6±3.1	2.0 (1.6)	0.74",38955:39179,5830038,29489818,Unavailable
5830038,Cerebral metabolic rate of oxigen in parietal region,Ketone body infusion with 3-hydroxybutyrate,Control,No significant difference,"Parietal	131.2±4.6	127.5±4.2	3.7 (2.8)	0.55",39234:39459,5830038,29489818,Unavailable
5830038,Cerebral metabolic rate of oxigen in temporal region,Ketone body infusion with 3-hydroxybutyrate,Control,No significant difference,"Temporal	117.1±3.8	117.1±3.4	0.0 (0)	0.99",39514:39737,5830038,29489818,Unavailable
5830038,Cerebral metabolic rate of oxigen in occipital region,Ketone body infusion with 3-hydroxybutyrate,Control,No significant difference,"Occipital	142.2±4.5	139.1±5.3	3.1 (2.2)	0.65",39792:40018,5830038,29489818,Unavailable
4717542,Renal calcium excretion after 8 weeks,1 g phosphorus,Placebo,Significantly decreased,Renal calcium and magnesium excretion decreased significantly after eight weeks of P1000/Ca0 intervention compared to placebo.,26072:26249,4717542,26786148,Unavailable
4717542,Renal magnesium excretion after 8 weeks,1 g phosphorus,Placebo,Significantly decreased,Renal calcium and magnesium excretion decreased significantly after eight weeks of P1000/Ca0 intervention compared to placebo.,26072:26249,4717542,26786148,Unavailable
4717542,Renal calcium excretion after 4 weeks,1 g phosphorus,Placebo,Significantly decreased,The renal Ca excretion significantly decreased after four (p = 0.001) and eight (p = 0.029) weeks of P1000/Ca0 intervention compared to placebo,26072:26249,4717542,26786148,Unavailable
4717542,Renal calcium excretion after 8 weeks,1 g phosphorus,Placebo,Significantly decreased,The renal Ca excretion significantly decreased after four (p = 0.001) and eight (p = 0.029) weeks of P1000/Ca0 intervention compared to placebo,26072:26249,4717542,26786148,Unavailable
4717542,Fecal calcium concentration after 8 weeks,1 g phosphorus + 500 mg calcium,Placebo,Significantly increased,Fecal Ca concentrations were significantly increased after eight week intervention compared to placebo in the P1000/Ca500 (p ≤ 0.001) and P1000/Ca1000 (p ≤ 0.001) groups,26299:26502,4717542,26786148,Unavailable
4717542,Fecal calcium concentration after 8 weeks,1 g phosphorus + 1 g calcium,Placebo,Significantly increased,Fecal Ca concentrations were significantly increased after eight week intervention compared to placebo in the P1000/Ca500 (p ≤ 0.001) and P1000/Ca1000 (p ≤ 0.001) groups,26299:26502,4717542,26786148,Unavailable
4717542,Renal phosphate concentration after 8 weeks,1 g phosphorus + 1 g calcium,Placebo,Significantly increased,"After all interventions renal phosphate concentrations significantly increased after eight weeks compared to placebo (P1000/Ca0 p ≤ 0.001, P1000/Ca500 p = 0.007, P1000/Ca1000 p = 0.008)",30632:30868,4717542,26786148,Unavailable
4717542,Renal phosphate concentration after 8 weeks,1 g phosphorus + 500 mg calcium,Placebo,Significantly increased,"After all interventions renal phosphate concentrations significantly increased after eight weeks compared to placebo (P1000/Ca0 p ≤ 0.001, P1000/Ca500 p = 0.007, P1000/Ca1000 p = 0.008)",30632:30868,4717542,26786148,Unavailable
4717542,Renal phosphate concentration after 8 weeks,1 g phosphorus ,Placebo,Significantly increased,"After all interventions renal phosphate concentrations significantly increased after eight weeks compared to placebo (P1000/Ca0 p ≤ 0.001, P1000/Ca500 p = 0.007, P1000/Ca1000 p = 0.008)",30632:30868,4717542,26786148,Unavailable
4717542,Renal phosphate excretion after 4 weeks,1 g phosphorus ,Placebo,Significantly increased,In the P1000/Ca0 and P1000/Ca500 groups renal phosphate excretions increased after four weeks as well (both p ≤ 0.001),30917:31053,4717542,26786148,Unavailable
4717542,Renal phosphate excretion after 4 weeks,1 g phosphorus + 500 mg calcium,Placebo,Significantly increased,In the P1000/Ca0 and P1000/Ca500 groups renal phosphate excretions increased after four weeks as well (both p ≤ 0.001),30917:31053,4717542,26786148,Unavailable
4717542,Fecal phosphate concentration after 8 weeks,1 g phosphorus + 500 mg calcium,Placebo,Significantly increased,"Fecal P concentrations significantly increased after eight weeks of all interventions compared to placebo (P1000/Ca0 ≤ 0.001, P1000/Ca500 ≤ 0.001, P1000/Ca1000 p = 0.012)",31103:31290,4717542,26786148,Unavailable
4717542,Fecal phosphate concentration after 8 weeks,1 g phosphorus + 1 g calcium,Placebo,Significantly increased,"Fecal P concentrations significantly increased after eight weeks of all interventions compared to placebo (P1000/Ca0 ≤ 0.001, P1000/Ca500 ≤ 0.001, P1000/Ca1000 p = 0.012)",42100:42381,4717542,26786148,Unavailable
4717542,Fecal phosphate concentration after 8 weeks,1 g phosphorus ,Placebo,Significantly increased,"Fecal P concentrations significantly increased after eight weeks of all interventions compared to placebo (P1000/Ca0 ≤ 0.001, P1000/Ca500 ≤ 0.001, P1000/Ca1000 p = 0.012)",31103:31290,4717542,26786148,Unavailable
4717542,Plasma transferrin concentrations after 8 weeks,1 g phosphorus + 500 mg calcium,Placebo,Significantly increased,"Plasma transferrin concentrations increased significantly after eight weeks of intervention with P1000/Ca500 compared to placebo and four weeks (Table 4; placebo p ≤ 0.005, four weeks p ≤ 0.037).",31837:32136,4717542,26786148,Unavailable
4717542,Plasma transferrin concentrations after 4 weeks,1 g phosphorus + 500 mg calcium,Placebo,Significantly increased,"Plasma transferrin concentrations increased significantly after eight weeks of intervention with P1000/Ca500 compared to placebo and four weeks (Table 4; placebo p ≤ 0.005, four weeks p ≤ 0.037).",31837:32136,4717542,26786148,Unavailable
4717542,Vit D3 concentration after 8 weeks,1 g phosphorus ,Placebo,Significantly increased,"After eight weeks of P1000/Ca0 supplementation 1,25(OH)2D concentration in plasma increased significantly compared to placebo (p = 0.047)",34697:34862,4717542,26786148,Unavailable
4717542,Fibroblast growth factor after 4 weeks,1 g phosphorus + 1 g calcium,Placebo,Significantly increased,"In the P1000/Ca1000 group the concentration of FGF23 was significantly higher after four weeks compared to placebo, too (p = 0.020)",42100:42381,4717542,26786148,Unavailable
4717542,Osteocalcin concentration after 8 weeks,1 g phosphorus + 1 g calcium,Placebo,Significantly decreased,"Due to supplementation of P and Ca (P1000/Ca1000, P1000/Ca500) the concentrations of the bone formation marker osteocalcin significantly decreased after eight weeks of intervention compared to placebo (P1000/Ca500 p = 0.008; P1000/Ca1000 p ≤ 0.001",42100:42381,4717542,26786148,Unavailable
4717542,Osteocalcin concentration after 8 weeks,1 g phosphorus + 500 mg calcium,Placebo,Significantly decreased,"Due to supplementation of P and Ca (P1000/Ca1000, P1000/Ca500) the concentrations of the bone formation marker osteocalcin significantly decreased after eight weeks of intervention compared to placebo (P1000/Ca500 p = 0.008; P1000/Ca1000 p ≤ 0.001",42100:42381,4717542,26786148,Unavailable
4717542,Bone-specific alkaline phosphatase after 4 weeks,1 g phosphorus + 500 mg calcium,Placebo,Significantly decreased,Compared to placebo BAP concentration significantly decreased in the P1000/Ca500 supplemented group after four weeks of intervention (p ≤ 0.007).,42434:42596,4717542,26786148,Unavailable
4717542,Bone-specific alkaline phosphatase after 8 weeks,1 g phosphorus + 1 g calcium,Placebo,Significantly decreased,"In the P1000/Ca1000 supplemented group, the BAP concentration significantly decreased after four and eight weeks of intervention compared to placebo (four weeks p = 0.005; eight weeks p = 0.003).",42596:42826,4717542,26786148,Unavailable
4717542,Bone-specific alkaline phosphatase after 4 weeks,1 g phosphorus + 1 g calcium,Placebo,Significantly decreased,"In the P1000/Ca1000 supplemented group, the BAP concentration significantly decreased after four and eight weeks of intervention compared to placebo (four weeks p = 0.005; eight weeks p = 0.003).",42596:42826,4717542,26786148,Unavailable
4717542,CTX concentration after 8 weeks,1 g phosphorus + 500 mg calcium,Placebo,Significantly decreased,After P1000/Ca500 intervention the CTX concentration significantly decreased after eight weeks of intervention compared to placebo (p = 0.003).,43063:43223,4717542,26786148,Unavailable
5804062,Sitting clinic systolic blood pressure,Azilsartan medoxomil 40 mg,Placebo,Significantly decreased,"The least-squares mean (standard error) change from baseline in trough scSBP in the placebo, AZL-M 40-mg, and 80-mg groups at week 6 were − 8.8 (2.00), − 22.1 (1.41), and − 23.7 (1.40) mmHg, respectively (p &lt; 0.001 for AZL-M 40 and 80 mg vs placebo).",5484:5751,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,"The least-squares mean (standard error) change from baseline in trough scSBP in the placebo, AZL-M 40-mg, and 80-mg groups at week 6 were − 8.8 (2.00), − 22.1 (1.41), and − 23.7 (1.40) mmHg, respectively (p &lt; 0.001 for AZL-M 40 and 80 mg vs placebo).",5484:5751,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure,Azilsartan medoxomil 40 mg,Placebo,Significantly decreased,"For the primary endpoint, least squares (LS) mean reductions from baseline in trough scSBP to week 6 was 8.8 mmHg, 22.1 mmHg, and 23.7 mmHg in the placebo, AZL-M 40-mg, and AZL-M 80-mg groups, respectively. Relative to placebo, LS mean differences in scSBP were − 13.3 mmHg (95% CI –18.1 to − 8.5) in the AZL-M 40-mg group and − 15.0 mmHg (95% CI –19.8 to − 10.1) in the AZL-M 80-mg group (p &lt; 0.001 for both)",28494:28923,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,"For the primary endpoint, least squares (LS) mean reductions from baseline in trough scSBP to week 6 was 8.8 mmHg, 22.1 mmHg, and 23.7 mmHg in the placebo, AZL-M 40-mg, and AZL-M 80-mg groups, respectively. Relative to placebo, LS mean differences in scSBP were − 13.3 mmHg (95% CI –18.1 to − 8.5) in the AZL-M 40-mg group and − 15.0 mmHg (95% CI –19.8 to − 10.1) in the AZL-M 80-mg group (p &lt; 0.001 for both)",28494:28923,5804062,29445520,Unavailable
5804062,Sitting clinic diastolic blood pressure,Azilsartan medoxomil 40 mg,Placebo,Significantly decreased,"For the secondary efficacy endpoint, the LS mean reduction in baseline trough scDBP to week 6 was 2.1 mmHg, 10.8 mmHg, and 11.7 mmHg in the placebo, AZL-M 40-mg, and AZL-M 80-mg groups, respectively. LS mean differences for scDBP relative to placebo were − 8.7 mmHg (95% CI –11.5 to − 6.0) in the AZL-M 40-mg group and − 9.6 mmHg (95% CI –12.3 to − 6.9) in the AZL-M 80-mg group (p &lt; 0.001 for both)",29833:30249,5804062,29445520,Unavailable
5804062,Sitting clinic diastolic blood pressure,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,"For the secondary efficacy endpoint, the LS mean reduction in baseline trough scDBP to week 6 was 2.1 mmHg, 10.8 mmHg, and 11.7 mmHg in the placebo, AZL-M 40-mg, and AZL-M 80-mg groups, respectively. LS mean differences for scDBP relative to placebo were − 8.7 mmHg (95% CI –11.5 to − 6.0) in the AZL-M 40-mg group and − 9.6 mmHg (95% CI –12.3 to − 6.9) in the AZL-M 80-mg group (p &lt; 0.001 for both)",29833:30249,5804062,29445520,Unavailable
5804062,Achieving scSBP&lt; 140 mmHg and/or a reduction of ≥20 mmHg,Azilsartan medoxomil 40 mg,Placebo,Significantly increased,"The percentage of patients who achieved scSBP &lt; 140 mmHg and/or a reduction of ≥20 mmHg at week 6 was 38.1% (24/63) in the placebo group compared with 63.0% (80/127) in the AZL-M 40-mg group (odds ratio 2.8, 95% CI 1.5–5.3, p = 0.001) and 65.9% (85/129) in the AZL-M 80-mg group (odds ratio 3.3, 95% CI 1.8–6.3, p &lt; 0.001) (Fig. 4p &lt; 0.001)",30323:30759,5804062,29445520,Unavailable
5804062,Achieving scSBP&lt; 140 mmHg and/or a reduction of ≥20 mmHg,Azilsartan medoxomil 80 mg,Placebo,Significantly increased,"The percentage of patients who achieved scSBP &lt; 140 mmHg and/or a reduction of ≥20 mmHg at week 6 was 38.1% (24/63) in the placebo group compared with 63.0% (80/127) in the AZL-M 40-mg group (odds ratio 2.8, 95% CI 1.5–5.3, p = 0.001) and 65.9% (85/129) in the AZL-M 80-mg group (odds ratio 3.3, 95% CI 1.8–6.3, p &lt; 0.001) (Fig. 4p &lt; 0.001)",30323:30759,5804062,29445520,Unavailable
5804062,Achieving target response in both scSBP and scDBP,Azilsartan medoxomil 40 mg,Placebo,Significantly increased,"The percentage of patients who achieved the target response in both scSBP and scDBP was 25.4% (16/63) in the placebo group compared with 62.2% (79/127) in the AZL-M 40-mg group (odds ratio 4.9, 95% CI 2.5–9.7, p &lt; 0.001) and 65.9% (85/129) in the AZL-M 80-mg group (odds ratio 6.0, 95% CI 3.0–11.8, p &lt; 0.001)",30926:31272,5804062,29445520,Unavailable
5804062,Achieving target response in both scSBP and scDBP,Azilsartan medoxomil 80 mg,Placebo,Significantly increased,"The percentage of patients who achieved the target response in both scSBP and scDBP was 25.4% (16/63) in the placebo group compared with 62.2% (79/127) in the AZL-M 40-mg group (odds ratio 4.9, 95% CI 2.5–9.7, p &lt; 0.001) and 65.9% (85/129) in the AZL-M 80-mg group (odds ratio 6.0, 95% CI 3.0–11.8, p &lt; 0.001)",30926:31272,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure in patients under 65 years of age,Azilsartan medoxomil 40 mg,Placebo,Significantly decreased,"After 6 weeks of treatment, the LS mean difference of AZL-M from placebo on scSBP in patients &lt; 65 years of age was − 14.7 (95% CI –20.5 to − 8.9; p &lt; 0.001) for the AZL-M 40-mg group and − 14.1 (95% CI –19.8 to − 8.4; p &lt; 0.001) for the AZL-M 80-mg group",32709:33004,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure in patients under 65 years of age,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,"After 6 weeks of treatment, the LS mean difference of AZL-M from placebo on scSBP in patients &lt; 65 years of age was − 14.7 (95% CI –20.5 to − 8.9; p &lt; 0.001) for the AZL-M 40-mg group and − 14.1 (95% CI –19.8 to − 8.4; p &lt; 0.001) for the AZL-M 80-mg group",32709:33004,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure in patients over 65 years of age,Azilsartan medoxomil 40 mg,Placebo,Significantly decreased,"For patients ≥65 years, the LS mean difference in scSBP was − 11.4 (95% CI –19.9 to − 2.9; p = 0.009) in the 40-mg group and − 16.4 (95% CI –25.1 to − 7.7; p &lt; 0.001) in the 80-mg group.",33058:33278,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure in patients over 65 years of age,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,"For patients ≥65 years, the LS mean difference in scSBP was − 11.4 (95% CI –19.9 to − 2.9; p = 0.009) in the 40-mg group and − 16.4 (95% CI –25.1 to − 7.7; p &lt; 0.001) in the 80-mg group.",33058:33278,5804062,29445520,Unavailable
5804062,Sitting clinic diastolic blood pressure in patients under 65 years of age,Azilsartan medoxomil 40 mg,Placebo,Significantly decreased,"For patients aged &lt; 65 years, the LS mean difference in scDBP of AZL-M compared with placebo was − 9.9 (95% CI –13.3 to − 6.4; p &lt; 0.001) for the AZL-M 40-mg group and − 10.1 (95% CI –13.5 to − 6.7; p &lt; 0.001) for the AZL-M 80-mg group.",33279:33559,5804062,29445520,Unavailable
5804062,Sitting clinic diastolic blood pressure in patients under 65 years of age,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,"For patients aged &lt; 65 years, the LS mean difference in scDBP of AZL-M compared with placebo was − 9.9 (95% CI –13.3 to − 6.4; p &lt; 0.001) for the AZL-M 40-mg group and − 10.1 (95% CI –13.5 to − 6.7; p &lt; 0.001) for the AZL-M 80-mg group.",33279:33559,5804062,29445520,Unavailable
5804062,Sitting clinic diastolic blood pressure in patients over 65 years of age,Azilsartan medoxomil 40 mg,Placebo,Significantly decreased,The LS mean difference in scDBP for patients aged ≥65 years was − 6.9 (− 11.3 to − 2.5; p = 0.002) for the AZL-M 40-mg group and − 8.5 (− 13.0 to − 4.0; p &lt; 0.001) for the AZL-M 80-mg group.,33559:33786,5804062,29445520,Unavailable
5804062,Sitting clinic diastolic blood pressure in patients over 65 years of age,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,The LS mean difference in scDBP for patients aged ≥65 years was − 6.9 (− 11.3 to − 2.5; p = 0.002) for the AZL-M 40-mg group and − 8.5 (− 13.0 to − 4.0; p &lt; 0.001) for the AZL-M 80-mg group.,33559:33786,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure in diabetic patients,Azilsartan medoxomil 40 mg,Placebo,No significant difference,"However, the LS mean difference of AZL-M compared with placebo at week 6 on scSBP was significant at 80 mg (LS mean − 20.8 [95% CI –41.5 to − 0.1]; p = 0.049); the LS mean difference for 40 mg is − 19.5 (95% CI –39.2 to 0.2; p = 0.052)",35647:36169,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure in diabetic patients,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,"However, the LS mean difference of AZL-M compared with placebo at week 6 on scSBP was significant at 80 mg (LS mean − 20.8 [95% CI –41.5 to − 0.1]; p = 0.049); the LS mean difference for 40 mg is − 19.5 (95% CI –39.2 to 0.2; p = 0.052)",35114:35383,5804062,29445520,Unavailable
5804062,Sitting clinic diastolic blood pressure in diabetic patients,Azilsartan medoxomil 40 mg,Placebo,Significantly decreased,"For scDBP, the LS mean difference was − 10.4 (95% CI –19.6 to − 1.2; p = 0.028) for the AZL-M 40-mg group and − 12.2 (95% CI –21.9 to − 2.5; p = 0.015) for the AZL-M 80-mg group.",35434:35647,5804062,29445520,Unavailable
5804062,Sitting clinic diastolic blood pressure in diabetic patients,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,"For scDBP, the LS mean difference was − 10.4 (95% CI –19.6 to − 1.2; p = 0.028) for the AZL-M 40-mg group and − 12.2 (95% CI –21.9 to − 2.5; p = 0.015) for the AZL-M 80-mg group.",35434:35647,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure in non-diabetic patients,Azilsartan medoxomil 40 mg,Placebo,Significantly decreased,"For patients without diabetes, the LS mean difference at week 6 in scSBP and scDBP was − 12.7 (95% CI –17.8 to − 7.7; p &lt; 0.001) and − 8.6 (95% CI –11.5 to − 5.7; p &lt; 0.001) for the AZL-M 40-mg group, respectively, and − 14.5 (95% CI –19.5 to − 9.5; p &lt; 0.001) and − 9.6 (95% CI –12.4 to − 6.7; p &lt; 0.001) for the AZL-M 80-mg group (see Fig. 5c). These differences were considered clinically meaningful.",35647:36169,5804062,29445520,Unavailable
5804062,Sitting clinic diastolic blood pressure in non-diabetic patients,Azilsartan medoxomil 40 mg,Placebo,Significantly decreased,"For patients without diabetes, the LS mean difference at week 6 in scSBP and scDBP was − 12.7 (95% CI –17.8 to − 7.7; p &lt; 0.001) and − 8.6 (95% CI –11.5 to − 5.7; p &lt; 0.001) for the AZL-M 40-mg group, respectively, and − 14.5 (95% CI –19.5 to − 9.5; p &lt; 0.001) and − 9.6 (95% CI –12.4 to − 6.7; p &lt; 0.001) for the AZL-M 80-mg group (see Fig. 5c). These differences were considered clinically meaningful.",35647:36169,5804062,29445520,Unavailable
5804062,Sitting clinic systolic blood pressure in non-diabetic patients,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,"For patients without diabetes, the LS mean difference at week 6 in scSBP and scDBP was − 12.7 (95% CI –17.8 to − 7.7; p &lt; 0.001) and − 8.6 (95% CI –11.5 to − 5.7; p &lt; 0.001) for the AZL-M 40-mg group, respectively, and − 14.5 (95% CI –19.5 to − 9.5; p &lt; 0.001) and − 9.6 (95% CI –12.4 to − 6.7; p &lt; 0.001) for the AZL-M 80-mg group (see Fig. 5c). These differences were considered clinically meaningful.",35647:36169,5804062,29445520,Unavailable
5804062,Sitting clinic diastolic blood pressure in non-diabetic patients,Azilsartan medoxomil 80 mg,Placebo,Significantly decreased,"For patients without diabetes, the LS mean difference at week 6 in scSBP and scDBP was − 12.7 (95% CI –17.8 to − 7.7; p &lt; 0.001) and − 8.6 (95% CI –11.5 to − 5.7; p &lt; 0.001) for the AZL-M 40-mg group, respectively, and − 14.5 (95% CI –19.5 to − 9.5; p &lt; 0.001) and − 9.6 (95% CI –12.4 to − 6.7; p &lt; 0.001) for the AZL-M 80-mg group (see Fig. 5c). These differences were considered clinically meaningful.",35647:36169,5804062,29445520,Unavailable
5804062,Adverse events,Azilsartan medoxomil 80 mg,Placebo,No significant difference,"In the safety analysis set, 62 patients (19.0%, 69/327) had at least one treatment-emergent AE and the percentage of patients with treatment-emergent AEs was similar between the placebo (20.0%, 13/65), AZL-M 40-mg (15.2%, 20/132), and AZL-M 80-mg (22.3%, 29/130) groups",36355:36625,5804062,29445520,Unavailable
5804062,Adverse events,Azilsartan medoxomil 80 mg,Azilsartan medoxomil 40 mg,No significant difference,"In the safety analysis set, 62 patients (19.0%, 69/327) had at least one treatment-emergent AE and the percentage of patients with treatment-emergent AEs was similar between the placebo (20.0%, 13/65), AZL-M 40-mg (15.2%, 20/132), and AZL-M 80-mg (22.3%, 29/130) groups",36355:36625,5804062,29445520,Unavailable
5804062,Adverse events,Azilsartan medoxomil 40 mg,Placebo,No significant difference,"In the safety analysis set, 62 patients (19.0%, 69/327) had at least one treatment-emergent AE and the percentage of patients with treatment-emergent AEs was similar between the placebo (20.0%, 13/65), AZL-M 40-mg (15.2%, 20/132), and AZL-M 80-mg (22.3%, 29/130) groups",36355:36625,5804062,29445520,Unavailable
2699711,Mean duration of treatment,Glulisine insulin,Regular insulin,No significant difference,There were no differences in the mean duration of treatment or in the amount of insulin infusion until resolution of DKA between intravenous treatment with regular and glulisine insulin.,5765:5951,2699711,19366972,Unavailable
2699711,Amount of insulin infusion,Glulisine insulin,Regular insulin,No significant difference,There were no differences in the mean duration of treatment or in the amount of insulin infusion until resolution of DKA between intravenous treatment with regular and glulisine insulin.,5765:5951,2699711,19366972,Unavailable
2699711,Mean daily blood glucose levels,Glulisine insulin + subcutaneous glargine,Regular insuline + subcutaneous NPH,No significant difference,"After transition to subcutaneous insulin, there were no differences in mean daily blood glucose levels",5952:6054,2699711,19366972,Unavailable
2699711,Hypoglycemia frequency ,Glulisine insulin + subcutaneous glargine,Regular insuline + subcutaneous NPH,Significantly decreased,Fourteen patients (41%) treated with NPH and regular insulin had 26 episodes of hypoglycemia and 5 patients (15%) in the glargine and glulisine group had 8 episodes of hypoglycemia (P = 0.03).,6167:6379,2699711,19366972,Unavailable
2699711,Blood glucose concentration decline during treatment ,Glulisine insulin,Regular insulin,No significant difference,the rate of decline of blood glucose concentration and changes in acid base parameters during treatment were not significantly different between treatment groups,21918:22104,2699711,19366972,Unavailable
2699711,Acid-base parameters during treatment ,Glulisine insulin,Regular insulin,No significant difference,the rate of decline of blood glucose concentration and changes in acid base parameters during treatment were not significantly different between treatment groups,21918:22104,2699711,19366972,Unavailable
2699711,Mean duration of treatment,Glulisine insulin,Regular insulin,No significant difference,The mean duration of treatment until resolution of ketoacidosis was not statistically different between those treated with glulisine (8.9 ± 4.7 h) and regular insulin (10.5 ± 6.3 h) (NS),21918:22104,2699711,19366972,Unavailable
2699711,Blood glucose concentration decline at resolution,Glulisine insulin,Regular insulin,No significant difference,"At resolution of DKA, the mean blood glucose concentration and acid-base parameters in patients treated with glulisine insulin (glucose 153 ± 61 mg/dl, bicarbonate 20 ± 3 mmol/l, pH 7.33 ± 0.04, and anion gap 8.3 ± 2.1 mEq/l) were similar to those in patients treated with intravenous regular insulin (glucose 185 ± 58 mg/dl, bicarbonate 19.5 ± 3.7 mEq/l, pH 7.32 ± 0.04, and anion gap 9 ± 3 mEq/l).",22106:22505,2699711,19366972,Unavailable
2699711,Acid-base parameters at resolution,Glulisine insulin,Regular insulin,No significant difference,"At resolution of DKA, the mean blood glucose concentration and acid-base parameters in patients treated with glulisine insulin (glucose 153 ± 61 mg/dl, bicarbonate 20 ± 3 mmol/l, pH 7.33 ± 0.04, and anion gap 8.3 ± 2.1 mEq/l) were similar to those in patients treated with intravenous regular insulin (glucose 185 ± 58 mg/dl, bicarbonate 19.5 ± 3.7 mEq/l, pH 7.32 ± 0.04, and anion gap 9 ± 3 mEq/l).",22106:22505,2699711,19366972,Unavailable
2699711,Amount of insulin infusion,Glulisine insulin,Regular insulin,No significant difference,"The amount of insulin administered until resolution of DKA (70 ± 33 and 76 ± 46 units) and the mean total duration of insulin infusion (15.7 ± 4.5 and 20.5 ± 12 h) were not different between glulisine and regular insulin, respectively",22709:22944,2699711,19366972,Unavailable
2699711,Total duration of insulin infusion,Glulisine insulin,Regular insulin,No significant difference,"The amount of insulin administered until resolution of DKA (70 ± 33 and 76 ± 46 units) and the mean total duration of insulin infusion (15.7 ± 4.5 and 20.5 ± 12 h) were not different between glulisine and regular insulin, respectively",22709:22944,2699711,19366972,Unavailable
2699711,Mean daily blood glucose levels,Glulisine insulin + subcutaneous glargine,Regular insuline + subcutaneous NPH,No significant difference,"After transition to subcutaneous insulin therapy, cross-sectional analyses based on two-sample Wilcoxon tests showed that there were no significant differences in the mean daily glucose concentration between treatment groups.",23537:23762,2699711,19366972,Unavailable
2699711,Blood glucose concentration decline after resolution ,Glulisine insulin + subcutaneous glargine,Regular insulin+ subcutaneous NPH,Significantly increased,"However, fitting of a repeated-measures linear model with or without adjustment for age, sex, race, and BMI indicated a greater decline rate of blood glucose in the glargine and glulisine group than that in the NPH and regular insulin group (P &lt; 0.01)",23763:24031,2699711,19366972,Unavailable
2699711,Hypoglycemia frequency ,Glulisine insulin + subcutaneous glargine,Regular insuline + subcutaneous NPH,Significantly decreased,atients treated with NPH and regular insulin had a higher rate of hypoglycemic events than those treated with a basal bolus regimen (Table 2). Fourteen patients (41%) treated with NPH and regular insulin had 26 episodes of hypoglycemia and five patients (15%) in the glargine and glulisine group had 8 episodes of hypoglycemia (P &lt; 0.01).,24043:24437,2699711,19366972,Unavailable
2699711,Total daily dose after resolution,Glulisine insulin + subcutaneous glargine,Regular insuline + subcutaneous NPH,No significant difference,The TDD of subcutaneous insulin was similar between groups (Table 3). The mean total daily insulin dose including supplemental insulin was 60 ± 30 units in the glargine and glulisine group and 58 ± 24 units in the NPH and regular insulin group (NS),27401:27688,2699711,19366972,Unavailable
5557997,Mean push-out bond strength,Ultrasonic cleaning,Control,Significantly increased,The lowest bond strength was noted in the control group. The control group had significant differences with ultrasonic and Clearfil Repair groups (P&lt;0.05).,4783:4939,5557997,28828018,Unavailable
5557997,Mean push-out bond strength,Clearfil Repair,Control,Significantly increased,The lowest bond strength was noted in the control group. The control group had significant differences with ultrasonic and Clearfil Repair groups (P&lt;0.05).,4783:4939,5557997,28828018,Unavailable
5557997,Mean push-out bond strength,Endsolv R,Control,No significant difference,The lowest bond strength was noted in the control group. The control group had significant differences with ultrasonic and Clearfil Repair groups (P&lt;0.05).,4783:4939,5557997,28828018,Unavailable
5557997,Mean push-out bond strength,Ultrasonic cleaning,Control,Significantly increased,"The control group had the lowest bond strength, followed by group 3 (Endosolv R), group 4 (Clearfil Repair) and group 2 (ultrasonic), respectively. The control group had a significant difference with groups 2 (P=0.002) and 4 (P=0.007).",17483:17718,5557997,28828018,Unavailable
5557997,Mean push-out bond strength,Clearfil Repair,Control,Significantly increased,"The control group had the lowest bond strength, followed by group 3 (Endosolv R), group 4 (Clearfil Repair) and group 2 (ultrasonic), respectively. The control group had a significant difference with groups 2 (P=0.002) and 4 (P=0.007).",17483:17718,5557997,28828018,Unavailable
5557997,Mean push-out bond strength,Endsolv R,Clearfil Repair,No significant difference,Group 3 had no significant difference with the other groups (P&gt;0.05).,17719:17788,5557997,28828018,Unavailable
5557997,Mean push-out bond strength,Endsolv R,Ultrasonic cleaning,No significant difference,Group 3 had no significant difference with the other groups (P&gt;0.05).,17719:17788,5557997,28828018,Unavailable
5557997,Mean push-out bond strength,Endsolv R,Control,No significant difference,Group 3 had no significant difference with the other groups (P&gt;0.05).,17719:17788,5557997,28828018,Unavailable
5398527,Minimum dietary diversity,Nutrition education intervention,Control,Significantly increased,"A positive impact on child dietary diversity was observed (B (SE) = 0.39 (0.15), p = 0.01; 95%CI 0.09–0.68).",104468:104470,5398527,28426678,Unavailable
5398527,Mean height-for-age z-scores,Nutrition education intervention,Control,No significant difference,"There was a non-significant positive intervention effect on mean height-for-age z-scores (B (SE) = 0.17 (0.12), p = 0.15; 95%CI -0.06–0.41).",10318:10458,5398527,28426678,Unavailable
5398527,Dietary diversity,Nutrition education intervention,Control,Significantly increased,"The DiD model adjusted for sex of the child, child’s age (days), education of caregiver (years) and wealth status showed a significant positive intervention effect on CDD (B (SE) = 0.39 (0.15), p = 0.01; 95%CI 0.09–0.68).",104347:104586,5398527,28426678,Unavailable
5398527,Minimal meal frequency ,Nutrition education intervention,Control,No significant difference,"There was almost no improvement regarding MMF at endline (C = 81.6%, I = 90.3%).",105831:105912,5398527,28426678,Unavailable
5398527,Minimum acceptable diet improvement ,Nutrition education intervention,Control,Significantly increased,The combined WHO indicator MAD showed a significant intervention effect of 12 percentage points at endline (p = 0.02),105912:106029,5398527,28426678,Unavailable
5398527,Mean height-for-age z-scores,Nutrition education intervention,Control,No significant difference,"The DiD model adjusted for sex of the child, child’s age (days), education of caregiver (years), wealth, and height of mother (cm) showed a non-significant, but small positive intervention effect on mean HAZ (B (SE) = 0.17 (0.12), p = 0.15; 95%CI -0.06–0.41).",106104:106380,5398527,28426678,Unavailable
5398527,"Grains, roots &amp; tubers consumption",Nutrition education intervention,Control,No significant difference,"Grains, roots &amp; tubers	96.4	98.3	0.08	96.6	98.2	95.2	97.6	0.06	95.3	97.5	0.66	0.69",87173:87914,5398527,28426678,Unavailable
5398527,Grains consumption,Nutrition education intervention,Control,No significant difference,"Grains	96.4	98.3	0.08	96.7	98.2	94.7	97.4	0.04	94.8	97.3	0.92	0.58",87970:88697,5398527,28426678,Unavailable
5398527,Roots &amp; tubers consumption,Nutrition education intervention,Control,No significant difference,"Roots &amp; tubers	24.9	25.1	0.97	26.1	24.7	19.4	18.7	0.79	18.9	18.6	1.13	0.78",88753:89479,5398527,28426678,Unavailable
5398527,Legumes &amp; nuts consumption,Nutrition education intervention,Control,No significant difference,"Legumes &amp; nuts	57.1	67.5	&lt;0.01	59.4	66.7	65.4	77.9	0.01	64.8	77.3	4.86	0.35",89540:90303,5398527,28426678,Unavailable
5398527,Groundnuts consumption,Nutrition education intervention,Control,Significantly increased,Groundnuts 35.8 46.3 &lt;0.01 37.4 45.7 38.9 62.4 &lt;0.01 38.7 61.9 14.96 &lt;0.01,90359:91122,5398527,28426678,Unavailable
5398527,Other legumes &amp; nuts consumption,Nutrition education intervention,Control,No significant difference,"Other legumes &amp; nuts	41.2	49.4	0.02	43.1	48.6	50.9	61.4	&lt;0.01	50.5	60.9	4.87	0.34",91185:91947,5398527,28426678,Unavailable
5398527,Dairy products consumption,Nutrition education intervention,Control,No significant difference,"Dairy products	12.9	13.4	0.83	13.5	12.5	15.6	20.9	0.03	16.2	20.6	5.47	0.15",92008:92750,5398527,28426678,Unavailable
5398527,Flesh foods consumption,Nutrition education intervention,Control,No significant difference,"Flesh foods	31.2	35.3	0.21	32.3	34.5	27.4	38.2	&lt;0.01	27.0	38.4	9.20	0.09",92811:93554,5398527,28426678,Unavailable
5398527,Meat consumption,Nutrition education intervention,Control,No significant difference,"Meat	15.5	16.7	0.64	16.0	15.9	12.8	18.9	0.01	13.0	19.1	6.18	0.11",93610:94335,5398527,28426678,Unavailable
5398527,Organ meat consumption,Nutrition education intervention,Control,No significant difference,"Organ meat	2.7	2.8	0.80	2.8	2.3	1.3	2.6	0.14	1.2	2.6	1.96	0.16",94391:95101,5398527,28426678,Unavailable
5398527,Fish &amp; seafood consumption,Nutrition education intervention,Control,No significant difference,"Fish &amp; seafood	19.9	23.2	0.25	20.6	22.9	18.5	24.1	0.04	18.2	24.1	3.57	0.43",95157:95896,5398527,28426678,Unavailable
5398527,Egg consumption,Nutrition education intervention,Control,Significantly increased,"Eggs	12.1	13.4	0.59	12.8	12.9	6.1	16.3	&lt;0.01	6.1	16.2	9.92	&lt;0.01",95957:96701,5398527,28426678,Unavailable
5398527,Vitamin A-rich fruit &amp; vegetables consumption,Nutrition education intervention,Control,No significant difference,"Vitamin A rich fruit &amp; vegetables	69.0	75.7	0.03	71.1	75.6	71.6	77.5	0.04	70.2	77.3	2.62	0.53",96769:97547,5398527,28426678,Unavailable
5398527,Vitamin A rich roots &amp; tubers consumption,Nutrition education intervention,Control,No significant difference,"Vitamin A rich roots &amp; tubers	11.9	7.6	0.04	12.1	7.3	12.2	12.9	0.74	12.1	13.2	5.82	0.11",97603:98355,5398527,28426678,Unavailable
5398527,Vitamin A rich vegetables consumption,Nutrition education intervention,Control,No significant difference,"Vitamin A rich vegetables	65.9	73.0	0.03	68.0	72.9	67.8	73.3	0.07	66.4	73.1	1.77	0.67",98411:99157,5398527,28426678,Unavailable
5398527,Vitamin A rich fruit consumption,Nutrition education intervention,Control,No significant difference,"Vitamin A rich fruit	10.4	16.2	0.01	10.8	16.1	6.7	16.9	&lt;0.01	6.5	16.9	5.14	0.25",99213:99969,5398527,28426678,Unavailable
5398527,Other fruit &amp; vegetables consumption,Nutrition education intervention,Control,No significant difference,"Other fruit &amp; vegetables	72.4	78.3	&lt;0.05	74.6	78.0	73.5	82.5	&lt;0.01	72.5	82.0	6.16	0.11",100030:100807,5398527,28426678,Unavailable
5398527,Minimum dietary diversity,Nutrition education intervention,Control,Significantly increased,"MDD	56.3	62.8	0.06	59.9	61.9	56.3	71.7	&lt;0.01	55.5	71.1	12.70	0.01",101517:102259,5398527,28426678,Unavailable
5398527,Minimal meal frequency ,Nutrition education intervention,Control,No significant difference,"MMF	80.0	89.2	&lt;0.01	80.4	88.6	81.0	90.6	&lt;0.01	81.6	90.3	0.43	0.91",102327:103079,5398527,28426678,Unavailable
5398527,Minimum acceptable diet,Nutrition education intervention,Control,Significantly increased,"MAD	47.9	57.7	&lt;0.01	55.2	56.7	47.7	66.5	&lt;0.01	47.3	65.8	11.86	0.02",103140:103899,5398527,28426678,Unavailable
5398527,Groundnuts consumption,Nutrition education intervention,Control,Significantly increased,"The intervention significantly influenced consumption of eggs (p = &lt;0.01), as well as groundnuts (p = &lt;0.01).",105035:105144,5398527,28426678,Unavailable
5398527,Egg consumption,Nutrition education intervention,Control,Significantly increased,"The intervention significantly influenced consumption of eggs (p = &lt;0.01), as well as groundnuts (p = &lt;0.01).",105035:105144,5398527,28426678,Unavailable
31582,Ventilatory parameters,BIPAP,Assisted spontaneous breathing,No significant difference,"No differences in patient characteristics, ventilatory parameters, complications of ventilation or use of sedatives were noted.",3415:3542,31582,11353935,Unavailable
31582,Complications of ventilation,BIPAP,Assisted spontaneous breathing,No significant difference,"No differences in patient characteristics, ventilatory parameters, complications of ventilation or use of sedatives were noted.",3415:3542,31582,11353935,Unavailable
31582,Use of sedatives,BIPAP,Assisted spontaneous breathing,No significant difference,"No differences in patient characteristics, ventilatory parameters, complications of ventilation or use of sedatives were noted.",3415:3542,31582,11353935,Unavailable
31582,Ventilatory parameters,BIPAP,Assisted spontaneous breathing,No significant difference,"No differences in patient characteristics, duration of ventilation, complications of ventilation or need for sedatives were noted.",11288:11418,31582,11353935,Unavailable
31582,Complications of ventilation,BIPAP,Assisted spontaneous breathing,No significant difference,"No differences in patient characteristics, duration of ventilation, complications of ventilation or need for sedatives were noted.",11288:11418,31582,11353935,Unavailable
31582,Use of sedatives,BIPAP,Assisted spontaneous breathing,No significant difference,"No differences in patient characteristics, duration of ventilation, complications of ventilation or need for sedatives were noted.",11288:11418,31582,11353935,Unavailable
2899362,Surgery time,Open wedge osteotomy,Closed wedge osteotomy,Significantly decreased,Surgery time was significantly longer in the CWO group,4472:4526,2899362,19707760,Unavailable
2899362,Hip-knee-ankle valgus angle,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,The mean postoperative HKA angle was 3.8º valgus (SD 2.2) in the OWO group and 4.4º valgus (SD 2.7) in the CWO group (p = 0.474),16382:16527,2899362,19707760,Unavailable
2899362,Medial collateral knee laxity,Open wedge osteotomy,Closed wedge osteotomy,Significantly decreased,The OWO group showed a mean postoperative reduction of the mean medial collateral knee laxity of 4.5º (SD 1.5) versus 5.3º (SD 1.2) in the CWO group. This difference was significant (p = 0.041).,18632:18844,2899362,19707760,Unavailable
2899362,Lateral collateral knee laxity,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"The mean lateral collateral laxity did not change significantly, i.e. 5.3º (SD 1.1) after OWO and 5.5º (SD 1.0) after CWO (p = 0.505).",18843:18995,2899362,19707760,Unavailable
2899362,WOMAC score,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"The WOMAC and KS scores showed equal effects between the groups. The mean WOMAC score decreased to 20.0 (SD 19.4) and 16.0 (SD 15.0) after OWO and CWO, respectively. The mean KS score increased to 176.6 (SD 23.4) in the OWO group and 180.2 (SD 22.2) in the CWO group.",19144:19412,2899362,19707760,Unavailable
2899362,KS score,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"The WOMAC and KS scores showed equal effects between the groups. The mean WOMAC score decreased to 20.0 (SD 19.4) and 16.0 (SD 15.0) after OWO and CWO, respectively. The mean KS score increased to 176.6 (SD 23.4) in the OWO group and 180.2 (SD 22.2) in the CWO group.",19144:19412,2899362,19707760,Unavailable
2899362,Knee pain,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,The mean VASknee pain decreased to 2.5 (SD 1.9) after OWO and 1.8 (SD 1.5) after CWO.,19412:19508,2899362,19707760,Unavailable
2899362,Satisfaction,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,The mean VASsatisfaction increased to 7.8 (SD 1.8) in the OWO group and 8.7 (SD 1.4) in the CWO group. There were no significant differences between the groups.,19583:19754,2899362,19707760,Unavailable
2899362,Caton index,Open wedge osteotomy,Closed wedge osteotomy,Significantly decreased,The mean CI after OWO was 0.86 (SD 0.14) and after CWO it was 1.04 (SD 0.17). This difference was significant (p &lt; 0.001).,19889:20028,2899362,19707760,Unavailable
2899362,Surgery time,Open wedge osteotomy,Closed wedge osteotomy,Significantly decreased,The mean surgery time of 54.8 min (SD 10.8) in the OWO group was significantly shorter than the mean surgery time for the CWO of 68.0 min (SD 22.2) (p = 0.010),20038:20214,2899362,19707760,Unavailable
2899362,Hospital stay,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"No difference was detected for the mean hospital stay, with 3.4 days (SD 1.8) for the OWO group and 3.9 days (SD 1.5) for CWO.",20216:20342,2899362,19707760,Unavailable
2899362,Hip-knee-ankle valgus angle,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"HKA valgus angle(°)	3.8 (2.2)	4.4 (2.7)	0.6	−0.82; 1.93	0.420",16993:17094,2899362,19707760,Unavailable
2899362,Medial collateral knee laxity,Open wedge osteotomy,Closed wedge osteotomy,Significantly decreased,"Medial laxity (°)	4.5 (1.5)	5.3 (1.2)	0.8	0.03; 1.59	0.041*",17112:17211,2899362,19707760,Unavailable
2899362,Lateral collateral knee laxity,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"Lateral laxity (°)	5.3 (1.1)	5.5 (1.0)	0.2	−0.39; 0.78	0.505",17229:17329,2899362,19707760,Unavailable
2899362,WOMAC score,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"WOMAC (0-96)	20.0 (19.4)	16.0 (15.0)	4.0	−13.85; 5.85	0.418",17395:17494,2899362,19707760,Unavailable
2899362,KS score,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"KS (0–200)	176.6 (23.4)	180.2 (22.2)	3.6	−9.36; 16.56	0.579",17512:17611,2899362,19707760,Unavailable
2899362,Knee pain,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"VAS (0–10) knee pain	2.5 (1.9)	1.8 (1.5)	0.6	−1..60; 0.38	0.221",17629:17732,2899362,19707760,Unavailable
2899362,Satisfaction,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"VAS (0–10) satisfaction	7.8 (1.8)	8.7 (1.4)	0.9	−0.07; 1.78	0.07",17750:17854,2899362,19707760,Unavailable
2899362,Caton index,Open wedge osteotomy,Closed wedge osteotomy,Significantly decreased,"Caton index	0.86 (0.14)	1.04 (0.17)	0.18	0.09; 0.27	&lt;0.001*",17872:17971,2899362,19707760,Unavailable
2899362,Surgery time,Open wedge osteotomy,Closed wedge osteotomy,Significantly decreased,"Surgery time (min)	54.8 (10.8)	68.0 (22.2)	13.2	3.27; 23.12	0.010*",17992:18098,2899362,19707760,Unavailable
2899362,Hospital stay,Open wedge osteotomy,Closed wedge osteotomy,No significant difference,"Hospital stay (days)	3.4 (1.8))	3.9 (1.5)	0.5	−0.46; 1.42	0.311",18116:18219,2899362,19707760,Unavailable
3600293,General stress level improvement ,Medical yoga,Control,Significantly increased,"Patients assigned to the Yoga group showed significantly greater improvements on measures of general stress level (P &lt; 0.000), anxiety (P &lt; 0.019), and overall health status (P &lt; 0.018) compared to controls.",4750:5015,3600293,23533465,Unavailable
3600293,Anxiety improvement ,Medical yoga,Control,Significantly increased,"Patients assigned to the Yoga group showed significantly greater improvements on measures of general stress level (P &lt; 0.000), anxiety (P &lt; 0.019), and overall health status (P &lt; 0.018) compared to controls.",21683:21912,3600293,23533465,Unavailable
3600293,Overall health status improvement ,Medical yoga,Control,Significantly increased,"Patients assigned to the Yoga group showed significantly greater improvements on measures of general stress level (P &lt; 0.000), anxiety (P &lt; 0.019), and overall health status (P &lt; 0.018) compared to controls.",21683:21912,3600293,23533465,Unavailable
3600293,General stress level improvement ,Medical yoga,Control,Significantly increased,A significantly greater improvement in PSS scores was seen in the yoga group compared with the control group (P &lt; 0.000) after the completion of the study,20654:20826,3600293,23533465,Unavailable
3600293,Burnout Symptoms,Medical yoga,Control,No significant difference,No significant differences between the control group and the yoga group were shown with regard to changes in self-reported burnout symptoms after the study period (P &lt; 0.412),21133:21324,3600293,23533465,Unavailable
3600293,Anxiety improvement ,Medical yoga,Control,Significantly increased,"The subscales showed that the decrease in anxiety symptoms was significantly more pronounced in yoga group than in control group (P &lt; 0.019), but there was no significant difference between groups regarding the subscale for depression (P &lt; 0.123)",21968:22251,3600293,23533465,Unavailable
3600293,Depression improvement ,Medical yoga,Control,No significant difference,"The subscales showed that the decrease in anxiety symptoms was significantly more pronounced in yoga group than in control group (P &lt; 0.019), but there was no significant difference between groups regarding the subscale for depression (P &lt; 0.123)",21968:22251,3600293,23533465,Unavailable
3600293,HADS score improvement ,Medical yoga,Control,Significantly increased,"After the 12-week intervention, there was a significant difference between the groups regarding the decrease in anxiety/depression symptom scores measured as total HADS score, favouring the yoga group (P &lt; 0.047)",21968:22251,3600293,23533465,Unavailable
3600293,Insomnia improvement ,Medical yoga,Control,No significant difference,"After the medical yoga intervention, the values were unchanged in the control group, and had improved in the yoga group (Table 2), but when comparing the change from baseline between the groups no statistically significant difference was present.",22501:22788,3600293,23533465,Unavailable
3600293,Pain improvement ,Medical yoga,Control,No significant difference,"After 3 months, the pain had decreased in both groups (control group 3.5 ± 1.9 and yoga group 2.2 ± 2.5). The reduction was comparable between the control group and yoga group after the study period (P = 0.871).",22944:23172,3600293,23533465,Unavailable
3600293,Overall health status improvement ,Medical yoga,Control,Significantly increased,"Change in perception of overall health status, measured by EQ-VAS, showed significant differences between the groups after the 12-week period (P &lt; 0.018)",23410:23580,3600293,23533465,Unavailable
3600293,Thoracic mobility improvement ,Medical yoga,Control,Significantly increased,There was a significant difference between the two groups in change in thoracic mobility as measured by thoracic excursion measurements (P &lt; 0.007).,24305:24470,3600293,23533465,Unavailable
3600293,Heart rate,Medical yoga,Control,No significant difference,"Values for heart rate, SaO2, and blood pressure are presented in Table 4. No significant differences were noted between the groups, before or after the medical yoga intervention.",24697:24930,3600293,23533465,Unavailable
3600293,SaO2,Medical yoga,Control,No significant difference,"Values for heart rate, SaO2, and blood pressure are presented in Table 4. No significant differences were noted between the groups, before or after the medical yoga intervention.",24697:24930,3600293,23533465,Unavailable
3600293,Blood pressure,Medical yoga,Control,No significant difference,"Values for heart rate, SaO2, and blood pressure are presented in Table 4. No significant differences were noted between the groups, before or after the medical yoga intervention.",24697:24930,3600293,23533465,Unavailable
5984593,Knee pain after 6 treatments ,Boosted acupuncture,Standard acupuncture,Significantly decreased,We found significantly decreased knee pain in the boosted acupuncture group compared to the standard acupuncture or TAU groups after both six and ten treatments.,37834:38112,5984593,29868449,Unavailable
5984593,Knee pain after 6 treatments ,Boosted acupuncture,Usual treatment,Significantly decreased,We found significantly decreased knee pain in the boosted acupuncture group compared to the standard acupuncture or TAU groups after both six and ten treatments.,37834:38112,5984593,29868449,Unavailable
5984593,Knee pain after 10 treatments ,Boosted acupuncture,Standard acupuncture,Significantly decreased,We found significantly decreased knee pain in the boosted acupuncture group compared to the standard acupuncture or TAU groups after both six and ten treatments.,37834:38112,5984593,29868449,Unavailable
5984593,Knee pain after 10 treatments ,Boosted acupuncture,Usual treatment,Significantly decreased,We found significantly decreased knee pain in the boosted acupuncture group compared to the standard acupuncture or TAU groups after both six and ten treatments.,37834:38112,5984593,29868449,Unavailable
5984593,rsFC increase ,Boosted acupuncture,Standard acupuncture,Significantly increased,Resting state functional connectivity (rsFC) analyses using the nucleus accumbens (NAc) as the seed showed rsFC increases between the NAc and the medial prefrontal cortex (MPFC)/rostral anterior cingulate cortex (rACC) and dorsolateral prefrontal cortex in the boosted group as compared to the standard acupuncture group after multiple treatments.,37834:38112,5984593,29868449,Unavailable
5984593,Knee pain after 6 treatments ,Boosted acupuncture,Standard acupuncture,Significantly decreased,Post hoc analysis indicated that the boosted acupuncture significantly decreased pain compared to standard acupuncture (p = 0.005) and TAU control groups (p = 0.015).,37834:38112,5984593,29868449,Unavailable
5984593,Knee pain after 6 treatments ,Boosted acupuncture,Usual treatment,Significantly decreased,Post hoc analysis indicated that the boosted acupuncture significantly decreased pain compared to standard acupuncture (p = 0.005) and TAU control groups (p = 0.015).,37834:38112,5984593,29868449,Unavailable
5984593,Knee function in sports,Boosted acupuncture,Standard acupuncture,Significantly increased,"In addition, we also found significant differences between the boosted acupuncture and standard acupuncture groups in KOOS Sport subscale scores, and between boosted acupuncture and TAU groups. There was no significant difference between the standard acupuncture and TAU control",37834:38112,5984593,29868449,Unavailable
5984593,Knee function in sports,Boosted acupuncture,Usual treament ,Significantly increased,"In addition, we also found significant differences between the boosted acupuncture and standard acupuncture groups in KOOS Sport subscale scores, and between boosted acupuncture and TAU groups. There was no significant difference between the standard acupuncture and TAU control",37834:38112,5984593,29868449,Unavailable
5984593,Knee function in sports,Standard acupuncture,Usual treament ,No significant difference,"In addition, we also found significant differences between the boosted acupuncture and standard acupuncture groups in KOOS Sport subscale scores, and between boosted acupuncture and TAU groups. There was no significant difference between the standard acupuncture and TAU control",37834:38112,5984593,29868449,Unavailable
5984593,Knee pain after 10 treatments ,Boosted acupuncture,Standard acupuncture,Significantly decreased,Post hoc analysis indicated that the boosted treatment significantly decreased pain compared to standard acupuncture (p = 0.027) and TAU control groups (p = 0.005).,42435:42616,5984593,29868449,Unavailable
5984593,Knee pain after 10 treatments ,Boosted acupuncture,Usual treatment,Significantly decreased,Post hoc analysis indicated that the boosted treatment significantly decreased pain compared to standard acupuncture (p = 0.027) and TAU control groups (p = 0.005).,42435:42616,5984593,29868449,Unavailable
5984593,Activities of daily living,Boosted acupuncture,Usual treatment,Significantly increased,"In addition, we also found significant differences between the boosted acupuncture and TAU group in KOOS ADL and QOL subscale scores.",42617:42750,5984593,29868449,Unavailable
5984593,Knee-related quality of life,Boosted acupuncture,Usual treatment,Significantly increased,"In addition, we also found significant differences between the boosted acupuncture and TAU group in KOOS ADL and QOL subscale scores.",42617:42750,5984593,29868449,Unavailable
5984593,Activities of daily living,Standard acupuncture,Usual treatment,No significant difference,There were no significant differences between standard acupuncture and TAU control groups,42751:42840,5984593,29868449,Unavailable
5984593,Knee-related quality of life,Standard acupuncture,Usual treatment,Significantly increased,There were no significant differences between standard acupuncture and TAU control groups,42751:42840,5984593,29868449,Unavailable
5984593,Knee pain,Standard acupuncture,Usual treatment,No significant difference,There were no significant differences between standard acupuncture and TAU control groups,42751:42840,5984593,29868449,Unavailable
5984593,Knee function in sports,Standard acupuncture,Usual treatment,No significant difference,There were no significant differences between standard acupuncture and TAU control groups,42751:42840,5984593,29868449,Unavailable
5984593,Other symptoms ,Standard acupuncture,Usual treatment,No significant difference,There were no significant differences between standard acupuncture and TAU control groups,42751:42840,5984593,29868449,Unavailable
5984593,Expectancy of acupuncture in response to heat pain,Boosted acupuncture,Standard acupuncture,Significantly increased,"We found significant group differences in expectancy scores following the expectancy manipulation during the first scan for both heat pain (F(2,42) = 7.04, p = 0.002; post hoc analysis: Boosted vs Standard Acupuncture p = 0.041, Boosted vs TAU p = 0.003; Standard vs TAU p = 0.477)",43204:43547,5984593,29868449,Unavailable
5984593,Expectancy of acupuncture in response to heat pain,Boosted acupuncture,Usual treatment ,Significantly increased,"We found significant group differences in expectancy scores following the expectancy manipulation during the first scan for both heat pain (F(2,42) = 7.04, p = 0.002; post hoc analysis: Boosted vs Standard Acupuncture p = 0.041, Boosted vs TAU p = 0.003; Standard vs TAU p = 0.477)",43204:43547,5984593,29868449,Unavailable
5984593,Expectancy of acupuncture in response to heat pain,Standard acupuncture,Usual treatment ,No significant difference,"We found significant group differences in expectancy scores following the expectancy manipulation during the first scan for both heat pain (F(2,42) = 7.04, p = 0.002; post hoc analysis: Boosted vs Standard Acupuncture p = 0.041, Boosted vs TAU p = 0.003; Standard vs TAU p = 0.477)",43548:43783,5984593,29868449,Unavailable
5984593,Expectancy of acupuncture in response to knee pain,Boosted acupuncture,Standard acupuncture,Significantly increased,"and knee pain (F(2,42) = 4.46, p = 0.018; post hoc analysis: Boosted vs Standard Acupuncture p = 0.025, Boosted vs TAU p = 0.091; Standard vs TAU p = 0.99).",43548:43783,5984593,29868449,Unavailable
5984593,Expectancy of acupuncture in response to knee pain,Boosted acupuncture,Usual treatment,No significant difference,"and knee pain (F(2,42) = 4.46, p = 0.018; post hoc analysis: Boosted vs Standard Acupuncture p = 0.025, Boosted vs TAU p = 0.091; Standard vs TAU p = 0.99).",43548:43783,5984593,29868449,Unavailable
5984593,Expectancy of acupuncture in response to knee pain,Standard acupuncture,Usual treatment,No significant difference,"and knee pain (F(2,42) = 4.46, p = 0.018; post hoc analysis: Boosted vs Standard Acupuncture p = 0.025, Boosted vs TAU p = 0.091; Standard vs TAU p = 0.99).",43548:43783,5984593,29868449,Unavailable
5984593,rsFC increase ,Boosted acupuncture,Standard acupuncture,Significantly increased,"Representative brain regions showed a significant rsFC increase in boosted acupuncture as compared to standard acupuncture (voxel-wise p &lt; 0.005, and cluster-level p &lt; 0.05 FWE corrected)",47052:47277,5984593,29868449,Unavailable
5984593,rsFC increase between NAc and vMPFC,Boosted acupuncture,Usual treatment ,Significantly increased,Boosted acupuncture treatment produced greater rsFC increases between the NAc and left ventral medial prefrontal cortex (vMPFC) compared to the TAU group,48777:48931,5984593,29868449,Unavailable
5435074,T4 concentration 4 weeks into treatment ,8-week  levothyroxine regime ,16-week  levothyroxine regime ,Significantly increased,"At week 4, T4, fT4, and T3 concentrations were higher in group 1 compared to group 2 (P = .009, .02, and .01, respectively).",29860:30034,5435074,28432797,Unavailable
5435074,Free T4 concentration 4 weeks into treatment ,8-week  levothyroxine regime ,16-week  levothyroxine regime ,Significantly increased,"At week 4, T4, fT4, and T3 concentrations were higher in group 1 compared to group 2 (P = .009, .02, and .01, respectively).",29860:30034,5435074,28432797,Unavailable
5435074,T3 concentration 4 weeks into treatment ,8-week  levothyroxine regime ,16-week  levothyroxine regime ,Significantly increased,"At week 4, T4, fT4, and T3 concentrations were higher in group 1 compared to group 2 (P = .009, .02, and .01, respectively).",29860:30034,5435074,28432797,Unavailable
5435074,TSH concentration 1 week into withdrawal period,8-week  levothyroxine regime ,16-week  levothyroxine regime ,Significantly decreased,"The serum TSH concentration was higher in group 2 than in group 1 at week 1 (P = .05), week 4 (P = .04), and week 8 (P = .01) of the withdrawal period.",31473:31676,5435074,28432797,Unavailable
5435074,TSH concentration 4 weeks into withdrawal period,8-week  levothyroxine regime ,16-week  levothyroxine regime ,Significantly decreased,"The serum TSH concentration was higher in group 2 than in group 1 at week 1 (P = .05), week 4 (P = .04), and week 8 (P = .01) of the withdrawal period.",31473:31676,5435074,28432797,Unavailable
5435074,TSH concentration 8 weeks into withdrawal period,8-week  levothyroxine regime ,16-week  levothyroxine regime ,Significantly decreased,"The serum TSH concentration was higher in group 2 than in group 1 at week 1 (P = .05), week 4 (P = .04), and week 8 (P = .01) of the withdrawal period.",31473:31676,5435074,28432797,Unavailable
4419514,Intubation time,Airtraq laryngoscope,GlideScope,Significantly decreased,"The intubation time of group A was shorter than that of group G (36.6 ± 20.2&nbsp;s vs. 54.6 ± 25.7&nbsp;s, p = 0.002).",5320:5444,4419514,25927657,Unavailable
4419514,Cormack-Lehane grade improvement ,Airtraq laryngoscope,GlideScope,Significantly increased,"The Cormack-Lehane grade (I/II/III/IV) was significantly better in group A (33/2/0/0 vs. 28/7/0/0, p = 0.042).",4932:5060,4419514,25927657,Unavailable
4419514,Having an increased mean arterial pressure,Airtraq laryngoscope,GlideScope,Significantly decreased,The mean arterial pressure and heart rate rose to higher levels during intubation with the GlideScope than with the Airtraq laryngoscope.,5061:5198,4419514,25927657,Unavailable
4419514,Having an increased heart rate,Airtraq laryngoscope,GlideScope,Significantly decreased,The mean arterial pressure and heart rate rose to higher levels during intubation with the GlideScope than with the Airtraq laryngoscope.,5061:5198,4419514,25927657,Unavailable
4419514,Success of the first intubation,Airtraq laryngoscope,GlideScope,No significant difference,The success of the first intubation attempt and the intubation difficulty scales were comparable between the two groups.,5199:5320,4419514,25927657,Unavailable
4419514,Intubation difficulty,Airtraq laryngoscope,GlideScope,No significant difference,The success of the first intubation attempt and the intubation difficulty scales were comparable between the two groups.,5199:5320,4419514,25927657,Unavailable
4419514,Postoperative sore throat,Airtraq laryngoscope,GlideScope,No significant difference,The numbers of patients who experienced postoperative sore throat were similar (6 vs. 8) in the two groups.,5320:5444,4419514,25927657,Unavailable
4419514,Intubation time,Airtraq laryngoscope,GlideScope,Significantly decreased,"The intubation time with the Airtraq laryngoscope was shorter than that with the GlideScope (36.6 ± 20.2&nbsp;s vs. 54.6 ± 25.7&nbsp;s, P = 0.002 &lt; 0.01).",18073:18217,4419514,25927657,Unavailable
4419514,Cormack-Lehane grade improvement ,Airtraq laryngoscope,GlideScope,Significantly increased,"Furthermore, the Airtraq laryngoscope provided better glottis views than did the GlideScope (P = 0.042 &lt; 0.05, Figure&nbsp;2).",18532:18698,4419514,25927657,Unavailable
4419514,Success of the first intubation,Airtraq laryngoscope,GlideScope,No significant difference,The success of the first intubation attempt and the intubation difficulty scales (IDS) were similar between two devices.,19595:19716,4419514,25927657,Unavailable
4419514,Intubation difficulty,Airtraq laryngoscope,GlideScope,No significant difference,The success of the first intubation attempt and the intubation difficulty scales (IDS) were similar between two devices.,19595:19716,4419514,25927657,Unavailable
4419514,Having an increased mean arterial pressure,Airtraq laryngoscope,GlideScope,Significantly decreased,Significant differences were found between two groups on the levels of increase in blood pressures and heart rates.,22015:22130,4419514,25927657,Unavailable
4419514,Having an increased heart rate,Airtraq laryngoscope,GlideScope,Significantly decreased,Significant differences were found between two groups on the levels of increase in blood pressures and heart rates.,22014:22131,4419514,25927657,Unavailable
4419514,Postoperative sore throat,Airtraq laryngoscope,GlideScope,No significant difference,"The incidences of sore throat were comparable between group A (6, 17%) and group G (8, 23%) after 24&nbsp;h of postoperative followed-up",22348:22479,4419514,25927657,Unavailable
4419514,Intubation time,Airtraq laryngoscope,GlideScope,Significantly decreased,"Intubation time (s)	36.6 ± 20.2 (12–91)	54.6 ± 25.7 (28–133)	P = 0.002*",20541:20636,4419514,25927657,Unavailable
4419514,Success of the first intubation,Airtraq laryngoscope,GlideScope,No significant difference,"Success rate of first intubation attempt (n, %)	33 (94%)	34 (97%)	0.55",20654:20748,4419514,25927657,Unavailable
4419514,Intubation difficulty,Airtraq laryngoscope,GlideScope,No significant difference,"Intubation difficulty scale (IDS) (0/1/2/3/4, n)	10/17/5/2/1	9/13/7/5/1	0.327",20766:20867,4419514,25927657,Unavailable
4419514,Postoperative sore throat,Airtraq laryngoscope,GlideScope,No significant difference,"Sore throat (n, %)	6 (17%)	8 (23%)	0.766",21096:21160,4419514,25927657,Unavailable
4419514,Ease of tube advancement,Airtraq laryngoscope,GlideScope,No significant difference,"Ease of tube advancement (0/1/2/3, n)	24/3/5/3	26/3/5/1	0.525",20993:21078,4419514,25927657,Unavailable
4419514,Ease of laryngoscope insertion,Airtraq laryngoscope,GlideScope,No significant difference,"Ease of laryngoscope insertion (0/1/2/3, n)	33/1/1/0	33/2/0/0	0.98",20885:20975,4419514,25927657,Unavailable
4419514,Ease of tube advancement,Airtraq laryngoscope,GlideScope,No significant difference,Only one patient in group A was rated as difficult insertion because of dental problem. 5 cases and 3 cases in group A were considered as difficult or very difficult to advance the tube.,19965:20151,4419514,25927657,Unavailable
4419514,Ease of laryngoscope insertion,Airtraq laryngoscope,GlideScope,No significant difference,Only one patient in group A was rated as difficult insertion because of dental problem. 5 cases and 3 cases in group A were considered as difficult or very difficult to advance the tube.,19964:20151,4419514,25927657,Unavailable
5836509,Calorie intakes at 4 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,"Both groups reduced calorie intakes at 4 and 6 mo, with no group difference",22232:22307,5836509,29517074,Unavailable
5836509,Calorie intakes at 6 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,"Both groups reduced calorie intakes at 4 and 6 mo, with no group difference",23947:24042,5836509,29517074,Unavailable
5836509,6-minute walk test results at 4 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,"However, there was no significant difference detected in 6MWT results between treatment groups.",23947:24042,5836509,29517074,Unavailable
5836509,6-minute walk test results at 6 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,"However, there was no significant difference detected in 6MWT results between treatment groups.",23947:24042,5836509,29517074,Unavailable
5836509,Lean mass at 4 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,"However, the comparison for changes in lean mass between treatment groups was nonsignificant.",25472:25593,5836509,29517074,Unavailable
5836509,Lean mass at 6 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,"However, the comparison for changes in lean mass between treatment groups was nonsignificant.",24371:24464,5836509,29517074,Unavailable
5836509,Short Physical Performance Battery performance at 4 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,We did not find a significant group effect for any of these measures of function or for body fat or waist circumference.,25472:25593,5836509,29517074,Unavailable
5836509,Short Physical Performance Battery performance at 6 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,We did not find a significant group effect for any of these measures of function or for body fat or waist circumference.,25472:25593,5836509,29517074,Unavailable
5836509,30 second chair stands performance at 4 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,We did not find a significant group effect for any of these measures of function or for body fat or waist circumference.,25472:25593,5836509,29517074,Unavailable
5836509,30 second chair stands performance at 6 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,We did not find a significant group effect for any of these measures of function or for body fat or waist circumference.,25472:25593,5836509,29517074,Unavailable
5836509,8-foot up-and-go test performance at 4 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,We did not find a significant group effect for any of these measures of function or for body fat or waist circumference.,25472:25593,5836509,29517074,Unavailable
5836509,8-foot up-and-go test performance at 6 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,We did not find a significant group effect for any of these measures of function or for body fat or waist circumference.,25472:25593,5836509,29517074,Unavailable
5836509,Body fat at 4 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,We did not find a significant group effect for any of these measures of function or for body fat or waist circumference.,26884:26961,5836509,29517074,Unavailable
5836509,Body fat at 6 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,We did not find a significant group effect for any of these measures of function or for body fat or waist circumference.,26884:26961,5836509,29517074,Unavailable
5836509,Waist circumference at 4 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,We did not find a significant group effect for any of these measures of function or for body fat or waist circumference.,26884:26961,5836509,29517074,Unavailable
5836509,Waist circumference at 6 months,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,We did not find a significant group effect for any of these measures of function or for body fat or waist circumference.,26884:26961,5836509,29517074,Unavailable
5836509,Drop-out rate,High-Protein–Weight-Loss program,Control–Weight-Loss program,No significant difference,There was no difference in drop-out rate by group (P = 0.30),26884:26961,5836509,29517074,Unavailable
5812853,Maximal heart rate,GlideTrak running with body weight support,Normal-weight treadmill running,Significantly decreased,"Maximal HR and VO2 values were significantly (p&nbsp;&lt;&nbsp;0.001) lower during GTR (183.4&nbsp;±&nbsp;9.1 bpm, 38.1&nbsp;±&nbsp;7.2 mL&nbsp;kg−1&nbsp;min−1) compared to TMR (194.3&nbsp;±&nbsp;8.6 bpm, 49.5&nbsp;±&nbsp;8.9&nbsp;kg−1&nbsp;min−1).",4473:4724,5812853,29541129,Unavailable
5812853,Maximal VO2 value,GlideTrak running with body weight support,Normal-weight treadmill running,Significantly decreased,"Maximal HR and VO2 values were significantly (p&nbsp;&lt;&nbsp;0.001) lower during GTR (183.4&nbsp;±&nbsp;9.1 bpm, 38.1&nbsp;±&nbsp;7.2 mL&nbsp;kg−1&nbsp;min−1) compared to TMR (194.3&nbsp;±&nbsp;8.6 bpm, 49.5&nbsp;±&nbsp;8.9&nbsp;kg−1&nbsp;min−1).",4473:4724,5812853,29541129,Unavailable
5812853,Intercept of the HR-VO2 relationship at a HR of 140 bpm,GlideTrak running with body weight support,Normal-weight treadmill running,Significantly decreased,"There was a significant difference in the HR-VO2 relationship between GTR and TMR. Compared to TMR, exercising at a HR of 140 bpm resulted in a VO2 that was 4.0 mL&nbsp;kg−1&nbsp;min−1 lower during GTR.",4723:4960,5812853,29541129,Unavailable
5812853,Maximal heart rate,GlideTrak running with body weight support,Normal-weight treadmill running,Significantly decreased,"Maximal HR (bpm)a	194.3&nbsp;±&nbsp;8.6	184.0&nbsp;±&nbsp;8.8	0.001",21309:21427,5812853,29541129,Unavailable
5812853,Maximal VO2 value,GlideTrak running with body weight support,Normal-weight treadmill running,Significantly decreased,"VO2max(mL&nbsp;kg−1&nbsp;min−1)a	49.5&nbsp;±&nbsp;8.9	38.1&nbsp;±&nbsp;7.2	&lt;0.001",21752:21907,5812853,29541129,Unavailable
5812853,Maximal respiratory exchange ratio ,GlideTrak running with body weight support,Normal-weight treadmill running,No significant difference,"Maximal RER	1.11&nbsp;±&nbsp;0.04	1.10&nbsp;±&nbsp;0.05	0.464",21588:21653,5812853,29541129,Unavailable
5812853,Maximal perceived exertion,GlideTrak running with body weight support,Normal-weight treadmill running,Significantly decreased,"Maximal RPE	19.4&nbsp;±&nbsp;0.6	18.3&nbsp;±&nbsp;0.9	0.029",21671:21734,5812853,29541129,Unavailable
5812853,Intercept of the HR-VO2 relationship at a HR of 140 bpm,GlideTrak running with body weight support,Normal-weight treadmill running,Significantly decreased,The intercept of the HR-VO2 relationship at a HR of 140 bpm was significantly less (p&nbsp;&lt;&nbsp;0.05) during GTR (23.2&nbsp;mL·kg−1·min−1) compared to TMR (27.2 mL·kg−·min−1).,22624:22861,5812853,29541129,Unavailable
3702149,Job satisfaction ,6-session communication skills program,Control,Significantly increased,"After the communication skills training program in the experimental group, mean score of job satisfaction increased and it was significant compared to the control group (p &lt; 0.01).",4907:5087,3702149,23833629,Unavailable
3702149,Job satisfaction ,6-session communication skills program,Control,Significantly increased,"Independent t-test showed that mean score of job satisfaction had no significant difference in the test and control groups before the intervention (p = 0.92), but had a significant difference after the intervention (p &lt; 0.01).",14749:14976,3702149,23833629,Unavailable
3575556,Compliance,S9 CPAP,Normal CPAP before S9,Significantly increased,"Patients were significantly more compliant when using the S9 than their usual CPAP device both pre- and post-S9 based on average daily usage. CPAP pre-S9 = 6.58 ± 1.95 (mean hours ± SD), S9 = 7.08 ± 1.18&nbsp;h and CPAP post-S9 = 6.71 ± 1.72&nbsp;h. The difference between CPAP pre-S9 and S9 was 0.5&nbsp;h (p = 0.003). The difference between S9 and CPAP post-S9 was 0.35&nbsp;h (p = 0.01).",3334:3738,3575556,22286779,Unavailable
3575556,Compliance,S9 CPAP,Normal CPAP after S9,Significantly increased,"Patients were significantly more compliant when using the S9 than their usual CPAP device both pre- and post-S9 based on average daily usage. CPAP pre-S9 = 6.58 ± 1.95 (mean hours ± SD), S9 = 7.08 ± 1.18&nbsp;h and CPAP post-S9 = 6.71 ± 1.72&nbsp;h. The difference between CPAP pre-S9 and S9 was 0.5&nbsp;h (p = 0.003). The difference between S9 and CPAP post-S9 was 0.35&nbsp;h (p = 0.01).",3334:3739,3575556,22286779,Unavailable
3575556,Compliance,Normal CPAP before S9,Normal CPAP after S9,No significant difference,There was no significant difference between CPAP pre-S9 and CPAP post-S9 (p = 0.34).,3739:3840,3575556,22286779,Unavailable
3575556,Compliance,S9 CPAP,Normal CPAP before S9,Significantly increased,Average daily usage on the S9 system increased 30&nbsp;min from a mean of 6.58 ± 1.95&nbsp;h on the patient's usual CPAP before trialling S9 to 7.08 ± 1.18&nbsp;h when trialling S9 (p = 0.003).,14140:14335,3575556,22286779,Unavailable
3575556,Compliance,S9 CPAP,Normal CPAP after S9,Significantly increased,"The S9 was also used an average of 21&nbsp;min longer than the subject's usual device when they resumed use post-trialling S9, with the mean average usage on the S9 of 7.07 ± 1.2&nbsp;h compared with the subject's usual device usage post-S9 of 6.72 ± 1.72&nbsp;h (p = 0.010).",14336:14613,3575556,22286779,Unavailable
3575556,Compliance,Normal CPAP before S9,Normal CPAP after S9,No significant difference,"Compliance on the subject's usual device was not significantly different pre- and post-trialling the S9, with the average daily usage of 6.57 ± 1.98&nbsp;h before trialling the S9 compared to 6.72 ± 1.72&nbsp;h after trialling the S9 (p = 0.34).",14614:14866,3575556,22286779,Unavailable
3575556,Compliance,S9 CPAP,Normal CPAP before S9,Significantly increased,"6.58 ± 1.95	7.08 ± 1.18		0.003a",15301:15361,3575556,22286779,Unavailable
3575556,Compliance,S9 CPAP,Normal CPAP after S9,Significantly increased,"7.07 ± 1.2	6.72 ± 1.72	0.010a",15405:15455,3575556,22286779,Unavailable
3575556,Compliance,Normal CPAP before S9,Normal CPAP after S9,No significant difference,"44	6.57 ± 1.98		6.72 ± 1.72	ns",15479:15541,3575556,22286779,Unavailable
3575556,Days used &lt; 4 h,S9 CPAP,Normal CPAP before S9,Significantly decreased,"The usual CPAP pre-S9 was used &lt; 4&nbsp;h an average of 2.04&nbsp;days, whereas the S9 was used &lt; 4&nbsp;h an average of 1.00&nbsp;day (p = 0.003).",16596:16752,3575556,22286779,Unavailable
3575556,Days used &lt;4 h,S9 CPAP,Normal CPAP after S9,No significant difference,There was no significant difference between days used &lt; 4&nbsp;h on the S9 (1&nbsp;day) and average number of days used &lt; 4&nbsp;h on the patient's usual device post-CPAP (1.64&nbsp;days) (p = 0.134),16753:16956,3575556,22286779,Unavailable
3575556,Days used &lt; 4 h,Normal CPAP before S9,Normal CPAP after S9,No significant difference,There was also no significant difference between days used &lt; 4&nbsp;h on the usual CPAP pre-S9 (1.54&nbsp;days) and days used &lt; 4&nbsp;h on the usual CPAP post-S9 (1.50&nbsp;days) (p = 0.277).,16955:17151,3575556,22286779,Unavailable
3575556,Averge daily usage ,S9 CPAP,Normal CPAP before S9,Significantly increased,These subjects improved their average daily usage from 2.67 ± 0.9&nbsp;h on their usual CPAP pre-S9 to 5.43 ± 1.23&nbsp;h on the S9 (p = 0.001).,17310:17462,3575556,22286779,Unavailable
3575556,Averge daily usage ,S9 CPAP,Normal CPAP after S9,Significantly increased,There was a decrease in usage hours when these patients resumed their usual CPAP post-S9 from 5.43 ± 1.23&nbsp;h on S9 to 4.03 ± 2.07&nbsp;h on their CPAP post-S9 (p = 0.041).,17462:17645,3575556,22286779,Unavailable
3575556,Average daily usage ,Normal CPAP before S9,Normal CPAP after S9,No significant difference,There was no significant difference in average daily usage between CPAP pre-S9 and post-S9 (p = 0.080).,17645:17766,3575556,22286779,Unavailable
3575556,Mask leak,S9 CPAP,Normal CPAP before S9,No significant difference,"There were no significant clinical differences in any of the other therapy parameters, including leak, pressure and AHI downloaded from the devices, as shown in Table&nbsp;3.",18743:18953,3575556,22286779,Unavailable
3575556,Mask leak,S9 CPAP,Normal CPAP after S9,No significant difference,"There were no significant clinical differences in any of the other therapy parameters, including leak, pressure and AHI downloaded from the devices, as shown in Table&nbsp;3.",18743:18953,3575556,22286779,Unavailable
3575556,Mask leak,Normal CPAP before S9,Normal CPAP after S9,No significant difference,"There were no significant clinical differences in any of the other therapy parameters, including leak, pressure and AHI downloaded from the devices, as shown in Table&nbsp;3.",18743:18953,3575556,22286779,Unavailable
3575556,Pressure ,S9 CPAP,Normal CPAP before S9,No significant difference,"There were no significant clinical differences in any of the other therapy parameters, including leak, pressure and AHI downloaded from the devices, as shown in Table&nbsp;3.",18743:18953,3575556,22286779,Unavailable
3575556,Pressure ,S9 CPAP,Normal CPAP after S9,No significant difference,"There were no significant clinical differences in any of the other therapy parameters, including leak, pressure and AHI downloaded from the devices, as shown in Table&nbsp;3.",18743:18953,3575556,22286779,Unavailable
3575556,Pressure ,Normal CPAP before S9,Normal CPAP after S9,No significant difference,"There were no significant clinical differences in any of the other therapy parameters, including leak, pressure and AHI downloaded from the devices, as shown in Table&nbsp;3.",18743:18953,3575556,22286779,Unavailable
3575556,Apnea hypopnea index,S9 CPAP,Normal CPAP before S9,No significant difference,"There were no significant clinical differences in any of the other therapy parameters, including leak, pressure and AHI downloaded from the devices, as shown in Table&nbsp;3.",18743:18953,3575556,22286779,Unavailable
3575556,Apnea hypopnea index,S9 CPAP,Normal CPAP after S9,No significant difference,"There were no significant clinical differences in any of the other therapy parameters, including leak, pressure and AHI downloaded from the devices, as shown in Table&nbsp;3.",18743:18953,3575556,22286779,Unavailable
3575556,Apnea hypopnea index,Normal CPAP before S9,Normal CPAP after S9,No significant difference,"There were no significant clinical differences in any of the other therapy parameters, including leak, pressure and AHI downloaded from the devices, as shown in Table&nbsp;3.",18743:18953,3575556,22286779,Unavailable
3575556,Comfort of breathing,S9 CPAP,Normal CPAP ,Significantly increased,"Subjects rated the S9 significantly better than their usual device in comfort of breathing (p &lt; 0.001), dryness of nose and mouth (p = 0.027), amount of condensation in the tube and mask (p &lt; 0.001) and noise (p &lt; 0.001).",20135:20434,3575556,22286779,Unavailable
3575556,Dryness of nose and mouth,S9 CPAP,Normal CPAP ,Significantly decreased,"Subjects rated the S9 significantly better than their usual device in comfort of breathing (p &lt; 0.001), dryness of nose and mouth (p = 0.027), amount of condensation in the tube and mask (p &lt; 0.001) and noise (p &lt; 0.001).",20135:20434,3575556,22286779,Unavailable
3575556,Amount of condensation in the tube and mask ,S9 CPAP,Normal CPAP ,Significantly decreased,"Subjects rated the S9 significantly better than their usual device in comfort of breathing (p &lt; 0.001), dryness of nose and mouth (p = 0.027), amount of condensation in the tube and mask (p &lt; 0.001) and noise (p &lt; 0.001).",20135:20434,3575556,22286779,Unavailable
3575556,Noise ,S9 CPAP,Normal CPAP ,Significantly decreased,"Subjects rated the S9 significantly better than their usual device in comfort of breathing (p &lt; 0.001), dryness of nose and mouth (p = 0.027), amount of condensation in the tube and mask (p &lt; 0.001) and noise (p &lt; 0.001).",20135:20434,3575556,22286779,Unavailable
3575556,Feeling of being refreshed,S9 CPAP,Normal CPAP ,No significant difference,No difference was found in the feeling of being refreshed after using each device (p = 0.066).,20434:20549,3575556,22286779,Unavailable
1968611,Severe alopecia,Verapamil,Control,Significantly increased,"There were no significant differences in general toxicities between the two arms, except for more severe alopecia in the verapamil treatment group (P = 0.045).",2088:2248,1968611,8398713,Unavailable
1968611,Cardiovascular toxicity,Verapamil,Control,No significant difference,There was no significant difference in cardiovascular or haematological toxicity,2249:2329,1968611,8398713,Unavailable
1968611,Haematological toxicity,Verapamil,Control,No significant difference,There was no significant difference in cardiovascular or haematological toxicity,2249:2329,1968611,8398713,Unavailable
1968611, Nadir white cell count after Cycle 1,Verapamil,Control,Significantly decreased,the median nadir white cell count after Cycle 1 chemotherapy was lower in the verapamil arm (P = 0.065) and there were significantly more dose reductions after Cycle 1 in the verapamil arm (P = 0.031).,2339:2541,1968611,8398713,Unavailable
1968611,Dose reductions ,Verapamil,Control,Significantly increased,the median nadir white cell count after Cycle 1 chemotherapy was lower in the verapamil arm (P = 0.065) and there were significantly more dose reductions after Cycle 1 in the verapamil arm (P = 0.031).,2339:2541,1968611,8398713,Unavailable
1968611,Response to chemotherapy ,Verapamil,Control,No significant difference,No statistically significant differences in response (P = 0.582) or survival (P = 0.290) data were seen.,2542:2646,1968611,8398713,Unavailable
1968611,Survival ,Verapamil,Control,No significant difference,No statistically significant differences in response (P = 0.582) or survival (P = 0.290) data were seen.,2542:2646,1968611,8398713,Unavailable
5769199,Heart rate,Slow breathing exercises ,Control,Significantly decreased,There was a significant reduction in HR from baseline compared to the control group.,19657:19741,5769199,29343931,Unavailable
5769199,Systolic blood pressure ,Slow breathing exercises ,Control,No significant difference,"The SBP and DBP values following 12 weeks of slow, deep breathing exercise also showed a statistically significant reduction, but the marginal reduction in blood pressure seems to be clinically insignificant",19742:19967,5769199,29343931,Unavailable
5769199,Diastolic blood pressure ,Slow breathing exercises ,Control,No significant difference,"The SBP and DBP values following 12 weeks of slow, deep breathing exercise also showed a statistically significant reduction, but the marginal reduction in blood pressure seems to be clinically insignificant",19742:19967,5769199,29343931,Unavailable
5769199,Perceived Stress Score ,Slow breathing exercises ,Control,Significantly decreased,The magnitude of change (delta change) of the Perceived Stress Score in the study group was significant compared to that of the control group,20198:20339,5769199,29343931,Unavailable
5769199,Heart rate,Slow breathing exercises ,Control,Significantly decreased,"HR, SBP, DBP, and PSS decreased significantly (P &lt; 0.05) in the study group following 12 weeks slow breathing exercise training",4707:4851,5769199,29343931,Unavailable
5769199,Systolic blood pressure ,Slow breathing exercises ,Control,No significant difference,"HR, SBP, DBP, and PSS decreased significantly (P &lt; 0.05) in the study group following 12 weeks slow breathing exercise training",4707:4851,5769199,29343931,Unavailable
5769199,Diastolic blood pressure ,Slow breathing exercises ,Control,No significant difference,"HR, SBP, DBP, and PSS decreased significantly (P &lt; 0.05) in the study group following 12 weeks slow breathing exercise training",4707:4851,5769199,29343931,Unavailable
5769199,Perceived Stress Score ,Slow breathing exercises ,Control,Significantly decreased,"HR, SBP, DBP, and PSS decreased significantly (P &lt; 0.05) in the study group following 12 weeks slow breathing exercise training",4707:4851,5769199,29343931,Unavailable
5769199,Body mass index,Slow breathing exercises ,Control,No significant difference,no significant change (P &gt; 0.05) was observed in BMI and WHR.,4859:4940,5769199,29343931,Unavailable
5769199,Waist-hip ratio,Slow breathing exercises ,Control,No significant difference,no significant change (P &gt; 0.05) was observed in BMI and WHR.,4859:4940,5769199,29343931,Unavailable
3544370,All symptom duration,0.6 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,All symptom duration,1.2 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Main symptom duration,0.6 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Main symptom duration,1.2 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Minor symptom duration,0.6 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Minor symptom duration,1.2 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Cumulative symptom score,0.6 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Cumulative symptom score,1.2 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Main symptom score,0.6 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Main symptom score,1.2 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Minor symptom score,0.6 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Minor symptom score,1.2 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,All symptom duration,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Main symptom duration,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Minor symptom duration,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Cumulative symptom score,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Main symptom score,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Minor symptom score,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant.",5994:6422,3544370,23346193,Unavailable
3544370,Adverse events,0.6 g of Shi-cha,Placebo,No significant difference,There were no differences in adverse events.,6422:6467,3544370,23346193,Unavailable
3544370,Adverse events,1.2 g of Shi-cha,Placebo,No significant difference,There were no differences in adverse events.,6422:6467,3544370,23346193,Unavailable
3544370,Adverse events,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,There were no differences in adverse events.,6422:6467,3544370,23346193,Unavailable
3544370,Main symptom duration,0.6 g of Shi-cha,Placebo,Significantly decreased,"There was a significant difference in main symptom duration (Figures 2(c) and 2(e); P &lt; 0.0001) and minor symptom duration of arthralgia of extremities, stuffy nose, sneezing, as well as spiritlessness and weakness between patients with SCC treatment and without both the ITT and PP analyses (data not shown, P &lt; 0.0001).",20807:21243,3544370,23346193,Unavailable
3544370,Main symptom duration,1.2 g of Shi-cha,Placebo,Significantly decreased,"There was a significant difference in main symptom duration (Figures 2(c) and 2(e); P &lt; 0.0001) and minor symptom duration of arthralgia of extremities, stuffy nose, sneezing, as well as spiritlessness and weakness between patients with SCC treatment and without both the ITT and PP analyses (data not shown, P &lt; 0.0001).",20807:21243,3544370,23346193,Unavailable
3544370,Minor symptom duration,0.6 g of Shi-cha,Placebo,Significantly decreased,"There was a significant difference in main symptom duration (Figures 2(c) and 2(e); P &lt; 0.0001) and minor symptom duration of arthralgia of extremities, stuffy nose, sneezing, as well as spiritlessness and weakness between patients with SCC treatment and without both the ITT and PP analyses (data not shown, P &lt; 0.0001).",20807:21243,3544370,23346193,Unavailable
3544370,Minor symptom duration,1.2 g of Shi-cha,Placebo,Significantly decreased,"There was a significant difference in main symptom duration (Figures 2(c) and 2(e); P &lt; 0.0001) and minor symptom duration of arthralgia of extremities, stuffy nose, sneezing, as well as spiritlessness and weakness between patients with SCC treatment and without both the ITT and PP analyses (data not shown, P &lt; 0.0001).",20806:21243,3544370,23346193,Unavailable
3544370,All symptom duration,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"In addition, all symptom duration and main symptom duration showed a slight superiority of group B over group A, although these differences were not statistically significant.",20491:20666,3544370,23346193,Unavailable
3544370,Main symptom duration,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"In addition, all symptom duration and main symptom duration showed a slight superiority of group B over group A, although these differences were not statistically significant.",20491:20666,3544370,23346193,Unavailable
3544370,Cumulative symptom score,0.6 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, the ITT and PP analyses showed that patients in groups A and B had significant improvement in change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4 (P &lt; 0.0001).",21856:22118,3544370,23346193,Unavailable
3544370,Cumulative symptom score,1.2 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, the ITT and PP analyses showed that patients in groups A and B had significant improvement in change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4 (P &lt; 0.0001).",21856:22118,3544370,23346193,Unavailable
3544370,Main symptom score,0.6 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, the ITT and PP analyses showed that patients in groups A and B had significant improvement in change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4 (P &lt; 0.0001).",21856:22118,3544370,23346193,Unavailable
3544370,Main symptom score,1.2 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, the ITT and PP analyses showed that patients in groups A and B had significant improvement in change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4 (P &lt; 0.0001).",21856:22118,3544370,23346193,Unavailable
3544370,Minor symptom score,0.6 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, the ITT and PP analyses showed that patients in groups A and B had significant improvement in change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4 (P &lt; 0.0001).",21856:22118,3544370,23346193,Unavailable
3544370,Minor symptom score,1.2 g of Shi-cha,Placebo,Significantly decreased,"Compared with patients in group C, the ITT and PP analyses showed that patients in groups A and B had significant improvement in change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4 (P &lt; 0.0001).",21856:22118,3544370,23346193,Unavailable
3544370,Cumulative symptom score,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"In addition, the scores showed a slight superiority of group B over group A at day 4, although these differences were not statistically significant",22118:22267,3544370,23346193,Unavailable
3544370,Main symptom score,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"In addition, the scores showed a slight superiority of group B over group A at day 4, although these differences were not statistically significant",22119:22266,3544370,23346193,Unavailable
3544370,Minor symptom score,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"In addition, the scores showed a slight superiority of group B over group A at day 4, although these differences were not statistically significant",22118:22266,3544370,23346193,Unavailable
3544370,Adverse events,0.6 g of Shi-cha,Placebo,No significant difference,"There were one, one, and two patients with adverse effects in group A, group B, and group C, respectively (P = 0.774).",22416:22551,3544370,23346193,Unavailable
3544370,Adverse events,1.2 g of Shi-cha,Placebo,No significant difference,"There were one, one, and two patients with adverse effects in group A, group B, and group C, respectively (P = 0.774).",22416:22551,3544370,23346193,Unavailable
3544370,Adverse events,0.6 g of Shi-cha,1.2 g of Shi-cha,No significant difference,"There were one, one, and two patients with adverse effects in group A, group B, and group C, respectively (P = 0.774).",22416:22551,3544370,23346193,Unavailable
3653802,Neonatal mortality rate at year 1,Maternal-and-Newborn Stakeholder Groups ,Control,No significant difference,"No significant difference in NMR was observed during the first 2 y of the trial (July 2008 to June 2009 and July 2009 to June 2010, respectively) while the third year (July 2010 to June 2011) showed a significantly lower NMR in intervention arm; adjusted OR 0.51 (95% CI 0.30–0.89)",54100:54381,3653802,23690755,Unavailable
3653802,Neonatal mortality rate at year 2,Maternal-and-Newborn Stakeholder Groups ,Control,No significant difference,"No significant difference in NMR was observed during the first 2 y of the trial (July 2008 to June 2009 and July 2009 to June 2010, respectively) while the third year (July 2010 to June 2011) showed a significantly lower NMR in intervention arm; adjusted OR 0.51 (95% CI 0.30–0.89)",54100:54381,3653802,23690755,Unavailable
3653802,Neonatal mortality rate at year 3,Maternal-and-Newborn Stakeholder Groups ,Control,Significantly decreased,"No significant difference in NMR was observed during the first 2 y of the trial (July 2008 to June 2009 and July 2009 to June 2010, respectively) while the third year (July 2010 to June 2011) showed a significantly lower NMR in intervention arm; adjusted OR 0.51 (95% CI 0.30–0.89)",54100:54381,3653802,23690755,Unavailable
3653802,Frequency of antenatal care,Maternal-and-Newborn Stakeholder Groups ,Control,Significantly increased,"Antenatal care was significantly more common among women in intervention communes (adjusted OR 2.27, 95% CI 1.07–4.80) with a significant time trend in the intervention arm.",54996:55170,3653802,23690755,Unavailable
3653802,Tetanus immunisation,Maternal-and-Newborn Stakeholder Groups ,Control,No significant difference,"There were no significant differences in the following secondary outcomes: tetanus immunisation as part of the antenatal services (OR 1.64, 95% CI 0.83–3.24), the presence of delivery preparedness (OR 1.33, 95% CI 0.67–2.64), institutional delivery (OR 1.88, 95% CI 0.60–5.87), temperature control at delivery (OR 1.28, 95% CI 0.50–3.25), early initiation of breastfeeding (OR 0.93, 95% CI 0.6–1.37), or home visit of a midwife during the first week after delivery (OR 1.06, 95% CI 0.51–2.20)",55170:55662,3653802,23690755,Unavailable
3653802,Delivery preparedness,Maternal-and-Newborn Stakeholder Groups ,Control,No significant difference,"There were no significant differences in the following secondary outcomes: tetanus immunisation as part of the antenatal services (OR 1.64, 95% CI 0.83–3.24), the presence of delivery preparedness (OR 1.33, 95% CI 0.67–2.64), institutional delivery (OR 1.88, 95% CI 0.60–5.87), temperature control at delivery (OR 1.28, 95% CI 0.50–3.25), early initiation of breastfeeding (OR 0.93, 95% CI 0.6–1.37), or home visit of a midwife during the first week after delivery (OR 1.06, 95% CI 0.51–2.20)",55170:55662,3653802,23690755,Unavailable
3653802,Institutional deliveries,Maternal-and-Newborn Stakeholder Groups ,Control,No significant difference,"There were no significant differences in the following secondary outcomes: tetanus immunisation as part of the antenatal services (OR 1.64, 95% CI 0.83–3.24), the presence of delivery preparedness (OR 1.33, 95% CI 0.67–2.64), institutional delivery (OR 1.88, 95% CI 0.60–5.87), temperature control at delivery (OR 1.28, 95% CI 0.50–3.25), early initiation of breastfeeding (OR 0.93, 95% CI 0.6–1.37), or home visit of a midwife during the first week after delivery (OR 1.06, 95% CI 0.51–2.20)",55170:55662,3653802,23690755,Unavailable
3653802,Temperature control at delivery,Maternal-and-Newborn Stakeholder Groups ,Control,No significant difference,"There were no significant differences in the following secondary outcomes: tetanus immunisation as part of the antenatal services (OR 1.64, 95% CI 0.83–3.24), the presence of delivery preparedness (OR 1.33, 95% CI 0.67–2.64), institutional delivery (OR 1.88, 95% CI 0.60–5.87), temperature control at delivery (OR 1.28, 95% CI 0.50–3.25), early initiation of breastfeeding (OR 0.93, 95% CI 0.6–1.37), or home visit of a midwife during the first week after delivery (OR 1.06, 95% CI 0.51–2.20)",55170:55662,3653802,23690755,Unavailable
3653802,Early initiation of breastfeeding,Maternal-and-Newborn Stakeholder Groups ,Control,No significant difference,"There were no significant differences in the following secondary outcomes: tetanus immunisation as part of the antenatal services (OR 1.64, 95% CI 0.83–3.24), the presence of delivery preparedness (OR 1.33, 95% CI 0.67–2.64), institutional delivery (OR 1.88, 95% CI 0.60–5.87), temperature control at delivery (OR 1.28, 95% CI 0.50–3.25), early initiation of breastfeeding (OR 0.93, 95% CI 0.6–1.37), or home visit of a midwife during the first week after delivery (OR 1.06, 95% CI 0.51–2.20)",55170:55662,3653802,23690755,Unavailable
3653802,Home visit of a midwife during the first week,Maternal-and-Newborn Stakeholder Groups ,Control,No significant difference,"There were no significant differences in the following secondary outcomes: tetanus immunisation as part of the antenatal services (OR 1.64, 95% CI 0.83–3.24), the presence of delivery preparedness (OR 1.33, 95% CI 0.67–2.64), institutional delivery (OR 1.88, 95% CI 0.60–5.87), temperature control at delivery (OR 1.28, 95% CI 0.50–3.25), early initiation of breastfeeding (OR 0.93, 95% CI 0.6–1.37), or home visit of a midwife during the first week after delivery (OR 1.06, 95% CI 0.51–2.20)",55170:55662,3653802,23690755,Unavailable
2699657,Time to dropout,Quetiapine,Control,No significant difference,"The primary outcome, time to dropout, was examined using survival analysis. It was shown that patients in the quetiapine group dropped out earlier than those in the placebo group, but this difference was not significant (p = 0.68)",4008:4238,2699657,19557142,Unavailable
2699657,Improvement in psychotic symptoms,Quetiapine,Control,No significant difference,No significant changes were found for any of the secondary outcome measures in either group.,4240:4332,2699657,19557142,Unavailable
2699657,Unified Parkinson’s Disease Rating Scale,Quetiapine,Control,No significant difference,No significant changes were found for any of the secondary outcome measures in either group.,4240:4332,2699657,19557142,Unavailable
2699657,Brief Psychiatric Rating Scale,Quetiapine,Control,No significant difference,No significant changes were found for any of the secondary outcome measures in either group.,14875:15165,2699657,19557142,Unavailable
2699657,Neuropsychiatric Inventory,Quetiapine,Control,No significant difference,No significant changes were found for any of the secondary outcome measures in either group.,11971:11975,2699657,19557142,Unavailable
2699657,Baylor PD hallucination scale,Quetiapine,Control,No significant difference,No significant changes were found for any of the secondary outcome measures in either group.,11971:11975,2699657,19557142,Unavailable
2699657,Time to dropout,Quetiapine,Control,No significant difference,The graph shows that patients on quetiapine dropped out faster than patients on placebo. The log rank test was used to compare the survival distributions; they were not found to be significantly different (p =0.68). Quetiapine therefore did not have a significant effect on time to dropout.,14875:15165,2699657,19557142,Unavailable
2699657,Improvement in psychotic symptoms,Quetiapine,Control,No significant difference,"Due to the small numbers and high drop out rate, the secondary outcome measures (Baylor PD hallucination scale, UPDRS, NPI, and BPRS) were only analyzed at six weeks. The analysis was by intention to treat and missing values were imputed using last observation carried forward. No significant changes were found for any of the secondary outcome measures in either group.",15172:15542,2699657,19557142,Unavailable
2699657,Unified Parkinson’s Disease Rating Scale,Quetiapine,Control,No significant difference,"Due to the small numbers and high drop out rate, the secondary outcome measures (Baylor PD hallucination scale, UPDRS, NPI, and BPRS) were only analyzed at six weeks. The analysis was by intention to treat and missing values were imputed using last observation carried forward. No significant changes were found for any of the secondary outcome measures in either group.",15172:15543,2699657,19557142,Unavailable
2699657,Brief Psychiatric Rating Scale,Quetiapine,Control,No significant difference,"Due to the small numbers and high drop out rate, the secondary outcome measures (Baylor PD hallucination scale, UPDRS, NPI, and BPRS) were only analyzed at six weeks. The analysis was by intention to treat and missing values were imputed using last observation carried forward. No significant changes were found for any of the secondary outcome measures in either group.",15172:15543,2699657,19557142,Unavailable
2699657,Neuropsychiatric Inventory,Quetiapine,Control,No significant difference,"Due to the small numbers and high drop out rate, the secondary outcome measures (Baylor PD hallucination scale, UPDRS, NPI, and BPRS) were only analyzed at six weeks. The analysis was by intention to treat and missing values were imputed using last observation carried forward. No significant changes were found for any of the secondary outcome measures in either group.",15172:15543,2699657,19557142,Unavailable
2699657,Baylor PD hallucination scale,Quetiapine,Control,No significant difference,"Due to the small numbers and high drop out rate, the secondary outcome measures (Baylor PD hallucination scale, UPDRS, NPI, and BPRS) were only analyzed at six weeks. The analysis was by intention to treat and missing values were imputed using last observation carried forward. No significant changes were found for any of the secondary outcome measures in either group.",15172:15543,2699657,19557142,Unavailable
3611754,Intraoperative total fluid input,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly decreased,"The patients who received the HS-HES solution had a significant decrease in the intraoperative total fluid input (p&lt;0.01), the volume of Ringer's solution required (p&lt;0.05), the fluid balance (p&lt;0.01) and their dural tension scores (p&lt;0.05).",4819:5138,3611754,23644851,Unavailable
3611754,Volume of Ringer's solution required ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly decreased,"The patients who received the HS-HES solution had a significant decrease in the intraoperative total fluid input (p&lt;0.01), the volume of Ringer's solution required (p&lt;0.05), the fluid balance (p&lt;0.01) and their dural tension scores (p&lt;0.05).",4819:5138,3611754,23644851,Unavailable
3611754,Fluid balance,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly decreased,"The patients who received the HS-HES solution had a significant decrease in the intraoperative total fluid input (p&lt;0.01), the volume of Ringer's solution required (p&lt;0.05), the fluid balance (p&lt;0.01) and their dural tension scores (p&lt;0.05).",4819:5138,3611754,23644851,Unavailable
3611754,Dural tension scores,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly decreased,"The patients who received the HS-HES solution had a significant decrease in the intraoperative total fluid input (p&lt;0.01), the volume of Ringer's solution required (p&lt;0.05), the fluid balance (p&lt;0.01) and their dural tension scores (p&lt;0.05).",4819:5138,3611754,23644851,Unavailable
3611754,Total urine output,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"The total urine output, blood loss, bleeding severity scores, operation duration and hemodynamic variables were similar in both groups (p&gt;0.05).",5138:5302,3611754,23644851,Unavailable
3611754,Blood loss,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"The total urine output, blood loss, bleeding severity scores, operation duration and hemodynamic variables were similar in both groups (p&gt;0.05).",5138:5302,3611754,23644851,Unavailable
3611754,Bleeding severity ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"The total urine output, blood loss, bleeding severity scores, operation duration and hemodynamic variables were similar in both groups (p&gt;0.05).",5138:5302,3611754,23644851,Unavailable
3611754,Operation duration,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"The total urine output, blood loss, bleeding severity scores, operation duration and hemodynamic variables were similar in both groups (p&gt;0.05).",5138:5302,3611754,23644851,Unavailable
3611754,Heart rate,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"The total urine output, blood loss, bleeding severity scores, operation duration and hemodynamic variables were similar in both groups (p&gt;0.05).",5138:5302,3611754,23644851,Unavailable
3611754,Mean arterial pressure ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"The total urine output, blood loss, bleeding severity scores, operation duration and hemodynamic variables were similar in both groups (p&gt;0.05).",5138:5302,3611754,23644851,Unavailable
3611754,Central venous pressure ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"The total urine output, blood loss, bleeding severity scores, operation duration and hemodynamic variables were similar in both groups (p&gt;0.05).",5138:5302,3611754,23644851,Unavailable
3611754,Plasma osmolality,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly increased,"Moreover, compared with the HES group, the HS-HES group had significantly higher plasma concentrations of sodium and chloride, increasing the osmolality (p&lt;0.01).",5303:5485,3611754,23644851,Unavailable
3611754,Intraoperative total fluid input,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly decreased,"Compared with HES infusion, HS-HES infusion reduced the total fluid input (p&lt;0.01, Table&nbsp;2 and the volume of Ringer's solution (p&lt;0.05, Table&nbsp;2 required during the operation.",16363:16677,3611754,23644851,Unavailable
3611754,Volume of Ringer's solution required ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly decreased,"Compared with HES infusion, HS-HES infusion reduced the total fluid input (p&lt;0.01, Table&nbsp;2 and the volume of Ringer's solution (p&lt;0.05, Table&nbsp;2 required during the operation.",16363:16677,3611754,23644851,Unavailable
3611754,Fluid balance,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly decreased,"Moreover, the fluid balance of the HS-HES group was significantly lower than the HES group (p&lt;0.01, Table&nbsp;2, and HS-HES treatment also led to a significant decrease in the dural tension scores compared with HES infusion (p&lt;0.05, Table&nbsp;2.",16678:17055,3611754,23644851,Unavailable
3611754,Dural tension scores,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly decreased,"Moreover, the fluid balance of the HS-HES group was significantly lower than the HES group (p&lt;0.01, Table&nbsp;2, and HS-HES treatment also led to a significant decrease in the dural tension scores compared with HES infusion (p&lt;0.05, Table&nbsp;2.",16678:17055,3611754,23644851,Unavailable
3611754,Heart rate,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"The changes in HR, MAP and CVP were similar in both groups during the study period",17062:17144,3611754,23644851,Unavailable
3611754,Mean arterial pressure ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"The changes in HR, MAP and CVP were similar in both groups during the study period",17062:17144,3611754,23644851,Unavailable
3611754,Central venous pressure ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"The changes in HR, MAP and CVP were similar in both groups during the study period",17062:17144,3611754,23644851,Unavailable
3611754,Total urine output,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"With regard to the clinical measurements, the two groups did not significantly differ by operation duration, volume of PRBC, intraoperative total urine output, blood loss or intraoperative bleeding severity scores",15886:16099,3611754,23644851,Unavailable
3611754,Blood loss,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"With regard to the clinical measurements, the two groups did not significantly differ by operation duration, volume of PRBC, intraoperative total urine output, blood loss or intraoperative bleeding severity scores",15886:16099,3611754,23644851,Unavailable
3611754,Bleeding severity ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"With regard to the clinical measurements, the two groups did not significantly differ by operation duration, volume of PRBC, intraoperative total urine output, blood loss or intraoperative bleeding severity scores",15886:16099,3611754,23644851,Unavailable
3611754,Operation duration,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"With regard to the clinical measurements, the two groups did not significantly differ by operation duration, volume of PRBC, intraoperative total urine output, blood loss or intraoperative bleeding severity scores",15886:16099,3611754,23644851,Unavailable
3611754,Packed red blood cell volume,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"With regard to the clinical measurements, the two groups did not significantly differ by operation duration, volume of PRBC, intraoperative total urine output, blood loss or intraoperative bleeding severity scores",15886:16099,3611754,23644851,Unavailable
3611754,Plasma sodium ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly increased,"Moreover, compared with the HES group, the HS-HES group had significantly higher plasma concentrations of sodium and chloride, increasing the osmolality (p&lt;0.01).",15886:16099,3611754,23644851,Unavailable
3611754,Plasma chloride ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly increased,"Moreover, compared with the HES group, the HS-HES group had significantly higher plasma concentrations of sodium and chloride, increasing the osmolality (p&lt;0.01).",15886:16099,3611754,23644851,Unavailable
3611754,Hemoglobin concentration ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"There were no significant differences between the groups in terms of the Hb, Plt, Hct, PT, APTT and Fbg values and the plasma potassium or calcium concentrations",17492:17653,3611754,23644851,Unavailable
3611754,Platelet count ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"There were no significant differences between the groups in terms of the Hb, Plt, Hct, PT, APTT and Fbg values and the plasma potassium or calcium concentrations",17492:17653,3611754,23644851,Unavailable
3611754,Hematocrit  ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"There were no significant differences between the groups in terms of the Hb, Plt, Hct, PT, APTT and Fbg values and the plasma potassium or calcium concentrations",17492:17653,3611754,23644851,Unavailable
3611754,Prothrombin time,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"There were no significant differences between the groups in terms of the Hb, Plt, Hct, PT, APTT and Fbg values and the plasma potassium or calcium concentrations",17492:17653,3611754,23644851,Unavailable
3611754,Activated partial thromboplastin time,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"There were no significant differences between the groups in terms of the Hb, Plt, Hct, PT, APTT and Fbg values and the plasma potassium or calcium concentrations",17492:17653,3611754,23644851,Unavailable
3611754,Fibrinogen concentration,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"There were no significant differences between the groups in terms of the Hb, Plt, Hct, PT, APTT and Fbg values and the plasma potassium or calcium concentrations",17492:17653,3611754,23644851,Unavailable
3611754,Plasma potasium,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"There were no significant differences between the groups in terms of the Hb, Plt, Hct, PT, APTT and Fbg values and the plasma potassium or calcium concentrations",17492:17653,3611754,23644851,Unavailable
3611754,Plasma calcium ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,No significant difference,"There were no significant differences between the groups in terms of the Hb, Plt, Hct, PT, APTT and Fbg values and the plasma potassium or calcium concentrations",17492:17653,3611754,23644851,Unavailable
3611754,Plasma sodium ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly increased,but the plasma levels of sodium and chloride and the osmolality were markedly increased in the HS-HES group compared with the HES group,17655:17790,3611754,23644851,Unavailable
3611754,Plasma chloride ,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly increased,but the plasma levels of sodium and chloride and the osmolality were markedly increased in the HS-HES group compared with the HES group,17655:17790,3611754,23644851,Unavailable
3611754,Plasma osmolality,7.2% hypertonic saline - 6% hydroxyethyl starch,6% hydroxyethyl starch,Significantly increased,but the plasma levels of sodium and chloride and the osmolality were markedly increased in the HS-HES group compared with the HES group,17655:17790,3611754,23644851,Unavailable
5799991,Mesiodistal transportation at 3mm,WaveOne Gold,Neoniti,Significantly decreased,"Mesiodistal and buccolingual transportation showed a statistically significant difference at 3 mm (P = 0.009) and 7 mm (P = 0.002), respectively, when instrumented with Neoniti than WaveOne Gold.",4214:4443,5799991,29430097,Unavailable
5799991,Buccolingual transportation at 7mm,WaveOne Gold,Neoniti,Significantly decreased,"Mesiodistal and buccolingual transportation showed a statistically significant difference at 3 mm (P = 0.009) and 7 mm (P = 0.002), respectively, when instrumented with Neoniti than WaveOne Gold.",4214:4443,5799991,29430097,Unavailable
5799991,Mesiodistal transportation at 3mm,WaveOne Gold,Neoniti,Significantly decreased,Intergroup comparison of mesiodistal transportation between the groups showed a statistically significant difference at 3 mm (P = 0.009) when instrumented with Neoniti than WaveOne Gold.,14729:14932,5799991,29430097,Unavailable
5799991,Mesiodistal transportation at 5mm,WaveOne Gold,Neoniti,No significant difference,There was no significance at 5 mm and 7 mm mesiodistally between the groups,14933:15008,5799991,29430097,Unavailable
5799991,Mesiodistal transportation at 7mm,WaveOne Gold,Neoniti,No significant difference,There was no significance at 5 mm and 7 mm mesiodistally between the groups,14933:15008,5799991,29430097,Unavailable
5799991,Buccolingual transportation at 7mm,WaveOne Gold,Neoniti,Significantly decreased,Intergroup comparison of buccolingual transportation between the groups showed a statistically significant difference at 7 mm (P = 0.002) when instrumented with Neoniti than WaveOne Gold.,15057:15262,5799991,29430097,Unavailable
5799991,Buccolingual transportation at 3mm,WaveOne Gold,Neoniti,No significant difference,There was no significance at 3 mm and 5 mm buccolingually between the groups,15263:15339,5799991,29430097,Unavailable
5799991,Buccolingual transportation at 5mm,WaveOne Gold,Neoniti,No significant difference,There was no significance at 3 mm and 5 mm buccolingually between the groups,15263:15339,5799991,29430097,Unavailable
4132095,Circulating selenium concentrations,On-Pump surgery,Off-pump CAB surgery,No significant difference,"At end of surgery, both groups showed a comparable decrease of circulating selenium concentrations.",10070:10169,4132095,25118980,Unavailable
4132095,Levels of oxidative stress,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Likewise, levels of oxidative stress and IL-6 were comparable in both groups.",10170:10248,4132095,25118980,Unavailable
4132095,Levels of IL-6,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Likewise, levels of oxidative stress and IL-6 were comparable in both groups.",10170:10248,4132095,25118980,Unavailable
4132095,Circulating selenium concentrations,On-Pump surgery,Off-pump CAB surgery,No significant difference,Both groups demonstrated a significant and comparable intraoperative decrease of circulating selenium levels,45846:45954,4132095,25118980,Unavailable
4132095,Mann–Whitney U test measures,On-Pump surgery,Off-pump CAB surgery,Significantly increased,"The extent of decrease, measured with the Mann–Whitney U test, was more pronounced in the on-pump group (31.2±13.6 (mean ± SD) % vs. 20.2±16.3%; p = 0.040)",46018:46191,4132095,25118980,Unavailable
4132095,Glutathione peroxidase activity,On-Pump surgery,Off-pump CAB surgery,No significant difference,The extent of intraoperative decrease showed a trend towards a significant higher reduction in the on-pump group when compared to the OPCAB (26.1±11.6% (mean ± SD) vs. 19.1±15.6%; p = 0.121).,56756:57164,4132095,25118980,Unavailable
4132095,Levels of IL-6,On-Pump surgery,Off-pump CAB surgery,No significant difference,The time course of perioperative IL-6 levels showed a comparable increase in both groups,49895:49983,4132095,25118980,Unavailable
4132095,Creatine kinase MB,On-Pump surgery,Off-pump CAB surgery,Significantly increased,CK-MB showed a significant intraoperative increase in both groups (Fig. 4C) with a significantly higher percentual increase in the on-pump group (1195.9±1230.3% (mean ± SD) vs. 478.8±582.1; p = 0.044).,51656:51910,4132095,25118980,Unavailable
4132095,Atrial fibrillation,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Atrial fibrillation	n (%)	6 (15)		1 (5)		5 (25)		0.182",56268:56691,4132095,25118980,Unavailable
4132095,Stroke,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Stroke	n (%)	1 (3)		0 (0)		1 (5)		1.000",56756:57164,4132095,25118980,Unavailable
4132095,Delir,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Delir	n (%)	6 (15)		2 (10)		4 (20)		0.661",57229:57639,4132095,25118980,Unavailable
4132095,Acute Kidney Injury,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Acute Kidney Injury	n (%)	3 (8)		0 (0)		3 (15)		0.231",57704:58126,4132095,25118980,Unavailable
4132095,Pneumonia,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Pneumonia	n (%)	6 (15)		4 (20)		2 (10)		0.661",58191:58605,4132095,25118980,Unavailable
4132095,Cardiogenic shock,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Cardiogenic shock	n (%)	1 (3)		0 (0)		1 (5)		1.000",58670:59089,4132095,25118980,Unavailable
4132095,Wound infections ,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Wound infections	n (%)	1 (3)		1 (5)		0 (0)		1.000",59154:59572,4132095,25118980,Unavailable
4132095,SOFA score 1.POD,On-Pump surgery,Off-pump CAB surgery,No significant difference,"SOFA score 1.POD	n	6 (3–11)		6 (3–9)		6 (3–11)		0.719",59637:60059,4132095,25118980,Unavailable
4132095,SAPS II 1.POD,On-Pump surgery,Off-pump CAB surgery,No significant difference,"SAPS II 1.POD	n	29 (18–39)		29 (18–38)		29 (21–39)		0.951",60124:60550,4132095,25118980,Unavailable
4132095,Systemic Inflammatory Response Syndrome,On-Pump surgery,Off-pump CAB surgery,No significant difference,"SIRS	n (%)	14 (35)		6 (30)		8 (40)		0.507",61215:61625,4132095,25118980,Unavailable
4132095,"Severe SIRS and Sepsis	",On-Pump surgery,Off-pump CAB surgery,No significant difference,"Severe SIRS and Sepsis	n (%)	1 (3)		1 (5)		0 (0)		1.000",61690:62114,4132095,25118980,Unavailable
4132095,Septic shock,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Septic shock	n (%)	3 (8)		1 (5)		2 (10)		1.000",62179:62594,4132095,25118980,Unavailable
4132095,Hours of sedation,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Sedation	hours	10±8	[7]–[12]	9±5	[7]–[11]	11±10	[6]–[15]	0.539",63299:64091,4132095,25118980,Unavailable
4132095,"Duration of mechanical ventilation	",On-Pump surgery,Off-pump CAB surgery,No significant difference,"Duration of mechanical ventilation	hours	12±9	[9]–[15]	11±5	[9]–[14]	13±12	[7]–[19]	0.586",64156:64980,4132095,25118980,Unavailable
4132095,"ICU stay	",On-Pump surgery,Off-pump CAB surgery,No significant difference,"ICU stay	hours	80±108	[45–115]	67±90	[25–109]	93±126	[33–154]	0.459",65045:65481,4132095,25118980,Unavailable
4132095,"Hospital length of stay	",On-Pump surgery,Off-pump CAB surgery,No significant difference,"Hospital length of stay	days	15±10	[12]–[18]	14±11	[9]–[20]	16±8	[12]–[20]	0.635",65546:66346,4132095,25118980,Unavailable
4132095,Mortality,On-Pump surgery,Off-pump CAB surgery,No significant difference,"Mortality	n (%)	1 (3)		0 (0)		1 (5)		1.000",66411:66822,4132095,25118980,Unavailable
1619936,Improvement on number of urgency episodes,Solifenacin 5 mg,Placebo,Significantly increased,"Compared with placebo, solifenacin treatment at either the 5 or 10 mg dose resulted in a significant improvement in all of the symptoms measured.",19643:19789,1619936,16893438,Unavailable
1619936,Improvement on number of urgency episodes,Solifenacin 10 mg,Placebo,Significantly increased,"Compared with placebo, solifenacin treatment at either the 5 or 10 mg dose resulted in a significant improvement in all of the symptoms measured.",19643:19789,1619936,16893438,Unavailable
1619936,Improvement on number of incontinence episodes,Solifenacin 5 mg,Placebo,Significantly increased,"Compared with placebo, solifenacin treatment at either the 5 or 10 mg dose resulted in a significant improvement in all of the symptoms measured.",19643:19789,1619936,16893438,Unavailable
1619936,Improvement on number of incontinence episodes,Solifenacin 10 mg,Placebo,Significantly increased,"Compared with placebo, solifenacin treatment at either the 5 or 10 mg dose resulted in a significant improvement in all of the symptoms measured.",19643:19789,1619936,16893438,Unavailable
1619936,"Improvement on micturition frequency	",Solifenacin 5 mg,Placebo,Significantly increased,"Compared with placebo, solifenacin treatment at either the 5 or 10 mg dose resulted in a significant improvement in all of the symptoms measured.",19643:19789,1619936,16893438,Unavailable
1619936,"Improvement on micturition frequency	",Solifenacin 10 mg,Placebo,Significantly increased,"Compared with placebo, solifenacin treatment at either the 5 or 10 mg dose resulted in a significant improvement in all of the symptoms measured.",19643:19789,1619936,16893438,Unavailable
1619936,"Improvement on volume voided per micturition	",Solifenacin 5 mg,Placebo,Significantly increased,"Compared with placebo, solifenacin treatment at either the 5 or 10 mg dose resulted in a significant improvement in all of the symptoms measured.",19643:19789,1619936,16893438,Unavailable
1619936,"Improvement on volume voided per micturition	",Solifenacin 10 mg,Placebo,Significantly increased,"Compared with placebo, solifenacin treatment at either the 5 or 10 mg dose resulted in a significant improvement in all of the symptoms measured.",19643:19789,1619936,16893438,Unavailable
1619936,Improvement on mumber of nocturia episodes,Solifenacin 5 mg,Placebo,Significantly increased,"Compared with placebo, solifenacin treatment at either the 5 or 10 mg dose resulted in a significant improvement in all of the symptoms measured.",19643:19789,1619936,16893438,Unavailable
1619936,"Improvement on number of nocturia episodes	",Solifenacin 10 mg,Placebo,Significantly increased,"Compared with placebo, solifenacin treatment at either the 5 or 10 mg dose resulted in a significant improvement in all of the symptoms measured.",19643:19789,1619936,16893438,Unavailable
1619936,Resolution of urgency episodes,Solifenacin 5 mg,Placebo,Significantly increased,"In patients treated with solifenacin 5 and 10 mg who had urgency at baseline, 29% and 25%, respectively, had no urgency episodes at endpoint when compared with placebo (15%). This difference was statistically significant for both doses of solifenacin (p &lt; 0.001)",35510:35773,1619936,16893438,Unavailable
1619936,Resolution of urgency episodes,Solifenacin 10 mg,Placebo,Significantly increased,"In patients treated with solifenacin 5 and 10 mg who had urgency at baseline, 29% and 25%, respectively, had no urgency episodes at endpoint when compared with placebo (15%). This difference was statistically significant for both doses of solifenacin (p &lt; 0.001)",35510:35773,1619936,16893438,Unavailable
1619936,Resolution of incontinence episodes,Solifenacin 5 mg,Placebo,Significantly increased,"Furthermore, of those patients who had incontinence at baseline, 51% and 52% of patients receiving 5 and 10 mg solifenacin, respectively, reported no incontinence episodes at the study endpoint, compared with only 34% of patients receiving placebo (p &lt; 0.001",35828:36086,1619936,16893438,Unavailable
1619936,Resolution of incontinence episodes,Solifenacin 10 mg,Placebo,Significantly increased,"Furthermore, of those patients who had incontinence at baseline, 51% and 52% of patients receiving 5 and 10 mg solifenacin, respectively, reported no incontinence episodes at the study endpoint, compared with only 34% of patients receiving placebo (p &lt; 0.001",35828:36086,1619936,16893438,Unavailable
1619936,"Normalization of micturition frequency	",Solifenacin 5 mg,Placebo,Significantly increased,"Patients treated with either solifenacin dose also experienced normalisation of micturition frequency, which was statistically significantly greater than placebo (p &lt; 0.001 for both solifenacin dose groups",36141:36347,1619936,16893438,Unavailable
1619936,"Normalization of micturition frequency	",Solifenacin 10 mg,Placebo,Significantly increased,"Patients treated with either solifenacin dose also experienced normalisation of micturition frequency, which was statistically significantly greater than placebo (p &lt; 0.001 for both solifenacin dose groups",36141:36347,1619936,16893438,Unavailable
1619936,Resolution of nocturia ,Solifenacin 10 mg,Placebo,Significantly increased,"Similar results were seen with respect to resolution of nocturia, with 10 mg solifenacin producing statistically significant resolution of symptoms compared with placebo.",36403:36573,1619936,16893438,Unavailable
1619936,Frequency of ≥50% improvement in urgency symptoms ,Solifenacin 5 mg,Placebo,Significantly increased,"In line with ICS guidelines for the presentation of data (1), the ≥50% improvement rates (i.e. the per cent of patients who achieved ≥50% improvement in symptoms that were present at baseline) are provided in Table 4. The per cent of solifenacin-treated patients achieving a ≥50% reduction in symptoms was significantly greater than placebo for urgency, incontinence, frequency and nocturia.",36573:37044,1619936,16893438,Unavailable
1619936,Frequency of ≥50% improvement in urgency symptoms ,Solifenacin 10 mg,Placebo,Significantly increased,"In line with ICS guidelines for the presentation of data (1), the ≥50% improvement rates (i.e. the per cent of patients who achieved ≥50% improvement in symptoms that were present at baseline) are provided in Table 4. The per cent of solifenacin-treated patients achieving a ≥50% reduction in symptoms was significantly greater than placebo for urgency, incontinence, frequency and nocturia.",36573:37044,1619936,16893438,Unavailable
1619936,Frequency of ≥50% improvement in incontinence symptoms ,Solifenacin 5 mg,Placebo,Significantly increased,"In line with ICS guidelines for the presentation of data (1), the ≥50% improvement rates (i.e. the per cent of patients who achieved ≥50% improvement in symptoms that were present at baseline) are provided in Table 4. The per cent of solifenacin-treated patients achieving a ≥50% reduction in symptoms was significantly greater than placebo for urgency, incontinence, frequency and nocturia.",36573:37044,1619936,16893438,Unavailable
1619936,Frequency of ≥50% improvement in incontinence symptoms ,Solifenacin 10 mg,Placebo,Significantly increased,"In line with ICS guidelines for the presentation of data (1), the ≥50% improvement rates (i.e. the per cent of patients who achieved ≥50% improvement in symptoms that were present at baseline) are provided in Table 4. The per cent of solifenacin-treated patients achieving a ≥50% reduction in symptoms was significantly greater than placebo for urgency, incontinence, frequency and nocturia.",36573:37044,1619936,16893438,Unavailable
1619936,Frequency of ≥50% improvement in micturition frequency ,Solifenacin 5 mg,Placebo,Significantly increased,"In line with ICS guidelines for the presentation of data (1), the ≥50% improvement rates (i.e. the per cent of patients who achieved ≥50% improvement in symptoms that were present at baseline) are provided in Table 4. The per cent of solifenacin-treated patients achieving a ≥50% reduction in symptoms was significantly greater than placebo for urgency, incontinence, frequency and nocturia.",36573:37044,1619936,16893438,Unavailable
1619936,Frequency of ≥50% improvement in micturition frequency ,Solifenacin 10 mg,Placebo,Significantly increased,"In line with ICS guidelines for the presentation of data (1), the ≥50% improvement rates (i.e. the per cent of patients who achieved ≥50% improvement in symptoms that were present at baseline) are provided in Table 4. The per cent of solifenacin-treated patients achieving a ≥50% reduction in symptoms was significantly greater than placebo for urgency, incontinence, frequency and nocturia.",36573:37044,1619936,16893438,Unavailable
1619936,Frequency of ≥50% improvement in nocturia frequency ,Solifenacin 5 mg,Placebo,Significantly increased,"In line with ICS guidelines for the presentation of data (1), the ≥50% improvement rates (i.e. the per cent of patients who achieved ≥50% improvement in symptoms that were present at baseline) are provided in Table 4. The per cent of solifenacin-treated patients achieving a ≥50% reduction in symptoms was significantly greater than placebo for urgency, incontinence, frequency and nocturia.",36573:37044,1619936,16893438,Unavailable
1619936,Frequency of ≥50% improvement in nocturia frequency ,Solifenacin 10 mg,Placebo,Significantly increased,"In line with ICS guidelines for the presentation of data (1), the ≥50% improvement rates (i.e. the per cent of patients who achieved ≥50% improvement in symptoms that were present at baseline) are provided in Table 4. The per cent of solifenacin-treated patients achieving a ≥50% reduction in symptoms was significantly greater than placebo for urgency, incontinence, frequency and nocturia.",36573:37044,1619936,16893438,Unavailable
1619936,General health perception improvement,Solifenacin 5 mg,Placebo,Significantly increased,"it was shown that a significantly greater percentage of patients receiving solifenacin achieved an MID in certain individual domains than those receiving placebo [solifenacin 5 mg: general health perception, incontinence impact, role limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45137:45489,1619936,16893438,Unavailable
1619936,Incontinence impact improvement,Solifenacin 5 mg,Placebo,Significantly increased,"it was shown that a significantly greater percentage of patients receiving solifenacin achieved an MID in certain individual domains than those receiving placebo [solifenacin 5 mg: general health perception, incontinence impact, role limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45137:45489,1619936,16893438,Unavailable
1619936,Role limitations improvement,Solifenacin 5 mg,Placebo,Significantly increased,"it was shown that a significantly greater percentage of patients receiving solifenacin achieved an MID in certain individual domains than those receiving placebo [solifenacin 5 mg: general health perception, incontinence impact, role limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45137:45489,1619936,16893438,Unavailable
1619936,Social limitations improvement,Solifenacin 5 mg,Placebo,Significantly increased,"it was shown that a significantly greater percentage of patients receiving solifenacin achieved an MID in certain individual domains than those receiving placebo [solifenacin 5 mg: general health perception, incontinence impact, role limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45137:45489,1619936,16893438,Unavailable
1619936,Emotions improvement,Solifenacin 5 mg,Placebo,Significantly increased,"it was shown that a significantly greater percentage of patients receiving solifenacin achieved an MID in certain individual domains than those receiving placebo [solifenacin 5 mg: general health perception, incontinence impact, role limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45137:45489,1619936,16893438,Unavailable
1619936,Sleep/energy improvement,Solifenacin 5 mg,Placebo,Significantly increased,"it was shown that a significantly greater percentage of patients receiving solifenacin achieved an MID in certain individual domains than those receiving placebo [solifenacin 5 mg: general health perception, incontinence impact, role limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45137:45489,1619936,16893438,Unavailable
1619936,Severity measures improvement ,Solifenacin 5 mg,Placebo,Significantly increased,"it was shown that a significantly greater percentage of patients receiving solifenacin achieved an MID in certain individual domains than those receiving placebo [solifenacin 5 mg: general health perception, incontinence impact, role limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45428:45446,1619936,16893438,Unavailable
1619936,Symptom severity improvement ,Solifenacin 5 mg,Placebo,Significantly increased,"it was shown that a significantly greater percentage of patients receiving solifenacin achieved an MID in certain individual domains than those receiving placebo [solifenacin 5 mg: general health perception, incontinence impact, role limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45428:45446,1619936,16893438,Unavailable
1619936,General health perception improvement,Solifenacin 10 mg,Placebo,Significantly increased,"solifenacin 10 mg: general health perception, incontinence impact, role limitations, physical limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45491:45702,1619936,16893438,Unavailable
1619936,Incontinence impact improvement,Solifenacin 10 mg,Placebo,Significantly increased,"solifenacin 10 mg: general health perception, incontinence impact, role limitations, physical limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45491:45702,1619936,16893438,Unavailable
1619936,Role limitations improvement,Solifenacin 10 mg,Placebo,Significantly increased,"solifenacin 10 mg: general health perception, incontinence impact, role limitations, physical limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45491:45702,1619936,16893438,Unavailable
1619936,Physical limitations improvement,Solifenacin 10 mg,Placebo,Significantly increased,"solifenacin 10 mg: general health perception, incontinence impact, role limitations, physical limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45491:45702,1619936,16893438,Unavailable
1619936,Social limitations improvement,Solifenacin 10 mg,Placebo,Significantly increased,"solifenacin 10 mg: general health perception, incontinence impact, role limitations, physical limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45491:45702,1619936,16893438,Unavailable
1619936,Emotions improvement,Solifenacin 10 mg,Placebo,Significantly increased,"solifenacin 10 mg: general health perception, incontinence impact, role limitations, physical limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45491:45702,1619936,16893438,Unavailable
1619936,Sleep/energy improvement,Solifenacin 10 mg,Placebo,Significantly increased,"solifenacin 10 mg: general health perception, incontinence impact, role limitations, physical limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45491:45702,1619936,16893438,Unavailable
1619936,Severity measures improvement,Solifenacin 10 mg,Placebo,Significantly increased,"solifenacin 10 mg: general health perception, incontinence impact, role limitations, physical limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45491:45702,1619936,16893438,Unavailable
1619936,Symptom severity improvement,Solifenacin 10 mg,Placebo,Significantly increased,"solifenacin 10 mg: general health perception, incontinence impact, role limitations, physical limitations, social limitations, emotions, sleep/energy, severity measures and symptom severity; p &lt; 0.05 vs. placebo",45491:45702,1619936,16893438,Unavailable
1619936,Treatment discontinuing ,Solifenacin 5 mg,Placebo,No significant difference,"the number of patients discontinuing treatment due to AEs was low and comparable with placebo at both solifenacin doses (4.4% placebo, 2.8% solifenacin 5 mg, 6.8% solifenacin 10 mg).",46754:46936,1619936,16893438,Unavailable
1619936,Treatment discontinuing ,Solifenacin 10 mg,Placebo,No significant difference,"the number of patients discontinuing treatment due to AEs was low and comparable with placebo at both solifenacin doses (4.4% placebo, 2.8% solifenacin 5 mg, 6.8% solifenacin 10 mg).",46754:46936,1619936,16893438,Unavailable
1619936,Treatment discontinuing ,Solifenacin 5 mg,Solifenacin 10 mg,No significant difference,"the number of patients discontinuing treatment due to AEs was low and comparable with placebo at both solifenacin doses (4.4% placebo, 2.8% solifenacin 5 mg, 6.8% solifenacin 10 mg).",46754:46936,1619936,16893438,Unavailable
3611069,Postoperative nausea and vomiting after 6 hrs,Aprepitant 125 mg,Placebo,Significantly decreased,"Overall PONV occurrence rate of Ap125 group (1/26, 3.9%) was lower (P = 0.015) than the control group (7/24, 29.2%) at 6 hr after surgery.",14620:14802,3611069,23560185,Unavailable
3611069,Nausea distress score after 6 hrs,Aprepitant 125 mg,Placebo,Significantly decreased,The nausea distress score of Ap125 group (0.04 ± 0.20) was lower (P = 0.032) than the control group (0.67 ± 1.24) at 6 hr after surgery.,14620:14802,3611069,23560185,Unavailable
3611069,Postoperative nausea and vomiting after 6 hrs,Aprepitant 125 mg,Placebo,Significantly decreased,"There was a significant statistical difference only between the control group and the Ap125 group (P = 0.015), and there was not any significant difference between the other groups.",14620:14802,3611069,23560185,Unavailable
3611069,Postoperative nausea and vomiting after 6 hrs,Aprepitant 125 mg,Aprepitant 80 mg,No significant difference,"There was a significant statistical difference only between the control group and the Ap125 group (P = 0.015), and there was not any significant difference between the other groups.",14620:14802,3611069,23560185,Unavailable
3611069,Postoperative nausea and vomiting after 6 hrs,Aprepitant 80 mg,Placebo,No significant difference,"There was a significant statistical difference only between the control group and the Ap125 group (P = 0.015), and there was not any significant difference between the other groups.",14620:14802,3611069,23560185,Unavailable
3611069,Nausea distress score after 6 hrs,Aprepitant 125 mg,Placebo,Significantly decreased,"Based on a comparison of the RINVR scores, there was statistical significance (P = 0.032) between the control group (0.67 ± 1.24) and the Ap125 group (0.04 ± 0.20) in nausea distress scores",15537:15726,3611069,23560185,Unavailable
3611069,Postoperative nausea and vomiting after 6 hours,Aprepitant 125 mg,Control,Significantly decreased,"Overall PONV occurrence rate of Ap125 group (1/26, 3.9%) was lower (P = 0.015) than the control group (7/24, 29.2%) at 6 hr after surgery.",14620:14802,3611069,23560185,Unavailable
3611069,Nausea distress score after 6 hours,Aprepitant 125 mg,Control,Significantly decreased,The nausea distress score of Ap125 group (0.04 ± 0.20) was lower (P = 0.032) than the control group (0.67 ± 1.24) at 6 hr after surgery.,14620:14802,3611069,23560185,Unavailable
3611069,Postoperative nausea and vomiting after 6 hours,Aprepitant 125 mg,Control,Significantly decreased,"There was a significant statistical difference only between the control group and the Ap125 group (P = 0.015), and there was not any significant difference between the other groups.",14620:14802,3611069,23560185,Unavailable
3611069,Postoperative nausea and vomiting after 6 hours,Aprepitant 80 mg,Control,No significant difference,"There was a significant statistical difference only between the control group and the Ap125 group (P = 0.015), and there was not any significant difference between the other groups.",14620:14802,3611069,23560185,Unavailable
3611069,Postoperative nausea and vomiting after 6 hours,Aprepitant 125 mg,Aprepitant 80 mg,No significant difference,"There was a significant statistical difference only between the control group and the Ap125 group (P = 0.015), and there was not any significant difference between the other groups.",14620:14802,3611069,23560185,Unavailable
3611069,Nausea distress score after 6 hours,Aprepitant 125 mg,Control,Significantly decreased,"Based on a comparison of the RINVR scores, there was statistical significance (P = 0.032) between the control group (0.67 ± 1.24) and the Ap125 group (0.04 ± 0.20) in nausea distress scores",15537:15726,3611069,23560185,Unavailable
5799388,Global clinical scores ,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,Global clinical scores decreased significantly from baseline in all groups; there were no significant differences between groups,4906:5051,5799388,28693297,Unavailable
5799388,Global clinical scores ,Fortekor Plus,Vetmedin + Fortekor once daily,No significant difference,Global clinical scores decreased significantly from baseline in all groups; there were no significant differences between groups,4906:5051,5799388,28693297,Unavailable
5799388,Global clinical scores ,Vetmedin + Fortekor twice daily,Vetmedin + Fortekor once daily,No significant difference,Global clinical scores decreased significantly from baseline in all groups; there were no significant differences between groups,4651:4779,5799388,28693297,Unavailable
5799388,Clinical chemistry variables ,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events.,4906:5051,5799388,28693297,Unavailable
5799388,Clinical chemistry variables ,Fortekor Plus ,Vetmedin + Fortekor once daily,No significant difference,There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events.,4906:5051,5799388,28693297,Unavailable
5799388,Clinical chemistry variables ,Vetmedin + Fortekor twice daily,Vetmedin + Fortekor once daily,No significant difference,There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events.,4906:5051,5799388,28693297,Unavailable
5799388,Hematology variables,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events.,4906:5051,5799388,28693297,Unavailable
5799388,Hematology variables,Fortekor Plus ,Vetmedin + Fortekor once daily,No significant difference,There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events.,4906:5051,5799388,28693297,Unavailable
5799388,Hematology variables,Vetmedin + Fortekor twice daily,Vetmedin + Fortekor once daily,No significant difference,There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events.,4906:5051,5799388,28693297,Unavailable
5799388,Adverse events ,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events.,4906:5051,5799388,28693297,Unavailable
5799388,Adverse events ,Fortekor Plus ,Vetmedin + Fortekor once daily,No significant difference,There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events.,4906:5051,5799388,28693297,Unavailable
5799388,Adverse events ,Vetmedin + Fortekor twice daily,Vetmedin + Fortekor once daily,No significant difference,There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events.,4906:5051,5799388,28693297,Unavailable
5799388,Global clinical scores ,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,"The RMANCOVA results also demonstrated no significant differences in GCS between the IVP group and the Control I (p = 0.91), Control II (p = 0.17)",26029:26209,5799388,28693297,Unavailable
5799388,Global clinical scores ,Fortekor Plus,Vetmedin + Fortekor once daily,No significant difference,"The RMANCOVA results also demonstrated no significant differences in GCS between the IVP group and the Control I (p = 0.91), Control II (p = 0.17)",26029:26209,5799388,28693297,Unavailable
5799388,Global clinical scores ,Vetmedin + Fortekor twice daily,Vetmedin + Fortekor once daily,No significant difference,"The RMANCOVA results also demonstrated no significant differences in GCS between the IVP group and the Control I (p = 0.91), Control II (p = 0.17)",26029:26209,5799388,28693297,Unavailable
5799388,NYHA classification,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,"The NYHA classification distribution is shown in Table 4; the improvement rate from baseline ranged from 35.7% to 58.8%. There was no significant treatment effect (p = 0.56; Table 6), and non-inferiority was shown for the IVP group vs. Control I, II",28233:28594,5799388,28693297,Unavailable
5799388,NYHA classification,Fortekor Plus,Vetmedin + Fortekor once daily,No significant difference,"The NYHA classification distribution is shown in Table 4; the improvement rate from baseline ranged from 35.7% to 58.8%. There was no significant treatment effect (p = 0.56; Table 6), and non-inferiority was shown for the IVP group vs. Control I, II",28233:28594,5799388,28693297,Unavailable
5799388,NYHA classification,Vetmedin + Fortekor twice daily,Vetmedin + Fortekor once daily,No significant difference,"The NYHA classification distribution is shown in Table 4; the improvement rate from baseline ranged from 35.7% to 58.8%. There was no significant treatment effect (p = 0.56; Table 6), and non-inferiority was shown for the IVP group vs. Control I, II",28233:28594,5799388,28693297,Unavailable
5799388,Pulmonary edema scores,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,"With regard to pulmonary edema scores, there was a significant change (improvement) from D0 to both D28 and D56 in all groups: IVP from 2.24 ± 0.50 to 1.56 ± 0.61 and 1.65 ± 0.73; Control I from 2.29 ± 0.61 to 1.7 ± 0.61 and 1.57 ± 0.65; and Control II from 2.41 ± 0.71 to 1.41 ± 0.51 and 1.65 ± 0.79, respectively. There was no significant overall treatment effect (p = 0.30; Table 6), and non-inferiority was demonstrated for the IVP vs. the Control I",28670:29196,5799388,28693297,Unavailable
5799388,Adverse events ,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,Adverse events: There were no significant differences between groups in the frequency of all AEs,29419:29522,5799388,28693297,Unavailable
5799388,Adverse events ,Fortekor Plus ,Vetmedin + Fortekor once daily,No significant difference,Adverse events: There were no significant differences between groups in the frequency of all AEs,29419:29522,5799388,28693297,Unavailable
5799388,Adverse events ,Vetmedin + Fortekor twice daily,Vetmedin + Fortekor once daily,No significant difference,Adverse events: There were no significant differences between groups in the frequency of all AEs,29419:29522,5799388,28693297,Unavailable
5799388,Emesis,Fortekor Plus ,Vetmedin + Fortekor twice daily,Significantly decreased,"The only AE with a significant difference between groups was emesis, which was significantly less frequent in the IVP group than in the Control I (p = 0.0034)",29717:29892,5799388,28693297,Unavailable
5799388,Clinical chemistry variables ,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,"With the exception of an effect on plasma glucose, there was no significant overall treatment effect or differences between the IVP and Control I or Control II groups for any clinical chemistry or hematology variable",30263:30480,5799388,28693297,Unavailable
5799388,Clinical chemistry variables ,Fortekor Plus ,Vetmedin + Fortekor once daily,No significant difference,"With the exception of an effect on plasma glucose, there was no significant overall treatment effect or differences between the IVP and Control I or Control II groups for any clinical chemistry or hematology variable",30263:30479,5799388,28693297,Unavailable
5799388,Clinical chemistry variables ,Vetmedin + Fortekor twice daily,Vetmedin + Fortekor once daily,No significant difference,"With the exception of an effect on plasma glucose, there was no significant overall treatment effect or differences between the IVP and Control I or Control II groups for any clinical chemistry or hematology variable",30263:30480,5799388,28693297,Unavailable
5799388,Hematology variables,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,"With the exception of an effect on plasma glucose, there was no significant overall treatment effect or differences between the IVP and Control I or Control II groups for any clinical chemistry or hematology variable",30263:30480,5799388,28693297,Unavailable
5799388,Hematology variables,Fortekor Plus ,Vetmedin + Fortekor once daily,No significant difference,"With the exception of an effect on plasma glucose, there was no significant overall treatment effect or differences between the IVP and Control I or Control II groups for any clinical chemistry or hematology variable",30263:30480,5799388,28693297,Unavailable
5799388,Hematology variables,Vetmedin + Fortekor twice daily,Vetmedin + Fortekor once daily,No significant difference,"With the exception of an effect on plasma glucose, there was no significant overall treatment effect or differences between the IVP and Control I or Control II groups for any clinical chemistry or hematology variable",30263:30480,5799388,28693297,Unavailable
5799388,Potassium levels,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,"For potassium, there were numerically higher concentrations (mEq/L) in the Control I (5.1 ± 0.5) and Control II (5.0 ± 0.5) groups vs. the IVP group (4.9 ± 0.6), but the overall treatment effect was not significant (p = 0.12).",30787:31048,5799388,28693297,Unavailable
5799388,Potassium levels,Fortekor Plus ,Vetmedin + Fortekor once daily,No significant difference,"For potassium, there were numerically higher concentrations (mEq/L) in the Control I (5.1 ± 0.5) and Control II (5.0 ± 0.5) groups vs. the IVP group (4.9 ± 0.6), but the overall treatment effect was not significant (p = 0.12).",30787:31048,5799388,28693297,Unavailable
5799388,Glucose levels,Fortekor Plus ,Vetmedin + Fortekor once daily,Significantly increased,"For glucose, values (mg/dL) were significantly (p = 0.016) higher in the IVP group (92.9 ± 17.6) than in the Control II group (78.9 ± 15.4).",31048:31206,5799388,28693297,Unavailable
5799388,Plasma creatinine levels ,Fortekor Plus ,Vetmedin + Fortekor twice daily,No significant difference,"For plasma creatinine, the number of cases with increases from baseline by &gt; 0.3 mg/dL, &gt; 20%, or &gt; 30% were calculated. There were no significant treatment effects or differences between groups.",31313:31509,5799388,28693297,Unavailable
5799388,Plasma creatinine levels ,Fortekor Plus ,Vetmedin + Fortekor once daily,No significant difference,"For plasma creatinine, the number of cases with increases from baseline by &gt; 0.3 mg/dL, &gt; 20%, or &gt; 30% were calculated. There were no significant treatment effects or differences between groups.",31313:31509,5799388,28693297,Unavailable
5799388,Plasma creatinine levels ,Vetmedin + Fortekor twice daily,Vetmedin + Fortekor once daily,No significant difference,"For plasma creatinine, the number of cases with increases from baseline by &gt; 0.3 mg/dL, &gt; 20%, or &gt; 30% were calculated. There were no significant treatment effects or differences between groups.",31313:31509,5799388,28693297,Unavailable
4511432,Total Costs ,Lifestyle Advice intervention ,Standard Care,No significant difference,"Overall, the increase in mean costs associated with providing the intervention was offset by savings associated with improved immediate neonatal outcomes, rendering the intervention cost neutral (Lifestyle Advice Group $11261.19±$14573.97 versus Standard Care Group $11306.70±$14562.02; p=0.094).",8202:8498,4511432,26217529,Unavailable
4511432,Antenatal outpatient costs,Lifestyle Advice intervention ,Standard Care,Significantly increased,"Mean antenatal outpatient costs were $83.40 higher for women randomised to the Lifestyle Advice Group, compared with women receiving Standard Care (Lifestyle Advice Group $2116.39 ± $895.14 versus Standard Care $2032.99 ± $805.63; p = 0.022)",29724:29965,4511432,26217529,Unavailable
4511432,Maternal intpatient costs,Lifestyle Advice intervention ,Standard Care,No significant difference,"However, mean costs were lower, albeit not reaching statistical significance, for women in the Lifestyle Advice Group, reflecting a mean of $281.01 savings in inpatient costs (Lifestyle Advice Group $6125.04 ± $4640.78 versus Standard Care Group $6404.05 ± $5274.54; p = 0.185)",30297:30453,4511432,26217529,Unavailable
4511432,Neonatal intpatient costs,Lifestyle Advice intervention ,Standard Care,No significant difference,"The average VO2, as well as the percentage of VO2max, during the entire protocol was significantly higher in CE compared to FW and CM.",36868:37024,5104360,27832062,Unavailable
5104360,Average VO2,Combined exercise,Machine exercises,Significantly increased,"The average VO2, as well as the percentage of VO2max, during the entire protocol was significantly higher in CE compared to FW and CM.",36868:37024,5104360,27832062,Unavailable
5104360,VO2 Max,Combined exercise,Free weight exercises,Significantly increased,"The average VO2, as well as the percentage of VO2max, during the entire protocol was significantly higher in CE compared to FW and CM.",36868:37024,5104360,27832062,Unavailable
5104360,VO2 Max,Combined exercise,Machine exercises,Significantly increased,"The average VO2, as well as the percentage of VO2max, during the entire protocol was significantly higher in CE compared to FW and CM.",36868:37024,5104360,27832062,Unavailable
5104360,Lactate ,Combined exercise,Free weight exercises,Significantly decreased,significantly lower values were found in CE vs. CM and FW,48931:48989,5104360,27832062,Unavailable
5104360,Lactate ,Combined exercise,Machine exercises,Significantly decreased,significantly lower values were found in CE vs. CM and FW,48931:48989,5104360,27832062,Unavailable
3590695,Physical health,Combined aerobic and resistance exercises,Control,Significantly decreased,Results showed that there was no significant difference in the mean score of the physical dimension of quality of life in the study group before and after intervention while the score of physical health was significantly better in the control group (p &lt; 0.00).,17355:17362,3590695,23493334,Unavailable
3590695,Mental health,Combined aerobic and resistance exercises,Control,No significant difference,"The mean score of mental dimension had increased in the study group, while it had decreased in the control group.",17041:17444,3590695,23493334,Unavailable
3590695,Social health,Combined aerobic and resistance exercises,Control,No significant difference,The mean score of social health showed no significant difference before and after intervention.,6247:6343,3590695,23493334,Unavailable
3590695,Spiritual health,Combined aerobic and resistance exercises,Control,Significantly increased,"The mean score of spiritual health had significantly decreased in the control group, while it had significantly increased in the study group (p = 0.004).",6343:6496,3590695,23493334,Unavailable
3590695,Physical health,Combined aerobic and resistance exercises,Control,Significantly decreased,"There was no significant difference in the mean score of physical health before and after intervention in the study group, while it had significantly increased in the control group (p = 0.003). The percentage of physical health score decreased about 3.9% in the study group but increased 4.1% in the control group.",17355:17362,3590695,23493334,Unavailable
3590695,Social health,Combined aerobic and resistance exercises,Control,No significant difference,"There was no significant difference in the mean score of social health before and after intervention in the study group, while it significantly decreased in the control group p = 0.03). Social health decreased by 0.1% in the study group and 1.7% in the control group. The student's t-test showed no significant difference in mean percentage difference of social health in both groups.",16650:17034,3590695,23493334,Unavailable
3590695,Spiritual health,Combined aerobic and resistance exercises,Control,Significantly increased,"For the spiritual health of the control group, the mean score difference had significantly decreased (p = 0.02), while it had significantly increased in the study group (p = 0.04).Percentage of spiritual health had increased by 0.1% in the study group but decreased by 1.7% in the control group. The t-test showed a significant difference in the spiritual health score of both groups (p = 0.006).",17041:17444,3590695,23493334,Unavailable
3590695,Mental health,Combined aerobic and resistance exercises,Control,No significant difference,The mean score of mental health increased by 6.2% in the study group but decreased by 0.4% in the control group. The student's t-test showed no significant difference between the mean percentage differences of mental health score in both groups.,16398:16643,3590695,23493334,Unavailable
3534307,Achieving sufficient biopsy quality,OnControl device,Standard manual device,No significant difference,Biopsy quality was rated ‘sufficient for diagnosis’ in 24/30 in the control group and 25/30 in the powered group (p=0.74).,5102:5224,3534307,23105124,Unavailable
3534307,Cylinder length,OnControl device,Standard manual device,No significant difference,"Biopsy cylinder length, procedure time (from skin contact of the biopsy needle to placement of the biopsy cylinder in the formalin container) and patient reported pain during the procedure (T1), 15 min after the procedure (T2) and 3–5 days after the procedure (T3) there were comparable between groups.",5224:5528,3534307,23105124,Unavailable
3534307,Procedure time,OnControl device,Standard manual device,No significant difference,"Biopsy cylinder length, procedure time (from skin contact of the biopsy needle to placement of the biopsy cylinder in the formalin container) and patient reported pain during the procedure (T1), 15 min after the procedure (T2) and 3–5 days after the procedure (T3) there were comparable between groups.",5224:5528,3534307,23105124,Unavailable
3534307,Pain during the procedure,OnControl device,Standard manual device,No significant difference,"Biopsy cylinder length, procedure time (from skin contact of the biopsy needle to placement of the biopsy cylinder in the formalin container) and patient reported pain during the procedure (T1), 15 min after the procedure (T2) and 3–5 days after the procedure (T3) there were comparable between groups.",5224:5528,3534307,23105124,Unavailable
3534307,Pain after 15 min,OnControl device,Standard manual device,No significant difference,"Biopsy cylinder length, procedure time (from skin contact of the biopsy needle to placement of the biopsy cylinder in the formalin container) and patient reported pain during the procedure (T1), 15 min after the procedure (T2) and 3–5 days after the procedure (T3) there were comparable between groups.",5224:5528,3534307,23105124,Unavailable
3534307,Pain after 3-5 days,OnControl device,Standard manual device,No significant difference,"Biopsy cylinder length, procedure time (from skin contact of the biopsy needle to placement of the biopsy cylinder in the formalin container) and patient reported pain during the procedure (T1), 15 min after the procedure (T2) and 3–5 days after the procedure (T3) there were comparable between groups.",5224:5528,3534307,23105124,Unavailable
3534307,Pain during procedure when not receiving conscious sedation,OnControl device,Standard manual device,Significantly decreased,"In the small subgroup of patients that did not receive conscious sedation (n=15; manual 6, powered 9) significantly lower median pain scores were observed with the powered system (median pain score 3 vs 7; p=0.015).",24781:25096,3534307,23105124,Unavailable
3534307,Patient satisfaction,OnControl device,Standard manual device,No significant difference,"Patients were satisfied with either device whether sedation was used (sedation: median 9 for both groups, range 3–10 (manual) and 0–10 (powered)) no sedation (median 8 (manual) vs 9 (powered)).",5743:5937,3534307,23105124,Unavailable
3534307,Achieving sufficient biopsy quality,OnControl device,Standard manual device,No significant difference,Biopsy quality was rated ‘sufficient for diagnosis’ in 24/30 in the control group and 25/30 in the powered Group (p=0.74),17968:18089,3534307,23105124,Unavailable
3534307,Cylinder length,OnControl device,Standard manual device,No significant difference,"Cylinder length was similar in both groups (figure 2; 14.2 mm (5–37 mm) vs 14.6 mm (6–27 mm), p=0.79).",18090:18249,3534307,23105124,Unavailable
3534307,Number of marrow spaces,OnControl device,Standard manual device,No significant difference,"The median number of marrow spaces was higher in the powered group than in the manual group (n=8 vs 6), but this difference was not statistically significant (p=0.459).",18367:18535,3534307,23105124,Unavailable
3534307,Crush artifacts,OnControl device,Standard manual device,No significant difference,"By contrast, crush artefacts and aspiration artifacts were slightly more frequent with the powered system than with the manual device (n=17 vs 12 and 14 vs 13), but again this did not reach statistical significance (crush artefacts p=0.301, aspiration artefacts p=1.0).",18536:18806,3534307,23105124,Unavailable
3534307,Aspiration artifacts,OnControl device,Standard manual device,No significant difference,"By contrast, crush artefacts and aspiration artifacts were slightly more frequent with the powered system than with the manual device (n=17 vs 12 and 14 vs 13), but again this did not reach statistical significance (crush artefacts p=0.301, aspiration artefacts p=1.0).",18536:18806,3534307,23105124,Unavailable
3534307,Achieving sufficient biopsy quality,OnControl device,Standard manual device,No significant difference,"Cylinder diagnostic	24/30	25/30	p=0.74",19744:19878,3534307,23105124,Unavailable
3534307,Cylinder length,OnControl device,Standard manual device,No significant difference,"Cylinder length mm (median, length)	14.2 (5–37 mm)	14.6 (6–27 mm)	p=0.79",19920:20088,3534307,23105124,Unavailable
3534307,Number of marrow spaces,OnControl device,Standard manual device,No significant difference,"Marrow spaces, median, (range)	6 (1–15)	8 (1–20)	p=0.46",20130:20281,3534307,23105124,Unavailable
3534307,Crush artifacts,OnControl device,Standard manual device,No significant difference,"Fractured cylinder n	12 (40%)	17 (57%)	p=0.301",20323:20465,3534307,23105124,Unavailable
3534307,Aspiration artifacts,OnControl device,Standard manual device,No significant difference,"Aspiration artefacts n	13 (43%)	14 (47%)	p=1.0",20507:20649,3534307,23105124,Unavailable
3534307,Procedure time,OnControl device,Standard manual device,No significant difference,"Procedure time duration, in seconds median, (range)	180 (80–480)	150 (60–720)	p=0.947",20691:20872,3534307,23105124,Unavailable
3534307,Pain during the procedure,OnControl device,Standard manual device,No significant difference,"Patient pain (median; mean, range)  T1	2: 3.2 (0–10)	1: 2.1 (0–10)	p=0.09",20914:21125,3534307,23105124,Unavailable
3534307,Pain after 15 min,OnControl device,Standard manual device,No significant difference,"T2	2: 0.28 (0–3)	1: 0.44 (0–5)	p=0.82",21169:21302,3534307,23105124,Unavailable
3534307,Pain after 3-5 days,OnControl device,Standard manual device,No significant difference,"T3	0: 0.86 (0–8)	0: 1 (0–8)	p=0.78",21346:21476,3534307,23105124,Unavailable
3534307,Pain during procedure when not receiving conscious sedation,OnControl device,Standard manual device,Significantly decreased,T1 without conscious sedation 7: 6.3 (3–8) 3: 2.90 (0–6) p=0.015,24781:25096,3534307,23105124,Unavailable
3534307,Patient satisfaction,OnControl device,Standard manual device,No significant difference,"Patient satisfaction overall	9 (3–10)	9 (0–10)	p=0.69",21721:21870,3534307,23105124,Unavailable
3534307,Patient satisfaction without sedation,OnControl device,Standard manual device,No significant difference,"Patient satisfaction without sedation	9 (8–10)	10 (2–10)	p=0.12",21912:22071,3534307,23105124,Unavailable
3534307,Procedure time,OnControl device,Standard manual device,No significant difference,"Although intervention time tended to be shorter with the powered device, there was no significant difference between the groups in procedure time. With the manual system, median time was 180s compared with 150s with the powered system (range 80–480s vs 60–720s; p=0.947).",22682:22953,3534307,23105124,Unavailable
3534307,Pain during the procedure,OnControl device,Standard manual device,No significant difference,"In all three time points there was no difference in patient reported median pain between the devices used (pain level manual vs powered T1: 2/10 vs 1/10, T2: 0/10 vs 0/10, T3: 0/10 vs 0/10; p=0.086, p=0.815, p=0.787 respectively",23371:23599,3534307,23105124,Unavailable
3534307,Pain after 15 min,OnControl device,Standard manual device,No significant difference,"In all three time points there was no difference in patient reported median pain between the devices used (pain level manual vs powered T1: 2/10 vs 1/10, T2: 0/10 vs 0/10, T3: 0/10 vs 0/10; p=0.086, p=0.815, p=0.787 respectively",23371:23599,3534307,23105124,Unavailable
3534307,Pain after 3-5 days,OnControl device,Standard manual device,No significant difference,"In all three time points there was no difference in patient reported median pain between the devices used (pain level manual vs powered T1: 2/10 vs 1/10, T2: 0/10 vs 0/10, T3: 0/10 vs 0/10; p=0.086, p=0.815, p=0.787 respectively",23371:23599,3534307,23105124,Unavailable
3534307,Usage of conscious sedation,OnControl device,Standard manual device,No significant difference,"The usage of conscious sedation, dosage of lidocaine/pethidin was similar between groups.",5012:5101,3534307,23105124,Unavailable
3534307,Dosage of lidocaine ,OnControl device,Standard manual device,No significant difference,"The usage of conscious sedation, dosage of lidocaine/pethidin was similar between groups.",5012:5101,3534307,23105124,Unavailable
3534307,Dosage of phetidin,OnControl device,Standard manual device,No significant difference,"The usage of conscious sedation, dosage of lidocaine/pethidin was similar between groups.",5012:5101,3534307,23105124,Unavailable
3534307,Usage of conscious sedation,OnControl device,Standard manual device,No significant difference,"Usage of conscious sedation (24/30 patients and 21/30 patients respectively (p=0.56)) and dosages of lidocaine (10 ml vs 13 ml p=0.24), pethidin (23 mg vs 21 mg, p=0.68) and midazolam (2.5 mg vs 2.6 mg p=0.89) was similar between groups.",23602:23839,3534307,23105124,Unavailable
3534307,Dosage of lidocaine ,OnControl device,Standard manual device,No significant difference,"Usage of conscious sedation (24/30 patients and 21/30 patients respectively (p=0.56)) and dosages of lidocaine (10 ml vs 13 ml p=0.24), pethidin (23 mg vs 21 mg, p=0.68) and midazolam (2.5 mg vs 2.6 mg p=0.89) was similar between groups.",23602:23839,3534307,23105124,Unavailable
3534307,Dosage of phetidin,OnControl device,Standard manual device,No significant difference,"Usage of conscious sedation (24/30 patients and 21/30 patients respectively (p=0.56)) and dosages of lidocaine (10 ml vs 13 ml p=0.24), pethidin (23 mg vs 21 mg, p=0.68) and midazolam (2.5 mg vs 2.6 mg p=0.89) was similar between groups.",23602:23839,3534307,23105124,Unavailable
3534307,Dosage of midazolam ,OnControl device,Standard manual device,No significant difference,"Usage of conscious sedation (24/30 patients and 21/30 patients respectively (p=0.56)) and dosages of lidocaine (10 ml vs 13 ml p=0.24), pethidin (23 mg vs 21 mg, p=0.68) and midazolam (2.5 mg vs 2.6 mg p=0.89) was similar between groups.",23602:23839,3534307,23105124,Unavailable
3534307,Pain during procedure when not receiving conscious sedation,OnControl device,Standard manual device,Significantly decreased,"In the small subgroup of patients that did not receive sedation (n=15; manual 6, powered 9) significantly lower median pain scores were observed with the powered system than with the manual device (median score 3 vs 7 respectively; p=0.015). No difference was observed in T2 and T3 between devices in this subgroup.",24781:25096,3534307,23105124,Unavailable
3534307,Pain after 15 min when not receiving conscious sedation,OnControl device,Standard manual device,No significant difference,"In the small subgroup of patients that did not receive sedation (n=15; manual 6, powered 9) significantly lower median pain scores were observed with the powered system than with the manual device (median score 3 vs 7 respectively; p=0.015). No difference was observed in T2 and T3 between devices in this subgroup.",24781:25096,3534307,23105124,Unavailable
3534307,Pain after 3-5 days when not receiving conscious sedation,OnControl device,Standard manual device,No significant difference,"In the small subgroup of patients that did not receive sedation (n=15; manual 6, powered 9) significantly lower median pain scores were observed with the powered system than with the manual device (median score 3 vs 7 respectively; p=0.015). No difference was observed in T2 and T3 between devices in this subgroup.",24781:25096,3534307,23105124,Unavailable
3534307,Patient satisfaction,OnControl device,Standard manual device,No significant difference,"Patients were very satisfied with either device whether sedation was used (median 9 for both groups, range 3–10 (manual) and 0–10 (powered)) or not (median 8 (manual) vs 9 (powered)).",25158:25341,3534307,23105124,Unavailable
3534307,Patient satisfaction without sedation,OnControl device,Standard manual device,No significant difference,"Patients were very satisfied with either device whether sedation was used (median 9 for both groups, range 3–10 (manual) and 0–10 (powered)) or not (median 8 (manual) vs 9 (powered)).",25158:25341,3534307,23105124,Unavailable
3534307,Patient satisfaction without sedation ,OnControl device,Standard manual device,No significant difference,"Patients were satisfied with either device whether sedation was used (sedation: median 9 for both groups, range 3–10 (manual) and 0–10 (powered)) no sedation (median 8 (manual) vs 9 (powered)).",25158:25341,3534307,23105124,Unavailable
3534307,Operator satisfaction,OnControl device,Standard manual device,No significant difference,"Operator satisfaction was equally high with both devices (manual: median 8 (6–10), powered 9 (8–10); p=0.213).",25655:25765,3534307,23105124,Unavailable
5801522,Trait anxiety,DeStressify app,Control,Significantly decreased,"Using DeStressify was shown to reduce trait anxiety (P=.01) and improve general health (P=.001), energy (P=.01), and emotional well-being (P=.01) in university students",6473:6709,5801522,29362209,Unavailable
5801522,General health,DeStressify app,Control,Significantly increased,"Using DeStressify was shown to reduce trait anxiety (P=.01) and improve general health (P=.001), energy (P=.01), and emotional well-being (P=.01) in university students",6473:6709,5801522,29362209,Unavailable
5801522,Energy ,DeStressify app,Control,Significantly increased,"Using DeStressify was shown to reduce trait anxiety (P=.01) and improve general health (P=.001), energy (P=.01), and emotional well-being (P=.01) in university students",6473:6709,5801522,29362209,Unavailable
5801522,Emotional well-being,DeStressify app,Control,Significantly increased,"Using DeStressify was shown to reduce trait anxiety (P=.01) and improve general health (P=.001), energy (P=.01), and emotional well-being (P=.01) in university students",6473:6709,5801522,29362209,Unavailable
5801522,Stress,DeStressify app,Control,No significant difference,"The app did not significantly improve stress, state anxiety, physical and social functioning, and role limitations because of physical or emotional health problems or pain (P&gt;.05).",6951:7148,5801522,29362209,Unavailable
5801522,State anxiety,DeStressify app,Control,No significant difference,"The app did not significantly improve stress, state anxiety, physical and social functioning, and role limitations because of physical or emotional health problems or pain (P&gt;.05).",6951:7148,5801522,29362209,Unavailable
5801522,Physical functioning,DeStressify app,Control,No significant difference,"The app did not significantly improve stress, state anxiety, physical and social functioning, and role limitations because of physical or emotional health problems or pain (P&gt;.05).",6951:7148,5801522,29362209,Unavailable
5801522,Social functioning,DeStressify app,Control,No significant difference,"The app did not significantly improve stress, state anxiety, physical and social functioning, and role limitations because of physical or emotional health problems or pain (P&gt;.05).",6951:7148,5801522,29362209,Unavailable
5801522,Role limitations because of physical health,DeStressify app,Control,No significant difference,"The app did not significantly improve stress, state anxiety, physical and social functioning, and role limitations because of physical or emotional health problems or pain (P&gt;.05).",6951:7148,5801522,29362209,Unavailable
5801522,Role limitations because of emotional health,DeStressify app,Control,No significant difference,"The app did not significantly improve stress, state anxiety, physical and social functioning, and role limitations because of physical or emotional health problems or pain (P&gt;.05).",6951:7148,5801522,29362209,Unavailable
5801522,Pain,DeStressify app,Control,No significant difference,"The app did not significantly improve stress, state anxiety, physical and social functioning, and role limitations because of physical or emotional health problems or pain (P&gt;.05).",6951:7148,5801522,29362209,Unavailable
5801522,Stress,DeStressify app,Control,No significant difference,"StressPerceived stress scores within the experimental condition decreased in value, whereas control condition scores slightly increased in value from baseline to postintervention (see Table 2). However, differences in scores between conditions at postintervention did not reach statistical significance",NaN:43593,5801522,29362209,Unavailable
5801522,Depression,DeStressify app,Control,No significant difference,Postintervention transformed QIDS-SR scores for the experimental condition showed no significant difference from the control condition,44198:44332,5801522,29362209,Unavailable
5801522,Trait anxiety,DeStressify app,Control,Significantly decreased,"ANCOVA results demonstrate that individuals in the experimental condition reported less trait anxiety, F1,160=8.23, P=.01, ηp2=.049, than individuals in the control condition after 4 weeks of using the DeStressify app.",45134:45419,5801522,29362209,Unavailable
5801522,State anxiety,DeStressify app,Control,No significant difference,"State anxiety scores did not significantly differ between conditions at postintervention, F1,160=1.93, P=.17, ηp2=.01.",45420:45605,5801522,29362209,Unavailable
5801522,Sleep Quality,DeStressify app,Control,No significant difference,"(ANOVAs) were conducted as they are robust given the data’s traits [51]. There was no significant differences between treatment conditions in the postintervention scores for both raw, F1,158=2.51, P=.12, ηp2=.02, and transformed scores, F1,158=1.89, P=.17, ηp2=.01, when outliers were excluded. Results were similar when outliers were included (raw: F1,160=2.58, P=.11, ηp2=.016; transformed: F1,160=1.91, P=.17, ηp2=.01).",55419:56151,5801522,29362209,Unavailable
5801522,General health,DeStressify app,Control,Significantly increased,"The general health subscale was shown to significantly differ in postintervention scores between treatment conditions, F1,160=12.44, P=.001, ηp2=.07, such that scores decreased in the control condition and increased in the experimental condition",58303:58615,5801522,29362209,Unavailable
5801522,Energy ,DeStressify app,Control,Significantly increased,"A significant difference was also found between treatment conditions in regards to postintervention energy or fatigue subscale scores, F1,160=8.19, P=.01, ηp2=.05",58686:58915,5801522,29362209,Unavailable
5801522,Work Productivity,DeStressify app,Control,No significant difference,"A subscore was calculated using these work-related data, labeled “percent overall work impairment due to health” [49]. No significant difference was found between treatment conditions, F1,47=1.10, P=.30, ηp2=.02.",61614:61934,5801522,29362209,Unavailable
4233228,Deep venous thrombosis,Alternate sequential compression device,Simultaneous sequential compression device,No significant difference,"DVT developed in 7 patients (20.6%), all of whom were asymptomatic for isolated calf DVTs. Two of these patients were from the ASCD group (11.8%) and the other five were from the SSCD group (29.4%), but there was no significant difference (p = 0.331).",5130:5399,4233228,25436073,Unavailable
4233228,Flow enhancement,Alternate sequential compression device,Simultaneous sequential compression device,No significant difference,"However, the degrees of flow and velocity enhancement did not differ significantly between the groups.",5558:5661,4233228,25436073,Unavailable
4233228,Velocity enhancement,Alternate sequential compression device,Simultaneous sequential compression device,No significant difference,"However, the degrees of flow and velocity enhancement did not differ significantly between the groups.",5558:5661,4233228,25436073,Unavailable
4233228,Deep venous thrombosis,Alternate sequential compression device,Simultaneous sequential compression device,No significant difference,"Two of them were in the ASCD group (SCD Express, 11.8%) and the other five were in the SSCD group (DVT-3000, 29.4%). The difference was not significant (p = 0.331).",18343:18525,4233228,25436073,Unavailable
4233228,Flow enhancement,Alternate sequential compression device,Simultaneous sequential compression device,No significant difference,"Furthermore, the amounts of venous flow and volume enhancements were not different between the devices.",20121:20224,4233228,25436073,Unavailable
4233228,Velocity enhancement,Alternate sequential compression device,Simultaneous sequential compression device,No significant difference,"Furthermore, the amounts of venous flow and volume enhancements were not different between the devices.",20120:20225,4233228,25436073,Unavailable
4312941,Change of postprandial plasma glucose AUC,Lixisenatide twice daily,Placebo,Significantly increased,Change from baseline in PPG AUC[0:29–4:30 h] with lixisenatide QD and BID was significantly greater than placebo (p &lt; 0.0001 for all study populations),4921:5083,4312941,24524806,Unavailable
4312941,2 h postprandial plasma glucose ,Lixisenatide twice daily,Placebo,Significantly decreased,"In the overall population, changes from baseline for 2-h PPG, HbA1c and FPG were significant with lixisenatide QD and BID versus placebo (p &lt; 0.01 for all).",5330:5486,4312941,24524806,Unavailable
4312941,HbA1c ,Lixisenatide twice daily,Placebo,Significantly decreased,"In the overall population, changes from baseline for 2-h PPG, HbA1c and FPG were significant with lixisenatide QD and BID versus placebo (p &lt; 0.01 for all).",5330:5486,4312941,24524806,Unavailable
4312941,Fasting plasma glucose,Lixisenatide twice daily,Placebo,Significantly decreased,"In the overall population, changes from baseline for 2-h PPG, HbA1c and FPG were significant with lixisenatide QD and BID versus placebo (p &lt; 0.01 for all).",5330:5486,4312941,24524806,Unavailable
4312941,Change of postprandial plasma glucose AUC,Lixisenatide once daily,Placebo,Significantly increased,Change from baseline in PPG AUC[0:29–4:30 h] with lixisenatide QD and BID was significantly greater than placebo (p &lt; 0.0001 for all study populations),5330:5486,4312941,24524806,Unavailable
4312941,2 h postprandial plasma glucose ,Lixisenatide once daily,Placebo,Significantly decreased,"In the overall population, changes from baseline for 2-h PPG, HbA1c and FPG were significant with lixisenatide QD and BID versus placebo (p &lt; 0.01 for all).",5330:5486,4312941,24524806,Unavailable
4312941,HbA1c ,Lixisenatide once daily,Placebo,Significantly decreased,"In the overall population, changes from baseline for 2-h PPG, HbA1c and FPG were significant with lixisenatide QD and BID versus placebo (p &lt; 0.01 for all).",5330:5486,4312941,24524806,Unavailable
4312941,Fasting plasma glucose,Lixisenatide once daily,Placebo,Significantly decreased,"In the overall population, changes from baseline for 2-h PPG, HbA1c and FPG were significant with lixisenatide QD and BID versus placebo (p &lt; 0.01 for all).",5330:5486,4312941,24524806,Unavailable
4312941,Change of postprandial plasma glucose AUC,Lixisenatide twice daily,Placebo,Significantly increased,"In the PP population, least square (LS) mean (s.e.) differences in PPG AUC[0:29–4:30 h] were −333.4 (26.9) and −288.8 (26.1) h · mg/dl for lixisenatide QD and BID versus placebo, respectively (p &lt; 0.0001 for both",39827:40050,4312941,24524806,Unavailable
4312941,Change of postprandial plasma glucose AUC,Lixisenatide once daily,Placebo,Significantly increased,"In the PP population, least square (LS) mean (s.e.) differences in PPG AUC[0:29–4:30 h] were −333.4 (26.9) and −288.8 (26.1) h · mg/dl for lixisenatide QD and BID versus placebo, respectively (p &lt; 0.0001 for both",39827:40050,4312941,24524806,Unavailable
4312941,Fasting plasma glucose,Lixisenatide twice daily,Placebo,Significantly decreased,"In the overall population, change from baseline in FPG on the last day of the highest well-tolerated dose was significantly greater with lixisenatide QD and BID compared with placebo [LS mean (s.e.) difference −18.6 (5.8) and −26.8 (5.6) mg/dl, respectively; p &lt; 0.01 for both].",43732:44010,4312941,24524806,Unavailable
4312941,Fasting plasma glucose,Lixisenatide once daily,Placebo,Significantly decreased,"In the overall population, change from baseline in FPG on the last day of the highest well-tolerated dose was significantly greater with lixisenatide QD and BID compared with placebo [LS mean (s.e.) difference −18.6 (5.8) and −26.8 (5.6) mg/dl, respectively; p &lt; 0.01 for both].",43732:44010,4312941,24524806,Unavailable
4312941,HbA1c ,Lixisenatide twice daily,Placebo,Significantly decreased,"In the overall population, the LS mean (s.e.) differences in change from baseline in HbA1c at the last day of the highest well-tolerated dose of lixisenatide QD and BID compared with placebo were −0.53% (0.09%) and −0.72% (0.09%), respectively (p &lt; 0.0001 for both).",44327:44594,4312941,24524806,Unavailable
4312941,HbA1c ,Lixisenatide once daily,Placebo,Significantly decreased,"In the overall population, the LS mean (s.e.) differences in change from baseline in HbA1c at the last day of the highest well-tolerated dose of lixisenatide QD and BID compared with placebo were −0.53% (0.09%) and −0.72% (0.09%), respectively (p &lt; 0.0001 for both).",44327:44594,4312941,24524806,Unavailable
4312941,2 h postprandial plasma glucose ,Lixisenatide twice daily,Placebo,Significantly decreased,"The LS mean (s.e.) differences in 2-h PPG after a standardized breakfast in patients treated with lixisenatide QD and BID versus placebo in the overall population at the highest well-tolerated dose were −124.9 (10.0) and −103.4 (9.8) mg/dl, respectively (p &lt; 0.0001 for both).",42893:43170,4312941,24524806,Unavailable
4312941,2 h postprandial plasma glucose ,Lixisenatide once daily,Placebo,Significantly decreased,"The LS mean (s.e.) differences in 2-h PPG after a standardized breakfast in patients treated with lixisenatide QD and BID versus placebo in the overall population at the highest well-tolerated dose were −124.9 (10.0) and −103.4 (9.8) mg/dl, respectively (p &lt; 0.0001 for both).",42893:43169,4312941,24524806,Unavailable
4312941,Weight change,Lixisenatide twice daily,Placebo,No significant difference,"In the overall population, weight change from baseline to the last day of the highest well-tolerated dose did not reach statistical significance [LS mean (s.e.) difference −0.59 (0.43) and −0.49 (0.42) kg versus placebo for the lixisenatide QD- and BID-treated patients, respectively].",44985:45270,4312941,24524806,Unavailable
4312941,Weight change,Lixisenatide once daily,Placebo,No significant difference,"In the overall population, weight change from baseline to the last day of the highest well-tolerated dose did not reach statistical significance [LS mean (s.e.) difference −0.59 (0.43) and −0.49 (0.42) kg versus placebo for the lixisenatide QD- and BID-treated patients, respectively].",44985:45270,4312941,24524806,Unavailable
3943841,Systolic blood pressure reduction &gt;10 mmHg,Hypertension education,Control,No significant difference,"At six months, we observed a SBP reduction of ≥10 mmHg -primary outcome- in 48% of the intervention group and 43% of the control group. When adjusted for pre-specified covariates age, sex, hypertension duration, education, baseline measurement and clustering effect, the between-group difference was not significant (OR; 0.42; 95% CI: 0.11 to 1.54; P = 0.19).",56777:57050,3943841,24598584,Unavailable
3943841,Adherence to lifestyle recommendations ,Hypertension education,Control,Significantly increased,"Mean scores for adherence to lifestyle recommendations increased in the intervention group, but decreased in the control group. Mean medication adherence scores improved slightly in both groups. After adjustment, the between-group difference for adherence to lifestyle recommendations was 0.34 (0.12 to 0.55; P = 0.003).",7876:8197,3943841,24598584,Unavailable
3943841,Systolic blood pressure reduction &gt;10 mmHg,Hypertension education,Control,No significant difference,"After adjustment for pre-specified covariates of age, sex, duration of HTN, education, baseline BP and clustering effect, the estimated between-group difference in the proportion of patients with a SBP reduction of at least 10 mmHg was not significant (OR: 0.42; 95% CI: 0.11 to 1.54; P = 0.19)",56777:57050,3943841,24598584,Unavailable
3943841,Diastolic blood pressure improvement ,Hypertension education,Control,Significantly increased,"After adjustment for pre-specified covariates of age, sex, duration of HTN, education, baseline BP and clustering effect, the estimated between-group difference in improvement was statistically significant for DBP: mean change −3.01 mmHg (95% CI: −5.73 to −0.30; p = 0.03),",56777:57050,3943841,24598584,Unavailable
3943841,Systolic blood pressure improvement ,Hypertension education,Control,No significant difference,"After adjustment for pre-specified covariates of age, sex, duration of HTN, education, baseline BP and clustering effect, the estimated between-group difference in improvement was statistically significant for DBP: mean change −3.01 mmHg (95% CI: −5.73 to −0.30; p = 0.03), but not for the SBP: mean change −1.69 mmHg (95% CI: −6.01 to 2.62; p = 0.44)",56777:57128,3943841,24598584,Unavailable
3943841,Systolic blood pressure improvement ,Hypertension education,Control,No significant difference,"Systolic blood pressure (mmHg)	71	68	156.73 (12.26)	155.19 (10.69)	146.78 (16.23)	148.93 (13.25)	−3.69 (−8.34 to 0.96)	0.119	−1.59 (−6.08 to 2.89)	0.488	−1.69 (−6.01 to 2.62)	0.444",60000:60720,3943841,24598584,Unavailable
3943841,Diastolic blood pressure improvement ,Hypertension education,Control,Significantly increased,"Diastolic blood pressure (mmHg)	71	68	91.02 (9.61)	89.60 (9.36)	85.30 (10.93)	87.90 (9.53)	−4.03 (−7.01 to −1.04)	0.009	−2.98 (−5.81 to −0.16)	0.04	−3.01 (−5.73 to −0.30)	0.032",60828:61544,3943841,24598584,Unavailable
3943841,Adherence to lifestyle recommendations ,Hypertension education,Control,Significantly increased,"Lifestyle adherencea	52	45	2.74 (0.73)	2.98 (0.70)	3.05 (0.52)	2.86 (0.63)	0.43 (0.16 to 0.71)	0.002	0.28 (0.07 to 0.51)	0.013	0.34 (0.12 to 0.55)	0.003",61651:62389,3943841,24598584,Unavailable
3943841,Adherence to medication recommendations ,Hypertension education,Control,No significant difference,"Medication adherenceb	50	60	5.99 (1.95)	5.59 (2.17)	6.49 (1.69)	6.24 (1.82)	−0.15 (−0.84 to 0.55)	0.672	−0.13 (−0.69 to 0.43)	0.649	−0.09 (−0.65 to 0.46)	0.738",62497:63242,3943841,24598584,Unavailable
3943841,Adherence to medication recommendations ,Hypertension education,Control,No significant difference,"After adjustment, the between-group difference for adherence to lifestyle recommendations was 0.34 (0.12 to 0.55; P = 0.003). For medication adherence it was −0.09 (−0.65 to 0.46; P = 0.74).",8071:8261,3943841,24598584,Unavailable
3943841,Sodium excretion ,Hypertension education,Control,No significant difference,The mean sodium excretion between baseline and follow-up decreased from 65.81 mmol/L (SD 56.73) to 47.69 mmol/L (SD 38.94) in the intervention group and slightly increased from 54.93 mmol/L (SD 39.92) to 55.55 mmol/L (SD 48.75) in the control group (adjusted between-group difference −15.56: 95% CI: −39.36 to 8.23; P = 0.197).,65131:65458,3943841,24598584,Unavailable
3943841,BMI,Hypertension education,Control,No significant difference,The mean BMI between baseline and follow-up decreased from 31.13 (SD 5.26) to 30.97 (SD 5.20) in the intervention group and increased from 31.07 (SD 4.80) to 31.13 (SD 4.81) in the control group (adjusted between-group difference −0.49: 95% CI: −1.08 to 0.10; P = 0.10).,65459:65729,3943841,24598584,Unavailable
3685573,Oro-cecal transit time ,Late suppertime,Control,Significantly increased,OCTT (minutes)278 ± 53b315 ± 27b0.023,26167:NaN,3685573,23705984,Unavailable
3685573,Unabsorbed dietary carbohydrates,Late suppertime,Control,Significantly decreased,UDC (g)9.16 ± 7.785.48 ± 4.620.029,26429:26610,3685573,23705984,Unavailable
3685573,%  of unabsorbed dietary carbohydrates,Late suppertime,Control,Significantly decreased,% UDC12.6 ± 10.68.0 ± 6.80.016,26666:26843,3685573,23705984,Unavailable
3685573,"Whole gut transit time 	",Late suppertime,Control,No significant difference,"Whole gut transit time (hours)	30.7 ± 16.4	34.4 ± 18.3	0.389",26883:NaN,3685573,23705984,Unavailable
3685573,Blood glucose level at 30 min,Late suppertime,Control,Significantly increased,"There were significant differences in the blood glucose level between the two conditions at 30, 60, 120, 150, and 180 minutes after having breakfast, whereas the mean blood glucose level under late suppertime conditions was significantly higher than under usual suppertime conditions.",4931:5215,3685573,23705984,Unavailable
3685573,Blood glucose level at 60 min,Late suppertime,Control,Significantly increased,"There were significant differences in the blood glucose level between the two conditions at 30, 60, 120, 150, and 180 minutes after having breakfast, whereas the mean blood glucose level under late suppertime conditions was significantly higher than under usual suppertime conditions.",4931:5215,3685573,23705984,Unavailable
3685573,Blood glucose level at 120 min,Late suppertime,Control,Significantly increased,"There were significant differences in the blood glucose level between the two conditions at 30, 60, 120, 150, and 180 minutes after having breakfast, whereas the mean blood glucose level under late suppertime conditions was significantly higher than under usual suppertime conditions.",4931:5215,3685573,23705984,Unavailable
3685573,Blood glucose level at 150 min,Late suppertime,Control,Significantly increased,"There were significant differences in the blood glucose level between the two conditions at 30, 60, 120, 150, and 180 minutes after having breakfast, whereas the mean blood glucose level under late suppertime conditions was significantly higher than under usual suppertime conditions.",4931:5215,3685573,23705984,Unavailable
3685573,Blood glucose level at 180 min,Late suppertime,Control,Significantly increased,"There were significant differences in the blood glucose level between the two conditions at 30, 60, 120, 150, and 180 minutes after having breakfast, whereas the mean blood glucose level under late suppertime conditions was significantly higher than under usual suppertime conditions.",4931:5215,3685573,23705984,Unavailable
3685573,Respiratory quotient ,Late suppertime,Control,No significant difference,"Figure&nbsp;3 shows the time course of the RQ values (mean with SD bars) after having breakfast (▲ - ▲, usual suppertime condition, ● - ●, late suppertime condition). Two factor repeated measures ANOVA showed that there was a significant main effect for time [F(8, 88) = 24.9, P = 0.000], while there was no significant difference between the two conditions [F(1, 12 ) = 0.024, P = 0.879]",4931:5215,3685573,23705984,Unavailable
3685573,Blood glucose level at 30 min,Late suppertime,Control,Significantly increased,"Student’s paired t test showed that there was a significant difference in the blood glucose level between the two conditions at 30 ,60, 120 , 150 and 180 min after having breakfast, where the mean blood glucose level under the late suppertime condition was significantly higher than that under the usual suppertime condition (P &lt;0.05).",29127:29496,3685573,23705984,Unavailable
3685573,Blood glucose level at 60 min,Late suppertime,Control,Significantly increased,"Student’s paired t test showed that there was a significant difference in the blood glucose level between the two conditions at 30 ,60, 120 , 150 and 180 min after having breakfast, where the mean blood glucose level under the late suppertime condition was significantly higher than that under the usual suppertime condition (P &lt;0.05).",29127:29496,3685573,23705984,Unavailable
3685573,Blood glucose level at 120 min,Late suppertime,Control,Significantly increased,"Student’s paired t test showed that there was a significant difference in the blood glucose level between the two conditions at 30 ,60, 120 , 150 and 180 min after having breakfast, where the mean blood glucose level under the late suppertime condition was significantly higher than that under the usual suppertime condition (P &lt;0.05).",29127:29496,3685573,23705984,Unavailable
3685573,Blood glucose level at 150 min,Late suppertime,Control,Significantly increased,"Student’s paired t test showed that there was a significant difference in the blood glucose level between the two conditions at 30 ,60, 120 , 150 and 180 min after having breakfast, where the mean blood glucose level under the late suppertime condition was significantly higher than that under the usual suppertime condition (P &lt;0.05).",29127:29496,3685573,23705984,Unavailable
3685573,Blood glucose level at 180 min,Late suppertime,Control,Significantly increased,"Student’s paired t test showed that there was a significant difference in the blood glucose level between the two conditions at 30 ,60, 120 , 150 and 180 min after having breakfast, where the mean blood glucose level under the late suppertime condition was significantly higher than that under the usual suppertime condition (P &lt;0.05).",29127:29496,3685573,23705984,Unavailable
3685573,Oro-cecal transit time ,Late suppertime,Control,Significantly increased,The efficiency of the digestion and absorption of dietary carbohydrates in the breakfast under late suppertime conditions was higher than that under usual suppertime conditions.,4631:4808,3685573,23705984,Unavailable
3685573,Unabsorbed dietary carbohydrates,Late suppertime,Control,Significantly decreased,The efficiency of the digestion and absorption of dietary carbohydrates in the breakfast under late suppertime conditions was higher than that under usual suppertime conditions.,4631:4808,3685573,23705984,Unavailable
3685573,%  of unabsorbed dietary carbohydrates,Late suppertime,Control,Significantly decreased,The efficiency of the digestion and absorption of dietary carbohydrates in the breakfast under late suppertime conditions was higher than that under usual suppertime conditions.,4631:4808,3685573,23705984,Unavailable
3685573,"Whole gut transit time 	",Late suppertime,Control,No significant difference,The efficiency of the digestion and absorption of dietary carbohydrates in the breakfast under late suppertime conditions was higher than that under usual suppertime conditions.,4631:4808,3685573,23705984,Unavailable
5862462,Running performance, Pilates training programme,Control,Significantly increased,"Confirming our hypothesis, a significant improvement (p&lt;0.05) was observed for running performance in the PG (pre: 25.65±0.4 min; post: 23.23±0.4 min) compared to the CG (pre: 25.33±0.58 min; post: 24.61±0.52 min).",12284:12498,5862462,29561907,Unavailable
5862462,VO2max, Pilates training programme,Control,Significantly increased,"In the post-training period, the PG had significantly higher VO2max values (p&lt;0.001), a significantly shorter 5-km running time (p&lt;0.001), and a significantly lower Cmet12 (p = 0.019).",42284:42496,5862462,29561907,Unavailable
5862462,Running performance, Pilates training programme,Control,Significantly increased,"In the post-training period, the PG had significantly higher VO2max values (p&lt;0.001), a significantly shorter 5-km running time (p&lt;0.001), and a significantly lower Cmet12 (p = 0.019).",42284:42496,5862462,29561907,Unavailable
5862462,Metabolic cost at 12 km/h, Pilates training programme,Control,Significantly decreased,"Similarly, the PG (4.33±0.07 J.kg-1.m-1) had better responses than the CG (4.71±0.11 J.kg-1.m-1) during post-training for Cmet.",42284:42496,5862462,29561907,Unavailable
5862462,Running performance, Pilates training programme,Control,Significantly increased,"5-km running time	CG	25.33 (0.58)	24.61 (0.52)*	&lt;0.001	0.441	&lt;0.001",44676:45072,5862462,29561907,Unavailable
5862462,VO2max, Pilates training programme,Control,Significantly increased,"VO2max	CG	51.32 (1.20)	53.72 (1.58)*	&lt;0.001	0.204	&lt;0.001",45609:46018,5862462,29561907,Unavailable
5862462,Metabolic cost at 10 km/h, Pilates training programme,Control,No significant difference,Cmet10 CG 4.27 (0.09) 3.85 (0.13)* &lt;0.001 0.868 0.923,47491:47897,5862462,29561907,Unavailable
5862462,Metabolic cost at 12 km/h, Pilates training programme,Control,Significantly decreased,"Cmet12	CG	5.22 (0.08)	4.71 (0.11)*	&lt;0.001	0.014	0.019",47491:47897,5862462,29561907,Unavailable
5862462,Obliquus externus abdominis Max voluntary isometric contraction, Pilates training programme,Control,Significantly increased,OE MVIC CG 233.00 (28.41) 229.36 (41.75) 0.005 0.048 0.047(mV) PG 249.87 (22.12) 316.95 (26.70)*a,51205:NaN,5862462,29561907,Unavailable
5862462,Obliquus internus abdominis Max voluntary isometric contraction, Pilates training programme,Control,Significantly increased,"OI MVIC	CG	527.14 (60.5)	510.52 (71.19)	0.03	0.037	0.006(mV)	PG	550.69 (60.85)	685.48 (73.46)*a",52077:NaN,5862462,29561907,Unavailable
5862462,Longissimus Max voluntary isometric contraction, Pilates training programme,Control,Significantly increased,"LO MVIC	CG	284.31 (17.51)	285.79 (15.25)	0.012	0.027	0.016(mV)	PG	299.39 (21.31)	371.22 (21.49)*a",53808:NaN,5862462,29561907,Unavailable
5862462,Gluteus medius Max voluntary isometric contraction, Pilates training programme,Control,Significantly increased,"GM MVIC	CG	471.15 (39.47)	529.03 (53.10)	0.006	0.007	0.040(mV)	PG	450.12 (33.60)	587.68 (45.61) *a",55544:NaN,5862462,29561907,Unavailable
5862462,Vastus lateralis Max voluntary isometric contraction, Pilates training programme,Control,No significant difference,"VL MVIC	CG	425.53 (26.82)	483.16 (36.73)*	0.032	0.193	0.138(mV)	PG	432.39 (40.79)	561.93 (46.61)*",52947:NaN,5862462,29561907,Unavailable
5862462,Biceps femoralis Max voluntary isometric contraction, Pilates training programme,Control,No significant difference,"BF MVIC	CG	379.40 (29.5)	452.78 (37.11)*	&lt;0.001	0.559	0.034(mV)	PG	370.47 (30.56)	510.20 (27.59)*",54680:NaN,5862462,29561907,Unavailable
5862462,Latissimus dorsi Max voluntary isometric contraction, Pilates training programme,Control,No significant difference,"LD MVIC	CG	348.14 (28.00)	376.24 (32.59)	0.502	0.660	0.745(mV)	PG	376.05 (32.86)	385.81 (47.95)",56417:NaN,5862462,29561907,Unavailable
5862462,Obliquus externus abdominis Max voluntary isometric contraction, Pilates training programme,Control,Significantly increased,"In post-training, the MVIC of the OE, OI, LO, and GM muscles was significantly higher in the PG than in the CG.",49238:49349,5862462,29561907,Unavailable
5862462,Obliquus internus abdominis Max voluntary isometric contraction, Pilates training programme,Control,Significantly increased,"In post-training, the MVIC of the OE, OI, LO, and GM muscles was significantly higher in the PG than in the CG.",49237:49349,5862462,29561907,Unavailable
5862462,Longissimus Max voluntary isometric contraction, Pilates training programme,Control,Significantly increased,"In post-training, the MVIC of the OE, OI, LO, and GM muscles was significantly higher in the PG than in the CG.",49238:49349,5862462,29561907,Unavailable
5862462,Gluteus medius Max voluntary isometric contraction, Pilates training programme,Control,Significantly increased,"In post-training, the MVIC of the OE, OI, LO, and GM muscles was significantly higher in the PG than in the CG.",49238:49349,5862462,29561907,Unavailable
5862462,Obliquus externus abdominis level of activation, Pilates training programme,Control,No significant difference,"However, no differences in the level of activation of this muscle were found between groups (p = 0.983).",58240:58346,5862462,29561907,Unavailable
5862462,Obliquus internus abdominis level of activation, Pilates training programme,Control,Significantly decreased,the level of muscle activation in the PG was lower than that in the CG (p = 0.003).,60111:60195,5862462,29561907,Unavailable
5862462,Vastus lateralis level of activation, Pilates training programme,Control,No significant difference,"For the VA muscle in particular, there were no differences between the groups",61899:61976,5862462,29561907,Unavailable
5862462,Longissimus level of activation, Pilates training programme,Control,Significantly decreased,"Furthermore, in post-training, muscle activation in the PG was significantly lower than that in the CG (p = 0.002).",63308:63424,5862462,29561907,Unavailable
5862462,Longissimus level of activation (at 10km/h), Pilates training programme,Control,No significant difference,"In the swing phase at 10 km.h-1, there were no significant differences in the level of activation of the LO between groups (p = 0.630)",64254:64399,5862462,29561907,Unavailable
5862462,Gluteus medius level of activation, Pilates training programme,Control,Significantly decreased,and muscle activation in the PG was significantly lower than in the CG (p = 0.005) in post-training (Fig 6).,67086:67249,5862462,29561907,Unavailable
5094573,Abdominal contribution,Aerobic training combined with respiratory muscle stretching,Control,Significantly increased,"After the intervention, the TG showed improved abdominal (ABD) contribution, compartmental volume, mobility, and functional exercise capacity with decreased dyspnea when compared with the CG (P&lt;0.01).",5598:5815,5094573,27822031,Unavailable
5094573,Abdominal compartmental volume,Aerobic training combined with respiratory muscle stretching,Control,Significantly increased,"After the intervention, the TG showed improved abdominal (ABD) contribution, compartmental volume, mobility, and functional exercise capacity with decreased dyspnea when compared with the CG (P&lt;0.01).",24793:25030,5094573,27822031,Unavailable
5094573,Abdominal compartment mobility,Aerobic training combined with respiratory muscle stretching,Control,Significantly increased,"After the intervention, the TG showed improved abdominal (ABD) contribution, compartmental volume, mobility, and functional exercise capacity with decreased dyspnea when compared with the CG (P&lt;0.01).",24793:25030,5094573,27822031,Unavailable
5094573,Functional exercise capacity,Aerobic training combined with respiratory muscle stretching,Control,Significantly increased,"After the intervention, the TG showed improved abdominal (ABD) contribution, compartmental volume, mobility, and functional exercise capacity with decreased dyspnea when compared with the CG (P&lt;0.01).",5598:5815,5094573,27822031,Unavailable
5094573,Respiratory muscle effort,Aerobic training combined with respiratory muscle stretching,Control,Significantly decreased,The TG also showed a decreased respiratory muscle effort required to obtain the same pulmonary volume compared to the CG (P&lt;0.001).,5816:5967,5094573,27822031,Unavailable
5094573,Chest wall volume,Aerobic training combined with respiratory muscle stretching,Control,Significantly increased,"Patients from the TG presented an increase in CW volume after the intervention when compared with the CG (140±170 mL vs −86±240 mL, respectively; P&lt;0.001)",24793:25030,5094573,27822031,Unavailable
5094573,Abdominal compartmental volume,Aerobic training combined with respiratory muscle stretching,Control,Significantly increased,"which was mainly due to an increased ABD volume (140±120 mL vs −108±210 mL, respectively; P&lt;0.001).",24793:25030,5094573,27822031,Unavailable
5094573,Upper ribcage volume,Aerobic training combined with respiratory muscle stretching,Control,No significant difference,"In contrast, no difference was observed in the URC and LRC volumes (P&gt;0.05; Figure 2).",24267:24427,5094573,27822031,Unavailable
5094573,Lower ribcage volume,Aerobic training combined with respiratory muscle stretching,Control,No significant difference,"In contrast, no difference was observed in the URC and LRC volumes (P&gt;0.05; Figure 2).",24267:24427,5094573,27822031,Unavailable
5094573,Minute volume,Aerobic training combined with respiratory muscle stretching,Control,Significantly increased,"The TG also demonstrated an increase in the VE compared with that of the CG (2.4±3.6 L/min vs −1.8±4.1 L/min, respectively; P&lt;0.001; Figure 3A) as well as in EF (80±100 mL/s vs −30±100 mL/s, respectively; P&lt;0.001",24428:24727,5094573,27822031,Unavailable
5094573,Expiratory flow ,Aerobic training combined with respiratory muscle stretching,Control,Significantly increased,"The TG also demonstrated an increase in the VE compared with that of the CG (2.4±3.6 L/min vs −1.8±4.1 L/min, respectively; P&lt;0.001; Figure 3A) as well as in EF (80±100 mL/s vs −30±100 mL/s, respectively; P&lt;0.001",24428:24727,5094573,27822031,Unavailable
5094573,Abdominal compartment mobility,Aerobic training combined with respiratory muscle stretching,Control,Significantly increased,"The TG showed an increase in ABD compartment mobility (lower RC/ABD values) when compared with the CG (−0.19±0.41 mL vs 0.10±0.14 mL, respectively; P&lt;0.05; Figure 4).",24793:25030,5094573,27822031,Unavailable
5094573,Respiratory muscle effort,Aerobic training combined with respiratory muscle stretching,Control,Significantly decreased,"In addition, the TG showed a decrease in respiratory effort and improved efficiency of inspiratory muscle activity when analyzed altogether (EMG/VT; −47.9±82.8 10−3 mV/L vs 20.3±69.1 10−3 mV/L, respectively; P=0.03",25242:25496,5094573,27822031,Unavailable
5094573,Functional exercise capacity,Aerobic training combined with respiratory muscle stretching,Control,Significantly increased,"Functional exercise capacityAfter the intervention, the TG had test results similar to those of the CG (488.0±17.4 m vs 454.0±17.5 m, respectively); however, the difference of 33.2 m between groups was clinically significant",NaN:25815,5094573,27822031,Unavailable
5094573,Dyspnea,Aerobic training combined with respiratory muscle stretching,Control,Significantly decreased,"After the intervention, the TG showed improved abdominal (ABD) contribution, compartmental volume, mobility, and functional exercise capacity with decreased dyspnea when compared with the CG (P&lt;0.01).",NaN:25815,5094573,27822031,Unavailable
5094573,Dyspnea,Aerobic training combined with respiratory muscle stretching,Control,Significantly decreased,"Moreover, the TG reported a lower sensation of dyspnea after the 6MWT than was reported by the CG (1.53±0.31 points vs 2.78±0.30 points, P&lt;0.001; Figure 7).",25878:26104,5094573,27822031,Unavailable
3621778,Child length,Nutritional program,Control,No significant difference,The intervention did not show statistically significant effects on length,4967:5040,3621778,23496939,Unavailable
3621778, BMI for age Z-score ,Nutritional program,Control,Significantly decreased,"Significant reductions of BMI-for-age Z-score (−0.31, 95%CI −0.49; -0.12) and of BMI-for-age &gt; 85th percentile (0.43, 95%CI 0.23; 0.77) were observed.",5212:5376,3621778,23496939,Unavailable
3621778,BMI-for-age &gt; 85th percentile ,Nutritional program,Control,Significantly decreased,"Significant reductions of BMI-for-age Z-score (−0.31, 95%CI −0.49; -0.12) and of BMI-for-age &gt; 85th percentile (0.43, 95%CI 0.23; 0.77) were observed.",5212:5376,3621778,23496939,Unavailable
3621778,Weight-for-length Z-score &lt; -2,Nutritional program,Control,No significant difference,"The results of the anthropometric indicators revealed a low prevalence of wasting (weight-for-length Z-score &lt; −2) both in the control group and in the intervention group, respectively 1.16% and 2.07%, with no significant difference (P=0.436).",42566:42958,3621778,23496939,Unavailable
3621778,Low weight-for-age,Nutritional program,Control,No significant difference,"the prevalence of low weight-for-age in children under 5 was 3.1%; in our study it was 3.86% in the control group and 2.07% in the intervention group, a difference that lacks statistical significance (P=0.278).",38748:38975,3621778,23496939,Unavailable
3621778,Child length,Nutritional program,Control,No significant difference,The results on length were not statistically significant,38982:39038,3621778,23496939,Unavailable
3621778,Length-for-age Z-score,Nutritional program,Control,No significant difference,"The mean length-for-age Z-score (LAZ) was −0.66 in the control group and −0.46 in the intervention group, resulting in an adjusted difference of 0.21 (P = 0.067).",39089:39285,3621778,23496939,Unavailable
3621778,Length-for-age Z-score &lt; -2,Nutritional program,Control,No significant difference,"The prevalence of stunting was 11.97% in the control group and 7.25% in the intervention group, with an adjusted odds ratio of 0.50 (P = 0.085).",39286:39447,3621778,23496939,Unavailable
3621778,Length-for-age Z-score &lt; -1,Nutritional program,Control,No significant difference,"On the other hand, an analysis of LAZ &lt; −1showed a prevalence of 36.29% in the control group and 33.16% in the intervention group (P=0.490). No significant interaction effects were found.",39448:39655,3621778,23496939,Unavailable
3621778,Length-for-age Z-score,Nutritional program,Control,No significant difference,Length-for-age (Z score) a−0.66 ± 1.09−0.46 ± 1.210.20 (−0.01; 0.41)0.0670.21 (−0.02; 0.44)0.067,41160:41561,3621778,23496939,Unavailable
3621778, BMI for age Z-score ,Nutritional program,Control,Significantly decreased,BMI-for-age (Z score) b0.35 ± 0.920.13 ± 0.94−0.22 (−0.40; -0.05)0.012−0.31 (−0.49; -0.12)0.001,41617:42017,3621778,23496939,Unavailable
3621778,Length-for-age Z-score &lt; -2,Nutritional program,Control,No significant difference,Stunting (LAZ &lt; −2) c31 (11.97)14 (7.25)0.58 (0.30; 1.11)0.1010.50 (0.22; 1.10)0.085,42566:42958,3621778,23496939,Unavailable
3621778, BMI for age Z-score ,Nutritional program,Control,Significantly decreased,"The mean BMI-for-age Z-score was 35 ± 0.92 in the control group and 0.13 ± 0.94 in the intervention group, with an adjusted effect of −0.31 (P=0.001).",43805:43990,3621778,23496939,Unavailable
3621778,BMI-for-age &amp;gt; 85th percentile ,Nutritional program,Control,Significantly decreased,"The categorical analysis of this variable found a difference in the proportion of children with BMI-for-age &gt; 85th percentile, with values of 22.39% in the control group and 15.54% in the intervention group, with an adjusted odds ratio of 0.43 and confidence interval between 0.23 and 0.77 (P=0.005).",43990:44322,3621778,23496939,Unavailable
3621778, BMI for age Z-score +2,Nutritional program,Control,No significant difference,"On the other hand, when the Z-score with cut-off point +2 was considered instead of 85th percentile, the resulting prevalence was 3.47% in the control group and 1.55% in the intervention group (P=0.209).",44633:44881,3621778,23496939,Unavailable
3621778,Child was weighed in the last 4 months,Nutritional program,Control,Significantly increased,Child was weighed in the last 4&nbsp;months131 (51.37)159 (83.25)4.64 (2.95; 7.32)&lt; 0.001,47523:47803,3621778,23496939,Unavailable
3621778,The child growth curve was explained,Nutritional program,Control,Significantly increased,The child growth curve was explained to the mother69 (27.71)136 (71.20)6.45 (4.24; 9.80)&lt; 0.001,48212:48546,3621778,23496939,Unavailable
3621778,Counseling on infant and young child feeding practices,Nutritional program,Control,Significantly increased,Mother received counseling on infant and young child feeding practices in the last 4&nbsp;months47 (18.36)134 (70.16)11.19 (7.02; 17.82)&lt; 0.001,48212:48546,3621778,23496939,Unavailable
3621778,Home visit from a community health agent or health professional,Nutritional program,Control,Significantly increased,Mother received a home visit from a community health agent or health professional in the last 4&nbsp;months30 (12.00)132 (69.11)16.41 (10.06; 26.77)&lt; 0.001,48605:48951,3621778,23496939,Unavailable
3621778,Participation  in child health and nutrition meeting,Nutritional program,Control,Significantly increased,Mother participated in child health and nutrition meeting since the child’s birth33 (13.10)188 (97.92)311.9 (108.5; 896.5)&lt; 0.001,49010:49335,3621778,23496939,Unavailable
3621778,Taking vitamin A capsules (mother),Nutritional program,Control,Significantly increased,Mother took a Vitamin A capsule in the 8&nbsp;weeks following birth51 (20.73)126 (68.85)8.45 (5.45; 13.11)&lt; 0.001,56165:NaN,3621778,23496939,Unavailable
3621778,Exclusive breastfeeding through 6 months of age,Nutritional program,Control,Significantly increased,Exclusive breastfeeding through 6&nbsp;months of age6 (2.34)14 (7.29)3.28 (1.24; 8.69)0.017,50047:50329,3621778,23496939,Unavailable
3621778,Predominant breastfeeding through 6 months of age ,Nutritional program,Control,Significantly increased,Predominant breastfeeding through 6&nbsp;months of age c13 (5.08)31 (16.15)3.60 (1.83; 7.09)&lt; 0.001,50385:50686,3621778,23496939,Unavailable
3621778,Children currently breastfeeding,Nutritional program,Control,No significant difference,Child currently breastfeeding67 (26.17)50 (26.04)0.97 (0.63; 1.49)0.885,50745:51012,3621778,23496939,Unavailable
3621778, + 5 or more feedings with solid or semisolid foods,Nutritional program,Control,Significantly increased,Child received 5 or more feedings with solid or semisolid foods in the last 24&nbsp;hours48 (18.53)53 (27.46)1.62 (1.03; 2.55)0.037,51068:51390,3621778,23496939,Unavailable
3621778,Consuming Vit A rich foods (child),Nutritional program,Control,No significant difference,Child consumed foods rich in vitamin A in the last 24&nbsp;hours d66 (25.48)46 (23.83)0.92 (0.59; 1.41)0.688,56165:NaN,3621778,23496939,Unavailable
3621778,Consuming fruits,Nutritional program,Control,Significantly increased,Child consumed fruits in the last 24&nbsp;hours146 (56.37)129 (66.84)1.52 (1.02; 2.26)0.039,51812:52094,3621778,23496939,Unavailable
3621778,Receiving vitamin A supplement (child),Nutritional program,Control,Significantly increased,Child received vitamin A supplement171 (66.80)159 (82.81)2.35 (1.49; 3.71)&lt; 0.001,56165:NaN,3621778,23496939,Unavailable
3621778,Receiving iron supplement,Nutritional program,Control,Significantly increased,Child received iron supplement in the last 3&nbsp;months109 (43.43)165 (86.39)8.23 (5.07; 13.37)&lt; 0.001,52486:52780,3621778,23496939,Unavailable
3621778,Consuming non-boiled faucet water,Nutritional program,Control,Significantly decreased,"Child consumed water from the faucet, not boiled, without chlorine50 (19.53)21 (10.94)0.48 (0.28; 0.85)0.011",53144:53448,3621778,23496939,Unavailable
3621778,Bottle usage,Nutritional program,Control,No significant difference,Child used bottle in the last 24&nbsp;hours198 (77.34)140 (72.92)0.79 (0.51; 1.23)0.298,53781:54059,3621778,23496939,Unavailable
3621778,Diarrhea prevalence ,Nutritional program,Control,No significant difference,Child had diarrhea in the last 2&nbsp;weeks41 (16.02)29 (15.10)0.99 (0.59; 1.67)0.980,57886:58087,3621778,23496939,Unavailable
3621778,Receiving more liquids during diarrhea,Nutritional program,Control,Significantly increased,Child received more liquids during diarrhea25 (58.14)24 (77.42)3.42 (1.06; 11.07)0.040,54447:54729,3621778,23496939,Unavailable
3621778,Receiving ORS during diarrhea,Nutritional program,Control,Significantly increased,Child received ORS during diarrhea28 (63.64)27 (87.10)3.86 (1.14; 13.02)0.030,54785:55058,3621778,23496939,Unavailable
3621778,Amount of food during diarrhea,Nutritional program,Control,No significant difference,Child received equal or greater amount of foods during diarrhea23 (53.49)14 (45.16)0.63 (0.24; 1.66)0.347,55114:55415,3621778,23496939,Unavailable
3621778,Mentioning signs of emergency during diarrhea,Nutritional program,Control,Significantly increased,Mother mentioned a sign of emergency during diarrhea170 (65.64)147 (76.17)1.67 (1.10; 2.54)0.016,55471:55763,3621778,23496939,Unavailable
3621778,Completed vaccination schedule,Nutritional program,Control,Significantly increased,Child completed vaccination schedule in the first year of life90 (35.16)100 (52.08)2.00 (1.37; 2.94)&lt; 0.001,55819:56122,3621778,23496939,Unavailable
3621778,Hospitalization ,Nutritional program,Control,No significant difference,"Child was hospitalized in the last 12&nbsp;months	60 (23.44)	48 (25.00)	1.09 (0.70; 1.68)	0.702",56165:NaN,3621778,23496939,Unavailable
3621778,Taking vitamin A capsules (mother),Nutritional program,Control,Significantly increased,The results related to some of the feeding practices show a higher consumption of vitamin A and iron supplements by children and mothers in the intervention group.,56917:57081,3621778,23496939,Unavailable
3621778,Receiving vitamin A supplement (child),Nutritional program,Control,Significantly increased,The results related to some of the feeding practices show a higher consumption of vitamin A and iron supplements by children and mothers in the intervention group.,56917:57080,3621778,23496939,Unavailable
3621778,Receiving iron supplement,Nutritional program,Control,Significantly increased,The results related to some of the feeding practices show a higher consumption of vitamin A and iron supplements by children and mothers in the intervention group.,56917:57080,3621778,23496939,Unavailable
3621778,Exclusive breastfeeding through 6 months of age,Nutritional program,Control,Significantly increased,the prevalence of exclusive breastfeeding was shown to be 2.34% in the control group and 7.29% in the intervention group (P=0.017).,57186:57334,3621778,23496939,Unavailable
3621778, + 5 or more feedings with solid or semisolid foods,Nutritional program,Control,Significantly increased,"in the intervention group there was a higher proportion of children that consumed five or more solid or semisolid food items over the past 24&nbsp;hours (27.46% vs 18.53% in the control group, P=0.037).",57354:57568,3621778,23496939,Unavailable
3621778,Consuming Vit A rich foods (child),Nutritional program,Control,No significant difference,"However, there was no difference either in the consumption of vitamin A rich food or in most of the particular food items in the previous 24&nbsp;hours or in the previous 7&nbsp;days.",57569:57742,3621778,23496939,Unavailable
3621778,Completed vaccination schedule,Nutritional program,Control,Significantly increased,"Differences were found that indicate more adequate practices in the intervention group related to immunization, drinking water and administration of liquids and oral rehydration salts during diarrhea.",57887:58087,3621778,23496939,Unavailable
3621778,Consuming non-boiled faucet water,Nutritional program,Control,Significantly decreased,"Differences were found that indicate more adequate practices in the intervention group related to immunization, drinking water and administration of liquids and oral rehydration salts during diarrhea.",57887:58087,3621778,23496939,Unavailable
3621778,Receiving more liquids during diarrhea,Nutritional program,Control,Significantly increased,"Differences were found that indicate more adequate practices in the intervention group related to immunization, drinking water and administration of liquids and oral rehydration salts during diarrhea.",57887:58088,3621778,23496939,Unavailable
3621778,Receiving ORS during diarrhea,Nutritional program,Control,Significantly increased,"Differences were found that indicate more adequate practices in the intervention group related to immunization, drinking water and administration of liquids and oral rehydration salts during diarrhea.",57886:58087,3621778,23496939,Unavailable
3621778,Bottle usage,Nutritional program,Control,No significant difference,"However, there was no difference between the groups with regard to the use of bottle and the amount of food consumed during diarrhea.",58088:58221,3621778,23496939,Unavailable
3621778,Amount of food during diarrhea,Nutritional program,Control,No significant difference,"However, there was no difference between the groups with regard to the use of bottle and the amount of food consumed during diarrhea.",58088:58221,3621778,23496939,Unavailable
3621778,Diarrhea ,Nutritional program,Control,No significant difference,Neither were there any differences between the groups with regard to the prevalence of diarrhea over the past two weeks or in the proportion of children hospitalized during the past 12&nbsp;months.,58222:58414,3621778,23496939,Unavailable
3621778,Hospitalization ,Nutritional program,Control,No significant difference,Neither were there any differences between the groups with regard to the prevalence of diarrhea over the past two weeks or in the proportion of children hospitalized during the past 12&nbsp;months.,58221:58414,3621778,23496939,Unavailable
3692032,Broad-scaled cumulative axial Unified Parkinson’s Disease Rating Scale score,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,For the primary outcome measure no statistically significant improvement was observed for combined subthalamic nucleus and substantia nigra pars reticulata stimulation at the ‘3-week follow-up’.,7764:7959,3692032,23757762,Unavailable
3692032,Freezing of gait improvement ,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,Significantly increased,"The secondary endpoints, however, revealed that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata might specifically improve freezing of gait, whereas balance impairment remained unchanged.",7960:8185,3692032,23757762,Unavailable
3692032,Balance impairment improvement ,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,"The secondary endpoints, however, revealed that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata might specifically improve freezing of gait, whereas balance impairment remained unchanged.",7960:8185,3692032,23757762,Unavailable
3692032,Broad-scaled cumulative axial Unified Parkinson’s Disease Rating Scale score,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,"At ‘3-week follow-up’, no statistically significant difference was found on the axial score between conditions [combined STN+SNr stimulation: 13.42 ± 6.47; standard STN stimulation: 14.25 ± 5.75; effect = 0.83 ± 3.86; 95% confidence interval (CI)−1.62–3.82; P = 0.470",49152:49436,3692032,23757762,Unavailable
3692032,Axial motor symptoms improvement ,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,no difference was found at the ‘3-week follow-up’ (8.08 ± 4.38 versus 8.08 ± 4.01; P &gt; 0.99),51469:51578,3692032,23757762,Unavailable
3692032,Freezing of gait improvement ,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,Significantly increased,"Similarly, patients presented with severe freezing of gait at baseline according to the Freezing of Gait Assessment Course (22.17 ± 11.74). This improved more with combined STN+SNr stimulation compared with standard STN stimulation in the ‘immediate testing’ (8.67 ± 10.92 versus 16.25 ± 12.78; P = 0.006) and at the ‘3-week follow-up’ (8.33 ± 10.91 versus 14.42 ± 13.19; P = 0.047).",51580:52000,3692032,23757762,Unavailable
3692032, CAPSIT-PD timed walking test ,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,In the CAPSIT-PD timed walking test no relevant differences were observed between combined STN+SNr stimulation and standard STN stimulation in the number of steps and time.,52310:52482,3692032,23757762,Unavailable
3692032, Freezing episodes,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,Freezing episodes occurred more frequently with standard STN stimulation compared with combined STN+SNr stimulation at ‘3-week follow-up’ (P = 0.063; Supplementary material) but not at ‘immediate testing’.,52483:52835,3692032,23757762,Unavailable
3692032,Giladi Freezing of Gait Questionnaire,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,"In the Giladi Freezing of Gait Questionnaire, freezing of gait improved with combined STN+SNr stimulation compared with standard STN stimulation, although not significantly (14.50 ± 4.89 versus 16.17 ± 3.83; P = 0.1).",52835:53070,3692032,23757762,Unavailable
3692032,Berg Balance Scale,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,No differences were observed in the Berg Balance Scale.,53071:53126,3692032,23757762,Unavailable
3692032,Quality of life - Mobility,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,A slightly greater improvement was observed with combined STN+SNr stimulation compared with standard STN stimulation on ‘mobility’ (49.38 ± 25.30 versus 54.32 ± 27.23; not statistically significant) and ‘social support’ (11.81 ± 10.93 versus 18.94 ± 23.89; not statistically significant).,53990:54279,3692032,23757762,Unavailable
3692032,Quality of life - Social support,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,A slightly greater improvement was observed with combined STN+SNr stimulation compared with standard STN stimulation on ‘mobility’ (49.38 ± 25.30 versus 54.32 ± 27.23; not statistically significant) and ‘social support’ (11.81 ± 10.93 versus 18.94 ± 23.89; not statistically significant).,53990:54279,3692032,23757762,Unavailable
3692032,Non-motor symptoms,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,No differences were identified in the distinct non-motor symptom domains.,54280:54353,3692032,23757762,Unavailable
3692032,Barrett Impulsivity Scale,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,"The comparison of standard STN stimulation and combined STN+SNr stimulation showed no differences between treatments on the Barrett Impulsivity Scale, on segmental motor symptoms (UPDRS III, items 20–26) and on motor fluctuations (UPDRS IV).",56591:56832,3692032,23757762,Unavailable
3692032,Segmental motor symptoms,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,"The comparison of standard STN stimulation and combined STN+SNr stimulation showed no differences between treatments on the Barrett Impulsivity Scale, on segmental motor symptoms (UPDRS III, items 20–26) and on motor fluctuations (UPDRS IV).",56591:56832,3692032,23757762,Unavailable
3692032,Motor fluctuations,Subthalamic nucleus and substantia nigra pars reticulata stimulation,Subthalamic nucleus stimulation,No significant difference,"The comparison of standard STN stimulation and combined STN+SNr stimulation showed no differences between treatments on the Barrett Impulsivity Scale, on segmental motor symptoms (UPDRS III, items 20–26) and on motor fluctuations (UPDRS IV).",56591:56832,3692032,23757762,Unavailable
3024329,Maintaining A1C goal,Insulin lispro mix,Insulin glargine,Significantly increased,A1C goal was maintained in 202 LM75/25-treated patients (43%) and in 147 glargine-treated patients (35%; P = 0.006).,26038:26180,3024329,21270182,Unavailable
3024329,Overall hypoglycemia,Insulin lispro mix,Insulin glargine,No significant difference,"No differences were observed in overall, nocturnal, or severe hypoglycemia.",5847:5922,3024329,21270182,Unavailable
3024329,Nocturnal hypoglycemia,Insulin lispro mix,Insulin glargine,No significant difference,"No differences were observed in overall, nocturnal, or severe hypoglycemia.",5847:5922,3024329,21270182,Unavailable
3024329,Severe  hypoglycemia,Insulin lispro mix,Insulin glargine,No significant difference,"No differences were observed in overall, nocturnal, or severe hypoglycemia.",5847:5922,3024329,21270182,Unavailable
3024329,Total daily insulin dose,Insulin lispro mix,Insulin glargine,Significantly increased,LM75/25 patients had higher total daily insulin dose (0.45 ± 0.21 vs. 0.37 ± 0.21 units/kg/day) and more weight gain (5.4 ± 5.8 vs. 3.7 ± 5.6 kg) from baseline.,5923:6083,3024329,21270182,Unavailable
3024329,Weight gain,Insulin lispro mix,Insulin glargine,Significantly increased,LM75/25 patients had higher total daily insulin dose (0.45 ± 0.21 vs. 0.37 ± 0.21 units/kg/day) and more weight gain (5.4 ± 5.8 vs. 3.7 ± 5.6 kg) from baseline.,5923:6083,3024329,21270182,Unavailable
3024329,Time of maintaining the A1C goal,Insulin lispro mix,Insulin glargine,Significantly increased,Median time of maintaining the A1C goal was 16.8 months for LM75/25 (95% CI 14.0–19.7) and 14.4 months for glargine (95% CI 13.4–16.8; P = 0.040),5549:5711,3024329,21270182,Unavailable
3024329,Time of maintaining the A1C goal,Insulin lispro mix,Insulin glargine,Significantly increased,The median time of maintaining the A1C goal was 16.8 months (95% CI 14.0–19.7) for LM75/25 and 14.4 months (95% CI 13.4–16.8) for glargine (P = 0.040; Fig. 2A).,15790:16021,3024329,21270182,Unavailable
3024329,Time to initial attainment of A1C ≤7.0%,Insulin lispro mix,Insulin glargine,No significant difference,"The time to initial attainment of A1C ≤7.0% was not different (LM75/25: 3.7 ± 1.3 months vs. glargine: 3.8 ± 1.4 months, P = 0.173).",16514:16663,3024329,21270182,Unavailable
3024329,Maintaining A1C goal,Insulin lispro mix,Insulin glargine,Significantly increased,The A1C goal was maintained for 202 patients (43%) receiving LM75/25 and for 147 patients (35%) receiving glargine (P = 0.006),26037:26180,3024329,21270182,Unavailable
3024329,A1C reduction,Insulin lispro mix,Insulin glargine,Significantly increased,"At the end point, A1C reduction was greater in LM75/25-treated patients (−1.6 ± 1.2%) versus glargine (−1.4 ± 1.2%, P = 0.017)",26270:26413,3024329,21270182,Unavailable
3024329,Fasting plasma glucose,Insulin lispro mix,Insulin glargine,Significantly increased,"For LM75/25-treated patients, the end point FPG was higher (P &lt; 0.001)",26793:26881,3024329,21270182,Unavailable
3024329,Prelunch plasma glucose,Insulin lispro mix,Insulin glargine,Significantly decreased,whereas prelunch (P = 0.031) and dinner 2-h postprandial (P &lt; 0.001) glucose levels were lower compared with glargine-treated patients.,26883:27055,3024329,21270182,Unavailable
3024329,Dinner 2-h postprandial glucose,Insulin lispro mix,Insulin glargine,Significantly decreased,whereas prelunch (P = 0.031) and dinner 2-h postprandial (P &lt; 0.001) glucose levels were lower compared with glargine-treated patients.,26883:27055,3024329,21270182,Unavailable
3024329,"1,5-anhydroglucitol levels",Insulin lispro mix,Insulin glargine,Significantly increased,"At the end point, 1,5-anhydroglucitol was significantly higher for LM75/25-treated patients (5.8 ± 5.2 μg/dL) compared with glargine-treated patients (4.8 ± 5.3 μg/dL; P = 0.004)",27065:27260,3024329,21270182,Unavailable
3024329,Weight gain,Insulin lispro mix,Insulin glargine,Significantly increased,"During the entire study, LM75/25-treated patients gained more weight than glargine-treated patients (5.4 ± 5.8 vs. 3.7 ± 5.6 kg; P &lt; 0.001)",27331:27487,3024329,21270182,Unavailable
3024329,Weight gain during maintenance ,Insulin lispro mix,Insulin glargine,No significant difference,but weight gain during maintenance was similar (1.6 ± 4.7 vs. 1.8 ± 4.5 kg; P = 0.599),27488:27595,3024329,21270182,Unavailable
3024329,Total daily insulin at 6 months,Insulin lispro mix,Insulin glargine,Significantly increased,"At 6 months, total daily insulin was 0.43 ± 0.19 units/kg/day for LM75/25 and 0.36 ± 0.19 units/kg/day for glargine (P &lt; 0.001).",27597:27742,3024329,21270182,Unavailable
3024329,Total daily insulin at 30 months,Insulin lispro mix,Insulin glargine,Significantly increased,"At 30 months, total daily insulin was 0.45 ± 0.21 units/kg/day for LM75/25 vs. 0.37 ± 0.21 units/kg/day for glargine (P &lt; 0.001).",27743:27892,3024329,21270182,Unavailable
3024329,Overall hypoglycemia,Insulin lispro mix,Insulin glargine,No significant difference,"Overall	235 (49.9)	188 (45.3)	0.370",28916:29099,3024329,21270182,Unavailable
3024329,Documented symptomatic hypoglycemia,Insulin lispro mix,Insulin glargine,No significant difference,"Documented symptomatic (PG ≤70 mg/dL [3.9 mmol/L])	173 (36.7)	128 (30.8)	0.128",29167:29393,3024329,21270182,Unavailable
3024329,Documented asymptomatic hypoglycemia,Insulin lispro mix,Insulin glargine,No significant difference,"Documented asymptomatic (PG ≤70 mg/dL [3.9 mmol/L])	108 (22.9)	102 (24.6)	0.375",29461:29688,3024329,21270182,Unavailable
3024329,Nocturnal hypoglycemia,Insulin lispro mix,Insulin glargine,No significant difference,"Nocturnal	136 (28.9)	126 (30.4)	0.397",29756:29941,3024329,21270182,Unavailable
3024329,Severe  hypoglycemia,Insulin lispro mix,Insulin glargine,No significant difference,"Severe†	20 (4.2)	12 (2.9)	0.391",30009:30188,3024329,21270182,Unavailable
3024329,Serious adverse events (overall),Insulin lispro mix,Insulin glargine,No significant difference,"There was no difference in SAE incidence between groups (LM75/25: 13.1%, glargine: 14.1%, P = 0.696).",34949:35067,3024329,21270182,Unavailable
3024329,Serious adverse events (cardiovascular),Insulin lispro mix,Insulin glargine,No significant difference,"The incidence of SAEs related to the cardiovascular system (LM75/25: 5.9%, glargine: 7.2%; P = 0.497), and cancer (LM75/25: 1.9%, glargine: 0.7%; P = 0.152) were similar between groups.",35068:35287,3024329,21270182,Unavailable
3024329,Serious adverse events (cancer ),Insulin lispro mix,Insulin glargine,No significant difference,"The incidence of SAEs related to the cardiovascular system (LM75/25: 5.9%, glargine: 7.2%; P = 0.497), and cancer (LM75/25: 1.9%, glargine: 0.7%; P = 0.152) were similar between groups.",35068:35287,3024329,21270182,Unavailable
3024329,Discontinuation,Insulin lispro mix,Insulin glargine,No significant difference,"In each group, there were four adverse events that led to discontinuation (P = 1.000; Fig. 1) and four deaths (P = 1.000; Fig. 1)",35288:35525,3024329,21270182,Unavailable
3024329,Mortality,Insulin lispro mix,Insulin glargine,No significant difference,"In each group, there were four adverse events that led to discontinuation (P = 1.000; Fig. 1) and four deaths (P = 1.000; Fig. 1)",35288:35525,3024329,21270182,Unavailable
5754509,MR-proADM levels,Liraglutide ,Placebo,No significant difference,"Mean percentage differences (95% CI) between liraglutide and placebo group after treatment were as follows: MR-proADM −6% (−11 to 2, P = 0.058), MR-proANP −25% (−37 to −11, P = 0.001) and copeptin +4% (−13 to 25, P = 0.64).",5365:5639,5754509,29295870,Unavailable
5754509,MR-proANP levels,Liraglutide ,Placebo,Significantly decreased,"Mean percentage differences (95% CI) between liraglutide and placebo group after treatment were as follows: MR-proADM −6% (−11 to 2, P = 0.058), MR-proANP −25% (−37 to −11, P = 0.001) and copeptin +4% (−13 to 25, P = 0.64).",5365:5639,5754509,29295870,Unavailable
5754509,Copeptin levels,Liraglutide ,Placebo,No significant difference,"Mean percentage differences (95% CI) between liraglutide and placebo group after treatment were as follows: MR-proADM −6% (−11 to 2, P = 0.058), MR-proANP −25% (−37 to −11, P = 0.001) and copeptin +4% (−13 to 25, P = 0.64).",5365:5639,5754509,29295870,Unavailable
5754509,MR-proADM levels,Liraglutide ,Placebo,No significant difference,"Mean differences between treatment groups over time showed a change in MR-proANP of −25% (95% CI −37 to −11, P = 0.001), a trend in MR-proADM of −6% (95% CI −11 to 2, P = 0.057) and no change in levels of copeptin in the liraglutide group compared with placebo",31497:31791,5754509,29295870,Unavailable
5754509,MR-proANP levels,Liraglutide ,Placebo,Significantly decreased,"Mean differences between treatment groups over time showed a change in MR-proANP of −25% (95% CI −37 to −11, P = 0.001), a trend in MR-proADM of −6% (95% CI −11 to 2, P = 0.057) and no change in levels of copeptin in the liraglutide group compared with placebo",31497:31791,5754509,29295870,Unavailable
5754509,Copeptin levels,Liraglutide ,Placebo,No significant difference,"Mean differences between treatment groups over time showed a change in MR-proANP of −25% (95% CI −37 to −11, P = 0.001), a trend in MR-proADM of −6% (95% CI −11 to 2, P = 0.057) and no change in levels of copeptin in the liraglutide group compared with placebo",31496:31791,5754509,29295870,Unavailable
5754509,HbA1c ,Liraglutide ,Placebo,Significantly decreased,We observed a reduction in mean difference of HbA1c in the liraglutide group compared with placebo,32265:32363,5754509,29295870,Unavailable
5754509,Markers of insulin resistance,Liraglutide ,Placebo,No significant difference,"whereas there was no difference between treatment groups neither regarding markers of insulin resistance, HOMA2-IR and Matsuda index, nor eGFR. Fasting total, HDL and LDL cholesterol and triglycerides did not change during liraglutide/placebo treatment.",32365:32619,5754509,29295870,Unavailable
5754509,HOMA2-IR ,Liraglutide ,Placebo,No significant difference,"whereas there was no difference between treatment groups neither regarding markers of insulin resistance, HOMA2-IR and Matsuda index, nor eGFR. Fasting total, HDL and LDL cholesterol and triglycerides did not change during liraglutide/placebo treatment.",32365:32619,5754509,29295870,Unavailable
5754509,Matsuda index,Liraglutide ,Placebo,No significant difference,"whereas there was no difference between treatment groups neither regarding markers of insulin resistance, HOMA2-IR and Matsuda index, nor eGFR. Fasting total, HDL and LDL cholesterol and triglycerides did not change during liraglutide/placebo treatment.",32365:32619,5754509,29295870,Unavailable
5754509,Glomerular filtration rate,Liraglutide ,Placebo,No significant difference,"whereas there was no difference between treatment groups neither regarding markers of insulin resistance, HOMA2-IR and Matsuda index, nor eGFR. Fasting total, HDL and LDL cholesterol and triglycerides did not change during liraglutide/placebo treatment.",32365:32619,5754509,29295870,Unavailable
5754509,HDL,Liraglutide ,Placebo,No significant difference,"whereas there was no difference between treatment groups neither regarding markers of insulin resistance, HOMA2-IR and Matsuda index, nor eGFR. Fasting total, HDL and LDL cholesterol and triglycerides did not change during liraglutide/placebo treatment.",32365:32619,5754509,29295870,Unavailable
5754509,LDL,Liraglutide ,Placebo,No significant difference,"whereas there was no difference between treatment groups neither regarding markers of insulin resistance, HOMA2-IR and Matsuda index, nor eGFR. Fasting total, HDL and LDL cholesterol and triglycerides did not change during liraglutide/placebo treatment.",32365:32619,5754509,29295870,Unavailable
5754509,Triglycerides ,Liraglutide ,Placebo,No significant difference,"whereas there was no difference between treatment groups neither regarding markers of insulin resistance, HOMA2-IR and Matsuda index, nor eGFR. Fasting total, HDL and LDL cholesterol and triglycerides did not change during liraglutide/placebo treatment.",32365:32619,5754509,29295870,Unavailable
5754509,Sex hormone-binding globulin,Liraglutide ,Placebo,Significantly increased,Plasma SHBG increased and a trend toward a reduction in free testosterone in the liraglutide group compared with placebo was found,32619:32750,5754509,29295870,Unavailable
5754509,Free testosterone,Liraglutide ,Placebo,No significant difference,Plasma SHBG increased and a trend toward a reduction in free testosterone in the liraglutide group compared with placebo was found,32619:32750,5754509,29295870,Unavailable
1484471,Headache frequency,Intra-oral appliance of prosthesis,Amitriptyline,No significant difference,"Both the oral appliance and amitriptyline significantly reduced headache frequency (Fig.2): the two-way ANOVA with the treatment and the condition as factors, showed a significant effect of the treatment (F = 56.5 p &lt; 0.0001), which was not dissimilar between the two groups (treatment × condition : F = 0.4 p = 0.53)",25365:25719,1484471,16725028,Unavailable
1484471,Total Tenderness Score,Intra-oral appliance of prosthesis,Amitriptyline,No significant difference,"any way, the difference between the two groups approached the statistical significance when the effect of the condition was considered (ANOVA with condition × treatment as factors: F: 4.36 p = 0.052)",25893:26092,1484471,16725028,Unavailable
1484471,Anxiety levels,Intra-oral appliance of prosthesis,Amitriptyline,No significant difference,"The anxiety levels, tested by the Zung scale, were similar in the two groups (ANOVA with treatment as factor: F = 0.86 p = 0.35), the effect of the condition was not statistically relevant (condition × treatment: F = 0.64;p = 0.42).",26142:26374,1484471,16725028,Unavailable
1484471, Laser-evoked potentials (vertex P2),Intra-oral appliance of prosthesis,Amitriptyline,Significantly increased,"The mean percent rate of reduction of the vertex P2 across the whole range of pericranial sites was 35.4 ± 12.6 in amitriptyline group, and 9.9 ± 7.8 in the appliance treated group (ANOVA with cases as factor: F = 25.4 p &lt; 0.001)",27665:27894,1484471,16725028,Unavailable
5856865,Pain response,Single posterior-anterior field,Two opposed anterior-posterior (APPA) fields,No significant difference,Pain response was similar between both techniques (74%),7324:7380,5856865,29576859,Unavailable
5856865,Treatment with systemic therapy,Single posterior-anterior field,Two opposed anterior-posterior (APPA) fields,Significantly increased,"More patients in the group treated with a PA field were treated with systemic therapy (59%), compared to patients treated with an APPA technique (43%, p&nbsp;=&nbsp;0.009)",23355:23533,5856865,29576859,Unavailable
5856865,Pain response,Single posterior-anterior field,Two opposed anterior-posterior (APPA) fields,No significant difference,"In total, 241 (74%) of the 325 evaluable patients had a pain response to radiotherapy, with no significant difference between the two treatment techniques (74% each).",24261:24427,5856865,29576859,Unavailable
5856865,Diarrhea,Single posterior-anterior field,Two opposed anterior-posterior (APPA) fields,Significantly decreased,Patients treated with the APPA technique had significantly more severe complaints of diarrhea (p&nbsp;=&nbsp;0.044).,27723:27947,5856865,29576859,Unavailable
5856865,Nausea,Single posterior-anterior field,Two opposed anterior-posterior (APPA) fields,Significantly decreased,"For all studied items (nausea, vomiting, abdominal pain, and diarrhea), patients treated with the APPA technique experienced more complaints than patients treated with the PA technique (p values all &lt;0.009).",27723:27947,5856865,29576859,Unavailable
5856865,Vomiting,Single posterior-anterior field,Two opposed anterior-posterior (APPA) fields,Significantly decreased,"For all studied items (nausea, vomiting, abdominal pain, and diarrhea), patients treated with the APPA technique experienced more complaints than patients treated with the PA technique (p values all &lt;0.009).",27723:27947,5856865,29576859,Unavailable
5856865,Abdominal pain,Single posterior-anterior field,Two opposed anterior-posterior (APPA) fields,Significantly decreased,"For all studied items (nausea, vomiting, abdominal pain, and diarrhea), patients treated with the APPA technique experienced more complaints than patients treated with the PA technique (p values all &lt;0.009).",27723:27947,5856865,29576859,Unavailable
5856865,Diarrhea,Single posterior-anterior field,Two opposed anterior-posterior (APPA) fields,Significantly decreased,"For all studied items (nausea, vomiting, abdominal pain, and diarrhea), patients treated with the APPA technique experienced more complaints than patients treated with the PA technique (p values all &lt;0.009).",27723:27947,5856865,29576859,Unavailable
5293238,Apolipoprotein B levels,High saturated fat diet,Low saturated fat diet,Significantly increased,"Compared to the LSF diet, consumption of the HSF diet resulted in significantly greater increases from baseline (% change; 95% CI) in plasma concentrations of apolipoprotein B (HSF vs. LSF: 9.5; 3.6 to 15.7 vs. -6.8; -11.7 to -1.76; p = 0.0003)",10212:10456,5293238,28166253,Unavailable
5293238,Medium LDL particles,High saturated fat diet,Low saturated fat diet,Significantly increased,"and medium (8.8; -1.3 to 20.0 vs. -7.3; -15.7 to 2.0; p = 0.03), small (6.1; -10.3 to 25.6 vs. -20.8; -32.8 to -6.7; p = 0.02), and total LDL (3.6; -3.2 to 11.0 vs. -7.9; -13.9 to -1.5; p = 0.03) particles",10457:10662,5293238,28166253,Unavailable
5293238,Small LDL particles,High saturated fat diet,Low saturated fat diet,Significantly increased,"and medium (8.8; -1.3 to 20.0 vs. -7.3; -15.7 to 2.0; p = 0.03), small (6.1; -10.3 to 25.6 vs. -20.8; -32.8 to -6.7; p = 0.02), and total LDL (3.6; -3.2 to 11.0 vs. -7.9; -13.9 to -1.5; p = 0.03) particles",10457:10662,5293238,28166253,Unavailable
5293238,Total LDL particles,High saturated fat diet,Low saturated fat diet,Significantly increased,"and medium (8.8; -1.3 to 20.0 vs. -7.3; -15.7 to 2.0; p = 0.03), small (6.1; -10.3 to 25.6 vs. -20.8; -32.8 to -6.7; p = 0.02), and total LDL (3.6; -3.2 to 11.0 vs. -7.9; -13.9 to -1.5; p = 0.03) particles",10738:10949,5293238,28166253,Unavailable
5293238,Large LDL particles,High saturated fat diet,Low saturated fat diet,No significant difference,with no differences in change of large and very small LDL concentrations.,10664:10737,5293238,28166253,Unavailable
5293238,Very small LDL particles,High saturated fat diet,Low saturated fat diet,No significant difference,with no differences in change of large and very small LDL concentrations.,10664:10737,5293238,28166253,Unavailable
5293238, Total-cholesterol,High saturated fat diet,Low saturated fat diet,Significantly increased,"As expected, total-cholesterol (11.0; 6.5 to 15.7 vs. -5.7; -9.4 to -1.8; p&lt;0.0001) and LDL-cholesterol (16.7; 7.9 to 26.2 vs. -8.7; -15.4 to -1.4; p = 0.0001) also increased with increased saturated fat intake.",10738:10949,5293238,28166253,Unavailable
5293238,LDL-cholesterol levels,High saturated fat diet,Low saturated fat diet,Significantly increased,"As expected, total-cholesterol (11.0; 6.5 to 15.7 vs. -5.7; -9.4 to -1.8; p&lt;0.0001) and LDL-cholesterol (16.7; 7.9 to 26.2 vs. -8.7; -15.4 to -1.4; p = 0.0001) also increased with increased saturated fat intake.",10738:10949,5293238,28166253,Unavailable
5293238, Total-cholesterol,High saturated fat diet,Low saturated fat diet,Significantly increased,"Compared to the LSF diet, the HSF diet significantly increased plasma TC, LDL-C, and apoB levels and marginally increased plasma TG",42495:42627,5293238,28166253,Unavailable
5293238,LDL-cholesterol levels,High saturated fat diet,Low saturated fat diet,Significantly increased,"Compared to the LSF diet, the HSF diet significantly increased plasma TC, LDL-C, and apoB levels and marginally increased plasma TG",42495:42626,5293238,28166253,Unavailable
5293238,Apolipoprotein B levels,High saturated fat diet,Low saturated fat diet,Significantly increased,"Compared to the LSF diet, the HSF diet significantly increased plasma TC, LDL-C, and apoB levels and marginally increased plasma TG",42495:42626,5293238,28166253,Unavailable
5293238,HDL-cholesterol levels,High saturated fat diet,Low saturated fat diet,No significant difference,There were no significant changes in HDL-C or apoAI.,42692:42744,5293238,28166253,Unavailable
5293238,Apolipoprotein A1 levels,High saturated fat diet,Low saturated fat diet,No significant difference,There were no significant changes in HDL-C or apoAI.,45412:45603,5293238,28166253,Unavailable
5293238,Triglycerides ,High saturated fat diet,Low saturated fat diet,No significant difference,"Compared to the LSF diet, the HSF diet significantly increased plasma TC, LDL-C, and apoB levels and marginally increased plasma TG",42495:42626,5293238,28166253,Unavailable
5293238,Triglycerides ,High saturated fat diet,Low saturated fat diet,No significant difference,"TG	-11.5 (-23.4, 2.2)	9.8 (-5.2, 27.2)	0.06",43906:44097,5293238,28166253,Unavailable
5293238, Total-cholesterol,High saturated fat diet,Low saturated fat diet,Significantly increased,"TC	-5.7 (-9.4, -1.8)	11.0 (6.5, 15.7)	&lt;0.0001",44153:44346,5293238,28166253,Unavailable
5293238,LDL-cholesterol levels,High saturated fat diet,Low saturated fat diet,Significantly increased,"LDL-C	-8.7 (-15.4, -1.4)	16.7 (7.9, 26.2)	0.0001",44405:44601,5293238,28166253,Unavailable
5293238,HDL-cholesterol levels,High saturated fat diet,Low saturated fat diet,No significant difference,"HDL-C	2.8 (-2.0, 7.8)	2.8 (-2.0, 7.9)	0.99",44657:44847,5293238,28166253,Unavailable
5293238,Apolipoprotein B levels,High saturated fat diet,Low saturated fat diet,Significantly increased,"ApoB	-6.8 (-11.7, -1.6)	9.5 (3.6, 15.7)	0.0003",45162:45356,5293238,28166253,Unavailable
5293238,Apolipoprotein A1 levels,High saturated fat diet,Low saturated fat diet,No significant difference,"ApoAI	-1.3 (-4.8, 2.2)	3.2 (-0.5, 7.1)	0.11",45412:45603,5293238,28166253,Unavailable
5293238,Non-HDL-cholesterol levels,High saturated fat diet,Low saturated fat diet,Significantly increased,"NonHDL-C	-7.9 (-12.3, -3.3)	13.2 (7.7, 19.0)	&lt;0.0001",44903:45103,5293238,28166253,Unavailable
5293238,VLDL levels,High saturated fat diet,Low saturated fat diet,No significant difference,"There were no other significant differences in VLDL, intermediate density lipoprotein (IDL), LDL, or HDL subfraction concentrations or LDL peak particle diameter as measured by ion mobility after consuming the LSF vs. the HSF diets",46564:46795,5293238,28166253,Unavailable
5293238,IDL levels,High saturated fat diet,Low saturated fat diet,No significant difference,"There were no other significant differences in VLDL, intermediate density lipoprotein (IDL), LDL, or HDL subfraction concentrations or LDL peak particle diameter as measured by ion mobility after consuming the LSF vs. the HSF diets",46564:46795,5293238,28166253,Unavailable
5293238,LDL peak particle diameter,High saturated fat diet,Low saturated fat diet,No significant difference,"There were no other significant differences in VLDL, intermediate density lipoprotein (IDL), LDL, or HDL subfraction concentrations or LDL peak particle diameter as measured by ion mobility after consuming the LSF vs. the HSF diets",46564:46795,5293238,28166253,Unavailable
5293238,Proportion of LDL phenotype ,High saturated fat diet,Low saturated fat diet,No significant difference,and no differences in the proportion of LDL phenotype or LDL phenotype conversions (p = 0.23,46861:46953,5293238,28166253,Unavailable
5293238,LDL phenotype conversions,High saturated fat diet,Low saturated fat diet,No significant difference,and no differences in the proportion of LDL phenotype or LDL phenotype conversions (p = 0.23,46861:46953,5293238,28166253,Unavailable
5293238,Small LDL particles,High saturated fat diet,Low saturated fat diet,Significantly increased,Small LDL-C measured by gradient gel electrophoresis was significantly higher after the HSF compared to the LSF diet (p&lt;0.05,46972:47096,5293238,28166253,Unavailable
5293238,VLDL levels,High saturated fat diet,Low saturated fat diet,No significant difference,"Total VLDL	-7.8 (-16.4, 1.6)	-1.3 (-10.7, 9.0)	0.37",48495:48694,5293238,28166253,Unavailable
5293238,Large VLDL levels,High saturated fat diet,Low saturated fat diet,No significant difference,"Large VLDL	-13.3 (-26.3, 1.9)	0.0 (-15.3, 18.1)	0.26",48751:48951,5293238,28166253,Unavailable
5293238, Medium VLDL levels,High saturated fat diet,Low saturated fat diet,No significant difference,"Medium VLDL	-6.9 (-16.3, 3.6)	-1.1 (-11.2, 10.3)	0.46",49008:49209,5293238,28166253,Unavailable
5293238,Small VLDL levels,High saturated fat diet,Low saturated fat diet,No significant difference,"Small VLDL	-7.9 (-15.7, 0.7)	-0.7 (-9.3, 8.7)	0.28",49266:49464,5293238,28166253,Unavailable
5293238,IDL levels,High saturated fat diet,Low saturated fat diet,No significant difference,"IDL	-8.3 (-15.7, -0.4)	3.5 (-5.0, 12.7)	0.06",49520:49712,5293238,28166253,Unavailable
5293238,LDL-cholesterol levels,High saturated fat diet,Low saturated fat diet,Significantly increased,"Total LDL	-7.9 (-13.9, -1.5)	3.6 (-3.3, 11.0)	0.03",49768:49966,5293238,28166253,Unavailable
5293238,Large LDL particles,High saturated fat diet,Low saturated fat diet,No significant difference,"Large LDL	2.1 (-7.1, 12.2)	8.6 (-1.4, 19.6)	0.40",50023:50219,5293238,28166253,Unavailable
5293238,Medium LDL particles,High saturated fat diet,Low saturated fat diet,Significantly increased,"Medium LDL	-7.3 (-15.7, 2.0)	8.8 (-1.3, 20.0)	0.03",50276:50474,5293238,28166253,Unavailable
5293238,Small LDL particles,High saturated fat diet,Low saturated fat diet,Significantly increased,"Small LDL	-20.8 (-32.8, -6.7)	6.1 (-10.3, 25.6)	0.02",50531:50731,5293238,28166253,Unavailable
5293238,Very small LDL particles,High saturated fat diet,Low saturated fat diet,No significant difference,"Very small LDL	-19.3 (-31.1, -5.3)	-11.8 (-25.0, 3.7)	0.48",50788:50994,5293238,28166253,Unavailable
5293238,LDL peak particle diameter,High saturated fat diet,Low saturated fat diet,No significant difference,"LDL peak diameter	0.7 (0.1, 1.3)	0.2 (-0.5, 0.8)	0.27",51050:51251,5293238,28166253,Unavailable
5293238,HDL-cholesterol levels,High saturated fat diet,Low saturated fat diet,No significant difference,"Total HDL	0.6 (-9.2, 11.4)	6.3 (-4.3, 17.9)	0.49",51307:51503,5293238,28166253,Unavailable
5293238,Large HDL particles,High saturated fat diet,Low saturated fat diet,No significant difference,"There were no other significant differences in VLDL, intermediate density lipoprotein (IDL), LDL, or HDL subfraction concentrations",51307:51503,5293238,28166253,Unavailable
5293238,Small HDL particles,High saturated fat diet,Low saturated fat diet,No significant difference,"There were no other significant differences in VLDL, intermediate density lipoprotein (IDL), LDL, or HDL subfraction concentrations",51307:51503,5293238,28166253,Unavailable
5293238,Large HDL particles,High saturated fat diet,Low saturated fat diet,No significant difference,"Large HDL	-2.6 (-11.0, 6.7)	0.5 (-8.4, 10.2)	0.66",51560:51757,5293238,28166253,Unavailable
5293238,Small HDL particles,High saturated fat diet,Low saturated fat diet,No significant difference,"Small HDL	1.0 (-9.4, 12.5)	7.1 (-4.1, 19.6)	0.48",51814:52010,5293238,28166253,Unavailable
5293238,Hepatic lipase activity,High saturated fat diet,Low saturated fat diet,Significantly increased,"HL activityc -9.5 (-15.4, -3.2) 1.3 (-5.8, 8.8) 0.04",52066:52277,5293238,28166253,Unavailable
5293238,Lipoprotein lipase activity,High saturated fat diet,Low saturated fat diet,No significant difference,"LPL activityc	-15.7 (-38.2, 15.2)	-8.2 (-33.3, 26.2)	0.72",52333:52549,5293238,28166253,Unavailable
5293238,Cholesteryl ester transfer protein activity,High saturated fat diet,Low saturated fat diet,Significantly increased,"CETP activity	-0.6 (-7.0, 6.2)	10.0 (2.7, 17.7)	0.05",52605:NaN,5293238,28166253,Unavailable
5293238,Hepatic lipase activity,High saturated fat diet,Low saturated fat diet,Significantly increased,"Both plasma HL and CETP activities were higher on the HSF diet compared to the LSF diet, but with borderline statistical significance (p = 0.04 and 0.05, respectively).",53947:54115,5293238,28166253,Unavailable
5293238,Cholesteryl ester transfer protein activity,High saturated fat diet,Low saturated fat diet,Significantly increased,"Both plasma HL and CETP activities were higher on the HSF diet compared to the LSF diet, but with borderline statistical significance (p = 0.04 and 0.05, respectively).",53947:54115,5293238,28166253,Unavailable
5293238,Lipoprotein lipase activity,High saturated fat diet,Low saturated fat diet,No significant difference,There was no significant difference in LPL activity,53947:54115,5293238,28166253,Unavailable
5426597,Device related adverse events,AnapnoGuard™ 100 system,Control,No significant difference,No difference in adverse events rate was identified between the groups.,10296:10368,5426597,28493877,Unavailable
5426597,Volume of evacuated subglottic secretions,AnapnoGuard™ 100 system,Control,No significant difference,"trend to a greater volume of aspirated SS secretions: (192.0[64–413] ml vs. 150[50–200], p = 0.19",10544:10661,5426597,28493877,Unavailable
5426597,Throat pain,AnapnoGuard™ 100 system,Control,No significant difference,"No inter-group difference was detected using AG system vs. controls in terms of post-extubation throat pain level (0 [0–2] vs. 0 [0–3]; p = 0.7), hoarseness (42.9% vs. 75%; p = 0.55) and tracheal mucosa oedema (16.7% vs. 10%; p = 0.65).",10746:11016,5426597,28493877,Unavailable
5426597,Hoarseness ,AnapnoGuard™ 100 system,Control,No significant difference,"No inter-group difference was detected using AG system vs. controls in terms of post-extubation throat pain level (0 [0–2] vs. 0 [0–3]; p = 0.7), hoarseness (42.9% vs. 75%; p = 0.55) and tracheal mucosa oedema (16.7% vs. 10%; p = 0.65).",10746:11016,5426597,28493877,Unavailable
5426597,Tracheal mucosa edema,AnapnoGuard™ 100 system,Control,No significant difference,"No inter-group difference was detected using AG system vs. controls in terms of post-extubation throat pain level (0 [0–2] vs. 0 [0–3]; p = 0.7), hoarseness (42.9% vs. 75%; p = 0.55) and tracheal mucosa oedema (16.7% vs. 10%; p = 0.65).",10746:11016,5426597,28493877,Unavailable
5426597,Ventilator-associated pneumonia (total),AnapnoGuard™ 100 system,Control,No significant difference,Patients enrolled in the AG group had a trend to reduced VAP risk of ventilator-associated pneumonia(VAP) (14.8% vs. 40%; p = 0.06),40289:40587,5426597,28493877,Unavailable
5426597,Mortality,AnapnoGuard™ 100 system,Control,No significant difference,"No statistically significant difference was observed in duration of mechanical ventilation, ICU stay, and mortality.",11262:NaN,5426597,28493877,Unavailable
5426597,Length of ICU stay ,AnapnoGuard™ 100 system,Control,No significant difference,"No statistically significant difference was observed in duration of mechanical ventilation, ICU stay, and mortality.",11262:NaN,5426597,28493877,Unavailable
5426597,Length of mechanical ventilation,AnapnoGuard™ 100 system,Control,No significant difference,"No statistically significant difference was observed in duration of mechanical ventilation, ICU stay, and mortality.",11262:NaN,5426597,28493877,Unavailable
5426597,Throat pain,AnapnoGuard™ 100 system,Control,No significant difference,"Eleven patients were reliably evaluable for post-extubation hoarseness and throat pain (i.e breathing and fully cooperative) and no differences were detected between the two groups (p = 0.65 and p = 0.7, respectively).",35874:36143,5426597,28493877,Unavailable
5426597,Hoarseness ,AnapnoGuard™ 100 system,Control,No significant difference,"Eleven patients were reliably evaluable for post-extubation hoarseness and throat pain (i.e breathing and fully cooperative) and no differences were detected between the two groups (p = 0.65 and p = 0.7, respectively).",35874:36143,5426597,28493877,Unavailable
5426597,Device related adverse events,AnapnoGuard™ 100 system,Control,No significant difference,No AE/SAE potentially related to under or over inflation of the endotracheal tube (ETT) cuff or suction dysfunction was detected in either the AG or control group,35319:35481,5426597,28493877,Unavailable
5426597,Serious AE,AnapnoGuard™ 100 system,Control,No significant difference,No AE/SAE potentially related to under or over inflation of the endotracheal tube (ETT) cuff or suction dysfunction was detected in either the AG or control group,35319:35481,5426597,28493877,Unavailable
5426597,Tracheal mucosa edema,AnapnoGuard™ 100 system,Control,No significant difference,"Among 38 patients undergoing tracheal bronchoscopic evaluation, five showed mucosa oedema (three in the AG group and two in the control group, p = 0.65).",35703:35873,5426597,28493877,Unavailable
5426597,Tracheal mucosa edema,AnapnoGuard™ 100 system,Control,No significant difference,"Post-extubation tracheal mucosa edema, (38 pts)b	5 (13.2)	3 (16.7)	2 (10)	0.65",38794:39127,5426597,28493877,Unavailable
5426597,Throat pain,AnapnoGuard™ 100 system,Control,No significant difference,"Post-extubation throat pain, median [IQR], (11pts) a	0 [0–3]	0 [0–2]	0 [0–3]	0.7",38027:38362,5426597,28493877,Unavailable
5426597,Hoarseness ,AnapnoGuard™ 100 system,Control,No significant difference,"Post-extubation hoarseness, (11 pts)a	6 (54.5)	3 (42.9)	3 (75)	0.55",38417:38739,5426597,28493877,Unavailable
5426597,Volume of evacuated subglottic secretions,AnapnoGuard™ 100 system,Control,No significant difference,"Total subglottic secretions drained, ml, median, IQRd	150 [52–294.5]	192.0 [64–413]	150 [50–200]	0.19",39880:40234,5426597,28493877,Unavailable
5426597,Ventilator-associated pneumonia (total),AnapnoGuard™ 100 system,Control,No significant difference,"VAP, totale 14 (26.9) 4 (14.8) 10 (40) 0.06",40289:40587,5426597,28493877,Unavailable
5426597,Ventilator-associated pneumonia (Early),AnapnoGuard™ 100 system,Control,No significant difference,"Early-onset VAP	4 (7.7)	1 (3.7)	3 (12)	0.34",40643:40881,5426597,28493877,Unavailable
5426597,Ventilator-associated pneumonia (Late),AnapnoGuard™ 100 system,Control,No significant difference,"Late-onset VAP	10 (19.2)	3 (11.1)	7 (28)	0.17",40937:41177,5426597,28493877,Unavailable
5426597,Length of mechanical ventilation,AnapnoGuard™ 100 system,Control,No significant difference,"Duration of MV, days, median [IQR]	4.9 [3–13]	4 [2–13]	5 [3–13.5]	0.1",41232:41494,5426597,28493877,Unavailable
5426597,Length of ICU stay ,AnapnoGuard™ 100 system,Control,No significant difference,"Length of ICU stay, days, median [IQR]	10 [5–29.1]	13 [6–25]	10 [4.5–17.5]	0.2",42162:42435,5426597,28493877,Unavailable
5426597,Mortality,AnapnoGuard™ 100 system,Control,No significant difference,"ICU deaths	9 (16.1)	7 (25)	2 (7.1)	0.14",43083:43317,5426597,28493877,Unavailable
5426597,Extubation rate,AnapnoGuard™ 100 system,Control,No significant difference,Extubation 30 (53.6) 15 (53.6) 15 (53.6) 0.79,11173:11255,5426597,28493877,Unavailable
5426597,Tracheostomy rate,AnapnoGuard™ 100 system,Control,No significant difference,Tracheostomy 17 (29.3) 6 (21.4%) 11 (39.3%) 0.15,11173:11255,5426597,28493877,Unavailable
5426597,Pcuff (cmH20),AnapnoGuard™ 100 system,Control,Significantly increased,"Pcuff, cmH20, mean±SD	27.2±4.2	29.1±3.2	25.2±4.4	&lt;0.001",39559:39815,5426597,28493877,Unavailable
5426597,Pcuff (cmH20),AnapnoGuard™ 100 system,Control,Significantly increased,We observed a lower mean Pcuff among patients from the control group compared to the AG group (25.2±4.4 cmH20 vs. 29.1±3.2 cmH20; p&lt;0.01).,44928:45099,5426597,28493877,Unavailable
5426597,Pcuff determinations within the predefined safety target ,AnapnoGuard™ 100 system,Control,Significantly increased,"Conversely, the proportion of Pcuff determinations within the predefined safety target was higher in the AG group compared with controls (97.3% vs. 71%; p&lt;0.01).",45100:45275,5426597,28493877,Unavailable
5426597,Pcuff determinations within the predefined safety target ,AnapnoGuard™ 100 system,Control,Significantly increased,The use of AG system was associated with a significantly higher incidence of Pcuff determinations in the safety range (97.3% vs. 71%; p&lt;0.01),10368:10537,5426597,28493877,Unavailable
5426597,Volume of evacuated subglottic secretions,AnapnoGuard™ 100 system,Control,No significant difference,"The total and the daily amounts of SS evacuated were higher in the AG group compared with controls (192 [64–413] vs. 150 [50–200], p = 0.19; 67.8 [20–89] vs. 50 [19–62], p = 0.11, respectively)",45276:45506,5426597,28493877,Unavailable
5426597,Ventilator-associated pneumonia (total),AnapnoGuard™ 100 system,Control,No significant difference,"The rates of microbiologically confirmed VAP was 14.8% in the AG group and 40% in controls, for a relative risk reduction of 63%. Survival curve analysis showed a trend to a reduced VAP risk associated with AG 100 use (p = 0.06)",46902:47147,5426597,28493877,Unavailable
5426597,Polymicrobial VAP,AnapnoGuard™ 100 system,Control,Significantly decreased,"The rates of polymicrobial VAP and of positive microbiological respiratory samples were significantly higher in the control group (70% vs. 25%, p = 0.03 and 76% vs. 18.5%, p&lt;0.01, respectively).",48107:48335,5426597,28493877,Unavailable
5426597,Positive microbiological respiratory samples,AnapnoGuard™ 100 system,Control,Significantly decreased,"The rates of polymicrobial VAP and of positive microbiological respiratory samples were significantly higher in the control group (70% vs. 25%, p = 0.03 and 76% vs. 18.5%, p&lt;0.01, respectively).",48107:48335,5426597,28493877,Unavailable
5426597,Polymicrobial VAP,AnapnoGuard™ 100 system,Control,Significantly decreased,which were more frequently monomicrobial (25% vs. 70%; p = 0.03).,11173:11255,5426597,28493877,Unavailable
5426597,Tracheostomy rate,AnapnoGuard™ 100 system,Control,No significant difference,"The tracheostomy rate, duration of mechanical ventilation, and length of ICU stay were not significantly different between the two populations.",48345:48489,5426597,28493877,Unavailable
5426597,Length of mechanical ventilation,AnapnoGuard™ 100 system,Control,No significant difference,"The tracheostomy rate, duration of mechanical ventilation, and length of ICU stay were not significantly different between the two populations.",48345:48488,5426597,28493877,Unavailable
5426597,Length of ICU stay ,AnapnoGuard™ 100 system,Control,No significant difference,"The tracheostomy rate, duration of mechanical ventilation, and length of ICU stay were not significantly different between the two populations.",48345:48488,5426597,28493877,Unavailable
5426597,Mortality,AnapnoGuard™ 100 system,Control,No significant difference,ICU mortality was 25% in patients connected to the AG system and 7.1% in the controls (p = 0.14),48489:48602,5426597,28493877,Unavailable
1097728,Mean safety climate scores (all providers),Executive walk rounds,Control,No significant difference,"After EWRs the mean safety climate scores were not significantly different for all providers nor for nurses in the control units and EWR units (77.93 and 78.33, P = 0.854)",5193:5364,1097728,15823204,Unavailable
1097728,Mean safety climate scores (nurses),Executive walk rounds,Control,No significant difference,"After EWRs the mean safety climate scores were not significantly different for all providers nor for nurses in the control units and EWR units (77.93 and 78.33, P = 0.854)",5193:5364,1097728,15823204,Unavailable
1097728,Mean safety climate scores (all providers),Executive walk rounds,Control,No significant difference,"After EWRs the mean safety climate scores and percent positive scores were not significantly different in the control units and EWR units (77.93 and 78.33, P = 0.854) and (56.5% positive and 62.7% positive)",38373:38579,1097728,15823204,Unavailable
4748325,Time to reach target heart rate,Resistance training,Control,No significant difference,Time to reach target heart rate (THR) during the Bruce treadmill test. No differences were observed between the groups (P &gt; 0.05),26820:26966,4748325,26865871,Unavailable
4748325,Upper body strength ,Resistance training,Control,Significantly increased,The between-group difference from BL to DET was also statistically significant (increase of 3.5 ± 3.4&nbsp;kg in RT vs decrease of 1.0 ± 3.3&nbsp;kg in CON; P &lt; 0.001).,26820:26967,4748325,26865871,Unavailable
4748325,TUG performace,Resistance training,Control,Significantly increased,Changes in TUG performance from BL in RT and CON during the 16-week intervention and after the DET period. *Statistically significant between-group difference at post-test (P = 0.01),25724:25923,4748325,26865871,Unavailable
4748325,Time to reach target heart rate,Resistance training,Control,No significant difference,Time to reach target heart rate (THR) during the Bruce treadmill test. No differences were observed between the groups (P &gt; 0.05).,26820:26967,4748325,26865871,Unavailable
4748325,Upper body strength ,Resistance training,Control,Significantly increased,Changes in lower body strength (a) and upper body strength (b) from BL in RT and CON during the 16-week intervention and after the DET period. *Statistically significant between-group differences (P &lt; 0.001),23220:23470,4748325,26865871,Unavailable
4748325,Lower body strength ,Resistance training,Control,Significantly increased,Changes in lower body strength (a) and upper body strength (b) from BL in RT and CON during the 16-week intervention and after the DET period. *Statistically significant between-group differences (P &lt; 0.001),23220:23470,4748325,26865871,Unavailable
5801253,Mean gray-scale median CCA,Alogliptin,Control,No significant difference,there was no significant difference in changes in mean GSM-CCA between the treatment groups (p&nbsp;=&nbsp;0.95).,8042:8166,5801253,29330812,Unavailable
5801253,Gray-scale median Left  CCA,Alogliptin,Control,No significant difference,"Additionally, there were no differences in the changes in the left and right GSM-CCA between the groups.",NaN:NaN,5801253,29330812,Unavailable
5801253,Gray-scale median Right CCA,Alogliptin,Control,No significant difference,"Additionally, there were no differences in the changes in the left and right GSM-CCA between the groups.",NaN:NaN,5801253,29330812,Unavailable
5801253,Mean intima-media thickness CCA,Alogliptin,Control,Significantly decreased,"According to the results of the SPEAD-A trial, reductions in the mean common and the right and left maximum IMT of the carotid arteries at 104&nbsp;weeks were significantly greater after alogliptin treatment than after conventional treatment [−&nbsp;0.026 (SE 0.009) vs. 0.005&nbsp;mm (SE 0.009), p&nbsp;=&nbsp;0.022; −&nbsp;0.045 (SE 0.018) vs. 0.011&nbsp;mm (SE 0.017), p&nbsp;=&nbsp;0.025, and −&nbsp;0.079 (SE 0.018) vs. −&nbsp;0.015&nbsp;mm (SE 0.018), p&nbsp;=&nbsp;0.013, respectively",26526:26998,5801253,29330812,Unavailable
5801253,Intima-media thickness left CCA,Alogliptin,Control,Significantly decreased,"According to the results of the SPEAD-A trial, reductions in the mean common and the right and left maximum IMT of the carotid arteries at 104&nbsp;weeks were significantly greater after alogliptin treatment than after conventional treatment [−&nbsp;0.026 (SE 0.009) vs. 0.005&nbsp;mm (SE 0.009), p&nbsp;=&nbsp;0.022; −&nbsp;0.045 (SE 0.018) vs. 0.011&nbsp;mm (SE 0.017), p&nbsp;=&nbsp;0.025, and −&nbsp;0.079 (SE 0.018) vs. −&nbsp;0.015&nbsp;mm (SE 0.018), p&nbsp;=&nbsp;0.013, respectively",26526:26998,5801253,29330812,Unavailable
5801253,Intima-media thickness right CCA,Alogliptin,Control,Significantly decreased,"According to the results of the SPEAD-A trial, reductions in the mean common and the right and left maximum IMT of the carotid arteries at 104&nbsp;weeks were significantly greater after alogliptin treatment than after conventional treatment [−&nbsp;0.026 (SE 0.009) vs. 0.005&nbsp;mm (SE 0.009), p&nbsp;=&nbsp;0.022; −&nbsp;0.045 (SE 0.018) vs. 0.011&nbsp;mm (SE 0.017), p&nbsp;=&nbsp;0.025, and −&nbsp;0.079 (SE 0.018) vs. −&nbsp;0.015&nbsp;mm (SE 0.018), p&nbsp;=&nbsp;0.013, respectively",26526:26998,5801253,29330812,Unavailable
5801253,Mean gray-scale median CCA,Alogliptin,Control,No significant difference,"However, there was no significant difference in the change in GSM measures from baseline at 52 and 104&nbsp;weeks between the two groups.",34566:34698,5801253,29330812,Unavailable
5801253,Gray-scale median Left  CCA,Alogliptin,Control,No significant difference,"However, there was no significant difference in the change in GSM measures from baseline at 52 and 104&nbsp;weeks between the two groups.",34566:34698,5801253,29330812,Unavailable
5801253,Gray-scale median Right CCA,Alogliptin,Control,No significant difference,"However, there was no significant difference in the change in GSM measures from baseline at 52 and 104&nbsp;weeks between the two groups.",34566:34698,5801253,29330812,Unavailable
5041571,Plasma glutation,A2 β-casein ,A1 + A2 β-casein,Significantly increased,Consumption of milk containing only the A2 β-casein type was associated with significantly greater increases in plasma GSH concentrations from baseline to the end of the study phase compared with the consumption of milk containing both β-casein types.,17472:17723,5041571,27680716,Unavailable
5037966,Type II collagen content,Trabecular metal,Trabecular metal/periosteal graft,No significant difference,The highest type II collagen content was found in neo-cartilage after TM compared with TMPG and ED (TM 60%/TMPG 40%/ED 39%). Inter-treatment differences were not significant.,6679:6853,5037966,27660334,Unavailable
5037966,Type II collagen content,Trabecular metal ,Empty defect,No significant difference,The highest type II collagen content was found in neo-cartilage after TM compared with TMPG and ED (TM 60%/TMPG 40%/ED 39%). Inter-treatment differences were not significant.,6679:6853,5037966,27660334,Unavailable
5037966,Type II collagen content,Trabecular metal/periosteal graft,Empty defect,No significant difference,The highest type II collagen content was found in neo-cartilage after TM compared with TMPG and ED (TM 60%/TMPG 40%/ED 39%). Inter-treatment differences were not significant.,6679:6853,5037966,27660334,Unavailable
5037966,Total histological score,Trabecular metal,Trabecular metal/periosteal graft,No significant difference,"Total histological score (maximum 30 points), and cartilage (maximum 22 points) and bone (maximum 8 points) breakdown of regenerates found after different treatments. There was no statistically significant difference between the treatment groups",6469:6678,5037966,27660334,Unavailable
5037966,Total histological score,Trabecular metal ,Empty defect,No significant difference,"Total histological score (maximum 30 points), and cartilage (maximum 22 points) and bone (maximum 8 points) breakdown of regenerates found after different treatments. There was no statistically significant difference between the treatment groups",6469:6678,5037966,27660334,Unavailable
5037966,Total histological score,Trabecular metal/periosteal graft,Empty defect,No significant difference,"Total histological score (maximum 30 points), and cartilage (maximum 22 points) and bone (maximum 8 points) breakdown of regenerates found after different treatments. There was no statistically significant difference between the treatment groups",6469:6678,5037966,27660334,Unavailable
5037966,Cartilage score,Trabecular metal,Trabecular metal/periosteal graft,No significant difference,"Total histological score (maximum 30 points), and cartilage (maximum 22 points) and bone (maximum 8 points) breakdown of regenerates found after different treatments. There was no statistically significant difference between the treatment groups",30730:30976,5037966,27660334,Unavailable
5037966,Cartilage score,Trabecular metal ,Empty defect,No significant difference,"Total histological score (maximum 30 points), and cartilage (maximum 22 points) and bone (maximum 8 points) breakdown of regenerates found after different treatments. There was no statistically significant difference between the treatment groups",30730:30976,5037966,27660334,Unavailable
5037966,Cartilage score,Trabecular metal/periosteal graft,Empty defect,No significant difference,"Total histological score (maximum 30 points), and cartilage (maximum 22 points) and bone (maximum 8 points) breakdown of regenerates found after different treatments. There was no statistically significant difference between the treatment groups",30730:30976,5037966,27660334,Unavailable
5037966,Bone score,Trabecular metal,Trabecular metal/periosteal graft,No significant difference,"Total histological score (maximum 30 points), and cartilage (maximum 22 points) and bone (maximum 8 points) breakdown of regenerates found after different treatments. There was no statistically significant difference between the treatment groups",30730:30976,5037966,27660334,Unavailable
5037966,Bone score,Trabecular metal ,Empty defect,No significant difference,"Total histological score (maximum 30 points), and cartilage (maximum 22 points) and bone (maximum 8 points) breakdown of regenerates found after different treatments. There was no statistically significant difference between the treatment groups",30730:30976,5037966,27660334,Unavailable
5037966,Bone score,Trabecular metal/periosteal graft,Empty defect,No significant difference,"Total histological score (maximum 30 points), and cartilage (maximum 22 points) and bone (maximum 8 points) breakdown of regenerates found after different treatments. There was no statistically significant difference between the treatment groups",30730:30976,5037966,27660334,Unavailable
5037966,Double-stranded DNA,Trabecular metal,Trabecular metal/periosteal graft,Significantly increased,Neo-cartilage after TM contained significantly more dsDNA than after TMPG,32987:33060,5037966,27660334,Unavailable
5037966,Double-stranded DNA,Trabecular metal,Empty defect,No significant difference,No significance was found comparing TM or TMPG with ED.,33126:33181,5037966,27660334,Unavailable
5037966,Double-stranded DNA,Trabecular metal/periosteal graft,Empty defect,No significant difference,No significance was found comparing TM or TMPG with ED.,33126:33181,5037966,27660334,Unavailable
5037966,Sulfated glycosaminoglycan,Trabecular metal,Trabecular metal/periosteal graft,No significant difference,"Although the neo-cartilage of the ED group contained more sGAG than the neo-cartilage of the implant groups, neither significant inter-treatment nor inter-AC control differences were found.",31924:32113,5037966,27660334,Unavailable
5037966,Sulfated glycosaminoglycan,Trabecular metal,Empty defect,No significant difference,"Although the neo-cartilage of the ED group contained more sGAG than the neo-cartilage of the implant groups, neither significant inter-treatment nor inter-AC control differences were found.",31924:32113,5037966,27660334,Unavailable
5037966,Sulfated glycosaminoglycan,Trabecular metal/periosteal graft,Empty defect,No significant difference,"Although the neo-cartilage of the ED group contained more sGAG than the neo-cartilage of the implant groups, neither significant inter-treatment nor inter-AC control differences were found.",31924:32113,5037966,27660334,Unavailable
5037966,Type II collagen content,Trabecular metal,Trabecular metal/periosteal graft,No significant difference,The highest type II collagen content was found in the neo-cartilage of the TM treatment group compared with the TMPG and ED groups (Fig. 4 right; mean values after TM 59.6 / TMPG 39.4 / ED 39.2 %). Inter-treatment differences were not significant.,33348:33665,5037966,27660334,Unavailable
5037966,Type II collagen content,Trabecular metal ,Empty defect,No significant difference,The highest type II collagen content was found in the neo-cartilage of the TM treatment group compared with the TMPG and ED groups (Fig. 4 right; mean values after TM 59.6 / TMPG 39.4 / ED 39.2 %). Inter-treatment differences were not significant.,33348:33664,5037966,27660334,Unavailable
5037966,Type II collagen content,Trabecular metal/periosteal graft,Empty defect,No significant difference,The highest type II collagen content was found in the neo-cartilage of the TM treatment group compared with the TMPG and ED groups (Fig. 4 right; mean values after TM 59.6 / TMPG 39.4 / ED 39.2 %). Inter-treatment differences were not significant.,33348:33664,5037966,27660334,Unavailable
5037966,Sulfated glycosaminoglycan,Trabecular metal,Control,No significant difference,"The sGAG yield was lower in the neo-cartilage regions compared with the articular cartilage (AC) controls (TMPG 20.8/AC 39.5, TM 25.6/AC 33.3, ED 32.2/AC 40.2 µg sGAG/1 mg respectively), with statistical significance being achieved for the TMPG group (p &lt; 0.05).",6206:6468,5037966,27660334,Unavailable
5037966,Sulfated glycosaminoglycan,Empty defect,Control,No significant difference,"The sGAG yield was lower in the neo-cartilage regions compared with the articular cartilage (AC) controls (TMPG 20.8/AC 39.5, TM 25.6/AC 33.3, ED 32.2/AC 40.2 µg sGAG/1 mg respectively), with statistical significance being achieved for the TMPG group (p &lt; 0.05).",6206:6468,5037966,27660334,Unavailable
5037966,Sulfated glycosaminoglycan,Trabecular metal/periosteal graft,Control,Significantly decreased,"The sGAG yield was lower in the neo-cartilage regions compared with the articular cartilage (AC) controls (TMPG 20.8/AC 39.5, TM 25.6/AC 33.3, ED 32.2/AC 40.2 µg sGAG/1 mg respectively), with statistical significance being achieved for the TMPG group (p &lt; 0.05).",6206:6468,5037966,27660334,Unavailable
5037966,Double-stranded DNA,Trabecular metal,Control,Significantly increased,"Hypercellularity of the neo-cartilage was found in TM and ED, as the dsDNA content was significantly higher (p &lt; 0.05) compared with contralateral AC controls (TM 126.7/AC 71.1, ED 99.3/AC 62.8 ng dsDNA/1 mg).",6469:6678,5037966,27660334,Unavailable
5037966,Double-stranded DNA,Empty defect,Control,Significantly increased,"Hypercellularity of the neo-cartilage was found in TM and ED, as the dsDNA content was significantly higher (p &lt; 0.05) compared with contralateral AC controls (TM 126.7/AC 71.1, ED 99.3/AC 62.8 ng dsDNA/1 mg).",6469:6678,5037966,27660334,Unavailable
5037966,Total histological score,Trabecular metal,Trabecular metal/periosteal graft,No significant difference,"At 16 weeks post-operatively, histological scores amongst treatment groups were not statistically different (TMPG: overall 12.7, cartilage 8.6, bone 4.1; TM: overall 14.2, cartilage 9.5, bone 4.9; ED: overall 13.6, cartilage 9.1, bone 4.5).",5883:6123,5037966,27660334,Unavailable
5037966,Total histological score,Trabecular metal ,Empty defect,No significant difference,"At 16 weeks post-operatively, histological scores amongst treatment groups were not statistically different (TMPG: overall 12.7, cartilage 8.6, bone 4.1; TM: overall 14.2, cartilage 9.5, bone 4.9; ED: overall 13.6, cartilage 9.1, bone 4.5).",5883:6123,5037966,27660334,Unavailable
5037966,Total histological score,Trabecular metal/periosteal graft,Empty defect,No significant difference,"At 16 weeks post-operatively, histological scores amongst treatment groups were not statistically different (TMPG: overall 12.7, cartilage 8.6, bone 4.1; TM: overall 14.2, cartilage 9.5, bone 4.9; ED: overall 13.6, cartilage 9.1, bone 4.5).",5883:6123,5037966,27660334,Unavailable
5037966,Cartilage score,Trabecular metal,Trabecular metal/periosteal graft,No significant difference,"At 16 weeks post-operatively, histological scores amongst treatment groups were not statistically different (TMPG: overall 12.7, cartilage 8.6, bone 4.1; TM: overall 14.2, cartilage 9.5, bone 4.9; ED: overall 13.6, cartilage 9.1, bone 4.5).",5883:6123,5037966,27660334,Unavailable
5037966,Cartilage score,Trabecular metal ,Empty defect,No significant difference,"t 16 weeks post-operatively, histological scores amongst treatment groups were not statistically different (TMPG: overall 12.7, cartilage 8.6, bone 4.1; TM: overall 14.2, cartilage 9.5, bone 4.9; ED: overall 13.6, cartilage 9.1, bone 4.5).",5883:6123,5037966,27660334,Unavailable
5037966,Cartilage score,Trabecular metal/periosteal graft,Empty defect,No significant difference,"At 16 weeks post-operatively, histological scores amongst treatment groups were not statistically different (TMPG: overall 12.7, cartilage 8.6, bone 4.1; TM: overall 14.2, cartilage 9.5, bone 4.9; ED: overall 13.6, cartilage 9.1, bone 4.5).",5883:6123,5037966,27660334,Unavailable
5037966,Bone score,Trabecular metal,Trabecular metal/periosteal graft,No significant difference,"At 16 weeks post-operatively, histological scores amongst treatment groups were not statistically different (TMPG: overall 12.7, cartilage 8.6, bone 4.1; TM: overall 14.2, cartilage 9.5, bone 4.9; ED: overall 13.6, cartilage 9.1, bone 4.5).",5883:6123,5037966,27660334,Unavailable
5037966,Bone score,Trabecular metal ,Empty defect,No significant difference,"t 16 weeks post-operatively, histological scores amongst treatment groups were not statistically different (TMPG: overall 12.7, cartilage 8.6, bone 4.1; TM: overall 14.2, cartilage 9.5, bone 4.9; ED: overall 13.6, cartilage 9.1, bone 4.5).",5883:6123,5037966,27660334,Unavailable
5037966,Bone score,Trabecular metal/periosteal graft,Empty defect,No significant difference,"At 16 weeks post-operatively, histological scores amongst treatment groups were not statistically different (TMPG: overall 12.7, cartilage 8.6, bone 4.1; TM: overall 14.2, cartilage 9.5, bone 4.9; ED: overall 13.6, cartilage 9.1, bone 4.5).",5883:6123,5037966,27660334,Unavailable
5037966,Sulfated glycosaminoglycan,Trabecular metal,Control,No significant difference,"sGAG yield was consistently lower in the neo-cartilage regions compared with contralateral AC controls (Fig. 4 left; mean values after TMPG 20.8 / AC 39.5, TM 25.6 / AC 33.3, ED 32.2 / AC 40.2 µg sGAG / 1 mg tissue). This was statistically significant for the TMPG treatment group only (p &lt; 0.05).",31557:31923,5037966,27660334,Unavailable
5037966,Sulfated glycosaminoglycan,Empty defect, Control,No significant difference,"sGAG yield was consistently lower in the neo-cartilage regions compared with contralateral AC controls (Fig. 4 left; mean values after TMPG 20.8 / AC 39.5, TM 25.6 / AC 33.3, ED 32.2 / AC 40.2 µg sGAG / 1 mg tissue). This was statistically significant for the TMPG treatment group only (p &lt; 0.05).",31557:31923,5037966,27660334,Unavailable
5037966,Sulfated glycosaminoglycan,Trabecular metal/periosteal graft,Control,Significantly decreased,"sGAG yield was consistently lower in the neo-cartilage regions compared with contralateral AC controls (Fig. 4 left; mean values after TMPG 20.8 / AC 39.5, TM 25.6 / AC 33.3, ED 32.2 / AC 40.2 µg sGAG / 1 mg tissue). This was statistically significant for the TMPG treatment group only (p &lt; 0.05).",31557:31923,5037966,27660334,Unavailable
5037966,Double-stranded DNA,Trabecular metal,Control,Significantly increased,"A hypercellularity of the neo-cartilage was found in the TM and ED treatment groups, as the dsDNA content was significantly higher (p &lt; 0.05) compared with relating AC controls",32437:32613,5037966,27660334,Unavailable
5037966,Double-stranded DNA,Empty defect,Control,Significantly increased,"A hypercellularity of the neo-cartilage was found in the TM and ED treatment groups, as the dsDNA content was significantly higher (p &lt; 0.05) compared with relating AC controls",32437:32614,5037966,27660334,Unavailable
5037966,Type II collagen content,Empty defect,Control,Significantly decreased,Neo-cartilage in the ED group contained significantly less (p &lt; 0.005) type II collagen compared with the relating AC control,33665:33791,5037966,27660334,Unavailable
5037966,Type II collagen content,Trabecular metal,Control,No significant difference,"Differences between the implant groups and contralateral AC were not statistically significant (mean values after TM 59.6 / AC 57.3, TMPG 39.4 / AC 49.3 %).",33832:33989,5037966,27660334,Unavailable
5037966,Type II collagen content,Trabecular metal/periosteal graft,Control,No significant difference,"Differences between the implant groups and contralateral AC were not statistically significant (mean values after TM 59.6 / AC 57.3, TMPG 39.4 / AC 49.3 %).",33832:33989,5037966,27660334,Unavailable
3823994,Objective barriers,Salt-restriction-spoon,Control,Significantly decreased,"After 6 months of intervention, the intervention group felt significantly less objective barriers, and got access to significantly more cues to action as compared to the control group.",6409:6594,3823994,24244395,Unavailable
3823994,Cues to action,Salt-restriction-spoon,Control,Significantly increased,"After 6 months of intervention, the intervention group felt significantly less objective barriers, and got access to significantly more cues to action as compared to the control group.",6409:6594,3823994,24244395,Unavailable
3823994,Daily salt intake,Salt-restriction-spoon,Control,Significantly decreased,"The daily salt intake decreased by 1.42 g in the intervention group and by 0.28 g in the control group, and repeated measures analysis of variance showed significant change over time (F = 7.044, P&lt;0.001) and significant difference between groups by time (F = 2.589, P = 0.041).",6717:7065,3823994,24244395,Unavailable
3823994,24-hour urinary sodium excretion,Salt-restriction-spoon,Control,No significant difference,"The 24HUNa decreased by 34.84 mmol in the intervention group and by 33.65 mmol in the control group, and repeated measures analysis of variance showed significant change over time (F = 14.648, P&lt;0.001) without significant difference between groups by time (F = 0.222, P = 0.870).",7066:7416,3823994,24244395,Unavailable
3823994,Objective barriers,Salt-restriction-spoon,Control,Significantly decreased,"Objective barriers	Corrected baseline	27.54	27.54	221.725	0.000",43088:43376,3823994,24244395,Unavailable
3823994,Cues to action,Salt-restriction-spoon,Control,Significantly increased,"Cues to action	Corrected baseline	2.80	2.80	7.143	0.008",45035:45315,3823994,24244395,Unavailable
3823994,Susceptibility,Salt-restriction-spoon,Control,No significant difference,"Susceptibility	Corrected baseline	13.96	13.96	3.393	0.067",40497:40779,3823994,24244395,Unavailable
3823994,Severity,Salt-restriction-spoon,Control,No significant difference,"Severity	Corrected baseline	23.98	23.98	0.040	0.841",41144:41420,3823994,24244395,Unavailable
3823994,Benefits,Salt-restriction-spoon,Control,No significant difference,"Benefits	Baseline	25.11±3.51	25.19±3.31	0.385	0.535",41785:42061,3823994,24244395,Unavailable
3823994,"Subjective barriers	",Salt-restriction-spoon,Control,No significant difference,"Subjective barriers	Corrected baseline	13.06	13.06	3.176	0.076",42436:42723,3823994,24244395,Unavailable
3823994,"Self-efficacy	",Salt-restriction-spoon,Control,No significant difference,"Self-efficacy	Baseline	37.63±5.47	37.50±5.64	0.010	0.920",43741:44022,3823994,24244395,Unavailable
3823994,Knowledge,Salt-restriction-spoon,Control,No significant difference,"Knowledge	Corrected baseline	3.13	3.13	0.653	0.420",44397:44672,3823994,24244395,Unavailable
3823994,Daily salt intake,Salt-restriction-spoon,Control,Significantly decreased,"Figure 2 shows that the salt intake in both groups declined in the first month of intervention, climbed in the second to fourth months of intervention, and declined again in the last two months of intervention. Repeated measures analysis of variance showed significant change over time (F = 7.044, P&lt;0.001), and significant difference between groups by time (F = 2.589, P = 0.041), indicating that the salt intake declined more for the intervention group than for the control group.",55072:55633,3823994,24244395,Unavailable
3823994,24-hour urinary sodium excretion,Salt-restriction-spoon,Control,No significant difference,"Repeated measures analysis of variance showed significant change over time (F = 14.648, P&lt;0.001), but no significant difference between groups by time (F = 0.222, P = 0.870), indicating that the level of 24HUNa changed with time similarly in the two groups.",64482:64810,3823994,24244395,Unavailable
4456883,Overall adverse events,Benzoyl peroxide 2.5% gel and clindamycin 1% gel,Benzoyl peroxide 2.5% gel and nadifloxacin 1% cream,No significant difference,"For safety assessment, about 94.4% patients do not show any adverse event during the treatment by all the three groups.",18036:18155,4456883,26097817,Unavailable
4456883,Overall adverse events,Benzoyl peroxide 2.5% gel and clindamycin 1% gel,Tretinoin 0.025% and clindamycin 1% gel,No significant difference,"For safety assessment, about 94.4% patients do not show any adverse event during the treatment by all the three groups.",18036:18155,4456883,26097817,Unavailable
4456883,Overall adverse events,Benzoyl peroxide 2.5% gel and nadifloxacin 1% cream,Tretinoin 0.025% and clindamycin 1% gel,No significant difference,"For safety assessment, about 94.4% patients do not show any adverse event during the treatment by all the three groups.",18036:18155,4456883,26097817,Unavailable
4456883,Burning sensation,Benzoyl peroxide 2.5% gel and clindamycin 1% gel,Benzoyl peroxide 2.5% gel and nadifloxacin 1% cream,No significant difference,"This shows that these groups are safer than Group A (2.14) for burning sensation. There was no statistically significant difference (P &gt; 0.05, χ2 = 2.00).",18468:18653,4456883,26097817,Unavailable
4456883,Burning sensation,Benzoyl peroxide 2.5% gel and clindamycin 1% gel,Tretinoin 0.025% and clindamycin 1% gel,No significant difference,"This shows that these groups are safer than Group A (2.14) for burning sensation. There was no statistically significant difference (P &gt; 0.05, χ2 = 2.00).",18468:18653,4456883,26097817,Unavailable
4456883,Burning sensation,Benzoyl peroxide 2.5% gel and nadifloxacin 1% cream,Tretinoin 0.025% and clindamycin 1% gel,No significant difference,"This shows that these groups are safer than Group A (2.14) for burning sensation. There was no statistically significant difference (P &gt; 0.05, χ2 = 2.00).",18468:18653,4456883,26097817,Unavailable
5771539,ADHD-RS-IV total score,SHP465 mixed amphetamine salts,Placebo,Significantly decreased,"The LS mean (95% CI) treatment difference for the change from baseline in ADHD-RS-IV total score at week 4 significantly favored SHP465 MAS over placebo (−9.9 [−13.0, −6.8]; degrees of freedom = 241, t-statistic = −6.23, p &lt; 0.001; effect size = 0.80).",33156:33442,5771539,28816509,Unavailable
5771539,ADHD-RS-IV (hyperactivity/impulsivity),SHP465 mixed amphetamine salts,Placebo,Significantly decreased,The LS mean (95% CI) treatment differences for the change from baseline at week 4 on the ADHD-RS-IV hyperactivity/impulsivity and inattentiveness subscales favored SHP465 MAS over placebo (both nominal p &lt; 0.001,34526:34754,5771539,28816509,Unavailable
5771539,ADHD-RS-IV (inattentiveness ),SHP465 mixed amphetamine salts,Placebo,Significantly decreased,The LS mean (95% CI) treatment differences for the change from baseline at week 4 on the ADHD-RS-IV hyperactivity/impulsivity and inattentiveness subscales favored SHP465 MAS over placebo (both nominal p &lt; 0.001,34526:34754,5771539,28816509,Unavailable
5771539,CGI-I score,SHP465 mixed amphetamine salts,Placebo,Significantly decreased,"The LS mean (95% CI) treatment difference for CGI-I score at week 4 significantly favored SHP465 MAS over placebo (−0.8 [−1.1, −0.5]; degrees of freedom = 242, t-statistic = −5.10, p &lt; 0.001; effect size = 0.65).",34526:34754,5771539,28816509,Unavailable
5771539,Improvement at the final assessment,SHP465 mixed amphetamine salts,Placebo,Significantly increased,"On the dichotomized CGI-I, the percentage of participants categorized as improved at the final on-treatment assessment was greater with SHP465 MAS than with placebo (nominal p &lt; 0.001 based on CMH test",34840:35059,5771539,28816509,Unavailable
5771539,Treatment-emergent adverse events,SHP465 mixed amphetamine salts,Placebo,Significantly increased,The frequency of TEAEs was greater with SHP465 MAS than with placebo,35207:35275,5771539,28816509,Unavailable
4173581,Hemoglobin concentration (right after surgery),Tranexamic acid (intravenous),Control,Significantly increased,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,16466:16754,4173581,25886103,Unavailable
4173581,Hemoglobin concentration (right after surgery),Tranexamic acid (topical),Control,Significantly increased,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,15944:16202,4173581,25886103,Unavailable
4173581,Hemoglobin concentration (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,16466:16754,4173581,25886103,Unavailable
4173581,Hemoglobin concentration (24h after surgery),Tranexamic acid (intravenous),Control,Significantly increased,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,16466:16754,4173581,25886103,Unavailable
4173581,Hemoglobin concentration (24h after surgery),Tranexamic acid (topical),Control,Significantly increased,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,15944:16202,4173581,25886103,Unavailable
4173581,Hemoglobin concentration (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,16466:16754,4173581,25886103,Unavailable
4173581,Hematocrit  (right after surgery),Tranexamic acid (intravenous),Control,Significantly increased,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,16466:16754,4173581,25886103,Unavailable
4173581,Hematocrit  (right after surgery),Tranexamic acid (topical),Control,Significantly increased,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,15944:16202,4173581,25886103,Unavailable
4173581,Hematocrit  (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,16466:16754,4173581,25886103,Unavailable
4173581,Hematocrit (24h after surgery),Tranexamic acid (intravenous),Control,Significantly increased,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,16466:16754,4173581,25886103,Unavailable
4173581,Hematocrit (24h after surgery),Tranexamic acid (topical),Control,Significantly increased,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,15944:16202,4173581,25886103,Unavailable
4173581,Hematocrit (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (P &lt; 0.05).,16466:16754,4173581,25886103,Unavailable
4173581,Platelet count (right after surgery),Tranexamic acid (intravenous),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Platelet count (right after surgery),Tranexamic acid (topical),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16212:16406,4173581,25886103,Unavailable
4173581,Platelet count (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Platelet count (24h after surgery),Tranexamic acid (intravenous),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Platelet count (24h after surgery),Tranexamic acid (topical),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16212:16406,4173581,25886103,Unavailable
4173581,Platelet count (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Prothrombin time (right after surgery),Tranexamic acid (intravenous),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Prothrombin time (right after surgery),Tranexamic acid (topical),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16212:16406,4173581,25886103,Unavailable
4173581,Prothrombin time (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Prothrombin time (24h after surgery),Tranexamic acid (intravenous),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Prothrombin time (24h after surgery),Tranexamic acid (topical),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16212:16406,4173581,25886103,Unavailable
4173581,Prothrombin time (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Activated partial thromboplastin time (right after surgery),Tranexamic acid (intravenous),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Activated partial thromboplastin time (right after surgery),Tranexamic acid (topical),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16212:16406,4173581,25886103,Unavailable
4173581,Activated partial thromboplastin time (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Activated partial thromboplastin time (24h after surgery),Tranexamic acid (intravenous),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Activated partial thromboplastin time (24h after surgery),Tranexamic acid (topical),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16212:16406,4173581,25886103,Unavailable
4173581,Activated partial thromboplastin time (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,INR (right after surgery),Tranexamic acid (intravenous),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,INR (right after surgery),Tranexamic acid (topical),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16212:16406,4173581,25886103,Unavailable
4173581,INR (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,INR (24h after surgery),Tranexamic acid (intravenous),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,INR (24h after surgery),Tranexamic acid (topical),Control,No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16212:16406,4173581,25886103,Unavailable
4173581,INR (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,"Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (P &gt; 0.05)",16466:16754,4173581,25886103,Unavailable
4173581,Blood loss,Tranexamic acid (intravenous),Control,Significantly decreased,Considering the mean total blood loss during the first 24 h in all groups there was no significant difference between Groups A and B (P &gt; 0.05) while there was a significant increase in mean blood loss in Group C compared to Groups A and B (P &lt; 0.05),16466:16754,4173581,25886103,Unavailable
4173581,Blood loss,Tranexamic acid (topical),Control,Significantly decreased,Considering the mean total blood loss during the first 24 h in all groups there was no significant difference between Groups A and B (P &gt; 0.05) while there was a significant increase in mean blood loss in Group C compared to Groups A and B (P &lt; 0.05),16466:16754,4173581,25886103,Unavailable
4173581,Blood loss,Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,Considering the mean total blood loss during the first 24 h in all groups there was no significant difference between Groups A and B (P &gt; 0.05) while there was a significant increase in mean blood loss in Group C compared to Groups A and B (P &lt; 0.05),16466:16754,4173581,25886103,Unavailable
4173581,Need of packed RBCs,Tranexamic acid (intravenous),Control,Significantly decreased,Regarding the primary outcome patients receiving packed red blood cells (RBCs) during the first 24 h post-operatively we found a significant increase in number of patients receiving packed RBCs in Group C compared to Groups A and B (P &lt; 0.05),17012:17271,4173581,25886103,Unavailable
4173581,Need of packed RBCs,Tranexamic acid (topical),Control,Significantly decreased,Regarding the primary outcome patients receiving packed red blood cells (RBCs) during the first 24 h post-operatively we found a significant increase in number of patients receiving packed RBCs in Group C compared to Groups A and B (P &lt; 0.05),17012:17271,4173581,25886103,Unavailable
4173581,r-time (right after surgery),Tranexamic acid (intravenous),Control,Significantly decreased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,r-time (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),Significantly decreased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,k-time (right after surgery),Tranexamic acid (intravenous),Control,Significantly decreased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,k-time (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),Significantly decreased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,Maximum amplitude (right after surgery),Tranexamic acid (intravenous),Control,Significantly increased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,Maximum amplitude (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),Significantly increased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,α-angle (right after surgery),Tranexamic acid (intravenous),Control,Significantly increased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,α-angle (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),Significantly increased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,r-time (24h after surgery),Tranexamic acid (intravenous),Control,Significantly decreased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,r-time (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),Significantly decreased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,k-time (24h after surgery),Tranexamic acid (intravenous),Control,Significantly decreased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,k-time (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),Significantly decreased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,Maximum amplitude (24h after surgery),Tranexamic acid (intravenous),Control,Significantly increased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,Maximum amplitude (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),Significantly increased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,α-angle (24h after surgery),Tranexamic acid (intravenous),Control,Significantly increased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,α-angle (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),Significantly increased,Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (P &lt; 0.05),18213:18425,4173581,25886103,Unavailable
4173581,LY 30 (right after surgery),Tranexamic acid (intravenous),Control,No significant difference,"However, there was no significant differences in LY 30 among the three groups either immediate or after first 24 h post-operatively (P &gt; 0.05)",18479:18638,4173581,25886103,Unavailable
4173581,LY 30 (right after surgery),Tranexamic acid (topical),Control,No significant difference,"However, there was no significant differences in LY 30 among the three groups either immediate or after first 24 h post-operatively (P &gt; 0.05)",18479:18638,4173581,25886103,Unavailable
4173581,LY 30 (right after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,"However, there was no significant differences in LY 30 among the three groups either immediate or after first 24 h post-operatively (P &gt; 0.05)",18479:18638,4173581,25886103,Unavailable
4173581,LY 30 (24h after surgery),Tranexamic acid (intravenous),Control,No significant difference,"However, there was no significant differences in LY 30 among the three groups either immediate or after first 24 h post-operatively (P &gt; 0.05)",18479:18638,4173581,25886103,Unavailable
4173581,LY 30 (24h after surgery),Tranexamic acid (topical),Control,No significant difference,"However, there was no significant differences in LY 30 among the three groups either immediate or after first 24 h post-operatively (P &gt; 0.05)",18479:18638,4173581,25886103,Unavailable
4173581,LY 30 (24h after surgery),Tranexamic acid (intravenous),Tranexamic acid (topical),No significant difference,"However, there was no significant differences in LY 30 among the three groups either immediate or after first 24 h post-operatively (P &gt; 0.05)",18479:18638,4173581,25886103,Unavailable
4173581,Thromboembolic events (deep vein thrombosis),Tranexamic acid (intravenous),Control,Significantly increased,There was statistically significant increase in the incidence of thromboembolic events in the form of DVT in Group A patients compared to patients in Groups B and C (P &lt; 0.05),19264:19456,4173581,25886103,Unavailable
4173581,Thromboembolic events (deep vein thrombosis),Tranexamic acid (intravenous),Tranexamic acid (topical),Significantly increased,There was statistically significant increase in the incidence of thromboembolic events in the form of DVT in Group A patients compared to patients in Groups B and C (P &lt; 0.05),19264:19456,4173581,25886103,Unavailable
3610917,Self-reported Quality of Life (after 6 months),Cognitive training,Active control (nature documentaries) ,Significantly decreased,"Compared to the CT group, 6 months after the end of training, those in the AC group experienced a significant increase in their self-reported Quality of Life (Effect Size g = .34 vs −.15; TIME×GROUP p = .003), decrease in stress levels (g = .22 vs −.19; TIME x GROUP p = .03), and overall improvement in Psychological Wellbeing (g = .32 vs −.06; TIME×GROUP p = .02)",8285:8752,3610917,23555855,Unavailable
3610917,Stress (after 6 months),Cognitive training,Active control (nature documentaries) ,Significantly increased,"Compared to the CT group, 6 months after the end of training, those in the AC group experienced a significant increase in their self-reported Quality of Life (Effect Size g = .34 vs −.15; TIME×GROUP p = .003), decrease in stress levels (g = .22 vs −.19; TIME x GROUP p = .03), and overall improvement in Psychological Wellbeing (g = .32 vs −.06; TIME×GROUP p = .02)",8285:8752,3610917,23555855,Unavailable
3610917,Psychological Wellbeing (after 6 months),Cognitive training,Active control (nature documentaries) ,Significantly decreased,"Compared to the CT group, 6 months after the end of training, those in the AC group experienced a significant increase in their self-reported Quality of Life (Effect Size g = .34 vs −.15; TIME×GROUP p = .003), decrease in stress levels (g = .22 vs −.19; TIME x GROUP p = .03), and overall improvement in Psychological Wellbeing (g = .32 vs −.06; TIME×GROUP p = .02)",8285:8752,3610917,23555855,Unavailable
3610917,Psychological Wellbeing (right after intervention),Cognitive training,Active control (nature documentaries) ,No significant difference,"Those who completed CT became faster at the task, while little or no improvement was observed in the AC group on this measure. However, this was no longer significant after correction for multiple testing",35504:35709,3610917,23555855,Unavailable
3610917,Language measure (after 6 months),Cognitive training,Active control (nature documentaries) ,Significantly decreased,"In contrast, although both the CT and AC groups improved in the Language measure (COWAT) over the 6 month period (TIME: F(1,91) = 7.92; p = .006), the AC group achieved a greater effect size (g = .50) than the CT group (g = .28; TIME x GROUP: F(1,91) = 4.41, p = .04).",35504:35709,3610917,23555855,Unavailable
3610917,Self-reported Quality of Life (after 6 months),Cognitive training,Active control (nature documentaries) ,Significantly decreased,"Unexpectedly, these benefits occurred in the AC rather than the CT intervention. Those in the AC group experienced a significant increase in their self-reported Quality of Life (g = .34) compared to the CT group (g = −.15; p = .003)",37714:37998,3610917,23555855,Unavailable
3610917,Stress (after 6 months),Cognitive training,Active control (nature documentaries) ,Significantly increased,stress levels also declined significantly for the AC group (g = .22) but increased for the CT group (g = −.19; p = .03).,38002:38173,3610917,23555855,Unavailable
3610917,Psychological Wellbeing (after 6 months),Cognitive training,Active control (nature documentaries) ,Significantly decreased,"Overall, Psychological Wellbeing improved for the AC group (g = .32) but not for the CT group (g = −.06; p = .02).",38260:38425,3610917,23555855,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 2 weeks),Pamphlet + education,Control,No significant difference,"Adjusting for baseline scores demonstrated no significant differences in beliefs (2 or at 8 weeks) between pamphlet (with or without education) versus control, or between ‘pamphlet with’ versus ‘without’ education.",8605:8820,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 8 weeks),Pamphlet + education,Control,No significant difference,"Adjusting for baseline scores demonstrated no significant differences in beliefs (2 or at 8 weeks) between pamphlet (with or without education) versus control, or between ‘pamphlet with’ versus ‘without’ education.",8605:8820,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 2 weeks),Pamphlet only,Control,No significant difference,"Adjusting for baseline scores demonstrated no significant differences in beliefs (2 or at 8 weeks) between pamphlet (with or without education) versus control, or between ‘pamphlet with’ versus ‘without’ education.",8605:8820,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 8 weeks),Pamphlet only,Control,No significant difference,"Adjusting for baseline scores demonstrated no significant differences in beliefs (2 or at 8 weeks) between pamphlet (with or without education) versus control, or between ‘pamphlet with’ versus ‘without’ education.",8605:8820,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 2 weeks),Pamphlet + education,Pamphlet only,No significant difference,"Adjusting for baseline scores demonstrated no significant differences in beliefs (2 or at 8 weeks) between pamphlet (with or without education) versus control, or between ‘pamphlet with’ versus ‘without’ education.",8605:8820,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 8 weeks),Pamphlet + education,Pamphlet only,No significant difference,"Adjusting for baseline scores demonstrated no significant differences in beliefs (2 or at 8 weeks) between pamphlet (with or without education) versus control, or between ‘pamphlet with’ versus ‘without’ education.",8820:8984,3748095,23977178,Unavailable
3748095,Work-related fear,Pamphlet + education,Control,Significantly decreased,"Work-related fear (FABQ) was significantly lower in consumers receiving pamphlet (with or without education) versus control (difference −2.3, 95%CI: −4.4 to −0.2).",8820:8984,3748095,23977178,Unavailable
3748095,Work-related fear,Pamphlet only,Control,Significantly decreased,"Work-related fear (FABQ) was significantly lower in consumers receiving pamphlet (with or without education) versus control (difference −2.3, 95%CI: −4.4 to −0.2).",8820:8984,3748095,23977178,Unavailable
3748095,Work-related fear,Pamphlet + education,Pamphlet only,No significant difference,There was no significant difference between “pamphlet with” versus “pamphlet without” groups.,8984:9078,3748095,23977178,Unavailable
3748095,Perceived usefulness,Pamphlet + education,Pamphlet only,Significantly increased,Consumers receiving the “pamphlet with” reported greater perceived usefulness than consumers receiving the “pamphlet without” (difference 0.9 (95%CI: 0.0 to 1.8)).,9078:9241,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 2 weeks),Pamphlet + education,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in back beliefs at 2 or at 8 weeks between pamphlet (with or without education) versus control (usual care), or between pamphlet with versus without education",52268:52502,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 8 weeks),Pamphlet + education,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in back beliefs at 2 or at 8 weeks between pamphlet (with or without education) versus control (usual care), or between pamphlet with versus without education",52267:52501,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 2 weeks),Pamphlet only,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in back beliefs at 2 or at 8 weeks between pamphlet (with or without education) versus control (usual care), or between pamphlet with versus without education",52268:52501,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 8 weeks),Pamphlet only,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in back beliefs at 2 or at 8 weeks between pamphlet (with or without education) versus control (usual care), or between pamphlet with versus without education",52268:52501,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 2 weeks),Pamphlet + education,Pamphlet only,No significant difference,"After adjusting for baseline scores, there were no significant differences in back beliefs at 2 or at 8 weeks between pamphlet (with or without education) versus control (usual care), or between pamphlet with versus without education",52268:52502,3748095,23977178,Unavailable
3748095,Back Pain Beliefs Questionnaire score (at 8 weeks),Pamphlet + education,Pamphlet only,No significant difference,"After adjusting for baseline scores, there were no significant differences in back beliefs at 2 or at 8 weeks between pamphlet (with or without education) versus control (usual care), or between pamphlet with versus without education",52267:52501,3748095,23977178,Unavailable
3748095,Physical activity-related fear (at 2 weeks),Pamphlet + education,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in physical activity-related fear at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",61566:61801,3748095,23977178,Unavailable
3748095,Physical activity-related fear (at 8 weeks),Pamphlet + education,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in physical activity-related fear at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",61566:61801,3748095,23977178,Unavailable
3748095,Physical activity-related fear (at 2 weeks),Pamphlet only,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in physical activity-related fear at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",61566:61801,3748095,23977178,Unavailable
3748095,Physical activity-related fear (at 8 weeks),Pamphlet only,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in physical activity-related fear at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",61566:61801,3748095,23977178,Unavailable
3748095,Physical activity-related fear (at 2 weeks),Pamphlet + education,Pamphlet only,No significant difference,"After adjusting for baseline scores, there were no significant differences in physical activity-related fear at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",61566:61801,3748095,23977178,Unavailable
3748095,Physical activity-related fear (at 8 weeks),Pamphlet + education,Pamphlet only,No significant difference,"After adjusting for baseline scores, there were no significant differences in physical activity-related fear at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",61566:61801,3748095,23977178,Unavailable
3748095,Work-related fear,Pamphlet + education,Pamphlet only,No significant difference,but there was no significant difference between pamphlet with versus without education,63080:63166,3748095,23977178,Unavailable
3748095,Pain Severity (at 2 weeks),Pamphlet + education,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in pain severity at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",64110:64329,3748095,23977178,Unavailable
3748095,Pain Severity (at 8 weeks),Pamphlet + education,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in pain severity at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",64110:64329,3748095,23977178,Unavailable
3748095,Pain Severity (at 2 weeks),Pamphlet only,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in pain severity at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",64110:64329,3748095,23977178,Unavailable
3748095,Pain Severity (at 8 weeks),Pamphlet only,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in pain severity at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",64110:64329,3748095,23977178,Unavailable
3748095,Pain Severity (at 2 weeks),Pamphlet + education,Pamphlet only,No significant difference,"After adjusting for baseline scores, there were no significant differences in pain severity at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",64110:64329,3748095,23977178,Unavailable
3748095,Pain Severity (at 8 weeks),Pamphlet + education,Pamphlet only,No significant difference,"After adjusting for baseline scores, there were no significant differences in pain severity at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",64110:64329,3748095,23977178,Unavailable
3748095,Activity Impairment (at 2 weeks),Pamphlet + education,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in disability at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",65039:65254,3748095,23977178,Unavailable
3748095,Activity Impairment (at 8 weeks),Pamphlet + education,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in disability at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",65039:65254,3748095,23977178,Unavailable
3748095,Activity Impairment (at 2 weeks),Pamphlet only,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in disability at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",65039:65254,3748095,23977178,Unavailable
3748095,Activity Impairment (at 8 weeks),Pamphlet only,Control,No significant difference,"After adjusting for baseline scores, there were no significant differences in disability at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",65039:65254,3748095,23977178,Unavailable
3748095,Activity Impairment (at 2 weeks),Pamphlet + education,Pamphlet only,No significant difference,"After adjusting for baseline scores, there were no significant differences in disability at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",65039:65254,3748095,23977178,Unavailable
3748095,Activity Impairment (at 8 weeks),Pamphlet + education,Pamphlet only,No significant difference,"After adjusting for baseline scores, there were no significant differences in disability at 2 or 8 weeks between pamphlet (with or without education) versus control, or between pamphlet with versus without education",65039:65254,3748095,23977178,Unavailable
3748095,Perceived usefulness,Pamphlet + education,Pamphlet only,Significantly increased,"although the estimated difference between the two groups was not significant at either time-point (0.9; 95%CI:−0.1 to 1.9 at both T1 and T2), there was weak evidence for a difference pooled over the two time points (0.9∶95%CI:0 to 1.8).",65733:65969,3748095,23977178,Unavailable
4331948,Visual analouge scale,Intra-acupoint + Intraarticular BVP Injection,Intra-acupoint BVP injection,No significant difference,"However, when the groups were compared, no statistically significant differences in VAS and KWOMAC were noted",4819:4928,4331948,25780649,Unavailable
4331948,Visual analouge scale,Intra-acupoint + Intraarticular BVP Injection,Intraarticular  BVP injection,No significant difference,"However, when the groups were compared, no statistically significant differences in VAS and KWOMAC were noted",4819:4928,4331948,25780649,Unavailable
4331948,Visual analouge scale,Intra-acupoint BVP  Injection,Intraarticular BVP injection,No significant difference,"However, when the groups were compared, no statistically significant differences in VAS and KWOMAC were noted",4819:4928,4331948,25780649,Unavailable
4331948,Korea Western Ontario and McMaster Universities Osteoarthritis Index,Intra-acupoint + Intraarticular BVP Injection,Intra-acupoint BVP injection,No significant difference,"However, when the groups were compared, no statistically significant differences in VAS and KWOMAC were noted",4819:4928,4331948,25780649,Unavailable
4331948,Korea Western Ontario and McMaster Universities Osteoarthritis Index,Intra-acupoint + Intraarticular BVP Injection,Intraarticular  BVP injection,No significant difference,"However, when the groups were compared, no statistically significant differences in VAS and KWOMAC were noted",4819:4928,4331948,25780649,Unavailable
4331948,Korea Western Ontario and McMaster Universities Osteoarthritis Index,Intra-acupoint BVP  Injection,Intraarticular BVP injection,No significant difference,"However, when the groups were compared, no statistically significant differences in VAS and KWOMAC were noted",4819:4928,4331948,25780649,Unavailable
4331948,Visual analouge scale,Intra-acupoint + Intraarticular BVP Injection,Intra-acupoint BVP injection,No significant difference,The three groups showed no significant differences in improvement at each stage,16043:16122,4331948,25780649,Unavailable
4331948,Visual analouge scale,Intra-acupoint + Intraarticular BVP Injection,Intraarticular  BVP injection,No significant difference,The three groups showed no significant differences in improvement at each stage,16043:16122,4331948,25780649,Unavailable
4331948,Visual analouge scale,Intra-acupoint BVP  Injection,Intraarticular BVP injection,No significant difference,The three groups showed no significant differences in improvement at each stage,16043:16122,4331948,25780649,Unavailable
4331948,Korea Western Ontario and McMaster Universities Osteoarthritis Index,Intra-acupoint + Intraarticular BVP Injection,Intra-acupoint BVP injection,No significant difference,The three groups showed no significant difference in improvement at each stage.,34355:34434,4331948,25780649,Unavailable
4331948,Korea Western Ontario and McMaster Universities Osteoarthritis Index,Intra-acupoint + Intraarticular BVP Injection,Intraarticular  BVP injection,No significant difference,The three groups showed no significant difference in improvement at each stage.,34355:34434,4331948,25780649,Unavailable
4331948,Korea Western Ontario and McMaster Universities Osteoarthritis Index,Intra-acupoint BVP  Injection,Intraarticular BVP injection,No significant difference,The three groups showed no significant difference in improvement at each stage.,34355:34434,4331948,25780649,Unavailable
4743514,Diaphragmatic mobility,BiPAP before surgery,BiPAP after surgery,No significant difference,There was no significant difference in diaphragmatic mobility amongst the groups.,4874:4955,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,BiPAP before surgery,Positive End Expiratory Pressure,No significant difference,There was no significant difference in diaphragmatic mobility amongst the groups.,4874:4955,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,BiPAP before surgery,Control,No significant difference,There was no significant difference in diaphragmatic mobility amongst the groups.,4874:4955,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,BiPAP after surgery,Positive End Expiratory Pressure,No significant difference,There was no significant difference in diaphragmatic mobility amongst the groups.,4874:4955,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,BiPAP after surgery,Control,No significant difference,There was no significant difference in diaphragmatic mobility amongst the groups.,4874:4955,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,Positive End Expiratory Pressure,Control,No significant difference,There was no significant difference in diaphragmatic mobility amongst the groups.,4874:4955,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,BiPAP before surgery,BiPAP after surgery,No significant difference,There was no significant difference in diaphragmatic mobility between the groups (Table 3).,34094:34226,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,BiPAP before surgery,Positive End Expiratory Pressure,No significant difference,There was no significant difference in diaphragmatic mobility between the groups (Table 3).,34095:34226,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,BiPAP before surgery,Control,No significant difference,There was no significant difference in diaphragmatic mobility between the groups (Table 3).,34095:34226,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,BiPAP after surgery,Positive End Expiratory Pressure,No significant difference,There was no significant difference in diaphragmatic mobility between the groups (Table 3).,34094:34226,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,BiPAP after surgery,Control,No significant difference,There was no significant difference in diaphragmatic mobility between the groups (Table 3).,34095:34226,4743514,25409961,Unavailable
4743514,Diaphragmatic mobility,Positive End Expiratory Pressure,Control,No significant difference,There was no significant difference in diaphragmatic mobility between the groups (Table 3).,34095:34226,4743514,25409961,Unavailable
3554515,PCR corrected adequate clinical and parasitological response (at day 28),Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,PCR corrected ACPR at day 28 was at 95.5% in the AM arm while that in the AL arm was at 96.7% (p = 0.83).,5631:5727,3554515,23234606,Unavailable
3554515,Efficacy ,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Therapeutic efficacy was at 98.5% in the AM arm versus 98.2% in the AL group at day 42 (p = 1).,5631:5727,3554515,23234606,Unavailable
3554515,Adequate clinical and parasitological response (at day 63),Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,"At day 63, ACPR in the AM and AL arms was at 98.2% and 97.7%, respectively (p = 0.32).",5727:5814,3554515,23234606,Unavailable
3554515,Dizziness ,Artesunate-mefloquine,Artemether-lumefantrine,Significantly increased,dizziness was more frequent in the AM arm.,5904:5946,3554515,23234606,Unavailable
3554515,Cumulative incidence of failure rate (at day 28),Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,"the Kaplan-Meier PCR adjusted analysis did not show any significant difference between the two treatment groups in terms of cumulative incidence of failure rate, up to day 28 (log rank test, p = 0.67)",26061:26261,3554515,23234606,Unavailable
3554515,PCR corrected adequate clinical and parasitological response (at day 28),Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,"PCR corrected adequate clinical parasitological response (ACPR) at day 28 (primary end point), was evaluated at 95.5% in the AM arm versus 96.7% in the AL arm (p = 0.58) (difference −0.01 (95%CI [−0.05;0.03]).",25665:25875,3554515,23234606,Unavailable
3554515,Crude Parasitological failure at day 28,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Crude Parasitological failure at day 281 (0.64%)4 (2.61%)0.35,28067:28275,3554515,23234606,Unavailable
3554515,PCR adjusted cure rate,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,PCR adjusted cure rate at day 28150 (95.54%)148 (96.73%)0.58,28578:28785,3554515,23234606,Unavailable
3554515,PCR adjusted failure rate,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,PCR adjusted failure rate1/151 (0.66%)1/149 (0.67%)0.99,29835:30037,3554515,23234606,Unavailable
3554515,Crude Parasitological failure at day 42,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Crude parasitological failure at day 422/70 (2.8%)5/57 (8.7%0.20,30364:30575,3554515,23234606,Unavailable
3554515,PCR corrected adequate clinical and parasitological response (at day 42),Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,PCR adjusted ACPR at day 4269/70 (98.5%)56/57 (98.2%)1,30631:30832,3554515,23234606,Unavailable
3554515,Crude Parasitological failure at day 63,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Crude parasitological failure at day 634/57 (7%)6/44 (13%)0.32,30888:31097,3554515,23234606,Unavailable
3554515,PCR corrected adequate clinical and parasitological response (at day 63),Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,"PCR adjusted ACPR at day 63	56/57 (98.2%)	43/44 (97.7%)	1",31137:31263,3554515,23234606,Unavailable
3554515,Decrease of fever,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,"The decrease of fever was similar in the two treatments groups. Following the first treatment dose (at day 0), 2.6% of patients in the AM arm were found with fever (temperature &gt;37.5 °C) while 5.3% of patients in the AL arm were febrile after the first treatment day (p = 0.25).",31647:31926,3554515,23234606,Unavailable
3554515,Parasitaemia ,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,"It decreased to 864 trophozoites/μL in the AM group versus 949 trophozoites/μL in the AL group, 24 hours after the first dose (p = 0.28).",32179:32324,3554515,23234606,Unavailable
3554515,Dizziness ,Artesunate-mefloquine,Artemether-lumefantrine,Significantly increased,Dizziness were more frequent in the AM arm (22.9%) than in the AL arm (11.1%) (p = 0.008).,32726:32817,3554515,23234606,Unavailable
3554515,Anaemia rate ,Artesunate-mefloquine,Artemether-lumefantrine,Significantly decreased,Anaemia was more frequent at day 7 in the AL arm (68.6%) than in the AM arm (54.7%) (p = 0.01).,41901:42084,3554515,23234606,Unavailable
3554515,ALT,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,No significant difference was noted between the two treatment groups at day 7 in term of ALAT and ASAT level as well as bilirubin and creatinine concentration,40658:40817,3554515,23234606,Unavailable
3554515,AST,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,No significant difference was noted between the two treatment groups at day 7 in term of ALAT and ASAT level as well as bilirubin and creatinine concentration,40658:40817,3554515,23234606,Unavailable
3554515,Bilirubin ,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,No significant difference was noted between the two treatment groups at day 7 in term of ALAT and ASAT level as well as bilirubin and creatinine concentration,40658:40817,3554515,23234606,Unavailable
3554515,Creatinine ,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,No significant difference was noted between the two treatment groups at day 7 in term of ALAT and ASAT level as well as bilirubin and creatinine concentration,40658:40817,3554515,23234606,Unavailable
3554515,Hemoglobin level,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Mean haemoglobin11.3 ± 1.810.6 ± 1.50.11,41658:41845,3554515,23234606,Unavailable
3554515,Anaemia rate ,Artesunate-mefloquine,Artemether-lumefantrine,Significantly decreased,Anaemia (%)86 (54.7%)105 (68.6%)0.01,41901:42084,3554515,23234606,Unavailable
3554515,ALT,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Median ALAT1919.30.93,42140:42308,3554515,23234606,Unavailable
3554515,AST,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Median ASAT24250.53,42364:42530,3554515,23234606,Unavailable
3554515,Rate of AST &lt; 40,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Patients with ASAT &lt; 40 (%)143 (91%)139 (90.8%)0.94,43342:43559,3554515,23234606,Unavailable
3554515,Rate of ALT &lt; 40,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Patients with ALAT &lt; 40 (%)146 (92.9%)145 (94.7%)0.51,43342:43559,3554515,23234606,Unavailable
3554515,Bilirubin ,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Median bilirubin1.101.080.36,43615:43790,3554515,23234606,Unavailable
3554515,Creatinine ,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Mean creatinine7.7 ± 4.78.2 ± 7.00.50,43102:43286,3554515,23234606,Unavailable
3554515,Rate of normal creatinine ,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,Patients with normal level of creatinine (%)149 (94.9%)150 (98.0%)0.13,43342:43559,3554515,23234606,Unavailable
3554515,Rate of normal bilirubin,Artesunate-mefloquine,Artemether-lumefantrine,No significant difference,"Patients with normal level of bilirubin (%)	92 (58.6%)	82 (53.6%)	0.37",43830:43969,3554515,23234606,Unavailable
4865704,Recurrence rate,Limberg flap,Mutaf technique,No significant difference,Early results showed similar recurrence rates and surgical-site complications between the 2 groups.,4936:5035,4865704,27186571,Unavailable
4865704,Induration at the surgical wound,Limberg flap,Mutaf technique,No significant difference,"Rate of surgical site complications such as induration at the surgical wound, wound dehiscence, hematoma formation, and sensory loss were comparable between the 2 groups.",13358:13528,4865704,27186571,Unavailable
4865704,Wound dehiscence,Limberg flap,Mutaf technique,No significant difference,"Rate of surgical site complications such as induration at the surgical wound, wound dehiscence, hematoma formation, and sensory loss were comparable between the 2 groups.",13358:13528,4865704,27186571,Unavailable
4865704,Hematoma formation,Limberg flap,Mutaf technique,No significant difference,"Rate of surgical site complications such as induration at the surgical wound, wound dehiscence, hematoma formation, and sensory loss were comparable between the 2 groups.",13358:13528,4865704,27186571,Unavailable
4865704,Sensory loss,Limberg flap,Mutaf technique,No significant difference,"Rate of surgical site complications such as induration at the surgical wound, wound dehiscence, hematoma formation, and sensory loss were comparable between the 2 groups.",13358:13528,4865704,27186571,Unavailable
4865704,VAS score (day 1),Limberg flap,Mutaf technique,Significantly increased,A significant difference in favor of Mutaf technique was found with regard to VAS scores at postoperative day 1,13789:13870,4865704,27186571,Unavailable
4865704,VAS score (day 10),Limberg flap,Mutaf technique,No significant difference,while no difference in VAS scores were observed at postoperative days 10 and 30.,13789:13870,4865704,27186571,Unavailable
4865704,VAS score (day 30),Limberg flap,Mutaf technique,No significant difference,while no difference in VAS scores were observed at postoperative days 10 and 30.,13789:13870,4865704,27186571,Unavailable
4865704,VAS score (day 1),Limberg flap,Mutaf technique,Significantly increased,"Although a lower visual analogue scale score was found in group 2 at postoperative day 1, seroma persistence, time to withdrawal of surgical drains, and wound healing were more prolonged.",5036:5223,4865704,27186571,Unavailable
4865704,Seroma persistence,Limberg flap,Mutaf technique,Significantly decreased,"Although a lower visual analogue scale score was found in group 2 at postoperative day 1, seroma persistence, time to withdrawal of surgical drains, and wound healing were more prolonged.",5036:5223,4865704,27186571,Unavailable
4865704,Time to withdrawal of surgical drains,Limberg flap,Mutaf technique,Significantly decreased,"Although a lower visual analogue scale score was found in group 2 at postoperative day 1, seroma persistence, time to withdrawal of surgical drains, and wound healing were more prolonged.",5036:5223,4865704,27186571,Unavailable
4865704,Wound healing time,Limberg flap,Mutaf technique,Significantly decreased,"Although a lower visual analogue scale score was found in group 2 at postoperative day 1, seroma persistence, time to withdrawal of surgical drains, and wound healing were more prolonged.",5036:5223,4865704,27186571,Unavailable
4865704,Seroma persistence,Limberg flap,Mutaf technique,Significantly decreased,"However, significant differences were found between the 2 groups in terms of seroma formation, surgical drain removal time, and healing time.",13529:13670,4865704,27186571,Unavailable
4865704,Time to withdrawal of surgical drains,Limberg flap,Mutaf technique,Significantly decreased,"However, significant differences were found between the 2 groups in terms of seroma formation, surgical drain removal time, and healing time.",13529:13670,4865704,27186571,Unavailable
4865704,Wound healing time,Limberg flap,Mutaf technique,Significantly decreased,"However, significant differences were found between the 2 groups in terms of seroma formation, surgical drain removal time, and healing time.",13529:13670,4865704,27186571,Unavailable
4865704,Hospital stay,Limberg flap,Mutaf technique,No significant difference,"The duration of hospital stay was similar between the 2 groups, as were the rates of recurrence at 6 months postoperative.",13877:13999,4865704,27186571,Unavailable
4865704,Recurrence rate,Limberg flap,Mutaf technique,No significant difference,"The duration of hospital stay was similar between the 2 groups, as were the rates of recurrence at 6 months postoperative.",13877:13999,4865704,27186571,Unavailable
3532098,Post-injective pain reaction,Platelet-rich plasma ,Hyaluronic acid ,Significantly increased,"in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039).",5776:5889,3532098,23176112,Unavailable
3532098, EQ-VAS,Platelet-rich plasma ,Hyaluronic acid ,No significant difference,The EQ-VAS presented the same trend with improvements in both groups but without any inter-group difference.,24028:24136,3532098,23176112,Unavailable
3532098,Range of motion,Platelet-rich plasma ,Hyaluronic acid ,No significant difference,ROM and knee circumference measurements were also comparable at the different follow-up times,23485:23578,3532098,23176112,Unavailable
3532098,Knee circumference,Platelet-rich plasma ,Hyaluronic acid ,No significant difference,ROM and knee circumference measurements were also comparable at the different follow-up times,23485:23578,3532098,23176112,Unavailable
3532098,Post-injective pain reaction,Platelet-rich plasma ,Hyaluronic acid ,Significantly increased,"When comparing the two treatments, a significantly higher post-injective pain reaction was observed in the PRP group (p=0.039)",21506:21633,3532098,23176112,Unavailable
3532098,IKDC 6 months,Platelet-rich plasma ,Hyaluronic acid ,No significant difference,"A tendency towards better results for PRP in this patient category is observed at both 6 and 12 months: p = 0.08 and p = 0.07, respectively.",30499:30639,3532098,23176112,Unavailable
3532098,IKDC 12 months,Platelet-rich plasma ,Hyaluronic acid ,No significant difference,"A tendency towards better results for PRP in this patient category is observed at both 6 and 12 months: p = 0.08 and p = 0.07, respectively.",30499:30639,3532098,23176112,Unavailable
3532098,Post-injective pain reaction,Platelet-rich plasma ,Hyaluronic acid ,Significantly increased,The PRP group showed a significantly higher post injective pain reaction (p=0.039),21860:21942,3532098,23176112,Unavailable
3532098,Tegner score,Platelet-rich plasma ,Hyaluronic acid ,No significant difference,"The activity level, evaluated by the Tegner score, also showed a similar improvement for the PRP group (from basal 2.9 ±1.4 to 3.8 ± 1.3 at 12 months of follow-up) and HA group (from basal 2.6 ± 1.2 to 3.4 ± 1.6 at 12 months of follow-up).",24137:24376,3532098,23176112,Unavailable
3532098,KOOS score at 2 months (symptoms),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 6 months (symptoms),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 12 months (symptoms),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 2 months (Pain),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 6 months (Pain),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 12 months (Pain),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 2 months (Activity of daily life),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 6 months (Activity of daily life),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 12 months (Activity of daily life),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 2 months (Sport),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 6 months (Sport),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 12 months (Sport),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 2 months (Quality of life),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 6 months (Quality of life),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3532098,KOOS score at 12 months (Quality of life),Platelet-rich plasma ,Hyaluronic acid ,No significant difference,No statistical difference was reported in any subcategory between groups.,29590:29663,3532098,23176112,Unavailable
3708637,Nausea,Jawarish amla,Placebo,Significantly decreased,"The minor side effects of the incidence of nausea (p&lt;0.001), vomiting (p&lt;0.001), abdominal pain (p&lt;0.001), itching (p&lt;0.001) and burning sensation in feet (p&lt;0.001) were significantly less in Group B than in Group A",18426:18641,3708637,23864996,Unavailable
3708637,Vomiting ,Jawarish amla,Placebo,Significantly decreased,"The minor side effects of the incidence of nausea (p&lt;0.001), vomiting (p&lt;0.001), abdominal pain (p&lt;0.001), itching (p&lt;0.001) and burning sensation in feet (p&lt;0.001) were significantly less in Group B than in Group A",18426:18641,3708637,23864996,Unavailable
3708637,Abdominal pain,Jawarish amla,Placebo,Significantly decreased,"The minor side effects of the incidence of nausea (p&lt;0.001), vomiting (p&lt;0.001), abdominal pain (p&lt;0.001), itching (p&lt;0.001) and burning sensation in feet (p&lt;0.001) were significantly less in Group B than in Group A",18426:18641,3708637,23864996,Unavailable
3708637,Itching ,Jawarish amla,Placebo,Significantly decreased,"The minor side effects of the incidence of nausea (p&lt;0.001), vomiting (p&lt;0.001), abdominal pain (p&lt;0.001), itching (p&lt;0.001) and burning sensation in feet (p&lt;0.001) were significantly less in Group B than in Group A",18426:18641,3708637,23864996,Unavailable
3708637,Burning sensation in feet,Jawarish amla,Placebo,Significantly decreased,"The minor side effects of the incidence of nausea (p&lt;0.001), vomiting (p&lt;0.001), abdominal pain (p&lt;0.001), itching (p&lt;0.001) and burning sensation in feet (p&lt;0.001) were significantly less in Group B than in Group A",18426:18641,3708637,23864996,Unavailable
3708637,Insomnia ,Jawarish amla,Placebo,Significantly decreased,The incidence of insomnia (p&lt;0.001) and body ache (p&lt;0.04) was significantly less in Group B than in Group A.,19491:19600,3708637,23864996,Unavailable
3708637,Body ache,Jawarish amla,Placebo,Significantly decreased,The incidence of insomnia (p&lt;0.001) and body ache (p&lt;0.04) was significantly less in Group B than in Group A.,19491:19600,3708637,23864996,Unavailable
3708637,Creatinine ,Jawarish amla,Placebo,No significant difference,"Serum creatinine and serum uric acid levels after treatment were lower in Group B than in Group A, but the differences were not statistically significant.",20139:20294,3708637,23864996,Unavailable
3708637,Uric acid,Jawarish amla,Placebo,No significant difference,"Serum creatinine and serum uric acid levels after treatment were lower in Group B than in Group A, but the differences were not statistically significant.",20139:20294,3708637,23864996,Unavailable
3708637,ALT ,Jawarish amla,Placebo,Significantly decreased,Group B’s ALT values were significantly lower after treatment than those of Group A (p=0.008),20681:20775,3708637,23864996,Unavailable
3708637,AST ,Jawarish amla,Placebo,Significantly decreased,Group B’s AST values were significantly lower after treatment than those of Group A (p=0.009),20999:21092,3708637,23864996,Unavailable
3708637,Alkaline phosphatase,Jawarish amla,Placebo,Significantly decreased,Group B’s alkaline phosphatase values were significantly lower after treatment than those of Group A (p=0.029),21354:21465,3708637,23864996,Unavailable
3708637,Bilirubin ,Jawarish amla,Placebo,No significant difference,Group B’s total bilirubin values were not significantly lower after treatment than those of Group A,21711:21811,3708637,23864996,Unavailable
3728070,Cure rate (day 42),Winthrop,Coartem,No significant difference,The day 42 genotyping-adjusted cure rate estimates were 97.3% [95% CI: 91.6-99.1] for ASAQ and 94.2% [88.1-97.2] for AL (Kaplan-Meier survival estimates). The difference in day 42 cure rates was −3.1% [upper limit 95% CI: 1.2%].,8307:8367,3728070,23866774,Unavailable
3728070,Parasite clearance (day 3),Winthrop,Coartem,No significant difference,Parasite clearance was 100% (ASAQ) and 99.3% (AL) on day 3.,8307:8367,3728070,23866774,Unavailable
3728070,Probability to remain free of re-infection,Winthrop,Coartem,Significantly decreased,The probability to remain free of re-infection was 0.55 [95% CI: 0.46-0.63] (ASAQ) and 0.66 [0.57-0.73] (AL) (p = 0.017).,8307:8367,3728070,23866774,Unavailable
3728070,Cure rate (day 42),Winthrop,Coartem,No significant difference,"The cure rate difference (AL-ASAQ) was −3.1% with an upper limit 95% CI of 1.2%, demonstrating non-inferiority of ASAQ to AL.",8307:8367,3728070,23866774,Unavailable
3728070,Cure rate (day 28),Winthrop,Coartem,No significant difference,Day 28 genotyping-adjusted cure rate estimates were 99.3% [95.1-99.9] (ASAQ) and 97.9% [93.6-99.3] (AL),54483:54587,3728070,23866774,Unavailable
3728070,Parasite clearance (day 2),Winthrop,Coartem,No significant difference,Day 2 parasite clearance was 98% in both treatment arms,55330:55385,3728070,23866774,Unavailable
3728070,Probability to remain free of re-infection,Winthrop,Coartem,Significantly decreased,"The Kaplan Meier estimated probability to remain free of re-infection was 0.55 [95% CI 0.46-0.63] in the ASAQ arm and 0.66 [0.57-0.73] in the AL arm (log-rank test, p = 0.017)",54940:55116,3728070,23866774,Unavailable
3685784,Pain duration (1 month),Shirazi Thymus Vulgaris ,Ibuprofen,No significant difference,Pain duration at the first and second month of treatment was also similar between two groups.,4263:4356,3685784,23798928,Unavailable
3685784,Pain duration (2 months),Shirazi Thymus Vulgaris ,Ibuprofen,No significant difference,Pain duration at the first and second month of treatment was also similar between two groups.,4263:4356,3685784,23798928,Unavailable
3685784,Pain severity (2 months),Shirazi Thymus Vulgaris ,Ibuprofen,No significant difference,There was no significant difference in pain score between groups at the second month of intervention (P&lt;0.54).,12922:13049,3685784,23798928,Unavailable
3685784,Pain duration (2 months),Shirazi Thymus Vulgaris ,Ibuprofen,No significant difference,Pain duration at second month of treatment was similar between groups (P&lt;0.62).,13050:13149,3685784,23798928,Unavailable
3685784,Pain severity (1 month),Shirazi Thymus Vulgaris ,Ibuprofen,No significant difference,There was no statistically significant decrease in pain score and pain duration in the women who received classic treatment compared to those in herbal group.,4263:4356,3685784,23798928,Unavailable
3685784,Pain severity (2 months),Shirazi Thymus Vulgaris ,Ibuprofen,No significant difference,There was no statistically significant decrease in pain score and pain duration in the women who received classic treatment compared to those in herbal group.,4263:4356,3685784,23798928,Unavailable
3685784,Pain duration (1 month),Shirazi Thymus Vulgaris ,Ibuprofen,No significant difference,There was no statistically significant decrease in pain score and pain duration in the women who received classic treatment compared to those in herbal group.,4263:4356,3685784,23798928,Unavailable
3685784,Pain duration (2 months),Shirazi Thymus Vulgaris ,Ibuprofen,No significant difference,There was no statistically significant decrease in pain score and pain duration in the women who received classic treatment compared to those in herbal group.,4263:4356,3685784,23798928,Unavailable
3681558,Alzheimer’s Disease Cooperative Study-Activities of Daily Living improvement,Onepezil 23 mg/d,Onepezil 10mg/d,Significantly increased,"Donepezil 23 mg/d provided statistically significant incremental cognitive benefits over donepezil 10 mg/d irrespective of baseline functional severity, measured by scores on the Alzheimer’s Disease Cooperative Study-Activities of Daily Living-severe version (P &lt; 0.05).",24447:24645,3681558,23742728,Unavailable
3681558,Alzheimer’s Disease Cooperative Study-Activities of Daily Living improvement,Onepezil 23 mg/d,Onepezil 10mg/d,Significantly increased,Donepezil 23 mg/d provided statistically significant incremental cognitive benefits (P &lt; 0.05 for both subgroups) over donepezil 10 mg/d irrespective of baseline functional severity,24447:24645,3681558,23742728,Unavailable
5789503,Postextubation laryngospasm,IV lidocaine,Placebo,Significantly decreased,"The incidence of postextubation laryngospasm was 19.5% in the placebo group and 0% in the treatment (lidocaine) group; this difference was statistically significant (P = 0.017; 95% confidence interval, 4.6% to 36.0%).",3697:3931,5789503,29416449,Unavailable
5789503,Postextubation laryngospasm,IV lidocaine,Placebo,Significantly decreased,"The incidence of postextubation laryngospasm per protocol approach was 19.5% in the placebo group and 0% in the lidocaine group. There was a 19.5% reduction in the incidence of laryngospasm after administering IV lidocaine (P = 0.017; 95% confidence interval [CI], 4.6% to 36.0%); this difference was statistically significant according to the comparison of proportions",18224:18610,5789503,29416449,Unavailable
3714483,HbA1c,Gastric bypass,Intensive medical therapy,Significantly decreased,"with a mean HbA1c of 6.7 ± 1.2% for gastric bypass, 7.1 ± 0.8% for sleeve gastrectomy, and 8.4 ± 2.3% for IMT (P &lt; 0.05 for each surgical group versus IMT).",20508:20661,3714483,23439632,Unavailable
3714483,HbA1c,Sleeve gastrectomy,Intensive medical therapy,Significantly decreased,"with a mean HbA1c of 6.7 ± 1.2% for gastric bypass, 7.1 ± 0.8% for sleeve gastrectomy, and 8.4 ± 2.3% for IMT (P &lt; 0.05 for each surgical group versus IMT).",6548:6733,3714483,23439632,Unavailable
3714483,Body fat (truncal fat),Gastric bypass,Sleeve gastrectomy,Significantly decreased,"Reduction in body fat was similar for both surgery groups, with greater absolute reduction in truncal fat in gastric bypass versus sleeve gastrectomy (−16 vs. −10%; P = 0.04).",22120:22260,3714483,23439632,Unavailable
3714483,β-Cell function,Gastric bypass,Intensive medical therapy,Significantly increased,"β-Cell function (oral disposition index) increased 5.8-fold in gastric bypass from baseline, was markedly greater than IMT (P = 0.001), and was not different between sleeve gastrectomy versus IMT (P = 0.30).",20508:20661,3714483,23439632,Unavailable
3714483,β-Cell function,Sleeve gastrectomy,Intensive medical therapy,No significant difference,"β-Cell function (oral disposition index) increased 5.8-fold in gastric bypass from baseline, was markedly greater than IMT (P = 0.001), and was not different between sleeve gastrectomy versus IMT (P = 0.30).",7094:7335,3714483,23439632,Unavailable
3714483,HbA1c,Gastric bypass,Intensive medical therapy,Significantly decreased,the gastric bypass group had significantly greater reduction in fasting glucose and HbA1c levels compared with IMT (P &lt; 0.05),20508:20661,3714483,23439632,Unavailable
3714483,Fasting glucose,Gastric bypass,Intensive medical therapy,Significantly decreased,the gastric bypass group had significantly greater reduction in fasting glucose and HbA1c levels compared with IMT (P &lt; 0.05),20508:20661,3714483,23439632,Unavailable
3714483, Need of insulin,Gastric bypass,Intensive medical therapy,Significantly decreased,The percent of patients using insulin at 24 months was markedly lower in gastric bypass and sleeve gastrectomy groups as compared with IMT.,20884:21023,3714483,23439632,Unavailable
3714483, Need of insulin,Sleeve gastrectomy,Intensive medical therapy,Significantly decreased,The percent of patients using insulin at 24 months was markedly lower in gastric bypass and sleeve gastrectomy groups as compared with IMT.,20884:21023,3714483,23439632,Unavailable
3714483,HDL,Gastric bypass,Intensive medical therapy,Significantly increased,Large increases in HDL cholesterol and reductions in levels of triglycerides and high-sensitivity C-reactive protein were noted in both surgery groups as compared with the IMT group.,21023:21206,3714483,23439632,Unavailable
3714483,HDL,Sleeve gastrectomy,Intensive medical therapy,Significantly increased,Large increases in HDL cholesterol and reductions in levels of triglycerides and high-sensitivity C-reactive protein were noted in both surgery groups as compared with the IMT group.,21023:21206,3714483,23439632,Unavailable
3714483,Triglycerides ,Gastric bypass,Intensive medical therapy,Significantly decreased,Large increases in HDL cholesterol and reductions in levels of triglycerides and high-sensitivity C-reactive protein were noted in both surgery groups as compared with the IMT group.,21023:21206,3714483,23439632,Unavailable
3714483,Triglycerides ,Sleeve gastrectomy,Intensive medical therapy,Significantly decreased,Large increases in HDL cholesterol and reductions in levels of triglycerides and high-sensitivity C-reactive protein were noted in both surgery groups as compared with the IMT group.,21023:21206,3714483,23439632,Unavailable
3714483, C-reactive protein,Gastric bypass,Intensive medical therapy,Significantly decreased,Large increases in HDL cholesterol and reductions in levels of triglycerides and high-sensitivity C-reactive protein were noted in both surgery groups as compared with the IMT group.,21023:21206,3714483,23439632,Unavailable
3714483, C-reactive protein,Sleeve gastrectomy,Intensive medical therapy,Significantly decreased,Large increases in HDL cholesterol and reductions in levels of triglycerides and high-sensitivity C-reactive protein were noted in both surgery groups as compared with the IMT group.,21023:21206,3714483,23439632,Unavailable
3714483,Total body weight (12 months),Sleeve gastrectomy,Intensive medical therapy,Significantly decreased,Greater total body weight loss occurred after bariatric procedures compared with IMT at 12 months and was maintained at 24-month follow-up.,22120:22260,3714483,23439632,Unavailable
3714483,Total body weight (12 months),Gastric bypass,Intensive medical therapy,Significantly decreased,Greater total body weight loss occurred after bariatric procedures compared with IMT at 12 months and was maintained at 24-month follow-up.,22260:22430,3714483,23439632,Unavailable
3714483,Total body weight (24 months),Sleeve gastrectomy,Intensive medical therapy,Significantly decreased,Greater total body weight loss occurred after bariatric procedures compared with IMT at 12 months and was maintained at 24-month follow-up.,22260:22430,3714483,23439632,Unavailable
3714483,Total body weight (24 months),Gastric bypass,Intensive medical therapy,Significantly decreased,Greater total body weight loss occurred after bariatric procedures compared with IMT at 12 months and was maintained at 24-month follow-up.,22260:22430,3714483,23439632,Unavailable
3714483,Total body weight (24 months),Gastric bypass,Sleeve gastrectomy,No significant difference,"A similar reduction in body weight, BMI, and absolute change in total body fat percent was observed between the sleeve gastrectomy and gastric bypass group at 24 months.",22260:22430,3714483,23439632,Unavailable
3714483,BMI,Gastric bypass,Sleeve gastrectomy,No significant difference,"A similar reduction in body weight, BMI, and absolute change in total body fat percent was observed between the sleeve gastrectomy and gastric bypass group at 24 months.",22260:22430,3714483,23439632,Unavailable
3714483,Total body fat,Gastric bypass,Sleeve gastrectomy,No significant difference,"A similar reduction in body weight, BMI, and absolute change in total body fat percent was observed between the sleeve gastrectomy and gastric bypass group at 24 months.",22260:22430,3714483,23439632,Unavailable
3714483,Body fat (truncal fat),Gastric bypass,Sleeve gastrectomy,Significantly decreased,"However, despite similar weight loss, the absolute reduction in percent truncal fat was greater in the gastric bypass versus sleeve gastrectomy group (−16% vs. −10%; P = 0.04).",22260:22430,3714483,23439632,Unavailable
3714483,Leptin levels,Gastric bypass,Intensive medical therapy,Significantly decreased,"Leptin levels reduced markedly after surgical weight loss, especially gastric bypass, compared with IMT.",22624:22728,3714483,23439632,Unavailable
3714483,AUC for insulin secretion rate,Gastric bypass,Intensive medical therapy,Significantly increased,The average AUC for insulin secretion rate at 24 months was significantly greater with both gastric bypass (4.4 ± 4 pmol/min) and sleeve gastrectomy (3.3 ± 2.5 pmol/min) than IMT (1.7 ± 2.4 pmol/min; both P &lt; 0.01).,23879:24111,3714483,23439632,Unavailable
3714483,AUC for insulin secretion rate,Sleeve gastrectomy,Intensive medical therapy,Significantly increased,The average AUC for insulin secretion rate at 24 months was significantly greater with both gastric bypass (4.4 ± 4 pmol/min) and sleeve gastrectomy (3.3 ± 2.5 pmol/min) than IMT (1.7 ± 2.4 pmol/min; both P &lt; 0.01).,23879:24111,3714483,23439632,Unavailable
3714483,β-Cell function,Gastric bypass,Intensive medical therapy,Significantly increased,The absolute change in median values for pancreatic β-cell function (oral disposition index) at 24 months was markedly greater in gastric bypass than IMT (0.196 [quartile 1: 0.14; quartile 3: 0.29) vs. 0.027 [quartile 1: −0.011; quartile 3: 0.074]; P = 0.001),25487:25764,3714483,23439632,Unavailable
3714483,β-Cell function,Sleeve gastrectomy,Intensive medical therapy,No significant difference,but not different between sleeve gastrectomy and medical therapy (0.058 [quartile 1: −0.009; quartile 3: 0.416] vs. 0.027 [quartile 1: −0.011; quartile 3: 0.074]; P = 0.30).,25763:25954,3714483,23439632,Unavailable
3714483,Fasting glucagon (12 months),Gastric bypass ,Intensive medical therapy,No significant difference,"At 12 months, median glucagon levels tended to be lower in gastric bypass versus IMT (46 vs. 77 pg/mL; P = 0.07) and were reduced in sleeve gastrectomy versus IMT (38 vs. 77 pg/mL; P &lt; 0.02).",26969:27194,3714483,23439632,Unavailable
3714483,Fasting glucagon (12 months),Sleeve gastrectomy,Intensive medical therapy,Significantly decreased,"At 12 months, median glucagon levels tended to be lower in gastric bypass versus IMT (46 vs. 77 pg/mL; P = 0.07) and were reduced in sleeve gastrectomy versus IMT (38 vs. 77 pg/mL; P &lt; 0.02).",26969:27194,3714483,23439632,Unavailable
3714483,Fasting glucagon (24 months),Gastric bypass ,Intensive medical therapy,No significant difference,"However, at 24 months fasting glucagon levels were not different among the three groups (∼60 pg/mL).",27195:27295,3714483,23439632,Unavailable
3714483,Fasting glucagon  (24 months),Sleeve gastrectomy,Intensive medical therapy,No significant difference,"However, at 24 months fasting glucagon levels were not different among the three groups (∼60 pg/mL).",27195:27295,3714483,23439632,Unavailable
3714483,Fasting glucagon (24 months),Gastric bypass ,Sleeve gastrectomy,No significant difference,"However, at 24 months fasting glucagon levels were not different among the three groups (∼60 pg/mL).",27195:27295,3714483,23439632,Unavailable
3714483,Postprandial glucagon,Gastric bypass ,Intensive medical therapy,Significantly increased,"Postprandial glucagon levels reduced in all three groups at 24 months from baseline values, but postprandial glucagon levels in gastric bypass were higher (77 pg/mL) than IMT (64 pg/mL; P &lt; 0.05) and not different between sleeve gastrectomy (65 pg/mL) and IMT.",27305:27582,3714483,23439632,Unavailable
3714483,Postprandial glucagon,Sleeve gastrectomy,Intensive medical therapy,No significant difference,"Postprandial glucagon levels reduced in all three groups at 24 months from baseline values, but postprandial glucagon levels in gastric bypass were higher (77 pg/mL) than IMT (64 pg/mL; P &lt; 0.05) and not different between sleeve gastrectomy (65 pg/mL) and IMT.",27305:27582,3714483,23439632,Unavailable
3714483,GIP response to meal ,Gastric bypass ,Intensive medical therapy,Significantly decreased,"In contrast, median levels of GIP in response to mixed meal were reduced 24 months after gastric bypass (13.5 vs. 30.7 pmol/L; P &lt; 0.01) and were significantly different (P &lt; 0.01) from sleeve gastrectomy (36.9 pmol/L) and IMT (29.7 pmol/L).",28315:28717,3714483,23439632,Unavailable
3714483,GIP response to meal ,Gastric bypass ,Sleeve gastrectomy ,Significantly decreased,"In contrast, median levels of GIP in response to mixed meal were reduced 24 months after gastric bypass (13.5 vs. 30.7 pmol/L; P &lt; 0.01) and were significantly different (P &lt; 0.01) from sleeve gastrectomy (36.9 pmol/L) and IMT (29.7 pmol/L).",28315:28717,3714483,23439632,Unavailable
3714483,GLP-1 response to meal,Gastric bypass ,Intensive medical therapy,Significantly increased,Both surgical groups had an overall increase in the incremental change in median GLP-1 response to mixed meal as compared with IMT at 24 months (gastric bypass 10.0 pmol/L [quartile 1: 5.2; quartile 3: 15.2] vs. sleeve gastrectomy 4.5 pmol/L [quartile 1: 2.9; quartile 3: 8.2]; P = 0.07; vs. IMT −0.4 pmol/L [quartile 1: −1.8; quartile 3: 1.1]; P &lt; 0.001 for both).,28315:28717,3714483,23439632,Unavailable
3714483,GLP-1 response to meal,Sleeve gastrectomy ,Intensive medical therapy,Significantly increased,Both surgical groups had an overall increase in the incremental change in median GLP-1 response to mixed meal as compared with IMT at 24 months (gastric bypass 10.0 pmol/L [quartile 1: 5.2; quartile 3: 15.2] vs. sleeve gastrectomy 4.5 pmol/L [quartile 1: 2.9; quartile 3: 8.2]; P = 0.07; vs. IMT −0.4 pmol/L [quartile 1: −1.8; quartile 3: 1.1]; P &lt; 0.001 for both).,28315:28717,3714483,23439632,Unavailable
3685780,Systolic blood pressure,Aspart,Regular insulin ,No significant difference,The mean difference of both systolic (P = 0.65) and diastolic blood pressure (P = 0.56) of three groups were compared and found to be non-significant.,16155:16339,3685780,23798924,Unavailable
3685780,Systolic blood pressure,Lispro,Regular insulin ,No significant difference,The mean difference of both systolic (P = 0.65) and diastolic blood pressure (P = 0.56) of three groups were compared and found to be non-significant.,16155:16339,3685780,23798924,Unavailable
3685780,Systolic blood pressure,Aspart,Lispro,No significant difference,The mean difference of both systolic (P = 0.65) and diastolic blood pressure (P = 0.56) of three groups were compared and found to be non-significant.,16155:16339,3685780,23798924,Unavailable
3685780,Diastolic blood pressure,Aspart,Regular insulin ,No significant difference,The mean difference of both systolic (P = 0.65) and diastolic blood pressure (P = 0.56) of three groups were compared and found to be non-significant.,16155:16339,3685780,23798924,Unavailable
3685780,Diastolic blood pressure,Lispro,Regular insulin ,No significant difference,The mean difference of both systolic (P = 0.65) and diastolic blood pressure (P = 0.56) of three groups were compared and found to be non-significant.,16155:16339,3685780,23798924,Unavailable
3685780,Diastolic blood pressure,Aspart,Lispro,No significant difference,The mean difference of both systolic (P = 0.65) and diastolic blood pressure (P = 0.56) of three groups were compared and found to be non-significant.,16155:16339,3685780,23798924,Unavailable
3685780,Fasting blood glucose,Aspart,Regular insulin ,Significantly decreased,Analysis of the mean difference of both fasting and postprandial blood glucose of three groups reveals that change in aspart group (P = 0.01) was superior to RHI and lispro group.,17135:17331,3685780,23798924,Unavailable
3685780,Fasting blood glucose,Aspart,Lispro,Significantly decreased,Analysis of the mean difference of both fasting and postprandial blood glucose of three groups reveals that change in aspart group (P = 0.01) was superior to RHI and lispro group.,17135:17331,3685780,23798924,Unavailable
3685780,Postprandial blood glucose,Aspart,Regular insulin ,Significantly decreased,Analysis of the mean difference of both fasting and postprandial blood glucose of three groups reveals that change in aspart group (P = 0.01) was superior to RHI and lispro group.,17135:17331,3685780,23798924,Unavailable
3685780,Postprandial blood glucose,Aspart,Lispro,Significantly decreased,Analysis of the mean difference of both fasting and postprandial blood glucose of three groups reveals that change in aspart group (P = 0.01) was superior to RHI and lispro group.,17135:17331,3685780,23798924,Unavailable
3685780,Fasting blood glucose,Aspart,Regular insulin ,Significantly decreased,"Fasting, postprandial blood glucose and HbA1c were decreased in all three groups significantly but change in aspart group was superior (P = 0.01).",5101:5276,3685780,23798924,Unavailable
3685780,Fasting blood glucose,Aspart,Lispro,Significantly decreased,"Fasting, postprandial blood glucose and HbA1c were decreased in all three groups significantly but change in aspart group was superior (P = 0.01).",5101:5275,3685780,23798924,Unavailable
3685780,Postprandial blood glucose,Aspart,Regular insulin ,Significantly decreased,"Fasting, postprandial blood glucose and HbA1c were decreased in all three groups significantly but change in aspart group was superior (P = 0.01).",5101:5275,3685780,23798924,Unavailable
3685780,Postprandial blood glucose,Aspart,Lispro,Significantly decreased,"Fasting, postprandial blood glucose and HbA1c were decreased in all three groups significantly but change in aspart group was superior (P = 0.01).",5101:5275,3685780,23798924,Unavailable
3685780,Glycosylated hemoglobin,Aspart,Regular insulin ,Significantly decreased,"When mean differences were compared, it was found significant (P = 0.01) and the change in aspart group was superior to RHI group (P &lt; 0.05).",17609:17784,3685780,23798924,Unavailable
3685780,Glycosylated hemoglobin,Aspart,Regular insulin ,Significantly decreased,"Fasting, postprandial blood glucose and HbA1c were decreased in all three groups significantly but change in aspart group was superior (P = 0.01).",5101:5276,3685780,23798924,Unavailable
3685780,Triglycerides ,Lispro,Regular insulin ,Significantly decreased,The mean difference of triglyceride level of three groups was found to be significant (P = 0.01) and the change in lispro group was superior to RHI groups (P &lt; 0.01).,18100:18300,3685780,23798924,Unavailable
3685780,Triglycerides ,Lispro,Regular insulin ,Significantly decreased,Triglyceride was significantly better controlled by lispro (P &lt; 0.01),5276:5363,3685780,23798924,Unavailable
3685780,Total cholesterol,Aspart,Regular insulin ,Significantly decreased,"When mean differences were compared, it was found significant (P = 0.038) and the change in aspart group was superior to RHI group (P &lt; 0.05).",18484:18660,3685780,23798924,Unavailable
3685780,Total cholesterol,Aspart,Regular insulin ,Significantly decreased,aspart insulin was superior to decrease total cholesterol and LDL (P &lt; 0.05).,5371:5469,3685780,23798924,Unavailable
3685780,LDL cholesterol,Aspart,Regular insulin ,Significantly decreased,"When mean differences were compared, it was found significant (P = 0.039) and the change in aspart group was superior to RHI group (P &lt; 0.05).",18833:19009,3685780,23798924,Unavailable
3685780,LDL cholesterol,Aspart,Regular insulin ,Significantly decreased,aspart insulin was superior to decrease total cholesterol and LDL (P &lt; 0.05).,5370:5469,3685780,23798924,Unavailable
3685780,HDL cholesterol,Aspart,Regular insulin ,No significant difference,The mean difference of both HDL and VLDL cholesterol of three groups were compared and found to be non-significant.,19281:19396,3685780,23798924,Unavailable
3685780,HDL cholesterol,Lispro,Regular insulin ,No significant difference,The mean difference of both HDL and VLDL cholesterol of three groups were compared and found to be non-significant.,19281:19396,3685780,23798924,Unavailable
3685780,HDL cholesterol,Aspart,Lispro,No significant difference,The mean difference of both HDL and VLDL cholesterol of three groups were compared and found to be non-significant.,19281:19396,3685780,23798924,Unavailable
3685780,VLDL cholesterol,Aspart,Regular insulin ,No significant difference,The mean difference of both HDL and VLDL cholesterol of three groups were compared and found to be non-significant.,19281:19396,3685780,23798924,Unavailable
3685780,VLDL cholesterol,Lispro,Regular insulin ,No significant difference,The mean difference of both HDL and VLDL cholesterol of three groups were compared and found to be non-significant.,19281:19396,3685780,23798924,Unavailable
3685780,VLDL cholesterol,Aspart,Lispro,No significant difference,The mean difference of both HDL and VLDL cholesterol of three groups were compared and found to be non-significant.,19281:19396,3685780,23798924,Unavailable
3685780,Potassium loss,Aspart,Regular insulin ,Significantly decreased,"When mean differences were compared, it was found significant (P = 0.004) and degree of potassium loss was significantly more with RHI in comparison to aspart and lispro group.",19732:19925,3685780,23798924,Unavailable
3685780,Potassium loss,Lispro,Regular insulin ,Significantly decreased,"When mean differences were compared, it was found significant (P = 0.004) and degree of potassium loss was significantly more with RHI in comparison to aspart and lispro group.",19732:19925,3685780,23798924,Unavailable
3685780,Potassium loss,Aspart,Regular insulin ,Significantly decreased,The extent of potassium loss was significantly more with RHI (P = 0.004) than others.,5469:5575,3685780,23798924,Unavailable
3685780,Potassium loss,Lispro,Regular insulin ,Significantly decreased,The extent of potassium loss was significantly more with RHI (P = 0.004) than others.,5469:5574,3685780,23798924,Unavailable
3685780,High sensitivity CRP,Aspart,Regular insulin ,Significantly decreased,The mean difference of hsCRP level of three groups was found to be significant (P = 0.017) and the change in aspart (P &lt; 0.05) and lispro group (P &lt; 0.05) was superior to RHI group,20221:20456,3685780,23798924,Unavailable
3685780,High sensitivity CRP,Lispro,Regular insulin ,Significantly decreased,The mean difference of hsCRP level of three groups was found to be significant (P = 0.017) and the change in aspart (P &lt; 0.05) and lispro group (P &lt; 0.05) was superior to RHI group,20221:20455,3685780,23798924,Unavailable
3685780,High sensitivity CRP,Aspart,Regular insulin ,Significantly decreased,CRP-lowering effect (P = 0.017) and decrease in UKPDS risk scoring (P = 0.019) in aspart and lispro group was superior to RHI group.,5575:5741,3685780,23798924,Unavailable
3685780,High sensitivity CRP,Lispro,Regular insulin ,Significantly decreased,CRP-lowering effect (P = 0.017) and decrease in UKPDS risk scoring (P = 0.019) in aspart and lispro group was superior to RHI group.,5575:5741,3685780,23798924,Unavailable
3685780,UKPDS ,Aspart,Regular insulin ,Significantly decreased,"When mean differences were compared, it was found significant (P = 0.019) and the change in aspart and lispro group was superior to RHI group [Table 3].",20722:20930,3685780,23798924,Unavailable
3685780,UKPDS ,Lispro,Regular insulin ,Significantly decreased,"When mean differences were compared, it was found significant (P = 0.019) and the change in aspart and lispro group was superior to RHI group [Table 3].",20722:20930,3685780,23798924,Unavailable
3685780,UKPDS ,Aspart,Regular insulin ,Significantly decreased,decrease in UKPDS risk scoring (P = 0.019) in aspart and lispro group was superior to RHI group.,5628:5741,3685780,23798924,Unavailable
3685780,UKPDS ,Lispro,Regular insulin ,Significantly decreased,decrease in UKPDS risk scoring (P = 0.019) in aspart and lispro group was superior to RHI group.,5628:5741,3685780,23798924,Unavailable
3640892,Stress/overload levels (overall),Stress coping strategy,Control,Significantly decreased,"Participants in the intervention group reported significantly less stress/overload levels compared to the control group (mean difference: -0.6 (95% CI −1.3, -0.1), p=0.04).",25902:26196,3640892,23607331,Unavailable
3640892,Leadership statements,Stress coping strategy,Control,No significant difference,"Leadership statements did not differ between groups,",5518:5570,3640892,23607331,Unavailable
3640892,Hands-on time,Stress coping strategy,Control,No significant difference,"Hands-on time was longer in the intervention- group, but the difference was not statistically significant (difference 5.5 (95% CI −3.1, 14.2), p=0.2)",5637:5787,3640892,23607331,Unavailable
3640892,Time to start CPR,Stress coping strategy,Control,No significant difference,"there were no differences in time to start CPR (difference −1.4 (95% CI −8.4, 5.7), p=0.71).",5788:5881,3640892,23607331,Unavailable
3640892,Stress/overload levels (overall),Stress coping strategy,Control,Significantly decreased,"participants in the intervention group reported significantly smaller amounts of perceived stress/overload compared to the control group (difference of mean perceived stress: -0.6 (95% CI −1.3, -0.1), p=0.04)",25902:26196,3640892,23607331,Unavailable
3640892,Stress/overload levels (during resuscitation),Stress coping strategy,Control,No significant difference,"Stress/overload during resuscitation, mean (SE)15.9 (±0.34)15.6 (±0.34)0.2 (95% CI −0.7, -1.2)0.66",25902:26196,3640892,23607331,Unavailable
3640892,Stress/overload levels (when patient awakes),Stress coping strategy,Control,No significant difference,"Stress/overload when patients awakes, mean (SE)9.3 (±0.41)10.4 (±0.48)−1.0 (95% CI −2.3, 0.2)0.1",26261:26553,3640892,23607331,Unavailable
3640892,Stress/overload levels (during debriefing),Stress coping strategy,Control,No significant difference,"tress/overload during debriefing, mean (SE)7.4 (±0.36)7.8 (±0.36)−0.4 (95% CI −1.4, 0.6)0.42",26619:NaN,3640892,23607331,Unavailable
3640892,Hands-on time,Stress coping strategy,Control,No significant difference,"The intervention group had about 10% more hands-on time in the first 120 sec compared to the control group; this difference was, however, not statistically significant (57.8 sec (±3.28) vs 52.2 sec (±2.86), difference 5.5 (95% CI −3.1, 14.2), p=0.2).",30422:30673,3640892,23607331,Unavailable
3640892,Leadership statements,Stress coping strategy,Control,No significant difference,No differences between the groups also emerged for the number of leadership statements.,30894:30983,3640892,23607331,Unavailable
3640892,Time to start CPR,Stress coping strategy,Control,No significant difference,There were no differences between the two randomisation groups with regard to time to start CPR,30894:30983,3640892,23607331,Unavailable
3640892,Time to chest compression,Stress coping strategy,Control,No significant difference,"There were no differences between the two randomisation groups with regard to time to start CPR, particularly time to chest compression, ventilation and defibrillation",30673:30841,3640892,23607331,Unavailable
3640892,Time to ventilation ,Stress coping strategy,Control,No significant difference,"There were no differences between the two randomisation groups with regard to time to start CPR, particularly time to chest compression, ventilation and defibrillation",30673:30841,3640892,23607331,Unavailable
3640892,Time to defibrillation ,Stress coping strategy,Control,No significant difference,"There were no differences between the two randomisation groups with regard to time to start CPR, particularly time to chest compression, ventilation and defibrillation",30673:30841,3640892,23607331,Unavailable
3640892,Time to start CPR,Stress coping strategy,Control,No significant difference,"Time to first meaningful measure (sec), mean (SE)42 (±2.63)43.3 (±2.43)−1.4 (95% CI −8.4, 5.7)0.71",32642:32943,3640892,23607331,Unavailable
3640892,Time to chest compression,Stress coping strategy,Control,No significant difference,"Time to chest compressions (sec), mean (SE)57.3 (±3.61)60 (±3.26)−2.8 (95% CI −12.4, 6.9)0.57",33011:33301,3640892,23607331,Unavailable
3640892,Time to ventilation ,Stress coping strategy,Control,No significant difference,"Time to ventilation (sec), mean (SE)67.6 (±3.68)66.3 (±3.44)1.4 (95% CI −8.6, 11.3)0.79",33370:33653,3640892,23607331,Unavailable
3640892,Time to defibrillation ,Stress coping strategy,Control,No significant difference,"Time to defibrillation (sec), mean (SE)69.7 (±3.93)66 (±3.84)3.7 (95% CI −7.2, 14.6)0.54",33722:34006,3640892,23607331,Unavailable
3640892,Leadership statements,Stress coping strategy,Control,No significant difference,"Leadership statements, mean (SE)10.4 (±0.59)10.9 (±0.56)−0.5 (95% CI −2.1, 1.1)0.54",34079:34365,3640892,23607331,Unavailable
3640892,Hands-on time,Stress coping strategy,Control,No significant difference,"Hands-on time (sec), mean (SE)57.8 (±3.28)52.2 (±2.86)5.5 (95% CI −3.1, 14.2)0.2",32286:32569,3640892,23607331,Unavailable
5951773,Short-term knowledge retention,Virtual Patient-based training session,Video-recorded standard lecture,No significant difference,"However, no significant differences in short-term and long-term knowledge retention were observed between the two teaching methods.",6026:6157,5951773,29599421,Unavailable
5951773,Long-term knowledge retention,Virtual Patient-based training session,Video-recorded standard lecture,No significant difference,"However, no significant differences in short-term and long-term knowledge retention were observed between the two teaching methods.",6026:6157,5951773,29599421,Unavailable
5951773,Short-term knowledge retention,Virtual Patient-based training session,Video-recorded standard lecture,No significant difference,"The repeated-measures analysis of variance showed that there was no significant difference in the knowledge acquisition test (Test 1) between the VP and L groups, implying similar short-term retention in both groups.",19766:19982,5951773,29599421,Unavailable
5951773,Long-term knowledge retention,Virtual Patient-based training session,Video-recorded standard lecture,No significant difference,"However, no significant differences in the long-term retention test (Test 2) were observed between the two groups.",19766:19982,5951773,29599421,Unavailable
3375195,Weight regain,Tapas Acupressure Technique,Social-support group meetings,No significant difference,"In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p &lt; 0.097)",6007:6206,3375195,22417316,Unavailable
3375195,Change in depression,Tapas Acupressure Technique,Social-support group meetings,No significant difference,Tests of between- arm differences for secondary outcomes were also not significant.,6207:6291,3375195,22417316,Unavailable
3375195,Stress,Tapas Acupressure Technique,Social-support group meetings,No significant difference,Tests of between- arm differences for secondary outcomes were also not significant.,6207:6291,3375195,22417316,Unavailable
3375195,Insomnia,Tapas Acupressure Technique,Social-support group meetings,No significant difference,Tests of between- arm differences for secondary outcomes were also not significant.,6207:6291,3375195,22417316,Unavailable
3375195,Quality of life,Tapas Acupressure Technique,Social-support group meetings,No significant difference,Tests of between- arm differences for secondary outcomes were also not significant.,6207:6291,3375195,22417316,Unavailable
3375195,Weight regain,Tapas Acupressure Technique,Social-support group meetings,No significant difference,"The adjusted mean difference between the two arms (TAT-SS = - 1.24 kg (se 0.74)) was not significant (F[1,279] = 2.79, p &lt; .098).",35649:35779,3375195,22417316,Unavailable
3375195,Change in depression,Tapas Acupressure Technique,Social-support group meetings,No significant difference,"no significant difference was observed between treatments among the secondary outcomes of change from 0-M to 12 M in depression, stress, insomnia, or quality of life (all p &gt; .5",50764:50941,3375195,22417316,Unavailable
3375195,Stress,Tapas Acupressure Technique,Social-support group meetings,No significant difference,"no significant difference was observed between treatments among the secondary outcomes of change from 0-M to 12 M in depression, stress, insomnia, or quality of life (all p &gt; .5",50764:50941,3375195,22417316,Unavailable
3375195,Insomnia,Tapas Acupressure Technique,Social-support group meetings,No significant difference,"no significant difference was observed between treatments among the secondary outcomes of change from 0-M to 12 M in depression, stress, insomnia, or quality of life (all p &gt; .5,",50764:50942,3375195,22417316,Unavailable
3375195,Quality of life,Tapas Acupressure Technique,Social-support group meetings,No significant difference,"no significant difference was observed between treatments among the secondary outcomes of change from 0-M to 12 M in depression, stress, insomnia, or quality of life (all p &gt; .5",50764:50941,3375195,22417316,Unavailable
3375195,Change in depression,Tapas Acupressure Technique,Social-support group meetings,No significant difference,"PHQ8 (Depression)	-0.16	0.64	-1.52	1.21	0.8112",51446:51607,3375195,22417316,Unavailable
3375195,Stress,Tapas Acupressure Technique,Social-support group meetings,No significant difference,"PSS (Stress)	-0.55	0.88	-2.37	1.27	0.5405",51677:NaN,3375195,22417316,Unavailable
3375195,Insomnia,Tapas Acupressure Technique,Social-support group meetings,No significant difference,"ISI (Insomnia)	-0.13	0.60	-1.38	1.12	0.8326",51903:52061,3375195,22417316,Unavailable
3375195,Quality of life,Tapas Acupressure Technique,Social-support group meetings,No significant difference,"Q-les-Q-sf (Quality of Life)	-0.52	1.77	-4.23	3.19	0.7726",52131:NaN,3375195,22417316,Unavailable
3590693,Quality of life at 2 weeks (overall),Red clover isoflavones,Placebo,No significant difference,"Mean score of total quality of life (p &lt; 0.001 in both groups), mean score of quality of life in vasomotor domain (p &lt; 0.001 in both groups), psycho-social domain (p &lt; 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p &lt; 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values. However, the differences between two groups were significant neither for total quality of life nor for its domains.",23787:23901,3590693,23493172,Unavailable
3590693,Quality of life at 2 weeks (vasomotor domain),Red clover isoflavones,Placebo,No significant difference,"Mean score of total quality of life (p &lt; 0.001 in both groups), mean score of quality of life in vasomotor domain (p &lt; 0.001 in both groups), psycho-social domain (p &lt; 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p &lt; 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values. However, the differences between two groups were significant neither for total quality of life nor for its domains.",23787:23901,3590693,23493172,Unavailable
3590693,Quality of life at 2 weeks (psycho-social domain),Red clover isoflavones,Placebo,No significant difference,"Mean score of total quality of life (p &lt; 0.001 in both groups), mean score of quality of life in vasomotor domain (p &lt; 0.001 in both groups), psycho-social domain (p &lt; 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p &lt; 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values. However, the differences between two groups were significant neither for total quality of life nor for its domains.",23787:23901,3590693,23493172,Unavailable
3590693,Quality of life at 2 weeks (physical domain),Red clover isoflavones,Placebo,No significant difference,"Mean score of total quality of life (p &lt; 0.001 in both groups), mean score of quality of life in vasomotor domain (p &lt; 0.001 in both groups), psycho-social domain (p &lt; 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p &lt; 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values. However, the differences between two groups were significant neither for total quality of life nor for its domains.",23787:23901,3590693,23493172,Unavailable
3590693,Quality of life at 10 weeks (overall),Red clover isoflavones,Placebo,No significant difference,"Mean score of total quality of life (p &lt; 0.001 in both groups), mean score of quality of life in vasomotor domain (p &lt; 0.001 in both groups), psycho-social domain (p &lt; 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p &lt; 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values. However, the differences between two groups were significant neither for total quality of life nor for its domains.",23787:23901,3590693,23493172,Unavailable
3590693,Quality of life at 10 weeks (vasomotor domain),Red clover isoflavones,Placebo,No significant difference,"Mean score of total quality of life (p &lt; 0.001 in both groups), mean score of quality of life in vasomotor domain (p &lt; 0.001 in both groups), psycho-social domain (p &lt; 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p &lt; 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values. However, the differences between two groups were significant neither for total quality of life nor for its domains.",23787:23901,3590693,23493172,Unavailable
3590693,Quality of life at 10 weeks (psycho-social domain),Red clover isoflavones,Placebo,No significant difference,"Mean score of total quality of life (p &lt; 0.001 in both groups), mean score of quality of life in vasomotor domain (p &lt; 0.001 in both groups), psycho-social domain (p &lt; 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p &lt; 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values. However, the differences between two groups were significant neither for total quality of life nor for its domains.",23787:23901,3590693,23493172,Unavailable
3590693,Quality of life at 10 weeks (physical domain),Red clover isoflavones,Placebo,No significant difference,"Mean score of total quality of life (p &lt; 0.001 in both groups), mean score of quality of life in vasomotor domain (p &lt; 0.001 in both groups), psycho-social domain (p &lt; 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p &lt; 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values. However, the differences between two groups were significant neither for total quality of life nor for its domains.",23787:23901,3590693,23493172,Unavailable
3590693,Quality of life at 2 weeks (overall),Red clover isoflavones,Placebo,No significant difference,"At the end of the second week, there was no difference between the groups in mean score of total quality of life and both groups were matched (p = 0.14).",23357:23510,3590693,23493172,Unavailable
3590693,Quality of life at 10 weeks (overall),Red clover isoflavones,Placebo,No significant difference,"However, the difference in mean scores of total quality of life was not significant between the groups (p = 0.75).",23357:23510,3590693,23493172,Unavailable
3590693,Quality of life at 2 weeks (vasomotor domain),Red clover isoflavones,Placebo,No significant difference,"At the end of the second week, there was no difference between the groups in mean scores of quality of life in vasomotor domain and the groups were matched (p = 0.06).",23914:24081,3590693,23493172,Unavailable
3590693,Quality of life at 10 weeks (vasomotor domain),Red clover isoflavones,Placebo,No significant difference,"At the end of the study, mean scores of quality of life in this domain did not differ between the groups (p = 0.83), i.e. the effects of red clover and placebo on improvement of quality of life in this domain had been similar.",24229:24455,3590693,23493172,Unavailable
3590693,Quality of life at 2 weeks (psycho-social domain),Red clover isoflavones,Placebo,No significant difference,"At the end of the second week, there was no difference in mean scores of quality of life in psychosocial domain between the groups (p = 0.55).",24465:24608,3590693,23493172,Unavailable
3590693,Quality of life at 10 weeks (psycho-social domain),Red clover isoflavones,Placebo,No significant difference,"However, there was no significant difference in mean scores of quality of life in psychosocial domain between the groups (p = 0.90)",24778:24909,3590693,23493172,Unavailable
3590693,Quality of life at 2 weeks (physical domain),Red clover isoflavones,Placebo,No significant difference,"At the end of the second week, there was no difference in mean scores of quality of life in physical domain between the groups (p = 0.32)",24920:25057,3590693,23493172,Unavailable
3590693,Quality of life at 10 weeks (physical domain),Red clover isoflavones,Placebo,No significant difference,"at the end of the tenth week, a significant difference in mean scores of quality of life in this domain in each of the groups (red clover: p &lt; 0.01 and placebo: p = 0.01) was observed but the two groups were not significantly different (p = 0.10).",25064:25311,3590693,23493172,Unavailable
3590693,Quality of life at 2 weeks (sexual domain),Red clover isoflavones,Placebo,No significant difference,"At the end of the second week, the two groups had no significant difference in sexual domain (p = 0.46).",25424:25528,3590693,23493172,Unavailable
3590693,Quality of life at 10 weeks (sexual domain),Red clover isoflavones,Placebo,No significant difference,"In addition, the two groups were not significantly different in sexual domain (p = 0.12) at the end of the tenth week, i.e. the effect of red clover had been similar to placebo in improving quality of life in sexual domain",25736:25959,3590693,23493172,Unavailable
4586001,General practice contacts,Learning and coping education,Standard rehabilitation,No significant difference,"General practice	13.58 (0.56)	12.93 (0.58)	0.65 (−0.94;2.23)",27290:27418,4586001,26412226,Unavailable
4586001,Medical specialist contacts,Learning and coping education,Standard rehabilitation,No significant difference,Medical specialist 0.93 (0.10) 0.90 (0.11) 0.03 (−0.26;0.32),28258:28386,4586001,26412226,Unavailable
4586001,Physiotherapist contacts,Learning and coping education,Standard rehabilitation,No significant difference,"Physiotherapist	1.98 (0.39)	1.84 (0.35)	0.14 (−0.89;1.16)",27584:27709,4586001,26412226,Unavailable
4586001,Dentist contacts,Learning and coping education,Standard rehabilitation,No significant difference,"Dentist	1.66 (0.10)	1.49 (0.09)	0.17 (−0.09;0.44)",27728:27845,4586001,26412226,Unavailable
4586001,Outpatient visits,Learning and coping education,Standard rehabilitation,Significantly increased,Outpatient visits* 26.61 (0.43) 24.51(0.50) 2.10 (0.80;3.41),28258:28386,4586001,26412226,Unavailable
4586001,Hospital bed days,Learning and coping education,Standard rehabilitation,No significant difference,"Hospital bed days	1.54 (0.34)	1.38 (0.29)	0.17 (−0.71;1.05)",28405:28532,4586001,26412226,Unavailable
4586001,Hospital admissions,Learning and coping education,Standard rehabilitation,No significant difference,"Hospital admissionsb	0.49 (0.06)	0.57 (0.08)	−0.09 (−0.28;0.11)",28551:28694,4586001,26412226,Unavailable
4586001,"Sick-leave weeks	",Learning and coping education,Standard rehabilitation,No significant difference,"Sick-leave weeks	4.69 (0.44)	4.54 (0.44)	0.15 (−1.07;1.37)",28712:28838,4586001,26412226,Unavailable
4586001,Re-schooling,Learning and coping education,Standard rehabilitation,No significant difference,"Re-schoolingc	0.02 (0.02)	0.05 (0.05)	−3.03 (−0.15;0.08)",28857:28993,4586001,26412226,Unavailable
4586001,Disability pension,Learning and coping education,Standard rehabilitation,No significant difference,"Disability pension	2.12 (0.31)	1.60 (0.28)	0.52 (−0.30;1.33)",29012:29140,4586001,26412226,Unavailable
4586001,Sick Weeks,Learning and coping education,Standard rehabilitation,No significant difference,"Sick Weeks	2.13 (0.31)	2.33 (0.31)	−0.2 (−1.06;0.66)",29159:29279,4586001,26412226,Unavailable
4586001,Patient time in course (hours),Learning and coping education,Standard rehabilitation,Significantly increased,"Patient time in course (hours)*	40.92 (0.64)	36.68 (0.76)	4.23 (2.28;6.18)",29412:29554,4586001,26412226,Unavailable
4586001,General practice cost ,Learning and coping education,Standard rehabilitation,No significant difference,"General practice	1361 (6042)	1314 (66.33)	47 (−128.50;221.89)",30880:30965,4586001,26412226,Unavailable
4586001,Medical specialist cost ,Learning and coping education,Standard rehabilitation,No significant difference,"Medical specialist	252 (33.16)	234 (35.65)	17 (−77.51;112.57)",30984:31069,4586001,26412226,Unavailable
4586001,Physiotherapist cost ,Learning and coping education,Standard rehabilitation,No significant difference,"Physiotherapist	120 (28.35)	112 (26.01)	8 (−66.59;82.49)",31088:31168,4586001,26412226,Unavailable
4586001,Dentist cost ,Learning and coping education,Standard rehabilitation,No significant difference,"Dentist	186 (14.38)	160 (10.30)	26 (−8.67;60.52)",31187:31259,4586001,26412226,Unavailable
4586001,Total cost of staff,Learning and coping education,Standard rehabilitation,No significant difference,Total 1947 (81.49) 1853 (86.85) 94 (−140.80;329.06),31457:31547,4586001,26412226,Unavailable
4586001,Prescribed medicine cost ,Learning and coping education,Standard rehabilitation,No significant difference,"Prescribed medicine	2064 (95.18)	2022 (108.45)	42 (−239.60;323.62)",31457:31547,4586001,26412226,Unavailable
4586001,Outpatient visits cost,Learning and coping education,Standard rehabilitation,No significant difference,"Outpatient visits	44,050 (800.01)	41,513 (1018.42)	2537 (−16.31;5090.90)",31632:31728,4586001,26412226,Unavailable
4586001,Hospital admissions cost,Learning and coping education,Standard rehabilitation,No significant difference,"Hospital admissions	17,644 (3056.81)	19,250 (3027.52)	−1608 (−10091.22;6875.10)",31747:31850,4586001,26412226,Unavailable
4586001,Total hospital cost,Learning and coping education,Standard rehabilitation,No significant difference,"Total	61,692 (3171.31)	60,763 (3172.60)	929 (−7863.18;9721.64)",31868:31954,4586001,26412226,Unavailable
4586001,Re-schooling cost,Learning and coping education,Standard rehabilitation,No significant difference,Re-schooling 116 (114.41) 242 (237.63) −126 (−679.55;428.17),32257:32351,4586001,26412226,Unavailable
4586001,Disability pension cost,Learning and coping education,Standard rehabilitation,No significant difference,"Disability pension 13,392 (2030.54) 10,336 (1847.17) 3056 (−2290.51;8402.31)",32257:32351,4586001,26412226,Unavailable
4586001,Sick Weeks cost,Learning and coping education,Standard rehabilitation,No significant difference,"Sick Weeks	14,450 (2120.91)	15,660 (2144.589)	−1210 (−7203.09;4783.19)",32257:32351,4586001,26412226,Unavailable
4586001,Total productivity loss cost,Learning and coping education,Standard rehabilitation,No significant difference,"Total	27,958 (2738.37)	26,238 (2708.10)	1720 (−5885.65;9326.14)",32369:32456,4586001,26412226,Unavailable
4586001,SF-6D (quality of life) at 2 months,Learning and coping education,Standard rehabilitation,No significant difference,"After intervention (2&nbsp;months)	238	0.798	0.007	223	0.780	0.008	0.018 (−0.003;0.040)",35924:36062,4586001,26412226,Unavailable
4586001,SF-6D (quality of life) at 5 months,Learning and coping education,Standard rehabilitation,No significant difference,"After follow-up (5&nbsp;months)	238	0.794	0.008	223	0.792	0.008	0.002 (−0.020;0.025)",36081:36216,4586001,26412226,Unavailable
4586001,Quality-adjusted life year ,Learning and coping education,Standard rehabilitation,No significant difference,"QALY	238	0.327	0.003	223	0.322	0.003	0.005 (−0.003;0.014)",36234:36347,4586001,26412226,Unavailable
5778152,Total cholesterol (12 months),Toremifene ,Letrozole,Significantly decreased,Significant differences were observed in TC and LDL-C between the two groups at 12 and 24&nbsp;months.,7700:7798,5778152,29196963,Unavailable
5778152,Total cholesterol (24 months),Toremifene ,Letrozole,Significantly decreased,Significant differences were observed in TC and LDL-C between the two groups at 12 and 24&nbsp;months.,7700:7798,5778152,29196963,Unavailable
5778152,LDL (12 months),Toremifene ,Letrozole,Significantly decreased,Significant differences were observed in TC and LDL-C between the two groups at 12 and 24&nbsp;months.,7700:7798,5778152,29196963,Unavailable
5778152,LDL (24 months),Toremifene ,Letrozole,Significantly decreased,Significant differences were observed in TC and LDL-C between the two groups at 12 and 24&nbsp;months.,7700:7798,5778152,29196963,Unavailable
5778152,Triglycerides (12 months),Toremifene ,Letrozole,No significant difference,There was no significant TG change in either group,19184:19234,5778152,29196963,Unavailable
5778152,Triglycerides (24 months),Toremifene ,Letrozole,No significant difference,There was no significant TG change in either group,19184:19234,5778152,29196963,Unavailable
5778152,Triglycerides (6 months),Toremifene ,Letrozole,No significant difference,There was no significant TG change in either group,19184:19234,5778152,29196963,Unavailable
5778152,Total cholesterol (12 months),Toremifene ,Letrozole,Significantly decreased,Comparison of the TOR and LET groups revealed the percent changes in LDL and TC values to differ significantly between the two groups at 12 and 24&nbsp;months (P &lt; 0.005).,19000:19183,5778152,29196963,Unavailable
5778152,Total cholesterol (24 months),Toremifene ,Letrozole,Significantly decreased,Comparison of the TOR and LET groups revealed the percent changes in LDL and TC values to differ significantly between the two groups at 12 and 24&nbsp;months (P &lt; 0.005).,18999:19184,5778152,29196963,Unavailable
5778152,LDL (12 months),Toremifene ,Letrozole,Significantly decreased,Comparison of the TOR and LET groups revealed the percent changes in LDL and TC values to differ significantly between the two groups at 12 and 24&nbsp;months (P &lt; 0.005).,18999:19183,5778152,29196963,Unavailable
5778152,LDL (24 months),Toremifene ,Letrozole,Significantly decreased,Comparison of the TOR and LET groups revealed the percent changes in LDL and TC values to differ significantly between the two groups at 12 and 24&nbsp;months (P &lt; 0.005).,19000:19183,5778152,29196963,Unavailable
5778152,Bone-specific alkaline phosphatase (6 months),Toremifene ,Letrozole,No significant difference,"In the TOR group only, BAP was significantly decreased at 6, 12, and 24&nbsp;months and NTx was significantly decreased at 6 and 12&nbsp;months (P &lt; 0.05)(Tables&nbsp;2, 3). Comparison of the TOR and LET groups revealed percent changes in the values of all markers to differ significantly between the two at 6, 12, and 24&nbsp;months (P &lt; 0.05), the only exception being BAP at 6 months.",22662:23148,5778152,29196963,Unavailable
5778152,Bone-specific alkaline phosphatase (12 months),Toremifene ,Letrozole,Significantly decreased,"In the TOR group only, BAP was significantly decreased at 6, 12, and 24&nbsp;months and NTx was significantly decreased at 6 and 12&nbsp;months (P &lt; 0.05)(Tables&nbsp;2, 3). Comparison of the TOR and LET groups revealed percent changes in the values of all markers to differ significantly between the two at 6, 12, and 24&nbsp;months (P &lt; 0.05), the only exception being BAP at 6 months.",22662:23148,5778152,29196963,Unavailable
5778152,Bone-specific alkaline phosphatase (24 months),Toremifene ,Letrozole,Significantly decreased,"In the TOR group only, BAP was significantly decreased at 6, 12, and 24&nbsp;months and NTx was significantly decreased at 6 and 12&nbsp;months (P &lt; 0.05)(Tables&nbsp;2, 3). Comparison of the TOR and LET groups revealed percent changes in the values of all markers to differ significantly between the two at 6, 12, and 24&nbsp;months (P &lt; 0.05), the only exception being BAP at 6 months.",22662:23148,5778152,29196963,Unavailable
5778152, N-telopeptide of type-I collagen (6 months),Toremifene ,Letrozole,Significantly decreased,"In the TOR group only, BAP was significantly decreased at 6, 12, and 24&nbsp;months and NTx was significantly decreased at 6 and 12&nbsp;months (P &lt; 0.05)(Tables&nbsp;2, 3). Comparison of the TOR and LET groups revealed percent changes in the values of all markers to differ significantly between the two at 6, 12, and 24&nbsp;months (P &lt; 0.05), the only exception being BAP at 6 months.",22662:23148,5778152,29196963,Unavailable
5778152, N-telopeptide of type-I collagen (12 months),Toremifene ,Letrozole,Significantly decreased,"In the TOR group only, BAP was significantly decreased at 6, 12, and 24&nbsp;months and NTx was significantly decreased at 6 and 12&nbsp;months (P &lt; 0.05)(Tables&nbsp;2, 3). Comparison of the TOR and LET groups revealed percent changes in the values of all markers to differ significantly between the two at 6, 12, and 24&nbsp;months (P &lt; 0.05), the only exception being BAP at 6 months.",22662:23148,5778152,29196963,Unavailable
5778152, N-telopeptide of type-I collagen (24 months),Toremifene ,Letrozole,Significantly decreased,"In the TOR group only, BAP was significantly decreased at 6, 12, and 24&nbsp;months and NTx was significantly decreased at 6 and 12&nbsp;months (P &lt; 0.05)(Tables&nbsp;2, 3). Comparison of the TOR and LET groups revealed percent changes in the values of all markers to differ significantly between the two at 6, 12, and 24&nbsp;months (P &lt; 0.05), the only exception being BAP at 6 months.",22662:23148,5778152,29196963,Unavailable
5778152,Homocysteine (6 months),Toremifene ,Letrozole,No significant difference,Hcy levels did not differ significantly between the two groups,23149:23211,5778152,29196963,Unavailable
5778152,Homocysteine (12 months),Toremifene ,Letrozole,No significant difference,Hcy levels did not differ significantly between the two groups,23149:23211,5778152,29196963,Unavailable
5778152,Homocysteine (24 months),Toremifene ,Letrozole,No significant difference,Hcy levels did not differ significantly between the two groups,23149:23211,5778152,29196963,Unavailable
5778152,HDL (6 months),Toremifene ,Letrozole,No significant difference,"HDL was significantly increased at 6, 12, and 24&nbsp;months in the TOR group (P &lt; 0.0005) (Fig.&nbsp;2c), while these markers were essentially unchanged in the LET group.",18779:18999,5778152,29196963,Unavailable
5778152,HDL (12 months),Toremifene ,Letrozole,No significant difference,"HDL was significantly increased at 6, 12, and 24&nbsp;months in the TOR group (P &lt; 0.0005) (Fig.&nbsp;2c), while these markers were essentially unchanged in the LET group.",18779:18999,5778152,29196963,Unavailable
5778152,HDL (24 months),Toremifene ,Letrozole,No significant difference,"HDL was significantly increased at 6, 12, and 24&nbsp;months in the TOR group (P &lt; 0.0005) (Fig.&nbsp;2c), while these markers were essentially unchanged in the LET group.",18779:18999,5778152,29196963,Unavailable
4885151,Young Mania Rating Scale improvement (1 week),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,"Mean of YMRS SD-(First Week) Mean of CDI SD-(First Week)	6±135±15	7±2318.5±10.5	&lt;0.001&lt;0.002",30285:30603,4885151,27247580,Unavailable
4885151,Young Mania Rating Scale improvement (2 weeks),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,"Mean of YMRS SD-(Second Week) Mean of CDI SD-(Second Week)	6.4±74±8	8±189±17	&lt;0.0001&lt;0.0001",30704:31021,4885151,27247580,Unavailable
4885151,Young Mania Rating Scale improvement (3 weeks),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,"Mean of YMRS SD-(Third Week) Mean of CDI SD-(Third Week)	3.5±34±6	9±147±16	&lt;0.0001&lt;0.0001",31122:31437,4885151,27247580,Unavailable
4885151,Children Depression Inventory improvement (1 week),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,Mean of YMRS SD-(First Week) Mean of CDI SD-(First Week) 6±135±15 7±2318.5±10.5 &lt;0.001&lt;0.002,30285:30603,4885151,27247580,Unavailable
4885151,Children Depression Inventory improvement (2 weeks),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,Mean of YMRS SD-(Second Week) Mean of CDI SD-(Second Week) 6.4±74±8 8±189±17 &lt;0.0001&lt;0.0001,30285:30603,4885151,27247580,Unavailable
4885151,Children Depression Inventory improvement (3 weeks),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,Mean of YMRS SD-(Third Week) Mean of CDI SD-(Third Week) 3.5±34±6 9±147±16 &lt;0.0001&lt;0.0001,30285:30603,4885151,27247580,Unavailable
4885151,Young Mania Rating Scale improvement (1 week),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,There was no difference in the baseline score of YMRS and CDI in the treatment and control groups while a statistical significant difference (P &lt; 0.05) in these scores was found between and within the groups.,4757:4965,4885151,27247580,Unavailable
4885151,Young Mania Rating Scale improvement (2 weeks),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,There was no difference in the baseline score of YMRS and CDI in the treatment and control groups while a statistical significant difference (P &lt; 0.05) in these scores was found between and within the groups.,4757:4965,4885151,27247580,Unavailable
4885151,Young Mania Rating Scale improvement (3 weeks),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,There was no difference in the baseline score of YMRS and CDI in the treatment and control groups while a statistical significant difference (P &lt; 0.05) in these scores was found between and within the groups.,4757:4965,4885151,27247580,Unavailable
4885151,Children Depression Inventory improvement (1 week),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,There was no difference in the baseline score of YMRS and CDI in the treatment and control groups while a statistical significant difference (P &lt; 0.05) in these scores was found between and within the groups.,4757:4965,4885151,27247580,Unavailable
4885151,Children Depression Inventory improvement (2 weeks),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,There was no difference in the baseline score of YMRS and CDI in the treatment and control groups while a statistical significant difference (P &lt; 0.05) in these scores was found between and within the groups.,4757:4965,4885151,27247580,Unavailable
4885151,Children Depression Inventory improvement (3 weeks),Tamoxifen + lithium,Placebo+ lithium,Significantly increased,There was no difference in the baseline score of YMRS and CDI in the treatment and control groups while a statistical significant difference (P &lt; 0.05) in these scores was found between and within the groups.,4757:4965,4885151,27247580,Unavailable
4885151,Drowsiness,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Drowsiness	0.22	2.22	0.488",36281:36504,4885151,27247580,Unavailable
4885151,Vertigo,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Vertigo	0.22	2.22	0.488",36618:36838,4885151,27247580,Unavailable
4885151,Shivering,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Shivering	1.22	0.424	0.254",36952:37175,4885151,27247580,Unavailable
4885151,Overeating,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Overeating	0.22	1.22	1",37289:37508,4885151,27247580,Unavailable
4885151,Anorexia,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Anorexia	0.22	2.22	0.488",37622:37843,4885151,27247580,Unavailable
4885151,Blurred vision,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Blurred vision	1.22	2.22	1",37957:38180,4885151,27247580,Unavailable
4885151,Fatigue,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Fatigue	0.22	1.22	1",38294:38510,4885151,27247580,Unavailable
4885151,Agitation,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Agitation	1.22	0.22	1",38624:38842,4885151,27247580,Unavailable
4885151,Xerostomia,Tamoxifen + lithium,Placebo+ lithium,Significantly increased,"Xerostomia	7.22	0.22	0.009",38956:39179,4885151,27247580,Unavailable
4885151,Anxiety,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Anxiety	0.22	2.22	0.488",39293:39513,4885151,27247580,Unavailable
4885151,Diarrhea,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Diarrhea	0.22	0.22	1",39627:39844,4885151,27247580,Unavailable
4885151,Constipation,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Constipation	0.22	0.22	1",39958:40179,4885151,27247580,Unavailable
4885151,Low body movement,Tamoxifen + lithium,Placebo+ lithium,No significant difference,"Low body movement	0.22	0.22	1",40293:40519,4885151,27247580,Unavailable
3390686,Overall survival,Trastuzumab + chemotherapy,Chemotherapy,Significantly increased,"For the post hoc exploratory multivariate Cox regression analysis, the adjusted HRs for OS and PFS were 0.82 (95% CI 0.45–1.50) and 0.81 (95% CI 0.50–1.30), respectively",40481:40650,3390686,22179434,Unavailable
3390686,Progression-free survival ,Trastuzumab + chemotherapy,Chemotherapy,Significantly increased,"For the post hoc exploratory multivariate Cox regression analysis, the adjusted HRs for OS and PFS were 0.82 (95% CI 0.45–1.50) and 0.81 (95% CI 0.50–1.30), respectively",40481:40650,3390686,22179434,Unavailable
3823877,Knowledge on discharge instructions test (mean),Online Video support,Control,Significantly increased,"Patients in the video group had 19% higher mean scores (2.5, s.d. 0.7) than patients in the control group (2.1, s.d. 0.8) (p=0.002).",6471:6604,3823877,24244272,Unavailable
3823877,Knowledge on discharge instructions test (mean),Online Video support,Control,Significantly increased,"Patients in the intervention group had significantly higher mean scores (2.5, s.d. 0.8) than those in the control group (2.1, s.d. 0.7) (p=0.002).",33626:33772,3823877,24244272,Unavailable
3823877,Knowledge on discharge instructions test (median),Online Video support,Control,Significantly increased,"Median scores were also higher in the intervention group (3.0, IQR 2.0 to 3.0) than in the control group (2.5, IQR 1.5 to 3.0) (p=0.001",33773:33908,3823877,24244272,Unavailable
3823877,Chances of a perfect score,Online Video support,Control,Significantly increased,"In the adjusted analysis, the odds of receiving a score of 3 were 3.5 (95% confidence interval, 1.7 to 7.2) times higher in the intervention group, compared to the control group (p&lt;0.001)",33911:34098,3823877,24244272,Unavailable
3823877,Knowledge on discharge instructions test (mean),Online Video support,Control,Significantly increased,"Intervention group, mean (s.d.)	2.5 (0.7)	0.002",34964:35075,3823877,24244272,Unavailable
3823877,Knowledge on discharge instructions test (median),Online Video support,Control,Significantly increased,"Intervention group, median (q1 – q3)	3.0 (2.0-3.0)	0.001",35260:35380,3823877,24244272,Unavailable
3499794,CD40LG (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"Four cytokines showed a difference in expression between the treatment arms, all in a proinflammatory direction for the ABC arm: CD40LG 1.82-fold, (p=.027); IL-8 3.16-fold (p=.020); LTA 2.82-fold, (p=.008); and CCL5 −1.67-fold, (p=.035).",20915:21207,3499794,22789611,Unavailable
3499794,IL-8 (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"Four cytokines showed a difference in expression between the treatment arms, all in a proinflammatory direction for the ABC arm: CD40LG 1.82-fold, (p=.027); IL-8 3.16-fold (p=.020); LTA 2.82-fold, (p=.008); and CCL5 −1.67-fold, (p=.035).",20915:21207,3499794,22789611,Unavailable
3499794,LTA (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"Four cytokines showed a difference in expression between the treatment arms, all in a proinflammatory direction for the ABC arm: CD40LG 1.82-fold, (p=.027); IL-8 3.16-fold (p=.020); LTA 2.82-fold, (p=.008); and CCL5 −1.67-fold, (p=.035).",20915:21207,3499794,22789611,Unavailable
3499794,CCL5 (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"Four cytokines showed a difference in expression between the treatment arms, all in a proinflammatory direction for the ABC arm: CD40LG 1.82-fold, (p=.027); IL-8 3.16-fold (p=.020); LTA 2.82-fold, (p=.008); and CCL5 −1.67-fold, (p=.035).",20915:21207,3499794,22789611,Unavailable
3499794,CD40LG (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"All observed changes in transcription were in a proinflammatory direction for ABC: CD40LG, 1.82 (±0.35) fold (p=.027); IL-8, 3.16 (±0.87) fold (p=.020); LTA, 2.82 (±0.65) fold (p=.008); and CCL5, −1.67 (±0.33) fold (p=.035).",20915:21207,3499794,22789611,Unavailable
3499794,IL-8 (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"All observed changes in transcription were in a proinflammatory direction for ABC: CD40LG, 1.82 (±0.35) fold (p=.027); IL-8, 3.16 (±0.87) fold (p=.020); LTA, 2.82 (±0.65) fold (p=.008); and CCL5, −1.67 (±0.33) fold (p=.035).",20915:21207,3499794,22789611,Unavailable
3499794,LTA (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"All observed changes in transcription were in a proinflammatory direction for ABC: CD40LG, 1.82 (±0.35) fold (p=.027); IL-8, 3.16 (±0.87) fold (p=.020); LTA, 2.82 (±0.65) fold (p=.008); and CCL5, −1.67 (±0.33) fold (p=.035).",20915:21207,3499794,22789611,Unavailable
3499794,CCL5 (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"All observed changes in transcription were in a proinflammatory direction for ABC: CD40LG, 1.82 (±0.35) fold (p=.027); IL-8, 3.16 (±0.87) fold (p=.020); LTA, 2.82 (±0.65) fold (p=.008); and CCL5, −1.67 (±0.33) fold (p=.035).",20915:21207,3499794,22789611,Unavailable
3499794,CD40LG (12 months),Trizivir,Kaletra/Combivir,No significant difference,"By 12-months postpartum, when both arms had received no ART for 6-months, there was no difference in transcription of the five cytokines between the treatment arms",21348:21513,3499794,22789611,Unavailable
3499794,IL-8 (12 months),Trizivir,Kaletra/Combivir,No significant difference,"By 12-months postpartum, when both arms had received no ART for 6-months, there was no difference in transcription of the five cytokines between the treatment arms",21349:21512,3499794,22789611,Unavailable
3499794,LTA (12 months),Trizivir,Kaletra/Combivir,No significant difference,"By 12-months postpartum, when both arms had received no ART for 6-months, there was no difference in transcription of the five cytokines between the treatment arms",21349:21513,3499794,22789611,Unavailable
3499794,CCL5 (12 months),Trizivir,Kaletra/Combivir,No significant difference,"By 12-months postpartum, when both arms had received no ART for 6-months, there was no difference in transcription of the five cytokines between the treatment arms",21349:21512,3499794,22789611,Unavailable
3499794,CXCL1 (12 months),Trizivir,Kaletra/Combivir,No significant difference,"By 12-months postpartum, when both arms had received no ART for 6-months, there was no difference in transcription of the five cytokines between the treatment arms",21348:21513,3499794,22789611,Unavailable
3499794,CD40LG (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"CD40LG	0.060	0.043 to 0.077	0.033	0.024 to 0.042	1.82 (±0.35)	.027",25277:25625,3499794,22789611,Unavailable
3499794,IL-8 (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"IL8	0.018	0.010 to 0.026	0.006	0.004 to 0.008	3.16 (±0.87)	.020",26883:27228,3499794,22789611,Unavailable
3499794,LTA (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"LTA	0.335	0.222 to 0.448	0.119	0.080 to 0.158	2.82 (±0.65)	.008",27283:27628,3499794,22789611,Unavailable
3499794,CCL5 (6 months),Trizivir,Kaletra/Combivir,Significantly increased,"CCL5	0.325	0.226 to 0.423	0.543	0.401 to 0.684	−1.67 (±0.33)	.035",24072:24419,3499794,22789611,Unavailable
3499794,CCL2 (6 months),Trizivir,Kaletra/Combivir,No significant difference,"CCL2	0.003	0.001 to 0.004	0.002	0.001 to 0.003	1.46 (±0.53)	.366",23671:24017,3499794,22789611,Unavailable
3499794,CCR7 (6 months),Trizivir,Kaletra/Combivir,No significant difference,"CCR7	0.056	0.038 to 0.074	0.084	0.050 to 0.118	−1.50 (±0.38)	.304",24474:24821,3499794,22789611,Unavailable
3499794,CD40 (6 months),Trizivir,Kaletra/Combivir,No significant difference,"CD40	0.459	0.302 to 0.616	0.349	0.234 to 0.464	1.32 (±0.31)	.342",24876:25222,3499794,22789611,Unavailable
3499794,CXCL1 (6 months),Trizivir,Kaletra/Combivir,No significant difference,"CXCL1	0.009	0.006 to 0.012	0.007	0.004 to 0.009	1.36 (±0.31)	.263",25680:26027,3499794,22789611,Unavailable
3499794,CXCL5 (6 months),Trizivir,Kaletra/Combivir,No significant difference,"CXCL5	0.049	0.033 to 0.064	0.051	0.034 to 0.068	−1.05 (±0.23)	.829",26082:26430,3499794,22789611,Unavailable
3499794,IFNG (6 months),Trizivir,Kaletra/Combivir,No significant difference,"IFNG	10.68	5.16 to 16.20	8.81	4.52 to 13.09	1.21 (±0.42)	.639",26485:26828,3499794,22789611,Unavailable
3499794,NFKB1 (6 months),Trizivir,Kaletra/Combivir,No significant difference,"NFKB1	0.003	0.002 to 0.004	0.004	0.003 to 0.005	−1.33 (±0.24)	.266",27683:28031,3499794,22789611,Unavailable
3499794,TOLLIP (6 months),Trizivir,Kaletra/Combivir,No significant difference,"TOLLIP	0.067	0.029 to 0.104	0.028	0.014 to 0.043	2.34 (±0.86)	.140",28086:28434,3499794,22789611,Unavailable
3499794,CD40LG (12 months),Trizivir,Kaletra/Combivir,No significant difference,CD40LG 0.150 0.105 to 0.196 0.171 0.113 to 0.230 −1.14 (±0.25) .559,21349:21512,3499794,22789611,Unavailable
3499794,IL-8 (12 months),Trizivir,Kaletra/Combivir,No significant difference,IL8 0.030 0.017 to 0.042 0.039 0.020 to 0.058 −1.31 (±0.40) .664,21349:21512,3499794,22789611,Unavailable
3499794,LTA (12 months),Trizivir,Kaletra/Combivir,No significant difference,LTA 0.092 0.048 to 0.136 0.115 0.066 to 0.165 −1.25 (±0.39) .601,21349:21512,3499794,22789611,Unavailable
3499794,CCL5 (12 months),Trizivir,Kaletra/Combivir,No significant difference,CCL5 24.32 13.72 to 34.92 12.33 7.80 to 16.87 1.97 (±0.54) .198,21349:21512,3499794,22789611,Unavailable
3499794,CXCL1 (12 months),Trizivir,Kaletra/Combivir,No significant difference,CXCL1 0.021 0.014 to 0.029 0.030 0.017 to 0.043 −1.40 (±0.38) .610,21349:21512,3499794,22789611,Unavailable
4776353,Reported influence of regret in their decision-making ,Information on post-surgical regret,Standard decision aid,Significantly increased,A significantly greater proportion of the experimental group subjects reported regret played a role in their decision-making process compared to the control counterparts (78 vs. 65&nbsp;%; p = 0.039).,21276:21509,4776353,26941952,Unavailable
4776353,Odds of choosing less regret-inducing surgery,Information on post-surgical regret,Standard decision aid,Significantly increased,"Recipients of the regret-incorporated experimental decision aid had a threefold increased odds of choosing the less regret-inducing surgery (OR = 2.97; 95&nbsp;% CI = 1.25, 7.09; p value = 0.014).",5985:6193,4776353,26941952,Unavailable
4776353,Odds of choosing less regret-inducing surgery,Information on post-surgical regret,Standard decision aid,Significantly increased,"Subjects in the experimental group had a threefold increased odds of choosing the less regret-inducing surgery (OR = 2.97; 95&nbsp;% CI = 1.25, 7.09; p value = 0.014",19477:19654,4776353,26941952,Unavailable
4776353,Reported influence of regret in their decision-making ,Information on post-surgical regret,Standard decision aid,Significantly increased,Did regret play a role in your decision-making process?Yes (vs. no) 69 (78&nbsp;%) 62 (65&nbsp;%) 0.039,21276:21509,4776353,26941952,Unavailable
4776353,Choosing lumpectomy,Information on post-surgical regret,Standard decision aid,Significantly increased,"In the control group, which received the standard version of the decision aid, 74 out of 96 (77&nbsp;%) subjects chose lumpectomy over mastectomy, whereas in the experimental group that received the regret-incorporated decision aid, 80 out of 88 (91&nbsp;%) subjects chose lumpectomy over mastectomy (p = 0.011).",19157:19476,4776353,26941952,Unavailable
4776353,Choosing lumpectomy,Information on post-surgical regret,Standard decision aid,Significantly increased,"Lumpectomy (vs. mastectomy)	80 (91&nbsp;%)	74 (77&nbsp;%)	0.011",20103:20180,4776353,26941952,Unavailable
4776353,Odds of choosing less regret-inducing surgery,Information on post-surgical regret,Standard decision aid,Significantly increased,"Odds of choosing lumpectomy (vs. mastectomy)OR	95&nbsp;% CI	p valueExperimental group	2.97	1.24–7.09	0.014",20375:20579,4776353,26941952,Unavailable
4776353,Reported influence of regret in their decision-making ,Information on post-surgical regret,Standard decision aid,Significantly increased,"In the experimental group, 69 out of 88 (78&nbsp;%) reported that regret was considered during the decision-making process, compared to 62 out of 96 (65&nbsp;%) in the control group (p = 0.039).",21276:21509,4776353,26941952,Unavailable
4776353,Odds that regret was considered in decision,Information on post-surgical regret,Standard decision aid,Significantly increased,"Odds that regret was considered in decisionOR	95&nbsp;% CI	p valueExperimental group	1.99	1.03–3.84	0.04",20609:20811,4776353,26941952,Unavailable
4776353,Odds that regret was considered in decision,Information on post-surgical regret,Standard decision aid,Significantly increased,"Subjects in the experimental group had a twofold increased odds (OR = 1.99; 95&nbsp;% CI = 1.03, 3.84; p value = 0.04) of considering regret during the decision-making process as compared to subjects in the control group.",21276:21509,4776353,26941952,Unavailable
3487977,Mean arterial pressure,Remifentanil,Placebo,No significant difference,Mean arterial pressure and heart rates were comparable between the placebo and Remifentanil groups at all times of the procedure.,4369:4498,3487977,22800647,Unavailable
3487977,Heart rate,Remifentanil,Placebo,No significant difference,Mean arterial pressure and heart rates were comparable between the placebo and Remifentanil groups at all times of the procedure.,4369:4498,3487977,22800647,Unavailable
3487977, Bispectral Index values (during procedure),Remifentanil,Placebo,No significant difference,We did not observe differences in the variation of BIS values between the two groups during procedure.,16568:16685,3487977,22800647,Unavailable
3487977,Mean arterial pressure,Remifentanil,Placebo,No significant difference,Heart rates and mean arterial pressure were comparable between the placebo and Remifentanil groups during fiberoptic bronchoscopy procedure,15596:15735,3487977,22800647,Unavailable
3487977,Heart rate,Remifentanil,Placebo,No significant difference,Heart rates and mean arterial pressure were comparable between the placebo and Remifentanil groups during fiberoptic bronchoscopy procedure,15595:15736,3487977,22800647,Unavailable
3487977,SpO2 ,Remifentanil,Placebo,No significant difference,We observed no SpO2 and CO2 variations during procedure,15829:15906,3487977,22800647,Unavailable
3487977,CO2 ,Remifentanil,Placebo,No significant difference,We observed no SpO2 and CO2 variations during procedure,15829:15906,3487977,22800647,Unavailable
3487977, Bispectral Index values (during procedure),Remifentanil,Placebo,No significant difference,"Similarly, we observed no differences between the two groups in the variation of the BIS value during the procedure",16568:16685,3487977,22800647,Unavailable
3487977, Bispectral Index values (during procedure),Remifentanil,Placebo,No significant difference,Maximum BIS value during procedure53 ± 854 ± 11&gt;0.05,17802:18002,3487977,22800647,Unavailable
3487977, Bispectral Index values (after procedure) ,Remifentanil,Placebo,No significant difference,"BIS value post fiberoptic bronchoscopy	42 ± 6	46 ± 9	&gt;0.05",18051:18179,3487977,22800647,Unavailable
5043643,Autobiographical memory (specific),Spironolactone ,Placebo,Significantly decreased,"On autobiographical memory testing, mineralocorticoid receptor antagonism impaired, while glucocorticoid receptor antagonism improved, recall relative to placebo, as evinced by changes in the percent of specific memories recalled.",45518:45858,5043643,27207909,Unavailable
5043643,Autobiographical memory (specific),Mifepristone ,Placebo,Significantly increased,"On autobiographical memory testing, mineralocorticoid receptor antagonism impaired, while glucocorticoid receptor antagonism improved, recall relative to placebo, as evinced by changes in the percent of specific memories recalled.",45518:45858,5043643,27207909,Unavailable
5043643,Response to masked sad faces,Spironolactone ,Placebo,Significantly increased,"During fMRI, the amygdala hemodynamic response to masked sad faces was greater under both mineralocorticoid receptor and glucocorticoid receptor antagonism relative to placebo",5550:5725,5043643,27207909,Unavailable
5043643,Response to masked sad faces,Mifepristone ,Placebo,Significantly increased,"During fMRI, the amygdala hemodynamic response to masked sad faces was greater under both mineralocorticoid receptor and glucocorticoid receptor antagonism relative to placebo",5550:5725,5043643,27207909,Unavailable
5043643,Response to masked happy faces,Spironolactone ,Placebo,Significantly decreased,the response to masked happy faces was attenuated only during mineralocorticoid receptor antagonism relative to placebo.,5732:5853,5043643,27207909,Unavailable
5043643,Response to masked happy faces,Mifepristone ,Placebo,No significant difference,the response to masked happy faces was attenuated only during mineralocorticoid receptor antagonism relative to placebo.,5732:5853,5043643,27207909,Unavailable
5043643,Cortisol level,Spironolactone ,Placebo,Significantly increased,"Paired t tests revealed that all conditions significantly differed from each other at all time points after baseline (ts(9)&gt;7.24, Pscorrected&lt;.001), but did not differ at the baseline blood draw (ts(9) &lt;1.07, Ps&gt;.32; corrected Pscorrected =1.00). The time x condition interaction revealed that while cortisol levels following both MR and GR antagonism increased at all time points relative to baseline (ts(9)&gt;3,91, Ps&lt;.004), cortisol levels did not change from baseline in the placebo condition (ts(9)&lt;0.1.31, Ps&lt;.23).",29054:29641,5043643,27207909,Unavailable
5043643,Cortisol level,Mifepristone ,Placebo,Significantly increased,"Paired t tests revealed that all conditions significantly differed from each other at all time points after baseline (ts(9)&gt;7.24, Pscorrected&lt;.001), but did not differ at the baseline blood draw (ts(9) &lt;1.07, Ps&gt;.32; corrected Pscorrected =1.00). The time x condition interaction revealed that while cortisol levels following both MR and GR antagonism increased at all time points relative to baseline (ts(9)&gt;3,91, Ps&lt;.004), cortisol levels did not change from baseline in the placebo condition (ts(9)&lt;0.1.31, Ps&lt;.23).",30643:30909,5043643,27207909,Unavailable
5043643,Amygdala blood oxygen level-dependent activitythat for SN-NN contrast,Spironolactone ,Placebo,Significantly increased,"both MR and GR antagonism resulted in increased amygdala BOLD activity relative to placebo (ts(9)&gt;7.24, Pscorrected&lt;.001, ds&gt;1.79), while the BOLD response under MR and GR antagonism did not differ(t(9)=1.05, pcorrected=.96, d=0.15).",30643:30909,5043643,27207909,Unavailable
5043643,Amygdala blood oxygen level-dependent activity for SN-NN contrast,Mifepristone ,Placebo,Significantly increased,"both MR and GR antagonism resulted in increased amygdala BOLD activity relative to placebo (ts(9)&gt;7.24, Pscorrected&lt;.001, ds&gt;1.79), while the BOLD response under MR and GR antagonism did not differ(t(9)=1.05, pcorrected=.96, d=0.15).",30643:30909,5043643,27207909,Unavailable
5043643,Amygdala blood oxygen level-dependent activity for SN-NN contrast,Spironolactone ,Mifepristone ,No significant difference,"both MR and GR antagonism resulted in increased amygdala BOLD activity relative to placebo (ts(9)&gt;7.24, Pscorrected&lt;.001, ds&gt;1.79), while the BOLD response under MR and GR antagonism did not differ(t(9)=1.05, pcorrected=.96, d=0.15).",30643:30909,5043643,27207909,Unavailable
5043643,Amygdala blood oxygen level-dependent activity for HN-NN contrast,Spironolactone ,Placebo,Significantly decreased,"For the HN-NN contrast, the amygdala BOLD activity during MR antagonism was significantly less than that under placebo and GR antagonism (ts(9)5.40&gt;, Pscorrected&lt;.004, ds&gt;1.43), while the BOLD response under placebo and GR antagonism did not differ r(t(9)=0.32, pcorrected=1.00, d=0.40).",30909:31227,5043643,27207909,Unavailable
5043643,Amygdala blood oxygen level-dependent activity for HN-NN contrast,Spironolactone ,Mifepristone ,Significantly decreased,"For the HN-NN contrast, the amygdala BOLD activity during MR antagonism was significantly less than that under placebo and GR antagonism (ts(9)5.40&gt;, Pscorrected&lt;.004, ds&gt;1.43), while the BOLD response under placebo and GR antagonism did not differ r(t(9)=0.32, pcorrected=1.00, d=0.40).",30909:31227,5043643,27207909,Unavailable
5043643,Amygdala blood oxygen level-dependent activity for HN-NN contrast,Mifepristone ,Placebo,No significant difference,"For the HN-NN contrast, the amygdala BOLD activity during MR antagonism was significantly less than that under placebo and GR antagonism (ts(9)5.40&gt;, Pscorrected&lt;.004, ds&gt;1.43), while the BOLD response under placebo and GR antagonism did not differ r(t(9)=0.32, pcorrected=1.00, d=0.40).",30909:31227,5043643,27207909,Unavailable
5043643,Autobiographical memory (specific),Spironolactone ,Placebo,Significantly decreased,"For specific memory recall, during GR antagonism participants recalled significantly more specific memories than while under placebo (t(9)=3.57, pcorrected=.002, d=0.50), while during MR antagonism participants recalled significantly less specific memories than while under placebo (t(9)=3.00, pcorrected=.01, d=1.02).",47615:47942,5043643,27207909,Unavailable
5043643,Autobiographical memory (specific),Mifepristone ,Placebo,Significantly increased,"For specific memory recall, during GR antagonism participants recalled significantly more specific memories than while under placebo (t(9)=3.57, pcorrected=.002, d=0.50), while during MR antagonism participants recalled significantly less specific memories than while under placebo (t(9)=3.00, pcorrected=.01, d=1.02).",45518:45858,5043643,27207909,Unavailable
5043643,Autobiographical memory (categorical) ,Spironolactone ,Placebo,Significantly decreased,"With regard to categorical memories, participants recalled fewer categorical memories during both MR and GR antagonism relative to placebo (ts(9) &gt;7.43, Pscorrected&lt;.001, ds&gt;0.94), but did not differ from each other (t(9)=0.13, pcorrected=1.00, d=0.25).",46022:46310,5043643,27207909,Unavailable
5043643,Autobiographical memory (categorical) ,Mifepristone ,Placebo,Significantly decreased,"With regard to categorical memories, participants recalled fewer categorical memories during both MR and GR antagonism relative to placebo (ts(9) &gt;7.43, Pscorrected&lt;.001, ds&gt;0.94), but did not differ from each other (t(9)=0.13, pcorrected=1.00, d=0.25).",46022:46310,5043643,27207909,Unavailable
5043643,Autobiographical memory (categorical) ,Spironolactone ,Mifepristone,No significant difference,"With regard to categorical memories, participants recalled fewer categorical memories during both MR and GR antagonism relative to placebo (ts(9) &gt;7.43, Pscorrected&lt;.001, ds&gt;0.94), but did not differ from each other (t(9)=0.13, pcorrected=1.00, d=0.25).",46022:46310,5043643,27207909,Unavailable
5043643,Other memory types,Spironolactone ,Placebo,Significantly increased,"With regard to the other memory types, participants recalled more of these memory types during MR relative to placebo or GR antagonism (ts(9) &gt;7.15 Pscorrected&lt;.01, ds&gt;3.22), which did not differ from each other (t(9)=0.01, pcorrected=1.00, d=0.05).",46310:46590,5043643,27207909,Unavailable
5043643,Other memory types,Spironolactone ,Mifepristone,Significantly increased,"With regard to the other memory types, participants recalled more of these memory types during MR relative to placebo or GR antagonism (ts(9) &gt;7.15 Pscorrected&lt;.01, ds&gt;3.22), which did not differ from each other (t(9)=0.01, pcorrected=1.00, d=0.05).",46310:46590,5043643,27207909,Unavailable
5043643,Other memory types,Mifepristone,Placebo,No significant difference,"With regard to the other memory types, participants recalled more of these memory types during MR relative to placebo or GR antagonism (ts(9) &gt;7.15 Pscorrected&lt;.01, ds&gt;3.22), which did not differ from each other (t(9)=0.01, pcorrected=1.00, d=0.05).",46310:46590,5043643,27207909,Unavailable
5043643,Mood Rating,Spironolactone ,Placebo,No significant difference,"There was no difference in participants’ baseline mood ratings prior to any treatment condition (all ts(9)&lt;0.98 Ps&gt;.37), no difference in participants’ ratings obtained across the different drug conditions (ts(9)&lt;1.31, Ps&gt;.22), and no change between the baseline and session ratings for any drug condition (ts(9) &lt;1.50, Ps&gt;.17)",47615:47942,5043643,27207909,Unavailable
5043643,Mood Rating,Mifepristone,Placebo,No significant difference,"There was no difference in participants’ baseline mood ratings prior to any treatment condition (all ts(9)&lt;0.98 Ps&gt;.37), no difference in participants’ ratings obtained across the different drug conditions (ts(9)&lt;1.31, Ps&gt;.22), and no change between the baseline and session ratings for any drug condition (ts(9) &lt;1.50, Ps&gt;.17)",47615:47942,5043643,27207909,Unavailable
5043643,Mood Rating,Spironolactone ,Mifepristone ,No significant difference,"There was no difference in participants’ baseline mood ratings prior to any treatment condition (all ts(9)&lt;0.98 Ps&gt;.37), no difference in participants’ ratings obtained across the different drug conditions (ts(9)&lt;1.31, Ps&gt;.22), and no change between the baseline and session ratings for any drug condition (ts(9) &lt;1.50, Ps&gt;.17)",47615:47942,5043643,27207909,Unavailable
5791546,Number of cigarettes consumed,Transcranial direct current stimulation,Placebo,Significantly decreased,"the mean number of cigarettes consumed is significantly influenced by the treatment variable (p = 0.033). As the treament variable is dichotomous [1 = treatment, 0 = placebo], the regression can also be interpreted as a difference between the means of cigarette consumption between the two groups; subjects who received active tDCS consumed on average 7.11 cigarettes less than the sham group, when adjusted to these variables.",30313:30774,5791546,29434547,Unavailable
5791546,Number of cigarettes consumed,Transcranial direct current stimulation,Placebo,Significantly decreased,"In our multivariate analysis, as to take into account the mediation and moderation effects of motivation to quit, we found a significant main effect of tDCS, showing that tDCS was associated with a significant reduction of cigarettes smoked per day.",6769:7018,5791546,29434547,Unavailable
3150344,Telomere losses (last 2 years),Interferon-Alpha,Control,No significant difference,Telomere losses were similar in both groups during the final two years.,6384:6456,3150344,21829595,Unavailable
3150344,Telomere loss in CD4+ cells,Interferon-Alpha,Control,No significant difference,"The average linear regression slopes between S00 and M45 show higher average TL loss rates in the peg-IFNα treatment group across total CD4+ (Fig. 3A) and total CD8+ T cells (Fig. 3D), the naïve subsets (Figs. 3B, E) and memory subsets (Figs. 3C, F), although this difference was statistically significant only for naïve CD8+ T cells (p = 0.005).",22419:23008,3150344,21829595,Unavailable
3150344,Telomere loss in CD8+ cells,Interferon-Alpha,Control,Significantly increased,"The average linear regression slopes between S00 and M45 show higher average TL loss rates in the peg-IFNα treatment group across total CD4+ (Fig. 3A) and total CD8+ T cells (Fig. 3D), the naïve subsets (Figs. 3B, E) and memory subsets (Figs. 3C, F), although this difference was statistically significant only for naïve CD8+ T cells (p = 0.005).",22419:23008,3150344,21829595,Unavailable
3150344,Telomere loss in naive subsets ,Interferon-Alpha,Control,No significant difference,"The average linear regression slopes between S00 and M45 show higher average TL loss rates in the peg-IFNα treatment group across total CD4+ (Fig. 3A) and total CD8+ T cells (Fig. 3D), the naïve subsets (Figs. 3B, E) and memory subsets (Figs. 3C, F), although this difference was statistically significant only for naïve CD8+ T cells (p = 0.005).",22419:23008,3150344,21829595,Unavailable
3150344,Telomere loss in memory subsets ,Interferon-Alpha,Control,No significant difference,"The average linear regression slopes between S00 and M45 show higher average TL loss rates in the peg-IFNα treatment group across total CD4+ (Fig. 3A) and total CD8+ T cells (Fig. 3D), the naïve subsets (Figs. 3B, E) and memory subsets (Figs. 3C, F), although this difference was statistically significant only for naïve CD8+ T cells (p = 0.005).",22419:23008,3150344,21829595,Unavailable
3150344,CD57+ T cells in CD4+ CD45RA+/− subset,Interferon-Alpha,Control,No significant difference,CD57+ T cells in both CD4+ CD45RA+/− and CD8+ CD45RA+/− subsets showed no difference in TL between treatment groups,28105:28206,3150344,21829595,Unavailable
3150344,CD57+ T cells in CD8+ CD45RA+/− subset,Interferon-Alpha,Control,No significant difference,CD57+ T cells in both CD4+ CD45RA+/− and CD8+ CD45RA+/− subsets showed no difference in TL between treatment groups,28105:28206,3150344,21829595,Unavailable
3150344,Telomerase activity,Interferon-Alpha,Control,No significant difference,No difference in TA as a result of in vitro activation was detected between the two treatment groups,28105:28206,3150344,21829595,Unavailable
1523225,Bispectral index,Propofol injection in 240 s,Propofol injection in 5 s,Significantly increased,"The lowest mean BISmin was measured in group 1 (28.7 ± 10.3). In group 2, BISmin was 33.0 (±13.9), and in group 3, BISmin was 36.4 (±11.0). There were no significant differences between group 2 and groups 1 or 3, but there were significant differences between groups 1 and 3.",5189:5497,1523225,16878179,Unavailable
1523225,Bispectral index,Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,"The lowest mean BISmin was measured in group 1 (28.7 ± 10.3). In group 2, BISmin was 33.0 (±13.9), and in group 3, BISmin was 36.4 (±11.0). There were no significant differences between group 2 and groups 1 or 3, but there were significant differences between groups 1 and 3.",5189:5497,1523225,16878179,Unavailable
1523225,Bispectral index,Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,"The lowest mean BISmin was measured in group 1 (28.7 ± 10.3). In group 2, BISmin was 33.0 (±13.9), and in group 3, BISmin was 36.4 (±11.0). There were no significant differences between group 2 and groups 1 or 3, but there were significant differences between groups 1 and 3.",5189:5497,1523225,16878179,Unavailable
1523225,Bispectral index,Propofol injection in 240 s,Propofol injection in 5 s,Significantly increased,"The lowest mean BISmin was measured in group 1 (28.7 ± 10.3). In group 2, BISmin was 33.0 (±13.9), and in group 3, BISmin was 36.4 (±11.0). This difference was statistically significant only between groups 1 and 3, whereas BISmin of group 2 showed no significant difference from either of the other two groups",21457:21813,1523225,16878179,Unavailable
1523225,Bispectral index,Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,"The lowest mean BISmin was measured in group 1 (28.7 ± 10.3). In group 2, BISmin was 33.0 (±13.9), and in group 3, BISmin was 36.4 (±11.0). This difference was statistically significant only between groups 1 and 3, whereas BISmin of group 2 showed no significant difference from either of the other two groups",21457:21813,1523225,16878179,Unavailable
1523225,Bispectral index,Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,"The lowest mean BISmin was measured in group 1 (28.7 ± 10.3). In group 2, BISmin was 33.0 (±13.9), and in group 3, BISmin was 36.4 (±11.0). This difference was statistically significant only between groups 1 and 3, whereas BISmin of group 2 showed no significant difference from either of the other two groups",21457:21813,1523225,16878179,Unavailable
1523225,Time to maximum effect,Propofol injection in 240 s,Propofol injection in 5 s,Significantly increased,"In group 1, t-BISmin was reached after 102.91 s (±44.20), in group 2 after 172.33 s (±29.76), and in group 3 after 274.21 s (±45.40). These differences were statistically significant for all comparisons",22765:22978,1523225,16878179,Unavailable
1523225,Time to maximum effect,Propofol injection in 240 s,Propofol injection in 120 s,Significantly increased,"In group 1, t-BISmin was reached after 102.91 s (±44.20), in group 2 after 172.33 s (±29.76), and in group 3 after 274.21 s (±45.40). These differences were statistically significant for all comparisons",22765:22978,1523225,16878179,Unavailable
1523225,Time to maximum effect,Propofol injection in 120 s,Propofol injection in 5 s,Significantly increased,"In group 1, t-BISmin was reached after 102.91 s (±44.20), in group 2 after 172.33 s (±29.76), and in group 3 after 274.21 s (±45.40). These differences were statistically significant for all comparisons",22765:22978,1523225,16878179,Unavailable
1523225,Time to maximum effect,Propofol injection in 240 s,Propofol injection in 5 s,Significantly increased,"In group 1, BISmin was reached after 102.91 s (±44.20), in group 2 after 172.33 s (±29.76), and in group 3 after 274.21 s (±45.40). These differences were statistically significant for all comparisons. In summary, the lowest value for BISmin was achieved in the group with the fastest rate of propofol injection",5497:5831,1523225,16878179,Unavailable
1523225,Time to maximum effect,Propofol injection in 240 s,Propofol injection in 120 s,Significantly increased,"In group 1, BISmin was reached after 102.91 s (±44.20), in group 2 after 172.33 s (±29.76), and in group 3 after 274.21 s (±45.40). These differences were statistically significant for all comparisons. In summary, the lowest value for BISmin was achieved in the group with the fastest rate of propofol injection",5498:5831,1523225,16878179,Unavailable
1523225,Time to maximum effect,Propofol injection in 120 s,Propofol injection in 5 s,Significantly increased,"In group 1, BISmin was reached after 102.91 s (±44.20), in group 2 after 172.33 s (±29.76), and in group 3 after 274.21 s (±45.40). These differences were statistically significant for all comparisons. In summary, the lowest value for BISmin was achieved in the group with the fastest rate of propofol injection",5497:5831,1523225,16878179,Unavailable
1523225,BIS at loss of consciousness,Propofol injection in 240 s,Propofol injection in 5 s,Significantly decreased,"For both, BIS-LOC and BIS-LOL values in group 1 (5 s) were significantly higher than in group 2 (120 s) or group 3 (240 s). There were no significant differences between group 2 and group 3.",24762:24953,1523225,16878179,Unavailable
1523225,BIS at loss of consciousness,Propofol injection in 120 s,Propofol injection in 5 s,Significantly decreased,"For both, BIS-LOC and BIS-LOL values in group 1 (5 s) were significantly higher than in group 2 (120 s) or group 3 (240 s). There were no significant differences between group 2 and group 3.",24762:24953,1523225,16878179,Unavailable
1523225,BIS at loss of consciousness,Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,"For both, BIS-LOC and BIS-LOL values in group 1 (5 s) were significantly higher than in group 2 (120 s) or group 3 (240 s). There were no significant differences between group 2 and group 3.",24762:24953,1523225,16878179,Unavailable
1523225,BIS at loss of lash reflex,Propofol injection in 240 s,Propofol injection in 5 s,Significantly decreased,"For both, BIS-LOC and BIS-LOL values in group 1 (5 s) were significantly higher than in group 2 (120 s) or group 3 (240 s). There were no significant differences between group 2 and group 3.",24762:24953,1523225,16878179,Unavailable
1523225,BIS at loss of lash reflex,Propofol injection in 120 s,Propofol injection in 5 s,Significantly decreased,"For both, BIS-LOC and BIS-LOL values in group 1 (5 s) were significantly higher than in group 2 (120 s) or group 3 (240 s). There were no significant differences between group 2 and group 3.",24762:24953,1523225,16878179,Unavailable
1523225,BIS at loss of lash reflex,Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,"For both, BIS-LOC and BIS-LOL values in group 1 (5 s) were significantly higher than in group 2 (120 s) or group 3 (240 s). There were no significant differences between group 2 and group 3.",24762:24953,1523225,16878179,Unavailable
1523225,BIS 30s after loss of consciousness,Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,"BIS-LOC+30s is the BIS value 30 seconds after LOC. BIS-LOC+30s was 49.1 (±25.2) in group 1, 49.9 (±19.9) in group 2, and 50.7 (±14.6) in group 3. There were no significant differences in BIS-LOC+30s between the three groups.",25028:25285,1523225,16878179,Unavailable
1523225,BIS 30s after loss of consciousness,Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,"BIS-LOC+30s is the BIS value 30 seconds after LOC. BIS-LOC+30s was 49.1 (±25.2) in group 1, 49.9 (±19.9) in group 2, and 50.7 (±14.6) in group 3. There were no significant differences in BIS-LOC+30s between the three groups.",25028:25285,1523225,16878179,Unavailable
1523225,BIS 30s after loss of consciousness,Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,"BIS-LOC+30s is the BIS value 30 seconds after LOC. BIS-LOC+30s was 49.1 (±25.2) in group 1, 49.9 (±19.9) in group 2, and 50.7 (±14.6) in group 3. There were no significant differences in BIS-LOC+30s between the three groups.",25028:25285,1523225,16878179,Unavailable
1523225,Heart rate (Max),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,MAP (Max),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,SBP (Max),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,DBP (Max),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,Heart rate (Min),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,MAP (Min),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,SBP (Min),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,DBP (Min),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,Heart rate (Max),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,MAP (Max),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,SBP (Max),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,DBP (Max),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,Heart rate (Min),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,MAP (Min),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,SBP (Min),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,DBP (Min),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,Heart rate (Max),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,MAP (Max),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,SBP (Max),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,DBP (Max),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,Heart rate (Min),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,MAP (Min),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,SBP (Min),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,DBP (Min),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The maximum and minimum values of hemodynamic parameters from the beginning of propofol injection to the end of the investigation were identified. These minima and maxima did not show significant differences between groups,25902:26125,1523225,16878179,Unavailable
1523225,Heart rate (Max),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,MAP (Max),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,SBP (Max),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,DBP (Max),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5955:6029,1523225,16878179,Unavailable
1523225,Heart rate (Min),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,MAP (Min),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,SBP (Min),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,DBP (Min),Propofol injection in 240 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,Heart rate (Max),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5955:6029,1523225,16878179,Unavailable
1523225,MAP (Max),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,SBP (Max),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,DBP (Max),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,Heart rate (Min),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5955:6029,1523225,16878179,Unavailable
1523225,MAP (Min),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,SBP (Min),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,DBP (Min),Propofol injection in 120 s,Propofol injection in 5 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,Heart rate (Max),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,MAP (Max),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,SBP (Max),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5955:6029,1523225,16878179,Unavailable
1523225,DBP (Max),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,Heart rate (Min),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5955:6029,1523225,16878179,Unavailable
1523225,MAP (Min),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,SBP (Min),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
1523225,DBP (Min),Propofol injection in 240 s,Propofol injection in 120 s,No significant difference,The hemodynamic parameters were not significantly different among groups.,5956:6029,1523225,16878179,Unavailable
3665829,Knowledge of cyber bullying,Cyber Bullying Prevention Program,Control,Significantly increased,"The results show that the WebQuest course immediately and effectively enhanced the knowledge of cyber bullying, reduced the intentions, and retained the effects after the learning.",6251:6431,3665829,23724018,Unavailable
3665829,Intentions of cyber bullying,Cyber Bullying Prevention Program,Control,Significantly decreased,"The results show that the WebQuest course immediately and effectively enhanced the knowledge of cyber bullying, reduced the intentions, and retained the effects after the learning.",6251:6431,3665829,23724018,Unavailable
3665829,Attitude toward cyber bullying.,Cyber Bullying Prevention Program,Control,No significant difference,"The results show that the WebQuest course immediately and effectively enhanced the knowledge of cyber bullying, reduced the intentions, and retained the effects after the learning.",6251:6431,3665829,23724018,Unavailable
3665829,Knowledge of cyber bullying,Cyber Bullying Prevention Program,Control,Significantly increased,"With controlling the scores of the pre-test, the post-test, the follow-up posttest, and the interaction between group and time, the mean difference in the score of knowledge between the experimental and the control groups was 8.58, which was significantly different (p = .028).",25750:26028,3665829,23724018,Unavailable
3665829,Attitude toward cyber bullying.,Cyber Bullying Prevention Program,Control,No significant difference,"With controlling the scores of the pretest, the post-test, the post-posttest, and the interaction of group and time, the mean difference in the scores of the attitude scale between the experimental and the control groups was 2.87, which was not significantly different.",29637:29908,3665829,23724018,Unavailable
3665829,Intentions of cyber bullying,Cyber Bullying Prevention Program,Control,Significantly decreased,"With controlling pretest, group, the interaction of group and time, there was a significant difference for the post-test and the post-posttest. The score for the post-test decreased by 5.39, which was significant (p = .005); and the score for the follow-up posttest decreased by 5.81, which was significant (p = .002).",33830:34148,3665829,23724018,Unavailable
3510746,Attrition,Assessment and feedback,Feedback only,No significant difference,"Attrition was similar in groups 1 (697/1742, 40.01%) and 2 (737/1742, 42.31% retained) and lower in group 3 (902/1743, 51.75% retained).",7388:7524,3510746,23113955,Unavailable
3510746,Attrition,Assessment and feedback,Control,Significantly increased,"Attrition was similar in groups 1 (697/1742, 40.01%) and 2 (737/1742, 42.31% retained) and lower in group 3 (902/1743, 51.75% retained).",30914:30984,3510746,23113955,Unavailable
3510746,Attrition,Feedback only,Control,Significantly increased,"Attrition was similar in groups 1 (697/1742, 40.01%) and 2 (737/1742, 42.31% retained) and lower in group 3 (902/1743, 51.75% retained).",30914:30984,3510746,23113955,Unavailable
3510746,Attrition,Assessment and feedback,Feedback only,No significant difference,"At follow-up, however, attrition was higher in groups 1 and 2 than in group 3 (Table 1). Thus, the response rate for the follow-up survey was approximately 52% in group 3 compared with around 41% in group 1 and 2 (P &lt; .001, χ2 2 = 54.6).",26521:26843,3510746,23113955,Unavailable
3510746,Attrition,Assessment and feedback,Control,Significantly increased,"At follow-up, however, attrition was higher in groups 1 and 2 than in group 3 (Table 1). Thus, the response rate for the follow-up survey was approximately 52% in group 3 compared with around 41% in group 1 and 2 (P &lt; .001, χ2 2 = 54.6).",26521:26843,3510746,23113955,Unavailable
3510746,Attrition,Feedback only,Control,Significantly increased,"At follow-up, however, attrition was higher in groups 1 and 2 than in group 3 (Table 1). Thus, the response rate for the follow-up survey was approximately 52% in group 3 compared with around 41% in group 1 and 2 (P &lt; .001, χ2 2 = 54.6).",26521:26843,3510746,23113955,Unavailable
3510746,Total AUDIT score,Assessment and feedback,Feedback only,No significant difference,"AUDIT a scoreTotal, mean (SD)	7.3 (5.9)	6.9 (5.5)	7.3 (5.9)	1.31b (1432) .19	0.29b (1597) .77	–1.09b (1637) .28",36847:37365,3510746,23113955,Unavailable
3510746,Total AUDIT score,Assessment and feedback,Control,No significant difference,"AUDIT a scoreTotal, mean (SD) 7.3 (5.9) 6.9 (5.5) 7.3 (5.9) 1.31b (1432) .19 0.29b (1597) .77 –1.09b (1637) .28",36847:37365,3510746,23113955,Unavailable
3510746,Total AUDIT score,Feedback only,Control,No significant difference,"AUDIT a scoreTotal, mean (SD) 7.3 (5.9) 6.9 (5.5) 7.3 (5.9) 1.31b (1432) .19 0.29b (1597) .77 –1.09b (1637) .28",36847:37365,3510746,23113955,Unavailable
3510746, AUDIT score ≥8 (men)/6 (women),Assessment and feedback,Feedback only,No significant difference,"≥8 (men)/6 (women) (n, %)	354 (50.8%)	364 (49.4%)	454 (50.3%)	0.28c (1) .6	0.03c (1) .9	0.14c (1) .7",37455:37840,3510746,23113955,Unavailable
3510746, AUDIT score ≥8 (men)/6 (women),Assessment and feedback,Control,No significant difference,"≥8 (men)/6 (women) (n, %) 354 (50.8%) 364 (49.4%) 454 (50.3%) 0.28c (1) .6 0.03c (1) .9 0.14c (1) .7",37455:37840,3510746,23113955,Unavailable
3510746, AUDIT score ≥8 (men)/6 (women),Feedback only,Control,No significant difference,"≥8 (men)/6 (women) (n, %) 354 (50.8%) 364 (49.4%) 454 (50.3%) 0.28c (1) .6 0.03c (1) .9 0.14c (1) .7",37455:37840,3510746,23113955,Unavailable
3510746,Problem score,Assessment and feedback,Feedback only,No significant difference,"Problem score (mean, SD)	1.8 (2.7)	1.6 (2.4)	1.8 (2.6)	1.81b (1432) .07	0.50b (1597) .62	–1.41c (1637) .2",37930:38320,3510746,23113955,Unavailable
3510746,Problem score,Assessment and feedback,Control,No significant difference,"Problem score (mean, SD)	1.8 (2.7)	1.6 (2.4)	1.8 (2.6)	1.81b (1432) .07	0.50b (1597) .62	–1.41c (1637) .2",37930:38320,3510746,23113955,Unavailable
3510746,Problem score,Feedback only,Control,No significant difference,"Problem score (mean, SD)	1.8 (2.7)	1.6 (2.4)	1.8 (2.6)	1.81b (1432) .07	0.50b (1597) .62	–1.41c (1637) .2",37930:38320,3510746,23113955,Unavailable
3510746,Dependence score,Assessment and feedback,Feedback only,No significant difference,"Dependence score (mean, SD)	0.8 (1.4)	0.7 (1.2)	0.8 (1.4)	1.21b (1432) .23	–0.16b (1597) .87	–1.44c (1637) .2",38410:38804,3510746,23113955,Unavailable
3510746,Dependence score,Feedback only,Control,No significant difference,"Dependence score (mean, SD)	0.8 (1.4)	0.7 (1.2)	0.8 (1.4)	1.21b (1432) .23	–0.16b (1597) .87	–1.44c (1637) .2",38410:38804,3510746,23113955,Unavailable
3510746,Dependence score,Assessment and feedback,Control,No significant difference,"Dependence score (mean, SD) 0.8 (1.4) 0.7 (1.2) 0.8 (1.4) 1.21b (1432) .23 –0.16b (1597) .87 –1.44c (1637) .2",39335:39841,3510746,23113955,Unavailable
3510746,Weekly consumption,Assessment and feedback,Feedback only,No significant difference,"Weekly consumption (g), mean (median)	79.8 (48.0)	79.7 (48.0)	86.0 (48.0)	0.55b (1432) .58	–0.25b (1597) .80	–0.83b (1637) .41",38861:39272,3510746,23113955,Unavailable
3510746,Weekly consumption,Feedback only,Control,No significant difference,"Weekly consumption (g), mean (median)	79.8 (48.0)	79.7 (48.0)	86.0 (48.0)	0.55b (1432) .58	–0.25b (1597) .80	–0.83b (1637) .41",38861:39272,3510746,23113955,Unavailable
3510746,Weekly consumption,Assessment and feedback,Control,No significant difference,"Weekly consumption (g), mean (median) 79.8 (48.0) 79.7 (48.0) 86.0 (48.0) 0.55b (1432) .58 –0.25b (1597) .80 –0.83b (1637) .41",39335:39841,3510746,23113955,Unavailable
3510746,Absence of monthly heavy episodic drinking,Assessment and feedback,Feedback only,No significant difference,"Frequency of monthly heavy episodic drinkingNever	171 (24.5%)	189 (25.6%)	244 (27.1%)	2.61c (4) .6	4.70c (4) .3	0.78c (4) .9",39335:39841,3510746,23113955,Unavailable
3510746,Absence of monthly heavy episodic drinking,Feedback only,Control,No significant difference,"Frequency of monthly heavy episodic drinkingNever	171 (24.5%)	189 (25.6%)	244 (27.1%)	2.61c (4) .6	4.70c (4) .3	0.78c (4) .9",39335:39841,3510746,23113955,Unavailable
3510746,Absence of monthly heavy episodic drinking,Assessment and feedback,Control,No significant difference,Frequency of monthly heavy episodic drinkingNever 171 (24.5%) 189 (25.6%) 244 (27.1%) 2.61c (4) .6 4.70c (4) .3 0.78c (4) .9,39335:39841,3510746,23113955,Unavailable
3510746,Total AUDIT score,Assessment and feedback,Feedback only,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Total AUDIT score,Assessment and feedback,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Total AUDIT score,Feedback only,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7712,3510746,23113955,Unavailable
3510746, AUDIT score ≥8 (men)/6 (women),Assessment and feedback,Feedback only,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7712,3510746,23113955,Unavailable
3510746, AUDIT score ≥8 (men)/6 (women),Assessment and feedback,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7712,3510746,23113955,Unavailable
3510746, AUDIT score ≥8 (men)/6 (women),Feedback only,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Problem score,Assessment and feedback,Feedback only,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Problem score,Assessment and feedback,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Problem score,Feedback only,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7712,3510746,23113955,Unavailable
3510746,Dependence score,Assessment and feedback,Feedback only,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7712,3510746,23113955,Unavailable
3510746,Dependence score,Feedback only,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Dependence score,Assessment and feedback,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Weekly consumption,Assessment and feedback,Feedback only,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Weekly consumption,Feedback only,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7712,3510746,23113955,Unavailable
3510746,Weekly consumption,Assessment and feedback,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Absence of monthly heavy episodic drinking,Assessment and feedback,Feedback only,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Absence of monthly heavy episodic drinking,Feedback only,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7711,3510746,23113955,Unavailable
3510746,Absence of monthly heavy episodic drinking,Assessment and feedback,Control,No significant difference,Intention-to-treat analyses among all participants regardless of their baseline drinking status revealed no differences between groups in all alcohol parameters at the 2-month follow-up.,7525:7712,3510746,23113955,Unavailable
5688892,Patient Health Questionnaire 15,Cognitive behavior therapy-based counseling,Control,No significant difference,Both groups did not differ on change in the primary outcome measure: Patient Health Questionnaire – 15 scores (P = 0.055).,18525:18658,5688892,29200561,Unavailable
5688892,Workdays lost ,Cognitive behavior therapy-based counseling,Control,Significantly decreased,"However, at follow-up, the intervention group showed statistically greater reduction in the number of workdays lost (P = 0.005).",4913:5059,5688892,29200561,Unavailable
5688892,Patient Health Questionnaire 9,Cognitive behavior therapy-based counseling,Control,Significantly decreased,The intervention and control groups differed on change in PHQ-9 scores and the number of workdays lost in last 1 month from baseline.,19231:19433,5688892,29200561,Unavailable
5688892,Workdays lost ,Cognitive behavior therapy-based counseling,Control,Significantly decreased,The intervention and control groups differed on change in PHQ-9 scores and the number of workdays lost in last 1 month from baseline.,18525:18658,5688892,29200561,Unavailable
5688892,Patient Health Questionnaire 15,Cognitive behavior therapy-based counseling,Control,No significant difference,"For PHQ-15, time (i.e., follow-up) was not associated with significant decrease in the scores (Pillai's Trace F = 3.811, P = 0.055 and partial η2 = 0.054).",19231:19433,5688892,29200561,Unavailable
5688892,Generalized anxiety disorder 7,Cognitive behavior therapy-based counseling,Control,No significant difference,"Regarding secondary outcomes, the scores on GAD-7 decreased with time (Pillai's Trace F = 8.713, P = 0.004 and partial η2 = 0.115), but group membership (intervention versus control) or gender did not have a moderating influence on the outcome.",19514:19803,5688892,29200561,Unavailable
5688892,Workdays lost ,Cognitive behavior therapy-based counseling,Control,Significantly decreased,"For the number of workdays lost in a month, both time (Pillai's Trace F = 19.684, P &lt; 0.001 and partial η2 = 0.230) and time X group interaction were significant (Pillai's Trace F = 8.281, P = 0.005 and partial η2 = 0.111). This suggested that the number of workdays lost decreased in both groups, and the decrease was more in the intervention (SSC) group.",20477:20927,5688892,29200561,Unavailable
5688892,Patient Health Questionnaire 9,Cognitive behavior therapy-based counseling,Control,Significantly decreased,"The scores on PHQ-9 significantly decreased with time (Pillai's Trace F = 9.512, P = 0.003 and partial η2 = 0.124). The time X group interaction suggested a trend level significance with the reduction in scores more pronounced in the intervention group (Pillai's Trace F = 5.530, P = 0.022 and partial η2 = 0.076).",19804:20208,5688892,29200561,Unavailable
4920480,Pounds lost (week 16),Economical incentive (overall),No incentive ,Significantly increased,"IG lost on average more pounds (p=0.027), reduced BMI (p=0.04), and reduced in DRS (p=0.011) compared to NIG at week 16.",24584:24703,4920480,27347276,Unavailable
4920480,BMI (week 16),Economical incentive (overall),No incentive ,Significantly decreased,"IG lost on average more pounds (p=0.027), reduced BMI (p=0.04), and reduced in DRS (p=0.011) compared to NIG at week 16.",24584:24703,4920480,27347276,Unavailable
4920480,Diabetes risk score (week 16),Economical incentive (overall),No incentive ,Significantly decreased,"IG lost on average more pounds (p=0.027), reduced BMI (p=0.04), and reduced in DRS (p=0.011) compared to NIG at week 16.",24584:24703,4920480,27347276,Unavailable
4920480,Achieving weight loss goals (week 28),Economical incentive (standard) ,No incentive ,Significantly increased,"At the 12-week follow-up period, those in IG plus deposit subgroup had twice the odds (OR=2.2, p=0.042) and those in the standard IG had three times the odds of achieving weight loss goals than NIG",4638:4703,4920480,27347276,Unavailable
4920480,Achieving weight loss goals (week 28),Economical incentive (plus deposit),No incentive ,Significantly increased,"At the 12-week follow-up period, those in IG plus deposit subgroup had twice the odds (OR=2.2, p=0.042) and those in the standard IG had three times the odds of achieving weight loss goals than NIG",4638:4703,4920480,27347276,Unavailable
4920480,Diabetes risk score (week 28),Economical incentive (plus deposit),No incentive ,Significantly decreased,those in the IG plus deposit group reduced DRS by 0.4 (p=0.045).,4638:4703,4920480,27347276,Unavailable
4920480,Pounds lost (week 16),Economical incentive (overall),No incentive ,Significantly increased,Participants in the two IG subgroups collectively lost an average of 5.05 pounds more (p=0.027) than those in the NIG at week 16.,24584:24703,4920480,27347276,Unavailable
4920480,BMI (week 16),Economical incentive (overall),No incentive ,Significantly decreased,BMI decreased by an average of 1.73kg/m2 more in IG than in NIG participants (p=0.043).,24584:24703,4920480,27347276,Unavailable
4920480,Diabetes risk score (week 16),Economical incentive (overall),No incentive ,Significantly decreased,DRS decreased by an average 1.26 points more (p=0.011) among persons in the IG than those in the NIG.,24584:24703,4920480,27347276,Unavailable
4920480,Pounds lost (week 16),Economical incentive (plus deposit),No incentive ,Significantly increased,Participants in the standard plus deposit subgroup lost an average of 4.45 pounds more (p=0.042) than those in the NIG.,24584:24703,4920480,27347276,Unavailable
4920480,Achieving weight loss goals (week 16),Economical incentive (plus deposit),No incentive ,Significantly increased,Their odds of achieving weight-loss goals were 4.5 times those in the NIG (p=0.046).,24703:24788,4920480,27347276,Unavailable
4920480,BMI (week 16),Economical incentive (plus deposit),No incentive ,Significantly decreased,"For persons in the standard plus deposit subgroup, on average, BMI decreased by 1.62kg/m2 (p=0.042) and DRS decreased by 2.05 points more (p=0.001) than for those in the NIG.",24789:24974,4920480,27347276,Unavailable
4920480,Diabetes risk score (week 16),Economical incentive (plus deposit),No incentive ,Significantly decreased,"For persons in the standard plus deposit subgroup, on average, BMI decreased by 1.62kg/m2 (p=0.042) and DRS decreased by 2.05 points more (p=0.001) than for those in the NIG.",24789:24974,4920480,27347276,Unavailable
4920480,Healthy eating (week 16),Economical incentive (plus deposit),No incentive ,Significantly increased,The likelihood for persons in the standard plus deposit subgroup of healthy eating increased by 47 percentage points more (p=0.011) than for those in the NIG group.,24974:25140,4920480,27347276,Unavailable
4920480,Pounds lost (week 16),Economical incentive (standard),No incentive ,No significant difference,"At week 16, in the standard subgroup compared with the NIG group, the likelihood of healthy eating increased by 36 percentage points (p=0.020); there were no significant changes in the other outcome measures.",25139:25348,4920480,27347276,Unavailable
4920480,Achieving weight loss goals (week 16),Economical incentive (standard),No incentive ,No significant difference,"At week 16, in the standard subgroup compared with the NIG group, the likelihood of healthy eating increased by 36 percentage points (p=0.020); there were no significant changes in the other outcome measures.",25139:25348,4920480,27347276,Unavailable
4920480,BMI (week 16),Economical incentive (standard),No incentive ,No significant difference,"At week 16, in the standard subgroup compared with the NIG group, the likelihood of healthy eating increased by 36 percentage points (p=0.020); there were no significant changes in the other outcome measures.",25139:25348,4920480,27347276,Unavailable
4920480,Diabetes risk score (week 16),Economical incentive (standard),No incentive ,No significant difference,"At week 16, in the standard subgroup compared with the NIG group, the likelihood of healthy eating increased by 36 percentage points (p=0.020); there were no significant changes in the other outcome measures.",25139:25348,4920480,27347276,Unavailable
4920480,Healthy eating (week 16),Economical incentive (standard),No incentive ,Significantly increased,"At week 16, in the standard subgroup compared with the NIG group, the likelihood of healthy eating increased by 36 percentage points (p=0.020); there were no significant changes in the other outcome measures.",25139:25348,4920480,27347276,Unavailable
4920480,Pounds lost (week 28),Economical incentive (overall),No incentive ,No significant difference,"At week 28 (12 weeks follow-up), the likelihood of healthy eating, increased by 26 percentage points more (p=0.013) in the collective IG than in the NIG; this was the only significant change",25364:25555,4920480,27347276,Unavailable
4920480,BMI (week 28),Economical incentive (overall),No incentive ,No significant difference,"At week 28 (12 weeks follow-up), the likelihood of healthy eating, increased by 26 percentage points more (p=0.013) in the collective IG than in the NIG; this was the only significant change",25364:25554,4920480,27347276,Unavailable
4920480,Diabetes risk score (week 28),Economical incentive (overall),No incentive ,No significant difference,"At week 28 (12 weeks follow-up), the likelihood of healthy eating, increased by 26 percentage points more (p=0.013) in the collective IG than in the NIG; this was the only significant change",25364:25554,4920480,27347276,Unavailable
4920480,Healthy eating (week 28),Economical incentive (overall),No incentive ,Significantly increased,"At week 28 (12 weeks follow-up), the likelihood of healthy eating, increased by 26 percentage points more (p=0.013) in the collective IG than in the NIG; this was the only significant change",25364:25554,4920480,27347276,Unavailable
4920480,Achieving weight loss goals (week 28),Economical incentive (overall) ,No incentive ,No significant difference,"At week 28 (12 weeks follow-up), the likelihood of healthy eating, increased by 26 percentage points more (p=0.013) in the collective IG than in the NIG; this was the only significant change",25364:25554,4920480,27347276,Unavailable
4920480,Achieving weight loss goals (week 28),Economical incentive (plus deposit) ,No incentive ,Significantly increased,The odds of a person in the standard plus deposit subgroup achieving his or her weight-loss goal were 2.71 times more (p=0.042) than for a person in the NIG.,26017:26121,4920480,27347276,Unavailable
4920480,Diabetes risk score (week 28),Economical incentive (plus deposit) ,No incentive ,Significantly decreased,DRS was 0.40 lower (p=0.045) than for those in the NIG.,26017:26121,4920480,27347276,Unavailable
4920480,Healthy eating (week 28),Economical incentive (plus deposit) ,No incentive ,Significantly increased,The likelihood of healthy eating increased by 42 percentage points more (p=0.001) than in the NIG group.,26017:26121,4920480,27347276,Unavailable
4920480,Pounds lost (week 28),Economical incentive (standard) ,No incentive ,Significantly increased,"For participants in the standard subgroup, weight loss outcomes were significant at the end of the 28 weeks. Participants in the standard subgroup lost an average of 5.11 pounds more (p=0.047) than those in the NIG.",26137:26353,4920480,27347276,Unavailable
4920480,Achieving weight loss goals (week 28),Economical incentive (standard) ,No incentive ,Significantly increased,The odds of a person in the standard subgroup achieving his or her weight-loss goal were 2.89 times more (p=0.005) than for a person in the NIG.,26353:26497,4920480,27347276,Unavailable
3525317,Blood flow volume,LR3 ,ST36,Significantly increased,Stimulation at LR3 elicited a significant increase in BFV compared to that at ST36 and the non-acupoint.,4242:4346,3525317,23304231,Unavailable
3525317,Blood flow volume,LR3 ,Control,Significantly increased,Stimulation at LR3 elicited a significant increase in BFV compared to that at ST36 and the non-acupoint.,16688:16873,3525317,23304231,Unavailable
3525317,SBP,LR3 ,ST36,No significant difference,No significant differences were observed among the 3 groups or with respect to the percent change in systolic or diastolic blood pressure in each test before and after needle insertion.,16688:16873,3525317,23304231,Unavailable
3525317,SBP,LR3 ,Control,No significant difference,No significant differences were observed among the 3 groups or with respect to the percent change in systolic or diastolic blood pressure in each test before and after needle insertion.,16688:16873,3525317,23304231,Unavailable
3525317,SBP,ST36,Control,No significant difference,No significant differences were observed among the 3 groups or with respect to the percent change in systolic or diastolic blood pressure in each test before and after needle insertion.,16688:16873,3525317,23304231,Unavailable
3525317,DBP,LR3 ,ST36,No significant difference,No significant differences were observed among the 3 groups or with respect to the percent change in systolic or diastolic blood pressure in each test before and after needle insertion.,16688:16873,3525317,23304231,Unavailable
3525317,DBP,LR3 ,Control,No significant difference,No significant differences were observed among the 3 groups or with respect to the percent change in systolic or diastolic blood pressure in each test before and after needle insertion.,16688:16873,3525317,23304231,Unavailable
3525317,DBP,ST36,Control,No significant difference,No significant differences were observed among the 3 groups or with respect to the percent change in systolic or diastolic blood pressure in each test before and after needle insertion.,16688:16873,3525317,23304231,Unavailable
3525317,Heart rate,LR3 ,ST36,No significant difference,No significant differences were observed among the 3 groups with respect to the percent change in heart rate in each test.,16934:17056,3525317,23304231,Unavailable
3525317,Heart rate,LR3 ,Control,No significant difference,No significant differences were observed among the 3 groups with respect to the percent change in the CI in each test.,17367:17485,3525317,23304231,Unavailable
3525317,Heart rate,ST36,Control,No significant difference,No significant differences were observed among the 3 groups with respect to the percent change in the CI in each test.,17367:17486,3525317,23304231,Unavailable
3525317,Cardiac Index,LR3 ,ST36,No significant difference,No significant differences were observed among the 3 groups with respect to the percent change in the CI in each test.,17367:17485,3525317,23304231,Unavailable
3525317,Cardiac Index,LR3 ,Control,No significant difference,No significant differences were observed among the 3 groups with respect to the percent change in the CI in each test.,17367:17486,3525317,23304231,Unavailable
3525317,Cardiac Index,ST36,Control,No significant difference,No significant differences were observed among the 3 groups with respect to the percent change in the CI in each test.,17367:17486,3525317,23304231,Unavailable
3525317,Systemic Vascular Resistance Index,LR3 ,ST36,No significant difference,No significant differences were observed among the 3 groups with respect to the percent change in SVRI in each test,17776:17892,3525317,23304231,Unavailable
3525317,Systemic Vascular Resistance Index,LR3 ,Control,No significant difference,No significant differences were observed among the 3 groups with respect to the percent change in SVRI in each test,17776:17892,3525317,23304231,Unavailable
3525317,Systemic Vascular Resistance Index,ST36,Control,No significant difference,No significant differences were observed among the 3 groups with respect to the percent change in SVRI in each test,17776:17892,3525317,23304231,Unavailable
3525317,Blood flow volume,LR3 ,ST36,Significantly increased,The percent change in BFV in the BA was significantly different between the LR3 group and the other 2 groups.,18348:18458,3525317,23304231,Unavailable
3525317,Blood flow volume,LR3 ,Control,Significantly increased,The percent change in BFV in the BA was significantly different between the LR3 group and the other 2 groups.,18348:18457,3525317,23304231,Unavailable
4644570,Bone fill %,Bone matrix gelatin,Placebo,Significantly increased,The percentage of bone fill at specific time points showed significantly greater levels within BMG-treated defects than ACS-treated defects (p&lt;0.05).,15740:15903,4644570,26576263,Unavailable
4644570,Bone fill % (new bone),Bone matrix gelatin,Placebo,Significantly increased,The mean±SD percentage of bone fill of newly formed bone after 90 days in BMG-treated defects (27.83±3.07) was significantly (p=0.044) higher than that in ACS-treated defects (22.64±2.14).,15740:15903,4644570,26576263,Unavailable
4644570,Bone Density,Bone matrix gelatin,Placebo,Significantly increased,The percentage of bone density after 90 days in BMG-treated defects (65.45±4.54) was significantly (p=0.004) higher than that in ACS-treated defects (59.43±4.00).,15740:15903,4644570,26576263,Unavailable
4644570,Bone fill %,Bone matrix gelatin,Placebo,Significantly increased,Assessment of the alveolar bone indicated that patients treated with BMG had significantly (p&lt;0.05) better bone quality and quantity compared to the controls.,4406:4564,4644570,26576263,Unavailable
4644570,Bone fill % (new bone),Bone matrix gelatin,Placebo,Significantly increased,Assessment of the alveolar bone indicated that patients treated with BMG had significantly (p&lt;0.05) better bone quality and quantity compared to the controls.,4406:4564,4644570,26576263,Unavailable
4644570,Bone Density,Bone matrix gelatin,Placebo,Significantly increased,Assessment of the alveolar bone indicated that patients treated with BMG had significantly (p&lt;0.05) better bone quality and quantity compared to the controls.,4406:4564,4644570,26576263,Unavailable
4584965,Hunger (after 0 min),Inzone Preload,Control,Significantly decreased,"Regarding the questions on aspects of hunger, subjects reported a lower level of hunger after the Inzone Preload than after the habitual breakfast at 0 min (p = 0.047) and after 30 min (p = 0.352).",31996:32227,4584965,26441829,Unavailable
4584965,Hunger (after 30 min),Inzone Preload,Control,Significantly decreased,"Regarding the questions on aspects of hunger, subjects reported a lower level of hunger after the Inzone Preload than after the habitual breakfast at 0 min (p = 0.047) and after 30 min (p = 0.352).",31996:32227,4584965,26441829,Unavailable
4584965,AUC for hunger (after 0 min),Inzone Preload,Control,No significant difference,No differences were observed in the AUCs for hunger (p = 0.241),32228:32308,4584965,26441829,Unavailable
4584965,AUC for hunger (after 30 min),Inzone Preload,Control,No significant difference,No differences were observed in the AUCs for hunger (p = 0.241),32228:32308,4584965,26441829,Unavailable
4584965,Satiety (after 0 min),Inzone Preload,Control,Significantly increased,Feelings of satiety were significantly higher after Inzone Preload than after habitual breakfast (p &lt; 0.05).,7055:7181,4584965,26441829,Unavailable
4584965,Satiety (after 30 min),Inzone Preload,Control,Significantly increased,Feelings of satiety were significantly higher after Inzone Preload than after habitual breakfast (p &lt; 0.05).,7055:7181,4584965,26441829,Unavailable
4584965,Satiety (after 0 min),Inzone Preload,Control,Significantly increased,"The Inzone Preload intervention resulted in a significantly higher postprandial satiety at the onset of the meal (at time point 0 min, 30 min after preload was given) (p = 0.045) and 30 min (p = 0.042) after the habitual breakfast",31572:31837,4584965,26441829,Unavailable
4584965,Satiety (after 30 min),Inzone Preload,Control,Significantly increased,"The Inzone Preload intervention resulted in a significantly higher postprandial satiety at the onset of the meal (at time point 0 min, 30 min after preload was given) (p = 0.045) and 30 min (p = 0.042) after the habitual breakfast",31572:31836,4584965,26441829,Unavailable
4584965,AUCs for satiety (after 0 min),Inzone Preload,Control,No significant difference,The AUCs for satiety were not significantly larger at any time after Inzone Preload than habitual breakfast.,31572:31836,4584965,26441829,Unavailable
4584965,AUCs for satiety (after 30 min),Inzone Preload,Control,No significant difference,The AUCs for satiety were not significantly larger at any time after Inzone Preload than habitual breakfast.,31572:31836,4584965,26441829,Unavailable
5850666,Early diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"In the AM Group 2, significant improvements were noted in diastolic function 12 months after treatment than those of the control group, including the early diastolic mitral annular velocity (E’; 0.065 ± 0.007 m/s vs. 0.061 ± 0.008 m/s, P = 0.014), the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity (E/A; 0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), the ratio of E’ to the late diastolic mitral annular velocity (E’/A’; 0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), and the ratio of the early diastolic mitral peak flow velocity (E) to E’ (E/E’; 10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031).",5634:6338,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Late diastolic mitral peak flow velocity- improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"In the AM Group 2, significant improvements were noted in diastolic function 12 months after treatment than those of the control group, including the early diastolic mitral annular velocity (E’; 0.065 ± 0.007 m/s vs. 0.061 ± 0.008 m/s, P = 0.014), the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity (E/A; 0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), the ratio of E’ to the late diastolic mitral annular velocity (E’/A’; 0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), and the ratio of the early diastolic mitral peak flow velocity (E) to E’ (E/E’; 10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031).",5634:6338,5850666,29483384,Unavailable
5850666,Early diastolic mitral annular velocity/Late diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"In the AM Group 2, significant improvements were noted in diastolic function 12 months after treatment than those of the control group, including the early diastolic mitral annular velocity (E’; 0.065 ± 0.007 m/s vs. 0.061 ± 0.008 m/s, P = 0.014), the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity (E/A; 0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), the ratio of E’ to the late diastolic mitral annular velocity (E’/A’; 0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), and the ratio of the early diastolic mitral peak flow velocity (E) to E’ (E/E’; 10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031).",5634:6338,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Early diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"In the AM Group 2, significant improvements were noted in diastolic function 12 months after treatment than those of the control group, including the early diastolic mitral annular velocity (E’; 0.065 ± 0.007 m/s vs. 0.061 ± 0.008 m/s, P = 0.014), the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity (E/A; 0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), the ratio of E’ to the late diastolic mitral annular velocity (E’/A’; 0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), and the ratio of the early diastolic mitral peak flow velocity (E) to E’ (E/E’; 10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031).",5634:6338,5850666,29483384,Unavailable
5850666,Hip circumference,Astragalus membranaceus 10g,Control,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Hip circumference,Astragalus membranaceus 5g,Control,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Hip circumference,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Waist-hip ratio,Astragalus membranaceus 10g,Control,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Waist-hip ratio,Astragalus membranaceus 5g,Control,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Waist-hip ratio,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Weight ,Astragalus membranaceus 10g,Control,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Weight ,Astragalus membranaceus 5g,Control,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Weight ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,BMI ,Astragalus membranaceus 10g,Control,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,BMI ,Astragalus membranaceus 5g,Control,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,BMI ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Hip circumference,Astragalus membranaceus 10g,Control,No significant difference,"Hip circumference (cm)	−1.348	0.181	0.337	0.118	−1.375	0.172	−1.176	0.242",59916:60365,5850666,29483384,Unavailable
5850666,Hip circumference,Astragalus membranaceus 5g,Control,No significant difference,"Hip circumference (cm)	107.60 ± 4.70	107.72 ± 3.77	0.114	0.909	−0.008	0.994	0.337	0.737",47118:47581,5850666,29483384,Unavailable
5850666,Hip circumference,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"Hip circumference (cm)	−1.348	0.181	0.337	0.118	−1.375	0.172	−1.176	0.242",59916:60365,5850666,29483384,Unavailable
5850666,Waist-hip ratio,Astragalus membranaceus 10g,Control,No significant difference,"WHR	−1.363	0.176	0.597	0.434	−0.262	0.794	−0.154	0.878",60420:60850,5850666,29483384,Unavailable
5850666,Waist-hip ratio,Astragalus membranaceus 5g,Control,No significant difference,"WHR	0.87 ± 0.02	0.87 ± 0.02	0.296	0.764	1.027	0.307	0.597	0.552",47636:48075,5850666,29483384,Unavailable
5850666,Waist-hip ratio,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"WHR	−1.363	0.176	0.597	0.434	−0.262	0.794	−0.154	0.878",60420:60850,5850666,29483384,Unavailable
5850666,Weight ,Astragalus membranaceus 10g,Control,No significant difference,"Weight (kg)	−0.597	0.552	0.056	0.807	−0.254	0.800	−0.204	0.839",60905:61343,5850666,29483384,Unavailable
5850666,Weight ,Astragalus membranaceus 5g,Control,No significant difference,"Weight (kg)	67.04 ± 4.32	66.86 ± 4.16	0.697	0.489	0.365	0.716	0.056	0.955",48130:48579,5850666,29483384,Unavailable
5850666,Weight ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"Weight (kg)	−0.597	0.552	0.056	0.807	−0.254	0.800	−0.204	0.839",60905:61343,5850666,29483384,Unavailable
5850666,BMI ,Astragalus membranaceus 10g,Control,No significant difference,"BMI (kg/m2)	−0.350	0.727	−0.362	0.861	−0.268	0.789	−0.204	0.839",61398:61848,5850666,29483384,Unavailable
5850666,BMI ,Astragalus membranaceus 5g,Control,No significant difference,"BMI (kg/m2)	26.18 ± 1.20	26.11 ± 1.22	0.665	0.509	0.040	0.968	−0.362	0.718",48634:49095,5850666,29483384,Unavailable
5850666,BMI ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"BMI (kg/m2)	−0.350	0.727	−0.362	0.861	−0.268	0.789	−0.204	0.839",61398:61848,5850666,29483384,Unavailable
5850666,Uric acid,Astragalus membranaceus 10g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Uric acid,Astragalus membranaceus 5g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Uric acid,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Total cholesterol ,Astragalus membranaceus 10g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Total cholesterol ,Astragalus membranaceus 5g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Total cholesterol ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Triglycerides  ,Astragalus membranaceus 10g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Triglycerides  ,Astragalus membranaceus 5g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Triglycerides  ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,HDL,Astragalus membranaceus 10g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,HDL,Astragalus membranaceus 5g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,HDL,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,LDL,Astragalus membranaceus 10g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,LDL,Astragalus membranaceus 5g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,LDL,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Glucose,Astragalus membranaceus 10g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Glucose,Astragalus membranaceus 5g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Glucose,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,SBP,Astragalus membranaceus 10g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,SBP,Astragalus membranaceus 5g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,SBP,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,DBP,Astragalus membranaceus 10g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,DBP,Astragalus membranaceus 5g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,DBP,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Brain natriuretic peptide,Astragalus membranaceus 10g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Brain natriuretic peptide,Astragalus membranaceus 5g,Control,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Brain natriuretic peptide,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"There were no significant differences among the three groups in terms of uric acid (UA), TC, TG, HDL-c, LDL-c, GLU, SBP, DBP, or brain natriuretic peptide (BNP) at baseline and 12 months after treatment (all P &gt; 0.05).",30099:30337,5850666,29483384,Unavailable
5850666,Uric acid,Astragalus membranaceus 10g,Control,No significant difference,"UA (µmmol/L)	0.063	0.950	−0.992	0.484	−1.952	0.054	−1.609	0.111",62394:62833,5850666,29483384,Unavailable
5850666,Uric acid,Astragalus membranaceus 5g,Control,No significant difference,"UA (µmmol/L)	385.19 ± 50.30	390.66 ± 54.42	−1.355	0.181	−2.084	0.052	−0.992	0.324",49656:50113,5850666,29483384,Unavailable
5850666,Uric acid,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"UA (µmmol/L)	0.063	0.950	−0.992	0.484	−1.952	0.054	−1.609	0.111",62394:62833,5850666,29483384,Unavailable
5850666,Total cholesterol ,Astragalus membranaceus 10g,Control,No significant difference,"TC (mmol/L)	1.411	0.161	1.050	0.233	3.025	0.130	1.868	0.065",62888:63323,5850666,29483384,Unavailable
5850666,Total cholesterol ,Astragalus membranaceus 5g,Control,No significant difference,"TC (mmol/L)	4.76 ± 0.44	4.80 ± 0.41	−1.800	0.078	1.960	0.053	1.050	0.296",50168:50616,5850666,29483384,Unavailable
5850666,Total cholesterol ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"TC (mmol/L)	1.411	0.161	1.050	0.233	3.025	0.130	1.868	0.065",62888:63323,5850666,29483384,Unavailable
5850666,Triglycerides  ,Astragalus membranaceus 10g,Control,No significant difference,"TG (mmol/L)	0.323	0.747	−1.362	0.319	−0.740	0.461	−0.275	0.784",63378:63816,5850666,29483384,Unavailable
5850666,Triglycerides  ,Astragalus membranaceus 5g,Control,No significant difference,"TG (mmol/L)	2.31 ± 0.48	2.30 ± 0.40	0.204	0.839	−1.082	0.282	−1.362	0.176",50671:51120,5850666,29483384,Unavailable
5850666,Triglycerides  ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"TG (mmol/L)	0.323	0.747	−1.362	0.319	−0.740	0.461	−0.275	0.784",63378:63816,5850666,29483384,Unavailable
5850666,HDL,Astragalus membranaceus 10g,Control,No significant difference,"HDL-c (mmol/L)	−1.652	0.102	1.262	0.074	0.312	0.756	−0.430	0.668",63871:64311,5850666,29483384,Unavailable
5850666,HDL,Astragalus membranaceus 5g,Control,No significant difference,"HDL-c (mmol/L)	1.75 ± 0.35	1.77 ± 0.27	−0.672	0.505	1.871	0.064	1.262	0.210",51175:51626,5850666,29483384,Unavailable
5850666,HDL,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"HDL-c (mmol/L)	−1.652	0.102	1.262	0.074	0.312	0.756	−0.430	0.668",63871:64311,5850666,29483384,Unavailable
5850666,LDL,Astragalus membranaceus 10g,Control,No significant difference,"LDL-c (mmol/L)	−0.931	0.354	−0.572	0.544	−0.911	0.365	−1.565	0.121",64366:64808,5850666,29483384,Unavailable
5850666,LDL,Astragalus membranaceus 5g,Control,No significant difference,"LDL-c (mmol/L)	2.67 ± 0.53	2.72 ± 0.40	−1.389	0.171	0.109	0.913	−0.572	0.569",51681:52133,5850666,29483384,Unavailable
5850666,LDL,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"LDL-c (mmol/L)	−0.931	0.354	−0.572	0.544	−0.911	0.365	−1.565	0.121",64366:64808,5850666,29483384,Unavailable
5850666,Glucose,Astragalus membranaceus 10g,Control,No significant difference,"GLU (mmol/L)	−1.945	0.055	1.229	0.231	−0.563	0.575	0.087	0.931",64863:65301,5850666,29483384,Unavailable
5850666,Glucose,Astragalus membranaceus 5g,Control,No significant difference,"GLU (mmol/L)	6.78 ± 0.44	6.77 ± 0.40	0.006	0.995	1.171	0.244	1.229	0.222",52188:52636,5850666,29483384,Unavailable
5850666,Glucose,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"GLU (mmol/L)	−1.945	0.055	1.229	0.231	−0.563	0.575	0.087	0.931",64863:65301,5850666,29483384,Unavailable
5850666,SBP,Astragalus membranaceus 10g,Control,No significant difference,"SBP (mmHg)	1.308	0.194	0.163	0.354	−0.184	0.855	1.296	0.198",66830:67265,5850666,29483384,Unavailable
5850666,SBP,Astragalus membranaceus 5g,Control,No significant difference,"SBP (mmHg)	133.51 ± 7.71	132.96 ± 6.51	0.726	0.471	−1.468	0.145	0.163	0.871",54208:54659,5850666,29483384,Unavailable
5850666,SBP,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"SBP (mmHg)	1.308	0.194	0.163	0.354	−0.184	0.855	1.296	0.198",66830:67265,5850666,29483384,Unavailable
5850666,DBP,Astragalus membranaceus 10g,Control,No significant difference,"DBP (mmHg)	−0.082	0.935	1.413	0.738	1.230	0.222	0.959	0.340",67320:67755,5850666,29483384,Unavailable
5850666,DBP,Astragalus membranaceus 5g,Control,No significant difference,"DBP (mmHg)	77.40 ± 8.61	77.17 ± 7.56	0.389	0.699	1.385	0.169	1.413	0.161",54714:55162,5850666,29483384,Unavailable
5850666,DBP,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"DBP (mmHg)	−0.082	0.935	1.413	0.738	1.230	0.222	0.959	0.340",67320:67755,5850666,29483384,Unavailable
5850666,Brain natriuretic peptide,Astragalus membranaceus 10g,Control,No significant difference,"BNP (pg/ml)	−0.138	0.890	0.002	0.998	−0.095	0.925	0.017	0.986",67810:NaN,5850666,29483384,Unavailable
5850666,Brain natriuretic peptide,Astragalus membranaceus 5g,Control,No significant difference,"BNP (pg/ml)	85.42 ± 33.29	84.20 ± 29.40	0.437	0.664	0.043	0.965	0.014	0.989",55217:55668,5850666,29483384,Unavailable
5850666,Brain natriuretic peptide,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"BNP (pg/ml)	−0.138	0.890	0.002	0.998	−0.095	0.925	0.017	0.986",67810:NaN,5850666,29483384,Unavailable
5850666,White blood cells,Astragalus membranaceus 10g,Control,No significant difference,WBC (×109/L) −1.649 0.102 1.823 0.219 −1.254 0.213 0.469 0.640,44559:45018,5850666,29483384,Unavailable
5850666,White blood cells,Astragalus membranaceus 5g,Control,No significant difference,WBC (×109/L) 6.57 ± 1.18 6.47 ± 1.25 0.918 0.363 0.380 0.705 1.823 0.071,44559:45018,5850666,29483384,Unavailable
5850666,White blood cells,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,WBC (×109/L) −1.649 0.102 1.823 0.219 −1.254 0.213 0.469 0.640,44559:45018,5850666,29483384,Unavailable
5850666,Red blood cells,Astragalus membranaceus 10g,Control,No significant difference,"RBC (×1012/L)	0.832	0.408	−1.812	0.437	−0.940	0.349	−0.812	0.419",57927:58378,5850666,29483384,Unavailable
5850666,Red blood cells,Astragalus membranaceus 5g,Control,No significant difference,"RBC (×1012/L)	4.66 ± 0.55	4.65 ± 0.49	0.405	0.687	−2.067	0.068	−1.812	0.073",45073:45535,5850666,29483384,Unavailable
5850666,Red blood cells,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"RBC (×1012/L)	0.832	0.408	−1.812	0.437	−0.940	0.349	−0.812	0.419",57927:58378,5850666,29483384,Unavailable
5850666,Platelets ,Astragalus membranaceus 10g,Control,No significant difference,"PLT (×109/L)	0.730	0.467	0.515	0.707	1.571	0.119	0.853	0.396",58433:58880,5850666,29483384,Unavailable
5850666,Platelets ,Astragalus membranaceus 5g,Control,No significant difference,"PLT (×109/L)	203.64 ± 48.91	206.51 ± 49.19	−1.309	0.196	0.918	0.361	0.515	0.608",45590:46056,5850666,29483384,Unavailable
5850666,Platelets ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"PLT (×109/L)	0.730	0.467	0.515	0.707	1.571	0.119	0.853	0.396",58433:58880,5850666,29483384,Unavailable
5850666,Hemoglobin ,Astragalus membranaceus 10g,Control,No significant difference,"HGB (g/L)	−0.303	0.763	−0.694	0.828	−1.299	0.197	−0.926	0.357",58935:59372,5850666,29483384,Unavailable
5850666,Hemoglobin ,Astragalus membranaceus 5g,Control,No significant difference,"HGB (g/L)	133.76 ± 8.34	133.83 ± 8.53	−0.154	0.878	−0.935	0.352	−0.694	0.489",46111:46563,5850666,29483384,Unavailable
5850666,Hemoglobin ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"HGB (g/L)	−0.303	0.763	−0.694	0.828	−1.299	0.197	−0.926	0.357",58935:59372,5850666,29483384,Unavailable
5850666,Waist circumference ,Astragalus membranaceus 10g,Control,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Waist circumference ,Astragalus membranaceus 5g,Control,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Waist circumference ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,Anthropometrical measurements of the three groups were similar between baseline and 12 months after treatment (all P &gt; 0.05).,29956:30098,5850666,29483384,Unavailable
5850666,Waist circumference ,Astragalus membranaceus 10g,Control,No significant difference,"WC (cm)	−1.596	0.114	0.608	0.065	−1.219	0.226	−1.183	0.239",59427:59861,5850666,29483384,Unavailable
5850666,Waist circumference ,Astragalus membranaceus 5g,Control,No significant difference,"WC (cm)	93.32 ± 4.83	93.13 ± 3.11	0.375	0.710	0.343	0.733	0.608	0.544",46618:47063,5850666,29483384,Unavailable
5850666,Waist circumference ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"WC (cm)	−1.596	0.114	0.608	0.065	−1.219	0.226	−1.183	0.239",59427:59861,5850666,29483384,Unavailable
5850666,Creatinine ,Astragalus membranaceus 10g,Control,No significant difference,"CR (µmmol/L)	0.426	0.671	1.211	0.972	0.974	0.332	1.210	0.229",61903:62339,5850666,29483384,Unavailable
5850666,Creatinine ,Astragalus membranaceus 5g,Control,No significant difference,"CR (µmmol/L)	72.57 ± 7.99	73.85 ± 7.08	−1.683	0.098	0.483	0.630	1.211	0.229",49150:49601,5850666,29483384,Unavailable
5850666,Creatinine ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"CR (µmmol/L)	0.426	0.671	1.211	0.972	0.974	0.332	1.210	0.229",61903:62339,5850666,29483384,Unavailable
5850666,BUN,Astragalus membranaceus 10g,Control,No significant difference,"BUN (mmol/L)	0.659	0.512	−1.744	0.693	−1.150	0.253	−1.257	0.212",65356:65795,5850666,29483384,Unavailable
5850666,BUN,Astragalus membranaceus 5g,Control,No significant difference,"BUN (mmol/L)	6.31 ± 1.02	6.42 ± 0.92	−1.819	0.075	−1.829	0.070	−1.744	0.084",52691:53142,5850666,29483384,Unavailable
5850666,BUN,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"BUN (mmol/L)	0.659	0.512	−1.744	0.693	−1.150	0.253	−1.257	0.212",65356:65795,5850666,29483384,Unavailable
5850666,ALT,Astragalus membranaceus 10g,Control,No significant difference,"ALT (U/L)	1.390	0.168	0.165	0.788	0.628	0.531	−0.122	0.903",65850:66284,5850666,29483384,Unavailable
5850666,ALT,Astragalus membranaceus 5g,Control,No significant difference,"ALT (U/L)	38.64 ± 10.85	41.32 ± 8.98	−1.641	0.107	−0.807	0.422	0.165	0.869",53197:53647,5850666,29483384,Unavailable
5850666,ALT,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"ALT (U/L)	1.390	0.168	0.165	0.788	0.628	0.531	−0.122	0.903",65850:66284,5850666,29483384,Unavailable
5850666,AST,Astragalus membranaceus 10g,Control,No significant difference,"AST (U/L)	1.000	0.320	−1.977	0.265	−0.021	0.983	−0.701	0.485",66339:66775,5850666,29483384,Unavailable
5850666,AST,Astragalus membranaceus 5g,Control,No significant difference,"AST (U/L)	37.77 ± 10.22	40.13 ± 9.75	−1.463	0.149	−0.981	0.329	−1.977	0.051",53702:54153,5850666,29483384,Unavailable
5850666,AST,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"AST (U/L)	1.000	0.320	−1.977	0.265	−0.021	0.983	−0.701	0.485",66339:66775,5850666,29483384,Unavailable
5850666,Left atrial diameter ,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left atrial diameter ,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left atrial diameter ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666, Left ventricular end-diastolic dimension,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666, Left ventricular end-diastolic dimension,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666, Left ventricular end-diastolic dimension,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666, Left ventricular end-systolic dimension,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666, Left ventricular end-systolic dimension,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666, Left ventricular end-systolic dimension,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Interventricular septal thickness,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Interventricular septal thickness,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Interventricular septal thickness,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left ventricular posterior wall thickness,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left ventricular posterior wall thickness,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left ventricular posterior wall thickness,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left ventricular mass,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left ventricular mass,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left ventricular mass,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left ventricular mass index,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left ventricular mass index,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left ventricular mass index,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,End-diastolic volume,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,End-diastolic volume,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,End-diastolic volume,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,End-systolic volume,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,End-systolic volume,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,End-systolic volume,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Stroke volume,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Stroke volume,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Stroke volume,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Ejection fraction,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Ejection fraction,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Ejection fraction,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Fractional shortening,Astragalus membranaceus 10g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Fractional shortening,Astragalus membranaceus 5g,Control,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Fractional shortening,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"As shown in Table 3, the changes in LVEDd, IVST, LVPWT, LVM, LVMI, LAd, LVESd, EDV, ESV, SV, EF, and FS, at baseline and 12 months after treatment, were similar among the three groups (all P &gt; 0.05).",69251:69506,5850666,29483384,Unavailable
5850666,Left atrial diameter ,Astragalus membranaceus 10g,Control,No significant difference,"LAd (mm)	−0.202	0.841	0.247	0.805	−1.955	0.053	−1.162	0.248",86250:86685,5850666,29483384,Unavailable
5850666,Left atrial diameter ,Astragalus membranaceus 5g,Control,No significant difference,"LAd (mm)	28.55 ± 2.54	28.42 ± 2.07	0.528	0.600	−1.568	0.120	−1.372	0.173",78458:78906,5850666,29483384,Unavailable
5850666,Left atrial diameter ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"LAd (mm)	−0.202	0.841	0.247	0.805	−1.955	0.053	−1.162	0.248",86250:86685,5850666,29483384,Unavailable
5850666, Left ventricular end-diastolic dimension,Astragalus membranaceus 10g,Control,No significant difference,"LVEDd (mm)	0.100	0.921	−0.797	0.428	0.381	0.704	−1.037	0.302",86740:87176,5850666,29483384,Unavailable
5850666, Left ventricular end-diastolic dimension,Astragalus membranaceus 5g,Control,No significant difference,"LVEDd (mm)	44.45 ± 1.94	44.97 ± 1.88	−1.423	0.161	0.291	0.771	−0.345	0.731",78961:79411,5850666,29483384,Unavailable
5850666, Left ventricular end-diastolic dimension,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"LVEDd (mm)	0.100	0.921	−0.797	0.428	0.381	0.704	−1.037	0.302",86740:87176,5850666,29483384,Unavailable
5850666, Left ventricular end-systolic dimension,Astragalus membranaceus 10g,Control,No significant difference,"LVESd (mm)	1.671	0.098	0.330	0.742	1.954	0.053	0.786	0.433",87231:87665,5850666,29483384,Unavailable
5850666, Left ventricular end-systolic dimension,Astragalus membranaceus 5g,Control,No significant difference,"LVESd (mm)	29.88 ± 2.91	29.71 ± 2.90	−1.740	0.088	0.222	0.825	0.441	0.660",79466:79915,5850666,29483384,Unavailable
5850666, Left ventricular end-systolic dimension,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"LVESd (mm)	1.671	0.098	0.330	0.742	1.954	0.053	0.786	0.433",87231:87665,5850666,29483384,Unavailable
5850666,Interventricular septal thickness,Astragalus membranaceus 10g,Control,No significant difference,"IVST (mm)	−0.281	0.779	−0.564	0.574	0.520	0.604	0.645	0.520",87720:88155,5850666,29483384,Unavailable
5850666,Interventricular septal thickness,Astragalus membranaceus 5g,Control,No significant difference,"IVST (mm)	9.52 ± 0.88	9.51 ± 0.73	0.084	0.933	0.800	0.426	1.111	0.269",79970:80415,5850666,29483384,Unavailable
5850666,Interventricular septal thickness,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"IVST (mm)	−0.281	0.779	−0.564	0.574	0.520	0.604	0.645	0.520",87720:88155,5850666,29483384,Unavailable
5850666,Left ventricular posterior wall thickness,Astragalus membranaceus 10g,Control,No significant difference,"LVPWT (mm)	−0.454	0.651	0.240	0.811	0.333	0.740	0.686	0.494",88210:88645,5850666,29483384,Unavailable
5850666,Left ventricular posterior wall thickness,Astragalus membranaceus 5g,Control,No significant difference,"LVPWT (mm)	9.42 ± 0.72	9.14 ± 0.82	1.777	0.081	0.758	0.451	0.429	0.669",80470:80916,5850666,29483384,Unavailable
5850666,Left ventricular posterior wall thickness,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"LVPWT (mm)	−0.454	0.651	0.240	0.811	0.333	0.740	0.686	0.494",88210:88645,5850666,29483384,Unavailable
5850666,Left ventricular mass,Astragalus membranaceus 10g,Control,No significant difference,"LVM (g)	−0.346	0.730	−0.513	0.609	0.651	0.516	0.162	0.872",88700:89133,5850666,29483384,Unavailable
5850666,Left ventricular mass,Astragalus membranaceus 5g,Control,No significant difference,"LVM (g)	139.90 ± 17.53	139.63 ± 17.49	0.076	0.940	0.992	0.324	0.610	0.543",80971:81420,5850666,29483384,Unavailable
5850666,Left ventricular mass,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"LVM (g)	−0.346	0.730	−0.513	0.609	0.651	0.516	0.162	0.872",88700:89133,5850666,29483384,Unavailable
5850666,Left ventricular mass index,Astragalus membranaceus 10g,Control,No significant difference,"LVMI (g/m2)	0.281	0.780	−0.211	0.834	1.073	0.286	0.388	0.699",89188:89635,5850666,29483384,Unavailable
5850666,Left ventricular mass index,Astragalus membranaceus 5g,Control,No significant difference,"LVMI (g/m2)	81.91 ± 10.29	82.17 ± 11.43	−0.119	0.906	0.804	0.423	0.595	0.553",81475:81938,5850666,29483384,Unavailable
5850666,Left ventricular mass index,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"LVMI (g/m2)	0.281	0.780	−0.211	0.834	1.073	0.286	0.388	0.699",89188:89635,5850666,29483384,Unavailable
5850666,End-diastolic volume,Astragalus membranaceus 10g,Control,No significant difference,"EDV (ml)	−0.504	0.615	−0.196	0.845	−1.479	0.142	−1.116	0.267",89690:90126,5850666,29483384,Unavailable
5850666,End-diastolic volume,Astragalus membranaceus 5g,Control,No significant difference,"EDV (ml)	109.64 ± 14.56	110.72 ± 14.49	−0.751	0.456	−1.021	0.310	−0.958	0.340",81993:82446,5850666,29483384,Unavailable
5850666,End-diastolic volume,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"EDV (ml)	−0.504	0.615	−0.196	0.845	−1.479	0.142	−1.116	0.267",89690:90126,5850666,29483384,Unavailable
5850666,End-systolic volume,Astragalus membranaceus 10g,Control,No significant difference,"ESV (ml)	−0.154	0.878	0.219	0.827	−1.098	0.275	−0.413	0.681",90181:90616,5850666,29483384,Unavailable
5850666,End-systolic volume,Astragalus membranaceus 5g,Control,No significant difference,"ESV (ml)	43.17 ± 6.92	43.11 ± 8.12	0.074	0.942	−0.913	0.364	−0.676	0.501",82501:82949,5850666,29483384,Unavailable
5850666,End-systolic volume,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"ESV (ml)	−0.154	0.878	0.219	0.827	−1.098	0.275	−0.413	0.681",90181:90616,5850666,29483384,Unavailable
5850666,Stroke volume,Astragalus membranaceus 10g,Control,No significant difference,"SV (ml)	−0.695	0.489	−0.565	0.573	−1.563	0.121	−1.533	0.128",90671:91106,5850666,29483384,Unavailable
5850666,Stroke volume,Astragalus membranaceus 5g,Control,No significant difference,"SV (ml)	66.47 ± 8.91	67.60 ± 8.29	−1.273	0.209	−0.887	0.377	−1.042	0.300",83004:83452,5850666,29483384,Unavailable
5850666,Stroke volume,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"SV (ml)	−0.695	0.489	−0.565	0.573	−1.563	0.121	−1.533	0.128",90671:91106,5850666,29483384,Unavailable
5850666,Ejection fraction,Astragalus membranaceus 10g,Control,No significant difference,"EF (%)	−0.153	0.878	−0.597	0.552	0.329	0.743	−0.714	0.477",91161:91594,5850666,29483384,Unavailable
5850666,Ejection fraction,Astragalus membranaceus 5g,Control,No significant difference,"EF (%)	60.56 ± 2.59	61.00 ± 3.56	−1.123	0.267	0.461	0.646	−0.063	0.950",83507:83953,5850666,29483384,Unavailable
5850666,Ejection fraction,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"EF (%)	−0.153	0.878	−0.597	0.552	0.329	0.743	−0.714	0.477",91161:91594,5850666,29483384,Unavailable
5850666,Fractional shortening,Astragalus membranaceus 10g,Control,No significant difference,"FS (%)	−1.697	0.093	−0.756	0.451	−1.731	0.086	−1.423	0.158",91649:NaN,5850666,29483384,Unavailable
5850666,Fractional shortening,Astragalus membranaceus 5g,Control,No significant difference,"FS (%)	34.28 ± 5.28	34.07 ± 4.60	0.436	0.665	−0.198	0.843	−0.638	0.525",84008:84454,5850666,29483384,Unavailable
5850666,Fractional shortening,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"FS (%)	−1.697	0.093	−0.756	0.451	−1.731	0.086	−1.423	0.158",91649:92083,5850666,29483384,Unavailable
5850666,Early diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"With regard to the levels of diastolic function, patients in AM Group 2 had significantly higher E’ (0.065 ± 0.007 vs. 0.061 ± 0.008, P = 0.014), E/A (0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), and E’/A’ (0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), but lower E/E’ (10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031), than those in the control group at 12 months after treatment.",92981:93413,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Late diastolic mitral peak flow velocity- improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"With regard to the levels of diastolic function, patients in AM Group 2 had significantly higher E’ (0.065 ± 0.007 vs. 0.061 ± 0.008, P = 0.014), E/A (0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), and E’/A’ (0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), but lower E/E’ (10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031), than those in the control group at 12 months after treatment.",92981:93414,5850666,29483384,Unavailable
5850666,Early diastolic mitral annular velocity/Late diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"With regard to the levels of diastolic function, patients in AM Group 2 had significantly higher E’ (0.065 ± 0.007 vs. 0.061 ± 0.008, P = 0.014), E/A (0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), and E’/A’ (0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), but lower E/E’ (10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031), than those in the control group at 12 months after treatment.",92981:93414,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Early diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"With regard to the levels of diastolic function, patients in AM Group 2 had significantly higher E’ (0.065 ± 0.007 vs. 0.061 ± 0.008, P = 0.014), E/A (0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), and E’/A’ (0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), but lower E/E’ (10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031), than those in the control group at 12 months after treatment.",92981:93413,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity,Astragalus membranaceus 10g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity,Astragalus membranaceus 5g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Late diastolic mitral peak flow velocity,Astragalus membranaceus 10g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Late diastolic mitral peak flow velocity,Astragalus membranaceus 5g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Late diastolic mitral peak flow velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Deceleration time,Astragalus membranaceus 10g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Deceleration time,Astragalus membranaceus 5g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Deceleration time,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Late diastolic mitral annular velocity,Astragalus membranaceus 10g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Late diastolic mitral annular velocity,Astragalus membranaceus 5g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Late diastolic mitral annular velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666, Propagation velocity,Astragalus membranaceus 10g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666, Propagation velocity,Astragalus membranaceus 5g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666, Propagation velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Atrial reversal velocity,Astragalus membranaceus 10g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Atrial reversal velocity,Astragalus membranaceus 5g,Control,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Atrial reversal velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"However, among the three groups, E, A, DT, A’, propagation velocity (Vp), atrial reversal velocity (Ar), and E/Vp were not significantly different at baseline and 12 months after treatment (all P &gt; 0.05",93414:93633,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity,Astragalus membranaceus 10g,Control,No significant difference,"E (m/s)	−1.400	0.165	−0.190	0.849	−1.765	0.081	−1.362	0.176",109223:109658,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity,Astragalus membranaceus 5g,Control,No significant difference,"E (m/s)	0.68 ± 0.03	0.68 ± 0.05	0.685	0.497	−0.332	0.741	−1.105	0.272",101972:102417,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"E (m/s)	−1.400	0.165	−0.190	0.849	−1.765	0.081	−1.362	0.176",109223:109658,5850666,29483384,Unavailable
5850666,Late diastolic mitral peak flow velocity,Astragalus membranaceus 10g,Control,No significant difference,"A (m/s)	−1.502	0.136	0.960	0.339	−0.806	0.422	0.631	0.530",109713:110146,5850666,29483384,Unavailable
5850666,Late diastolic mitral peak flow velocity,Astragalus membranaceus 5g,Control,No significant difference,"A (m/s)	0.86 ± 0.03	0.85 ± 0.05	1.304	0.198	0.747	0.457	−0.485	0.629",102472:102916,5850666,29483384,Unavailable
5850666,Late diastolic mitral peak flow velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"A (m/s)	−1.502	0.136	0.960	0.339	−0.806	0.422	0.631	0.530",109713:110146,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Late diastolic mitral peak flow velocity- improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"E/A	0.410	0.683	−1.262	0.210	−0.650	0.517	−2.564	0.012",110201:110631,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Late diastolic mitral peak flow velocity- improvement ,Astragalus membranaceus 5g,Control,No significant difference,E/A 0.80 ± 0.04 0.81 ± 0.05 –0.765 0.448 −1.017 0.311 −1.037 0.302,105480:105922,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Late diastolic mitral peak flow velocity- improvement ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,E/A 0.410 0.683 −1.262 0.210 −0.650 0.517 −2.564 0.012,105480:105922,5850666,29483384,Unavailable
5850666,Deceleration time,Astragalus membranaceus 10g,Control,No significant difference,"DT (ms)	−0.026	0.979	0.566	0.573	0.765	0.446	1.636	0.105",110686:111118,5850666,29483384,Unavailable
5850666,Deceleration time,Astragalus membranaceus 5g,Control,No significant difference,"DT (ms)	268.74 ± 53.87	261.49 ± 44.41	2.047	0.046	0.761	0.449	0.956	0.341",103468:103917,5850666,29483384,Unavailable
5850666,Deceleration time,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"DT (ms)	−0.026	0.979	0.566	0.573	0.765	0.446	1.636	0.105",110686:111118,5850666,29483384,Unavailable
5850666,Early diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"E’ (m/s)	0.316	0.761	−1.666	0.096	−0.966	0.339	−2.653	0.014",111173:111608,5850666,29483384,Unavailable
5850666,Early diastolic mitral annular velocity improvement ,Astragalus membranaceus 5g,Control,No significant difference,E’ (m/s) 0.062 ± 0.008 0.065 ± 0.007 –1.906 0.062 −1.192 0.215 −0.741 0.436,105480:105922,5850666,29483384,Unavailable
5850666,Early diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,E’ (m/s) 0.316 0.761 −1.666 0.096 −0.966 0.339 −2.653 0.014,105480:105922,5850666,29483384,Unavailable
5850666,Late diastolic mitral annular velocity,Astragalus membranaceus 10g,Control,No significant difference,"A’ (m/s)	−1.161	0.248	0.768	0.444	−0.906	0.367	0.938	0.350",111663:112097,5850666,29483384,Unavailable
5850666,Late diastolic mitral annular velocity,Astragalus membranaceus 5g,Control,No significant difference,"A’ (m/s)	0.124 ± 0.020	0.119 ± 0.021	1.648	0.105	0.325	0.746	0.122	0.903",104478:104926,5850666,29483384,Unavailable
5850666,Late diastolic mitral annular velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"A’ (m/s)	−1.161	0.248	0.768	0.444	−0.906	0.367	0.938	0.350",111663:112097,5850666,29483384,Unavailable
5850666,Early diastolic mitral annular velocity/Late diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"E’/A’	0.883	0.358	−1.355	0.175	−0.257	0.803	−2.074	0.048",112152:112584,5850666,29483384,Unavailable
5850666,Early diastolic mitral annular velocity/Late diastolic mitral annular velocity improvement ,Astragalus membranaceus 5g,Control,No significant difference,E’/A’ 0.52 ± 0.13 0.56 ± 0.12 –2.418 0.019 −1.188 0.246 −0.583 0.549,105480:105922,5850666,29483384,Unavailable
5850666,Early diastolic mitral annular velocity/Late diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,E’/A’ 0.883 0.358 −1.355 0.175 −0.257 0.803 −2.074 0.048,105480:105922,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Early diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Control,Significantly increased,"E/E’	−0.558	0.603	1.834	0.078	0.825	0.400	2.228	0.031",112639:113068,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Early diastolic mitral annular velocity improvement ,Astragalus membranaceus 5g,Control,No significant difference,E/E’ 11.24 ± 1.56 10.70 ± 1.30 2.377 0.021 1.293 0.180 0.353 0.711,105480:105922,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Early diastolic mitral annular velocity improvement ,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,E/E’ −0.558 0.603 1.834 0.078 0.825 0.400 2.228 0.031,105480:105922,5850666,29483384,Unavailable
5850666, Propagation velocity,Astragalus membranaceus 10g,Control,No significant difference,"Vp (cm/s)	1.210	0.229	1.892	0.061	1.559	0.122	1.893	0.061",113123:113556,5850666,29483384,Unavailable
5850666, Propagation velocity,Astragalus membranaceus 5g,Control,No significant difference,"Vp (cm/s)	0.49 ± 0.06	0.48 ± 0.05	1.047	0.300	0.234	0.815	0.042	0.967",105977:106422,5850666,29483384,Unavailable
5850666, Propagation velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"Vp (cm/s)	1.210	0.229	1.892	0.061	1.559	0.122	1.893	0.061",113123:113556,5850666,29483384,Unavailable
5850666,Atrial reversal velocity,Astragalus membranaceus 10g,Control,No significant difference,"Ar (cm/s)	−0.616	0.539	−0.216	0.829	−0.693	0.490	−0.450	0.653",113611:114048,5850666,29483384,Unavailable
5850666,Atrial reversal velocity,Astragalus membranaceus 5g,Control,No significant difference,"Ar (cm/s)	26.70 ± 6.05	26.85 ± 4.50	–0.349	0.728	−0.047	0.962	−0.225	0.822",106477:106927,5850666,29483384,Unavailable
5850666,Atrial reversal velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"Ar (cm/s)	−0.616	0.539	−0.216	0.829	−0.693	0.490	−0.450	0.653",113611:114048,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Propagation velocity,Astragalus membranaceus 10g,Control,No significant difference,"E/Vp	−1.319	0.190	−1.652	0.102	−1.901	0.060	−1.878	0.063",114103:114535,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Propagation velocity,Astragalus membranaceus 5g,Control,No significant difference,"E/Vp	1.73 ± 0.22	1.73 ± 0.20	–0.149	0.877	−0.440	0.661	−0.283	0.778",106982:107425,5850666,29483384,Unavailable
5850666,Early diastolic mitral peak flow velocity/Propagation velocity,Astragalus membranaceus 10g,Astragalus membranaceus 5g,No significant difference,"E/Vp	−1.319	0.190	−1.652	0.102	−1.901	0.060	−1.878	0.063",114103:114535,5850666,29483384,Unavailable
1976090,ESRD cases,Moxonidine,Nitrendipine,Significantly decreased,"The model predicted that after three years, 38.9% (95%CI 31.8–45.8) of patients treated with nitrendipine progressed to ESRD compared to 7.5% (95%CI 3.5–12.7) of patients treated with moxonidine. Treatment with standard antihypertensive therapy and adjunctive moxonidine was predicted to reduce the number of ESRD cases by 81% over three years compared to adjunctive nitrendipine.",4390:4770,1976090,17645811,Unavailable
1976090,Costs per patient,Moxonidine,Nitrendipine,Significantly decreased,"The cumulative costs per patient were significantly lower in the moxonidine group €9,858 (95% CI 5,501–16,174) than in the nitrendipine group €37,472 (95% CI 27,957–49,478)",4777:4949,1976090,17645811,Unavailable
1976090,Life-years lived,Moxonidine,Nitrendipine,Significantly increased,"The model showed moxonidine to be dominant compared to nitrendipine, increasing life-years lived by 0.044 (95%CI 0.020–0.070) years",4957:5089,1976090,17645811,Unavailable
1976090,ESRD cases,Moxonidine,Nitrendipine,Significantly decreased,"The model predicted that after three years, 38.9% (95%CI 31.8–45.8) of patients treated with nitrendipine progressed to ESRD compared to only 7.5% (95%CI 3.5–12.7) of patients treated with moxonidine. Thus suggesting that standard treatment with adjunctive moxonidine could prevent 31.4% of new cases of ESRD compared to adjunctive nitrendipine (see Figure 2.), or reduce the number of ESRD cases by 81%.",24758:25199,1976090,17645811,Unavailable
1976090,Costs per patient,Moxonidine,Nitrendipine,Significantly decreased,"After three years, the cumulative costs per patient appeared to be lower in the moxonidine group (€9,858 with 95% CI 5,501–16,174) than in the nitrendipine group (€37,472 with 95% CI 27,957–49,478) (see Figure 3). Thus moxonidine provided a cost saving of €27,615 (95%CI 16,894–39,583).",25802:26125,1976090,17645811,Unavailable
1976090,Life-years lived,Moxonidine,Nitrendipine,Significantly increased,The proportion of survivors was 98.6% in the moxonidine group after three years compared to 93.9% in the nitrendipine group. Thus the model suggests that patients treated with moxonidine could gain on average 0.044 (95%CI 0.020–0.070) life-years compared to patients on nitrendipine (discounted life-years were 2.950 (95%CI 2.937–2.959) versus 2.907 (95%CI 2.882–2.927).,25802:26125,1976090,17645811,Unavailable
5870086,Nucleus accumbens activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"However, there were several clusters with greater activation during nonsocial reward anticipation in the OT condition relative to PLC, including the right NAcc, right frontal pole (FP), left ACC, left superior frontal cortex, and bilateral orbital frontal cortex (OFC)",43323:43593,5870086,29587625,Unavailable
5870086,Right frontal pole activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"However, there were several clusters with greater activation during nonsocial reward anticipation in the OT condition relative to PLC, including the right NAcc, right frontal pole (FP), left ACC, left superior frontal cortex, and bilateral orbital frontal cortex (OFC)",43323:43593,5870086,29587625,Unavailable
5870086,Left anterior cingulate cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"However, there were several clusters with greater activation during nonsocial reward anticipation in the OT condition relative to PLC, including the right NAcc, right frontal pole (FP), left ACC, left superior frontal cortex, and bilateral orbital frontal cortex (OFC)",43323:43593,5870086,29587625,Unavailable
5870086,Left superior frontal cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"However, there were several clusters with greater activation during nonsocial reward anticipation in the OT condition relative to PLC, including the right NAcc, right frontal pole (FP), left ACC, left superior frontal cortex, and bilateral orbital frontal cortex (OFC)",43323:43593,5870086,29587625,Unavailable
5870086,Left bilateral orbital frontal cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"However, there were several clusters with greater activation during nonsocial reward anticipation in the OT condition relative to PLC, including the right NAcc, right frontal pole (FP), left ACC, left superior frontal cortex, and bilateral orbital frontal cortex (OFC)",43323:43593,5870086,29587625,Unavailable
5870086,Right bilateral orbital frontal cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"However, there were several clusters with greater activation during nonsocial reward anticipation in the OT condition relative to PLC, including the right NAcc, right frontal pole (FP), left ACC, left superior frontal cortex, and bilateral orbital frontal cortex (OFC)",43323:43593,5870086,29587625,Unavailable
5870086,Nucleus accumbens activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"During nonsocial reward anticipation, there was greater activation in the right nucleus accumbens (NAcc), left anterior cingulate cortex (ACC), bilateral orbital frontal cortex (OFC), left superior frontal cortex, and right frontal pole (FP) during the OT condition relative to PLC.",11114:11397,5870086,29587625,Unavailable
5870086,Right frontal pole activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"During nonsocial reward anticipation, there was greater activation in the right nucleus accumbens (NAcc), left anterior cingulate cortex (ACC), bilateral orbital frontal cortex (OFC), left superior frontal cortex, and right frontal pole (FP) during the OT condition relative to PLC.",11114:11396,5870086,29587625,Unavailable
5870086,Left anterior cingulate cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"During nonsocial reward anticipation, there was greater activation in the right nucleus accumbens (NAcc), left anterior cingulate cortex (ACC), bilateral orbital frontal cortex (OFC), left superior frontal cortex, and right frontal pole (FP) during the OT condition relative to PLC.",11114:11396,5870086,29587625,Unavailable
5870086,Left superior frontal cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"During nonsocial reward anticipation, there was greater activation in the right nucleus accumbens (NAcc), left anterior cingulate cortex (ACC), bilateral orbital frontal cortex (OFC), left superior frontal cortex, and right frontal pole (FP) during the OT condition relative to PLC.",11113:11396,5870086,29587625,Unavailable
5870086,Left bilateral orbital frontal cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"During nonsocial reward anticipation, there was greater activation in the right nucleus accumbens (NAcc), left anterior cingulate cortex (ACC), bilateral orbital frontal cortex (OFC), left superior frontal cortex, and right frontal pole (FP) during the OT condition relative to PLC.",11114:11396,5870086,29587625,Unavailable
5870086,Right bilateral orbital frontal cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"During nonsocial reward anticipation, there was greater activation in the right nucleus accumbens (NAcc), left anterior cingulate cortex (ACC), bilateral orbital frontal cortex (OFC), left superior frontal cortex, and right frontal pole (FP) during the OT condition relative to PLC.",11114:11396,5870086,29587625,Unavailable
5870086,Right frontal pole activation during social reward anticipation,Intranasal oxytocin ,Placebo ,Significantly increased,"During social reward outcomes, there was significantly decreased activation in the right frontal pole in the OT condition relative to the PLC condition.",48256:48409,5870086,29587625,Unavailable
5870086,Nucleus accumbens activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,No significant difference,There were no other clusters with significant changes in activation during social anticipation or social outcomes in the OT condition relative to the PLC condition,48408:48573,5870086,29587625,Unavailable
5870086,Left anterior cingulate cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,No significant difference,There were no other clusters with significant changes in activation during social anticipation or social outcomes in the OT condition relative to the PLC condition,48409:48573,5870086,29587625,Unavailable
5870086,Left superior frontal cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,No significant difference,There were no other clusters with significant changes in activation during social anticipation or social outcomes in the OT condition relative to the PLC condition,48409:48572,5870086,29587625,Unavailable
5870086,Left bilateral orbital frontal cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,No significant difference,There were no other clusters with significant changes in activation during social anticipation or social outcomes in the OT condition relative to the PLC condition,48408:48572,5870086,29587625,Unavailable
5870086,Right bilateral orbital frontal cortex activation during nonsocial reward anticipation,Intranasal oxytocin ,Placebo ,No significant difference,There were no other clusters with significant changes in activation during social anticipation or social outcomes in the OT condition relative to the PLC condition,48409:48572,5870086,29587625,Unavailable
5820089,Self-leadership (independent goal setting),Flipped learning,Control,Significantly increased,Participants' independent goal setting and evaluation of beliefs and assumptions for the subscales of self-leadership and problem-solving skills were compared for the flipped learning group and the traditional learning group. The results showed greater improvement on these indicators for the flipped learning group in comparison to the traditional learning group.,22066:22429,5820089,29503755,Unavailable
5820089,Self-leadership (evaluating beliefs and assumptions),Flipped learning,Control,Significantly increased,Participants' independent goal setting and evaluation of beliefs and assumptions for the subscales of self-leadership and problem-solving skills were compared for the flipped learning group and the traditional learning group. The results showed greater improvement on these indicators for the flipped learning group in comparison to the traditional learning group.,22066:22429,5820089,29503755,Unavailable
5820089,Self-Efficacy (overall),Flipped learning,Control,No significant difference,All subscales of self-efficacy in clinical performance showed improvement on the post-test for both groups but no statistically significant differences between groups in the preand post-test were found.,21202:21405,5820089,29503755,Unavailable
5820089,Self-Efficacy (assessment ),Flipped learning,Control,No significant difference,"For example, assessment was improved to 3.8 (SD = 13.4) for the traditional learning group and 4.8 (SD = 14.6) for the flipped learning group (p = 0.719, effect size [ES] = 0.06) after the intervention",21405:21623,5820089,29503755,Unavailable
5820089,Self-leadership (evaluating beliefs and assumptions),Flipped learning,Control,Significantly increased,"Among the three subscales of the constructive thought pattern strategies, the evaluating beliefs and assumptions subscale improved significantly for the flipped learning group (mean difference = 0.8, SD = 2.5), while it decreased for the traditional learning group (mean difference = −0.2, SD = 1.3) (p = 0.023, ES = 0.38) after the intervention",22066:22429,5820089,29503755,Unavailable
5820089,Self-leadership (independent goal setting),Flipped learning,Control,Significantly increased,"Among the subscales of the behavior-focused strategies, the difference between the changes in the two groups concerning self-goal setting was significant (p = 0.043, ES = 0.27)",22066:22429,5820089,29503755,Unavailable
5820089,Rational problem solving,Flipped learning,Control,Significantly increased,"the flipped learning group (mean difference = 2.4, SD = 7.5) showed a significant improvement in rational problem solving in comparison to the traditional learning group (mean difference = 0.2, SD = 2.4) (p = 0.048, ES = 0.47).",22569:22813,5820089,29503755,Unavailable
5820089,Impulsive/careless style,Flipped learning,Control,No significant difference,"In addition, impulsive/careless style decreased for the flipped learning group (mean difference = −0.7, SD = 3.9), while it increased for the traditional learning group (mean difference = 0.4, SD = 3.8) after the intervention; however, no statistical significance was found (p = 0.152, ES = 0.43)",22814:23128,5820089,29503755,Unavailable
4937081,Overall AEs,Dapagliflozin,Placebo,Significantly increased,"Overall AEs and discontinuations owing to AEs were more common in patients aged ≥65 and ≥75&nbsp;years than in patients aged &lt;65&nbsp;years, and were more frequent with dapagliflozin than placebo",25519:25705,4937081,27357173,Unavailable
4937081,Discontinuations due to AEs,Dapagliflozin,Placebo,Significantly increased,"Overall AEs and discontinuations owing to AEs were more common in patients aged ≥65 and ≥75&nbsp;years than in patients aged &lt;65&nbsp;years, and were more frequent with dapagliflozin than placebo",25519:25705,4937081,27357173,Unavailable
4937081,Hypoglycaemia,Dapagliflozin,Placebo,Significantly increased,"The frequency of hypoglycaemia was similar between younger patients (aged &lt;65&nbsp;years) and older patients (aged ≥65 or ≥75&nbsp;years), and more frequent with dapagliflozin than placebo",32961:33139,4937081,27357173,Unavailable
4937081,Genital infection,Dapagliflozin,Placebo,Significantly increased,Events of genital infection occurred more frequently with dapagliflozin than placebo,33813:33897,4937081,27357173,Unavailable
4937081,AEs of UTI in patients  &lt;65&nbsp;years,Dapagliflozin,Placebo,Significantly increased,"Although AEs of UTI were more common with dapagliflozin than placebo treatment in patients aged &lt;65&nbsp;years, frequencies were similar between treatment groups in patients aged ≥65 and ≥75&nbsp;years",34189:34380,4937081,27357173,Unavailable
4937081,AEs of UTI in patients ≥65 years,Dapagliflozin,Placebo,No significant difference,"Although AEs of UTI were more common with dapagliflozin than placebo treatment in patients aged &lt;65&nbsp;years, frequencies were similar between treatment groups in patients aged ≥65 and ≥75&nbsp;years",34189:34380,4937081,27357173,Unavailable
4937081,AEs of UTI in patients ≥75 years,Dapagliflozin,Placebo,No significant difference,"Although AEs of UTI were more common with dapagliflozin than placebo treatment in patients aged &lt;65&nbsp;years, frequencies were similar between treatment groups in patients aged ≥65 and ≥75&nbsp;years",34189:34380,4937081,27357173,Unavailable
4937081,AEs of volume reduction &lt;65 years,Dapagliflozin,Placebo,No significant difference,The frequency of AEs of volume reduction was low in both treatment arms across all age groups,34828:34921,4937081,27357173,Unavailable
4937081,AEs of volume reduction ≥65 years,Dapagliflozin,Placebo,No significant difference,The frequency of AEs of volume reduction was low in both treatment arms across all age groups,34828:34921,4937081,27357173,Unavailable
4937081,AEs of volume reduction  ≥75 years,Dapagliflozin,Placebo,No significant difference,The frequency of AEs of volume reduction was low in both treatment arms across all age groups,34828:34921,4937081,27357173,Unavailable
4937081,eGFR,Dapagliflozin,Placebo,No significant difference,"Interestingly, after the first 24&nbsp;weeks of treatment, eGFR values were superimposable in patients receiving dapagliflozin and placebo",36588:36721,4937081,27357173,Unavailable
4937081,AEs of renal function ,Dapagliflozin,Placebo,Significantly increased,AEs of renal function were more common with dapagliflozin,37261:37318,4937081,27357173,Unavailable
4937081,Minor transient serum creatinine changes &lt;65 years,Dapagliflozin,Placebo,No significant difference,"The distribution of serum creatinine changes in patients with a reported AE of renal function was similar between the treatment groups in patients aged &lt;65 and ≥65&nbsp;years, with a higher frequency of minor, transient serum creatinine changes (9 to ≤27&nbsp;µmol/L) reported with dapagliflozin in patients aged ≥75&nbsp;years",37627:37940,4937081,27357173,Unavailable
4937081,Minor transient serum creatinine changes ≥65 years,Dapagliflozin,Placebo,No significant difference,"The distribution of serum creatinine changes in patients with a reported AE of renal function was similar between the treatment groups in patients aged &lt;65 and ≥65&nbsp;years, with a higher frequency of minor, transient serum creatinine changes (9 to ≤27&nbsp;µmol/L) reported with dapagliflozin in patients aged ≥75&nbsp;years",37627:37940,4937081,27357173,Unavailable
4937081,Minor transient serum creatinine changes ≥75 years,Dapagliflozin,Placebo,Significantly increased,"The distribution of serum creatinine changes in patients with a reported AE of renal function was similar between the treatment groups in patients aged &lt;65 and ≥65&nbsp;years, with a higher frequency of minor, transient serum creatinine changes (9 to ≤27&nbsp;µmol/L) reported with dapagliflozin in patients aged ≥75&nbsp;years",37627:37940,4937081,27357173,Unavailable
4937081,Frequency of fractures &lt;65 years,Dapagliflozin,Placebo,No significant difference,"The frequency of fractures was numerically similar or lower with dapagliflozin vs. placebo for all age groups [&lt;65&nbsp;years: 16 (1.1&nbsp;%) vs. 14 (1.1&nbsp;%); ≥65&nbsp;years: 7 (1.1&nbsp;%) vs. 18 (2.7&nbsp;%); ≥75&nbsp;years: 1 (1.0&nbsp;%) vs. 2 (2.6&nbsp;%), respectively].",39086:39323,4937081,27357173,Unavailable
4937081,Frequency of fractures ≥65 years,Dapagliflozin,Placebo,No significant difference,"The frequency of fractures was numerically similar or lower with dapagliflozin vs. placebo for all age groups [&lt;65&nbsp;years: 16 (1.1&nbsp;%) vs. 14 (1.1&nbsp;%); ≥65&nbsp;years: 7 (1.1&nbsp;%) vs. 18 (2.7&nbsp;%); ≥75&nbsp;years: 1 (1.0&nbsp;%) vs. 2 (2.6&nbsp;%), respectively].",39086:39323,4937081,27357173,Unavailable
4937081,Frequency of fractures ≥75 years,Dapagliflozin,Placebo,No significant difference,"The frequency of fractures was numerically similar or lower with dapagliflozin vs. placebo for all age groups [&lt;65&nbsp;years: 16 (1.1&nbsp;%) vs. 14 (1.1&nbsp;%); ≥65&nbsp;years: 7 (1.1&nbsp;%) vs. 18 (2.7&nbsp;%); ≥75&nbsp;years: 1 (1.0&nbsp;%) vs. 2 (2.6&nbsp;%), respectively].",39086:39323,4937081,27357173,Unavailable
4937081,Risk of falls &lt;65 years,Dapagliflozin,Placebo,No significant difference,"Dapagliflozin was not associated with an increased risk of falls compared with placebo in any age category [&lt;65&nbsp;years: 10 (0.7&nbsp;%) vs. 9 (0.7&nbsp;%); ≥65&nbsp;years: 4 (0.6&nbsp;%) vs. 14 (2.1&nbsp;%); ≥75&nbsp;years: 0 vs. 1 (1.3&nbsp;%), respectively).",39323:39547,4937081,27357173,Unavailable
4937081,Risk of falls ≥65 years,Dapagliflozin,Placebo,No significant difference,"Dapagliflozin was not associated with an increased risk of falls compared with placebo in any age category [&lt;65&nbsp;years: 10 (0.7&nbsp;%) vs. 9 (0.7&nbsp;%); ≥65&nbsp;years: 4 (0.6&nbsp;%) vs. 14 (2.1&nbsp;%); ≥75&nbsp;years: 0 vs. 1 (1.3&nbsp;%), respectively).",39323:39547,4937081,27357173,Unavailable
4937081,Risk of falls  ≥75 years,Dapagliflozin,Placebo,No significant difference,"Dapagliflozin was not associated with an increased risk of falls compared with placebo in any age category [&lt;65&nbsp;years: 10 (0.7&nbsp;%) vs. 9 (0.7&nbsp;%); ≥65&nbsp;years: 4 (0.6&nbsp;%) vs. 14 (2.1&nbsp;%); ≥75&nbsp;years: 0 vs. 1 (1.3&nbsp;%), respectively).",39323:39547,4937081,27357173,Unavailable
4937081,Electrolyte abnormalities &lt;65 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Electrolyte abnormalities ≥65 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Electrolyte abnormalities ≥75 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum calcium &lt;65 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum calcium ≥65 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum calcium ≥75 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum bicarbonate &lt;65 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum bicarbonate ≥65 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum bicarbonate ≥75 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum magnesium &lt;65 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum magnesium ≥65 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum magnesium ≥75 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum sodium &lt;65 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum sodium ≥65 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in serum sodium ≥75 years,Dapagliflozin,Placebo,No significant difference,"Electrolyte abnormalities were infrequent, and MAs in serum calcium, serum bicarbonate, serum magnesium and serum sodium were balanced between the treatment arms and across age groups",39560:39744,4937081,27357173,Unavailable
4937081,Marked abnormalities in potassium of ≥6.0 mmol/L ,Dapagliflozin,Placebo,Significantly increased,Dapagliflozin was associated with a higher frequency of serum potassium MAs of ≥6.0&nbsp;mmol/L than placebo,39765:39868,4937081,27357173,Unavailable
4937081,Marked abnormalities in inorganic phosphorus (≥1.81 mmol/L),Dapagliflozin,Placebo,Significantly increased,MAs of inorganic phosphorus (≥1.81 mmol/L) were more common with dapagliflozin,39986:40064,4937081,27357173,Unavailable
4937081,Marked abnormalities of haematocrit &gt;55 % &lt;65 years,Dapagliflozin,Placebo,Significantly increased,MAs of haematocrit &gt;55&nbsp;% were more common with dapagliflozin regardless of age.,40137:40216,4937081,27357173,Unavailable
4937081,Marked abnormalities of haematocrit &gt;55 % ≥65 years,Dapagliflozin,Placebo,Significantly increased,MAs of haematocrit &gt;55&nbsp;% were more common with dapagliflozin regardless of age.,40137:40216,4937081,27357173,Unavailable
4937081,Marked abnormalities of haematocrit &gt;55 % ≥75 years,Dapagliflozin,Placebo,Significantly increased,MAs of haematocrit &gt;55&nbsp;% were more common with dapagliflozin regardless of age.,40137:40216,4937081,27357173,Unavailable
4937081,HbA1c &lt;65 years,Dapagliflozin,Placebo,Significantly decreased,Dapagliflozin was associated with a greater reduction from baseline in HbA1c up to 104&nbsp;weeks compared with placebo in both patients aged &lt;65 and those aged ≥65&nbsp;years,40327:40503,4937081,27357173,Unavailable
4937081,HbA1c ≥65 years,Dapagliflozin,Placebo,Significantly decreased,Dapagliflozin was associated with a greater reduction from baseline in HbA1c up to 104&nbsp;weeks compared with placebo in both patients aged &lt;65 and those aged ≥65&nbsp;years,40327:40503,4937081,27357173,Unavailable
4937081,Proportion of patients with HbA1c &lt;53 mmol/mol &lt;65 years,Dapagliflozin,Placebo,Significantly increased,"A significantly greater proportion of patients achieved an HbA1c value of &lt;53&nbsp;mmol/mol (&lt;7&nbsp;%), with dapagliflozin vs. placebo in both age groups (&lt;65&nbsp;years: 25.6 vs. 15.2&nbsp;%; ≥65&nbsp;years: 18.2 vs. 12.3&nbsp;%).",40525:40740,4937081,27357173,Unavailable
4937081,Proportion of patients with HbA1c &lt;53 mmol/mol ≥65 years,Dapagliflozin,Placebo,Significantly increased,"A significantly greater proportion of patients achieved an HbA1c value of &lt;53&nbsp;mmol/mol (&lt;7&nbsp;%), with dapagliflozin vs. placebo in both age groups (&lt;65&nbsp;years: 25.6 vs. 15.2&nbsp;%; ≥65&nbsp;years: 18.2 vs. 12.3&nbsp;%)",40525:40740,4937081,27357173,Unavailable
4937081,Body weight &lt;65 years,Dapagliflozin,Placebo,Significantly decreased,"For both patients aged &lt;65&nbsp;years and those aged ≥65&nbsp;years, reductions in body weight were greater with dapagliflozin than with placebo up to 104&nbsp;weeks",40944:41095,4937081,27357173,Unavailable
4937081,Body weight ≥65 years,Dapagliflozin,Placebo,Significantly decreased,"For both patients aged &lt;65&nbsp;years and those aged ≥65&nbsp;years, reductions in body weight were greater with dapagliflozin than with placebo up to 104&nbsp;weeks",40944:41095,4937081,27357173,Unavailable
4937081,SBP &lt;65 years,Dapagliflozin,Placebo,Significantly decreased,"SBP reduction was more pronounced with dapagliflozin compared with placebo in both age categories, although absolute changes were generally small",41116:41261,4937081,27357173,Unavailable
4937081,SBP ≥65 years,Dapagliflozin,Placebo,Significantly decreased,"SBP reduction was more pronounced with dapagliflozin compared with placebo in both age categories, although absolute changes were generally small",41116:41261,4937081,27357173,Unavailable
4937081,Serious AEs &lt;65 years,Dapagliflozin,Placebo,No significant difference,The frequency of SAEs was similar between the treatment groups across all ages,41116:41261,4937081,27357173,Unavailable
4937081,Serious AEs ≥65 years,Dapagliflozin,Placebo,No significant difference,The frequency of SAEs was similar between the treatment groups across all ages,41116:41261,4937081,27357173,Unavailable
4937081,Serious AEs ≥75 years,Dapagliflozin,Placebo,No significant difference,The frequency of SAEs was similar between the treatment groups across all ages,41116:41261,4937081,27357173,Unavailable
3835251,Standing heart rate,Atomoxetine ,Placebo,Significantly increased,"Atomoxetine significantly increased standing HR compared with placebo (121±17 beats per minute versus 105±15 beats per minute; P=0.001) in POTS patients, with a trend toward higher standing systolic BP (P=0.072).",21435:21636,3835251,24002370,Unavailable
3835251,Standing SBP,Atomoxetine ,Placebo,No significant difference,"Atomoxetine significantly increased standing HR compared with placebo (121±17 beats per minute versus 105±15 beats per minute; P=0.001) in POTS patients, with a trend toward higher standing systolic BP (P=0.072).",24786:25822,3835251,24002370,Unavailable
3835251,Symptom scores worsening 2h,Atomoxetine ,Placebo,Significantly increased,Symptom scores worsened with atomoxetine compared to placebo (+4.2 au versus −3.5 au; P=0.028) from baseline to 2 hours after study drug administration.,28054:29087,3835251,24002370,Unavailable
3835251,Seated heart rate,Atomoxetine ,Placebo,Significantly increased,Atomoxetine increased seated HR compared with placebo over the 4 hours following drug administration,21435:21636,3835251,24002370,Unavailable
3835251,Seated heart rate at 1h,Atomoxetine ,Placebo,Significantly increased,"This effect was seen starting at 1 hour (P&lt;0.002) and continuing at 2 hours (P&lt;0.001), and 4 hours (P&lt;0.001) following study drug administration",21435:21636,3835251,24002370,Unavailable
3835251,Seated heart rate at 2h,Atomoxetine ,Placebo,Significantly increased,"This effect was seen starting at 1 hour (P&lt;0.002) and continuing at 2 hours (P&lt;0.001), and 4 hours (P&lt;0.001) following study drug administration",21435:21636,3835251,24002370,Unavailable
3835251,Seated heart rate at 4h,Atomoxetine ,Placebo,Significantly increased,"This effect was seen starting at 1 hour (P&lt;0.002) and continuing at 2 hours (P&lt;0.001), and 4 hours (P&lt;0.001) following study drug administration",21435:21636,3835251,24002370,Unavailable
3835251,Standing heart rate,Atomoxetine ,Placebo,Significantly increased,"Standing HR, bpm				Atomoxetine	110±18	121±17	117±14	Placebo	114±17	105±15.0	104±16	P Value (between drugs)	0.204	0.001	0.001	0.002",22608:23641,3835251,24002370,Unavailable
3835251,Standing heart rate 2h,Atomoxetine ,Placebo,Significantly increased,"Standing HR, bpm Atomoxetine 110±18 121±17 117±14 Placebo 114±17 105±15.0 104±16 P Value (between drugs) 0.204 0.001 0.001 0.002",22608:23641,3835251,24002370,Unavailable
3835251,Standing heart rate 4h,Atomoxetine ,Placebo,Significantly increased,"Standing HR, bpm Atomoxetine 110±18 121±17 117±14 Placebo 114±17 105±15.0 104±16 P Value (between drugs) 0.204 0.001 0.001 0.002",22608:23641,3835251,24002370,Unavailable
3835251,Seated heart rate,Atomoxetine ,Placebo,Significantly increased,"Seated HR, bpm				Atomoxetine	86±10	89±13	89±12	Placebo	84±12	79±10	78±11	P Value (between drugs)	0.334	&lt;0.001	&lt;0.001	&lt;0.001",23696:24728,3835251,24002370,Unavailable
3835251,Seated heart rate at 2h,Atomoxetine ,Placebo,Significantly increased,"Seated HR, bpm				Atomoxetine	86±10	89±13	89±12	Placebo	84±12	79±10	78±11	P Value (between drugs)	0.334	&lt;0.001	&lt;0.001	&lt;0.001",23696:24728,3835251,24002370,Unavailable
3835251,Seated heart rate at 4h,Atomoxetine ,Placebo,Significantly increased,"Seated HR, bpm				Atomoxetine	86±10	89±13	89±12	Placebo	84±12	79±10	78±11	P Value (between drugs)	0.334	&lt;0.001	&lt;0.001	&lt;0.001",23696:24728,3835251,24002370,Unavailable
3835251,Δ HR (standing–seated),Atomoxetine ,Placebo,No significant difference,"Δ HR (standing–seated), bpm				Atomoxetine	24±13	31±15	28±13	Placebo	31±14	26±12	26±12	P Value (between drugs)	0.010	0.119	0.508	0.080",24786:25822,3835251,24002370,Unavailable
3835251,Δ HR (standing–seated) 2h,Atomoxetine ,Placebo,No significant difference,"Δ HR (standing–seated), bpm Atomoxetine 24±13 31±15 28±13 Placebo 31±14 26±12 26±12 P Value (between drugs) 0.010 0.119 0.508 0.080",24786:25822,3835251,24002370,Unavailable
3835251,Δ HR (standing–seated) 4h,Atomoxetine ,Placebo,No significant difference,"Δ HR (standing–seated), bpm Atomoxetine 24±13 31±15 28±13 Placebo 31±14 26±12 26±12 P Value (between drugs) 0.010 0.119 0.508 0.080",24786:25822,3835251,24002370,Unavailable
3835251,Standing SBP,Atomoxetine ,Placebo,No significant difference,"Standing SBP, mm Hg				Atomoxetine	108±15	111±20	112±18	Placebo	104±10	107±12	110±15	P Value (between drugs)	0.113	0.239	0.501	0.072",25877:26911,3835251,24002370,Unavailable
3835251,Standing SBP 2h,Atomoxetine ,Placebo,No significant difference,"Standing SBP, mm Hg Atomoxetine 108±15 111±20 112±18 Placebo 104±10 107±12 110±15 P Value (between drugs) 0.113 0.239 0.501 0.072",25877:26911,3835251,24002370,Unavailable
3835251,Standing SBP 4h,Atomoxetine ,Placebo,No significant difference,"Standing SBP, mm Hg Atomoxetine 108±15 111±20 112±18 Placebo 104±10 107±12 110±15 P Value (between drugs) 0.113 0.239 0.501 0.072",25877:26911,3835251,24002370,Unavailable
3835251,Sitting SBP,Atomoxetine ,Placebo,Significantly increased,"Sitting SBP, mm Hg Atomoxetine 102±13 105±10 107±10 Placebo 102±10 102±10 103±10 P Value (between drugs) 0.918 0.128 0.040 0.042",32954:33066,3835251,24002370,Unavailable
3835251,Sitting SBP 2h,Atomoxetine ,Placebo,No significant difference,"Sitting SBP, mm Hg Atomoxetine 102±13 105±10 107±10 Placebo 102±10 102±10 103±10 P Value (between drugs) 0.918 0.128 0.040 0.042",26966:27999,3835251,24002370,Unavailable
3835251,Sitting SBP 4h,Atomoxetine ,Placebo,Significantly increased,"Sitting SBP, mm Hg Atomoxetine 102±13 105±10 107±10 Placebo 102±10 102±10 103±10 P Value (between drugs) 0.918 0.128 0.040 0.042",32954:33066,3835251,24002370,Unavailable
3835251,Δ SBP (standing–seated),Atomoxetine ,Placebo,No significant difference,"HR SBP (standing–seated), mm Hg				Atomoxetine	5±10	6±18	−5±15	Placebo	1±8	4±9	7±14	P Value (between drugs)	0.053	0.657	0.570	0.251",28054:29087,3835251,24002370,Unavailable
3835251,Δ SBP (standing–seated) 2h,Atomoxetine ,Placebo,No significant difference,"HR SBP (standing–seated), mm Hg Atomoxetine 5±10 6±18 −5±15 Placebo 1±8 4±9 7±14 P Value (between drugs) 0.053 0.657 0.570 0.251",28054:29087,3835251,24002370,Unavailable
3835251,Δ SBP (standing–seated) 4h,Atomoxetine ,Placebo,No significant difference,"HR SBP (standing–seated), mm Hg Atomoxetine 5±10 6±18 −5±15 Placebo 1±8 4±9 7±14 P Value (between drugs) 0.053 0.657 0.570 0.251",28054:29087,3835251,24002370,Unavailable
3835251,Symptom scores worsening ,Atomoxetine ,Placebo,Significantly increased,"Symptom score, au Atomoxetine 14±10 19±15 16±15 Placebo 18±16 15±14 14±12 P Value (between drugs) 0.054 0.250 0.622 0.038",33120:33378,3835251,24002370,Unavailable
3835251,Symptom scores worsening 2h,Atomoxetine ,Placebo,Significantly increased,"Symptom score, au				Atomoxetine	14±10	19±15	16±15	Placebo	18±16	15±14	14±12	P Value (between drugs)	0.054	0.250	0.622	0.038",29142:30168,3835251,24002370,Unavailable
3835251,Symptom scores worsening 4h,Atomoxetine ,Placebo,No significant difference,"Symptom score, au Atomoxetine 14±10 19±15 16±15 Placebo 18±16 15±14 14±12 P Value (between drugs) 0.054 0.250 0.622 0.038",29142:30168,3835251,24002370,Unavailable
3835251,Standing heart rate,Atomoxetine ,Placebo,Significantly increased,"Following study drug administration, standing HR increased with atomoxetine and decreased with placebo (PDrug&lt;0.001).",31809:31954,3835251,24002370,Unavailable
3835251,Standing heart rate 1h,Atomoxetine ,Placebo,Significantly increased,"Atomoxetine significantly increased HR compared with placebo at 1 hour (P=0.004), 2 hours (121±17 bpm versus 105±15 bpm; P=0.001; primary study endpoint), 3 hours (P&lt;0.001), and 4 hours (P=0.001).",31954:32225,3835251,24002370,Unavailable
3835251,Standing heart rate 2h,Atomoxetine ,Placebo,Significantly increased,"Atomoxetine significantly increased HR compared with placebo at 1 hour (P=0.004), 2 hours (121±17 bpm versus 105±15 bpm; P=0.001; primary study endpoint), 3 hours (P&lt;0.001), and 4 hours (P=0.001).",31954:32225,3835251,24002370,Unavailable
3835251,Standing heart rate 3h,Atomoxetine ,Placebo,Significantly increased,"Atomoxetine significantly increased HR compared with placebo at 1 hour (P=0.004), 2 hours (121±17 bpm versus 105±15 bpm; P=0.001; primary study endpoint), 3 hours (P&lt;0.001), and 4 hours (P=0.001).",31954:32225,3835251,24002370,Unavailable
3835251,Standing heart rate 4h,Atomoxetine ,Placebo,Significantly increased,"Atomoxetine significantly increased HR compared with placebo at 1 hour (P=0.004), 2 hours (121±17 bpm versus 105±15 bpm; P=0.001; primary study endpoint), 3 hours (P&lt;0.001), and 4 hours (P=0.001).",31954:32225,3835251,24002370,Unavailable
3835251,Δ HR (standing–seated),Atomoxetine ,Placebo,No significant difference,"Overall, there was not a statistically significant increase in ΔHR over time with atomoxetine compared with placebo (PDrug=0.080).",32232:32390,3835251,24002370,Unavailable
3835251,Standing SBP,Atomoxetine ,Placebo,No significant difference,"Overall, atomoxetine was associated with significantly higher seated SBP (PDrug=0.042) and a trend toward higher standing SBP (PDrug=0.072)",32586:32782,3835251,24002370,Unavailable
3835251,Sitting SBP,Atomoxetine ,Placebo,Significantly increased,"Overall, atomoxetine was associated with significantly higher seated SBP (PDrug=0.042) and a trend toward higher standing SBP (PDrug=0.072)",32954:33066,3835251,24002370,Unavailable
3835251,Symptom scores worsening ,Atomoxetine ,Placebo,No significant difference,"Over time, atomoxetine worsened the symptoms score compared with placebo (PInt=0.038",32954:33066,3835251,24002370,Unavailable
3835251,Symptom scores worsening 2h,Atomoxetine ,Placebo,Significantly increased,"From baseline to 2 hours (time of primary end point), symptom scores significantly increased with atomoxetine (worse) but decreased (improved) with placebo (+4.2 au versus −3.5 au; P=0.028; Figure 2B).",33120:33378,3835251,24002370,Unavailable
4195710,Health-care-related costs,Video-based condition ,Control,No significant difference,"No significant differences were found between the three conditions with regard to health-care-related costs and productivity costs. Furthermore, no significant group differences were found in QALYs",52432:52629,4195710,25310007,Unavailable
4195710,Health-care-related costs,Text-based condition,Control,No significant difference,"No significant differences were found between the three conditions with regard to health-care-related costs and productivity costs. Furthermore, no significant group differences were found in QALYs",52432:52629,4195710,25310007,Unavailable
4195710,Health-care-related costs,Video-based condition ,Text-based condition,No significant difference,"No significant differences were found between the three conditions with regard to health-care-related costs and productivity costs. Furthermore, no significant group differences were found in QALYs",52432:52629,4195710,25310007,Unavailable
4195710,Productivity costs,Video-based condition ,Control,No significant difference,"No significant differences were found between the three conditions with regard to health-care-related costs and productivity costs. Furthermore, no significant group differences were found in QALYs",52432:52629,4195710,25310007,Unavailable
4195710,Productivity costs,Text-based condition,Control,No significant difference,"No significant differences were found between the three conditions with regard to health-care-related costs and productivity costs. Furthermore, no significant group differences were found in QALYs",52432:52629,4195710,25310007,Unavailable
4195710,Productivity costs,Video-based condition ,Text-based condition,No significant difference,"No significant differences were found between the three conditions with regard to health-care-related costs and productivity costs. Furthermore, no significant group differences were found in QALYs",52432:52629,4195710,25310007,Unavailable
4195710,Quality-adjusted life-year,Video-based condition ,Control,No significant difference,"No significant differences were found between the three conditions with regard to health-care-related costs and productivity costs. Furthermore, no significant group differences were found in QALYs",55020:55401,4195710,25310007,Unavailable
4195710,Quality-adjusted life-year,Text-based condition,Control,No significant difference,"No significant differences were found between the three conditions with regard to health-care-related costs and productivity costs. Furthermore, no significant group differences were found in QALYs",55020:55401,4195710,25310007,Unavailable
4195710,Quality-adjusted life-year,Video-based condition ,Text-based condition,No significant difference,"No significant differences were found between the three conditions with regard to health-care-related costs and productivity costs. Furthermore, no significant group differences were found in QALYs",55020:55401,4195710,25310007,Unavailable
4195710,Prolonged abstinence,Video-based condition ,Control,Significantly increased,"Pairwise comparisons between the different groups revealed that the video-based condition significantly differed from the control condition (F (2, 2096) = 3.071; p = .047). A higher proportion of respondents in the video-based condition achieved PA than in the control condition.",61520:61833,4195710,25310007,Unavailable
4195710,Prolonged abstinence,Video-based condition ,Control,Significantly increased,"Prolonged abstinent (N = 2099)[% (N)]	9.9(66)	7.3(52)	6.4(46)		6.134(2)	.047",59861:60207,4195710,25310007,Unavailable
4195710,Quality-adjusted life-year,Video-based condition ,Control,No significant difference,"QALY (EQ-5D-3L) a (N = 2088) [M (SD)]	0.8(0.2)	0.8(0.2)	0.8(0.2)	.017(2, 2085)		.984",60682:NaN,4195710,25310007,Unavailable
4195710,Quality-adjusted life-year,Text-based condition,Control,No significant difference,"QALY (EQ-5D-3L) a (N = 2088) [M (SD)]	0.8(0.2)	0.8(0.2)	0.8(0.2)	.017(2, 2085)		.984",60682:NaN,4195710,25310007,Unavailable
4195710,Quality-adjusted life-year,Video-based condition ,Text-based condition,No significant difference,"QALY (EQ-5D-3L) a (N = 2088) [M (SD)]	0.8(0.2)	0.8(0.2)	0.8(0.2)	.017(2, 2085)		.984",60682:61081,4195710,25310007,Unavailable
4195710,7-day point prevalence abstinent,Video-based condition ,Control,No significant difference,"7-day point prevalence abstinent (N = 2099) [% (N)]	17.8(119)	17.7(125)	16.2(117)		.730(2)	.694",60262:60627,4195710,25310007,Unavailable
4195710,7-day point prevalence abstinent,Text-based condition,Control,No significant difference,7-day point prevalence abstinent (N = 2099) [% (N)] 17.8(119) 17.7(125) 16.2(117) .730(2) .694,60262:60627,4195710,25310007,Unavailable
4195710,7-day point prevalence abstinent,Video-based condition ,Text-based condition,No significant difference,"7-day point prevalence abstinent (N = 2099) [% (N)]	17.8(119)	17.7(125)	16.2(117)		.730(2)	.694",60262:60627,4195710,25310007,Unavailable
3757791,Minimal bleeding (15min),Tranexamic acid,Placebo ,Significantly increased,"Surgical field quality after 15 min revealed that seven patients in group I had minimal bleeding versus no one in group II, P=0.006.",3925:4027,3757791,24015121,Unavailable
3757791,Mild bleeding (15min),Tranexamic acid,Placebo ,No significant difference,"Meanwhile, 35 patients in group I had mild bleeding versus 26 patients in group II, P=0.064",4027:4159,3757791,24015121,Unavailable
3757791,Moderate bleeding (15min),Tranexamic acid,Placebo ,Significantly decreased,"Higher number of patients in group II than in group I had moderate bleeding, P=0006.",4027:4159,3757791,24015121,Unavailable
3757791,Minimal bleeding (30min),Tranexamic acid,Placebo ,Significantly increased,"Also, at 30 min, revealed that 10 patients in group I had minimal bleeding versus one patient in group II, P=0.004.",4027:4159,3757791,24015121,Unavailable
3757791,Mild bleeding (30min),Tranexamic acid,Placebo ,No significant difference,"Meanwhile, 37 patients in group I had mild bleeding versus 28 patients in group II, P=0.059.",4160:4269,3757791,24015121,Unavailable
3757791,Moderate bleeding (30min),Tranexamic acid,Placebo ,Significantly decreased,"Higher number of patients in group II than in group I had moderate bleeding, P&lt;0001.",13865:14033,3757791,24015121,Unavailable
3757791,Duration of the surgeries,Tranexamic acid,Placebo ,Significantly decreased,"Duration of the surgeries and volume of bleeding were significantly less in tranexamic group than the placebo group, P&lt;0.0001.",4372:4518,3757791,24015121,Unavailable
3757791,Volume of bleeding,Tranexamic acid,Placebo ,Significantly decreased,"Duration of the surgeries and volume of bleeding were significantly less in tranexamic group than the placebo group, P&lt;0.0001.",4372:4518,3757791,24015121,Unavailable
3757791,Minimal bleeding (15min),Tranexamic acid,Placebo ,Significantly increased,"Grading of the surgical field quality at 15 min of surgical procedure, [Table 4] revealed that 7 patients in group I had minimal bleeding, which was not a surgical nuisance and no suction required versus no one in group II, P=0.006.",13401:13689,3757791,24015121,Unavailable
3757791,Mild bleeding (15min),Tranexamic acid,Placebo ,No significant difference,"Meanwhile, 35 patients in group I had mild bleeding with occasional suction required, but does not affect dissection versus 26 patients in group II, P=0.064.",13690:13864,3757791,24015121,Unavailable
3757791,Moderate bleeding (15min),Tranexamic acid,Placebo ,Significantly decreased,"Higher number of patients in group II than in group I had moderate bleeding slightly compromises surgical field, and frequent suction required, P=0006.",13865:14033,3757791,24015121,Unavailable
3757791,Minimal bleeding (30min),Tranexamic acid,Placebo ,Significantly increased,"Grading of the surgical field quality at 30 min of surgical procedure [Table 5], revealed that 10 patients in group I had minimal bleeding, which was not a surgical nuisance and no suction required versus one patient in group II, P=0.004.",14290:14585,3757791,24015121,Unavailable
3757791,Mild bleeding (30min),Tranexamic acid,Placebo ,No significant difference,"Meanwhile, 37 patients in group I had mild bleeding with occasional suction required, but does not affect dissection versus 28 patients in group II, P=0.059.",14585:14759,3757791,24015121,Unavailable
3757791,Moderate bleeding (30min),Tranexamic acid,Placebo ,Significantly decreased,"Higher number of patients in group II than in group I had moderate bleeding slightly compromises surgical field, frequent suction required, P&lt;0.0001.",14760:14926,3757791,24015121,Unavailable
5879083,Anaerobic performance, School-Based Sports Program,Control,Significantly increased,A significant improvement of 16% in favor of the sport group was found for anaerobic performance (p = 0.003).,7997:8124,5879083,29632853,Unavailable
5879083,Fat loss, School-Based Sports Program,Control,Significantly increased,"In addition, the sport group lost 2.8% more fat mass compared to the control group (p = 0.007).",8124:8236,5879083,29632853,Unavailable
5879083,Aerobic performance, School-Based Sports Program,Control,No significant difference,"No changes were found for aerobic performance, VO2 peak, physical activity, blood pressure, arterial stiffness, and the metabolic profile.",8236:8386,5879083,29632853,Unavailable
5879083,VO2 peak, School-Based Sports Program,Control,No significant difference,"No changes were found for aerobic performance, VO2 peak, physical activity, blood pressure, arterial stiffness, and the metabolic profile.",8236:8386,5879083,29632853,Unavailable
5879083,Physical activity, School-Based Sports Program,Control,No significant difference,"No changes were found for aerobic performance, VO2 peak, physical activity, blood pressure, arterial stiffness, and the metabolic profile.",8236:8386,5879083,29632853,Unavailable
5879083,Blood pressure, School-Based Sports Program,Control,No significant difference,"No changes were found for aerobic performance, VO2 peak, physical activity, blood pressure, arterial stiffness, and the metabolic profile.",8236:8386,5879083,29632853,Unavailable
5879083,Arterial stiffness, School-Based Sports Program,Control,No significant difference,"No changes were found for aerobic performance, VO2 peak, physical activity, blood pressure, arterial stiffness, and the metabolic profile.",8236:8386,5879083,29632853,Unavailable
5879083,Metabolic profile, School-Based Sports Program,Control,No significant difference,"No changes were found for aerobic performance, VO2 peak, physical activity, blood pressure, arterial stiffness, and the metabolic profile.",8236:8386,5879083,29632853,Unavailable
5986231,Cure rate,Oral zinc sulfate,Placebo,No significant difference,Warts completely resolved in 26 patients in the treatment group (68.4%) and 23 patients in the placebo group (63.9%; p = .68).,4831:4979,5986231,29872682,Unavailable
5986231,Recurrence ,Oral zinc sulfate,Placebo,No significant difference,Three patients (7.9%) in the treatment group and six patients (16.6%) in the placebo group has a recurrence of the warts (p = .19).,4831:4979,5986231,29872682,Unavailable
5986231,Cure rate,Oral zinc sulfate,Placebo,No significant difference,Twenty-six patients (68.4%) in the treatment group and 23 patients (63.9%) in the placebo group showed a complete resolution of their warts with no significant difference (p = .68).,14655:14854,5986231,29872682,Unavailable
5986231,Cure after first session,Oral zinc sulfate,Placebo,No significant difference,There was no difference in the cure rate in each session of the cryotherapy between the two groups,14854:14952,5986231,29872682,Unavailable
5986231,"Cure after second session	",Oral zinc sulfate,Placebo,No significant difference,There was no difference in the cure rate in each session of the cryotherapy between the two groups,14854:14952,5986231,29872682,Unavailable
5986231,"Cure after third session	",Oral zinc sulfate,Placebo,No significant difference,There was no difference in the cure rate in each session of the cryotherapy between the two groups,14854:14952,5986231,29872682,Unavailable
5986231,Hyperpigmentation,Oral zinc sulfate,Placebo,No significant difference,"Local side effects such as hyperpigmentation, hypopigmentation, and scar formation were seen in both groups with no significant difference",15006:15144,5986231,29872682,Unavailable
5986231,Hypopigmentation,Oral zinc sulfate,Placebo,No significant difference,"Local side effects such as hyperpigmentation, hypopigmentation, and scar formation were seen in both groups with no significant difference",15006:15144,5986231,29872682,Unavailable
5986231,Scar formation ,Oral zinc sulfate,Placebo,No significant difference,"Local side effects such as hyperpigmentation, hypopigmentation, and scar formation were seen in both groups with no significant difference",15006:15144,5986231,29872682,Unavailable
5986231,Nausea,Oral zinc sulfate,Placebo,Significantly increased,"In the treatment group, there was a high frequency of gastrointestinal adverse effects such as nausea (68.89%), vomiting (17.77%), and epigastric pain (17.77%) in comparison with the placebo group.",15163:15361,5986231,29872682,Unavailable
5986231,Vomiting ,Oral zinc sulfate,Placebo,Significantly increased,"In the treatment group, there was a high frequency of gastrointestinal adverse effects such as nausea (68.89%), vomiting (17.77%), and epigastric pain (17.77%) in comparison with the placebo group.",15163:15361,5986231,29872682,Unavailable
5986231,Epigastric pain,Oral zinc sulfate,Placebo,Significantly increased,"In the treatment group, there was a high frequency of gastrointestinal adverse effects such as nausea (68.89%), vomiting (17.77%), and epigastric pain (17.77%) in comparison with the placebo group.",15163:15361,5986231,29872682,Unavailable
5986231,Recurrence ,Oral zinc sulfate,Placebo,No significant difference,Nine patients had a recurrence during the 6-month follow-up period including three patients (7.9%) in the treatment group and six patients (16.6%) in the placebo group. The recurrence rate was higher in the placebo group although the difference was not significant (p = .19,16487:16777,5986231,29872682,Unavailable
5986231,Cure rate,Oral zinc sulfate,Placebo,No significant difference,"Cure rate	26 (68.42%)	23 (63.9%)	.68",18617:18716,5986231,29872682,Unavailable
5986231,Cure after first session,Oral zinc sulfate,Placebo,No significant difference,"Cure after first session of cryotherapy	3 (7.89%)	2 (5.56%)	.69",18734:18860,5986231,29872682,Unavailable
5986231,"Cure after second session	",Oral zinc sulfate,Placebo,No significant difference,"Cure after second session	8 (21.05%)	6 (16.67%)	.77",18878:18992,5986231,29872682,Unavailable
5986231,"Cure after third session	",Oral zinc sulfate,Placebo,No significant difference,"Cure after third session	15 (39.47%)	15 (42.67%)	1",19010:19123,5986231,29872682,Unavailable
5986231,Recurrence ,Oral zinc sulfate,Placebo,No significant difference,"Recurrence	3 (7.89%)	6 (16.67%)	.19",19274:19372,5986231,29872682,Unavailable
5986231,"New lesions after treatment	",Oral zinc sulfate,Placebo,No significant difference,"New lesion after treatment	5 (13.16%)	4 (11.11%)	.78",19141:19256,5986231,29872682,Unavailable
4591119,Heart attack incidence (6 months), KM2H2 Program ,Control,Significantly decreased,"Relative to the standard care, receiving KM2H2 was associated with significant reductions in the incidence of heart attack (3.60% vs. 7.03%, p &lt; .05) and stroke (5.11% vs. 9.90%, p&lt;0.05), and moderate reduction in blood pressure (-3.72mmHg in DBP and -2.92 mmHg in DBP) at 6-month post-intervention",6212:6521,4591119,26426421,Unavailable
4591119,Stroke incidence (6 months), KM2H2 Program ,Control,Significantly decreased,"Relative to the standard care, receiving KM2H2 was associated with significant reductions in the incidence of heart attack (3.60% vs. 7.03%, p &lt; .05) and stroke (5.11% vs. 9.90%, p&lt;0.05), and moderate reduction in blood pressure (-3.72mmHg in DBP and -2.92 mmHg in DBP) at 6-month post-intervention",6212:6521,4591119,26426421,Unavailable
4591119,Blood pressure (6 months), KM2H2 Program ,Control,No significant difference,"Relative to the standard care, receiving KM2H2 was associated with significant reductions in the incidence of heart attack (3.60% vs. 7.03%, p &lt; .05) and stroke (5.11% vs. 9.90%, p&lt;0.05), and moderate reduction in blood pressure (-3.72mmHg in DBP and -2.92 mmHg in DBP) at 6-month post-intervention",6212:6521,4591119,26426421,Unavailable
4591119,Physical activity (6 months), KM2H2 Program ,Control,Significantly increased,"and significant increases in physical activity at 3- (d = 0.53, 95% CI: 0.21, 0.85) and 6-month (d = 0.45, 95% CI: 0.04, 0.85) post-intervention, respectively.",6523:6722,4591119,26426421,Unavailable
4591119,Physical activity (3 months), KM2H2 Program ,Control,Significantly increased,"and significant increases in physical activity at 3- (d = 0.53, 95% CI: 0.21, 0.85) and 6-month (d = 0.45, 95% CI: 0.04, 0.85) post-intervention, respectively.",6523:6722,4591119,26426421,Unavailable
4591119,Physical activity (6 months), KM2H2 Program ,Control,Significantly increased,"The actual physical activity levels (the lower panel of Table 2) were also significantly higher for the KM2H2 participants than for the control participants at three (d = 0.53, 95% CI: [0.21, 0.85]) and six months (d = 0.45, 95% CI: [.04, 0.85]) post-intervention.",51410:51774,4591119,26426421,Unavailable
4591119,Physical activity (3 months), KM2H2 Program ,Control,Significantly increased,"The actual physical activity levels (the lower panel of Table 2) were also significantly higher for the KM2H2 participants than for the control participants at three (d = 0.53, 95% CI: [0.21, 0.85]) and six months (d = 0.45, 95% CI: [.04, 0.85]) post-intervention.",51409:51773,4591119,26426421,Unavailable
4591119,Physical activity (6 months), KM2H2 Program ,Control,Significantly increased,"Levels of physical activityTotal sample Baseline	2.73(1.54)	2.68(1.40)	0.00 (n/a)	n/a	n/a 3 Months	2.81(1.35)	2.14(1.74)	0.74 (1.40)	0.53**	0.21,0.85 6 Months	3.37(1.28)	2.66(1.81)	0.54 (1.22)	0.45*",57121:58316,4591119,26426421,Unavailable
4591119,Physical activity (3 months), KM2H2 Program ,Control,Significantly increased,"Levels of physical activityTotal sample Baseline	2.73(1.54)	2.68(1.40)	0.00 (n/a)	n/a	n/a 3 Months	2.81(1.35)	2.14(1.74)	0.74 (1.40)	0.53**",57121:57917,4591119,26426421,Unavailable
4591119,Heart attack incidence (6 months), KM2H2 Program ,Control,Significantly decreased,"Relative to the standard care at the 6th month post-intervention, receiving KM2H2 was associated with significant reductions in the incidence (any events during follow-ups) of heart attack (3.60% vs. 7.03%, RR = 0.51, p &lt; .05) with Cohen’s d = .37, 95% CI: [.34, .40], and stroke (5.11% vs. 9.90%, RR = 0.52, p &lt; .05) with Cohen’s d = 0.36, 95% CI: [.32, .40].",71364:71809,4591119,26426421,Unavailable
4591119,Stroke incidence (6 months), KM2H2 Program ,Control,Significantly decreased,"Relative to the standard care at the 6th month post-intervention, receiving KM2H2 was associated with significant reductions in the incidence (any events during follow-ups) of heart attack (3.60% vs. 7.03%, RR = 0.51, p &lt; .05) with Cohen’s d = .37, 95% CI: [.34, .40], and stroke (5.11% vs. 9.90%, RR = 0.52, p &lt; .05) with Cohen’s d = 0.36, 95% CI: [.32, .40].",71364:71809,4591119,26426421,Unavailable
4591119,Heart attack incidence (6 months), KM2H2 Program ,Control,Significantly decreased,The intervention effect (interaction term in the model) was not significant at 3 months (p = .331) and significant at 6 months post intervention (p = .028).,72429:72619,4591119,26426421,Unavailable
4591119,Heart attack incidence (3 months), KM2H2 Program ,Control,No significant difference,The intervention effect (interaction term in the model) was not significant at 3 months (p = .331) and significant at 6 months post intervention (p = .028).,72429:72619,4591119,26426421,Unavailable
4591119,Stroke incidence (6 months), KM2H2 Program ,Control,Significantly decreased,The intervention effect (interaction term in the model) was not significant at 3 months (p = .230) and significant at 6 months post intervention (p = .015).,73305:73495,4591119,26426421,Unavailable
4591119,Stroke incidence (3 months), KM2H2 Program ,Control,No significant difference,The intervention effect (interaction term in the model) was not significant at 3 months (p = .230) and significant at 6 months post intervention (p = .015).,73305:73495,4591119,26426421,Unavailable
1636653,Simple reaction time,Transcranial DC stimulation,Placebo ,Significantly decreased,"Anodal tDCS shortened reaction times and improved pinch force in the paretic hand relative to Sham stimulation, an effect present in patients with higher impairment.",4561:4726,1636653,17083730,Unavailable
1636653,Pinch force,Transcranial DC stimulation,Placebo ,Significantly increased,"Anodal tDCS shortened reaction times and improved pinch force in the paretic hand relative to Sham stimulation, an effect present in patients with higher impairment.",4561:4726,1636653,17083730,Unavailable
1636653,Simple reaction time,Transcranial DC stimulation,Placebo ,Significantly decreased,"The ANOVARM revealed no significant effects of the factors INTERVENTION(tDCS, Sham) (F[1] = 0.02, ns) or TIME(Base, Post) (F[1] = 0.07, ns), but a significant interaction INTERVENTION(tDCS, Sham) × TIME(Base, Post) (F[1,10] = 11.9, p &lt; 0.01; Fig. 1) on RT. Post hoc testing showed that RT experienced a significant reduction with tDCS (from BasetDCS = 273.5 ± 15.4 msec to PosttDCS = 256.6 ± 13.9 msec, p &lt; 0.05; Fig. 1C) and a nonsignificant trend to lengthening with Sham (from BaseSham = 265.2 ± 10.7 msec to PostSham = 277.7 ± 11.6 msec, p = 0.06).",8858:9590,1636653,17083730,Unavailable
1636653,Pinch force,Transcranial DC stimulation,Placebo ,Significantly increased,"The ANOVARM revealed no significant effects of the factors INTERVENTION(tDCS , Sham) (F[1] = 2.3, ns) or TIME(Base, Post) (F[1] = 0.03, ns), but a significant interaction INTERVENTION(tDCS, Sham) × TIME(Base, Post) (F[1,10] = 6.1, p &lt; 0.05) on PF. Post hoc testing showed that tDCS elicited a nonsignificant trend towards increase in PF with tDCS (from BasetDCS = 118.8 ± 23.0 N to PosttDCS = 124.8 ± 24.0 N; p = 0.18) and towards decrease with Sham (from BaseSham = 114.8 ± 20.4 N to PostSham = 111.2 ± 19.8 N; p = 0.20, Fig 3)",10669:11336,1636653,17083730,Unavailable
5866326,Time to first ICD shock,Ultra‐conservative ICD programming,Control,No significant difference,"Among the 83 patients studied, we found no statistically significant difference in time to first ICD shock or total ICD shocks between groups.",8321:8464,5866326,29475875,Unavailable
5866326,Total ICD shocks,Ultra‐conservative ICD programming,Control,No significant difference,"Among the 83 patients studied, we found no statistically significant difference in time to first ICD shock or total ICD shocks between groups.",8321:8464,5866326,29475875,Unavailable
5866326,Experiencing at least one shock compared,Ultra‐conservative ICD programming,Control,No significant difference,In the ultra‐conservative group 16% of patients experienced at least one shock compared with 21% in the control group (P=0.66).,8463:8609,5866326,29475875,Unavailable
5866326,Mortality,Ultra‐conservative ICD programming,Control,No significant difference,"There was no difference in mortality, arrhythmic hospitalization, or hospitalization for heart failure.",8609:8713,5866326,29475875,Unavailable
5866326,Arrhythmia hospitalization,Ultra‐conservative ICD programming,Control,No significant difference,"There was no difference in mortality, arrhythmic hospitalization, or hospitalization for heart failure.",8609:8713,5866326,29475875,Unavailable
5866326,Hospitalization for heart failure,Ultra‐conservative ICD programming,Control,No significant difference,"There was no difference in mortality, arrhythmic hospitalization, or hospitalization for heart failure.",8609:8713,5866326,29475875,Unavailable
5866326,Total ICD shocks,Cardiac resynchronization therapy ON,Cardiac resynchronization therapy OFF,No significant difference,In the 41 patients with CRT ICDs fewer shocks were observed with CRT‐ON but this was not statistically significant: 10% of patients with CRT‐ON (n=21) versus 38% with CRT‐OFF (n=20) received shocks (P=0.08).,8713:8937,5866326,29475875,Unavailable
4733136,PASI score improvement of ≥75 % (overall) -16 weeks,Adalimumab ,Placebo,Significantly increased,"Rates for an improvement of ≥75&nbsp;% from baseline in the PASI score (PASI75 response) were significantly greater (p&nbsp;&lt;&nbsp;0.001) at week 16 in patients treated with adalimumab compared with patients who received placebo in the overall (72.1 vs. 8.0&nbsp;%, respectively), previously treated (72.7 vs. 8.5&nbsp;%), and previously failed treatment (70.4 vs. 8.1&nbsp;%) groups.",21848:22274,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥75 % (previously treated) -16 weeks,Adalimumab ,Placebo,Significantly increased,"Rates for an improvement of ≥75&nbsp;% from baseline in the PASI score (PASI75 response) were significantly greater (p&nbsp;&lt;&nbsp;0.001) at week 16 in patients treated with adalimumab compared with patients who received placebo in the overall (72.1 vs. 8.0&nbsp;%, respectively), previously treated (72.7 vs. 8.5&nbsp;%), and previously failed treatment (70.4 vs. 8.1&nbsp;%) groups.",21848:22274,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥75 % (previously failed treatment) -16 weeks,Adalimumab ,Placebo,Significantly increased,"Rates for an improvement of ≥75&nbsp;% from baseline in the PASI score (PASI75 response) were significantly greater (p&nbsp;&lt;&nbsp;0.001) at week 16 in patients treated with adalimumab compared with patients who received placebo in the overall (72.1 vs. 8.0&nbsp;%, respectively), previously treated (72.7 vs. 8.5&nbsp;%), and previously failed treatment (70.4 vs. 8.1&nbsp;%) groups.",21848:22274,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥90 % (previously treated) - 16 weeks,Adalimumab ,Placebo,Significantly increased,Improvements of ≥90 or ≥100&nbsp;% from baseline PASI score were also higher with adalimumab vs. placebo in previously treated patients.,21436:21848,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥100 % (previously treated) - 16 weeks,Adalimumab ,Placebo,Significantly increased,Improvements of ≥90 or ≥100&nbsp;% from baseline PASI score were also higher with adalimumab vs. placebo in previously treated patients.,21436:21848,4733136,26547918,Unavailable
4733136,Overall adverse events (overall),Adalimumab ,Placebo,No significant difference,Adverse events were similar among subgroups.,27120:27300,4733136,26547918,Unavailable
4733136,Overall adverse events (previously treated),Adalimumab ,Placebo,No significant difference,Adverse events were similar among subgroups.,27120:27300,4733136,26547918,Unavailable
4733136,Overall adverse events (previously failed treatment),Adalimumab ,Placebo,No significant difference,Adverse events were similar among subgroups.,27120:27300,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥75 % (overall) -16 weeks,Adalimumab ,Placebo,Significantly increased,"At 16&nbsp;weeks, a significantly higher (p&nbsp;&lt;&nbsp;0.001) percentage of patients treated with adalimumab compared with those receiving placebo achieved PASI75 in all treatment groups (overall, 72.1&nbsp;% [664/921] vs. 8.0&nbsp;% [36/451]; prior treatment, 72.7&nbsp;% [357/491] vs. 8.5&nbsp;% [21/247]; and prior failures, 70.4&nbsp;% [107/152] vs. 8.1&nbsp;% [5/62]; Fig.&nbsp;1b).Fig.&nbsp;1",21848:22274,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥75 % (previously treated) -16 weeks,Adalimumab ,Placebo,Significantly increased,"At 16&nbsp;weeks, a significantly higher (p&nbsp;&lt;&nbsp;0.001) percentage of patients treated with adalimumab compared with those receiving placebo achieved PASI75 in all treatment groups (overall, 72.1&nbsp;% [664/921] vs. 8.0&nbsp;% [36/451]; prior treatment, 72.7&nbsp;% [357/491] vs. 8.5&nbsp;% [21/247]; and prior failures, 70.4&nbsp;% [107/152] vs. 8.1&nbsp;% [5/62]; Fig.&nbsp;1b).Fig.&nbsp;1",21848:22274,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥75 % (previously failed treatment) -16 weeks,Adalimumab ,Placebo,Significantly increased,"At 16&nbsp;weeks, a significantly higher (p&nbsp;&lt;&nbsp;0.001) percentage of patients treated with adalimumab compared with those receiving placebo achieved PASI75 in all treatment groups (overall, 72.1&nbsp;% [664/921] vs. 8.0&nbsp;% [36/451]; prior treatment, 72.7&nbsp;% [357/491] vs. 8.5&nbsp;% [21/247]; and prior failures, 70.4&nbsp;% [107/152] vs. 8.1&nbsp;% [5/62]; Fig.&nbsp;1b).Fig.&nbsp;1",21848:22274,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥75 % (overall) -4 weeks,Adalimumab ,Placebo,Significantly increased,"By 4&nbsp;weeks (first evaluation), PASI75 response rates were significantly greater (p&nbsp;&lt;&nbsp;0.001) in patients treated with adalimumab compared with patients receiving placebo in all treatment groups (overall, 19.4&nbsp;% [187/966] vs. 1.4&nbsp;% [7/503]; prior treatment, 21.7&nbsp;% [111/511] vs. 1.5&nbsp;% [4/269]; and prior failures, 15.6&nbsp;% [25/160] vs. 0&nbsp;% [0/69]; Fig.&nbsp;1a).",21436:21848,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥75 % (previously treated) -4 weeks,Adalimumab ,Placebo,Significantly increased,"By 4&nbsp;weeks (first evaluation), PASI75 response rates were significantly greater (p&nbsp;&lt;&nbsp;0.001) in patients treated with adalimumab compared with patients receiving placebo in all treatment groups (overall, 19.4&nbsp;% [187/966] vs. 1.4&nbsp;% [7/503]; prior treatment, 21.7&nbsp;% [111/511] vs. 1.5&nbsp;% [4/269]; and prior failures, 15.6&nbsp;% [25/160] vs. 0&nbsp;% [0/69]; Fig.&nbsp;1a).",21436:21848,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥75 % (previously failed treatment) -4 weeks,Adalimumab ,Placebo,Significantly increased,"By 4&nbsp;weeks (first evaluation), PASI75 response rates were significantly greater (p&nbsp;&lt;&nbsp;0.001) in patients treated with adalimumab compared with patients receiving placebo in all treatment groups (overall, 19.4&nbsp;% [187/966] vs. 1.4&nbsp;% [7/503]; prior treatment, 21.7&nbsp;% [111/511] vs. 1.5&nbsp;% [4/269]; and prior failures, 15.6&nbsp;% [25/160] vs. 0&nbsp;% [0/69]; Fig.&nbsp;1a).",21436:21848,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥90 % (overall) - 4 weeks,Adalimumab ,Placebo,Significantly increased,"At 4 weeks, PASI90 response rates were significantly greater (p &lt;&nbsp;0.001) in patients treated with adalimumab compared with patients receiving placebo overall (4.6&nbsp;% [44/966] vs. 0.2&nbsp;% [1/503]) and in patients who had previously received systemic therapy (4.3&nbsp;% [22/511] vs. 0&nbsp;% [0/269]); improvement was not significantly different with adalimumab vs. placebo for patients who had not responded to prior therapy (1.3&nbsp;% [2/160] vs. 0&nbsp;% [0/69]; Fig.&nbsp;1a).",22983:23495,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥90 % (previously treated) - 4 weeks,Adalimumab ,Placebo,Significantly increased,"At 4 weeks, PASI90 response rates were significantly greater (p &lt;&nbsp;0.001) in patients treated with adalimumab compared with patients receiving placebo overall (4.6&nbsp;% [44/966] vs. 0.2&nbsp;% [1/503]) and in patients who had previously received systemic therapy (4.3&nbsp;% [22/511] vs. 0&nbsp;% [0/269]); improvement was not significantly different with adalimumab vs. placebo for patients who had not responded to prior therapy (1.3&nbsp;% [2/160] vs. 0&nbsp;% [0/69]; Fig.&nbsp;1a).",22983:23495,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥90 % (previously failed treatment) - 4 weeks,Adalimumab ,Placebo,No significant difference,"At 4 weeks, PASI90 response rates were significantly greater (p &lt;&nbsp;0.001) in patients treated with adalimumab compared with patients receiving placebo overall (4.6&nbsp;% [44/966] vs. 0.2&nbsp;% [1/503]) and in patients who had previously received systemic therapy (4.3&nbsp;% [22/511] vs. 0&nbsp;% [0/269]); improvement was not significantly different with adalimumab vs. placebo for patients who had not responded to prior therapy (1.3&nbsp;% [2/160] vs. 0&nbsp;% [0/69]; Fig.&nbsp;1a).",22983:23495,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥100 % (overall) - 4 weeks,Adalimumab ,Placebo,No significant difference,No statistically significant difference in PASI100 response rates was observed between adalimumab and placebo at 4&nbsp;weeks.,27120:27300,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥100 % (previously treated) - 4 weeks,Adalimumab ,Placebo,No significant difference,No statistically significant difference in PASI100 response rates was observed between adalimumab and placebo at 4&nbsp;weeks.,27120:27300,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥100 % (previously failed treatment) - 4 weeks,Adalimumab ,Placebo,No significant difference,No statistically significant difference in PASI100 response rates was observed between adalimumab and placebo at 4&nbsp;weeks.,27120:27300,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥90 % (previously treated) - 16 weeks,Adalimumab ,Placebo,Significantly increased,"At 16&nbsp;weeks, however, significantly higher (p&nbsp;&lt;&nbsp;0.001) percentages of patients treated with adalimumab compared with placebo achieved PASI90 and PASI100 in all groups based on prior treatment experience",23617:23836,4733136,26547918,Unavailable
4733136,PASI score improvement of ≥100 % (previously treated) - 16 weeks,Adalimumab ,Placebo,Significantly increased,"At 16&nbsp;weeks, however, significantly higher (p&nbsp;&lt;&nbsp;0.001) percentages of patients treated with adalimumab compared with placebo achieved PASI90 and PASI100 in all groups based on prior treatment experience",23617:23836,4733136,26547918,Unavailable
4733136,Overall adverse events (overall),Adalimumab ,Placebo,No significant difference,"AE	297 (59)	615 (64)	162 (60)	311 (65)	47 (68)	96 (60)",27120:27300,4733136,26547918,Unavailable
4733136,Overall adverse events (previously treated),Adalimumab ,Placebo,No significant difference,"AE	297 (59)	615 (64)	162 (60)	311 (65)	47 (68)	96 (60)",27120:27300,4733136,26547918,Unavailable
4733136,Overall adverse events (previously failed treatment),Adalimumab ,Placebo,No significant difference,"AE	297 (59)	615 (64)	162 (60)	311 (65)	47 (68)	96 (60)",27120:27300,4733136,26547918,Unavailable
4733136,Serious adverse events (overall),Adalimumab ,Placebo,No significant difference,"Serious AE	8 (2)	18 (2)	1 (&lt;1)	10 (2)	0	4 (3)",27332:27515,4733136,26547918,Unavailable
4733136,Serious adverse events (previously treated),Adalimumab ,Placebo,No significant difference,"Serious AE	8 (2)	18 (2)	1 (&lt;1)	10 (2)	0	4 (3)",27332:27515,4733136,26547918,Unavailable
4733136,Serious adverse events (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Serious AE	8 (2)	18 (2)	1 (&lt;1)	10 (2)	0	4 (3)",27332:27515,4733136,26547918,Unavailable
4733136," AE leading to discontinuation	 (overall)",Adalimumab ,Placebo,No significant difference,"AE leading to discontinuation	11 (2)	18 (2)	5 (2)	8 (2)	5 (7)	5 (3)",27547:27740,4733136,26547918,Unavailable
4733136," AE leading to discontinuation	 (previously treated)",Adalimumab ,Placebo,No significant difference,"AE leading to discontinuation	11 (2)	18 (2)	5 (2)	8 (2)	5 (7)	5 (3)",27547:27740,4733136,26547918,Unavailable
4733136," AE leading to discontinuation	 (previously failed treatment)",Adalimumab ,Placebo,No significant difference,"AE leading to discontinuation	11 (2)	18 (2)	5 (2)	8 (2)	5 (7)	5 (3)",27547:27740,4733136,26547918,Unavailable
4733136, Severe AE (overall),Adalimumab ,Placebo,No significant difference,"Severe AE	15 (3)	27 (3)	5 (2)	12 (2)	2 (3)	6 (4)",27772:27946,4733136,26547918,Unavailable
4733136,  Severe AE (previously treated),Adalimumab ,Placebo,No significant difference,"Severe AE	15 (3)	27 (3)	5 (2)	12 (2)	2 (3)	6 (4)",27772:27946,4733136,26547918,Unavailable
4733136,  Severe AE (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Severe AE	15 (3)	27 (3)	5 (2)	12 (2)	2 (3)	6 (4)",27771:27946,4733136,26547918,Unavailable
4733136, Drug-related AE (overall),Adalimumab ,Placebo,No significant difference,"Drug-related AE	87 (17)	221 (23)	55 (20)	122 (24)	14 (20)	31 (19)",27978:28169,4733136,26547918,Unavailable
4733136,   Drug-related AE (previously treated),Adalimumab ,Placebo,No significant difference,"Drug-related AE	87 (17)	221 (23)	55 (20)	122 (24)	14 (20)	31 (19)",27978:28169,4733136,26547918,Unavailable
4733136, Drug-related AE (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Drug-related AE	87 (17)	221 (23)	55 (20)	122 (24)	14 (20)	31 (19)",27978:28169,4733136,26547918,Unavailable
4733136,  AE leading to death (overall),Adalimumab ,Placebo,No significant difference,"AE leading to death	0	0	0	0	0	0",28201:28412,4733136,26547918,Unavailable
4733136, AE leading to death (previously treated),Adalimumab ,Placebo,No significant difference,"AE leading to death	0	0	0	0	0	0",28201:28412,4733136,26547918,Unavailable
4733136, AE leading to death (previously failed treatment),Adalimumab ,Placebo,No significant difference,"AE leading to death	0	0	0	0	0	0",28200:28412,4733136,26547918,Unavailable
4733136,Infections (overall),Adalimumab ,Placebo,No significant difference,"Infection	118 (23)	287 (30)	63 (23)	154 (30)	20 (29)	42 (26)",28443:28629,4733136,26547918,Unavailable
4733136,Infections (previously treated),Adalimumab ,Placebo,No significant difference,"Infection	118 (23)	287 (30)	63 (23)	154 (30)	20 (29)	42 (26)",28443:28629,4733136,26547918,Unavailable
4733136,Infections (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Infection	118 (23)	287 (30)	63 (23)	154 (30)	20 (29)	42 (26)",28443:28629,4733136,26547918,Unavailable
4733136, Serious infection (overall),Adalimumab ,Placebo,No significant difference,"Serious infection	4 (1)	5 (1)	0	3 (1)	0	1 (1)",28661:28850,4733136,26547918,Unavailable
4733136," Serious infection	(previously treated)",Adalimumab ,Placebo,No significant difference,"Serious infection	4 (1)	5 (1)	0	3 (1)	0	1 (1)",28661:28850,4733136,26547918,Unavailable
4733136," Serious infection	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Serious infection	4 (1)	5 (1)	0	3 (1)	0	1 (1)",28661:28850,4733136,26547918,Unavailable
4733136," Legionella infection	 (overall)",Adalimumab ,Placebo,No significant difference,"Legionella infection	0	0	0	0	0	0",28882:29094,4733136,26547918,Unavailable
4733136," Legionella infection	(previously treated)",Adalimumab ,Placebo,No significant difference,"Legionella infection	0	0	0	0	0	0",28882:29094,4733136,26547918,Unavailable
4733136," Legionella infection	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Legionella infection	0	0	0	0	0	0",28882:29094,4733136,26547918,Unavailable
4733136,"Diverticulitis	 (overall)",Adalimumab ,Placebo,No significant difference,"Diverticulitis	0	1 (&lt;1)	0	0	0	0",29126:29331,4733136,26547918,Unavailable
4733136,"Diverticulitis	(previously treated)",Adalimumab ,Placebo,No significant difference,"Diverticulitis	0	1 (&lt;1)	0	0	0	0",29126:29331,4733136,26547918,Unavailable
4733136,"Diverticulitis	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Diverticulitis	0	1 (&lt;1)	0	0	0	0",29126:29331,4733136,26547918,Unavailable
4733136,"Opportunistic infection (excluding oral candidiasis and TB)	(overall)",Adalimumab ,Placebo,No significant difference,"Opportunistic infection (excluding oral candidiasis and TB)	0	0	0	0	0	0",29362:29613,4733136,26547918,Unavailable
4733136,"Opportunistic infection (excluding oral candidiasis and TB)	(previously treated)",Adalimumab ,Placebo,No significant difference,Opportunistic infection (excluding oral candidiasis and TB) 0 0 0 0 0 0,29362:29613,4733136,26547918,Unavailable
4733136,"Opportunistic infection (excluding oral candidiasis and TB)	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Opportunistic infection (excluding oral candidiasis and TB)	0	0	0	0	0	0",29362:29613,4733136,26547918,Unavailable
4733136," Oral candidiasis	(overall)",Adalimumab ,Placebo,No significant difference,"Oral candidiasis	0	0	0	0	0	0",29645:29853,4733136,26547918,Unavailable
4733136," Oral candidiasis	(previously treated)",Adalimumab ,Placebo,No significant difference,"Oral candidiasis	0	0	0	0	0	0",29645:29853,4733136,26547918,Unavailable
4733136," Oral candidiasis	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Oral candidiasis	0	0	0	0	0	0",29645:29853,4733136,26547918,Unavailable
4733136,TB (overall),Adalimumab ,Placebo,No significant difference,"TB	0	0	0	0	0	0",29885:30079,4733136,26547918,Unavailable
4733136,TB (previously treated),Adalimumab ,Placebo,No significant difference,"TB	0	0	0	0	0	0",29885:30079,4733136,26547918,Unavailable
4733136,TB (previously failed treatment),Adalimumab ,Placebo,No significant difference,"TB	0	0	0	0	0	0",29885:30079,4733136,26547918,Unavailable
4733136," Parasitic infection	(overall)",Adalimumab ,Placebo,No significant difference,"Parasitic infection	0	0	0	0	0	0",30111:30322,4733136,26547918,Unavailable
4733136," Parasitic infection	(previously treated)",Adalimumab ,Placebo,No significant difference,"Parasitic infection	0	0	0	0	0	0",30111:30322,4733136,26547918,Unavailable
4733136," Parasitic infection	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Parasitic infection	0	0	0	0	0	0",30111:30322,4733136,26547918,Unavailable
4733136," Reactivation of hepatitis B	 (overall)",Adalimumab ,Placebo,No significant difference,"Reactivation of hepatitis B	0	0	0	0	0	0",30354:30573,4733136,26547918,Unavailable
4733136," Reactivation of hepatitis B	(previously treated)",Adalimumab ,Placebo,No significant difference,"Reactivation of hepatitis B	0	0	0	0	0	0",30354:30573,4733136,26547918,Unavailable
4733136," Reactivation of hepatitis B	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Reactivation of hepatitis B	0	0	0	0	0	0",30354:30573,4733136,26547918,Unavailable
4733136,PML (overall),Adalimumab ,Placebo,No significant difference,"PML	0	0	0	0	0	0",30605:30800,4733136,26547918,Unavailable
4733136,PML (previously treated),Adalimumab ,Placebo,No significant difference,"PML	0	0	0	0	0	0",30605:30800,4733136,26547918,Unavailable
4733136,PML (previously failed treatment),Adalimumab ,Placebo,No significant difference,"PML	0	0	0	0	0	0",30605:30800,4733136,26547918,Unavailable
4733136,Malignancy (overall),Adalimumab ,Placebo,No significant difference,"Malignancy	2 (&lt;1)	6 (1)	0	2 (&lt;1)	0	1 (1)",30831:31021,4733136,26547918,Unavailable
4733136,Malignancy (previously treated),Adalimumab ,Placebo,No significant difference,"Malignancy	2 (&lt;1)	6 (1)	0	2 (&lt;1)	0	1 (1)",30831:31021,4733136,26547918,Unavailable
4733136,Malignancy (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Malignancy	2 (&lt;1)	6 (1)	0	2 (&lt;1)	0	1 (1)",30831:31021,4733136,26547918,Unavailable
4733136,Lymphoma (overall),Adalimumab ,Placebo,No significant difference,"Lymphoma	0	0	0	0	0	0",31053:31253,4733136,26547918,Unavailable
4733136,Lymphoma (previously treated),Adalimumab ,Placebo,No significant difference,"Lymphoma	0	0	0	0	0	0",31053:31253,4733136,26547918,Unavailable
4733136,Lymphoma (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Lymphoma	0	0	0	0	0	0",31053:31253,4733136,26547918,Unavailable
4733136,Hepatosplenic T-cell lymphoma(overall),Adalimumab ,Placebo,No significant difference,"HSTCL	0	0	0	0	0	0",31285:31482,4733136,26547918,Unavailable
4733136,Hepatosplenic T-cell lymphoma(previously treated),Adalimumab ,Placebo,No significant difference,"HSTCL	0	0	0	0	0	0",31285:31482,4733136,26547918,Unavailable
4733136,Hepatosplenic T-cell lymphoma(previously failed treatment),Adalimumab ,Placebo,No significant difference,"HSTCL	0	0	0	0	0	0",31285:31482,4733136,26547918,Unavailable
4733136,Non-melanoma skin cancer (overall),Adalimumab ,Placebo,No significant difference,"NMSC	1 (&lt;1)	4 (&lt;1)	0	2 (&lt;1)	0	1 (1)",31514:31702,4733136,26547918,Unavailable
4733136,Non-melanoma skin cancer (previously treated),Adalimumab ,Placebo,No significant difference,"NMSC	1 (&lt;1)	4 (&lt;1)	0	2 (&lt;1)	0	1 (1)",31514:31702,4733136,26547918,Unavailable
4733136,Non-melanoma skin cancer (previously failed treatment),Adalimumab ,Placebo,No significant difference,"NMSC	1 (&lt;1)	4 (&lt;1)	0	2 (&lt;1)	0	1 (1)",31514:31702,4733136,26547918,Unavailable
4733136,Melanoma (overall),Adalimumab ,Placebo,No significant difference,"Melanoma	0	1 (&lt;1)	0	0	0	0",31734:31933,4733136,26547918,Unavailable
4733136,Melanoma (previously treated),Adalimumab ,Placebo,No significant difference,"Melanoma	0	1 (&lt;1)	0	0	0	0",31734:31933,4733136,26547918,Unavailable
4733136,Melanoma (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Melanoma	0	1 (&lt;1)	0	0	0	0",31734:31933,4733136,26547918,Unavailable
4733136,Leukemia (overall),Adalimumab ,Placebo,No significant difference,"Leukemia	0	0	0	0	0	0",31965:32165,4733136,26547918,Unavailable
4733136,Leukemia (previously treated),Adalimumab ,Placebo,No significant difference,"Leukemia	0	0	0	0	0	0",31965:32165,4733136,26547918,Unavailable
4733136,Leukemia (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Leukemia	0	0	0	0	0	0",31965:32165,4733136,26547918,Unavailable
4733136,Other cancers (overall),Adalimumab ,Placebo,No significant difference,"Malignancy other than lymphoma, HSTCL, leukemia, NMSC, or melanoma	1 (&lt;1)	1 (&lt;1)	0	0	0	0",32196:32452,4733136,26547918,Unavailable
4733136,Other cancers (previously treated),Adalimumab ,Placebo,No significant difference,"Malignancy other than lymphoma, HSTCL, leukemia, NMSC, or melanoma	1 (&lt;1)	1 (&lt;1)	0	0	0	0",32196:32452,4733136,26547918,Unavailable
4733136,Other cancers (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Malignancy other than lymphoma, HSTCL, leukemia, NMSC, or melanoma	1 (&lt;1)	1 (&lt;1)	0	0	0	0",32196:32452,4733136,26547918,Unavailable
4733136,Allergic reaction (including angioedema and anaphylaxis) (overall),Adalimumab ,Placebo,No significant difference,"Allergic reaction (including angioedema and anaphylaxis)	3 (1)	13 (1)	3 (1)	7 (1)	0	1 (1)",32483:32707,4733136,26547918,Unavailable
4733136,Allergic reaction (including angioedema and anaphylaxis) (previously treated),Adalimumab ,Placebo,No significant difference,"Allergic reaction (including angioedema and anaphylaxis)	3 (1)	13 (1)	3 (1)	7 (1)	0	1 (1)",32483:32707,4733136,26547918,Unavailable
4733136,Allergic reaction (including angioedema and anaphylaxis) (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Allergic reaction (including angioedema and anaphylaxis)	3 (1)	13 (1)	3 (1)	7 (1)	0	1 (1)",32483:32707,4733136,26547918,Unavailable
4733136,"Lupus-like reactions and SLE	(overall)",Adalimumab ,Placebo,No significant difference,"Lupus-like reactions and SLE	0	0	0	0	0	0",32738:32958,4733136,26547918,Unavailable
4733136,"Lupus-like reactions and SLE	(previously treated)",Adalimumab ,Placebo,No significant difference,"Lupus-like reactions and SLE	0	0	0	0	0	0",32738:32958,4733136,26547918,Unavailable
4733136,"Lupus-like reactions and SLE	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Lupus-like reactions and SLE	0	0	0	0	0	0",32738:32958,4733136,26547918,Unavailable
4733136,Vasculitis (overall),Adalimumab ,Placebo,No significant difference,"Vasculitis	0	0	0	0	0	0",32989:33191,4733136,26547918,Unavailable
4733136,Vasculitis (previously treated),Adalimumab ,Placebo,No significant difference,"Vasculitis	0	0	0	0	0	0",32989:33191,4733136,26547918,Unavailable
4733136,Vasculitis (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Vasculitis	0	0	0	0	0	0",32989:33191,4733136,26547918,Unavailable
4733136,Sarcoidosis (overall),Adalimumab ,Placebo,No significant difference,"Sarcoidosis	0	1 (&lt;1)	0	1 (&lt;1)	0	1 (1)",33222:33418,4733136,26547918,Unavailable
4733136,Sarcoidosis (previously treated),Adalimumab ,Placebo,No significant difference,"Sarcoidosis	0	1 (&lt;1)	0	1 (&lt;1)	0	1 (1)",33222:33418,4733136,26547918,Unavailable
4733136,Sarcoidosis (previously failed treatment),Adalimumab ,Placebo,No significant difference,"Sarcoidosis	0	1 (&lt;1)	0	1 (&lt;1)	0	1 (1)",33222:33418,4733136,26547918,Unavailable
4733136,"Autoimmune hepatitis	(overall)",Adalimumab ,Placebo,No significant difference,"Autoimmune hepatitis	0	0	0	0	0	0",33449:33661,4733136,26547918,Unavailable
4733136,"Autoimmune hepatitis	(previously treated)",Adalimumab ,Placebo,No significant difference,"Autoimmune hepatitis	0	0	0	0	0	0",33449:33661,4733136,26547918,Unavailable
4733136,"Autoimmune hepatitis	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Autoimmune hepatitis	0	0	0	0	0	0",33449:33661,4733136,26547918,Unavailable
4733136,"Myocardial infarction	(overall)",Adalimumab ,Placebo,No significant difference,"Myocardial infarction	1 (&lt;1)	1 (&lt;1)	1 (&lt;1)	0	0	0",33692:33902,4733136,26547918,Unavailable
4733136,"Myocardial infarction	(previously treated)",Adalimumab ,Placebo,No significant difference,"Myocardial infarction	1 (&lt;1)	1 (&lt;1)	1 (&lt;1)	0	0	0",33692:33902,4733136,26547918,Unavailable
4733136,"Myocardial infarction	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Myocardial infarction	1 (&lt;1)	1 (&lt;1)	1 (&lt;1)	0	0	0",33692:33902,4733136,26547918,Unavailable
4733136,"Cerebrovascular accident	(overall)",Adalimumab ,Placebo,No significant difference,"Cerebrovascular accident	0	0	0	0	0	0",33933:34149,4733136,26547918,Unavailable
4733136,"Cerebrovascular accident	(previously treated)",Adalimumab ,Placebo,No significant difference,"Cerebrovascular accident	0	0	0	0	0	0",33933:34149,4733136,26547918,Unavailable
4733136,"Cerebrovascular accident	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Cerebrovascular accident	0	0	0	0	0	0",33933:34149,4733136,26547918,Unavailable
4733136,Congestive heart failure (overall),Adalimumab ,Placebo,No significant difference,"CHF	0	1 (&lt;1)	0	0	0	0",34180:34374,4733136,26547918,Unavailable
4733136,Congestive heart failure (previously treated),Adalimumab ,Placebo,No significant difference,"CHF	0	1 (&lt;1)	0	0	0	0",34180:34374,4733136,26547918,Unavailable
4733136,Congestive heart failure  (previously failed treatment),Adalimumab ,Placebo,No significant difference,"CHF	0	1 (&lt;1)	0	0	0	0",34180:34374,4733136,26547918,Unavailable
4733136,"Pulmonary embolism	(overall)",Adalimumab ,Placebo,No significant difference,"Pulmonary embolism	0	0	0	0	0	0",34405:34615,4733136,26547918,Unavailable
4733136,"Pulmonary embolism	(previously treated)",Adalimumab ,Placebo,No significant difference,"Pulmonary embolism	0	0	0	0	0	0",34405:34615,4733136,26547918,Unavailable
4733136,"Pulmonary embolism	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Pulmonary embolism	0	0	0	0	0	0",34405:34615,4733136,26547918,Unavailable
4733136,"Interstitial lung disease	(overall)",Adalimumab ,Placebo,No significant difference,"Interstitial lung disease	0	0	0	0	0	0",34646:34863,4733136,26547918,Unavailable
4733136,"Interstitial lung disease	(previously treated)",Adalimumab ,Placebo,No significant difference,"Interstitial lung disease	0	0	0	0	0	0",34646:34863,4733136,26547918,Unavailable
4733136,"Interstitial lung disease	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Interstitial lung disease	0	0	0	0	0	0",34646:34863,4733136,26547918,Unavailable
4733136,"Intestinal perforation	(overall)",Adalimumab ,Placebo,No significant difference,"Intestinal perforation	0	0	0	0	0	0",34894:35108,4733136,26547918,Unavailable
4733136,"Intestinal perforation	(previously treated)",Adalimumab ,Placebo,No significant difference,"Intestinal perforation	0	0	0	0	0	0",34894:35108,4733136,26547918,Unavailable
4733136,"Intestinal perforation	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Intestinal perforation	0	0	0	0	0	0",34894:35108,4733136,26547918,Unavailable
4733136,Pancreatitis (overall),Adalimumab ,Placebo,No significant difference,"Pancreatitis	0	2 (&lt;1)	0	1 (&lt;1)	0	0",35139:35341,4733136,26547918,Unavailable
4733136,Pancreatitis(previously treated),Adalimumab ,Placebo,No significant difference,"Pancreatitis	0	2 (&lt;1)	0	1 (&lt;1)	0	0",35139:35341,4733136,26547918,Unavailable
4733136,Pancreatitis(previously failed treatment),Adalimumab ,Placebo,No significant difference,"Pancreatitis	0	2 (&lt;1)	0	1 (&lt;1)	0	0",35139:35341,4733136,26547918,Unavailable
4733136,"Stevens–Johnson syndrome	(overall)",Adalimumab ,Placebo,No significant difference,"Stevens–Johnson syndrome	0	0	0	0	0	0",35372:35588,4733136,26547918,Unavailable
4733136,"Stevens–Johnson syndrome	(previously treated)",Adalimumab ,Placebo,No significant difference,"Stevens–Johnson syndrome	0	0	0	0	0	0",35372:35588,4733136,26547918,Unavailable
4733136,"Stevens–Johnson syndrome	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Stevens–Johnson syndrome	0	0	0	0	0	0",35372:35588,4733136,26547918,Unavailable
4733136,"Erythema multiforme	(overall)",Adalimumab ,Placebo,No significant difference,"Erythema multiforme	0	0	0	0	0	0",35619:35830,4733136,26547918,Unavailable
4733136,"Erythema multiforme	(previously treated)",Adalimumab ,Placebo,No significant difference,"Erythema multiforme	0	0	0	0	0	0",35619:35830,4733136,26547918,Unavailable
4733136,"Erythema multiforme	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Erythema multiforme	0	0	0	0	0	0",35619:35830,4733136,26547918,Unavailable
4733136,"Psoriasis worsening or new onset	(overall)",Adalimumab ,Placebo,No significant difference,"Psoriasis worsening or new onset	11 (2)	10 (1)	5 (2)	4 (1)	3 (4)	3 (2)",35861:36057,4733136,26547918,Unavailable
4733136,"Psoriasis worsening or new onset	(previously treated)",Adalimumab ,Placebo,No significant difference,"Psoriasis worsening or new onset	11 (2)	10 (1)	5 (2)	4 (1)	3 (4)	3 (2)",35861:36057,4733136,26547918,Unavailable
4733136,"Psoriasis worsening or new onset	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Psoriasis worsening or new onset	11 (2)	10 (1)	5 (2)	4 (1)	3 (4)	3 (2)",35861:36057,4733136,26547918,Unavailable
4733136,"Demyelinating disorder	(overall)",Adalimumab ,Placebo,No significant difference,"Demyelinating disorder	0	0	0	0	0	0",36088:36302,4733136,26547918,Unavailable
4733136,"Demyelinating disorder	(previously treated)",Adalimumab ,Placebo,No significant difference,"Demyelinating disorder	0	0	0	0	0	0",36088:36302,4733136,26547918,Unavailable
4733136,"Demyelinating disorder	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Demyelinating disorder	0	0	0	0	0	0",36088:36302,4733136,26547918,Unavailable
4733136,"Amyotrophic lateral sclerosis	(overall)",Adalimumab ,Placebo,No significant difference,"Amyotrophic lateral sclerosis	0	0	0	0	0	0",36333:36554,4733136,26547918,Unavailable
4733136,"Amyotrophic lateral sclerosis	(previously treated)",Adalimumab ,Placebo,No significant difference,"Amyotrophic lateral sclerosis	0	0	0	0	0	0",36333:36554,4733136,26547918,Unavailable
4733136,"Amyotrophic lateral sclerosis	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Amyotrophic lateral sclerosis	0	0	0	0	0	0",36333:36554,4733136,26547918,Unavailable
4733136,"Reversible posterior leukoencephalopathy	(overall)",Adalimumab ,Placebo,No significant difference,"Reversible posterior leukoencephalopathy	0	0	0	0	0	0",36585:36817,4733136,26547918,Unavailable
4733136,"Reversible posterior leukoencephalopathy	(previously treated)",Adalimumab ,Placebo,No significant difference,"Reversible posterior leukoencephalopathy	0	0	0	0	0	0",36585:36817,4733136,26547918,Unavailable
4733136,"Reversible posterior leukoencephalopathy	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Reversible posterior leukoencephalopathy	0	0	0	0	0	0",36585:36817,4733136,26547918,Unavailable
4733136,"Hematologic disorders (including pancytopenia)	(overall)",Adalimumab ,Placebo,No significant difference,"Hematologic disorders (including pancytopenia)	1 (&lt;1)	2 (&lt;1)	1 (&lt;1)	1 (&lt;1)	1 (1)	0",36848:37077,4733136,26547918,Unavailable
4733136,"Hematologic disorders (including pancytopenia)	(previously treated)",Adalimumab ,Placebo,No significant difference,"Hematologic disorders (including pancytopenia)	1 (&lt;1)	2 (&lt;1)	1 (&lt;1)	1 (&lt;1)	1 (1)	0",36848:37077,4733136,26547918,Unavailable
4733136,"Hematologic disorders (including pancytopenia)	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Hematologic disorders (including pancytopenia)	1 (&lt;1)	2 (&lt;1)	1 (&lt;1)	1 (&lt;1)	1 (1)	0",36848:37077,4733136,26547918,Unavailable
4733136,"Liver failure/event	(overall)",Adalimumab ,Placebo,No significant difference,"Liver failure/event	2 (&lt;1)	2 (&lt;1)	0	1 (&lt;1)	0	0",37108:37316,4733136,26547918,Unavailable
4733136,"Liver failure/event	(previously treated)",Adalimumab ,Placebo,No significant difference,"Liver failure/event	2 (&lt;1)	2 (&lt;1)	0	1 (&lt;1)	0	0",37108:37316,4733136,26547918,Unavailable
4733136,"Liver failure/event	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Liver failure/event	2 (&lt;1)	2 (&lt;1)	0	1 (&lt;1)	0	0",37108:37316,4733136,26547918,Unavailable
4733136,"Administration-related medication error	(overall)",Adalimumab ,Placebo,No significant difference,"Administration-related medication error	0	0	0	0	0	0",37347:37578,4733136,26547918,Unavailable
4733136,"Administration-related medication error	(previously treated)",Adalimumab ,Placebo,No significant difference,"Administration-related medication error	0	0	0	0	0	0",37347:37578,4733136,26547918,Unavailable
4733136,"Administration-related medication error	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Administration-related medication error	0	0	0	0	0	0",37347:37578,4733136,26547918,Unavailable
4733136,"Injection-site reaction	(overall)",Adalimumab ,Placebo,No significant difference,"Injection-site reaction	26 (5)	69 (7)	16 (6)	40 (8)	1 (1)	10 (6)",37609:37799,4733136,26547918,Unavailable
4733136,"Injection-site reaction	(previously treated)",Adalimumab ,Placebo,No significant difference,"Injection-site reaction	26 (5)	69 (7)	16 (6)	40 (8)	1 (1)	10 (6)",37609:37799,4733136,26547918,Unavailable
4733136,"Injection-site reaction	(previously failed treatment)",Adalimumab ,Placebo,No significant difference,"Injection-site reaction	26 (5)	69 (7)	16 (6)	40 (8)	1 (1)	10 (6)",37609:37799,4733136,26547918,Unavailable
4717600,Total abdominal fat area,75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"After intervention, decreases in abdominal fat area (AFA), especially subcutaneous fat area (SFA), were significantly greater in the G-hesperidin with 50-mg caffeine group (AFA:-8.4 ± 21.9 v.s. 16.3 ± 34.1&nbsp;cm2; p &lt; 0.05, SFA: -9.3 ± 17.1 v.s. 11.2 ± 18.3&nbsp;cm2; p &lt; 0.01) and in the G-hesperidin with 75-mg caffeine group (AFA:-17.0 ± 31.4 v.s. 16.3 ± 34.1&nbsp;cm2; p &lt; 0.01, SFA: -12.4 ± 18.7 v.s. 11.2 ± 18.3&nbsp;cm2; p &lt; 0.01) than in the placebo group.",22514:22791,4717600,26786000,Unavailable
4717600,Subcutaneous fat area,50 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"After intervention, decreases in abdominal fat area (AFA), especially subcutaneous fat area (SFA), were significantly greater in the G-hesperidin with 50-mg caffeine group (AFA:-8.4 ± 21.9 v.s. 16.3 ± 34.1&nbsp;cm2; p &lt; 0.05, SFA: -9.3 ± 17.1 v.s. 11.2 ± 18.3&nbsp;cm2; p &lt; 0.01) and in the G-hesperidin with 75-mg caffeine group (AFA:-17.0 ± 31.4 v.s. 16.3 ± 34.1&nbsp;cm2; p &lt; 0.01, SFA: -12.4 ± 18.7 v.s. 11.2 ± 18.3&nbsp;cm2; p &lt; 0.01) than in the placebo group.",4483:5051,4717600,26786000,Unavailable
4717600,Subcutaneous fat area ,75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"After intervention, decreases in abdominal fat area (AFA), especially subcutaneous fat area (SFA), were significantly greater in the G-hesperidin with 50-mg caffeine group (AFA:-8.4 ± 21.9 v.s. 16.3 ± 34.1&nbsp;cm2; p &lt; 0.05, SFA: -9.3 ± 17.1 v.s. 11.2 ± 18.3&nbsp;cm2; p &lt; 0.01) and in the G-hesperidin with 75-mg caffeine group (AFA:-17.0 ± 31.4 v.s. 16.3 ± 34.1&nbsp;cm2; p &lt; 0.01, SFA: -12.4 ± 18.7 v.s. 11.2 ± 18.3&nbsp;cm2; p &lt; 0.01) than in the placebo group.",4483:5051,4717600,26786000,Unavailable
4717600,BMI (week 8),75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,. BMI decreases were significantly greater in the G-hesperidin with 75-mg caffeine group than in the placebo group (-0.56 ± 0.74 v.s. -0.02 ± 0.58&nbsp;kg/m2; p &lt; 0.05).,31456:31605,4717600,26786000,Unavailable
4717600,Triglycerides ,75 mg caffeine + G-hesperidin ,Placebo,No significant difference,G-hesperidin with/without caffeine had no effect on serum TG (p &gt; 0.05 v.s. placebo).,5337:5442,4717600,26786000,Unavailable
4717600,Triglycerides ,50 mg caffeine + G-hesperidin ,Placebo,No significant difference,G-hesperidin with/without caffeine had no effect on serum TG (p &gt; 0.05 v.s. placebo).,5337:5442,4717600,26786000,Unavailable
4717600,Triglycerides ,25 mg caffeine + G-hesperidin ,Placebo,No significant difference,G-hesperidin with/without caffeine had no effect on serum TG (p &gt; 0.05 v.s. placebo).,43012:43275,4717600,26786000,Unavailable
4717600,Triglycerides ,G-hesperidin alone ,Placebo,No significant difference,G-hesperidin with/without caffeine had no effect on serum TG (p &gt; 0.05 v.s. placebo).,5337:5442,4717600,26786000,Unavailable
4717600,Energy intake,75 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Energy intake,75 mg caffeine + G-hesperidin ,50 mg caffeine + G-hesperidin ,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Energy intake,75 mg caffeine + G-hesperidin ,25 mg caffeine + G-hesperidin ,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Energy intake,75 mg caffeine + G-hesperidin ,G-hesperidin alone ,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Energy intake,50 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Energy intake,50 mg caffeine + G-hesperidin ,25 mg caffeine + G-hesperidin ,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Energy intake,50 mg caffeine + G-hesperidin ,G-hesperidin alone,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Energy intake,25 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Energy intake,25 mg caffeine + G-hesperidin ,G-hesperidin alone,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Energy intake,G-hesperidin alone,Placebo,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Exercise volume,75 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Exercise volume,75 mg caffeine + G-hesperidin ,50 mg caffeine + G-hesperidin ,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Exercise volume,75 mg caffeine + G-hesperidin ,25 mg caffeine + G-hesperidin ,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Exercise volume,75 mg caffeine + G-hesperidin ,G-hesperidin alone ,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Exercise volume,50 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Exercise volume,50 mg caffeine + G-hesperidin ,25 mg caffeine + G-hesperidin ,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Exercise volume,50 mg caffeine + G-hesperidin ,G-hesperidin alone,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Exercise volume,25 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Exercise volume,25 mg caffeine + G-hesperidin ,G-hesperidin alone,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Exercise volume,G-hesperidin alone,Placebo,No significant difference,"Energy intake and exercise volume throughout the intervention period and post-ingestion period are shown in Table&nbsp;3. Occasionally, significant differences were found within groups, but there was no significant difference between groups.",22514:22791,4717600,26786000,Unavailable
4717600,Total abdominal fat area,50 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"After intervention, decreases in abdominal fat area (AFA), especially subcutaneous fat area (SFA), were significantly greater in the G-hesperidin with 50-mg caffeine group (AFA:-8.4 ± 21.9 v.s. 16.3 ± 34.1&nbsp;cm2; p &lt; 0.05, SFA: -9.3 ± 17.1 v.s. 11.2 ± 18.3&nbsp;cm2; p &lt; 0.01) and in the G-hesperidin with 75-mg caffeine group (AFA:-17.0 ± 31.4 v.s. 16.3 ± 34.1&nbsp;cm2; p &lt; 0.01, SFA: -12.4 ± 18.7 v.s. 11.2 ± 18.3&nbsp;cm2; p &lt; 0.01) than in the placebo group.",22514:22791,4717600,26786000,Unavailable
4717600,Total abdominal fat area,75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,Decreases in TFA in the G-hesperidin with 50-mg caffeine group and in the G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group.,26560:26733,4717600,26786000,Unavailable
4717600,Subcutaneous fat area,50 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,Decreases in TFA in the G-hesperidin with 50-mg caffeine group and in the G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group.,26560:26732,4717600,26786000,Unavailable
4717600,Subcutaneous fat area ,75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,Decreases in SFA in the G-hesperidin with 50-mg caffeine group and G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group.,26820:26985,4717600,26786000,Unavailable
4717600,Subcutaneous fat area ,50 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,Decreases in SFA in the G-hesperidin with 50-mg caffeine group and G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group.,43276:43511,4717600,26786000,Unavailable
4717600,Total abdominal fat area,75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"GH + Caf 75	15	310.8 ± 43.9	293.9 ± 45.5	−17.0 ± 31.4##",28150:28308,4717600,26786000,Unavailable
4717600,Subcutaneous fat area,50 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"GH + Caf 50	15	295.1 ± 53.7	286.7 ± 48.9	−8.4 ± 21.9#",27969:28125,4717600,26786000,Unavailable
4717600,Subcutaneous fat area ,75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"GH + Caf 75	15	209.8 ± 45.4	197.3 ± 44.4*	−12.4 ± 18.7##",29942:30101,4717600,26786000,Unavailable
4717600,Total abdominal fat area,50 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"GH + Caf 50	15	187.0 ± 48.0	177.7 ± 44.0	−9.3 ± 17.1##",29760:29917,4717600,26786000,Unavailable
4717600,Visceral fat area ,75 mg caffeine + G-hesperidin ,Placebo,No significant difference,"However, there were no significant decreases in VFA between the placebo group and groups that ingested G-hesperidin with or without caffeine.",26986:27127,4717600,26786000,Unavailable
4717600,Visceral fat area ,50 mg caffeine + G-hesperidin ,Placebo,No significant difference,"However, there were no significant decreases in VFA between the placebo group and groups that ingested G-hesperidin with or without caffeine.",26986:27127,4717600,26786000,Unavailable
4717600,Visceral fat area ,25 mg caffeine + G-hesperidin ,Placebo,No significant difference,"However, there were no significant decreases in VFA between the placebo group and groups that ingested G-hesperidin with or without caffeine.",26986:27127,4717600,26786000,Unavailable
4717600,Visceral fat area ,G-hesperidin alone,Placebo,No significant difference,"However, there were no significant decreases in VFA between the placebo group and groups that ingested G-hesperidin with or without caffeine.",26986:27127,4717600,26786000,Unavailable
4717600,Body weight (week 8),75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,Decreases in body weight at week 8 (p = 0.045) but not at week 12 (p = 0.089) were significantly greater in the G-hesperidin with 75-mg caffeine group than in the placebo group.,31244:31456,4717600,26786000,Unavailable
4717600,Body weight (week 12),75 mg caffeine + G-hesperidin ,Placebo,No significant difference,Decreases in body weight at week 8 (p = 0.045) but not at week 12 (p = 0.089) were significantly greater in the G-hesperidin with 75-mg caffeine group than in the placebo group.,31244:31456,4717600,26786000,Unavailable
4717600,BMI (week 8),75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,Decreases in the BMI in the G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group at week 8 and week 12.,31456:31605,4717600,26786000,Unavailable
4717600,BMI (week 12),75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,Decreases in the BMI in the G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group at week 8 and week 12.,31456:31605,4717600,26786000,Unavailable
4717600,BMI (week 12),75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,. BMI decreases were significantly greater in the G-hesperidin with 75-mg caffeine group than in the placebo group (-0.56 ± 0.74 v.s. -0.02 ± 0.58&nbsp;kg/m2; p &lt; 0.05).,31456:31605,4717600,26786000,Unavailable
4717600,Waist circumference (week 8),25 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,Decreases in waist circumference were significantly greater in the G-hesperidin with 25&nbsp;mg caffeine group than in the placebo group at week-8 and at week-12.,31709:31868,4717600,26786000,Unavailable
4717600,Waist circumference (week 12),25 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,Decreases in waist circumference were significantly greater in the G-hesperidin with 25&nbsp;mg caffeine group than in the placebo group at week-8 and at week-12.,31709:31868,4717600,26786000,Unavailable
4717600,Waist circumference (week 8),75 mg caffeine + G-hesperidin ,Placebo,No significant difference,Similar decreases were observed in the G-hesperidin with 75&nbsp;mg caffeine group but were not significant.,31868:31972,4717600,26786000,Unavailable
4717600,Waist circumference (week 12),75 mg caffeine + G-hesperidin ,Placebo,No significant difference,Similar decreases were observed in the G-hesperidin with 75&nbsp;mg caffeine group but were not significant.,31868:31972,4717600,26786000,Unavailable
4717600,Hip circumference ,75 mg caffeine + G-hesperidin ,Placebo,No significant difference,"There were no significant differences in decreases in hip circumference between the placebo group, and groups that ingested G-hesperidin with or without caffeine.",31971:32134,4717600,26786000,Unavailable
4717600,Hip circumference ,50 mg caffeine + G-hesperidin ,Placebo,No significant difference,"There were no significant differences in decreases in hip circumference between the placebo group, and groups that ingested G-hesperidin with or without caffeine.",31971:32134,4717600,26786000,Unavailable
4717600,Hip circumference ,25 mg caffeine + G-hesperidin ,Placebo,No significant difference,"There were no significant differences in decreases in hip circumference between the placebo group, and groups that ingested G-hesperidin with or without caffeine.",31971:32134,4717600,26786000,Unavailable
4717600,Hip circumference ,G-hesperidin alone,Placebo,No significant difference,"There were no significant differences in decreases in hip circumference between the placebo group, and groups that ingested G-hesperidin with or without caffeine.",31971:32134,4717600,26786000,Unavailable
4717600,Body weight (week 8),75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"GH + Caf 75	15		−0.36 ± 1.0	−0.88 ± 1.4#",34731:34852,4717600,26786000,Unavailable
4717600,BMI (week 8),75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"GH + Caf 75	15		−0.13 ± 0.41	−0.35 ± 0.55#	−0.56 ± 0.74#",37129:NaN,4717600,26786000,Unavailable
4717600,BMI (week 12),75 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"GH + Caf 75	15		−0.13 ± 0.41	−0.35 ± 0.55#	−0.56 ± 0.74#",37129:37308,4717600,26786000,Unavailable
4717600,Waist circumference (week 8),25 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"GH + Caf 25	15		−0.49 ± 1.1	−1.17 ± 1.4#	−1.31 ± 1.6#",39068:39244,4717600,26786000,Unavailable
4717600,Waist circumference (week 12),25 mg caffeine + G-hesperidin ,Placebo,Significantly decreased,"GH + Caf 25	15		−0.49 ± 1.1	−1.17 ± 1.4#	−1.31 ± 1.6#",39068:39244,4717600,26786000,Unavailable
4717600,Triglycerides ,75 mg caffeine + G-hesperidin ,Placebo,No significant difference,"However, TG levels in the G-hesperidin-alone group did not decrease during the intervention period, and the changes from baseline (week 0) were not different from those of the placebo group. TG levels in the G-hesperidin with caffeine group also did not decrease.",43012:43276,4717600,26786000,Unavailable
4717600,Triglycerides ,50 mg caffeine + G-hesperidin ,Placebo,No significant difference,"However, TG levels in the G-hesperidin-alone group did not decrease during the intervention period, and the changes from baseline (week 0) were not different from those of the placebo group. TG levels in the G-hesperidin with caffeine group also did not decrease.",43012:43276,4717600,26786000,Unavailable
4717600,Triglycerides ,25 mg caffeine + G-hesperidin ,Placebo,No significant difference,"However, TG levels in the G-hesperidin-alone group did not decrease during the intervention period, and the changes from baseline (week 0) were not different from those of the placebo group. TG levels in the G-hesperidin with caffeine group also did not decrease.",43012:43275,4717600,26786000,Unavailable
4717600,Triglycerides ,G-hesperidin alone ,Placebo,No significant difference,"However, TG levels in the G-hesperidin-alone group did not decrease during the intervention period, and the changes from baseline (week 0) were not different from those of the placebo group. TG levels in the G-hesperidin with caffeine group also did not decrease.",43012:43275,4717600,26786000,Unavailable
4717600,Total cholesterol,75 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,Total cholesterol,50 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,Total cholesterol,25 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,Total cholesterol,G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,HDL,75 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,HDL,50 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,HDL,25 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,HDL,G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,LDL,75 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,LDL,50 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,LDL,25 mg caffeine + G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4717600,LDL,G-hesperidin ,Placebo,No significant difference,"Occasionally, serum levels of total cholesterol, HDL-C, and LDL-C decreased in G-hesperidin with/without caffeine groups during intervention periods but changes from baseline (week 0) were not different from those in the placebo group.",43276:43511,4717600,26786000,Unavailable
4602325,Resting bioelectrical activity,Cross taping,Kinesio taping ,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Resting bioelectrical activity,Cross taping,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Resting bioelectrical activity,Kinesio taping ,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,VAS score,Cross taping,Kinesio taping ,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,VAS score,Cross taping,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,VAS score,Kinesio taping ,Placebo,Significantly decreased,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Flexion ROM,Cross taping,Kinesio taping ,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Flexion ROM,Cross taping,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Flexion ROM,Kinesio taping ,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Extension ROM,Cross taping,Kinesio taping ,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Extension ROM,Cross taping,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Extension ROM,Kinesio taping ,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Left lateral flexion ROM,Cross taping,Kinesio taping ,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Left lateral flexion ROM,Cross taping,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Left lateral flexion ROM,Kinesio taping ,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Right lateral flexion ROM,Cross taping,Kinesio taping ,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Right lateral flexion ROM,Cross taping,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4602325,Right lateral flexion ROM,Kinesio taping ,Placebo,No significant difference,"The Kruskal-Wallis ANOVA showed no significant differences in almost all measurements between groups (Table 3). In the KT group, greater decrease of VAS score was found comparatively to sham group (p = 0.0018).",20870:21138,4602325,26491458,Unavailable
4033489,At least one adverse event,Low dose Canakinumab ,Placebo,Significantly increased,No dose response in AEs was observed but a trend towards more patients having at least one AE across canakinumab groups relative to placebo (P = 0.0152) was observed.,5421:5588,4033489,24884602,Unavailable
4033489,At least one adverse event,Intermediate dose Canakinumab ,Placebo,Significantly increased,No dose response in AEs was observed but a trend towards more patients having at least one AE across canakinumab groups relative to placebo (P = 0.0152) was observed.,5421:5588,4033489,24884602,Unavailable
4033489,At least one adverse event,Medium dose Canakinumab ,Placebo,Significantly increased,No dose response in AEs was observed but a trend towards more patients having at least one AE across canakinumab groups relative to placebo (P = 0.0152) was observed.,5421:5588,4033489,24884602,Unavailable
4033489,At least one adverse event,High dose Canakinumab ,Placebo,Significantly increased,No dose response in AEs was observed but a trend towards more patients having at least one AE across canakinumab groups relative to placebo (P = 0.0152) was observed.,5421:5588,4033489,24884602,Unavailable
4033489,Infections ,Low dose Canakinumab ,Placebo,No significant difference,"A small, non-significant increase in the incidence rate of infection AEs was observed on canakinumab groups relative to placebo.",5899:6028,4033489,24884602,Unavailable
4033489,Infections ,Intermediate dose Canakinumab ,Placebo,No significant difference,"A small, non-significant increase in the incidence rate of infection AEs was observed on canakinumab groups relative to placebo.",5899:6028,4033489,24884602,Unavailable
4033489,Infections ,Medium dose Canakinumab ,Placebo,No significant difference,"A small, non-significant increase in the incidence rate of infection AEs was observed on canakinumab groups relative to placebo.",5899:6028,4033489,24884602,Unavailable
4033489,Infections ,High dose Canakinumab ,Placebo,No significant difference,"A small, non-significant increase in the incidence rate of infection AEs was observed on canakinumab groups relative to placebo.",5899:6028,4033489,24884602,Unavailable
4033489,Infections ,Low dose Canakinumab ,Placebo,No significant difference,"Although the rate of infections was numerically higher in all canakinumab groups (4.41%, 4.05%, 5.13% and 4.02% per month in low, intermediate, medium and high doses, respectively) than placebo (3.17% per month), the difference was not statistically significant—neither for each individual dose nor when tested for a monotonic trend across doses versus placebo (P = 0.1255).",70868:71242,4033489,24884602,Unavailable
4033489,Infections ,Intermediate dose Canakinumab ,Placebo,No significant difference,"Although the rate of infections was numerically higher in all canakinumab groups (4.41%, 4.05%, 5.13% and 4.02% per month in low, intermediate, medium and high doses, respectively) than placebo (3.17% per month), the difference was not statistically significant—neither for each individual dose nor when tested for a monotonic trend across doses versus placebo (P = 0.1255).",70868:71243,4033489,24884602,Unavailable
4033489,Infections ,Medium dose Canakinumab ,Placebo,No significant difference,"Although the rate of infections was numerically higher in all canakinumab groups (4.41%, 4.05%, 5.13% and 4.02% per month in low, intermediate, medium and high doses, respectively) than placebo (3.17% per month), the difference was not statistically significant—neither for each individual dose nor when tested for a monotonic trend across doses versus placebo (P = 0.1255).",70868:71243,4033489,24884602,Unavailable
4033489,Infections ,High dose Canakinumab ,Placebo,No significant difference,"Although the rate of infections was numerically higher in all canakinumab groups (4.41%, 4.05%, 5.13% and 4.02% per month in low, intermediate, medium and high doses, respectively) than placebo (3.17% per month), the difference was not statistically significant—neither for each individual dose nor when tested for a monotonic trend across doses versus placebo (P = 0.1255).",70867:71243,4033489,24884602,Unavailable
4033489,Major adverse cardiovascular events,Low dose Canakinumab ,Placebo,No significant difference,"Major adverse cardiovascular events occurred in patients of all groups, except the low-dose group; however, incidences in the intermediate-, medium- and high-dose groups were lower versus the placebo group (0.19%, 0.44% and 0.23% versus 0.53% per month, respectively). This observed difference in favour of canakinumab was not statistically significant—neither for each individual dose nor when tested for a monotonic trend across doses versus placebo (P = 0.9371).",71897:72362,4033489,24884602,Unavailable
4033489,Major adverse cardiovascular events,Intermediate dose Canakinumab ,Placebo,No significant difference,"Major adverse cardiovascular events occurred in patients of all groups, except the low-dose group; however, incidences in the intermediate-, medium- and high-dose groups were lower versus the placebo group (0.19%, 0.44% and 0.23% versus 0.53% per month, respectively). This observed difference in favour of canakinumab was not statistically significant—neither for each individual dose nor when tested for a monotonic trend across doses versus placebo (P = 0.9371).",71897:72362,4033489,24884602,Unavailable
4033489,Major adverse cardiovascular events,Medium dose Canakinumab ,Placebo,No significant difference,"Major adverse cardiovascular events occurred in patients of all groups, except the low-dose group; however, incidences in the intermediate-, medium- and high-dose groups were lower versus the placebo group (0.19%, 0.44% and 0.23% versus 0.53% per month, respectively). This observed difference in favour of canakinumab was not statistically significant—neither for each individual dose nor when tested for a monotonic trend across doses versus placebo (P = 0.9371).",71897:72362,4033489,24884602,Unavailable
4033489,Major adverse cardiovascular events,High dose Canakinumab ,Placebo,No significant difference,"Major adverse cardiovascular events occurred in patients of all groups, except the low-dose group; however, incidences in the intermediate-, medium- and high-dose groups were lower versus the placebo group (0.19%, 0.44% and 0.23% versus 0.53% per month, respectively). This observed difference in favour of canakinumab was not statistically significant—neither for each individual dose nor when tested for a monotonic trend across doses versus placebo (P = 0.9371).",71897:72362,4033489,24884602,Unavailable
4033489,Hepatic disorders AEs,High dose Canakinumab ,Placebo,Significantly increased,"The IR of hepatic disorders AEs was higher in the high-dose canakinumab (0.70% per month) than in the other canakinumab groups (0%, 0.06% and 0.22% per month for low, intermediate and medium groups, respectively) or placebo (0.12% per month), with an odds ratio versus placebo of 6.217 (95% CI: 1.504–25.697; P = 0.0116).",83536:83858,4033489,24884602,Unavailable
4033489,Abnormal neutrophil counts,Intermediate dose Canakinumab ,Placebo,Significantly increased,"There was also a decrease in absolute neutrophil counts (Figure&nbsp; 1B) with a higher IR of abnormal neutrophil counts in patients receiving intermediate (2.68% per visit), medium (4.95% per visit) and high doses (4.61% per visit) than in those receiving low-dose canakinumab (0.89% per visit) or placebo (1.22% per visit). The difference was statistically significant for each individual dose or when tested for a monotonic trend across doses versus placebo (P = 0.0001).",85546:86053,4033489,24884602,Unavailable
4033489,Abnormal neutrophil counts,Medium dose Canakinumab ,Placebo,Significantly increased,"There was also a decrease in absolute neutrophil counts (Figure&nbsp; 1B) with a higher IR of abnormal neutrophil counts in patients receiving intermediate (2.68% per visit), medium (4.95% per visit) and high doses (4.61% per visit) than in those receiving low-dose canakinumab (0.89% per visit) or placebo (1.22% per visit). The difference was statistically significant for each individual dose or when tested for a monotonic trend across doses versus placebo (P = 0.0001).",85546:86052,4033489,24884602,Unavailable
4033489,Abnormal neutrophil counts,High dose Canakinumab ,Placebo,No significant difference,"There was also a decrease in absolute neutrophil counts (Figure&nbsp; 1B) with a higher IR of abnormal neutrophil counts in patients receiving intermediate (2.68% per visit), medium (4.95% per visit) and high doses (4.61% per visit) than in those receiving low-dose canakinumab (0.89% per visit) or placebo (1.22% per visit). The difference was statistically significant for each individual dose or when tested for a monotonic trend across doses versus placebo (P = 0.0001).",85546:86052,4033489,24884602,Unavailable
4033489,Platelet count abnormality,Intermediate dose Canakinumab ,Placebo,No significant difference,"Patients receiving intermediate and medium doses showed similar IRs of platelet count abnormality compared with placebo (1.23%, 1.57% versus 1.00% per visit, respectively)",86344:86516,4033489,24884602,Unavailable
4033489,Platelet count abnormality,Medium dose Canakinumab ,Placebo,No significant difference,"Patients receiving intermediate and medium doses showed similar IRs of platelet count abnormality compared with placebo (1.23%, 1.57% versus 1.00% per visit, respectively)",86345:86516,4033489,24884602,Unavailable
4033489,Abnormal absolute lymphocyte counts,Low dose Canakinumab ,Placebo,No significant difference,No difference in the IR for abnormal absolute lymphocyte counts was seen between the canakinumab and placebo groups.,86974:87090,4033489,24884602,Unavailable
4033489,Abnormal absolute lymphocyte counts,Intermediate dose Canakinumab ,Placebo,No significant difference,No difference in the IR for abnormal absolute lymphocyte counts was seen between the canakinumab and placebo groups.,86974:87091,4033489,24884602,Unavailable
4033489,Abnormal absolute lymphocyte counts,Medium dose Canakinumab ,Placebo,No significant difference,No difference in the IR for abnormal absolute lymphocyte counts was seen between the canakinumab and placebo groups.,86973:87090,4033489,24884602,Unavailable
4033489,Abnormal absolute lymphocyte counts,High dose Canakinumab ,Placebo,No significant difference,No difference in the IR for abnormal absolute lymphocyte counts was seen between the canakinumab and placebo groups.,86974:87091,4033489,24884602,Unavailable
4033489,Elevated bilirubin levels ,Medium dose Canakinumab ,Placebo,No significant difference,There was no difference in incidence of elevated bilirubin levels reported in medium- and high-dose groups versus placebo.,117427:117549,4033489,24884602,Unavailable
4033489,Elevated bilirubin levels ,High dose Canakinumab ,Placebo,No significant difference,There was no difference in incidence of elevated bilirubin levels reported in medium- and high-dose groups versus placebo.,117426:117550,4033489,24884602,Unavailable
4033489,SBP,Low dose Canakinumab ,Placebo,No significant difference,"Modest increases from baseline in systolic and diastolic blood pressures were generally observed in the canakinumab groups throughout the duration of the observation period. However, the majority of these changes in either systolic or diastolic blood pressure were not significantly different from those seen in placebo",118591:118910,4033489,24884602,Unavailable
4033489,SBP,Intermediate dose Canakinumab ,Placebo,No significant difference,"Modest increases from baseline in systolic and diastolic blood pressures were generally observed in the canakinumab groups throughout the duration of the observation period. However, the majority of these changes in either systolic or diastolic blood pressure were not significantly different from those seen in placebo",118591:118911,4033489,24884602,Unavailable
4033489,SBP,Medium dose Canakinumab ,Placebo,No significant difference,"Modest increases from baseline in systolic and diastolic blood pressures were generally observed in the canakinumab groups throughout the duration of the observation period. However, the majority of these changes in either systolic or diastolic blood pressure were not significantly different from those seen in placebo",118591:118911,4033489,24884602,Unavailable
4033489,SBP,High dose Canakinumab ,Placebo,No significant difference,"Modest increases from baseline in systolic and diastolic blood pressures were generally observed in the canakinumab groups throughout the duration of the observation period. However, the majority of these changes in either systolic or diastolic blood pressure were not significantly different from those seen in placebo",118591:118911,4033489,24884602,Unavailable
4033489,DBP,Low dose Canakinumab ,Placebo,No significant difference,"Modest increases from baseline in systolic and diastolic blood pressures were generally observed in the canakinumab groups throughout the duration of the observation period. However, the majority of these changes in either systolic or diastolic blood pressure were not significantly different from those seen in placebo",118591:118911,4033489,24884602,Unavailable
4033489,DBP,Intermediate dose Canakinumab ,Placebo,No significant difference,"Modest increases from baseline in systolic and diastolic blood pressures were generally observed in the canakinumab groups throughout the duration of the observation period. However, the majority of these changes in either systolic or diastolic blood pressure were not significantly different from those seen in placebo",118591:118911,4033489,24884602,Unavailable
4033489,DBP,Medium dose Canakinumab ,Placebo,No significant difference,"Modest increases from baseline in systolic and diastolic blood pressures were generally observed in the canakinumab groups throughout the duration of the observation period. However, the majority of these changes in either systolic or diastolic blood pressure were not significantly different from those seen in placebo",118591:118911,4033489,24884602,Unavailable
4033489,DBP,High dose Canakinumab ,Placebo,No significant difference,"Modest increases from baseline in systolic and diastolic blood pressures were generally observed in the canakinumab groups throughout the duration of the observation period. However, the majority of these changes in either systolic or diastolic blood pressure were not significantly different from those seen in placebo",118591:118911,4033489,24884602,Unavailable
4033489,Body weight ,Low dose Canakinumab ,Placebo,No significant difference,No considerable change in body weight was observed across groups.,119079:119144,4033489,24884602,Unavailable
4033489,Body weight ,Intermediate dose Canakinumab ,Placebo,No significant difference,No considerable change in body weight was observed across groups.,119079:119144,4033489,24884602,Unavailable
4033489,Body weight ,Medium dose Canakinumab ,Placebo,No significant difference,No considerable change in body weight was observed across groups.,119079:119144,4033489,24884602,Unavailable
4033489,Body weight ,High dose Canakinumab ,Placebo,No significant difference,No considerable change in body weight was observed across groups.,119079:119144,4033489,24884602,Unavailable
4734812,Mean SBP (overall),Aged garlic extract ,Placebo,Significantly decreased,"Mean blood pressure was significantly reduced by 5.0±2.1 mmHg (P=0.016) systolic, and in responders by 11.5±1.9 mmHg systolic and 6.3±1.1 mmHg diastolic compared to placebo (P&lt;0.001).",4590:4807,4734812,26869811,Unavailable
4734812,Mean SBP (respondents) ,Aged garlic extract ,Placebo,Significantly decreased,"Mean blood pressure was significantly reduced by 5.0±2.1 mmHg (P=0.016) systolic, and in responders by 11.5±1.9 mmHg systolic and 6.3±1.1 mmHg diastolic compared to placebo (P&lt;0.001).",4590:4807,4734812,26869811,Unavailable
4734812,Mean DBP (respondents) ,Aged garlic extract ,Placebo,Significantly decreased,"Mean blood pressure was significantly reduced by 5.0±2.1 mmHg (P=0.016) systolic, and in responders by 11.5±1.9 mmHg systolic and 6.3±1.1 mmHg diastolic compared to placebo (P&lt;0.001).",4590:4807,4734812,26869811,Unavailable
4734812,Central systolic blood pressure,Aged garlic extract ,Placebo,No significant difference,"Central hemodynamic-measures tended to improve in the garlic group more than in the placebo group, including central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness.",4807:5057,4734812,26869811,Unavailable
4734812,Central pulse pressure,Aged garlic extract ,Placebo,No significant difference,"Central hemodynamic-measures tended to improve in the garlic group more than in the placebo group, including central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness.",4807:5057,4734812,26869811,Unavailable
4734812,Mean arterial pressure,Aged garlic extract ,Placebo,No significant difference,"Central hemodynamic-measures tended to improve in the garlic group more than in the placebo group, including central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness.",4807:5057,4734812,26869811,Unavailable
4734812,Augmentation pressure,Aged garlic extract ,Placebo,No significant difference,"Central hemodynamic-measures tended to improve in the garlic group more than in the placebo group, including central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness.",4807:5057,4734812,26869811,Unavailable
4734812,Pulse-wave velocity,Aged garlic extract ,Placebo,No significant difference,"Central hemodynamic-measures tended to improve in the garlic group more than in the placebo group, including central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness.",4807:5057,4734812,26869811,Unavailable
4734812,Arterial stiffness,Aged garlic extract ,Placebo,No significant difference,"Central hemodynamic-measures tended to improve in the garlic group more than in the placebo group, including central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness.",4807:5057,4734812,26869811,Unavailable
4734812,TNFα,Aged garlic extract ,Placebo,No significant difference,"trends in beneficial effects of garlic on the inflammatory markers TNFα, total cholesterol, low-density lipid cholesterol, and apolipoproteins were observed.",5186:5344,4734812,26869811,Unavailable
4734812,Total cholesterol,Aged garlic extract ,Placebo,No significant difference,"trends in beneficial effects of garlic on the inflammatory markers TNFα, total cholesterol, low-density lipid cholesterol, and apolipoproteins were observed.",5186:5344,4734812,26869811,Unavailable
4734812,Low-density lipid cholesterol,Aged garlic extract ,Placebo,No significant difference,"trends in beneficial effects of garlic on the inflammatory markers TNFα, total cholesterol, low-density lipid cholesterol, and apolipoproteins were observed.",5186:5344,4734812,26869811,Unavailable
4734812,Apolipoproteins,Aged garlic extract ,Placebo,No significant difference,"trends in beneficial effects of garlic on the inflammatory markers TNFα, total cholesterol, low-density lipid cholesterol, and apolipoproteins were observed.",5186:5344,4734812,26869811,Unavailable
4734812,Mean SBP (overall),Aged garlic extract ,Placebo,Significantly decreased,"Analysis of all participants (n=88) revealed a significant reduction in SBP from baseline in the garlic group compared with placebo over 12 weeks (mean difference in SBP ± standard error =−5.0±2.1 mmHg, P=0.016), but not for DBP (mean difference in DBP ± standard error =−1.9±1.2, P=0.12",22913:23234,4734812,26869811,Unavailable
4734812,Mean DBP (overall),Aged garlic extract ,Placebo,No significant difference,"Analysis of all participants (n=88) revealed a significant reduction in SBP from baseline in the garlic group compared with placebo over 12 weeks (mean difference in SBP ± standard error =−5.0±2.1 mmHg, P=0.016), but not for DBP (mean difference in DBP ± standard error =−1.9±1.2, P=0.12",27695:27875,4734812,26869811,Unavailable
4734812,Mean SBP (respondents) ,Aged garlic extract ,Placebo,Significantly decreased,Subgroup analysis of responders revealed an average reduction of 11.5±1.9 mmHg SBP and 6.3±1.1 DBP compared to placebo (P&lt;0.001,24225:24369,4734812,26869811,Unavailable
4734812,Mean DBP (respondents) ,Aged garlic extract ,Placebo,Significantly decreased,Subgroup analysis of responders revealed an average reduction of 11.5±1.9 mmHg SBP and 6.3±1.1 DBP compared to placebo (P&lt;0.001,24225:24369,4734812,26869811,Unavailable
4734812,Central systolic blood pressure,Aged garlic extract ,Placebo,No significant difference,"A number of central hemodynamic measures tended to improve more in the garlic group compared to placebo, including central SBP (mean difference =−3.8±1.9 mmHg, P=0.05), central pulse pressure (mean difference =−2.7±1.5 mmHg, P=0.08), total vascular resistance (mean difference =−0.07±0.03 s · mmHg/mL, P=0.06), mean arterial pressure (mean difference =−3.1±1.8 mmHg, P=0.09), augmentation pressure if high at baseline (mean difference =−3.5±1.8 mmHg, P=0.06), and PWV if high at baseline (mean difference =−0.33±0.14 m/s, P=0.02)",24501:25132,4734812,26869811,Unavailable
4734812,Central pulse pressure,Aged garlic extract ,Placebo,No significant difference,"A number of central hemodynamic measures tended to improve more in the garlic group compared to placebo, including central SBP (mean difference =−3.8±1.9 mmHg, P=0.05), central pulse pressure (mean difference =−2.7±1.5 mmHg, P=0.08), total vascular resistance (mean difference =−0.07±0.03 s · mmHg/mL, P=0.06), mean arterial pressure (mean difference =−3.1±1.8 mmHg, P=0.09), augmentation pressure if high at baseline (mean difference =−3.5±1.8 mmHg, P=0.06), and PWV if high at baseline (mean difference =−0.33±0.14 m/s, P=0.02)",24501:25132,4734812,26869811,Unavailable
4734812,Mean arterial pressure,Aged garlic extract ,Placebo,No significant difference,"A number of central hemodynamic measures tended to improve more in the garlic group compared to placebo, including central SBP (mean difference =−3.8±1.9 mmHg, P=0.05), central pulse pressure (mean difference =−2.7±1.5 mmHg, P=0.08), total vascular resistance (mean difference =−0.07±0.03 s · mmHg/mL, P=0.06), mean arterial pressure (mean difference =−3.1±1.8 mmHg, P=0.09), augmentation pressure if high at baseline (mean difference =−3.5±1.8 mmHg, P=0.06), and PWV if high at baseline (mean difference =−0.33±0.14 m/s, P=0.02)",24501:25132,4734812,26869811,Unavailable
4734812,Augmentation pressure,Aged garlic extract ,Placebo,No significant difference,"A number of central hemodynamic measures tended to improve more in the garlic group compared to placebo, including central SBP (mean difference =−3.8±1.9 mmHg, P=0.05), central pulse pressure (mean difference =−2.7±1.5 mmHg, P=0.08), total vascular resistance (mean difference =−0.07±0.03 s · mmHg/mL, P=0.06), mean arterial pressure (mean difference =−3.1±1.8 mmHg, P=0.09), augmentation pressure if high at baseline (mean difference =−3.5±1.8 mmHg, P=0.06), and PWV if high at baseline (mean difference =−0.33±0.14 m/s, P=0.02)",24501:25133,4734812,26869811,Unavailable
4734812,Pulse-wave velocity,Aged garlic extract ,Placebo,No significant difference,"A number of central hemodynamic measures tended to improve more in the garlic group compared to placebo, including central SBP (mean difference =−3.8±1.9 mmHg, P=0.05), central pulse pressure (mean difference =−2.7±1.5 mmHg, P=0.08), total vascular resistance (mean difference =−0.07±0.03 s · mmHg/mL, P=0.06), mean arterial pressure (mean difference =−3.1±1.8 mmHg, P=0.09), augmentation pressure if high at baseline (mean difference =−3.5±1.8 mmHg, P=0.06), and PWV if high at baseline (mean difference =−0.33±0.14 m/s, P=0.02)",24501:25132,4734812,26869811,Unavailable
4734812,Arterial stiffness,Aged garlic extract ,Placebo,No significant difference,"A number of central hemodynamic measures tended to improve more in the garlic group compared to placebo, including central SBP (mean difference =−3.8±1.9 mmHg, P=0.05), central pulse pressure (mean difference =−2.7±1.5 mmHg, P=0.08), total vascular resistance (mean difference =−0.07±0.03 s · mmHg/mL, P=0.06), mean arterial pressure (mean difference =−3.1±1.8 mmHg, P=0.09), augmentation pressure if high at baseline (mean difference =−3.5±1.8 mmHg, P=0.06), and PWV if high at baseline (mean difference =−0.33±0.14 m/s, P=0.02)",24501:25133,4734812,26869811,Unavailable
4734812,TNFα,Aged garlic extract ,Placebo,No significant difference,"The inflammatory marker TNFα was reduced in the garlic group compared to placebo with borderline significance (P=0.05), while changes in IL-1β were not significant",26915:27095,4734812,26869811,Unavailable
4734812,Total cholesterol,Aged garlic extract ,Placebo,No significant difference,"None of the blood markers tested changed significantly over time; however, lipid levels, including total cholesterol and LDL, tended to improve slightly more in the garlic group",25315:25492,4734812,26869811,Unavailable
4734812,Low-density lipid cholesterol,Aged garlic extract ,Placebo,No significant difference,"None of the blood markers tested changed significantly over time; however, lipid levels, including total cholesterol and LDL, tended to improve slightly more in the garlic group",25315:25492,4734812,26869811,Unavailable
4734812,Apolipoproteins,Aged garlic extract ,Placebo,No significant difference,"Reduction of ApoB when above the reference range was greater in the garlic group compared to placebo, albeit not statistically significant due to small sample size (mean difference =−29.1±46.3 mg/dL, P=0.3",25931:26156,4734812,26869811,Unavailable
4734812,IL-1β,Aged garlic extract ,Placebo,No significant difference,"The inflammatory marker TNFα was reduced in the garlic group compared to placebo with borderline significance (P=0.05), while changes in IL-1β were not significant",26915:27095,4734812,26869811,Unavailable
4734812,Platelet function,Aged garlic extract ,Placebo,No significant difference,"In contrast, platelet function tended to change more toward normal levels in the garlic group with high closure times (thin blood) at baseline for both agonists compared to the placebo group",26657:26847,4734812,26869811,Unavailable
4734812,Glucose levels,Aged garlic extract ,Placebo,No significant difference,Neither glucose levels nor kidney-function and liver-function test variables changed noticeably over time within or between groups,27357:27487,4734812,26869811,Unavailable
4734812,Kidney-function markers,Aged garlic extract ,Placebo,No significant difference,Neither glucose levels nor kidney-function and liver-function test variables changed noticeably over time within or between groups,27357:27487,4734812,26869811,Unavailable
4734812,Liver-function markers,Aged garlic extract ,Placebo,No significant difference,Neither glucose levels nor kidney-function and liver-function test variables changed noticeably over time within or between groups,27357:27487,4734812,26869811,Unavailable
4734812,Reflux ,Aged garlic extract ,Placebo,No significant difference,"About 40% of participants in both groups reported minor side effects, including reflux (8%), burping (5%), bloating (3%), and also improved digestion (7%) (P&gt;0.05",27695:27875,4734812,26869811,Unavailable
4734812,Burping ,Aged garlic extract ,Placebo,No significant difference,"About 40% of participants in both groups reported minor side effects, including reflux (8%), burping (5%), bloating (3%), and also improved digestion (7%) (P&gt;0.05",27695:27875,4734812,26869811,Unavailable
4734812,Bloating ,Aged garlic extract ,Placebo,No significant difference,"About 40% of participants in both groups reported minor side effects, including reflux (8%), burping (5%), bloating (3%), and also improved digestion (7%) (P&gt;0.05",27695:27875,4734812,26869811,Unavailable
4734812,Improvement in digestion ,Aged garlic extract ,Placebo,No significant difference,"About 40% of participants in both groups reported minor side effects, including reflux (8%), burping (5%), bloating (3%), and also improved digestion (7%) (P&gt;0.05",27695:27875,4734812,26869811,Unavailable
5985892,Erythrocyte sedimentation rate,Etanercept + Methotrexate,Methotrexate,No significant difference,"After two years of treatment the group with combined therapy resulted with improvement of acute phase reactants as erythrocyte sedimentation rate (ESR) for the first hour (41.1 vs. 10.3 mm/hour) and C - reactive protein (CRP) (40.8 vs. 6 mg/liter), and compared to the group treated with monotherapy, there were no significant changes (ESR: 45.7 vs 34.3 mm/hour; CRP: 48 vs 24 mg/liter).",4911:5298,5985892,None,Unavailable
5985892,C - reactive protein,Etanercept + Methotrexate,Methotrexate,No significant difference,"After two years of treatment the group with combined therapy resulted with improvement of acute phase reactants as erythrocyte sedimentation rate (ESR) for the first hour (41.1 vs. 10.3 mm/hour) and C - reactive protein (CRP) (40.8 vs. 6 mg/liter), and compared to the group treated with monotherapy, there were no significant changes (ESR: 45.7 vs 34.3 mm/hour; CRP: 48 vs 24 mg/liter).",4911:5298,5985892,None,Unavailable
5985892, DAS28 improvement ,Etanercept + Methotrexate,Methotrexate,Significantly increased,"After 2 years of treatment, we had significant changes in the results of DAS28, wherein the group treated with ETN plus MTX DAS28 was 2.12 ± 0.15, while in the group of patients treated with MTX DAS28 were 3.75 ± 0.39 (t = 13.03; df = 58; p &lt; 0.0001).",5470:5721,5985892,None,Unavailable
5985892,Radiographic progression of disease ,Etanercept + Methotrexate,Methotrexate,No significant difference,The group with combined therapy showed no evidence of radiographic progression comparing to the group of patients with monotherapy.,5722:5853,5985892,None,Unavailable
5985892,Erythrocyte sedimentation rate,Etanercept + Methotrexate,Methotrexate,No significant difference,"ESR (normal values &lt; 10 mm/hour), of the first group (ETN plus MTX) in the first hour of ESR was 41.1 vs. 10.3 mm/hour and CRP (normal value &lt; 6 mg/liter) was 40.8 vs. 6 mg/liter (p = 0.001) compared to the second (MTX alone) showed no significant changes (ESR: 45.7 vs 34.3 mm/hour; CRP: 48 vs 24 mg/liter), p = 0.17.",11085:11404,5985892,None,Unavailable
5985892,C - reactive protein,Etanercept + Methotrexate,Methotrexate,No significant difference,"ESR (normal values &lt; 10 mm/hour), of the first group (ETN plus MTX) in the first hour of ESR was 41.1 vs. 10.3 mm/hour and CRP (normal value &lt; 6 mg/liter) was 40.8 vs. 6 mg/liter (p = 0.001) compared to the second (MTX alone) showed no significant changes (ESR: 45.7 vs 34.3 mm/hour; CRP: 48 vs 24 mg/liter), p = 0.17.",11085:11404,5985892,None,Unavailable
5985892,ACR20,Etanercept + Methotrexate,Methotrexate,No significant difference,ACR20 responses were achieved at the level of 90% in patients with combined therapy group (ETN plus MTX) vs 84% of the monotherapy group (MTX) p = 0.63.,11557:11709,5985892,None,Unavailable
5985892,ACR50,Etanercept + Methotrexate,Methotrexate,No significant difference,ACR50 responses were achieved by 70% of the combination therapy group vs 46% of the monotherapy group p = 0.17.,11709:11821,5985892,None,Unavailable
5985892,ACR70,Etanercept + Methotrexate,Methotrexate,No significant difference,ACR70 responses were achieved by 40% of the combination group vs 16% of the monotherapy group p = 0.089.,11821:11926,5985892,None,Unavailable
5985892, DAS28 improvement ,Etanercept + Methotrexate,Methotrexate,Significantly increased,"The group treated with ETN plus MTX had DAS28 of 2.12 ± 0.15, while the group of patients treated with MTX had DAS28 of 3.75 ± 0.39 (t = 13.03; df = 58; p &lt; 0.0001)",12229:12393,5985892,None,Unavailable
5985892,ACR20,Etanercept + Methotrexate,Methotrexate,No significant difference,"ACR20	84%	90%	t=0.49; df=58; p=0.63",14214:14390,5985892,None,Unavailable
5985892,ACR50,Etanercept + Methotrexate,Methotrexate,No significant difference,"ACR50	46%	70%	t=1.39; df=58; p=0.17",14511:NaN,5985892,None,Unavailable
5985892,ACR70,Etanercept + Methotrexate,Methotrexate,No significant difference,"ACR70	16%	40%	t=1.73; df=58; p=0.089",14808:14985,5985892,None,Unavailable
5985892, DAS28 improvement ,Etanercept + Methotrexate,Methotrexate,Significantly increased,"Disease Activity Score (DAS28)		Before treatment	5.9 ± 0.49	5.32 ± 0.26	After treatment	3.75 ± 0.39	2.12 ± 0.15	t=13.03; df=58; p&lt;0.0001",15108:15860,5985892,None,Unavailable
5985892,Radiographic progression of disease ,Etanercept + Methotrexate,Methotrexate,No significant difference,"According to the Larsen’s method, in the group of combined therapy showed no evidence of radiographic progression comparing to the group of monotherapy",16406:16558,5985892,None,Unavailable
5981960,Proportion of suicidal events ,Mood-regulation focused cognitive behavioural therapy,Control ,No significant difference,The proportion of suicidal events after treatment was not significantly different between the two tretment groups (p = 0.07).,22163:22305,5981960,29734740,Unavailable
5981960,SMFQ scores,Mood-regulation focused cognitive behavioural therapy,Control ,No significant difference,"With both MR-CBT and TAU there was a significant reduction in pre-post SMFQ scores, without significant difference between the treatment groups.",22726:22870,5981960,29734740,Unavailable
5981960,WHO-5 scores,Mood-regulation focused cognitive behavioural therapy,Control ,No significant difference,"The pre-post treatment scores for WHO-5 showed a significant increase after both MR-CBT and TAU, and there was no significant difference between the treatments",22871:23030,5981960,29734740,Unavailable
5981960,Partial remission of depression,Mood-regulation focused cognitive behavioural therapy,Control ,No significant difference,here were ten subjects (67%) with partial remission of depression in the group treated with MR-CBT and three (25%) in the TAU group. The difference between the treatments was close to significant (p = 0.05).,23207:23432,5981960,29734740,Unavailable
5981960,SMFQ score &lt;6,Mood-regulation focused cognitive behavioural therapy,Control ,No significant difference,"When a lower cut-off (SMFQ score &lt;6) was used for analysis, there were eight subjects with partial remission (p &lt; 0.01) in the MR-CBT group and three in the TAU group (p = 0.2); the difference between the groups was not significant (p = 0.2).",23611:23910,5981960,29734740,Unavailable
5721510,Accuracy,Root ZX II,Raypex 6,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4763:5146,5721510,29259365,Unavailable
5721510,Accuracy,Root ZX II,I-Root,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4763:5146,5721510,29259365,Unavailable
5721510,Accuracy,Root ZX II,Romiapex,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4763:5146,5721510,29259365,Unavailable
5721510,Accuracy,Root ZX II,Sybron Endo Mini,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4763:5146,5721510,29259365,Unavailable
5721510,Accuracy,Root ZX II,Root ZX mini,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,Raypex 6,I-Root,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,Raypex 6,Romiapex,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,Raypex 6,Sybron Endo Mini,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,Raypex 6,Root ZX mini,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,I-Root,Romiapex,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,I-Root,Sybron Endo Mini,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,I-Root,Root ZX mini,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,Romiapex ,Sybron Endo Mini,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,Romiapex ,Root ZX mini,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,Sybron Endo Mini, Root ZX mini,No significant difference,"A total of 270 canals were evaluated, of which 233 (86.3%) canals exhibited acceptable working length, 28 (10.4%) canals exhibited short working length, and only 9 (3.3%) canals exhibited working length beyond the apex. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant.",4498:4510,5721510,29259365,Unavailable
5721510,Accuracy,Root ZX II,Raypex 6,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Root ZX II,I-Root,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Root ZX II,Romiapex,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Root ZX II,Sybron Endo Mini,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Root ZX II,Root ZX mini,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Raypex 6,I-Root,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Raypex 6,Romiapex,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Raypex 6,Sybron Endo Mini,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Raypex 6,Root ZX mini,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,I-Root,Romiapex,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,I-Root,Sybron Endo Mini,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,I-Root,Root ZX mini,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Romiapex ,Sybron Endo Mini,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Romiapex ,Root ZX mini,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
5721510,Accuracy,Sybron Endo Mini, Root ZX mini,No significant difference,"Accuracy of six different apex locatorsROOT ZX II had an accuracy of 97.8%, RAYPEX-6 had an accuracy of 95.6%, Romiapex had an accuracy of 95.6%, I-Root had an accuracy of 93.3%, Sybron Endo Mini had an accuracy of 73.3%, and Root ZX Mini had an accuracy of 62.2%, respectively. There were a statistically significant results in all the groups (P &lt; 0.05) and the comparison between the groups was statistically insignificant [Table 2 and Figure 1].",14791:15406,5721510,29259365,Unavailable
3616846,Fish intake ,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"From baseline to follow-up, intake of fish [Advice: 12 g/day (95% CI: -5, 29), Advice+GC: 22 g/day (5, 39)] and DHA [Advice: 70 mg/d (3, 137), Advice+GC: 161 mg/d (93, 229)] increased in both intervention groups, compared with controls.",41482:41774,3616846,23496848,Unavailable
3616846,Fish intake ,Advice + grocery store gift cards,Control,Significantly increased,"From baseline to follow-up, intake of fish [Advice: 12 g/day (95% CI: -5, 29), Advice+GC: 22 g/day (5, 39)] and DHA [Advice: 70 mg/d (3, 137), Advice+GC: 161 mg/d (93, 229)] increased in both intervention groups, compared with controls.",6510:6747,3616846,23496848,Unavailable
3616846, Consuming &gt;= 200mg/d of DHA from fish,Advice to consume low-mercury/high-DHA fish,Control,Significantly increased,"At follow-up, no control women consumed &gt;= 200mg/d of DHA from fish, compared with 33% in the Advice arm (p=0.005) and 53% in the Advice+GC arm (p=0.0002). We did not detect any differences in mercury intake or in biomarker levels of mercury and DHA between groups.",6747:7012,3616846,23496848,Unavailable
3616846, Consuming &gt;= 200mg/d of DHA from fish,Advice + grocery store gift cards,Control,Significantly increased,"At follow-up, no control women consumed &gt;= 200mg/d of DHA from fish, compared with 33% in the Advice arm (p=0.005) and 53% in the Advice+GC arm (p=0.0002). We did not detect any differences in mercury intake or in biomarker levels of mercury and DHA between groups.",6747:7012,3616846,23496848,Unavailable
3616846, Consuming &gt;= 200mg/d of DHA from fish,Advice to consume low-mercury/high-DHA fish,Control,Significantly increased,"At the follow-up visit there were substantial differences in dietary intake between intervention and control participants (Table&nbsp;2). At follow-up, no control women consumed the recommended 200mg/d of DHA from fish, compared with 33% of women in the Advice group (p=0.005) and 53% of women in the Advice+GC group (p=0.0002).",38208:38571,3616846,23496848,Unavailable
3616846, Consuming &gt;= 200mg/d of DHA from fish,Advice + grocery store gift cards,Control,Significantly increased,"At the follow-up visit there were substantial differences in dietary intake between intervention and control participants (Table&nbsp;2). At follow-up, no control women consumed the recommended 200mg/d of DHA from fish, compared with 33% of women in the Advice group (p=0.005) and 53% of women in the Advice+GC group (p=0.0002).",38208:38571,3616846,23496848,Unavailable
3616846,Fish intake ,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Over the 12 week intervention period, intake of fish increased in the Advice + Gift Card (+165 g/day) and Advice (+99 g/day) arms, but hardly changed in the control arm (+13 g/day).",41482:41774,3616846,23496848,Unavailable
3616846,Fish intake ,Advice + grocery store gift cards,Control,Significantly increased,"Over the 12 week intervention period, intake of fish increased in the Advice + Gift Card (+165 g/day) and Advice (+99 g/day) arms, but hardly changed in the control arm (+13 g/day).",38571:38752,3616846,23496848,Unavailable
3616846,DHA intake from supplements,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"In contrast, DHA intake from supplements remained essentially stable in all 3 groups",38954:39039,3616846,23496848,Unavailable
3616846,DHA intake from supplements,Advice + grocery store gift cards,Control,No significant difference,"In contrast, DHA intake from supplements remained essentially stable in all 3 groups",42937:43264,3616846,23496848,Unavailable
3616846,DHA intake from supplements,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,DHA from supplements (mg/day)10 (80)10 (52)34 (76)0.990.31,40800:41103,3616846,23496848,Unavailable
3616846,DHA intake from supplements,Advice + grocery store gift cards,Control,No significant difference,DHA from supplements (mg/day)10 (80)10 (52)34 (76)0.990.31,42937:43264,3616846,23496848,Unavailable
3616846,Fish intake ,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,Fish intake (g/day)2 (17)14 (22)24 (36)0.150.01,41482:41774,3616846,23496848,Unavailable
3616846,Fish intake ,Advice + grocery store gift cards,Control,Significantly increased,Fish intake (g/day)2 (17)14 (22)24 (36)0.150.01,41482:41774,3616846,23496848,Unavailable
3616846, Consuming &gt;= 200mg/d of DHA from fish,Advice to consume low-mercury/high-DHA fish,Control,Significantly increased,DHA from fish (mg/day)−12 (75)57 (114)149 (118)0.04&lt;0.0001,41830:42133,3616846,23496848,Unavailable
3616846, Consuming&gt;= 200mg/d of DHA from fish,Advice + grocery store gift cards,Control,Significantly increased,DHA from fish (mg/day)−12 (75)57 (114)149 (118)0.04&lt;0.0001,41830:42133,3616846,23496848,Unavailable
3616846,DHA from fish + supplements,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,DHA from fish + supplements (mg/day)2 (11)67 (130)183 (144)0.10&lt;0.0001,42192:42507,3616846,23496848,Unavailable
3616846,DHA from fish + supplements,Advice + grocery store gift cards,Control,Significantly increased,DHA from fish + supplements (mg/day)2 (11)67 (130)183 (144)0.10&lt;0.0001,42192:42507,3616846,23496848,Unavailable
3616846,Mercury intake from fish ,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,Mercury intake from fish (mcg/day)0.4 (1.8)−0.1 (2.1)0.9 (1.8)0.370.50,42566:42881,3616846,23496848,Unavailable
3616846,Mercury intake from fish ,Advice + grocery store gift cards,Control,No significant difference,Mercury intake from fish (mcg/day)0.4 (1.8)−0.1 (2.1)0.9 (1.8)0.370.50,42937:43264,3616846,23496848,Unavailable
3616846,Mercury intake from fish per kg,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,Mercury intake from fish (mcg/kg/day)0.007 (0.03)−0.003 (0.02)0.012 (0.03)0.270.55,42937:43264,3616846,23496848,Unavailable
3616846,Mercury intake from fish per kg,Advice + grocery store gift cards,Control,No significant difference,Mercury intake from fish (mcg/kg/day)0.007 (0.03)−0.003 (0.02)0.012 (0.03)0.270.55,42937:43264,3616846,23496848,Unavailable
3616846,Plasma DHA,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,Plasma DHA (% of total fatty acids)0.01 (0.45)−0.12 (0.66)−0.07 (0.29)0.030.52,45016:45235,3616846,23496848,Unavailable
3616846,Plasma DHA,Advice + grocery store gift cards,Control,No significant difference,Plasma DHA (% of total fatty acids)0.01 (0.45)−0.12 (0.66)−0.07 (0.29)0.030.52,43649:43972,3616846,23496848,Unavailable
3616846,Whole blood mercury,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,Whole blood mercury (mcg/L)0.35 (1.12)−0.26 (0.36)−0.40 (1.27)0.670.22,44028:44343,3616846,23496848,Unavailable
3616846,Whole blood mercury,Advice + grocery store gift cards,Control,No significant difference,Whole blood mercury (mcg/L)0.35 (1.12)−0.26 (0.36)−0.40 (1.27)0.670.22,44028:44343,3616846,23496848,Unavailable
3616846,Hair mercury ,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Hair mercury (mcg/g)	0.31 (0.31)	0.25 (0.23)	0.31 (0.30)	0.50	0.99",44724:44905,3616846,23496848,Unavailable
3616846,Hair mercury ,Advice + grocery store gift cards,Control,No significant difference,"Hair mercury (mcg/g)	0.31 (0.31)	0.25 (0.23)	0.31 (0.30)	0.50	0.99",44724:44905,3616846,23496848,Unavailable
3616846,Fish intake ,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Women in the Advice-only arm had a somewhat smaller increase in intake of fish (12 g/day, 95% CI: -5, 29), but still a significantly increased intake of DHA (70 mg/day, 95% CI: 3, 137), compared with controls",45285:45493,3616846,23496848,Unavailable
3616846,Fish intake ,Advice + grocery store gift cards,Control,Significantly increased,"Compared with the control group, women in the Advice + Gift Card group had significant increases over the duration of the study in intake of fish (22 g/day, 95% CI: 5, 39) and DHA from fish (161 mg/day, 95% CI: 93, 229)",45016:45235,3616846,23496848,Unavailable
3616846, Consuming &gt;= 200mg/d of DHA from fish,Advice to consume low-mercury/high-DHA fish,Control,Significantly increased,"Women in the Advice-only arm had a somewhat smaller increase in intake of fish (12 g/day, 95% CI: -5, 29), but still a significantly increased intake of DHA (70 mg/day, 95% CI: 3, 137), compared with controls",45016:45235,3616846,23496848,Unavailable
3616846, Consuming &gt;= 200mg/d of DHA from fish,Advice + grocery store gift cards,Control,Significantly increased,"Compared with the control group, women in the Advice + Gift Card group had significant increases over the duration of the study in intake of fish (22 g/day, 95% CI: 5, 39) and DHA from fish (161 mg/day, 95% CI: 93, 229)",45016:45235,3616846,23496848,Unavailable
3616846,Plasma DHA,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Despite the differences in estimated fish and DHA intake, we did not observe any difference vs. control in change in plasma concentrations of DHA (Table&nbsp;2) or n-3 eicosapentaenoic acid (Advice: -0.18%, 95% CI: -0.37, 0.01; Advice+ Gift Card: -0.14, 95% CI: -0.33, 0.05).",45897:46206,3616846,23496848,Unavailable
3616846,Plasma DHA,Advice + grocery store gift cards,Control,No significant difference,"Despite the differences in estimated fish and DHA intake, we did not observe any difference vs. control in change in plasma concentrations of DHA (Table&nbsp;2) or n-3 eicosapentaenoic acid (Advice: -0.18%, 95% CI: -0.37, 0.01; Advice+ Gift Card: -0.14, 95% CI: -0.33, 0.05).",45897:46206,3616846,23496848,Unavailable
3616846,Plasma n-3 eicosapentaenoic acid,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Despite the differences in estimated fish and DHA intake, we did not observe any difference vs. control in change in plasma concentrations of DHA (Table&nbsp;2) or n-3 eicosapentaenoic acid (Advice: -0.18%, 95% CI: -0.37, 0.01; Advice+ Gift Card: -0.14, 95% CI: -0.33, 0.05).",45897:46206,3616846,23496848,Unavailable
3616846,Plasma n-3 eicosapentaenoic acid,Advice + grocery store gift cards,Control,No significant difference,"Despite the differences in estimated fish and DHA intake, we did not observe any difference vs. control in change in plasma concentrations of DHA (Table&nbsp;2) or n-3 eicosapentaenoic acid (Advice: -0.18%, 95% CI: -0.37, 0.01; Advice+ Gift Card: -0.14, 95% CI: -0.33, 0.05).",45897:46206,3616846,23496848,Unavailable
3616846,Intake of higher mercury fish,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"We observed no differences in intake of higher mercury fish (Advice+ Gift Card: -0.5 g/day, 95% CI: -7, 6; Advice:-4 g/day, 95% CI: -10, 2).",45756:45896,3616846,23496848,Unavailable
3616846,Intake of higher mercury fish,Advice + grocery store gift cards,Control,No significant difference,"We observed no differences in intake of higher mercury fish (Advice+ Gift Card: -0.5 g/day, 95% CI: -7, 6; Advice:-4 g/day, 95% CI: -10, 2).",45756:45897,3616846,23496848,Unavailable
3616846,Mercury intake from fish ,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Intake of mercury from fish did not change substantially in any group (Table&nbsp;2), and there were no material differences in change from baseline to follow-up between intervention and control women",46640:46875,3616846,23496848,Unavailable
3616846,Mercury intake from fish ,Advice + grocery store gift cards,Control,No significant difference,"Intake of mercury from fish did not change substantially in any group (Table&nbsp;2), and there were no material differences in change from baseline to follow-up between intervention and control women",46640:46875,3616846,23496848,Unavailable
3616846,Hair mercury ,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Also, there were no differences between groups in hair mercury concentrations at follow-up, or in change from baseline to follow-up in blood mercury",46924:47072,3616846,23496848,Unavailable
3616846,Hair mercury ,Advice + grocery store gift cards,Control,No significant difference,"Also, there were no differences between groups in hair mercury concentrations at follow-up, or in change from baseline to follow-up in blood mercury",46923:47073,3616846,23496848,Unavailable
3616846,Whole blood mercury,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Also, there were no differences between groups in hair mercury concentrations at follow-up, or in change from baseline to follow-up in blood mercury",46924:47072,3616846,23496848,Unavailable
3616846,Whole blood mercury,Advice + grocery store gift cards,Control,No significant difference,"Also, there were no differences between groups in hair mercury concentrations at follow-up, or in change from baseline to follow-up in blood mercury",46923:47072,3616846,23496848,Unavailable
3616846,Enjoying eating fish,Advice to consume low-mercury/high-DHA fish,Control,Significantly increased,"Compared with women randomized to the control group, women randomized to the two intervention groups were substantially more likely to strongly agree that they “enjoy eating fish” (40% vs. 10%, p=0.02), that “fish contains nutrients that are healthy for my baby” (74% vs. 35%, p=0.004), and that “some kinds of fish are better for me to eat than other kinds” (83% vs. 55%, p=0.03).",47524:47906,3616846,23496848,Unavailable
3616846,Enjoying eating fish,Advice + grocery store gift cards,Control,Significantly increased,"Compared with women randomized to the control group, women randomized to the two intervention groups were substantially more likely to strongly agree that they “enjoy eating fish” (40% vs. 10%, p=0.02), that “fish contains nutrients that are healthy for my baby” (74% vs. 35%, p=0.004), and that “some kinds of fish are better for me to eat than other kinds” (83% vs. 55%, p=0.03).",47525:47906,3616846,23496848,Unavailable
3616846,Knowledge about fish contains nutrients,Advice to consume low-mercury/high-DHA fish,Control,Significantly increased,"Compared with women randomized to the control group, women randomized to the two intervention groups were substantially more likely to strongly agree that they “enjoy eating fish” (40% vs. 10%, p=0.02), that “fish contains nutrients that are healthy for my baby” (74% vs. 35%, p=0.004), and that “some kinds of fish are better for me to eat than other kinds” (83% vs. 55%, p=0.03).",47525:47906,3616846,23496848,Unavailable
3616846,Knowledge about fish contains nutrients,Advice + grocery store gift cards,Control,Significantly increased,"Compared with women randomized to the control group, women randomized to the two intervention groups were substantially more likely to strongly agree that they “enjoy eating fish” (40% vs. 10%, p=0.02), that “fish contains nutrients that are healthy for my baby” (74% vs. 35%, p=0.004), and that “some kinds of fish are better for me to eat than other kinds” (83% vs. 55%, p=0.03).",47525:47906,3616846,23496848,Unavailable
3616846,Knowledge about fish benefits differences ,Advice to consume low-mercury/high-DHA fish,Control,Significantly increased,"Compared with women randomized to the control group, women randomized to the two intervention groups were substantially more likely to strongly agree that they “enjoy eating fish” (40% vs. 10%, p=0.02), that “fish contains nutrients that are healthy for my baby” (74% vs. 35%, p=0.004), and that “some kinds of fish are better for me to eat than other kinds” (83% vs. 55%, p=0.03).",47525:47906,3616846,23496848,Unavailable
3616846,Knowledge about fish benefits differences ,Advice + grocery store gift cards,Control,Significantly increased,"Compared with women randomized to the control group, women randomized to the two intervention groups were substantially more likely to strongly agree that they “enjoy eating fish” (40% vs. 10%, p=0.02), that “fish contains nutrients that are healthy for my baby” (74% vs. 35%, p=0.004), and that “some kinds of fish are better for me to eat than other kinds” (83% vs. 55%, p=0.03).",47525:47906,3616846,23496848,Unavailable
3616846,Avoiding fish,Advice to consume low-mercury/high-DHA fish,Control,Significantly decreased,"Intervention women were more likely to strongly disagree that “I try NOT to eat fish because it might be harmful for me or my baby” (63% vs. 35%, p=0.05).",47906:48061,3616846,23496848,Unavailable
3616846,Avoiding fish,Advice + grocery store gift cards,Control,Significantly decreased,"Intervention women were more likely to strongly disagree that “I try NOT to eat fish because it might be harmful for me or my baby” (63% vs. 35%, p=0.05).",47906:48061,3616846,23496848,Unavailable
3616846,Receiving fish information from Ob/Gyn,Advice to consume low-mercury/high-DHA fish,Control,Significantly decreased,"Intervention women were somewhat less likely to report that their obstetrician had provided them with written information about fish intake during pregnancy (37% vs. 60%, p=0.10) or had discussed fish intake with them (31 vs. 55%, p=0.09) during the index pregnancy.",48220:48486,3616846,23496848,Unavailable
3616846,Receiving fish information from Ob/Gyn,Advice + grocery store gift cards,Control,Significantly decreased,"Intervention women were somewhat less likely to report that their obstetrician had provided them with written information about fish intake during pregnancy (37% vs. 60%, p=0.10) or had discussed fish intake with them (31 vs. 55%, p=0.09) during the index pregnancy. There was no difference in consumption of foods with added DHA (49% intervention, 35% control, p=0.33).",48220:48590,3616846,23496848,Unavailable
3616846,Discussed fish intake with Ob/Gyn,Advice to consume low-mercury/high-DHA fish,Control,Significantly decreased,"Intervention women were somewhat less likely to report that their obstetrician had provided them with written information about fish intake during pregnancy (37% vs. 60%, p=0.10) or had discussed fish intake with them (31 vs. 55%, p=0.09) during the index pregnancy.",48220:48590,3616846,23496848,Unavailable
3616846,Discussed fish intake with Ob/Gyn,Advice + grocery store gift cards,Control,Significantly decreased,"Intervention women were somewhat less likely to report that their obstetrician had provided them with written information about fish intake during pregnancy (37% vs. 60%, p=0.10) or had discussed fish intake with them (31 vs. 55%, p=0.09) during the index pregnancy. There was no difference in consumption of foods with added DHA (49% intervention, 35% control, p=0.33).",48220:48590,3616846,23496848,Unavailable
3616846,Consumption of foods with added DHA,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"There was no difference in consumption of foods with added DHA (49% intervention, 35% control, p=0.33).",48487:48590,3616846,23496848,Unavailable
3616846,Consumption of foods with added DHA,Advice + grocery store gift cards,Control,No significant difference,"There was no difference in consumption of foods with added DHA (49% intervention, 35% control, p=0.33).",50394:50561,3616846,23496848,Unavailable
3616846,Gestational diabetes mellitus,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846,Gestational diabetes mellitus,Advice + grocery store gift cards,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846,Pre-eclampsia,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846,Pre-eclampsia,Advice + grocery store gift cards,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846,Gestational hypertension,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846,Gestational hypertension,Advice + grocery store gift cards,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846, Need for induction of labor,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846, Need for induction of labor,Advice + grocery store gift cards,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846,Cesarean delivery rate,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846,Cesarean delivery rate,Advice + grocery store gift cards,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846,Postpartum depressive symptoms,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846,Postpartum depressive symptoms,Advice + grocery store gift cards,Control,No significant difference,"Among the 48 women from whom we obtained post-delivery information, we observed no differences by intervention arm in rates of gestational diabetes mellitus, pre-eclampsia, gestational hypertension, induction of labor, cesarean delivery, or postpartum depressive symptoms",50105:50376,3616846,23496848,Unavailable
3616846,Rate of preterm delivery ,Advice to consume low-mercury/high-DHA fish,Control,No significant difference,"However, there was a suggestion of a lower rate of preterm delivery (&lt;37 completed weeks gestation) among intervention vs. control women (0/31 vs. 2/17 [12%] p=0.12).",50394:50561,3616846,23496848,Unavailable
3616846,Rate of preterm delivery ,Advice + grocery store gift cards,Control,No significant difference,"However, there was a suggestion of a lower rate of preterm delivery (&lt;37 completed weeks gestation) among intervention vs. control women (0/31 vs. 2/17 [12%] p=0.12).",50394:50561,3616846,23496848,Unavailable
5852732,BMI-for-age z-score,GReat-Child™ Trial,Control,Significantly decreased,"IG showed significantly lower BAZ (weighted difference: −0.12; 95% CI: −0.21, −0.03; p = 0.009), body fat percentage (weighted difference: −2.6%; 95% CI: −3.7, −1.5; p &lt; 0.001) and waist circumference (weighted difference: −2.4 cm; 95% CI: −3.8, −1.0; p = 0.001) compared to CG.",4385:4717,5852732,29385769,Unavailable
5852732,Body fat percentage,GReat-Child™ Trial,Control,Significantly decreased,"IG showed significantly lower BAZ (weighted difference: −0.12; 95% CI: −0.21, −0.03; p = 0.009), body fat percentage (weighted difference: −2.6%; 95% CI: −3.7, −1.5; p &lt; 0.001) and waist circumference (weighted difference: −2.4 cm; 95% CI: −3.8, −1.0; p = 0.001) compared to CG.",4385:4717,5852732,29385769,Unavailable
5852732,Waist circumference,GReat-Child™ Trial,Control,Significantly decreased,"IG showed significantly lower BAZ (weighted difference: −0.12; 95% CI: −0.21, −0.03; p = 0.009), body fat percentage (weighted difference: −2.6%; 95% CI: −3.7, −1.5; p &lt; 0.001) and waist circumference (weighted difference: −2.4 cm; 95% CI: −3.8, −1.0; p = 0.001) compared to CG.",4385:4717,5852732,29385769,Unavailable
5852732,BMI-for-age z-score,GReat-Child™ Trial,Control,Significantly decreased,"Children in the intervention group showed significantly lower BAZ (weighted difference: −0.12; 95% CI: −0.21, −0.03; p = 0.009), body fat percentage (weighted difference: −2.6%; 95% CI: −3.7, −1.5; p &lt; 0.001) and waist circumference (weighted difference: −2.4 cm; 95% CI: −3.8, −1.0; p = 0.001) compared to the control group.",22158:22537,5852732,29385769,Unavailable
5852732,Body fat percentage,GReat-Child™ Trial,Control,Significantly decreased,"Children in the intervention group showed significantly lower BAZ (weighted difference: −0.12; 95% CI: −0.21, −0.03; p = 0.009), body fat percentage (weighted difference: −2.6%; 95% CI: −3.7, −1.5; p &lt; 0.001) and waist circumference (weighted difference: −2.4 cm; 95% CI: −3.8, −1.0; p = 0.001) compared to the control group.",22158:22538,5852732,29385769,Unavailable
5852732,Waist circumference,GReat-Child™ Trial,Control,Significantly decreased,"Children in the intervention group showed significantly lower BAZ (weighted difference: −0.12; 95% CI: −0.21, −0.03; p = 0.009), body fat percentage (weighted difference: −2.6%; 95% CI: −3.7, −1.5; p &lt; 0.001) and waist circumference (weighted difference: −2.4 cm; 95% CI: −3.8, −1.0; p = 0.001) compared to the control group.",22157:22537,5852732,29385769,Unavailable
5852732,Pedometer step-count,GReat-Child™ Trial,Control,No significant difference,"On the other hand, no significant difference in pedometer step-counts was found between the intervention and control groups.",22538:22662,5852732,29385769,Unavailable
3493831,Total dose of rFSH,Letrozole,Control,Significantly decreased,"As compared to control group (1756 ± 75IU), the study group i.e., Let-rFSH received (625 ± 98IU) significantly lower (P = 0.0001) total dose of rFSH.",4547:4714,3493831,23162355,Unavailable
3493831,Terminal E2,Letrozole,Control,Significantly decreased,Terminal E2 was significantly lower (P = 0.0001) in study group than control (830 ± 36 vs. 1076 ± 41 pg/ml),4714:4838,3493831,23162355,Unavailable
3493831,Risk of hyperstimulation,Letrozole,Control,Significantly decreased,The risk of hyperstimulation had significantly (P = 0.01) reduced in study group than control (0 vs. 7).,5032:5153,3493831,23162355,Unavailable
3493831,Pregnancy rate,Letrozole,Control,No significant difference,Treatment outcome in all other aspects including pregnancy rate were statistically comparable.,5153:5248,3493831,23162355,Unavailable
3493831,Miscarriage rate,Letrozole,Control,No significant difference,Treatment outcome in all other aspects including pregnancy rate were statistically comparable.,5153:5248,3493831,23162355,Unavailable
3493831,Multiple pregnancy rate /stimulated cycle,Letrozole,Control,No significant difference,Treatment outcome in all other aspects including pregnancy rate were statistically comparable.,5153:5248,3493831,23162355,Unavailable
3493831,Endometrial thickness ,Letrozole,Control,Significantly increased,"Terminal E2 was significantly lower (P = 0.0001) in study group than control (830 ± 36 vs. 1076 ± 41 pg/ml) with significant increment in endometrial thickness (P = 0.0008) in study group, (9.1 ± 0.32 vs. 8.7 ± 0.69) which maintained an improved pregnancy rate though nonsignificant.",4714:5031,3493831,23162355,Unavailable
3493831,Total dose of rFSH,Letrozole,Control,Significantly decreased,"Compared with the control i.e., continuous rFSH group, the study i.e. Letrozole + rFSH group had an, 64% reduction of (P = 0.0001) total dose of rFSH requirement (Let-rFSH 625 ± 98 IU/cycle versus continuous rFSH 1756 ± 75 IU/cycle",13149:13397,3493831,23162355,Unavailable
3493831,Terminal E2,Letrozole,Control,Significantly decreased,and had significantly (P = 0.0001) decreased levels of terminal E2 (Let-rFSH 830 ± 36 pg/ml versus continuous rFSH 1076 ± 41 pg/ml).,13400:13550,3493831,23162355,Unavailable
3493831,Matured follicles,Letrozole,Control,No significant difference,"However, the two groups did not differ significantly with respect to the numbers of matured follicles (Let-rFSH 6 ± 0.46 versus continuous rFSH 6 ± 0.41), the numbers of retrieved oocytes (Let-rFSH 4.6 ± 2.5 versus continuous rFSH 4.9 ± 2.3) and numbers of transferable embryo (Let-rFSH 3.5 ± 1.6 versus continuous rFSH 3.7 ± 1.7).",13550:13881,3493831,23162355,Unavailable
3493831,Number of retrieved oocytes,Letrozole,Control,No significant difference,"However, the two groups did not differ significantly with respect to the numbers of matured follicles (Let-rFSH 6 ± 0.46 versus continuous rFSH 6 ± 0.41), the numbers of retrieved oocytes (Let-rFSH 4.6 ± 2.5 versus continuous rFSH 4.9 ± 2.3) and numbers of transferable embryo (Let-rFSH 3.5 ± 1.6 versus continuous rFSH 3.7 ± 1.7).",13550:13881,3493831,23162355,Unavailable
3493831,Numbers of transferable embryo,Letrozole,Control,No significant difference,"However, the two groups did not differ significantly with respect to the numbers of matured follicles (Let-rFSH 6 ± 0.46 versus continuous rFSH 6 ± 0.41), the numbers of retrieved oocytes (Let-rFSH 4.6 ± 2.5 versus continuous rFSH 4.9 ± 2.3) and numbers of transferable embryo (Let-rFSH 3.5 ± 1.6 versus continuous rFSH 3.7 ± 1.7).",13550:13881,3493831,23162355,Unavailable
3493831,Endometrial thickness ,Letrozole,Control,Significantly increased,"Endometrial thickness (mm), on day of hCG, was significantly (P = 0.0008) increased in study i.e. Letrozole + rFSH group (Let-rFSH 9.1 ± 0.32 versus continuous rFSH 8.7 ± 0.69) as also the LH level (P = 0.001) on day of initiation of antagonist (Let-rFSH 4.4 ± 2.1 versus continuous rFSH 3 ± 1.9).",13882:14214,3493831,23162355,Unavailable
3493831,LH level ,Letrozole,Control,Significantly increased,"Endometrial thickness (mm), on day of hCG, was significantly (P = 0.0008) increased in study i.e. Letrozole + rFSH group (Let-rFSH 9.1 ± 0.32 versus continuous rFSH 8.7 ± 0.69) as also the LH level (P = 0.001) on day of initiation of antagonist (Let-rFSH 4.4 ± 2.1 versus continuous rFSH 3 ± 1.9).",13882:14214,3493831,23162355,Unavailable
3493831,Pregnancy rate,Letrozole,Control,No significant difference,The pregnancy rate (Let-FSH 36% versus continuous rFSH 33%) though increased in study group but remain statistically indifferent than control.,14271:14413,3493831,23162355,Unavailable
3493831,Miscarriage rate,Letrozole,Control,No significant difference,Similarly miscarriage rate (Let-FSH 19% versus continuous rFSH 25%) and multiple pregnancy rate /stimulated cycle (Let-FSH 7% versus continuous rFSH 17%) though decreased but remained statistically indifferent.,14414:14624,3493831,23162355,Unavailable
3493831,Multiple pregnancy rate /stimulated cycle,Letrozole,Control,No significant difference,Similarly miscarriage rate (Let-FSH 19% versus continuous rFSH 25%) and multiple pregnancy rate /stimulated cycle (Let-FSH 7% versus continuous rFSH 17%) though decreased but remained statistically indifferent.,14414:14625,3493831,23162355,Unavailable
3493831,Risk of hyperstimulation,Letrozole,Control,Significantly decreased,"The study group i.e., Let - rFSH had significantly (P = 0.01) reduced the risk of incidence of hyperstimulation compared with the control group (Let-FSH nil versus continuous rFSH 7 ).",14625:14827,3493831,23162355,Unavailable
3493831,Cost per cycle ,Letrozole,Control,Significantly decreased,Average cost per cycle was reduced by 34% in Let-FSH group in comparison to continuous rFSH group,14827:14924,3493831,23162355,Unavailable
3493831,Cost per cycle ,Letrozole,Control,Significantly decreased,[Average cost per cycle was reduced by 34% in Let-FSH group in comparison to continuous rFSH group (Let-FSH group Rs 48173/- versus continuous rFSH group Rs 73411/-)].,15783:15950,3493831,23162355,Unavailable
5496184,Choosing the preferred recommendation (round 2),Protein-based assay,Control,Significantly increased,"Using multinomial logistical regression, urologists who were given the assay results&nbsp;were significantly more likely to choose the preferred recommendation (active surveillance or active treatment) compared to controls (p&nbsp;=&nbsp;0.004).",6681:6836,5496184,28673277,Unavailable
5496184,Involving patients in treatment decision,Protein-based assay,Control,Significantly increased,These urologists were also&nbsp;significantly more likely to involve their patients in the treatment decision compared to controls (p&nbsp;=&nbsp;0.001).,6681:6836,5496184,28673277,Unavailable
5496184,Choosing the preferred recommendation (round 2),Protein-based assay,Control,Significantly increased,"urologists in the intervention group were significantly more likely to recommend the preferred treatment (AS or AT) in Round 2, with an odds ratio of 2.84 (95% CI 1.39, 5.82) (p&nbsp;=&nbsp;0.004).",31845:32049,5496184,28673277,Unavailable
5496184,Increase in correct treatment  (round 1),Protein-based assay,Control,Significantly increased,Intervention urologists saw a 6.9% greater increase in correct treatment than the controls (p&nbsp;=&nbsp;0.001) over the two rounds of data collection.,30184:30344,5496184,28673277,Unavailable
5496184,Increase in correct treatment  (round 2),Protein-based assay,Control,Significantly increased,Intervention urologists saw a 6.9% greater increase in correct treatment than the controls (p&nbsp;=&nbsp;0.001) over the two rounds of data collection.,30184:30344,5496184,28673277,Unavailable
5496184,Suboptimal treatment choice,Protein-based assay,Control,Significantly decreased,"Similarly, suboptimal treatment choice declined by 10.8% in the intervention group, compared to the controls (p&nbsp;=&nbsp;0.028).",30344:30483,5496184,28673277,Unavailable
5496184,Involving patients in treatment decision,Protein-based assay,Control,Significantly increased,"The same model found that the introduction of a protein-based assay prompted urologists to involve their patients in treatment discussions more often than controls (OR 2.72; 95%CI 1.47, 5.05) (p&nbsp;=&nbsp;0.001).",34984:35205,5496184,28673277,Unavailable
4753024,Average rectal temperature,Paracetamol,Diclofenac,No significant difference,"The average rectal temperature in the Paracetamol group was 39.6 ± 1.13°C, and 39.82 ± 1.07°C in the Diclofenac group (P = 0.37).",5196:5326,4753024,26889398,Unavailable
4753024,Average rectal temperature after 1h,Paracetamol,Diclofenac,No significant difference,"The average rectal temperature, one hour after the intervention, in the Paracetamol and the Diclofenac group was 38.39 ± 0.89°C and 38.95 ± 1.09°C, respectively (P = 0.02).",5326:5498,4753024,26889398,Unavailable
4753024,Average temperature changes,Paracetamol,Diclofenac,Significantly increased,Average temperature changes were 0.65 ± 0.17°C in the Paracetamol group and 1.73 ± 0.69°C in the Diclofenac group (P &lt; 0.001).,5499:5625,4753024,26889398,Unavailable
4753024,Average rectal temperature,Paracetamol,Diclofenac,No significant difference,"Despite the significant decrease in the measured temperatures, there were no significant differences between the two groups (P = 0.47)",25093:25228,4753024,26889398,Unavailable
4753024,Average temperature changes,Paracetamol,Diclofenac,Significantly increased,"Temperature Reduction			&lt; 0.001",26365:26584,4753024,26889398,Unavailable
4753024,Fever after treatmen,Paracetamol,Diclofenac,No significant difference,"Fever after treatmenta			0.1",28626:28912,4753024,26889398,Unavailable
4132277,Overall stone free rate, Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,No significant difference,Overall stone free rate for both groups was 95.8%.,4978:5104,4132277,25107528,Unavailable
4132277,Success of initial treatment , Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,Significantly increased,"The initial treatment was more successful in patients with distal ureteral calculi (100% vs. 82.40%, respectively, P = 0.008).",4978:5104,4132277,25107528,Unavailable
4132277,Overall stone free rate, Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,No significant difference,The overall stone free rate for both groups was 95.8%.,21714:21769,4132277,25107528,Unavailable
4132277,Number of all laser procedures, Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,Significantly decreased,"The mean number of all laser procedures was 1.07 ± 0.003, in the proximal ureter 1.1 ± 0.1 and in the distal ureter 1.0 ± 0.0 (P = 0.027).",21505:NaN,4132277,25107528,Unavailable
4132277,Success of initial treatment , Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,Significantly increased,"More successful initial treatments were done in the distal ureteral versus proximal calculi (100% vs. 82.40%, respectively).",21908:22032,4132277,25107528,Unavailable
4132277,Operation time, Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,Significantly decreased,"Operation time (min)*81,3 + 4,565.7 ± 3.80.017",19238:19425,4132277,25107528,Unavailable
4132277,Laser time , Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,Significantly decreased,Laser time (sec)*379.8 + 50.8154.3 ± 38.10.009,19481:19668,4132277,25107528,Unavailable
4132277,Total energy, Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,Significantly decreased,"Total energy (J)*2528,8 ± 422.61148.5 ± 400.70.002",19724:19915,4132277,25107528,Unavailable
4132277,Number of patients with postoperative stent, Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,No significant difference,Number of patients with postoperative stent (%)50 (87.7)31 (83.8)0.596,19971:20182,4132277,25107528,Unavailable
4132277,No of intra operative complications, Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,No significant difference,No of intra operative complications (%)1 (1.8)2 (5.4)0.334,20238:20437,4132277,25107528,Unavailable
4132277,No of early post-operative complications, Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,No significant difference,No of early post-operative complications (%)1 (1.8)3 (8.1)0.141,20493:20697,4132277,25107528,Unavailable
4132277,Overall stone free rate, Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,No significant difference,Overall SFR per patient48 (94.1)37 (100)0.139,20753:20939,4132277,25107528,Unavailable
4132277,Success of initial treatment , Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,Significantly increased,SFR after first treatment per patient (%)42 (82.4)37 (100)0.008,20995:21199,4132277,25107528,Unavailable
4132277,Number of all laser procedures, Ho:YAG laser in distal stones, Ho:YAG laser in proximal stones,Significantly decreased,No of laser procedures* 1.1 ± 0.1 1.0 ± 0.0 0.027,21505:NaN,4132277,25107528,Unavailable
3675645,Dentine hypersensitivity after procedure ,NovaMin® and NaF,Control,Significantly decreased,"Subjects having received the test prophylaxis pastes showed statistically lower (anova, p &lt; 0.05) dentine hypersensitivity compared with the control group immediately after the prophylaxis procedure (Yeaple Probe®: Test-A = 20.9 ± 12.6, Test-B = 22.7 ± 12.9, Control=11.2 ± 3.1; Schiff score: Test-A = 1.1 ± 0.6, Test-B = 1.1 ± 0.6, Control = 2.0 ± 0.7)",5614:5993,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after procedure ,NovaMin® ,Control,Significantly decreased,"Subjects having received the test prophylaxis pastes showed statistically lower (anova, p &lt; 0.05) dentine hypersensitivity compared with the control group immediately after the prophylaxis procedure (Yeaple Probe®: Test-A = 20.9 ± 12.6, Test-B = 22.7 ± 12.9, Control=11.2 ± 3.1; Schiff score: Test-A = 1.1 ± 0.6, Test-B = 1.1 ± 0.6, Control = 2.0 ± 0.7)",5614:5993,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after 28 days,NovaMin® and NaF,Control,Significantly decreased,"and after 28 days (Yeaple probe: Test-A = 21.5 ± 11.9, Test-B = 20.6 ± 11.3, Control = 11.8 ± 6.0; Schiff score: Test-A = 1.0 ± 0.6, Test-B = 1.0 ± 0.6, Control = 2.0 ± 0.7).",5994:6168,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after 28 days,NovaMin® ,Control,Significantly decreased,"and after 28 days (Yeaple probe: Test-A = 21.5 ± 11.9, Test-B = 20.6 ± 11.3, Control = 11.8 ± 6.0; Schiff score: Test-A = 1.0 ± 0.6, Test-B = 1.0 ± 0.6, Control = 2.0 ± 0.7).",5993:6168,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after procedure ,NovaMin® and NaF,Control,Significantly decreased,"Immediately following the scaling/root planing and prophylaxis procedure, the mean values resulted in statistically significant (p &lt; 0.0001) improvements for both test groups compared with the control.",23839:24059,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after procedure ,NovaMin® ,Control,Significantly decreased,"Immediately following the scaling/root planing and prophylaxis procedure, the mean values resulted in statistically significant (p &lt; 0.0001) improvements for both test groups compared with the control.",23839:24058,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after procedure ,NovaMin® and NaF,NovaMin®,No significant difference,There was no statistical difference between the test groups.,24058:24119,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after procedure ,NovaMin® and NaF,Control,Significantly decreased,"Test-A	49	20.87	12.64	15.00	10.0	55.0	49	10.46	12.58	5.00	0.0	45.0	&lt;0.0001	–	n.s.	&lt;.0001",28730:29541,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after procedure ,NovaMin® ,Control,Significantly decreased,"Test-B	52	22.74	12.99	20.00	10.0	55.0	52	12.36	12.91	10.00	−5.0	45.0	&lt;0.0001	n.s.	–	&lt;.0001",29599:30412,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after procedure ,NovaMin® and NaF,NovaMin®,No significant difference,"Test-A	49	20.87	12.64	15.00	10.0	55.0	49	10.46	12.58	5.00	0.0	45.0	&lt;0.0001	–	n.s.",28730:29489,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after 28 days,NovaMin® and NaF,Control,Significantly decreased,The Day 28 Yeaple Probe® exams resulted in statistically significant (p &lt; 0.0001) mean value differences for the test groups (21.48 and 20.58 grams) compared to the control (11.77 grams).,34287:34492,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after 28 days,NovaMin® ,Control,Significantly decreased,The Day 28 Yeaple Probe® exams resulted in statistically significant (p &lt; 0.0001) mean value differences for the test groups (21.48 and 20.58 grams) compared to the control (11.77 grams).,34287:34492,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after 28 days,NovaMin® and NaF,Control,Significantly decreased,"Test-A	49	21.48	11.86	20.00	10.0	55.0	49	11.07	11.90	10.00	0.0	45.0	&lt;0.0001	–	n.s.	&lt;.0001",31390:32202,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after 28 days,NovaMin® ,Control,Significantly decreased,"Test-B	52	20.58	11.32	17.50	10.0	55.0	52	10.19	11.37	5.00	−5.0	45.0	&lt;0.0001	n.s.	–	&lt;.0001",32260:33072,3675645,23414245,Unavailable
3675645,Dentine hypersensitivity after 28 days,NovaMin® and NaF,NovaMin®,No significant difference,"Test-A	49	21.48	11.86	20.00	10.0	55.0	49	11.07	11.90	10.00	0.0	45.0	&lt;0.0001	–	n.s",31390:32149,3675645,23414245,Unavailable
3675645,Air blast sensitivity after procedure ,NovaMin® and NaF,Control,Significantly decreased,"Immediately following the scaling/root planing and prophylaxis procedure, the Schiff scale sensitivity values for the test groups were statistically significantly (p &lt; 0.0001) less sensitive than the control",46040:46264,3675645,23414245,Unavailable
3675645,Air blast sensitivity after procedure ,NovaMin® ,Control,Significantly decreased,"Immediately following the scaling/root planing and prophylaxis procedure, the Schiff scale sensitivity values for the test groups were statistically significantly (p &lt; 0.0001) less sensitive than the control",46039:46264,3675645,23414245,Unavailable
3675645,Air blast sensitivity after procedure ,NovaMin® and NaF,NovaMin® ,No significant difference,The mean relative improvement from baseline immediately after the prophylaxis procedure was 44.6% for both Test-A and Test-B,46321:46445,3675645,23414245,Unavailable
3675645,Air blast sensitivity after 28 days,NovaMin® and NaF,Control,Significantly decreased,The Day 28 assessments resulted in statistically significant (p &lt; 0.0001) lower values for the test groups (0.98 and 0.99) compared to the control (2.03).,46321:46445,3675645,23414245,Unavailable
3675645,Air blast sensitivity after 28 days,NovaMin® ,Control,Significantly decreased,The Day 28 assessments resulted in statistically significant (p &lt; 0.0001) lower values for the test groups (0.98 and 0.99) compared to the control (2.03).,46321:46445,3675645,23414245,Unavailable
3675645,Air blast sensitivity after 28 days,NovaMin® and NaF,NovaMin®,No significant difference,The mean relative improvement from baseline 28 days after the prophylaxis procedure was 49.2% for Test-A and 48.7% for Test-B.,56937:57063,3675645,23414245,Unavailable
3675645,Air blast sensitivity after procedure ,NovaMin® and NaF,Control,Significantly decreased,"Test-A	49	1.07	0.64	1.00	0.0	3.0	49	−0.86	0.62	−1.00	−2.5	0.5	&lt;0.0001	–	n.s.	&lt;0.0001",50910:51717,3675645,23414245,Unavailable
3675645,Air blast sensitivity after procedure ,NovaMin® ,Control,Significantly decreased,"Test-B	52	1.07	0.62	1.00	0.0	2.5	52	−0.87	0.71	−1.00	−2.5	0.0	&lt;0.0001	n.s.	–	&lt;0.0001",51775:52582,3675645,23414245,Unavailable
3675645,Air blast sensitivity after procedure ,NovaMin® and NaF,NovaMin® ,No significant difference,"Test-A	49	1.07	0.64	1.00	0.0	3.0	49	−0.86	0.62	−1.00	−2.5	0.5	&lt;0.0001	–	n.s.",50910:51664,3675645,23414245,Unavailable
3675645,Air blast sensitivity after 28 days,NovaMin® and NaF,Control,Significantly decreased,"Test-A	49	0.98	0.62	1.00	0.0	3.0	49	−0.95	0.66	−1.00	−2.5	0.5	&lt;0.0001	–	n.s.	&lt;0.0001",53556:54363,3675645,23414245,Unavailable
3675645,Air blast sensitivity after 28 days,NovaMin® ,Control,Significantly decreased,"Test-B	52	0.99	0.55	1.00	0.0	2.5	52	−0.94	0.68	−1.00	−2.5	0.5	&lt;0.0001	n.s.	–	&lt;0.0001",54421:55228,3675645,23414245,Unavailable
3675645,Air blast sensitivity after 28 days,NovaMin® and NaF,NovaMin®,No significant difference,"Test-A	49	0.98	0.62	1.00	0.0	3.0	49	−0.95	0.66	−1.00	−2.5	0.5	&lt;0.0001	–	n.s",53556:54309,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after procedure ,NovaMin® and NaF,Control,No significant difference,"Immediately following the scaling and root planing procedures and following the prophylaxis procedure, all three groups showed an increase in sensitivity awareness. The statistical comparison demonstrated that none of the treatment groups were different from one another.",76059:76330,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after procedure ,NovaMin® ,Control,No significant difference,"Immediately following the scaling and root planing procedures and following the prophylaxis procedure, all three groups showed an increase in sensitivity awareness. The statistical comparison demonstrated that none of the treatment groups were different from one another.",76059:76330,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after procedure ,NovaMin® and NaF,NovaMin® ,No significant difference,"Immediately following the scaling and root planing procedures and following the prophylaxis procedure, all three groups showed an increase in sensitivity awareness. The statistical comparison demonstrated that none of the treatment groups were different from one another.",76059:76330,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after 28 days,NovaMin® and NaF,Control,Significantly decreased,The statistical analysis resulted in statistically significant reductions for both test groups compared to the control.,76852:76973,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after 28 days,NovaMin® ,Control,Significantly decreased,The statistical analysis resulted in statistically significant reductions for both test groups compared to the control.,76852:76973,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after procedure ,NovaMin® and NaF,Control,No significant difference,"Test-A	49	1.14	0.76	1	0	3	49	0.24	0.90	0	−2	3	n.s.	–	n.s.	n.s.",70669:71451,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after procedure ,NovaMin® ,Control,No significant difference,"Test-B	52	0.96	0.74	1	0	2	52	0.29	0.78	0	−2	2	0.0203	n.s.	–	n.s.",71506:72290,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after procedure ,NovaMin® and NaF,NovaMin® ,No significant difference,"Test-A	49	1.14	0.76	1	0	3	49	0.24	0.90	0	−2	3	n.s.	–	n.s.",70669:71401,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after 28 days,NovaMin® and NaF,Control,Significantly decreased,"Test-A	49	0.47	0.62	0	0	3	49	−0.43	0.82	0	−3	1	0.0006	–	n.s.	0.0010",73237:74024,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after 28 days,NovaMin® ,Control,Significantly decreased,"Test-B	52	0.52	0.64	0	0	2	52	−0.15	0.80	0	−2	2	n.s.	n.s.	–	0.0236",74079:74864,3675645,23414245,Unavailable
3675645,Self-assessed sensitivity after 28 days,NovaMin® and NaF,NovaMin®,No significant difference,est-A 49 0.47 0.62 0 0 3 49 −0.43 0.82 0 −3 1 0.0006 – n.s.,73238:73972,3675645,23414245,Unavailable
4706860,Peak torque (concentric),Kinesio Taping ,Placebo taping,No significant difference,"Testing concentric contractions at 60°/s or 180°/s isokinetic speed, no significant differences in peak torque (Nm), total work (J), or mean power (W) were noted among the application modes under different conditions.",4696:4913,4706860,26819953,Unavailable
4706860,Peak torque (concentric),Kinesio Taping ,No taping,No significant difference,"Testing concentric contractions at 60°/s or 180°/s isokinetic speed, no significant differences in peak torque (Nm), total work (J), or mean power (W) were noted among the application modes under different conditions.",4696:4913,4706860,26819953,Unavailable
4706860,Peak torque (concentric),Placebo taping,No taping,No significant difference,"Testing concentric contractions at 60°/s or 180°/s isokinetic speed, no significant differences in peak torque (Nm), total work (J), or mean power (W) were noted among the application modes under different conditions.",4696:4913,4706860,26819953,Unavailable
4706860,Total work (concentric),Kinesio Taping ,Placebo taping,No significant difference,"Testing concentric contractions at 60°/s or 180°/s isokinetic speed, no significant differences in peak torque (Nm), total work (J), or mean power (W) were noted among the application modes under different conditions.",4696:4913,4706860,26819953,Unavailable
4706860,Total work (concentric),Kinesio Taping ,No taping,No significant difference,"Testing concentric contractions at 60°/s or 180°/s isokinetic speed, no significant differences in peak torque (Nm), total work (J), or mean power (W) were noted among the application modes under different conditions.",4696:4913,4706860,26819953,Unavailable
4706860,Total work (concentric),Placebo taping,No taping,No significant difference,"Testing concentric contractions at 60°/s or 180°/s isokinetic speed, no significant differences in peak torque (Nm), total work (J), or mean power (W) were noted among the application modes under different conditions.",4696:4913,4706860,26819953,Unavailable
4706860,Mean power (concentric),Kinesio Taping ,Placebo taping,No significant difference,"Testing concentric contractions at 60°/s or 180°/s isokinetic speed, no significant differences in peak torque (Nm), total work (J), or mean power (W) were noted among the application modes under different conditions.",4696:4913,4706860,26819953,Unavailable
4706860,Mean power (concentric),Kinesio Taping ,No taping,No significant difference,"Testing concentric contractions at 60°/s or 180°/s isokinetic speed, no significant differences in peak torque (Nm), total work (J), or mean power (W) were noted among the application modes under different conditions.",4914:5058,4706860,26819953,Unavailable
4706860,Mean power (concentric),Placebo taping,No taping,No significant difference,"Testing concentric contractions at 60°/s or 180°/s isokinetic speed, no significant differences in peak torque (Nm), total work (J), or mean power (W) were noted among the application modes under different conditions.",4696:4913,4706860,26819953,Unavailable
4706860,Peak torque (eccentric),Kinesio Taping ,Placebo taping,No significant difference,"Testing eccentric contractions at 30°/s or 60°/s isokinetic speed, no significant differences in mentioned parameters were noted, respectively.",4914:5057,4706860,26819953,Unavailable
4706860,Peak torque (eccentric),Kinesio Taping ,No taping,No significant difference,"Testing eccentric contractions at 30°/s or 60°/s isokinetic speed, no significant differences in mentioned parameters were noted, respectively.",4914:5057,4706860,26819953,Unavailable
4706860,Peak torque (eccentric),Placebo taping,No taping,No significant difference,"Testing eccentric contractions at 30°/s or 60°/s isokinetic speed, no significant differences in mentioned parameters were noted, respectively.",4914:5058,4706860,26819953,Unavailable
4706860,Total work (eccentric),Kinesio Taping ,Placebo taping,No significant difference,"Testing eccentric contractions at 30°/s or 60°/s isokinetic speed, no significant differences in mentioned parameters were noted, respectively.",4914:5058,4706860,26819953,Unavailable
4706860,Total work (eccentric),Kinesio Taping ,No taping,No significant difference,"Testing eccentric contractions at 30°/s or 60°/s isokinetic speed, no significant differences in mentioned parameters were noted, respectively.",4914:5058,4706860,26819953,Unavailable
4706860,Total work (eccentric),Placebo taping,No taping,No significant difference,"Testing eccentric contractions at 30°/s or 60°/s isokinetic speed, no significant differences in mentioned parameters were noted, respectively.",4914:5058,4706860,26819953,Unavailable
4706860,Mean power (eccentric),Kinesio Taping ,Placebo taping,No significant difference,"Testing eccentric contractions at 30°/s or 60°/s isokinetic speed, no significant differences in mentioned parameters were noted, respectively.",4914:5058,4706860,26819953,Unavailable
4706860,Mean power (eccentric),Kinesio Taping ,No taping,No significant difference,"Testing eccentric contractions at 30°/s or 60°/s isokinetic speed, no significant differences in mentioned parameters were noted, respectively.",4914:5058,4706860,26819953,Unavailable
4706860,Mean power (eccentric),Placebo taping,No taping,No significant difference,"Testing eccentric contractions at 30°/s or 60°/s isokinetic speed, no significant differences in mentioned parameters were noted, respectively.",4914:5058,4706860,26819953,Unavailable
4706860,Peak torque (concentric),Kinesio Taping ,Placebo taping,No significant difference,"One-way analysis of variance did not reveal any significant effects of KT or PT for concentric contractions at 60°/s or 180°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.353, p = 0.705; F(2,17) = 0.027, p = 0.973), total work (F(2,17) = 0.443, p = 0.646; F(2,17) = 0.114, p = 0.893), or average power (F(2,17) = 0.560, p = 0.576; F(2,17) = 0.105, p = 0.901)",13969:14547,4706860,26819953,Unavailable
4706860,Peak torque (concentric),Kinesio Taping ,No taping,No significant difference,"One-way analysis of variance did not reveal any significant effects of KT or PT for concentric contractions at 60°/s or 180°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.353, p = 0.705; F(2,17) = 0.027, p = 0.973), total work (F(2,17) = 0.443, p = 0.646; F(2,17) = 0.114, p = 0.893), or average power (F(2,17) = 0.560, p = 0.576; F(2,17) = 0.105, p = 0.901)",13969:14547,4706860,26819953,Unavailable
4706860,Peak torque (concentric),Placebo taping,No taping,No significant difference,"One-way analysis of variance did not reveal any significant effects of KT or PT for concentric contractions at 60°/s or 180°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.353, p = 0.705; F(2,17) = 0.027, p = 0.973), total work (F(2,17) = 0.443, p = 0.646; F(2,17) = 0.114, p = 0.893), or average power (F(2,17) = 0.560, p = 0.576; F(2,17) = 0.105, p = 0.901)",13969:14548,4706860,26819953,Unavailable
4706860,Total work (concentric),Kinesio Taping ,Placebo taping,No significant difference,"One-way analysis of variance did not reveal any significant effects of KT or PT for concentric contractions at 60°/s or 180°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.353, p = 0.705; F(2,17) = 0.027, p = 0.973), total work (F(2,17) = 0.443, p = 0.646; F(2,17) = 0.114, p = 0.893), or average power (F(2,17) = 0.560, p = 0.576; F(2,17) = 0.105, p = 0.901)",13969:14548,4706860,26819953,Unavailable
4706860,Total work (concentric),Kinesio Taping ,No taping,No significant difference,"One-way analysis of variance did not reveal any significant effects of KT or PT for concentric contractions at 60°/s or 180°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.353, p = 0.705; F(2,17) = 0.027, p = 0.973), total work (F(2,17) = 0.443, p = 0.646; F(2,17) = 0.114, p = 0.893), or average power (F(2,17) = 0.560, p = 0.576; F(2,17) = 0.105, p = 0.901)",13969:14548,4706860,26819953,Unavailable
4706860,Total work (concentric),Placebo taping,No taping,No significant difference,"One-way analysis of variance did not reveal any significant effects of KT or PT for concentric contractions at 60°/s or 180°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.353, p = 0.705; F(2,17) = 0.027, p = 0.973), total work (F(2,17) = 0.443, p = 0.646; F(2,17) = 0.114, p = 0.893), or average power (F(2,17) = 0.560, p = 0.576; F(2,17) = 0.105, p = 0.901)",13969:14548,4706860,26819953,Unavailable
4706860,Mean power (concentric),Kinesio Taping ,Placebo taping,No significant difference,"One-way analysis of variance did not reveal any significant effects of KT or PT for concentric contractions at 60°/s or 180°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.353, p = 0.705; F(2,17) = 0.027, p = 0.973), total work (F(2,17) = 0.443, p = 0.646; F(2,17) = 0.114, p = 0.893), or average power (F(2,17) = 0.560, p = 0.576; F(2,17) = 0.105, p = 0.901)",13969:14548,4706860,26819953,Unavailable
4706860,Mean power (concentric),Kinesio Taping ,No taping,No significant difference,"One-way analysis of variance did not reveal any significant effects of KT or PT for concentric contractions at 60°/s or 180°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.353, p = 0.705; F(2,17) = 0.027, p = 0.973), total work (F(2,17) = 0.443, p = 0.646; F(2,17) = 0.114, p = 0.893), or average power (F(2,17) = 0.560, p = 0.576; F(2,17) = 0.105, p = 0.901)",13969:14547,4706860,26819953,Unavailable
4706860,Mean power (concentric),Placebo taping,No taping,No significant difference,"One-way analysis of variance did not reveal any significant effects of KT or PT for concentric contractions at 60°/s or 180°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.353, p = 0.705; F(2,17) = 0.027, p = 0.973), total work (F(2,17) = 0.443, p = 0.646; F(2,17) = 0.114, p = 0.893), or average power (F(2,17) = 0.560, p = 0.576; F(2,17) = 0.105, p = 0.901)",13969:14548,4706860,26819953,Unavailable
4706860,Peak torque (eccentric),Kinesio Taping ,Placebo taping,No significant difference,"Similarly, no real difference was noted between the tested conditions for eccentric contractions at 30°/s or 60°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.207, p = 0.814; F(2,17) = 0.139, p = 0.871), total work (F(2,17) = 0.459, p = 0.636; F(2,17) = 0.639, p = 0.534), and average power (F(2,17) = 0.166, p = 0.848; F(2,17) = 0.147, p = 0.864).",14599:15167,4706860,26819953,Unavailable
4706860,Peak torque (eccentric),Kinesio Taping ,No taping,No significant difference,"Similarly, no real difference was noted between the tested conditions for eccentric contractions at 30°/s or 60°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.207, p = 0.814; F(2,17) = 0.139, p = 0.871), total work (F(2,17) = 0.459, p = 0.636; F(2,17) = 0.639, p = 0.534), and average power (F(2,17) = 0.166, p = 0.848; F(2,17) = 0.147, p = 0.864).",14599:15167,4706860,26819953,Unavailable
4706860,Peak torque (eccentric),Placebo taping,No taping,No significant difference,"Similarly, no real difference was noted between the tested conditions for eccentric contractions at 30°/s or 60°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.207, p = 0.814; F(2,17) = 0.139, p = 0.871), total work (F(2,17) = 0.459, p = 0.636; F(2,17) = 0.639, p = 0.534), and average power (F(2,17) = 0.166, p = 0.848; F(2,17) = 0.147, p = 0.864).",14599:15167,4706860,26819953,Unavailable
4706860,Total work (eccentric),Kinesio Taping ,Placebo taping,No significant difference,"Similarly, no real difference was noted between the tested conditions for eccentric contractions at 30°/s or 60°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.207, p = 0.814; F(2,17) = 0.139, p = 0.871), total work (F(2,17) = 0.459, p = 0.636; F(2,17) = 0.639, p = 0.534), and average power (F(2,17) = 0.166, p = 0.848; F(2,17) = 0.147, p = 0.864).",14599:15167,4706860,26819953,Unavailable
4706860,Total work (eccentric),Kinesio Taping ,No taping,No significant difference,"Similarly, no real difference was noted between the tested conditions for eccentric contractions at 30°/s or 60°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.207, p = 0.814; F(2,17) = 0.139, p = 0.871), total work (F(2,17) = 0.459, p = 0.636; F(2,17) = 0.639, p = 0.534), and average power (F(2,17) = 0.166, p = 0.848; F(2,17) = 0.147, p = 0.864).",14599:15167,4706860,26819953,Unavailable
4706860,Total work (eccentric),Placebo taping,No taping,No significant difference,"Similarly, no real difference was noted between the tested conditions for eccentric contractions at 30°/s or 60°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.207, p = 0.814; F(2,17) = 0.139, p = 0.871), total work (F(2,17) = 0.459, p = 0.636; F(2,17) = 0.639, p = 0.534), and average power (F(2,17) = 0.166, p = 0.848; F(2,17) = 0.147, p = 0.864).",14599:15167,4706860,26819953,Unavailable
4706860,Mean power (eccentric),Kinesio Taping ,Placebo taping,No significant difference,"Similarly, no real difference was noted between the tested conditions for eccentric contractions at 30°/s or 60°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.207, p = 0.814; F(2,17) = 0.139, p = 0.871), total work (F(2,17) = 0.459, p = 0.636; F(2,17) = 0.639, p = 0.534), and average power (F(2,17) = 0.166, p = 0.848; F(2,17) = 0.147, p = 0.864).",14599:15167,4706860,26819953,Unavailable
4706860,Mean power (eccentric),Kinesio Taping ,No taping,No significant difference,"Similarly, no real difference was noted between the tested conditions for eccentric contractions at 30°/s or 60°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.207, p = 0.814; F(2,17) = 0.139, p = 0.871), total work (F(2,17) = 0.459, p = 0.636; F(2,17) = 0.639, p = 0.534), and average power (F(2,17) = 0.166, p = 0.848; F(2,17) = 0.147, p = 0.864).",14599:15167,4706860,26819953,Unavailable
4706860,Mean power (eccentric),Placebo taping,No taping,No significant difference,"Similarly, no real difference was noted between the tested conditions for eccentric contractions at 30°/s or 60°/s isokinetic speed on the quadriceps peak torque (F(2,17) = 0.207, p = 0.814; F(2,17) = 0.139, p = 0.871), total work (F(2,17) = 0.459, p = 0.636; F(2,17) = 0.639, p = 0.534), and average power (F(2,17) = 0.166, p = 0.848; F(2,17) = 0.147, p = 0.864).",14599:15167,4706860,26819953,Unavailable
3621765,Mini-Mental State Examination score (amnestic patients),Multicomponent exercise program,Control,Significantly increased,"the exercise group exhibited significantly better Mini-Mental State Examination (p = .04) and logical memory scores (p = .04), and reducing whole brain cortical atrophy (p&lt;.05) compared to the control group.",8368:8628,3621765,23585901,Unavailable
3621765,Logical memory score I (amnestic patients),Multicomponent exercise program,Control,Significantly increased,"the exercise group exhibited significantly better Mini-Mental State Examination (p = .04) and logical memory scores (p = .04), and reducing whole brain cortical atrophy (p&lt;.05) compared to the control group.",54111:54346,3621765,23585901,Unavailable
3621765,Whole brain cortical atrophy (amnestic patients),Multicomponent exercise program,Control,Significantly decreased,"the exercise group exhibited significantly better Mini-Mental State Examination (p = .04) and logical memory scores (p = .04), and reducing whole brain cortical atrophy (p&lt;.05) compared to the control group.",8368:8628,3621765,23585901,Unavailable
3621765,Mini-Mental State Examination score (amnestic patients),Multicomponent exercise program,Control,Significantly increased,"When the analyses were limited to subjects with aMCI, the repeated-measures ANOVA for MMSE showed a significant effect of group (p = .03) and there was a group × time interaction in MMSE (p = .04) indicating benefit of the exercise over time.",53372:53648,3621765,23585901,Unavailable
3621765,Logical memory score I (amnestic patients),Multicomponent exercise program,Control,Significantly increased,A repeated-measures ANOVA showed a significant effect of time (p&lt;.01) and group × time interaction (p = .04) in WMS-LM I.,54111:54346,3621765,23585901,Unavailable
3621765,Whole brain cortical atrophy (amnestic patients),Multicomponent exercise program,Control,Significantly decreased,The repeated-measures ANOVA revealed that there was a significant group × time interaction on WBC atrophy level (p&lt;.05) in older adults with aMCI.,55683:55846,3621765,23585901,Unavailable
3621765,WMS-LM II (amnestic patients),Multicomponent exercise program,Control,No significant difference,"The repeated-measures ANOVA for WMS-LM II (p&lt;.01) and MTA-ERC atrophy (p = .03) showed a significant effect of time. However, there were no main effects of group and no group × time interactions.",54111:54346,3621765,23585901,Unavailable
3621765,MTA-ERC atrophy (amnestic patients),Multicomponent exercise program,Control,No significant difference,"The repeated-measures ANOVA for WMS-LM II (p&lt;.01) and MTA-ERC atrophy (p = .03) showed a significant effect of time. However, there were no main effects of group and no group × time interactions.",54111:54346,3621765,23585901,Unavailable
3621765,Mini-Mental State Examination score (overall),Multicomponent exercise program,Control,No significant difference,"There were main effects of time in ADAS-cog (p = .01), WMS-LM I (p&lt;.01), WMS-LM II (p&lt;.01), and WBC atrophy level (p = .03), although no main effects of group and group × time interactions were detected on the cognitive tests and brain atrophy",45297:45615,3621765,23585901,Unavailable
3621765,Alzheimer's Disease Assessment Scale-cognitive subscale (overall),Multicomponent exercise program,Control,No significant difference,"There were main effects of time in ADAS-cog (p = .01), WMS-LM I (p&lt;.01), WMS-LM II (p&lt;.01), and WBC atrophy level (p = .03), although no main effects of group and group × time interactions were detected on the cognitive tests and brain atrophy",45297:45615,3621765,23585901,Unavailable
3621765,Logical memory score I (overall),Multicomponent exercise program,Control,No significant difference,"There were main effects of time in ADAS-cog (p = .01), WMS-LM I (p&lt;.01), WMS-LM II (p&lt;.01), and WBC atrophy level (p = .03), although no main effects of group and group × time interactions were detected on the cognitive tests and brain atrophy",45297:45615,3621765,23585901,Unavailable
3621765,WMS-LM II (overall),Multicomponent exercise program,Control,No significant difference,"There were main effects of time in ADAS-cog (p = .01), WMS-LM I (p&lt;.01), WMS-LM II (p&lt;.01), and WBC atrophy level (p = .03), although no main effects of group and group × time interactions were detected on the cognitive tests and brain atrophy",45297:45615,3621765,23585901,Unavailable
3621765,MTA-ERC atrophy (overall),Multicomponent exercise program,Control,No significant difference,"There were main effects of time in ADAS-cog (p = .01), WMS-LM I (p&lt;.01), WMS-LM II (p&lt;.01), and WBC atrophy level (p = .03), although no main effects of group and group × time interactions were detected on the cognitive tests and brain atrophy",45297:45615,3621765,23585901,Unavailable
3621765,Whole brain cortical atrophy (overall),Multicomponent exercise program,Control,No significant difference,"There were main effects of time in ADAS-cog (p = .01), WMS-LM I (p&lt;.01), WMS-LM II (p&lt;.01), and WBC atrophy level (p = .03), although no main effects of group and group × time interactions were detected on the cognitive tests and brain atrophy",45297:45615,3621765,23585901,Unavailable
3621765,Mini-Mental State Examination score (overall),Multicomponent exercise program,Control,No significant difference,"MMSE	0.2 (−0.5, 0.9)	−0.3 (−1.1, 0.4)	0.18	0.79	0.32",48154:48431,3621765,23585901,Unavailable
3621765,Alzheimer's Disease Assessment Scale-cognitive subscale (overall),Multicomponent exercise program,Control,No significant difference,"ADAS-cog	−0.8 (−1.4, −0.2)	−0.2 (−0.8, 0.4)	0.17	0.01	.16",48906:49188,3621765,23585901,Unavailable
3621765,Logical memory score I (overall),Multicomponent exercise program,Control,No significant difference,"WMS-LM I	2.8 (1.4, 4.2)	1.0 (−0.5, 2.4)	0.29	&lt;.01	0.08",49667:49949,3621765,23585901,Unavailable
3621765,WMS-LM II (overall),Multicomponent exercise program,Control,No significant difference,"WMS-LM II	3.4 (2.0, 4.8)	1.9 (0.4, 3.4)b	0.28	&lt;.01	0.15",50424:50753,3621765,23585901,Unavailable
3621765,MTA-ERC atrophy (overall),Multicomponent exercise program,Control,No significant difference,"MTA-ERC	0 (−0, 0.1)	0 (0, 0.1)	0.18	0.08	0.89",51181:51451,3621765,23585901,Unavailable
3621765,Whole brain cortical atrophy (overall),Multicomponent exercise program,Control,No significant difference,"WBC	0.1 (−0.4, 0.7)	0.7 (0.1, 1.2)	0.08	0.03	0.16",51873:52147,3621765,23585901,Unavailable
3621765,Mini-Mental State Examination score (amnestic patients),Multicomponent exercise program,Control,Significantly increased,"MMSE	0.2 (−0.5, 0.9)	−0.3 (−1.1, 0.4)	0.18	0.79	0.32	0.11	0.3 (−0.8, 1.3)	−1.4 (−2.5, −0.3)	0.03	0.14	.04b",48154:48793,3621765,23585901,Unavailable
3621765,Alzheimer's Disease Assessment Scale-cognitive subscale (amnestic patients),Multicomponent exercise program,Control,No significant difference,"ADAS-cog	−0.8 (−1.4, −0.2)	−0.2 (−0.8, 0.4)	0.17	0.01	.16 (1)c	0.15	−1.2 (−2.1, −0.3)	−0.1 (−1.0, 0.8)	0.1	0.06	0.1",48906:49562,3621765,23585901,Unavailable
3621765,Logical memory score I (amnestic patients),Multicomponent exercise program,Control,Significantly increased,"WMS-LM I	2.8 (1.4, 4.2)	1.0 (−0.5, 2.4)	0.29	&lt;.01	0.08	0.19	3.8 (1.6, 5.9)	0.5 (−1.6, 2.7)	0.14	&lt;.01	.04a",49667:50311,3621765,23585901,Unavailable
3621765,WMS-LM II (amnestic patients),Multicomponent exercise program,Control,No significant difference,"WMS-LM II	3.4 (2.0, 4.8)	1.9 (0.4, 3.4)b	0.28	&lt;.01	0.15	0.15	3.8 (1.8, 5.7)	2.1 (0.1, 4.2)	0.11	&lt;.01	0.26",50424:51076,3621765,23585901,Unavailable
3621765,MTA-ERC atrophy (amnestic patients),Multicomponent exercise program,Control,No significant difference,"MTA-ERC	0 (−0, 0.1)	0 (0, 0.1)	0.18	0.08	0.89	0.02	0.1 (0, 0.2)	0 (−0.1, 0.1)	0.91	0.03	0.27",51181:51768,3621765,23585901,Unavailable
3621765,Whole brain cortical atrophy (amnestic patients),Multicomponent exercise program,Control,Significantly decreased,"WBC	0.1 (−0.4, 0.7)	0.7 (0.1, 1.2)	0.08	0.03	0.16	0.15	−0.1 (−0.8, 0.6)	0.9 (0.2, 1.6)	0.86	0.08	&lt;.05b",51873:52511,3621765,23585901,Unavailable
5441109,Diarrhea,Early measles vaccine,Normal protocol ,Significantly decreased,"Early MV receipt was associated with a lower hazard for diarrhea (HR, 0.89; 95% CI, .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and reported fever (HR, 0.93; 95% CI, .87–1.00; Table 3). The remaining symptoms also tended to be less common in the intervention group.",33045:33361,5441109,28077730,Unavailable
5441109,Vomiting ,Early measles vaccine,Normal protocol ,Significantly decreased,"Early MV receipt was associated with a lower hazard for diarrhea (HR, 0.89; 95% CI, .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and reported fever (HR, 0.93; 95% CI, .87–1.00; Table 3). The remaining symptoms also tended to be less common in the intervention group.",33045:33361,5441109,28077730,Unavailable
5441109,Reported fever,Early measles vaccine,Normal protocol ,Significantly decreased,"Early MV receipt was associated with a lower hazard for diarrhea (HR, 0.89; 95% CI, .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and reported fever (HR, 0.93; 95% CI, .87–1.00; Table 3). The remaining symptoms also tended to be less common in the intervention group.",33045:33361,5441109,28077730,Unavailable
5441109,Coughing,Early measles vaccine,Normal protocol ,No significant difference,"Early MV receipt was associated with a lower hazard for diarrhea (HR, 0.89; 95% CI, .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and reported fever (HR, 0.93; 95% CI, .87–1.00; Table 3). The remaining symptoms also tended to be less common in the intervention group.",33045:33361,5441109,28077730,Unavailable
5441109,"Lack of appetite	",Early measles vaccine,Normal protocol ,No significant difference,"Early MV receipt was associated with a lower hazard for diarrhea (HR, 0.89; 95% CI, .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and reported fever (HR, 0.93; 95% CI, .87–1.00; Table 3). The remaining symptoms also tended to be less common in the intervention group.",33045:33361,5441109,28077730,Unavailable
5441109,Crying more than normal,Early measles vaccine,Normal protocol ,No significant difference,"Early MV receipt was associated with a lower hazard for diarrhea (HR, 0.89; 95% CI, .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and reported fever (HR, 0.93; 95% CI, .87–1.00; Table 3). The remaining symptoms also tended to be less common in the intervention group.",33045:33361,5441109,28077730,Unavailable
5441109,Reported consultations,Early measles vaccine,Normal protocol ,No significant difference,"Early MV receipt was associated with a lower hazard for diarrhea (HR, 0.89; 95% CI, .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and reported fever (HR, 0.93; 95% CI, .87–1.00; Table 3). The remaining symptoms also tended to be less common in the intervention group.",33045:33361,5441109,28077730,Unavailable
5441109,Reported use of medicine,Early measles vaccine,Normal protocol ,No significant difference,"Early MV receipt was associated with a lower hazard for diarrhea (HR, 0.89; 95% CI, .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and reported fever (HR, 0.93; 95% CI, .87–1.00; Table 3). The remaining symptoms also tended to be less common in the intervention group.",33045:33361,5441109,28077730,Unavailable
5441109,Diarrhea,Early measles vaccine,Normal protocol ,Significantly decreased,"Diarrhea	6.0 (1397/233)	6.7 (805/120)	0.89b (.82–.97)",35097:35257,5441109,28077730,Unavailable
5441109,Vomiting ,Early measles vaccine,Normal protocol ,Significantly decreased,"Vomiting	2.5 (598/241)	2.9 (358/124)	0.86b (.75–.98)",35300:35459,5441109,28077730,Unavailable
5441109,Reported fever,Early measles vaccine,Normal protocol ,Significantly decreased,"Reported fever	10.1 (2316/228)	10.9 (1273/117)	0.93b (.87–1.00)",36100:36270,5441109,28077730,Unavailable
5441109,Coughing,Early measles vaccine,Normal protocol ,No significant difference,"Coughing	9.4 (1929/206)	9.7 (1018/105)	0.96 (.89–1.04)",35502:35652,5441109,28077730,Unavailable
5441109,"Lack of appetite	",Early measles vaccine,Normal protocol ,No significant difference,"Lack of appetite	2.2 (525/236)	2.4 (290/121)	0.93 (.80–1.07)",35695:35851,5441109,28077730,Unavailable
5441109,Crying more than normal,Early measles vaccine,Normal protocol ,No significant difference,"Crying more than normal	3.5 (820/237)	3.5 (431/122)	0.98 (.87–1.10)",35894:36057,5441109,28077730,Unavailable
5441109,Reported consultations,Early measles vaccine,Normal protocol ,No significant difference,"Reported consultations	4.4 (1080/244)	4.4 (557/126)	1.00 (.90–1.11)",36313:36476,5441109,28077730,Unavailable
5441109,Reported use of medicine,Early measles vaccine,Normal protocol ,No significant difference,"Reported use of medicine	8.8 (1894/214)	9.2 (1017/110)	0.96 (.89–1.04)",36519:36685,5441109,28077730,Unavailable
5441109,Skin reactions,Early measles vaccine,Normal protocol ,Significantly decreased,"Skin reactionc	5.5 (185/34)	7.1 (124/18)	0.76b (.60–.95)",36798:36972,5441109,28077730,Unavailable
5441109,Conjunctivitis,Early measles vaccine,Normal protocol ,No significant difference,"Conjunctivitis	4.6 (156/34)	4.1 (72/18)	1.13 (.86–1.49)",37015:37166,5441109,28077730,Unavailable
5441109,Nasal discharge,Early measles vaccine,Normal protocol ,No significant difference,"Nasal discharge	93.1 (3171/34)	96.1 (1686/18)	0.97 (.91–1.03)",37209:37366,5441109,28077730,Unavailable
5441109,Measured fever,Early measles vaccine,Normal protocol ,No significant difference,"Measured fever	19.4 (662/34)	21.7 (381/18)	0.90 (.79–1.02)",37409:37563,5441109,28077730,Unavailable
5441109,Skin reactions,Early measles vaccine,Normal protocol ,Significantly decreased,"Early MV receipt was associated with a reduced risk of skin reactions (HR, 0.76; 95% CI, .60–.95; Table 3).",39464:39617,5441109,28077730,Unavailable
4809130,hsC-reactive protein,500 mg calcium-200 IU cholecalciferol supplement,Placebo,Significantly decreased,"Consumption of calcium-Vitamin D co-supplements resulted in a significant reduction of serum high-sensitivity C-reactive protein levels compared with placebo (−1856.8 ± 2657.7 vs. 707.1 ± 3139.4 μg/mL, P = 0.006).",6354:6584,4809130,27076887,Unavailable
4809130,Plasma total antioxidant capacity,500 mg calcium-200 IU cholecalciferol supplement,Placebo,Significantly increased,"We also found a significant elevation of plasma total antioxidant capacity (89.3 ± 118.0 vs. −9.4 ± 164.9 mmol/L, P = 0.03), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. −1.7 ± 1.7 ng/mL, P &lt; 0.0001), and calcium levels (0.6 ± 0.6 vs. −0.1 ± 0.4 mg/dL, P &lt; 0.0001).",6585:6901,4809130,27076887,Unavailable
4809130,Serum 25-hydroxyvitamin D ,500 mg calcium-200 IU cholecalciferol supplement,Placebo,Significantly increased,"We also found a significant elevation of plasma total antioxidant capacity (89.3 ± 118.0 vs. −9.4 ± 164.9 mmol/L, P = 0.03), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. −1.7 ± 1.7 ng/mL, P &lt; 0.0001), and calcium levels (0.6 ± 0.6 vs. −0.1 ± 0.4 mg/dL, P &lt; 0.0001).",6585:6901,4809130,27076887,Unavailable
4809130,Plasma calcium levels,500 mg calcium-200 IU cholecalciferol supplement,Placebo,Significantly increased,"We also found a significant elevation of plasma total antioxidant capacity (89.3 ± 118.0 vs. −9.4 ± 164.9 mmol/L, P = 0.03), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. −1.7 ± 1.7 ng/mL, P &lt; 0.0001), and calcium levels (0.6 ± 0.6 vs. −0.1 ± 0.4 mg/dL, P &lt; 0.0001).",6585:6901,4809130,27076887,Unavailable
4809130,Diastolic blood pressure,500 mg calcium-200 IU cholecalciferol supplement,Placebo,Significantly decreased,"The supplementation led to a significant decrease in diastolic blood pressure (−1.9 ± 8.3 vs. 3.1 ± 5.2 mmHg, P = 0.02) compared with placebo.",6900:7064,4809130,27076887,Unavailable
4809130,hsC-reactive protein,500 mg calcium-200 IU cholecalciferol supplement,Placebo,Significantly decreased,"Consumption of calcium-Vitamin D co-supplements resulted in a significant reduction of serum high-sensitivity C-reactive protein levels compared with placebo (−1856.8 ± 2657.7 vs. 707.1 ± 3139.4 μg/mL, P = 0.006).",6900:7064,4809130,27076887,Unavailable
4809130,Plasma total antioxidant capacity,500 mg calcium-200 IU cholecalciferol supplement,Placebo,Significantly increased,"We found a significant elevation of plasma TAC (89.3 ± 118.0 vs. −9.4 ± 164.9 mmol/L, P = 0.030), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. −1.7 ± 1.7 ng/mL, P &lt; 0.0001), and calcium levels (0.6 ± 0.6 vs. −0.1 ± 0.4 mg/dL, P &lt; 0.0001) following consumption of calcium-Vitamin D supplements.",22640:22984,4809130,27076887,Unavailable
4809130,Serum 25-hydroxyvitamin D ,500 mg calcium-200 IU cholecalciferol supplement,Placebo,Significantly increased,"We found a significant elevation of plasma TAC (89.3 ± 118.0 vs. −9.4 ± 164.9 mmol/L, P = 0.030), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. −1.7 ± 1.7 ng/mL, P &lt; 0.0001), and calcium levels (0.6 ± 0.6 vs. −0.1 ± 0.4 mg/dL, P &lt; 0.0001) following consumption of calcium-Vitamin D supplements.",22640:22983,4809130,27076887,Unavailable
4809130,Plasma calcium levels,500 mg calcium-200 IU cholecalciferol supplement,Placebo,Significantly increased,"We found a significant elevation of plasma TAC (89.3 ± 118.0 vs. −9.4 ± 164.9 mmol/L, P = 0.030), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. −1.7 ± 1.7 ng/mL, P &lt; 0.0001), and calcium levels (0.6 ± 0.6 vs. −0.1 ± 0.4 mg/dL, P &lt; 0.0001) following consumption of calcium-Vitamin D supplements.",22640:22983,4809130,27076887,Unavailable
4809130,Diastolic blood pressure,500 mg calcium-200 IU cholecalciferol supplement,Placebo,Significantly decreased,"Compared to placebo, the calcium-Vitamin D supplementation led to a significant decrease in DBP (−1.9 ± 8.3 vs. 3.1 ± 5.2 mmHg, P = 0.02).",22984:23143,4809130,27076887,Unavailable
4809130,Systolic blood pressure,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,"No significant effect of calcium-Vitamin D supplementation was seen on SBP, FPG, serum insulin levels, indicators of insulin action (HOMA-IR, HOMA-B, QUICKI index) as well as plasma total GSH.",23143:23335,4809130,27076887,Unavailable
4809130,Fasting plasma glucose,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,"No significant effect of calcium-Vitamin D supplementation was seen on SBP, FPG, serum insulin levels, indicators of insulin action (HOMA-IR, HOMA-B, QUICKI index) as well as plasma total GSH.",23143:23335,4809130,27076887,Unavailable
4809130,Serum insulin levels,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,"No significant effect of calcium-Vitamin D supplementation was seen on SBP, FPG, serum insulin levels, indicators of insulin action (HOMA-IR, HOMA-B, QUICKI index) as well as plasma total GSH.",23143:23335,4809130,27076887,Unavailable
4809130,HOMA-IR,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,"No significant effect of calcium-Vitamin D supplementation was seen on SBP, FPG, serum insulin levels, indicators of insulin action (HOMA-IR, HOMA-B, QUICKI index) as well as plasma total GSH.",23143:23335,4809130,27076887,Unavailable
4809130, HOMA-B,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,"No significant effect of calcium-Vitamin D supplementation was seen on SBP, FPG, serum insulin levels, indicators of insulin action (HOMA-IR, HOMA-B, QUICKI index) as well as plasma total GSH.",23143:23335,4809130,27076887,Unavailable
4809130,QUICKI index,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,"No significant effect of calcium-Vitamin D supplementation was seen on SBP, FPG, serum insulin levels, indicators of insulin action (HOMA-IR, HOMA-B, QUICKI index) as well as plasma total GSH.",23143:23335,4809130,27076887,Unavailable
4809130,Plasma total glutathione,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,"No significant effect of calcium-Vitamin D supplementation was seen on SBP, FPG, serum insulin levels, indicators of insulin action (HOMA-IR, HOMA-B, QUICKI index) as well as plasma total GSH.",23143:23335,4809130,27076887,Unavailable
4809130,Fasting plasma glucose,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,No significant effect of calcium-Vitamin D co-supplements was seen on other metabolic profiles.,7063:7159,4809130,27076887,Unavailable
4809130,Serum insulin levels,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,No significant effect of calcium-Vitamin D co-supplements was seen on other metabolic profiles.,7064:7160,4809130,27076887,Unavailable
4809130,HOMA-IR,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,No significant effect of calcium-Vitamin D co-supplements was seen on other metabolic profiles.,7063:7160,4809130,27076887,Unavailable
4809130, HOMA-B,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,No significant effect of calcium-Vitamin D co-supplements was seen on other metabolic profiles.,7064:7159,4809130,27076887,Unavailable
4809130,QUICKI index,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,No significant effect of calcium-Vitamin D co-supplements was seen on other metabolic profiles.,7064:7160,4809130,27076887,Unavailable
4809130,Plasma total glutathione,500 mg calcium-200 IU cholecalciferol supplement,Placebo,No significant difference,No significant effect of calcium-Vitamin D co-supplements was seen on other metabolic profiles.,7064:7160,4809130,27076887,Unavailable
3231767,Response rate,Simultaneous response mixed mode,Online mode,Significantly increased,"After adjusting for observed differences between the groups, the online mode had a 7 percentage point lower response rate compared to the simultaneous mixed mode, and a 7.7 percentage point lower response rate compared to sequential mixed mode.",58900:59336,3231767,21888678,Unavailable
3231767,Response rate,Sequential response mixed mode,Online mode,Significantly increased,"After adjusting for observed differences between the groups, the online mode had a 7 percentage point lower response rate compared to the simultaneous mixed mode, and a 7.7 percentage point lower response rate compared to sequential mixed mode.",58900:59336,3231767,21888678,Unavailable
3231767,Response rate,Simultaneous response mixed mode,Sequential response mixed mode,No significant difference,The difference in response rate between the sequential and simultaneous modes was not statistically significant.,58900:59336,3231767,21888678,Unavailable
3231767,Response rate,Simultaneous response mixed mode,Online mode,Significantly increased,"The difference in response rates across modes was statistically significant (Table 4). The table reports the marginal effects of each response mode compared with the online response, and can be interpreted as percentages. Controlling for other factors, the simultaneous mixed mode had a response rate 7 percentage points higher than online, and the sequential mixed mode was 7.7 percentage points higher than online.",58900:59336,3231767,21888678,Unavailable
3231767,Response rate,Sequential response mixed mode,Online mode,Significantly increased,"The difference in response rates across modes was statistically significant (Table 4). The table reports the marginal effects of each response mode compared with the online response, and can be interpreted as percentages. Controlling for other factors, the simultaneous mixed mode had a response rate 7 percentage points higher than online, and the sequential mixed mode was 7.7 percentage points higher than online.",58900:59336,3231767,21888678,Unavailable
3231767,Response rate,Simultaneous response mixed mode,Sequential response mixed mode,No significant difference,"The effect of sequential mixed mode was not significantly different from simultaneous mixed mode (χ2 = 0.16, p = 0.69).",58900:59336,3231767,21888678,Unavailable
3231767,Completing all questions ,Simultaneous response mixed mode,Online mode,Significantly decreased,"only 2.9% of respondents completed every question, and this was lowest for simultaneous mixed mode (1.1%), followed by sequential mixed mode (2.2%), and was highest for online mode (6.9%) (Table 7). These differences were statistically significant (second half of Table 8), with odds ratios of 0.13 for paper mode and 0.23 for mixed mode compared to online.",58900:59336,3231767,21888678,Unavailable
3231767,Completing all questions ,Sequential response mixed mode,Online mode,Significantly decreased,"only 2.9% of respondents completed every question, and this was lowest for simultaneous mixed mode (1.1%), followed by sequential mixed mode (2.2%), and was highest for online mode (6.9%) (Table 7). These differences were statistically significant (second half of Table 8), with odds ratios of 0.13 for paper mode and 0.23 for mixed mode compared to online.",58900:59336,3231767,21888678,Unavailable
5752792,Overall mortality,N-acetyl cysteine ,Control,No significant difference,The overall mortality in the study group was 88% with 87.5% mortality in the treatment group and 88.5% in the placebo group.,4180:4304,5752792,29307964,Unavailable
5752792,Overall mortality,N-acetyl cysteine ,Control,No significant difference,"Overall mortality in the study population was 88%. In NAC group, the unfavorable outcome was seen in 87.5% whereas in the placebo group, it was seen in 88.5%. There was no statistically significant difference in the outcome among the two groups",11736:11981,5752792,29307964,Unavailable
4557407,SBP (30m after end of PTCA),Music therapy,Control ,No significant difference,"Moreover, the differences between the two groups, regarding hemodynamic parameters, were not significant after the intervention (P &gt; 0.05).",5731:5910,4557407,26339666,Unavailable
4557407,DBP (30m after end of PTCA),Music therapy,Control ,No significant difference,"Moreover, the differences between the two groups, regarding hemodynamic parameters, were not significant after the intervention (P &gt; 0.05).",5731:5910,4557407,26339666,Unavailable
4557407,Heart rate (30m after end of PTCA),Music therapy,Control ,No significant difference,"Moreover, the differences between the two groups, regarding hemodynamic parameters, were not significant after the intervention (P &gt; 0.05).",5731:5910,4557407,26339666,Unavailable
4557407,SaO2 % (30m after end of PTCA),Music therapy,Control ,No significant difference,"Moreover, the differences between the two groups, regarding hemodynamic parameters, were not significant after the intervention (P &gt; 0.05).",27031:27168,4557407,26339666,Unavailable
4557407,Respiration rate (30m after end of PTCA),Music therapy,Control ,No significant difference,"Moreover, the differences between the two groups, regarding hemodynamic parameters, were not significant after the intervention (P &gt; 0.05).",5731:5910,4557407,26339666,Unavailable
4557407,Post-intervention anxiety ,Music therapy,Control ,Significantly decreased,"However, the level of post-intervention anxiety in the experimental group was significantly lower than the control group (32.06 ± 8.57 and 38.97 ± 12.77, respectively; P = 0.014).",5731:5910,4557407,26339666,Unavailable
4557407,SBP (10m before PTCA),Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,DBP (10m before PTCA),Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Heart rate (10m before PTCA),Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,SaO2 % (10m before PTCA),Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Respiration rate (10m before PTCA),Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,SBP (right after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,DBP (right after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Heart rate (right after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,SaO2 % (right after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Respiration rate (right after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,SBP (10m after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,DBP (10m after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Heart rate (10m after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,SaO2 % (10m after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Respiration rate (10m after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,SBP (20m after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,DBP (20m after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Heart rate (20m after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,SaO2 % (20m after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Respiration rate (20m after starting) ,Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,SBP (30m after end of PTCA),Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,DBP (30m after end of PTCA),Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Heart rate (30m after end of PTCA),Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,SaO2 % (30m after end of PTCA),Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Respiration rate (30m after end of PTCA),Music therapy,Control ,No significant difference,"Moreover, the study groups did not differ significantly in terms of hemodynamic parameters at different measurement time-points (P &gt; 0.05",27031:27168,4557407,26339666,Unavailable
4557407,Post-intervention anxiety ,Music therapy,Control ,Significantly decreased,"However, after the intervention, the level of anxiety in the experimental group was significantly lower than the control group (32.06 ± 8.57 vs. 38.97 ± 12.77, respectively; P = 0.014",27231:27414,4557407,26339666,Unavailable
4557407,SBP (10m before PTCA),Music therapy,Control ,No significant difference,"SBP, mmHg						Control	137.12 ± 17.69	139.94 ± 32.55	138.75 ± 24.28	136.32 ± 23.08	130.56 ± 3.21	0.208Experimental	138.81 ± 20.54	153.63 ± 32.57	142.38 ± 23.93	139.84 ± 22.34	130.09 ± 21.39	0.001P value c	0.726",28879:30336,4557407,26339666,Unavailable
4557407,DBP (10m before PTCA),Music therapy,Control ,No significant difference,"DBP, mmHg						Control	85.22 ± 11.64	83.22 ± 12.01	80.44 ± 10.29	81.19 ± 11.24	79.59 ± 10.15	0.094Experimental	84.81 ± 10.46	87.44 ± 15.65	85.38 ± 15.92	83.31 ± 12.51	78.56{14.16	0.006P value c	0.884",30711:32326,4557407,26339666,Unavailable
4557407,Heart rate (10m before PTCA),Music therapy,Control ,No significant difference,"HR, Per min						Control	75.34 ± 15.51	79.28 ± 14.40	80.16 ± 14.26	79.31 ± 12.64	74.37 ± 14.03	0.001Experimental	75.94 ± 12.91	78.28 ± 15.13	79.41 ± 13.31	78.68 ± 12.81	71.91 ± 9.64	0.001P value c	0.868",32701:34319,4557407,26339666,Unavailable
4557407,SaO2 % (10m before PTCA),Music therapy,Control ,No significant difference,"SaO2, %						Control	95.03 ± 2.18	93.72 ± 1.27	93.22 ± 2.3	93.19 ± 2.63	94.09 ± 1.91	0.001Experimental	94.38 ± 2.60	93.34 ± 2.54	91.91 ± 3.08	92.32 ± 3.37	94.19 ± 2.42	0.001P value c	0.278",34694:36298,4557407,26339666,Unavailable
4557407,Respiration rate (10m before PTCA),Music therapy,Control ,No significant difference,"RR, Per min						Control	19.22 ± 2.52	-	-	-	18.66 ± 3.31	-Experimental	19 ± 2.53	-	-	-	19.44 ± 10.14	-P value c	0.732",36673:38206,4557407,26339666,Unavailable
4557407,SBP (right after starting) ,Music therapy,Control ,No significant difference,"SBP, mmHg						Control	137.12 ± 17.69	139.94 ± 32.55	138.75 ± 24.28	136.32 ± 23.08	130.56 ± 3.21	0.208Experimental	138.81 ± 20.54	153.63 ± 32.57	142.38 ± 23.93	139.84 ± 22.34	130.09 ± 21.39	0.001P value c	0.726	0.098",28879:30402,4557407,26339666,Unavailable
4557407,DBP (right after starting) ,Music therapy,Control ,No significant difference,"DBP, mmHg						Control	85.22 ± 11.64	83.22 ± 12.01	80.44 ± 10.29	81.19 ± 11.24	79.59 ± 10.15	0.094Experimental	84.81 ± 10.46	87.44 ± 15.65	85.38 ± 15.92	83.31 ± 12.51	78.56{14.16	0.006P value c	0.884	0.231",30711:32392,4557407,26339666,Unavailable
4557407,Heart rate (right after starting) ,Music therapy,Control ,No significant difference,"HR, Per min						Control	75.34 ± 15.51	79.28 ± 14.40	80.16 ± 14.26	79.31 ± 12.64	74.37 ± 14.03	0.001Experimental	75.94 ± 12.91	78.28 ± 15.13	79.41 ± 13.31	78.68 ± 12.81	71.91 ± 9.64	0.001P value c	0.868	0.787",32701:34385,4557407,26339666,Unavailable
4557407,SaO2 % (right after starting) ,Music therapy,Control ,No significant difference,"SaO2, %						Control	95.03 ± 2.18	93.72 ± 1.27	93.22 ± 2.3	93.19 ± 2.63	94.09 ± 1.91	0.001Experimental	94.38 ± 2.60	93.34 ± 2.54	91.91 ± 3.08	92.32 ± 3.37	94.19 ± 2.42	0.001P value c	0.278	0.459",34694:36364,4557407,26339666,Unavailable
4557407,SBP (10m after starting) ,Music therapy,Control ,No significant difference,"SBP, mmHg						Control	137.12 ± 17.69	139.94 ± 32.55	138.75 ± 24.28	136.32 ± 23.08	130.56 ± 3.21	0.208Experimental	138.81 ± 20.54	153.63 ± 32.57	142.38 ± 23.93	139.84 ± 22.34	130.09 ± 21.39	0.001P value c	0.726	0.098	0.550",28879:30468,4557407,26339666,Unavailable
4557407,DBP (10m after starting) ,Music therapy,Control ,No significant difference,"DBP, mmHg						Control	85.22 ± 11.64	83.22 ± 12.01	80.44 ± 10.29	81.19 ± 11.24	79.59 ± 10.15	0.094Experimental	84.81 ± 10.46	87.44 ± 15.65	85.38 ± 15.92	83.31 ± 12.51	78.56{14.16	0.006P value c	0.884	0.231	0.147",30711:32458,4557407,26339666,Unavailable
4557407,Heart rate (10m after starting) ,Music therapy,Control ,No significant difference,"HR, Per min						Control	75.34 ± 15.51	79.28 ± 14.40	80.16 ± 14.26	79.31 ± 12.64	74.37 ± 14.03	0.001Experimental	75.94 ± 12.91	78.28 ± 15.13	79.41 ± 13.31	78.68 ± 12.81	71.91 ± 9.64	0.001P value c	0.868	0.787	0.829",32701:34451,4557407,26339666,Unavailable
4557407,SaO2 % (10m after starting) ,Music therapy,Control ,No significant difference,"SaO2, %						Control	95.03 ± 2.18	93.72 ± 1.27	93.22 ± 2.3	93.19 ± 2.63	94.09 ± 1.91	0.001Experimental	94.38 ± 2.60	93.34 ± 2.54	91.91 ± 3.08	92.32 ± 3.37	94.19 ± 2.42	0.001P value c	0.278	0.459	0.058",34694:36430,4557407,26339666,Unavailable
4557407,SBP (20m after starting) ,Music therapy,Control ,No significant difference,"SBP, mmHg						Control	137.12 ± 17.69	139.94 ± 32.55	138.75 ± 24.28	136.32 ± 23.08	130.56 ± 3.21	0.208Experimental	138.81 ± 20.54	153.63 ± 32.57	142.38 ± 23.93	139.84 ± 22.34	130.09 ± 21.39	0.001P value c	0.726	0.098	0.550	0.545",28879:30534,4557407,26339666,Unavailable
4557407,DBP (20m after starting) ,Music therapy,Control ,No significant difference,"DBP, mmHg						Control	85.22 ± 11.64	83.22 ± 12.01	80.44 ± 10.29	81.19 ± 11.24	79.59 ± 10.15	0.094Experimental	84.81 ± 10.46	87.44 ± 15.65	85.38 ± 15.92	83.31 ± 12.51	78.56{14.16	0.006P value c	0.884	0.231	0.147	0.279",30711:32524,4557407,26339666,Unavailable
4557407,Heart rate (20m after starting) ,Music therapy,Control ,No significant difference,"HR, Per min						Control	75.34 ± 15.51	79.28 ± 14.40	80.16 ± 14.26	79.31 ± 12.64	74.37 ± 14.03	0.001Experimental	75.94 ± 12.91	78.28 ± 15.13	79.41 ± 13.31	78.68 ± 12.81	71.91 ± 9.64	0.001P value c	0.868	0.787	0.829	0.844",32701:34517,4557407,26339666,Unavailable
4557407,SaO2 % (20m after starting) ,Music therapy,Control ,No significant difference,"SaO2, %						Control	95.03 ± 2.18	93.72 ± 1.27	93.22 ± 2.3	93.19 ± 2.63	94.09 ± 1.91	0.001Experimental	94.38 ± 2.60	93.34 ± 2.54	91.91 ± 3.08	92.32 ± 3.37	94.19 ± 2.42	0.001P value c	0.278	0.459	0.058	0.260",34694:36496,4557407,26339666,Unavailable
4557407,SBP (30m after end of PTCA),Music therapy,Control ,No significant difference,"SBP, mmHg						Control	137.12 ± 17.69	139.94 ± 32.55	138.75 ± 24.28	136.32 ± 23.08	130.56 ± 3.21	0.208Experimental	138.81 ± 20.54	153.63 ± 32.57	142.38 ± 23.93	139.84 ± 22.34	130.09 ± 21.39	0.001P value c	0.726	0.098	0.550	0.545	0.925",28879:30600,4557407,26339666,Unavailable
4557407,DBP (30m after end of PTCA),Music therapy,Control ,No significant difference,"DBP, mmHg						Control	85.22 ± 11.64	83.22 ± 12.01	80.44 ± 10.29	81.19 ± 11.24	79.59 ± 10.15	0.094Experimental	84.81 ± 10.46	87.44 ± 15.65	85.38 ± 15.92	83.31 ± 12.51	78.56{14.16	0.006P value c	0.884	0.231	0.147	0.279	0.739",30711:32590,4557407,26339666,Unavailable
4557407,Heart rate (30m after end of PTCA),Music therapy,Control ,No significant difference,"HR, Per min						Control	75.34 ± 15.51	79.28 ± 14.40	80.16 ± 14.26	79.31 ± 12.64	74.37 ± 14.03	0.001Experimental	75.94 ± 12.91	78.28 ± 15.13	79.41 ± 13.31	78.68 ± 12.81	71.91 ± 9.64	0.001P value c	0.868	0.787	0.829	0.844	0.415",32701:34583,4557407,26339666,Unavailable
4557407,SaO2 % (30m after end of PTCA),Music therapy,Control ,No significant difference,"SaO2, %						Control	95.03 ± 2.18	93.72 ± 1.27	93.22 ± 2.3	93.19 ± 2.63	94.09 ± 1.91	0.001Experimental	94.38 ± 2.60	93.34 ± 2.54	91.91 ± 3.08	92.32 ± 3.37	94.19 ± 2.42	0.001P value c	0.278	0.459	0.058	0.260	0.864",34694:36562,4557407,26339666,Unavailable
4557407,Respiration rate (30m after end of PTCA),Music therapy,Control ,No significant difference,"RR, Per min						Control	19.22 ± 2.52	-	-	-	18.66 ± 3.31	-Experimental	19 ± 2.53	-	-	-	19.44 ± 10.14	-P value c	0.732	-	-	-	0.680",36673:38458,4557407,26339666,Unavailable
4557407,Post-intervention anxiety ,Music therapy,Control ,Significantly decreased,"Control	41.91 ± 9.88	38.97 ± 12.77	0.101Experimental	41.16 ± 10.65	32.06 ± 8.57	0.001P value c	0.771	0.014",39697:40477,4557407,26339666,Unavailable
5984017,Mean arterial blood pressure (at recovery),Added dexamethasone ,Control,Significantly increased,Mean arterial blood pressure was higher in the L + D group (100.39±14.6 mmHg) in comparison to the L group (90.50±11 mmHg) (p=0.002).,22806:23095,5984017,None,Unavailable
5984017,Need for opioids,Added dexamethasone ,Control,No significant difference,Need for opioid was reported in 20 (35.7%) patients in the L + D group in comparison to 17 (31.5%) in the L group (p=0.639).,22806:23095,5984017,None,Unavailable
5984017,Intraoperative dose of fentanyl ,Added dexamethasone ,Control,No significant difference,The average intraoperative dose of fentanyl was 95±32.04 mcg and 88.44±18.77 mg in L + D and L groups respectively and there was no significant difference between the two groups in this respect (p=0.479).,22806:23095,5984017,None,Unavailable
5984017,Dose of pethidine in recovery room,Added dexamethasone ,Control,Significantly increased,"In addition, the average dose of pethidine administered in the recovery room for L + D group (19.34±15.22) mg was significantly higher than in the L group (9.44±12.26 mg) (p=0.001).",22806:23095,5984017,None,Unavailable
5984017,Mean arterial blood pressure (5 m after starting),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of systolic, diastolic blood pressure and mean arterial pressure base line, 5 and 20 minutes after the start of surgery and immediately after tourniquet deflation.",22806:23095,5984017,None,Unavailable
5984017,Mean arterial blood pressure (20 m after starting),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of systolic, diastolic blood pressure and mean arterial pressure base line, 5 and 20 minutes after the start of surgery and immediately after tourniquet deflation.",22806:23095,5984017,None,Unavailable
5984017,Mean arterial blood pressure (after tourniquet deflation),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of systolic, diastolic blood pressure and mean arterial pressure base line, 5 and 20 minutes after the start of surgery and immediately after tourniquet deflation.",22806:23095,5984017,None,Unavailable
5984017,Systolic blood pressure (5 m after starting),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of systolic, diastolic blood pressure and mean arterial pressure base line, 5 and 20 minutes after the start of surgery and immediately after tourniquet deflation.",22806:23095,5984017,None,Unavailable
5984017,Systolic blood pressure (20 m after starting),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of systolic, diastolic blood pressure and mean arterial pressure base line, 5 and 20 minutes after the start of surgery and immediately after tourniquet deflation.",22806:23095,5984017,None,Unavailable
5984017,Systolic blood pressure (after tourniquet deflation),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of systolic, diastolic blood pressure and mean arterial pressure base line, 5 and 20 minutes after the start of surgery and immediately after tourniquet deflation.",22806:23095,5984017,None,Unavailable
5984017,Diastolic blood pressure (5 m after starting),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of systolic, diastolic blood pressure and mean arterial pressure base line, 5 and 20 minutes after the start of surgery and immediately after tourniquet deflation.",22806:23095,5984017,None,Unavailable
5984017,Diastolic blood pressure (20 m after starting),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of systolic, diastolic blood pressure and mean arterial pressure base line, 5 and 20 minutes after the start of surgery and immediately after tourniquet deflation.",22806:23095,5984017,None,Unavailable
5984017,Diastolic blood pressure (after tourniquet deflation),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of systolic, diastolic blood pressure and mean arterial pressure base line, 5 and 20 minutes after the start of surgery and immediately after tourniquet deflation.",22806:23095,5984017,None,Unavailable
5984017,Mean arterial blood pressure (at recovery),Added dexamethasone ,Control,Significantly increased,"But the mean arterial blood pressure during recovery was 100.39±14.60 mm Hg and 90.50±11.00 mm Hg in the intervention and control groups, respectively, which significantly had higher values (p=0.002) in the intervention group (L + D)",22806:23095,5984017,None,Unavailable
5984017,Heart rate (5 m after starting),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of average heart rate during surgery, 5 and 20 minutes after the start of surgery, and immediately after recovery and tourniquet deflation",22806:23095,5984017,None,Unavailable
5984017,Heart rate (20 m after starting),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of average heart rate during surgery, 5 and 20 minutes after the start of surgery, and immediately after recovery and tourniquet deflation",22806:23095,5984017,None,Unavailable
5984017,Heart rate (at recovery),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of average heart rate during surgery, 5 and 20 minutes after the start of surgery, and immediately after recovery and tourniquet deflation",22806:23095,5984017,None,Unavailable
5984017,Heart rate (after tourniquet deflation),Added dexamethasone ,Control,No significant difference,"There was no significant difference between L and L + D groups in terms of average heart rate during surgery, 5 and 20 minutes after the start of surgery, and immediately after recovery and tourniquet deflation",22806:23095,5984017,None,Unavailable
5984017,Need for opioids,Added dexamethasone ,Control,No significant difference,"Also, there was no significant difference between the two groups in terms of the variable of number of individuals who needed the intraoperative opioid (opium requirement) (p=0.639).",22806:23095,5984017,None,Unavailable
5984017,Intraoperative dose of fentanyl ,Added dexamethasone ,Control,No significant difference,"The average intraoperative dose of fentanyl was 95±32.04 mcg and 88.44±18.77 mg in L + D and L groups respectively, and there was no significant difference between the two groups in this respect (p=0.479).",22806:23095,5984017,None,Unavailable
5984017,Intraoperative patient satisfaction ,Added dexamethasone ,Control,No significant difference,Average intraoperative patient satisfaction was 1.84±1.09 and 1.84±1.19 in the in L + D and L groups and there was no difference between the two groups in this regard.,22806:23095,5984017,None,Unavailable
5984017,Sensory block onset time (radial),Added dexamethasone ,Control,No significant difference,"Onset time and recovery of sensory block in each nerve (radial, median, and ulnar) was comparable in both L + D and L groups and there was no significant difference between the two groups in this regard (Table 3).",22806:23095,5984017,None,Unavailable
5984017,Sensory block recovery time (radial),Added dexamethasone ,Control,No significant difference,"Onset time and recovery of sensory block in each nerve (radial, median, and ulnar) was comparable in both L + D and L groups and there was no significant difference between the two groups in this regard (Table 3).",22806:23095,5984017,None,Unavailable
5984017,Sensory block onset time (median),Added dexamethasone ,Control,No significant difference,"Onset time and recovery of sensory block in each nerve (radial, median, and ulnar) was comparable in both L + D and L groups and there was no significant difference between the two groups in this regard (Table 3).",22806:23095,5984017,None,Unavailable
5984017,Sensory block recovery time (median),Added dexamethasone ,Control,No significant difference,"Onset time and recovery of sensory block in each nerve (radial, median, and ulnar) was comparable in both L + D and L groups and there was no significant difference between the two groups in this regard (Table 3).",22806:23095,5984017,None,Unavailable
5984017,Sensory block onset time (ulnar),Added dexamethasone ,Control,No significant difference,"Onset time and recovery of sensory block in each nerve (radial, median, and ulnar) was comparable in both L + D and L groups and there was no significant difference between the two groups in this regard (Table 3).",22806:23095,5984017,None,Unavailable
5984017,Sensory block recovery time (ulnar),Added dexamethasone ,Control,No significant difference,"Onset time and recovery of sensory block in each nerve (radial, median, and ulnar) was comparable in both L + D and L groups and there was no significant difference between the two groups in this regard (Table 3).",22806:23095,5984017,None,Unavailable
5984017,Postoperative opioid use,Added dexamethasone ,Control,Significantly increased,There was a significant difference between the two groups in terms of the need for postoperative opioid use (L + D) Group 64.3% vs. 31.5% in the L Group (p=0.001).,22806:23095,5984017,None,Unavailable
5984017,Dose of pethidine in recovery room,Added dexamethasone ,Control,Significantly increased,"In addition, the average dose of pethidine administered in the recovery room for L + D and L groups was 19.34±15.22 mg and 9.44±12.26 mg, respectively. Thus, mean dose of pethidine was significantly higher (p=0.001) in the L + D group than the control group.",22806:23095,5984017,None,Unavailable
5984017,Time for requesting first postoperative opioid ,Added dexamethasone ,Control,No significant difference,"Moreover, there was no significant difference between the two groups in terms of the mean time of the request for the first postoperative opioid (L+D=12.94±6.92 minutes and L=16.19±13.70 minutes) (p=0.764).",22806:23095,5984017,None,Unavailable
5984017,Itching ,Added dexamethasone ,Control,No significant difference,"In this study, a total of 5 patients suffered from an itching complication in the L + D group and one of them were excluded from the study due to the severity of itching. Also, there was no significant difference between the two groups based on Fisher’s exact test in this regard (p=0.118).",22805:23095,5984017,None,Unavailable
3620898,Fasting glucose (6 months),Estrogen patches ,Luteinising-hormone-releasing-hormone agonists,Significantly decreased,"In men who were still receiving the allocated treatment without additional therapy at 6 months, mean fasting glucose had increased in the LHRHa group and decreased in the oestrogen-patches group, which led to a significant difference between groups (table 3, figure 2).",30388:30737,3620898,23465742,Unavailable
3620898,Fasting glucose (12 months),Estrogen patches ,Luteinising-hormone-releasing-hormone agonists,Significantly decreased,"In men who remained on assigned treatments at 12 months, fasting glucose concentrations increased further in the LHRHa arm but remained similar in the oestrogen-patches group, with the mean changes from baseline being 0·33 mmol/L (5·5%) and −0·16 mmol/L (−2·4%), respectively (p=0·004).",30738:31024,3620898,23465742,Unavailable
3620898,Cardiovascular events ,Estrogen patches ,Luteinising-hormone-releasing-hormone agonists,No significant difference,The rate of cardiovascular events was 2·9% higher in the oestrogen-patch group than in the LHRHa group (95% CI −4·2 to 10·1). The wide 95% CI suggests no significant difference between groups,28168:28360,3620898,23465742,Unavailable
3620921,Success rate,Dimeticone liquid gel,Permethrin creme rinse,Significantly increased,"Intention to treat comparison of a single dimeticone liquid gel treatment with two of permethrin gave success for 30/43 (69.8%) of the dimeticone liquid gel group and 7/47 (14.9%) of the permethrin creme rinse group (OR 13.19, 95% CI 4.69 to 37.07) (p &lt; 0.001).",4155:4417,3620921,23548062,Unavailable
3620921,Success rate,Dimeticone liquid gel,Permethrin creme rinse,Significantly increased,"The difference in rate of success between the dimeticone and permethrin groups was estimated as 54.9% (95% CI of 35% to 75%) (OR 13.19, 95% CI 4.69 to 37.07) which meant that there was a highly significant (p &lt; 0.001) superiority of dimeticone liquid gel compared with permethrin creme rinse in the population tested.",18236:18553,3620921,23548062,Unavailable
3620921,Success rate,Dimeticone liquid gel,Permethrin creme rinse,Significantly increased,Cure or cure followed by reinfestation3069.8%714.9%&lt; 0.001,20859:21152,3620921,23548062,Unavailable
3620921,Cure (absolute) ,Dimeticone liquid gel,Permethrin creme rinse,Significantly increased,Cure2660.5%612.8%&lt; 0.001,21790:22071,3620921,23548062,Unavailable
3620921,Inhibition of egg hatching,Dimeticone liquid gel,Permethrin creme rinse,Significantly increased,Inhibition of egg hatching3274.4%612.8%&lt; 0.001,21790:22071,3620921,23548062,Unavailable
5426451,Bone density (2 days),Performing ovariectomy,Placebo surgery ,Significantly decreased,BD was significantly higher in the non-OVX group than in the OVX group 2 days and 8 weeks after fusion surgery.,5003:5114,5426451,28490162,Unavailable
5426451,Bone density (8 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,BD was significantly higher in the non-OVX group than in the OVX group 2 days and 8 weeks after fusion surgery.,5003:5114,5426451,28490162,Unavailable
5426451,Fusion rate (8 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,The fusion rate in the non-OVX group was higher than that in the OVX group 8 weeks after surgery (p=0.044).,5115:5239,5426451,28490162,Unavailable
5426451,Rate of bony connection (6 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,The bony connection of bone fragments with transverse processes and bone formation between transverse processes in non-OVX group were significantly superior to those of OVX group from 6 weeks after fusion surgery.,5240:5453,5426451,28490162,Unavailable
5426451,Rate of bony connection (8 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,The bony connection of bone fragments with transverse processes and bone formation between transverse processes in non-OVX group were significantly superior to those of OVX group from 6 weeks after fusion surgery.,5240:5453,5426451,28490162,Unavailable
5426451,Bone formation (6 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,The bony connection of bone fragments with transverse processes and bone formation between transverse processes in non-OVX group were significantly superior to those of OVX group from 6 weeks after fusion surgery.,5240:5453,5426451,28490162,Unavailable
5426451,Bone formation (8 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,The bony connection of bone fragments with transverse processes and bone formation between transverse processes in non-OVX group were significantly superior to those of OVX group from 6 weeks after fusion surgery.,5240:5453,5426451,28490162,Unavailable
5426451,Bone density (2 days),Performing ovariectomy,Placebo surgery ,Significantly decreased,"As expected, there was a significant difference in BD between the non-OVX group and the OVX group at 2 days and 8 weeks after fusion surgery (1.32±0.134 g/cm3 and 1.30±0.117 g/cm3, respectively; p&lt;0.0001, and 1.32±0.191 g/cm3 and 1.29±0.006 g/cm3, respectively; p=0.000). Therefore, the OVX group was osteopenic relative to the non-OVX group.",15289:15712,5426451,28490162,Unavailable
5426451,Bone density (8 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,"As expected, there was a significant difference in BD between the non-OVX group and the OVX group at 2 days and 8 weeks after fusion surgery (1.32±0.134 g/cm3 and 1.30±0.117 g/cm3, respectively; p&lt;0.0001, and 1.32±0.191 g/cm3 and 1.29±0.006 g/cm3, respectively; p=0.000). Therefore, the OVX group was osteopenic relative to the non-OVX group.",15289:15712,5426451,28490162,Unavailable
5426451,Fusion rate (2 weeks),Performing ovariectomy,Placebo surgery ,No significant difference,"The fusion rates of non-OVX vs. OVX groups at 2, 4, 6 and 8 weeks were 0% (0/18) vs. 5.6% (1/18) (p=0.310), 11.1% (2/18) vs. 11.1% (2/18) (p=1.000), 38.9% (7/18) vs. 22.8% (4/18) (p=0.278) and 61.1% (11/18) vs. 27.8% (5/18) (p=0.044), respectively.",17731:17990,5426451,28490162,Unavailable
5426451,Fusion rate (4 weeks),Performing ovariectomy,Placebo surgery ,No significant difference,"The fusion rates of non-OVX vs. OVX groups at 2, 4, 6 and 8 weeks were 0% (0/18) vs. 5.6% (1/18) (p=0.310), 11.1% (2/18) vs. 11.1% (2/18) (p=1.000), 38.9% (7/18) vs. 22.8% (4/18) (p=0.278) and 61.1% (11/18) vs. 27.8% (5/18) (p=0.044), respectively.",17731:17990,5426451,28490162,Unavailable
5426451,Fusion rate (6 weeks),Performing ovariectomy,Placebo surgery ,No significant difference,"The fusion rates of non-OVX vs. OVX groups at 2, 4, 6 and 8 weeks were 0% (0/18) vs. 5.6% (1/18) (p=0.310), 11.1% (2/18) vs. 11.1% (2/18) (p=1.000), 38.9% (7/18) vs. 22.8% (4/18) (p=0.278) and 61.1% (11/18) vs. 27.8% (5/18) (p=0.044), respectively.",17731:17990,5426451,28490162,Unavailable
5426451,Fusion rate (8 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,"The fusion rates of non-OVX vs. OVX groups at 2, 4, 6 and 8 weeks were 0% (0/18) vs. 5.6% (1/18) (p=0.310), 11.1% (2/18) vs. 11.1% (2/18) (p=1.000), 38.9% (7/18) vs. 22.8% (4/18) (p=0.278) and 61.1% (11/18) vs. 27.8% (5/18) (p=0.044), respectively.",15775:16091,5426451,28490162,Unavailable
5426451,Rate of bony connection (2 weeks),Performing ovariectomy,Placebo surgery ,No significant difference,"Until 4 weeks after fusion surgery, there was no significant difference between the groups in the rate of bony connection.",16747:16983,5426451,28490162,Unavailable
5426451,Rate of bony connection (4 weeks),Performing ovariectomy,Placebo surgery ,No significant difference,"Until 4 weeks after fusion surgery, there was no significant difference between the groups in the rate of bony connection.",16747:16983,5426451,28490162,Unavailable
5426451,Rate of bony connection (6 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,"However, the rate of bony connection in the non-OVX group was higher than that in the OVX group at 6 and 8 weeks postfusion surgery (66.7% vs. 22.2%, p=0.007 and 72.2% vs. 27.8%, p=0.008, respectively).",16747:16983,5426451,28490162,Unavailable
5426451,Rate of bony connection (8 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,"However, the rate of bony connection in the non-OVX group was higher than that in the OVX group at 6 and 8 weeks postfusion surgery (66.7% vs. 22.2%, p=0.007 and 72.2% vs. 27.8%, p=0.008, respectively).",16747:16983,5426451,28490162,Unavailable
5426451,Bone formation (4 weeks),Performing ovariectomy,Placebo surgery ,No significant difference,"However, endochondral bone formation is involved in the formation of the fusion mass as bridging bone between TPs14). The rate of presence of bridging bone between TPs in the non-OVX and OVX groups did not differ significantly at 4 weeks (38.7% vs. 22.2%, p=0.278).",16984:17320,5426451,28490162,Unavailable
5426451,Bone formation (6 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,"However, the rates of bridging bone in the non-OVX group at 6 and 8 weeks were superior to those in the OVX group (61.1% vs. 22.2%, p=0.018 and 66.7% vs. 27.8%, p=0.019, respectively) (Fig. 3).",17319:17598,5426451,28490162,Unavailable
5426451,Bone formation (8 weeks),Performing ovariectomy,Placebo surgery ,Significantly decreased,"However, the rates of bridging bone in the non-OVX group at 6 and 8 weeks were superior to those in the OVX group (61.1% vs. 22.2%, p=0.018 and 66.7% vs. 27.8%, p=0.019, respectively) (Fig. 3).",17320:17598,5426451,28490162,Unavailable
5426451,Bone volume fraction,Performing ovariectomy,Placebo surgery ,Significantly decreased,"However, the mean value of BV/TV in the non-OVX group was significantly higher than that of the OVX group 4 weeks after fusion surgery (p=0.000), and the mean values of BS and BS/BV in the non-OVX group were lower than those in the OVX group",17731:17990,5426451,28490162,Unavailable
5426451,Bone surface,Performing ovariectomy,Placebo surgery ,Significantly increased,"However, the mean value of BV/TV in the non-OVX group was significantly higher than that of the OVX group 4 weeks after fusion surgery (p=0.000), and the mean values of BS and BS/BV in the non-OVX group were lower than those in the OVX group",17731:17990,5426451,28490162,Unavailable
5426451,Bone surface ratio,Performing ovariectomy,Placebo surgery ,Significantly increased,"However, the mean value of BV/TV in the non-OVX group was significantly higher than that of the OVX group 4 weeks after fusion surgery (p=0.000), and the mean values of BS and BS/BV in the non-OVX group were lower than those in the OVX group",17731:17990,5426451,28490162,Unavailable
5328251,Successful preparation rate (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"In per-protocol analysis, patients in group B attained significantly higher successful preparation rate than group A (88.7% vs. 61.2%, p&lt;0.001) and similar with group C (88.7% vs. 85.0%, p = 0.316).",41712:41925,5328251,28241037,Unavailable
5328251,Successful preparation rate (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"In per-protocol analysis, patients in group B attained significantly higher successful preparation rate than group A (88.7% vs. 61.2%, p&lt;0.001) and similar with group C (88.7% vs. 85.0%, p = 0.316).",41712:41925,5328251,28241037,Unavailable
5328251,Polyp detection rate,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"The PDR in group B was significantly higher than group A (43.2% vs. 25.7%, p&lt;0.001).",11051:11136,5328251,28241037,Unavailable
5328251,Successful preparation rate (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"In PP analysis, both group B and C showed significantly higher adequate bowel preparation rate than group A (88.7% vs. 61.2%, pAB&lt;0.001; 85.0% vs. 61.2%, pAC&lt;0.001).",41712:41925,5328251,28241037,Unavailable
5328251,Successful preparation rate (overall),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"In PP analysis, both group B and C showed significantly higher adequate bowel preparation rate than group A (88.7% vs. 61.2%, pAB&lt;0.001; 85.0% vs. 61.2%, pAC&lt;0.001).",41712:41925,5328251,28241037,Unavailable
5328251,Successful preparation rate (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"There was no significant difference between group B and C in adequate bowel preparation rate (88.7% vs. 85.0%, pBC = 0.316).",41712:41925,5328251,28241037,Unavailable
5328251,Successful preparation rate (right colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"The adequate preparation rates in right colon were significantly higher in group B and C than that in group A (90.6% vs. 65.9%, pAB&lt;0.001; 87.8% vs. 65.9%, pAC&lt;0.001).",41520:41712,5328251,28241037,Unavailable
5328251,Successful preparation rate (right colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"The adequate preparation rates in right colon were significantly higher in group B and C than that in group A (90.6% vs. 65.9%, pAB&lt;0.001; 87.8% vs. 65.9%, pAC&lt;0.001).",41520:41712,5328251,28241037,Unavailable
5328251,Successful preparation rate (left colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"In transverse colon and left colon, the rates showed the similar tendency (pAB&lt;0.001, pAC&lt;0.001 for transverse colon; pAB = 0.001, pAC = 0.003 for left colon).",41712:41925,5328251,28241037,Unavailable
5328251,Successful preparation rate (left colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"In transverse colon and left colon, the rates showed the similar tendency (pAB&lt;0.001, pAC&lt;0.001 for transverse colon; pAB = 0.001, pAC = 0.003 for left colon).",41712:41925,5328251,28241037,Unavailable
5328251,Successful preparation rate (transverse colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"In transverse colon and left colon, the rates showed the similar tendency (pAB&lt;0.001, pAC&lt;0.001 for transverse colon; pAB = 0.001, pAC = 0.003 for left colon).",41712:41925,5328251,28241037,Unavailable
5328251,Successful preparation rate (transverse colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"In transverse colon and left colon, the rates showed the similar tendency (pAB&lt;0.001, pAC&lt;0.001 for transverse colon; pAB = 0.001, pAC = 0.003 for left colon).",42163:42273,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Group B and C showed significantly higher total BBPS scores than group A (pAB&lt;0.001, pAC&lt;0.001).",42372:42531,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (overall),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Group B and C showed significantly higher total BBPS scores than group A (pAB&lt;0.001, pAC&lt;0.001).",42372:42531,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,There was no significant difference between group B and C for total BBPS scores (pBC = 0.637).,42372:42531,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (right colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Compared with group A, group B and C showed significantly higher BBPS scores at each colon segment (p&lt;0.001).",42163:42273,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (right colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Compared with group A, group B and C showed significantly higher BBPS scores at each colon segment (p&lt;0.001).",42163:42273,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (left colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Compared with group A, group B and C showed significantly higher BBPS scores at each colon segment (p&lt;0.001).",42163:42273,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (left colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Compared with group A, group B and C showed significantly higher BBPS scores at each colon segment (p&lt;0.001).",42163:42273,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (transverse colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Compared with group A, group B and C showed significantly higher BBPS scores at each colon segment (p&lt;0.001).",42163:42273,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (transverse colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Compared with group A, group B and C showed significantly higher BBPS scores at each colon segment (p&lt;0.001).",42163:42273,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (right colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,There was no significant difference between group B and C in terms of BBPS scores at each segment.,42272:42371,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (left colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,There was no significant difference between group B and C in terms of BBPS scores at each segment.,42272:42371,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (transverse colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,There was no significant difference between group B and C in terms of BBPS scores at each segment.,42272:42371,5328251,28241037,Unavailable
5328251,Excellent bowel preparation,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Patients in group B acquired significantly higher rate of excellent bowel preparation quality than those in group A (39.9% vs. 13.1%, pAB&lt;0.001).",42372:42531,5328251,28241037,Unavailable
5328251,Successful preparation rate (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Adequate bowel preparation	131 (61.2%)	189 (88.7%)	181 (85.0%)	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.316",34513:34981,5328251,28241037,Unavailable
5328251,Successful preparation rate (overall),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Adequate bowel preparation	131 (61.2%)	189 (88.7%)	181 (85.0%)	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.316",34513:34981,5328251,28241037,Unavailable
5328251,Successful preparation rate (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Adequate bowel preparation	131 (61.2%)	189 (88.7%)	181 (85.0%)	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.316",34513:34981,5328251,28241037,Unavailable
5328251,Successful preparation rate (right colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Right colon	141 (65.9%)	193 (90.6%)	187 (87.8%)	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.435",35040:35493,5328251,28241037,Unavailable
5328251,Successful preparation rate (right colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Right colon	141 (65.9%)	193 (90.6%)	187 (87.8%)	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.435",35040:35493,5328251,28241037,Unavailable
5328251,Successful preparation rate (left colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Left colon	184 (86.0%)	203 (94.8%)	202 (94.8%)	&lt;0.001	&lt;0.001	0.001	0.003	1.000",36069:36513,5328251,28241037,Unavailable
5328251,Successful preparation rate (left colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Left colon	184 (86.0%)	203 (94.8%)	202 (94.8%)	&lt;0.001	&lt;0.001	0.001	0.003	1.000",36069:36513,5328251,28241037,Unavailable
5328251,Successful preparation rate (transverse colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Transverse colon	159 (74.3%)	197 (92.5%)	197 (92.5%)	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	1.000",35552:36010,5328251,28241037,Unavailable
5328251,Successful preparation rate (transverse colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Transverse colon	159 (74.3%)	197 (92.5%)	197 (92.5%)	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	1.000",35552:36010,5328251,28241037,Unavailable
5328251,Successful preparation rate (right colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Right colon 141 (65.9%) 193 (90.6%) 187 (87.8%) &lt;0.001 &lt;0.001 &lt;0.001 &lt;0.001 0.435,35552:36010,5328251,28241037,Unavailable
5328251,Successful preparation rate (left colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Left colon 184 (86.0%) 203 (94.8%) 202 (94.8%) &lt;0.001 &lt;0.001 0.001 0.003 1.000,35552:36010,5328251,28241037,Unavailable
5328251,Successful preparation rate (transverse colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Transverse colon 159 (74.3%) 197 (92.5%) 197 (92.5%) &lt;0.001 &lt;0.001 &lt;0.001 &lt;0.001 1.000,35552:36010,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Total BBPS scores	5.6±1.6	7.0±1.1	6.9±1.2	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.637",36568:37015,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (overall),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Total BBPS scores	5.6±1.6	7.0±1.1	6.9±1.2	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.637",36568:37015,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Total BBPS scores	5.6±1.6	7.0±1.1	6.9±1.2	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.637",36568:37015,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (right colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Right colon	1.6±0.6	2.1±0.3	2.0±0.3	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.697",37074:37515,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (right colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Right colon	1.6±0.6	2.1±0.3	2.0±0.3	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.697",37074:37515,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (left colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Left colon	2.1±0.6	2.6±0.5	2.5±0.6	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.663",38079:38519,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (left colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Left colon	2.1±0.6	2.6±0.5	2.5±0.6	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.663",38079:38519,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (transverse colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Transverse colon	1.8±0.6	2.3±0.6	2.3±0.6	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.841",37574:38020,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (transverse colon),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Transverse colon	1.8±0.6	2.3±0.6	2.3±0.6	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.841",37574:38020,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (right colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Right colon	1.6±0.6	2.1±0.3	2.0±0.3	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.697",37074:37515,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (left colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Left colon	2.1±0.6	2.6±0.5	2.5±0.6	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.663",38079:38519,5328251,28241037,Unavailable
5328251,Boston Bowel Preparation Scale score (transverse colon),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Transverse colon	1.8±0.6	2.3±0.6	2.3±0.6	&lt;0.001	&lt;0.001	&lt;0.001	&lt;0.001	0.841",37574:38020,5328251,28241037,Unavailable
5328251,Excellent bowel preparation,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Excellent	28 (13.1%)	85 (39.9%)	82 (38.5%)",39072:NaN,5328251,28241037,Unavailable
5328251,Successful caecal intubation rate,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"In group B, successful caecal intubation rate was 94.8%, which was significantly higher than that in group A (88.8%, pAB = 0.033) and similar with that in group C (95.3%, pAC = 0.019), respectively.",42706:42928,5328251,28241037,Unavailable
5328251,Successful caecal intubation rate,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"In group B, successful caecal intubation rate was 94.8%, which was significantly higher than that in group A (88.8%, pAB = 0.033) and similar with that in group C (95.3%, pAC = 0.019), respectively.",42706:42928,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (inadequate preparation),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly decreased,Incomplete colonoscopy rate due to inadequate preparation was significantly lower in group B than group A (pAB = 0.002).,43060:43237,5328251,28241037,Unavailable
5328251,Caecal intubation time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,There was lacking of significant difference in caecal intubation time (p = 0.166) and incomplete colonoscopy due to technical difficulty or stricture (p = 0.536) among 3 groups.,43060:43237,5328251,28241037,Unavailable
5328251,Caecal intubation time,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,There was lacking of significant difference in caecal intubation time (p = 0.166) and incomplete colonoscopy due to technical difficulty or stricture (p = 0.536) among 3 groups.,43060:43237,5328251,28241037,Unavailable
5328251,Caecal intubation time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,There was lacking of significant difference in caecal intubation time (p = 0.166) and incomplete colonoscopy due to technical difficulty or stricture (p = 0.536) among 3 groups.,43060:43237,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (technical difficulty or stricture),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,There was lacking of significant difference in caecal intubation time (p = 0.166) and incomplete colonoscopy due to technical difficulty or stricture (p = 0.536) among 3 groups.,43060:43237,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (technical difficulty or stricture),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,There was lacking of significant difference in caecal intubation time (p = 0.166) and incomplete colonoscopy due to technical difficulty or stricture (p = 0.536) among 3 groups.,43060:43237,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (technical difficulty or stricture),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,There was lacking of significant difference in caecal intubation time (p = 0.166) and incomplete colonoscopy due to technical difficulty or stricture (p = 0.536) among 3 groups.,43060:43237,5328251,28241037,Unavailable
5328251,Withdrawal time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"However, withdrawal time was significantly shorter in group B than group A (pAB&lt;0.001).",43238:43336,5328251,28241037,Unavailable
5328251,Polyp detection rate,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"The PDR in group B was significantly higher than that in group A (25.7% vs. 43.2%, pAB&lt;0.001) while lacking of significant difference comparing with that in group C (43.2% vs. 37.6%, pBC = 0.277).",43337:43562,5328251,28241037,Unavailable
5328251,Polyp detection rate,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"The PDR in group B was significantly higher than that in group A (25.7% vs. 43.2%, pAB&lt;0.001) while lacking of significant difference comparing with that in group C (43.2% vs. 37.6%, pBC = 0.277).",43337:43562,5328251,28241037,Unavailable
5328251,Need for repeat colonoscopy in 1 year,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly decreased,The rate of need for repeat colonoscopy in 1 year in group A was significantly higher than that in group B and C (p&lt;0.001).,43562:43685,5328251,28241037,Unavailable
5328251,Successful caecal intubation rate,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Successful colonoscopy	190 (88.8%)	202 (94.8%)	203 (95.3%)	0.013	0.033	0.019	1.000",46472:46869,5328251,28241037,Unavailable
5328251,Successful caecal intubation rate,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,Successful colonoscopy 190 (88.8%) 202 (94.8%) 203 (95.3%) 0.013 0.033 0.019 1.000,46472:46869,5328251,28241037,Unavailable
5328251,Successful caecal intubation rate,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Successful colonoscopy 190 (88.8%) 202 (94.8%) 203 (95.3%) 0.013 0.033 0.019 1.000,46472:46869,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (inadequate preparation),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"Inadequate preparation	21 (9.8%)	5 (2.3%)	4 (1.9%)	&lt;0.001	0.002	0.001	1.000",45527:45920,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (inadequate preparation),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly decreased,Inadequate preparation 21 (9.8%) 5 (2.3%) 4 (1.9%) &lt;0.001 0.002 0.001 1.000,45527:45920,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (inadequate preparation),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Inadequate preparation 21 (9.8%) 5 (2.3%) 4 (1.9%) &lt;0.001 0.002 0.001 1.000,45527:45920,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (technical difficulty or stricture),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Technical difficulty or stricture	3 (1.4%)	6 (2.8%)	6 (2.8%)	0.536",45979:46225,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (technical difficulty or stricture),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Technical difficulty or stricture	3 (1.4%)	6 (2.8%)	6 (2.8%)	0.536",45979:46225,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (technical difficulty or stricture),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Technical difficulty or stricture	3 (1.4%)	6 (2.8%)	6 (2.8%)	0.536",45979:46225,5328251,28241037,Unavailable
5328251,Caecal intubation time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Caecal intubation time (min)	8.6±4.2	7.9±3.6	7.8±3.8	0.166",46924:47162,5328251,28241037,Unavailable
5328251,Caecal intubation time,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Caecal intubation time (min)	8.6±4.2	7.9±3.6	7.8±3.8	0.166",46924:47162,5328251,28241037,Unavailable
5328251,Caecal intubation time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Caecal intubation time (min)	8.6±4.2	7.9±3.6	7.8±3.8	0.166",46924:47162,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"Incomplete colonoscopy	24 (11.2%)	11 (5.2%)	10 (4.7%)	0.013	0.033	0.019	1.000",45076:45468,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (overall),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"Incomplete colonoscopy	24 (11.2%)	11 (5.2%)	10 (4.7%)	0.013	0.033	0.019	1.000",45076:45468,5328251,28241037,Unavailable
5328251,Incomplete colonoscopy (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Incomplete colonoscopy	24 (11.2%)	11 (5.2%)	10 (4.7%)	0.013	0.033	0.019	1.000",45076:45468,5328251,28241037,Unavailable
5328251,Withdrawal time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"Withdrawal time (min)	7.5±2.4	6.3±2.1	6.4±1.9	&lt;0.001	&lt;0.001	&lt;0.001	0.900",47409:47805,5328251,28241037,Unavailable
5328251,Withdrawal time,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly decreased,Withdrawal time (min) 7.5±2.4 6.3±2.1 6.4±1.9 &lt;0.001 &lt;0.001 &lt;0.001 0.900,47409:47805,5328251,28241037,Unavailable
5328251,Withdrawal time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Withdrawal time (min) 7.5±2.4 6.3±2.1 6.4±1.9 &lt;0.001 &lt;0.001 &lt;0.001 0.900,47409:47805,5328251,28241037,Unavailable
5328251,Polyp detection rate,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Polyp detection rate	55 (25.7%)	92 (43.2%)	80 (37.6%)	0.001	&lt;0.001	0.009	0.277",47860:48256,5328251,28241037,Unavailable
5328251,Polyp detection rate,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Polyp detection rate	55 (25.7%)	92 (43.2%)	80 (37.6%)	0.001	&lt;0.001	0.009	0.277",47860:48256,5328251,28241037,Unavailable
5328251,Polyp detection rate,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Polyp detection rate	55 (25.7%)	92 (43.2%)	80 (37.6%)	0.001	&lt;0.001	0.009	0.277",47860:48256,5328251,28241037,Unavailable
5328251,Need for repeat colonoscopy in 1 year,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"Need for repeat colonoscopy within 1 year	44 (20.6%)	13 (6.1%)	17 (8.0%)	&lt;0.001	&lt;0.001	&lt;0.001	0.571",50602:NaN,5328251,28241037,Unavailable
5328251,Need for repeat colonoscopy in 1 year,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly decreased,Need for repeat colonoscopy within 1 year 44 (20.6%) 13 (6.1%) 17 (8.0%) &lt;0.001 &lt;0.001 &lt;0.001 0.571,50602:NaN,5328251,28241037,Unavailable
5328251,Need for repeat colonoscopy in 1 year,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Need for repeat colonoscopy within 1 year 44 (20.6%) 13 (6.1%) 17 (8.0%) &lt;0.001 &lt;0.001 &lt;0.001 0.571,50602:NaN,5328251,28241037,Unavailable
5328251,Diverticula findings ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Diverticula	4 (1.9%)	6 (2.8%)	4 (1.9%)	0.768",48719:NaN,5328251,28241037,Unavailable
5328251,Diverticula findings ,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Diverticula	4 (1.9%)	6 (2.8%)	4 (1.9%)	0.768",48719:48943,5328251,28241037,Unavailable
5328251,Diverticula findings ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Diverticula	4 (1.9%)	6 (2.8%)	4 (1.9%)	0.768",48719:48943,5328251,28241037,Unavailable
5328251,Colitis findings ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Colitis	12 (5.6%)	8 (3.8%)	10 (4.7%)	0.664",49194:49416,5328251,28241037,Unavailable
5328251,Colitis findings ,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Colitis	12 (5.6%)	8 (3.8%)	10 (4.7%)	0.664",49194:49416,5328251,28241037,Unavailable
5328251,Colitis findings ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Colitis	12 (5.6%)	8 (3.8%)	10 (4.7%)	0.664",49194:49416,5328251,28241037,Unavailable
5328251,Cancer findings ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Cancer	3 (1.4%)	4 (1.9%)	6 (2.8%)	0.574",49667:49886,5328251,28241037,Unavailable
5328251,Cancer findings ,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Cancer	3 (1.4%)	4 (1.9%)	6 (2.8%)	0.574",49667:49886,5328251,28241037,Unavailable
5328251,Cancer findings ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Cancer	3 (1.4%)	4 (1.9%)	6 (2.8%)	0.574",49667:49886,5328251,28241037,Unavailable
5328251,Other findings ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Other	3 (1.4%)	4 (1.9%)	2 (0.9%)	0.713",50137:50355,5328251,28241037,Unavailable
5328251,Other findings ,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Other	3 (1.4%)	4 (1.9%)	2 (0.9%)	0.713",50137:50355,5328251,28241037,Unavailable
5328251,Other findings ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Other	3 (1.4%)	4 (1.9%)	2 (0.9%)	0.713",50137:50355,5328251,28241037,Unavailable
5328251,Side effects (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,The incidence of side effects was not significantly different among 3 groups (p = 0.714).,51675:51764,5328251,28241037,Unavailable
5328251,Side effects (overall),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,The incidence of side effects was not significantly different among 3 groups (p = 0.714).,51675:51764,5328251,28241037,Unavailable
5328251,Side effects (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,The incidence of side effects was not significantly different among 3 groups (p = 0.714).,51675:51764,5328251,28241037,Unavailable
5328251,Satisfaction scores ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"Overall, satisfaction scores in group B and C was significantly lower than that in group A (pAB&lt;0.001, pAC&lt;0.001).",51765:51904,5328251,28241037,Unavailable
5328251,Satisfaction scores ,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"Overall, satisfaction scores in group B and C was significantly lower than that in group A (pAB&lt;0.001, pAC&lt;0.001).",51765:51904,5328251,28241037,Unavailable
5328251,Ease of taking scores,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,Ease of taking scores of preparation were not significantly different among 3 groups (p = 0.801).,51905:52002,5328251,28241037,Unavailable
5328251,Ease of taking scores,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,Ease of taking scores of preparation were not significantly different among 3 groups (p = 0.801).,51905:52002,5328251,28241037,Unavailable
5328251,Ease of taking scores,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Ease of taking scores of preparation were not significantly different among 3 groups (p = 0.801).,51905:52002,5328251,28241037,Unavailable
5328251,Willingness to repeat,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,The rate of willingness to repeat the same preparation was significantly lower in group A than that in group B (pAB = 0.002) and C (pAC = 0.001).,52003:52173,5328251,28241037,Unavailable
5328251,Willingness to repeat,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,The rate of willingness to repeat the same preparation was significantly lower in group A than that in group B (pAB = 0.002) and C (pAC = 0.001).,52003:52173,5328251,28241037,Unavailable
5328251,Sleeping quality,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,Sleeping quality was not significantly different among 3 groups (p = 0.779).,52174:52250,5328251,28241037,Unavailable
5328251,Sleeping quality,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,Sleeping quality was not significantly different among 3 groups (p = 0.779).,52174:52251,5328251,28241037,Unavailable
5328251,Sleeping quality,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Sleeping quality was not significantly different among 3 groups (p = 0.779).,52174:52251,5328251,28241037,Unavailable
5328251,Correct start time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,The majority of patients started preparation regimens at correct time (p = 0.938) and abided by correct diet restriction (p = 0.843).,52251:52384,5328251,28241037,Unavailable
5328251,Correct start time,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,The majority of patients started preparation regimens at correct time (p = 0.938) and abided by correct diet restriction (p = 0.843).,52251:52384,5328251,28241037,Unavailable
5328251,Correct start time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,The majority of patients started preparation regimens at correct time (p = 0.938) and abided by correct diet restriction (p = 0.843).,52251:52384,5328251,28241037,Unavailable
5328251,Correct diet restriction,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,The majority of patients started preparation regimens at correct time (p = 0.938) and abided by correct diet restriction (p = 0.843).,52251:52384,5328251,28241037,Unavailable
5328251,Correct diet restriction,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,The majority of patients started preparation regimens at correct time (p = 0.938) and abided by correct diet restriction (p = 0.843).,52251:52384,5328251,28241037,Unavailable
5328251,Correct diet restriction,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,The majority of patients started preparation regimens at correct time (p = 0.938) and abided by correct diet restriction (p = 0.843).,52251:52384,5328251,28241037,Unavailable
5328251,Side effects (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Presence of any of the following side effects, N (%)	72 (33.6%)	76 (35.7%)	68 (31.9%)	0.714",53657:53928,5328251,28241037,Unavailable
5328251,Side effects (overall),2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Presence of any of the following side effects, N (%)	72 (33.6%)	76 (35.7%)	68 (31.9%)	0.714",53657:53928,5328251,28241037,Unavailable
5328251,Side effects (overall),Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Presence of any of the following side effects, N (%)	72 (33.6%)	76 (35.7%)	68 (31.9%)	0.714",53657:53928,5328251,28241037,Unavailable
5328251,Nausea,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Nausea	50 (23.4%)	48 (22.5%)	51 (23.9%)	0.942",53987:54212,5328251,28241037,Unavailable
5328251,Nausea,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Nausea	50 (23.4%)	48 (22.5%)	51 (23.9%)	0.942",53987:54212,5328251,28241037,Unavailable
5328251,Nausea,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Nausea	50 (23.4%)	48 (22.5%)	51 (23.9%)	0.942",53987:54212,5328251,28241037,Unavailable
5328251,Bloating,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Bloating	24 (11.2%)	30 (14.1%)	24 (11.3%)	0.585",54271:54498,5328251,28241037,Unavailable
5328251,Bloating,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Bloating	24 (11.2%)	30 (14.1%)	24 (11.3%)	0.585",54271:54498,5328251,28241037,Unavailable
5328251,Bloating,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Bloating	24 (11.2%)	30 (14.1%)	24 (11.3%)	0.585",54271:54498,5328251,28241037,Unavailable
5328251,Abdominal pain,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Abdominal pain	10 (4.7%)	16 (7.5%)	11 (5.2%)	0.406",54557:54787,5328251,28241037,Unavailable
5328251,Abdominal pain,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Abdominal pain	10 (4.7%)	16 (7.5%)	11 (5.2%)	0.406",54557:54787,5328251,28241037,Unavailable
5328251,Abdominal pain,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Abdominal pain	10 (4.7%)	16 (7.5%)	11 (5.2%)	0.406",54557:54787,5328251,28241037,Unavailable
5328251,Vomiting,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Vomiting	17 (7.9%)	13 (6.1%)	18 (8.5%)	0.713",54846:55070,5328251,28241037,Unavailable
5328251,Vomiting,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Vomiting	17 (7.9%)	13 (6.1%)	18 (8.5%)	0.713",54846:55070,5328251,28241037,Unavailable
5328251,Vomiting,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Vomiting	17 (7.9%)	13 (6.1%)	18 (8.5%)	0.713",54846:55070,5328251,28241037,Unavailable
5328251,Lightheadedness,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Lightheadedness	4 (1.9%)	4 (1.9%)	2 (0.9%)	0.668",55129:55357,5328251,28241037,Unavailable
5328251,Lightheadedness,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Lightheadedness	4 (1.9%)	4 (1.9%)	2 (0.9%)	0.668",55129:55357,5328251,28241037,Unavailable
5328251,Lightheadedness,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Lightheadedness	4 (1.9%)	4 (1.9%)	2 (0.9%)	0.668",55129:55357,5328251,28241037,Unavailable
5328251,Satisfaction scores ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"Satisfaction scores (0–7 scale)	2.4±1.2	1.9±0.8	1.8±0.8	&lt;0.001",55668:55910,5328251,28241037,Unavailable
5328251,Satisfaction scores ,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"Satisfaction scores (0–7 scale)	2.4±1.2	1.9±0.8	1.8±0.8	&lt;0.001*",55668:55956,5328251,28241037,Unavailable
5328251,Ease of taking scores,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Ease of taking scores (0–7 scale)	2.1±0.9	2.2±0.9	2.1±1.0	0.801",56022:56265,5328251,28241037,Unavailable
5328251,Ease of taking scores,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Ease of taking scores (0–7 scale)	2.1±0.9	2.2±0.9	2.1±1.0	0.801",56022:56265,5328251,28241037,Unavailable
5328251,Ease of taking scores,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Ease of taking scores (0–7 scale)	2.1±0.9	2.2±0.9	2.1±1.0	0.801",56022:56265,5328251,28241037,Unavailable
5328251,Willingness to repeat,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Willingness to repeat	173 (80.8%)	195 (91.5%)	197 (92.5%)	&lt;0.001",56324:56568,5328251,28241037,Unavailable
5328251,Willingness to repeat,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"Willingness to repeat	173 (80.8%)	195 (91.5%)	197 (92.5%)	&lt;0.001#",56324:56614,5328251,28241037,Unavailable
5328251,Satisfaction scores ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Satisfaction scores (0–7 scale) 2.4±1.2 1.9±0.8 1.8±0.8 &lt;0.001,56324:56614,5328251,28241037,Unavailable
5328251,Willingness to repeat,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,Willingness to repeat 173 (80.8%) 195 (91.5%) 197 (92.5%) &lt;0.001,56324:56614,5328251,28241037,Unavailable
5328251,Sleeping quality,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Sleeping quality				0.779",56676:56881,5328251,28241037,Unavailable
5328251,Sleeping quality,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Sleeping quality				0.779",56676:56881,5328251,28241037,Unavailable
5328251,Sleeping quality,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Sleeping quality				0.779",56676:56881,5328251,28241037,Unavailable
5328251,Correct start time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Correct start time	197 (92.1%)	195 (91.5%)	197 (92.5%)	0.938",57766:58006,5328251,28241037,Unavailable
5328251,Correct start time,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Correct start time	197 (92.1%)	195 (91.5%)	197 (92.5%)	0.938",57766:58006,5328251,28241037,Unavailable
5328251,Correct start time,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Correct start time	197 (92.1%)	195 (91.5%)	197 (92.5%)	0.938",57766:58006,5328251,28241037,Unavailable
5328251,Correct diet restriction,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Correct diet restriction	200 (93.5%)	198 (93.0%)	196 (92.0%)	0.843",58065:58311,5328251,28241037,Unavailable
5328251,Correct diet restriction,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Correct diet restriction	200 (93.5%)	198 (93.0%)	196 (92.0%)	0.843",58065:58311,5328251,28241037,Unavailable
5328251,Correct diet restriction,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Correct diet restriction	200 (93.5%)	198 (93.0%)	196 (92.0%)	0.843",58065:58311,5328251,28241037,Unavailable
5328251,"Amount of solution intake &gt;80%	",Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),No significant difference,"Amount of solution intake&gt;80%	204 (95.3%)	202 (94.8%)	201 (94.4%)	0.904",58370:58624,5328251,28241037,Unavailable
5328251,"Amount of solution intake &gt;80%	",2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),No significant difference,"Amount of solution intake&gt;80%	204 (95.3%)	202 (94.8%)	201 (94.4%)	0.904",58370:58624,5328251,28241037,Unavailable
5328251,"Amount of solution intake &gt;80%	",Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"Amount of solution intake&gt;80%	204 (95.3%)	202 (94.8%)	201 (94.4%)	0.904",58370:58624,5328251,28241037,Unavailable
5328251,Satisfaction scores ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"p values for satisfaction scores comparing group A with group B, group A with group C and group B with group C are &lt;0.001, &lt;0.001 and 0.696, separately.",59021:59173,5328251,28241037,Unavailable
5328251,Satisfaction scores ,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly decreased,"p values for satisfaction scores comparing group A with group B, group A with group C and group B with group C are &lt;0.001, &lt;0.001 and 0.696, separately.",59021:59173,5328251,28241037,Unavailable
5328251,Satisfaction scores ,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"p values for satisfaction scores comparing group A with group B, group A with group C and group B with group C are &lt;0.001, &lt;0.001 and 0.696, separately.",59021:59173,5328251,28241037,Unavailable
5328251,Willingness to repeat,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 1-2),Significantly increased,"p values for willingness to repeat comparing group A with group B, group A with group C and group B with group C are 0.002, 0.001 and 0.858, separately.",59212:59364,5328251,28241037,Unavailable
5328251,Willingness to repeat,2 L PEG-ELP (in Bristol 3-7),2 L PEG-ELP (in Bristol 1-2),Significantly increased,"p values for willingness to repeat comparing group A with group B, group A with group C and group B with group C are 0.002, 0.001 and 0.858, separately.",59212:59364,5328251,28241037,Unavailable
5328251,Willingness to repeat,Bisacodyl + 2 L PEG-ELP ,2 L PEG-ELP (in Bristol 3-7),No significant difference,"p values for willingness to repeat comparing group A with group B, group A with group C and group B with group C are 0.002, 0.001 and 0.858, separately.",59211:59364,5328251,28241037,Unavailable
2852713,Adequate cleansing/image quality,M2A capsule,Sodium phosphate,Significantly decreased,"Overall cleansing of the small bowel was adequate in 43% of patients in group A, 77% of those in group B, and 56% of those in group C (group A vs group B, p=0.001).",15122:15543,2852713,20431743,Unavailable
2852713,Diagnoses for obscure gastrointestinal bleeding,M2A capsule,Sodium phosphate,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Diagnoses for obscure gastrointestinal bleeding,Polyethylene glycol,Sodium phosphate,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Diagnoses for obscure gastrointestinal bleeding,M2A capsule,Polyethylene glycol,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Gastric emptying time  ,M2A capsule,Sodium phosphate,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Gastric emptying time  ,Polyethylene glycol,Sodium phosphate,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Gastric emptying time  ,M2A capsule,Polyethylene glycol,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Small intestine transit time ,M2A capsule,Sodium phosphate,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Small intestine transit time ,Polyethylene glycol,Sodium phosphate,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Small intestine transit time ,M2A capsule,Polyethylene glycol,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Capsule reaching the cecum,M2A capsule,Sodium phosphate,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Capsule reaching the cecum,Polyethylene glycol,Sodium phosphate,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Capsule reaching the cecum,M2A capsule,Polyethylene glycol,No significant difference,"Diagnoses for obscure gastrointestinal bleeding were established in 9 patients (39%) in group A, 16 patients (69%) in group B, and 14 patients (50%) in group C. No significant difference in diagnostic yield was observed between groups.",6605:6840,2852713,20431743,Unavailable
2852713,Adequate cleansing/image quality,M2A capsule,Polyethylene glycol,No significant difference,"No significant difference in image quality was observed Group B and C, or between Group A and C.",15544:15640,2852713,20431743,Unavailable
2852713,Adequate cleansing/image quality,M2A capsule,Sodium phosphate,Significantly decreased,"The number of patients with ""adequate"" cleansing of the small intestine was 19 in Group A (43%), 33 in Group B (77%), and 25 in Group C (56%). The mean percentage of patients with ""adequate"" cleansing was significantly different among the three groups (p=0.002). In comparison with the other subgroups, Group B had significantly better image quality than Group A (p=0.001; Table 2).",15122:15543,2852713,20431743,Unavailable
2852713,Adequate cleansing/image quality,Polyethylene glycol,Sodium phosphate,No significant difference,"No significant difference in image quality was observed Group B and C, or between Group A and C.",15544:15640,2852713,20431743,Unavailable
2852713,Diagnoses for obscure gastrointestinal bleeding,M2A capsule,Sodium phosphate,No significant difference,"In patients with obscure gastrointestinal bleeding, a definite diagnosis was established for nine patients (39%) in Group A, 16 patients (69%) in Group B, and 14 patients (50%) in Group C (p=0.111).",15713:15911,2852713,20431743,Unavailable
2852713,Diagnoses for obscure gastrointestinal bleeding,Polyethylene glycol,Sodium phosphate,No significant difference,"In patients with obscure gastrointestinal bleeding, a definite diagnosis was established for nine patients (39%) in Group A, 16 patients (69%) in Group B, and 14 patients (50%) in Group C (p=0.111).",15713:15911,2852713,20431743,Unavailable
2852713,Diagnoses for obscure gastrointestinal bleeding,M2A capsule,Polyethylene glycol,No significant difference,"In patients with obscure gastrointestinal bleeding, a definite diagnosis was established for nine patients (39%) in Group A, 16 patients (69%) in Group B, and 14 patients (50%) in Group C (p=0.111).",15713:15911,2852713,20431743,Unavailable
2852713,Diagnoses for non-obscure gastrointestinal bleeding,M2A capsule,Sodium phosphate,No significant difference,"In patients with non-obscure gastrointestinal bleeding, a definite diagnosis was established for 14% of patients in Group A, 27% in Group C, and 33% in Group C (p=0.739; Tables 3 and 4). No significant difference was observed among groups in terms of diagnostic yield.",15911:16258,2852713,20431743,Unavailable
2852713,Diagnoses for non-obscure gastrointestinal bleeding,Polyethylene glycol,Sodium phosphate,No significant difference,"In patients with non-obscure gastrointestinal bleeding, a definite diagnosis was established for 14% of patients in Group A, 27% in Group C, and 33% in Group C (p=0.739; Tables 3 and 4). No significant difference was observed among groups in terms of diagnostic yield.",15911:16258,2852713,20431743,Unavailable
2852713,Diagnoses for non-obscure gastrointestinal bleeding,M2A capsule,Polyethylene glycol,No significant difference,"In patients with non-obscure gastrointestinal bleeding, a definite diagnosis was established for 14% of patients in Group A, 27% in Group C, and 33% in Group C (p=0.739; Tables 3 and 4). No significant difference was observed among groups in terms of diagnostic yield.",15912:16258,2852713,20431743,Unavailable
3724375,Extubation time,Dexamethasone ,Placebo ,Significantly decreased,Extubation time of DEX group was significantly reduced.,4147:4202,3724375,23914217,Unavailable
3724375,Delirium incidence (POD1),Dexamethasone ,Placebo ,Significantly decreased,"The first post-operative day deliriums, extubation time, hospital, and intensive-care unit length of stay significantly reduced in DEX group without increasing serious complications such as infectious disease.",16356:16556,3724375,23914217,Unavailable
3724375,Hospital length of stay,Dexamethasone ,Placebo ,Significantly decreased,"The first post-operative day deliriums, extubation time, hospital, and intensive-care unit length of stay significantly reduced in DEX group without increasing serious complications such as infectious disease.",4203:4412,3724375,23914217,Unavailable
3724375,ICU length of stay,Dexamethasone ,Placebo ,Significantly decreased,"The first post-operative day deliriums, extubation time, hospital, and intensive-care unit length of stay significantly reduced in DEX group without increasing serious complications such as infectious disease.",4203:4412,3724375,23914217,Unavailable
3724375,Hyperglycemia ,Dexamethasone ,Placebo ,Significantly increased,After administration of DEX only hyperglycemia as an adverse event was increased in DEX group.,4412:4507,3724375,23914217,Unavailable
3724375,Extubation time,Dexamethasone ,Placebo ,Significantly decreased,Analysis of post-operative data revealed that the patients of DEX group were significantly intubated for a shorter time (P = 0.04).,13808:13956,3724375,23914217,Unavailable
3724375,Hyperglycemia ,Dexamethasone ,Placebo ,Significantly increased,"Other significant difference was seen in mean of post-operative blood sugar between groups (P = 0.007), which DEX group had mean blood glucose 245 ± 68 mg/dl versus 212 ± 45 mg/dl in PCB group.",14072:14282,3724375,23914217,Unavailable
3724375,Chest tube drainage volume,Dexamethasone ,Placebo ,No significant difference,"The other Intra-operative variables includes chest tube drainage volume, transfusion of packed cell and fresh frozen plasma more than 2 units, arterial partial pressure of carbon dioxide more than 50 mmHg, and arterial partial pressure of oxygen less than 60 mmHg. These variables statistics did not show any significant difference between the groups.",14492:14843,3724375,23914217,Unavailable
3724375,Transfusion of packed cell and fresh frozen plasma + 2 units,Dexamethasone ,Placebo ,No significant difference,"The other Intra-operative variables includes chest tube drainage volume, transfusion of packed cell and fresh frozen plasma more than 2 units, arterial partial pressure of carbon dioxide more than 50 mmHg, and arterial partial pressure of oxygen less than 60 mmHg. These variables statistics did not show any significant difference between the groups.",14492:14843,3724375,23914217,Unavailable
3724375,Arterial partial pressure of carbon dioxide + 50 mmHg,Dexamethasone ,Placebo ,No significant difference,"The other Intra-operative variables includes chest tube drainage volume, transfusion of packed cell and fresh frozen plasma more than 2 units, arterial partial pressure of carbon dioxide more than 50 mmHg, and arterial partial pressure of oxygen less than 60 mmHg. These variables statistics did not show any significant difference between the groups.",14492:14843,3724375,23914217,Unavailable
3724375,Arterial partial pressure of oxygen less than 60 mmHg,Dexamethasone ,Placebo ,No significant difference,"The other Intra-operative variables includes chest tube drainage volume, transfusion of packed cell and fresh frozen plasma more than 2 units, arterial partial pressure of carbon dioxide more than 50 mmHg, and arterial partial pressure of oxygen less than 60 mmHg. These variables statistics did not show any significant difference between the groups.",14492:14843,3724375,23914217,Unavailable
3724375,Mini-mental status examination score (POD1),Dexamethasone ,Placebo ,Significantly increased,"the DEX group compared to the PCB group obtained higher scores in POD1 (27.53 ± 3.44 vs. 25.78 ± 4.70, respectively, P = 0.04).",15165:15310,3724375,23914217,Unavailable
3724375,Mini-mental status examination score (POD2),Dexamethasone ,Placebo ,Significantly increased,"DEX group significantly had a higher scores than PCB group in POD2 (28.12 ± 2.66 vs. 26.26 ± 4.20, respectively, P = 0.04).",15310:15450,3724375,23914217,Unavailable
3724375,Mini-mental status examination score (POD3),Dexamethasone ,Placebo ,No significant difference,"The scores of POD3 did not show any meaningful difference between the DEX and PCB groups (28.00 ± 3.08 vs. 27.40 ± 3.20, respectively, P = 0.36).",15451:15613,3724375,23914217,Unavailable
3724375,Delirium incidence (POD1),Dexamethasone ,Placebo ,Significantly decreased,"The results of POD1 were exhibited a significant reduction of delirium incidence in DEX in contrasted with PCB group (4 (9.3%) vs. 13 (26%), respectively, P = 0.03).",16022:16205,3724375,23914217,Unavailable
3724375,Delirium incidence (POD2),Dexamethasone ,Placebo ,No significant difference,"The results of POD2 did not show any significant difference between DEX and PCB groups (2 (4.7%) vs. 5 (10%), respectively, P = 0.40).",17685:17841,3724375,23914217,Unavailable
3724375,Delirium incidence (POD3),Dexamethasone ,Placebo ,No significant difference,"In the same way, there is no statistically difference in number of the patients who suffered from delirium in DEX versus PCB group in POD3 (1 (2.3%) vs. 1 (2%), respectively, P = 1).",17685:17841,3724375,23914217,Unavailable
3724375,ICU length of stay,Dexamethasone ,Placebo ,Significantly decreased,the patients of DEX group with 2.86 ± 1.3 days had a shorter ICU LOS than the patients of PCB group with 3.68 ± 1.33 days.,16850:16972,3724375,23914217,Unavailable
3724375,Hospital length of stay,Dexamethasone ,Placebo ,Significantly decreased,"In addition, the hospital LOS for DEX group was 12.93 ± 1.03 days versus 13.64 ± 1.75 days for the PCB group. Therefore, both parameters of ICU and hospital LOS was significantly shorter in the DEX group (P = 0.004, P = 0.02, respectively).",16972:17247,3724375,23914217,Unavailable
3724375,Deep sternal wound infection,Dexamethasone ,Placebo ,No significant difference,"The results shows that occurrences of deep sternal wound infection, leg infection, sepsis, and pneumonia did not statistically differed between the groups.",17685:17841,3724375,23914217,Unavailable
3724375,Leg infection,Dexamethasone ,Placebo ,No significant difference,"The results shows that occurrences of deep sternal wound infection, leg infection, sepsis, and pneumonia did not statistically differed between the groups.",17685:17841,3724375,23914217,Unavailable
3724375,Sepsis,Dexamethasone ,Placebo ,No significant difference,"The results shows that occurrences of deep sternal wound infection, leg infection, sepsis, and pneumonia did not statistically differed between the groups.",17685:17841,3724375,23914217,Unavailable
3724375,Pneumonia ,Dexamethasone ,Placebo ,No significant difference,"The results shows that occurrences of deep sternal wound infection, leg infection, sepsis, and pneumonia did not statistically differed between the groups.",17685:17841,3724375,23914217,Unavailable
3724375,Acute myocardial infarction,Dexamethasone ,Placebo ,No significant difference,"In addition, cardiac complications including acute myocardial infarction, cardiac arrest, atrioventricular block, atrial fibrillation (AF), and low cardiac output state were not statistically different.",17840:18043,3724375,23914217,Unavailable
3724375,Cardiac arrest,Dexamethasone ,Placebo ,No significant difference,"In addition, cardiac complications including acute myocardial infarction, cardiac arrest, atrioventricular block, atrial fibrillation (AF), and low cardiac output state were not statistically different.",17840:18043,3724375,23914217,Unavailable
3724375,Atrioventricular block,Dexamethasone ,Placebo ,No significant difference,"In addition, cardiac complications including acute myocardial infarction, cardiac arrest, atrioventricular block, atrial fibrillation (AF), and low cardiac output state were not statistically different.",17840:18043,3724375,23914217,Unavailable
3724375,Atrial fibrillation,Dexamethasone ,Placebo ,No significant difference,"In addition, cardiac complications including acute myocardial infarction, cardiac arrest, atrioventricular block, atrial fibrillation (AF), and low cardiac output state were not statistically different.",17840:18043,3724375,23914217,Unavailable
3724375,Low cardiac output state,Dexamethasone ,Placebo ,No significant difference,"In addition, cardiac complications including acute myocardial infarction, cardiac arrest, atrioventricular block, atrial fibrillation (AF), and low cardiac output state were not statistically different.",17840:18043,3724375,23914217,Unavailable
3724375,Transient ischemic attack,Dexamethasone ,Placebo ,No significant difference,"There is no significant difference in cerebrovascular (transient ischemic attack, stroke), respiratory (acute respiratory failure), and renal (acute tubular necrosis, renal failure) systems was seen.",18044:18243,3724375,23914217,Unavailable
3724375,Stroke,Dexamethasone ,Placebo ,No significant difference,"There is no significant difference in cerebrovascular (transient ischemic attack, stroke), respiratory (acute respiratory failure), and renal (acute tubular necrosis, renal failure) systems was seen.",18044:18243,3724375,23914217,Unavailable
3724375,Acute respiratory failure,Dexamethasone ,Placebo ,No significant difference,"There is no significant difference in cerebrovascular (transient ischemic attack, stroke), respiratory (acute respiratory failure), and renal (acute tubular necrosis, renal failure) systems was seen.",18044:18243,3724375,23914217,Unavailable
3724375,Acute tubular necrosis,Dexamethasone ,Placebo ,No significant difference,"There is no significant difference in cerebrovascular (transient ischemic attack, stroke), respiratory (acute respiratory failure), and renal (acute tubular necrosis, renal failure) systems was seen.",18044:18243,3724375,23914217,Unavailable
3724375,Renal failure,Dexamethasone ,Placebo ,No significant difference,"There is no significant difference in cerebrovascular (transient ischemic attack, stroke), respiratory (acute respiratory failure), and renal (acute tubular necrosis, renal failure) systems was seen.",18044:18243,3724375,23914217,Unavailable
3724375,Acute myocardial infarction,Dexamethasone ,Placebo ,No significant difference,"Other complications of renal, cardiac, cerebrovascular and respiratory system did not show any significant differences between groups.",4508:4642,3724375,23914217,Unavailable
3724375,Cardiac arrest,Dexamethasone ,Placebo ,No significant difference,"Other complications of renal, cardiac, cerebrovascular and respiratory system did not show any significant differences between groups.",4508:4642,3724375,23914217,Unavailable
3724375,Atrioventricular block,Dexamethasone ,Placebo ,No significant difference,"Other complications of renal, cardiac, cerebrovascular and respiratory system did not show any significant differences between groups.",4508:4642,3724375,23914217,Unavailable
3724375,Atrial fibrillation,Dexamethasone ,Placebo ,No significant difference,"Other complications of renal, cardiac, cerebrovascular and respiratory system did not show any significant differences between groups.",4508:4642,3724375,23914217,Unavailable
3724375,Low cardiac output state,Dexamethasone ,Placebo ,No significant difference,"Other complications of renal, cardiac, cerebrovascular and respiratory system did not show any significant differences between groups.",4508:4642,3724375,23914217,Unavailable
3724375,Transient ischemic attack,Dexamethasone ,Placebo ,No significant difference,"Other complications of renal, cardiac, cerebrovascular and respiratory system did not show any significant differences between groups.",4508:4642,3724375,23914217,Unavailable
3724375,Stroke,Dexamethasone ,Placebo ,No significant difference,"Other complications of renal, cardiac, cerebrovascular and respiratory system did not show any significant differences between groups.",4508:4642,3724375,23914217,Unavailable
3724375,Acute respiratory failure,Dexamethasone ,Placebo ,No significant difference,"Other complications of renal, cardiac, cerebrovascular and respiratory system did not show any significant differences between groups.",4508:4642,3724375,23914217,Unavailable
3724375,Acute tubular necrosis,Dexamethasone ,Placebo ,No significant difference,"Other complications of renal, cardiac, cerebrovascular and respiratory system did not show any significant differences between groups.",4508:4642,3724375,23914217,Unavailable
3724375,Renal failure,Dexamethasone ,Placebo ,No significant difference,"Other complications of renal, cardiac, cerebrovascular and respiratory system did not show any significant differences between groups.",4508:4642,3724375,23914217,Unavailable
3656397,ACE inhibitor prescriptions (3 months),Tailored evidence-based drug information,EBDI as usual ,No significant difference,The proportion of ACE inhibitor prescriptions (average proportion for GPs) was increased in both groups at the three- and six-month follow-up. There were no significant differences in the change in prescription proportion between groups,21289:21525,3656397,23465039,Unavailable
3656397,ACE inhibitor prescriptions (6 months),Tailored evidence-based drug information,EBDI as usual ,No significant difference,The proportion of ACE inhibitor prescriptions (average proportion for GPs) was increased in both groups at the three- and six-month follow-up. There were no significant differences in the change in prescription proportion between groups,21289:21525,3656397,23465039,Unavailable
3656397,ACE inhibitor prescriptions (3 months),Tailored evidence-based drug information,EBDI as usual ,No significant difference,"Relative change in proportion of ACE inhibitors 0–3 months after intervention2,3	+ 0.12 (0.43) + 0.029 (–0.11–0.32)	+ 0.12 (0.59) ± 0.00 (–0.17–0.27)",22796:23095,3656397,23465039,Unavailable
3656397,ACE inhibitor prescriptions (6 months),Tailored evidence-based drug information,EBDI as usual ,No significant difference,"Relative change in proportion of ACE inhibitors 4–6 months after intervention2,3	+ 0.12 (0.47) + 0.051 (–0.13–0.25)	+ 0.13 (0.56) + 0.0040 (–0.14–0.26)",23150:NaN,3656397,23465039,Unavailable
5842532,Graft survival ,Umbilical-cord-derived MSCs,Control,No significant difference,"Treatment with UC-MSCs achieved comparable graft and recipient survivals with non-MSC treatment (P&nbsp;=&nbsp;0.97 and 0.15, respectively).",32821:32922,5842532,29514693,Unavailable
5842532,Recipient survivals,Umbilical-cord-derived MSCs,Control,No significant difference,"Treatment with UC-MSCs achieved comparable graft and recipient survivals with non-MSC treatment (P&nbsp;=&nbsp;0.97 and 0.15, respectively).",8510:8641,5842532,29514693,Unavailable
5842532,Delayed graft function,Umbilical-cord-derived MSCs,Control,No significant difference,"No increase in postoperative complications, including DGF and acute rejection, were observed (incidence of DGF: 9.5% in the MSC group versus 33.3% in the non-MSC group, P&nbsp;=&nbsp;0.13; Incidence of acute rejection: 14.3% versus 4.8%, P&nbsp;=&nbsp;0.61).",8641:8880,5842532,29514693,Unavailable
5842532,Acute rejection,Umbilical-cord-derived MSCs,Control,No significant difference,"No increase in postoperative complications, including DGF and acute rejection, were observed (incidence of DGF: 9.5% in the MSC group versus 33.3% in the non-MSC group, P&nbsp;=&nbsp;0.13; Incidence of acute rejection: 14.3% versus 4.8%, P&nbsp;=&nbsp;0.61).",8641:8880,5842532,29514693,Unavailable
5842532,Postoperative estimated glomerular filtration,Umbilical-cord-derived MSCs,Control,No significant difference,Equal postoperative estimated glomerular filtration rates were found between the two groups (P&nbsp;=&nbsp;0.88).,8880:8984,5842532,29514693,Unavailable
5842532,Delayed graft function,Umbilical-cord-derived MSCs,Control,No significant difference,"DGF	2	7	0.13",29920:29995,5842532,29514693,Unavailable
5842532,Acute rejection,Umbilical-cord-derived MSCs,Control,No significant difference,"AR	3	1	0.61",30027:30101,5842532,29514693,Unavailable
5842532," Complicated urinary tract infection	",Umbilical-cord-derived MSCs,Control,No significant difference,"Complicated urinary tract infection	1	1	1",30133:30237,5842532,29514693,Unavailable
5842532," Severe pneumonia	",Umbilical-cord-derived MSCs,Control,No significant difference,"Severe pneumonia	2	5	0.41",30269:30357,5842532,29514693,Unavailable
5842532," Severe bleeding	",Umbilical-cord-derived MSCs,Control,No significant difference,"Severe bleeding	0	0	1",30389:30473,5842532,29514693,Unavailable
5842532," Renal allograft resection or embolism	",Umbilical-cord-derived MSCs,Control,No significant difference,"Renal allograft resection or embolism	1	1	1",30505:30611,5842532,29514693,Unavailable
5842532,Other complications ,Umbilical-cord-derived MSCs,Control,No significant difference,"Other	1	1	1",30643:30717,5842532,29514693,Unavailable
5842532,Delayed graft function,Umbilical-cord-derived MSCs,Control,No significant difference,No significant difference in postoperative complications between the two groups was noted (all P&nbsp;&gt;&nbsp;0.05,31123:31226,5842532,29514693,Unavailable
5842532,Acute rejection,Umbilical-cord-derived MSCs,Control,No significant difference,No significant difference in postoperative complications between the two groups was noted (all P&nbsp;&gt;&nbsp;0.05,31123:31226,5842532,29514693,Unavailable
5842532," Complicated urinary tract infection	",Umbilical-cord-derived MSCs,Control,No significant difference,No significant difference in postoperative complications between the two groups was noted (all P&nbsp;&gt;&nbsp;0.05,31123:31226,5842532,29514693,Unavailable
5842532," Severe pneumonia	",Umbilical-cord-derived MSCs,Control,No significant difference,No significant difference in postoperative complications between the two groups was noted (all P&nbsp;&gt;&nbsp;0.05,31123:31226,5842532,29514693,Unavailable
5842532," Severe bleeding	",Umbilical-cord-derived MSCs,Control,No significant difference,No significant difference in postoperative complications between the two groups was noted (all P&nbsp;&gt;&nbsp;0.05,31123:31226,5842532,29514693,Unavailable
5842532," Renal allograft resection or embolism	",Umbilical-cord-derived MSCs,Control,No significant difference,No significant difference in postoperative complications between the two groups was noted (all P&nbsp;&gt;&nbsp;0.05,31123:31226,5842532,29514693,Unavailable
5842532,Other complications ,Umbilical-cord-derived MSCs,Control,No significant difference,No significant difference in postoperative complications between the two groups was noted (all P&nbsp;&gt;&nbsp;0.05,31123:31226,5842532,29514693,Unavailable
5842532,Delayed graft function,Umbilical-cord-derived MSCs,Control,No significant difference,"In the MSC group, 9.5% developed DGF 1&nbsp;week postoperatively; in the non-MSC group, 33.3% (P&nbsp;=&nbsp;0.13).",31295:31395,5842532,29514693,Unavailable
5842532,Acute rejection,Umbilical-cord-derived MSCs,Control,No significant difference,"Moreover, 14.3% of cases from the MSC group and 4.8% in non-MSC group had AR (P&nbsp;=&nbsp;0.61).",31396:31484,5842532,29514693,Unavailable
5842532," Complicated urinary tract infection	",Umbilical-cord-derived MSCs,Control,No significant difference,"Although the incidences of severe infections related to urinary and respiratory tracts were lower in the MSC group, no significant difference was found",31485:31636,5842532,29514693,Unavailable
5842532," Severe pneumonia	",Umbilical-cord-derived MSCs,Control,No significant difference,"Although the incidences of severe infections related to urinary and respiratory tracts were lower in the MSC group, no significant difference was found",31485:31636,5842532,29514693,Unavailable
5842532,Postoperative estimated glomerular filtration,Umbilical-cord-derived MSCs,Control,No significant difference,"For the eGFR, patients in the MSC group had a mean eGFR value of 4.95&nbsp;±&nbsp;1.73&nbsp;ml/min/1.73&nbsp;m2 at baseline, which increased to 43.80&nbsp;±&nbsp;16.21&nbsp;ml/min/1.73&nbsp;m2 at the 12-month visit. The mean eGFR of patients in the non-MSC group increased from 5.48&nbsp;±&nbsp;1.50&nbsp;ml/min/1.73&nbsp;m2 (baseline) to 42.78&nbsp;±&nbsp;23.15&nbsp;ml/min/1.73&nbsp;m2 1&nbsp;year after cell infusion (P&nbsp;=&nbsp;0.88)",32232:32624,5842532,29514693,Unavailable
5842532,Postoperative estimated glomerular filtration,Umbilical-cord-derived MSCs,Control,No significant difference,No significant difference in eGFR changes postoperatively between the two groups was found (P&nbsp;=&nbsp;0.88),32821:32922,5842532,29514693,Unavailable
5842532,Graft survival ,Umbilical-cord-derived MSCs,Control,No significant difference,Graft survival in the MSC group was comparable to that in the non-MSC group (P&nbsp;=&nbsp;0.97; Fig.&nbsp;3a),33323:33457,5842532,29514693,Unavailable
5842532,Recipient survivals,Umbilical-cord-derived MSCs,Control,No significant difference,A similar analysis revealed no significant difference in recipient survival between the two groups (P&nbsp;=&nbsp;0.15; Fig.&nbsp;3b).,33459:33617,5842532,29514693,Unavailable
5842532,Graft survival ,Umbilical-cord-derived MSCs,Control,No significant difference,Graft survival in the MSC group was comparable to that in the non-MSC group (P&nbsp;=&nbsp;0.97).,34216:34303,5842532,29514693,Unavailable
5842532,Recipient survivals,Umbilical-cord-derived MSCs,Control,No significant difference,A similar analysis revealed no significant difference in recipient survival between the two groups (P&nbsp;=&nbsp;0.15),34319:34428,5842532,29514693,Unavailable
5852932,Centering ratio (coronal third) in inner–outer furcal direction,Wave One,Reciproc,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in inner–outer furcal direction,Wave One,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in inner–outer furcal direction,Wave One,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in inner–outer furcal direction,Reciproc,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in inner–outer furcal direction,Reciproc,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in inner–outer furcal direction,Pro Taper,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in inner–outer furcal direction,Wave One,Reciproc,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in inner–outer furcal direction,Wave One,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in inner–outer furcal direction,Wave One,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in inner–outer furcal direction,Reciproc,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in inner–outer furcal direction,Reciproc,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in inner–outer furcal direction,Pro Taper,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in buccolingual direction,Wave One,Reciproc,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in buccolingual direction,Wave One,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in buccolingual direction,Wave One,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in buccolingual direction,Reciproc,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in buccolingual direction,Reciproc,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (coronal third) in buccolingual direction,Pro Taper,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",16713:16896,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in buccolingual direction,Wave One,Reciproc,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in buccolingual direction,Wave One,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in buccolingual direction,Wave One,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in buccolingual direction,Reciproc,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in buccolingual direction,Reciproc,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Centering ratio (apical third) in buccolingual direction,Pro Taper,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Centering ratio (middle third) in inner–outer furcal direction,Wave One,Pro Taper,Significantly decreased,"However, at the middle third, reciprocal files had significantly smaller centering ratios than the rotational rotary files in inner–outer furcal direction (P &lt; 0.001).",16897:17084,5852932,29628644,Unavailable
5852932,Centering ratio (middle third) in inner–outer furcal direction,Wave One,Mtwo,Significantly decreased,"However, at the middle third, reciprocal files had significantly smaller centering ratios than the rotational rotary files in inner–outer furcal direction (P &lt; 0.001).",16897:17085,5852932,29628644,Unavailable
5852932,Centering ratio (middle third) in inner–outer furcal direction,Reciproc,Pro Taper,Significantly decreased,"However, at the middle third, reciprocal files had significantly smaller centering ratios than the rotational rotary files in inner–outer furcal direction (P &lt; 0.001).",16897:17085,5852932,29628644,Unavailable
5852932,Centering ratio (middle third) in inner–outer furcal direction,Reciproc,Mtwo,Significantly decreased,"However, at the middle third, reciprocal files had significantly smaller centering ratios than the rotational rotary files in inner–outer furcal direction (P &lt; 0.001).",16896:17084,5852932,29628644,Unavailable
5852932,Centering ratio (middle third) in buccolingual direction,Reciproc,Pro Taper,Significantly decreased,Reciproc group had a significantly lower mean centering ratio than the ProTaper group in buccolingual direction (P = 0.038).,17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in inner–outer furcal direction,Wave One,Reciproc,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in inner–outer furcal direction,Wave One,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in inner–outer furcal direction,Wave One,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in inner–outer furcal direction,Reciproc,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in inner–outer furcal direction,Reciproc,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in inner–outer furcal direction,Pro Taper,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in inner–outer furcal direction,Wave One,Reciproc,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in inner–outer furcal direction,Wave One,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in inner–outer furcal direction,Wave One,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in inner–outer furcal direction,Reciproc,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in inner–outer furcal direction,Reciproc,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in inner–outer furcal direction,Pro Taper,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in buccolingual direction,Wave One,Reciproc,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in buccolingual direction,Wave One,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in buccolingual direction,Wave One,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in buccolingual direction,Reciproc,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in buccolingual direction,Reciproc,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (coronal third) in buccolingual direction,Pro Taper,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in buccolingual direction,Wave One,Reciproc,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in buccolingual direction,Wave One,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in buccolingual direction,Wave One,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in buccolingual direction,Reciproc,Pro Taper,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in buccolingual direction,Reciproc,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (apical third) in buccolingual direction,Pro Taper,Mtwo,No significant difference,"At the coronal and apical third of canals, there were no significant group differences in centering ratio [Table 1], P &gt; 0.05].",17085:17229,5852932,29628644,Unavailable
5852932,Extension of canal transportation (middle third) in buccolingual direction,Reciproc,Pro Taper,Significantly decreased,"At the middle third, however, Reciproc group had a significantly lower mean of extension of the canal transportation compared to ProTaper in both directions (P = 0.038).",17799:17988,5852932,29628644,Unavailable
5852932,Extension of canal transportation (middle third) in inner–outer furcal direction,Reciproc,Pro Taper,Significantly decreased,"At the middle third, however, Reciproc group had a significantly lower mean of extension of the canal transportation compared to ProTaper in both directions (P = 0.038).",18774:18937,5852932,29628644,Unavailable
5852932,Working time,Wave One,Pro Taper,Significantly decreased,"Reciprocal rotary files took significantly less time than the rotational rotary files [Table 2, P &lt; 0.001].",18774:18937,5852932,29628644,Unavailable
5852932,Working time,Wave One,Mtwo,Significantly decreased,"Reciprocal rotary files took significantly less time than the rotational rotary files [Table 2, P &lt; 0.001].",18774:18937,5852932,29628644,Unavailable
5852932,Working time,Reciproc,Pro Taper,Significantly decreased,"Reciprocal rotary files took significantly less time than the rotational rotary files [Table 2, P &lt; 0.001].",18774:18937,5852932,29628644,Unavailable
5852932,Working time,Reciproc,Mtwo,Significantly decreased,"Reciprocal rotary files took significantly less time than the rotational rotary files [Table 2, P &lt; 0.001].",18774:18937,5852932,29628644,Unavailable
3510714,Physical Activity level (3 months),Web-Based Physical Activity Program,Control,No significant difference,We found no difference in PA level between the website and control groups at 3- and 6-month follow-ups.,6859:6963,3510714,23111127,Unavailable
3510714,Physical Activity level (6 months),Web-Based Physical Activity Program,Control,No significant difference,We found no difference in PA level between the website and control groups at 3- and 6-month follow-ups.,45369:45574,3510714,23111127,Unavailable
3510714,BMI,Web-Based Physical Activity Program,Control,No significant difference,"The follow-up health examination showed no significant reductions in body mass index, waist circumference, body fat percentage, and blood pressure, or improvements in arm strength and aerobic fitness in the website group.",7137:7358,3510714,23111127,Unavailable
3510714,Waist circumference,Web-Based Physical Activity Program,Control,No significant difference,"The follow-up health examination showed no significant reductions in body mass index, waist circumference, body fat percentage, and blood pressure, or improvements in arm strength and aerobic fitness in the website group.",7137:7358,3510714,23111127,Unavailable
3510714,Body fat percentage,Web-Based Physical Activity Program,Control,No significant difference,"The follow-up health examination showed no significant reductions in body mass index, waist circumference, body fat percentage, and blood pressure, or improvements in arm strength and aerobic fitness in the website group.",7137:7358,3510714,23111127,Unavailable
3510714,Systolic bood pressure,Web-Based Physical Activity Program,Control,No significant difference,"The follow-up health examination showed no significant reductions in body mass index, waist circumference, body fat percentage, and blood pressure, or improvements in arm strength and aerobic fitness in the website group.",48599:48824,3510714,23111127,Unavailable
3510714,Arm strength,Web-Based Physical Activity Program,Control,No significant difference,"The follow-up health examination showed no significant reductions in body mass index, waist circumference, body fat percentage, and blood pressure, or improvements in arm strength and aerobic fitness in the website group.",7137:7358,3510714,23111127,Unavailable
3510714,Aerobic fitness,Web-Based Physical Activity Program,Control,No significant difference,"The follow-up health examination showed no significant reductions in body mass index, waist circumference, body fat percentage, and blood pressure, or improvements in arm strength and aerobic fitness in the website group.",7137:7358,3510714,23111127,Unavailable
3510714,Physical Activity level (3 months),Web-Based Physical Activity Program,Control,No significant difference,The result was the same in the completer analysis and analysis at 3-month follow-up,31123:31206,3510714,23111127,Unavailable
3510714,Physical Activity level (6 months),Web-Based Physical Activity Program,Control,No significant difference,Participants in the website group did not report a significantly different level of PA compared with the control group at the 6-month follow-up,30919:31062,3510714,23111127,Unavailable
3510714,BMI,Web-Based Physical Activity Program,Control,No significant difference,The results from the follow-up health examination showed no significant differences between the website and control groups (Table 5).,31631:31808,3510714,23111127,Unavailable
3510714,Waist circumference,Web-Based Physical Activity Program,Control,No significant difference,The results from the follow-up health examination showed no significant differences between the website and control groups (Table 5).,31631:31807,3510714,23111127,Unavailable
3510714,Body fat percentage,Web-Based Physical Activity Program,Control,No significant difference,The results from the follow-up health examination showed no significant differences between the website and control groups (Table 5).,31631:31807,3510714,23111127,Unavailable
3510714,Systolic bood pressure,Web-Based Physical Activity Program,Control,No significant difference,The results from the follow-up health examination showed no significant differences between the website and control groups (Table 5).,48599:48824,3510714,23111127,Unavailable
3510714,Arm strength,Web-Based Physical Activity Program,Control,No significant difference,The results from the follow-up health examination showed no significant differences between the website and control groups (Table 5).,31631:31808,3510714,23111127,Unavailable
3510714,Aerobic fitness,Web-Based Physical Activity Program,Control,No significant difference,The results from the follow-up health examination showed no significant differences between the website and control groups (Table 5).,31631:31807,3510714,23111127,Unavailable
3510714,Work Physical Activity (6 months),Web-Based Physical Activity Program,Control,No significant difference,"Work	60	(0–800)	60	(0–825)	.62",44350:44540,3510714,23111127,Unavailable
3510714,Transportation Physical Activity (6 months),Web-Based Physical Activity Program,Control,No significant difference,"Transportation	180	(45–400)	200	(60–420)	.62",44595:44799,3510714,23111127,Unavailable
3510714,Household Physical Activity (6 months),Web-Based Physical Activity Program,Control,No significant difference,"Household	480	(180–1080)	480	(180–1080)	.17",44854:45057,3510714,23111127,Unavailable
3510714,Leisure time Physical Activity (6 months),Web-Based Physical Activity Program,Control,No significant difference,"Leisure time	200	(60–450)	200	(60–420)	.25",45112:45314,3510714,23111127,Unavailable
3510714,Sitting (6 months),Web-Based Physical Activity Program,Control,No significant difference,"Sitting	2220	(1500–3060)	2220	(1500–3150)	.52",45369:45574,3510714,23111127,Unavailable
3510714,Physical Activity level (6 months),Web-Based Physical Activity Program,Control,No significant difference,"Total physical activity	1575	(845–2580)	1560	(840–2520)	.25",45629:45848,3510714,23111127,Unavailable
3510714,BMI,Web-Based Physical Activity Program,Control,No significant difference,"BMIc (kg/m2)	25.3	(0.2)	25.0	(0.2)	.12",47003:47223,3510714,23111127,Unavailable
3510714,Waist circumference,Web-Based Physical Activity Program,Control,No significant difference,"Waist circumference (cm)	90.0	(0.5)	89.1	(0.5)	.34",47278:47488,3510714,23111127,Unavailable
3510714,Body fat percentage,Web-Based Physical Activity Program,Control,No significant difference,"Body fat (%)	30.4	(0.3)	30.5	(0.3)	.87",47543:47741,3510714,23111127,Unavailable
3510714,Systolic bood pressure,Web-Based Physical Activity Program,Control,No significant difference,"Systolic blood pressure (mmHg)	125.1	(0.7)	123.1	(0.7)	.04",47796:48014,3510714,23111127,Unavailable
3510714,Arm strength,Web-Based Physical Activity Program,Control,No significant difference,"Arm strength (kg)	27.5	(0.5)	26.9	(0.4)	.32",48341:48544,3510714,23111127,Unavailable
3510714,Aerobic fitness,Web-Based Physical Activity Program,Control,No significant difference,"Aerobic fitnessd (mL/min/kg)	31.6	(0.4)	31.8	(0.3)	.70",48599:48824,3510714,23111127,Unavailable
3510714,Diastolic bood pressure,Web-Based Physical Activity Program,Control,No significant difference,"The follow-up health examination showed no significant reductions in body mass index, waist circumference, body fat percentage, and blood pressure, or improvements in arm strength and aerobic fitness in the website group.",48599:48824,3510714,23111127,Unavailable
3510714,Diastolic bood pressure,Web-Based Physical Activity Program,Control,No significant difference,The results from the follow-up health examination showed no significant differences between the website and control groups (Table 5).,48599:48824,3510714,23111127,Unavailable
3510714,Diastolic bood pressure,Web-Based Physical Activity Program,Control,No significant difference,"Diastolic blood pressure (mmHg)	79.4	(0.4)	78.5	(0.4)	.12",48069:48286,3510714,23111127,Unavailable
5729493,Weight loss in kg (3 months),Smart scale,Control,No significant difference,"weight losses did not differ between‐groups at 3&nbsp;months (5.1&nbsp;±&nbsp;0.6&nbsp;kg in WWO‐E vs. 4.0&nbsp;±&nbsp;0.7&nbsp;kg in WWO, p&nbsp;=&nbsp;0.257) or 6&nbsp;months (5.3&nbsp;±&nbsp;0.6&nbsp;kg in WWO‐E vs. 3.9&nbsp;±&nbsp;0.7&nbsp;kg in WWO, p&nbsp;=&nbsp;0.116).",34216:34322,5729493,29259794,Unavailable
5729493,Weight loss in kg (6 months),Smart scale,Control,No significant difference,"weight losses did not differ between‐groups at 3&nbsp;months (5.1&nbsp;±&nbsp;0.6&nbsp;kg in WWO‐E vs. 4.0&nbsp;±&nbsp;0.7&nbsp;kg in WWO, p&nbsp;=&nbsp;0.257) or 6&nbsp;months (5.3&nbsp;±&nbsp;0.6&nbsp;kg in WWO‐E vs. 3.9&nbsp;±&nbsp;0.7&nbsp;kg in WWO, p&nbsp;=&nbsp;0.116).",34216:34322,5729493,29259794,Unavailable
5729493, ≥5% weight loss (3 months),Smart scale,Control,Significantly increased,"However, at 3&nbsp;months, a significantly greater proportion of participants assigned to WWO‐E (52.2%) achieved a ≥5% weight loss compared with WWO (28.3%; p&nbsp;=&nbsp;0.033).",34035:34215,5729493,29259794,Unavailable
5729493, ≥5% weight loss (6 months),Smart scale,Control,No significant difference,"This difference did not persist at 6&nbsp;months (43.5% in WWO‐E vs. 30.4% in WWO, p&nbsp;=&nbsp;0.280).",34216:34322,5729493,29259794,Unavailable
5729493,Weight loss in kg (3 months),Smart scale,Control,No significant difference,"Weight Loss, mean (SE), kg		3&nbsp;months	4.0 (0.7)	5.1 (0.6)",35046:35427,5729493,29259794,Unavailable
5729493,Weight loss in kg (6 months),Smart scale,Control,No significant difference,"Weight Loss, mean (SE), kg		3&nbsp;months	4.0 (0.7)	5.1 (0.6)6&nbsp;months	3.9 (0.7)	5.3 (0.6)",35046:35664,5729493,29259794,Unavailable
5729493, ≥5% weight loss (3 months),Smart scale,Control,Significantly increased,"Proportion achieving weight loss of ≥5% of initial weight, no. (%)		3&nbsp;months	13 (28.3)	24 (52.2)",36417:36860,5729493,29259794,Unavailable
5729493, ≥5% weight loss (6 months),Smart scale,Control,No significant difference,"Proportion achieving weight loss of ≥5% of initial weight, no. (%)		3&nbsp;months	13 (28.3)	24 (52.2)6&nbsp;months	14 (30.4)	20 (43.5)",36417:37105,5729493,29259794,Unavailable
5729493,Weight loss % (3 months),Smart scale,Control,No significant difference,"Weight Loss, mean (SE), %		3&nbsp;months	4.1 (0.7)	5.4 (0.7)",35732:36112,5729493,29259794,Unavailable
5729493,Weight loss % (6 months),Smart scale,Control,No significant difference,"Weight Loss, mean (SE), %		3&nbsp;months	4.1 (0.7)	5.4 (0.7)6&nbsp;months	4.0 (0.7)	5.8 (0.7)",35732:36349,5729493,29259794,Unavailable
5729493,Days of self monitoring ,Smart scale,Control,Significantly increased,"This led to a significant difference between WWO‐E and WWO in the total number of days that body weight was self‐monitored (80.5&nbsp;±&nbsp;54.5 vs. 12.0&nbsp;±&nbsp;9.6, respectively, p&nbsp;&lt;&nbsp;0.001).",37845:38040,5729493,29259794,Unavailable
5729493,Weeks with +1 day of self monitoring ,Smart scale,Control,Significantly increased,"The emphasis on daily self‐weighing in WWO‐E also increased the mean&nbsp;±&nbsp;SD number of weeks that participants self‐monitored their body weight at least once during the week (19.8&nbsp;±&nbsp;6.2 in WWO‐E vs. 11.1&nbsp;±&nbsp;8.6&nbsp;kg in WWO, p&nbsp;&lt;&nbsp;0.001), a commonly accepted threshold of clinical significance.",38040:38345,5729493,29259794,Unavailable
5729493,Participants monitoring at least weekly,Smart scale,Control,Significantly increased,There was a statistically significant between‐groups difference (p&nbsp;&lt;&nbsp;0.001) in the change in the proportion of participants weighing at least weekly over the 24‐week study period.,38780:38977,5729493,29259794,Unavailable
5729493,Satisfaction with the program (3 months),Smart scale,Control,No significant difference,"Mean&nbsp;±&nbsp;SD satisfaction with the weight loss program was moderately high and did not differ significantly between‐groups at both 3&nbsp;months (4.8&nbsp;±&nbsp;1.6 in WWO‐E vs. 4.3&nbsp;±&nbsp;1.2 in WWO, p&nbsp;=&nbsp;0.090) and 6&nbsp;months (5.2&nbsp;±&nbsp;1.4 in WWO‐E vs. 4.8&nbsp;±&nbsp;1.4 in WWO, p&nbsp;=&nbsp;0.234).",40204:40494,5729493,29259794,Unavailable
5729493,Satisfaction with the program (6 months),Smart scale,Control,No significant difference,"Mean&nbsp;±&nbsp;SD satisfaction with the weight loss program was moderately high and did not differ significantly between‐groups at both 3&nbsp;months (4.8&nbsp;±&nbsp;1.6 in WWO‐E vs. 4.3&nbsp;±&nbsp;1.2 in WWO, p&nbsp;=&nbsp;0.090) and 6&nbsp;months (5.2&nbsp;±&nbsp;1.4 in WWO‐E vs. 4.8&nbsp;±&nbsp;1.4 in WWO, p&nbsp;=&nbsp;0.234).",40204:40494,5729493,29259794,Unavailable
5840256,Overall survival (adjusted) ,Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Estimated overall survival adjusted for stratification factors at 5 years was 81·8% (95% CI 77·5–86·2) for patients in the chemoradiotherapy group versus 76·7% (72·1–81·6) for patients in the radiotherapy group (HR 0·76, 95% CI 0·54–1·06; p=0·109; table 2, figure 2).",57609:57772,5840256,29449189,Unavailable
5840256,5-year failure-free survival (adjusted) ,Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"5-year failure-free survival was 75·5% (70·3–79·9) in the chemoradiotherapy group versus 68·6% (63·1–73·4) in the radiotherapy group (HR 0·71, 0·53–0·95; p=0·022).",57773:58077,5840256,29449189,Unavailable
5840256,Overall survival (unadjusted) ,Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Without adjusting for the stratification factors, the HR for overall survival was 0·81 (95% CI 0·58–1·13; p=0·213) and for failure-free survival was 0·76 (0·57–1·02; p=0·067; table 2, figure 2).Figure 2",57773:58077,5840256,29449189,Unavailable
5840256,5-year failure-free survival (unadjusted) ,Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Without adjusting for the stratification factors, the HR for overall survival was 0·81 (95% CI 0·58–1·13; p=0·213) and for failure-free survival was 0·76 (0·57–1·02; p=0·067; table 2, figure 2).Figure 2",57773:58077,5840256,29449189,Unavailable
5840256,Overall survival (adjusted) ,Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Overall survival*	··	··	0·76 (0·54–1·06)	0·109",58984:59161,5840256,29449189,Unavailable
5840256,5-year failure-free survival (adjusted) ,Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Failure-free survival*	··	··	0·71 (0·53–0·95)	0·022",59204:59386,5840256,29449189,Unavailable
5840256,Overall survival (unadjusted) ,Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Overall survival†Chemoradiotherapy	61	81·8% (77·5–86·2)	0·81 (0·58–1·13)	0·213",59429:59678,5840256,29449189,Unavailable
5840256,5-year failure-free survival (unadjusted) ,Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Failure-free survival†Chemoradiotherapy	83	75·5% (70·3–79·9)	0·76 (0·57–1·02)	0·067",59884:60138,5840256,29449189,Unavailable
5840256,Vaginal recurrence (first),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Vaginal recurrence (first recurrence)†Chemoradiotherapy 1 0·3% (0·0–2·1) 0·99 (0·06–15·90) 0·999,60345:60612,5840256,29449189,Unavailable
5840256,Pelvic recurrence (first),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Pelvic recurrence (first recurrence)†Chemoradiotherapy	3	1·0% (0·3–2·9)	0·60 (0·14–2·49)	0·473",60814:61079,5840256,29449189,Unavailable
5840256,Distant metastases (first),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Distant metastases (first recurrence)†Chemoradiotherapy	76	22·4% (18·1–27·4)	0·78 (0·58–1·06)	0·108",61281:61551,5840256,29449189,Unavailable
5840256,Vaginal recurrence (total),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Vaginal recurrence (total)†Chemoradiotherapy	8	2·1% (1·0–4·4)	0·99 (0·37–2·65)	0·995",61757:62012,5840256,29449189,Unavailable
5840256,Pelvic recurrence (total),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly decreased,"Pelvic recurrence (total)†Chemoradiotherapy	16		0·51 (0·28–0·92)	0·026",62214:62455,5840256,29449189,Unavailable
5840256,Distant metastases (total),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Distant metastases (total)†Chemoradiotherapy	79	23·1% (18·8–28·3)	0·77 (0·57–1·03)	0·077",62659:62918,5840256,29449189,Unavailable
5840256,Vaginal recurrence (first),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Isolated vaginal and pelvic recurrences were rare, with isolated vaginal recurrence diagnosed in one (&lt;1%) patient in the chemoradiotherapy group and in one (&lt;1%) patient in the radiotherapy group (p=0·995), and isolated pelvic recurrence in three (1%) patients in the chemoradiotherapy group versus five (2%) patients in the radiotherapy group (p=0·473).",74512:74867,5840256,29449189,Unavailable
5840256,Pelvic recurrence (first),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Isolated vaginal and pelvic recurrences were rare, with isolated vaginal recurrence diagnosed in one (&lt;1%) patient in the chemoradiotherapy group and in one (&lt;1%) patient in the radiotherapy group (p=0·995), and isolated pelvic recurrence in three (1%) patients in the chemoradiotherapy group versus five (2%) patients in the radiotherapy group (p=0·473).",74512:74867,5840256,29449189,Unavailable
5840256,Distant metastases (first),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Most recurrences were distant metastases: 76 (22%) patients in the chemoradiotherapy group versus 93 (28%) patients in the radiotherapy group were diagnosed with distant metastases (p=0·108).,74868:75060,5840256,29449189,Unavailable
5840256,Pelvic recurrence (total),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly decreased,The 5-year estimate of pelvic recurrence (both isolated and combined pelvic and distant recurrences) was 4·9% (95% CI 3·0–7·9) for the chemoradiotherapy group versus 9·2% (6·5–12·9) for the radiotherapy group (p=0·026; table 2).,75060:75335,5840256,29449189,Unavailable
5840256,Grade 2 or worse adverse events (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Grade 2 or worse adverse events were reported during treatment in 308 (93%) women in the chemoradiotherapy group versus 144 (43%) in the radiotherapy group, and grade 3 or worse in 198 (60%) versus 41 (12%; p&lt;0·0001; table 5)",76699:76968,5840256,29449189,Unavailable
5840256,Grade 3 or worse adverse events (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Grade 2 or worse adverse events were reported during treatment in 308 (93%) women in the chemoradiotherapy group versus 144 (43%) in the radiotherapy group, and grade 3 or worse in 198 (60%) versus 41 (12%; p&lt;0·0001; table 5)",76699:76968,5840256,29449189,Unavailable
5840256,Grade 2 or worse adverse events (at 3 years),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"The number of patients with grade 2 or worse adverse events was 86 (32%) for chemoradiotherapy versus 64 (24%) for radiotherapy at 3 years (p=0·034), and 57 (40%) versus 38 (28%) at 5 years (p=0·033).",77454:77654,5840256,29449189,Unavailable
5840256,Grade 2 or worse adverse events (at 5 years),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"The number of patients with grade 2 or worse adverse events was 86 (32%) for chemoradiotherapy versus 64 (24%) for radiotherapy at 3 years (p=0·034), and 57 (40%) versus 38 (28%) at 5 years (p=0·033).",77454:77654,5840256,29449189,Unavailable
5840256,Sensory neuropathy Grade 2 or worse  (at 3 years),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"The most significant and clinically relevant difference between the arms was found for grade 2 or worse sensory neuropathy, which persisted in 20 (8%) women in the chemoradiotherapy group versus one (1%) women in the radiotherapy group at 3 years and 12 (9%) women versus no women at 5 years (both p&lt;0·0001).",78792:78979,5840256,29449189,Unavailable
5840256,Sensory neuropathy Grade 2 or worse (at 5 years),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"The most significant and clinically relevant difference between the arms was found for grade 2 or worse sensory neuropathy, which persisted in 20 (8%) women in the chemoradiotherapy group versus one (1%) women in the radiotherapy group at 3 years and 12 (9%) women versus no women at 5 years (both p&lt;0·0001).",78792:78979,5840256,29449189,Unavailable
5840256,Grade 2 or worse adverse events (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Any	110 (33%)	103 (31%)	&lt;0·0001	198 (60%)	41 (12%)	&lt;0·0001",78792:78979,5840256,29449189,Unavailable
5840256,Auditory or hearing issues Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Auditory or hearing	14 (4%)	3 (1%)	0·011	1 (&lt;1%)	1 (&lt;1%)	1·00",79439:79632,5840256,29449189,Unavailable
5840256,Allergy Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Allergy	23 (7%)	1 (&lt;1%)	&lt;0·0001	5 (2%)	0	0·062",79675:79853,5840256,29449189,Unavailable
5840256,Fatigue Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Fatigue	69 (21%)	7 (2%)	&lt;0·0001	10 (3%)	0	0·0018",79896:80073,5840256,29449189,Unavailable
5840256,Hypertension Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Hypertension	19 (6%)	12 (4%)	0·14	6 (2%)	3 (1%)	0·50",80116:80294,5840256,29449189,Unavailable
5840256,Alopecia Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Alopecia	187 (57%)	1 (&lt;1%)	&lt;0·0001",80337:NaN,5840256,29449189,Unavailable
5840256,Dermatitis Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Dermatitis	18 (5%)	5 (2%)	0·013	1 (&lt;1%)	1 (&lt;1%)	1·0",80555:80738,5840256,29449189,Unavailable
5840256,"Any gastrointestinal	 Grade 2 or worse (during treatment)",Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Any gastrointestinal	145 (44%)	79 (24%)	&lt;0·0001	47 (14%)	18 (5%)	&lt;0·0001",80781:80982,5840256,29449189,Unavailable
5840256,Diarrhoea Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Diarrhoea	104 (32%)	69 (21%)	&lt;0·0001	35 (11%)	14 (4%)	0·0027",81025:81214,5840256,29449189,Unavailable
5840256,Nausea Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Nausea	68 (21%)	24 (7%)	0·0010	9 (3%)	2 (1%)	0·06",81254:81429,5840256,29449189,Unavailable
5840256,Vomiting Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Vomiting	31 (9%)	9 (3%)	&lt;0·0001	5 (2%)	0	0·06",81469:81643,5840256,29449189,Unavailable
5840256,Anorexia Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Anorexia	30 (9%)	9 (3%)	0·0033	3 (1%)	4 (1%)	1·00",81683:81858,5840256,29449189,Unavailable
5840256,Constipation Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Constipation	32 (10%)	6 (2%)	&lt;0·0001	1 (&lt;1%)	0	1·00",81898:82081,5840256,29449189,Unavailable
5840256,Urinary frequency or urgency Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Genito-urinary: frequency or urgency	24 (7%)	10 (3%)	0·020	2 (1%)	2 (1%)	1·00",82124:82327,5840256,29449189,Unavailable
5840256,Any haematological problem Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Any haematological	100 (30%)	19 (6%)	&lt;0·0001	149 (45%)	18 (5%)	&lt;0·0001",82370:82569,5840256,29449189,Unavailable
5840256,Infection with neutropenia Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Infection with neutropenia	3 (1%)	0	0·0018	7 (2%)	0	0·015",82830:83013,5840256,29449189,Unavailable
5840256,Infection without neutropenia Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Infection without neutropenia	21 (6%)	1 (&lt;1%)	&lt;0·0001	12 (4%)	1 (&lt;1%)	&lt;0·0001",NaN:83265,5840256,29449189,Unavailable
5840256,Haemoglobin AE Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Haemoglobin 105 (32%) 0 &lt;0·0001 27 (8%) 0 &lt;0·0001,94741:94909,5840256,29449189,Unavailable
5840256,Leucocytes AE Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Leucocytes 98 (30%) 3 (1%) &lt;0·0001 76 (23%) 1 (&lt;1%) &lt;0·0001,94741:94909,5840256,29449189,Unavailable
5840256,Lymphocytes AE Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Lymphocytes 48 (15%) 16 (5%) &lt;0·0001 109 (33%) 17 (5%) &lt;0·0001,94741:94909,5840256,29449189,Unavailable
5840256,Neutrophils AE Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Neutrophils 62 (19%) 1 (&lt;1%) &lt;0·0001 66 (20%) 1 (&lt;1%) &lt;0·0001,94741:94909,5840256,29449189,Unavailable
5840256,Platelets AE Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Platelets 22 (7%) 0 &lt;0·0001 18 (5%) 0 &lt;0·0001,94741:94909,5840256,29449189,Unavailable
5840256,Metabolic or laboratory problems Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Metabolic or laboratory	15 (5%)	1 (&lt;1%)	&lt;0·0001	3 (1%)	0	0·25",84456:84649,5840256,29449189,Unavailable
5840256,Any neuropathy Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Any neuropathy	82 (25%)	1 (&lt;1%)	&lt;0·0001	23 (7%)	0	&lt;0·0001",84692:84881,5840256,29449189,Unavailable
5840256,Motor issues Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Motor	13 (4%)	1 (&lt;1%)	&lt;0·0001	4 (1%)	0	0·12",84924:85099,5840256,29449189,Unavailable
5840256,Sensory neuropathy Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Sensory 79 (24%) 0 &lt;0·0001 22 (7%) 0 &lt;0·0001,86487:86664,5840256,29449189,Unavailable
5840256,Any pain Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Any pain	101 (31%)	23 (7%)	&lt;0·0001	31 (9%)	4 (1%)	&lt;0·0001",85358:85544,5840256,29449189,Unavailable
5840256,Joint problems Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Joint	52 (16%)	2 (1%)	&lt;0·0001	10 (3%)	0	0·0018",85587:85762,5840256,29449189,Unavailable
5840256,Muscle problems Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Muscle	52 (16%)	1 (&lt;1%)	&lt;0·0001	9 (3%)	0	0·0037",85802:85981,5840256,29449189,Unavailable
5840256,"Pelvic, back, or limb problems Grade 2 or worse (during treatment)",Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Pelvic, back, or limb	10 (3%)	4 (1%)	&lt;0·0001	11 (3%)	0	&lt;0·0001",86021:86212,5840256,29449189,Unavailable
5840256,Dyspnoea Grade 2 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Pulmonary: dyspnoea	12 (4%)	2 (1%)	&lt;0·0001	5 (2%)	0	0·062",86258:86444,5840256,29449189,Unavailable
5840256,"Thrombosis or embolism	Grade 2 or worse (during treatment)",Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Thrombosis or embolism	2 (1%)	0	0·031	4 (1%)	0	0·12",86487:86664,5840256,29449189,Unavailable
5840256,Grade 3 or worse adverse events (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Any 110 (33%) 103 (31%) &lt;0·0001 198 (60%) 41 (12%) &lt;0·0001,86487:86664,5840256,29449189,Unavailable
5840256,Auditory or hearing issues Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Auditory or hearing 14 (4%) 3 (1%) 0·011 1 (&lt;1%) 1 (&lt;1%) 1·00,82612:82790,5840256,29449189,Unavailable
5840256,Allergy Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Allergy 23 (7%) 1 (&lt;1%) &lt;0·0001 5 (2%) 0 0·062,82612:82790,5840256,29449189,Unavailable
5840256,Fatigue Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Fatigue 69 (21%) 7 (2%) &lt;0·0001 10 (3%) 0 0·0018,82612:82790,5840256,29449189,Unavailable
5840256,Hypertension Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Hypertension 19 (6%) 12 (4%) 0·14 6 (2%) 3 (1%) 0·50,82612:82790,5840256,29449189,Unavailable
5840256,Dermatitis Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Dermatitis 18 (5%) 5 (2%) 0·013 1 (&lt;1%) 1 (&lt;1%) 1·0,82612:82790,5840256,29449189,Unavailable
5840256,"Any gastrointestinal	 Grade 3 or worse (during treatment)",Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Any gastrointestinal 145 (44%) 79 (24%) &lt;0·0001 47 (14%) 18 (5%) &lt;0·0001,82612:82790,5840256,29449189,Unavailable
5840256,Diarrhoea Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Diarrhoea 104 (32%) 69 (21%) &lt;0·0001 35 (11%) 14 (4%) 0·0027,82612:82790,5840256,29449189,Unavailable
5840256,Nausea Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Nausea 68 (21%) 24 (7%) 0·0010 9 (3%) 2 (1%) 0·06,82612:82790,5840256,29449189,Unavailable
5840256,Vomiting Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Vomiting 31 (9%) 9 (3%) &lt;0·0001 5 (2%) 0 0·06,82612:82790,5840256,29449189,Unavailable
5840256,Anorexia Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Anorexia 30 (9%) 9 (3%) 0·0033 3 (1%) 4 (1%) 1·00,82612:82790,5840256,29449189,Unavailable
5840256,Constipation Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Constipation 32 (10%) 6 (2%) &lt;0·0001 1 (&lt;1%) 0 1·00,82612:82790,5840256,29449189,Unavailable
5840256,Urinary frequency or urgency Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Genito-urinary: frequency or urgency 24 (7%) 10 (3%) 0·020 2 (1%) 2 (1%) 1·00,82612:82790,5840256,29449189,Unavailable
5840256,Any haematological problem Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Any haematological 100 (30%) 19 (6%) &lt;0·0001 149 (45%) 18 (5%) &lt;0·0001,82612:82790,5840256,29449189,Unavailable
5840256,Febrile neutropenia Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Febrile neutropenia	NA	NA	··	9 (3%)	1 (&lt;1%)	0·021",82612:82790,5840256,29449189,Unavailable
5840256,Infection with neutropenia Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Infection with neutropenia 3 (1%) 0 0·0018 7 (2%) 0 0·015,82612:82790,5840256,29449189,Unavailable
5840256,Infection without neutropenia Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Infection without neutropenia 21 (6%) 1 (&lt;1%) &lt;0·0001 12 (4%) 1 (&lt;1%) &lt;0·0001,82612:82790,5840256,29449189,Unavailable
5840256,Haemoglobin AE Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Haemoglobin 105 (32%) 0 &lt;0·0001 27 (8%) 0 &lt;0·0001,94741:94909,5840256,29449189,Unavailable
5840256,Leucocytes AE Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Leucocytes 98 (30%) 3 (1%) &lt;0·0001 76 (23%) 1 (&lt;1%) &lt;0·0001,94741:94909,5840256,29449189,Unavailable
5840256,Lymphocytes AE Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Lymphocytes 48 (15%) 16 (5%) &lt;0·0001 109 (33%) 17 (5%) &lt;0·0001,94741:94909,5840256,29449189,Unavailable
5840256,Neutrophils AE Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Neutrophils 62 (19%) 1 (&lt;1%) &lt;0·0001 66 (20%) 1 (&lt;1%) &lt;0·0001,94741:94909,5840256,29449189,Unavailable
5840256,Platelets AE Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Platelets 22 (7%) 0 &lt;0·0001 18 (5%) 0 &lt;0·0001,94741:94909,5840256,29449189,Unavailable
5840256,Metabolic or laboratory problems Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Metabolic or laboratory 15 (5%) 1 (&lt;1%) &lt;0·0001 3 (1%) 0 0·25,82612:82790,5840256,29449189,Unavailable
5840256,Any neuropathy Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Any neuropathy 82 (25%) 1 (&lt;1%) &lt;0·0001 23 (7%) 0 &lt;0·0001,82612:82790,5840256,29449189,Unavailable
5840256,Motor issues Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Motor 13 (4%) 1 (&lt;1%) &lt;0·0001 4 (1%) 0 0·12,82612:82790,5840256,29449189,Unavailable
5840256,Sensory neuropathy Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Sensory 79 (24%) 0 &lt;0·0001 22 (7%) 0 &lt;0·0001,82612:82790,5840256,29449189,Unavailable
5840256,Any pain Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Any pain 101 (31%) 23 (7%) &lt;0·0001 31 (9%) 4 (1%) &lt;0·0001,82612:82790,5840256,29449189,Unavailable
5840256,Joint problems Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Joint 52 (16%) 2 (1%) &lt;0·0001 10 (3%) 0 0·0018,82612:82790,5840256,29449189,Unavailable
5840256,Muscle problems Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Muscle 52 (16%) 1 (&lt;1%) &lt;0·0001 9 (3%) 0 0·0037,82612:82790,5840256,29449189,Unavailable
5840256,"Pelvic, back, or limb problems Grade 3 or worse (during treatment)",Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Pelvic, back, or limb 10 (3%) 4 (1%) &lt;0·0001 11 (3%) 0 &lt;0·0001",82612:82790,5840256,29449189,Unavailable
5840256,Dyspnoea Grade 3 or worse (during treatment),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Pulmonary: dyspnoea 12 (4%) 2 (1%) &lt;0·0001 5 (2%) 0 0·062,82612:82790,5840256,29449189,Unavailable
5840256,"Thrombosis or embolism	Grade 3 or worse (during treatment) ",Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Thrombosis or embolism 2 (1%) 0 0·031 4 (1%) 0 0·12,82612:82790,5840256,29449189,Unavailable
5840256,Grade 2 or worse adverse events (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Any	128 (39%)	96 (29%)	&lt;0·0001	54 (16%)	25 (8%)	&lt;0·0001",88232:88416,5840256,29449189,Unavailable
5840256,Auditory or hearing issues Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Auditory or hearing	8 (2%)	3 (1%)	0·22	0	0	1·00",88877:89050,5840256,29449189,Unavailable
5840256,Allergy Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Allergy	2 (1%)	1 (&lt;1%)	1·00	0	0	1·00",89093:89258,5840256,29449189,Unavailable
5840256,Fatigue Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Fatigue	10 (3%)	2 (1%)	0·054	1 (&lt;1%)	1 (&lt;1%)	1·00",89301:89482,5840256,29449189,Unavailable
5840256,Hypertension Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Hypertension	15 (5%)	18 (5%)	0·75	5 (2%)	5 (2%)	1·00",89525:89703,5840256,29449189,Unavailable
5840256,Alopecia Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Alopecia	64 (19%)	0	&lt;0·0001",89746:NaN,5840256,29449189,Unavailable
5840256,Dermatitis Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Dermatitis	1 (&lt;1%)	0	1·00	0	0	1·00",89954:90117,5840256,29449189,Unavailable
5840256,"Any gastrointestinal	 Grade 2 or worse (6 months)",Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Any gastrointestinal	19 (6%)	18 (5%)	0·89	7 (2%)	9 (3%)	0·80",90160:90346,5840256,29449189,Unavailable
5840256,Diarrhoea Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Diarrhoea	8 (2%)	11 (3%)	0·20	0	3 (1%)",90386:90529,5840256,29449189,Unavailable
5840256,Nausea Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Nausea	7 (2%)	5 (2%)	0·35	5 (2%)	2 (1%)	0·45",90591:90761,5840256,29449189,Unavailable
5840256,Vomiting Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Vomiting	7 (2%)	6 (2%)	0·45	3 (1%)	0	0·25",90801:90968,5840256,29449189,Unavailable
5840256,Anorexia Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Anorexia	1 (&lt;1%)	4 (1%)	0·50	2 (1%)	2 (1%)	1·00",91008:91184,5840256,29449189,Unavailable
5840256,Constipation Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Constipation	7 (2%)	4 (1%)	0·79	1 (&lt;1%)	2 (1%)	1·00",91224:91404,5840256,29449189,Unavailable
5840256,Urinary frequency or urgency Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Genito-urinary: frequency or urgency	5 (2%)	6 (2%)	0·77	1 (&lt;1%)	0	1·00",91447:91646,5840256,29449189,Unavailable
5840256,Any haematological problem Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Any haematological	54 (16%)	27 (8%)	&lt;0·0001	24 (7%)	6 (2%)	0·0001",91689:91883,5840256,29449189,Unavailable
5840256,"Infection with neutropenia	0	0	1·00	1 (&lt;1%)	0	1·00",Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Infection with neutropenia 3 (1%) 0 0·0018 7 (2%) 0 0·015,91689:91883,5840256,29449189,Unavailable
5840256,Infection without neutropenia Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Infection without neutropenia 5 (2%) 1 (&lt;1%) 0·22 0 0 1·00,92345:92532,5840256,29449189,Unavailable
5840256,Haemoglobin AE Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Haemoglobin 24 (7%) 0 &lt;0·0001 3 (1%) 0 0·25,94741:94909,5840256,29449189,Unavailable
5840256,Leucocytes AE Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Leucocytes 20 (6%) 1 (&lt;1%) &lt;0·0001 6 (2%) 1 (&lt;1%) 0·12,94741:94909,5840256,29449189,Unavailable
5840256,Lymphocytes AE Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Lymphocytes 43 (13%) 26 (8%) 0·0015 17 (5%) 5 (2%) 0·015,94741:94909,5840256,29449189,Unavailable
5840256,Neutrophils AE Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Neutrophils 4 (1%) 0 0·0018 6 (2%) 0 0·031,94741:94909,5840256,29449189,Unavailable
5840256,Platelets AE Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Platelets 5 (2%) 0 0·015 2 (1%) 0 0·50,94741:94909,5840256,29449189,Unavailable
5840256,Metabolic or laboratory problems Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Metabolic or laboratory	2 (1%)	0	0·12	2 (1%)	0	0·50",93650:93827,5840256,29449189,Unavailable
5840256,Any neuropathy Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Any neuropathy	42 (13%)	1 (&lt;1%)	&lt;0·0001	8 (2%)	2 (1%)	0·11",93870:94060,5840256,29449189,Unavailable
5840256,Motor issues Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Motor	7 (2%)	1 (&lt;1%)	0·09	3 (1%)	2 (1%)	1·00",94100:94273,5840256,29449189,Unavailable
5840256,Sensory neuropathy Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Sensory	41 (12%)	0	&lt;0·0001	6 (2%)	0	0·031",94313:94483,5840256,29449189,Unavailable
5840256,Any pain Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Any pain	31 (9%)	32 (10%)	0·54	3 (1%)	7 (2%)	0·34",94526:94701,5840256,29449189,Unavailable
5840256,Joint problems Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Joint	8 (2%)	6 (2%)	1·00	0	1 (&lt;1%)	1·00",94741:94909,5840256,29449189,Unavailable
5840256,Muscle problems Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Muscle	5 (2%)	1 (&lt;1%)	0·22	0	0	1·00",94949:95113,5840256,29449189,Unavailable
5840256,"Pelvic, back, or limb problems Grade 2 or worse (6 months)",Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Pelvic, back, or limb	10 (3%)	9 (3%)	0·33	0	3 (1%)	0·25",95153:95334,5840256,29449189,Unavailable
5840256,Dyspnoea Grade 2 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Pulmonary: dyspnoea	1 (&lt;1%)	0	1·00	1 (&lt;1%)	1 (&lt;1%)	1·00",95377:95567,5840256,29449189,Unavailable
5840256,"Thrombosis or embolism	Grade 2 or worse (6 months)",Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Thrombosis or embolism	3 (1%)	0	0·37	1 (&lt;1%)	1 (&lt;1%)	1·00",95610:95799,5840256,29449189,Unavailable
5840256,Grade 3 or worse adverse events (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Any 128 (39%) 96 (29%) &lt;0·0001 54 (16%) 25 (8%) &lt;0·0001,95610:95799,5840256,29449189,Unavailable
5840256,Auditory or hearing issues Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Auditory or hearing 8 (2%) 3 (1%) 0·22 0 0 1·00,95610:95799,5840256,29449189,Unavailable
5840256,Allergy Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Allergy 2 (1%) 1 (&lt;1%) 1·00 0 0 1·00,95610:95799,5840256,29449189,Unavailable
5840256,Fatigue Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Fatigue 10 (3%) 2 (1%) 0·054 1 (&lt;1%) 1 (&lt;1%) 1·00,95610:95799,5840256,29449189,Unavailable
5840256,Hypertension Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Hypertension 15 (5%) 18 (5%) 0·75 5 (2%) 5 (2%) 1·00,95610:95799,5840256,29449189,Unavailable
5840256,Dermatitis Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Dermatitis 1 (&lt;1%) 0 1·00 0 0 1·00,95610:95799,5840256,29449189,Unavailable
5840256,"Any gastrointestinal	 Grade 3 or worse (6 months)",Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Any gastrointestinal 19 (6%) 18 (5%) 0·89 7 (2%) 9 (3%) 0·80,95610:95799,5840256,29449189,Unavailable
5840256,Nausea Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Nausea 7 (2%) 5 (2%) 0·35 5 (2%) 2 (1%) 0·45,95610:95799,5840256,29449189,Unavailable
5840256,Vomiting Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Vomiting 7 (2%) 6 (2%) 0·45 3 (1%) 0 0·25,95610:95799,5840256,29449189,Unavailable
5840256,Anorexia Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Anorexia 1 (&lt;1%) 4 (1%) 0·50 2 (1%) 2 (1%) 1·00,95610:95799,5840256,29449189,Unavailable
5840256,Constipation Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Constipation 7 (2%) 4 (1%) 0·79 1 (&lt;1%) 2 (1%) 1·00,95610:95799,5840256,29449189,Unavailable
5840256,Urinary frequency or urgency Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Genito-urinary: frequency or urgency 5 (2%) 6 (2%) 0·77 1 (&lt;1%) 0 1·00,95610:95799,5840256,29449189,Unavailable
5840256,Any haematological problem Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Any haematological 54 (16%) 27 (8%) &lt;0·0001 24 (7%) 6 (2%) 0·0001,95610:95799,5840256,29449189,Unavailable
5840256,"Febrile neutropenia	Grade 3 or worse (6 months)",Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Febrile neutropenia	NA	NA	··	0	0	1·00",91923:92086,5840256,29449189,Unavailable
5840256,Infection with neutropenia Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Infection with neutropenia	0	0	1·00	1 (&lt;1%)	0	1·00",NaN:92305,5840256,29449189,Unavailable
5840256,Infection without neutropenia Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Infection without neutropenia 5 (2%) 1 (&lt;1%) 0·22 0 0 1·00,NaN:92305,5840256,29449189,Unavailable
5840256,Haemoglobin AE Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Haemoglobin 24 (7%) 0 &lt;0·0001 3 (1%) 0 0·25,94741:94909,5840256,29449189,Unavailable
5840256,Leucocytes AE Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Leucocytes 20 (6%) 1 (&lt;1%) &lt;0·0001 6 (2%) 1 (&lt;1%) 0·12,94741:94909,5840256,29449189,Unavailable
5840256,Lymphocytes AE Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Lymphocytes 43 (13%) 26 (8%) 0·0015 17 (5%) 5 (2%) 0·015,94741:94909,5840256,29449189,Unavailable
5840256,Neutrophils AE Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,Neutrophils 4 (1%) 0 0·0018 6 (2%) 0 0·031,94741:94909,5840256,29449189,Unavailable
5840256,Platelets AE Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Platelets 5 (2%) 0 0·015 2 (1%) 0 0·50,94741:94909,5840256,29449189,Unavailable
5840256,Metabolic or laboratory problems Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Metabolic or laboratory 2 (1%) 0 0·12 2 (1%) 0 0·50,93443:93607,5840256,29449189,Unavailable
5840256,Any neuropathy Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Any neuropathy 42 (13%) 1 (&lt;1%) &lt;0·0001 8 (2%) 2 (1%) 0·11,93443:93607,5840256,29449189,Unavailable
5840256,Motor issues Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Motor	7 (2%)	1 (&lt;1%)	0·09	3 (1%)	2 (1%)	1·00",94100:94273,5840256,29449189,Unavailable
5840256,Sensory neuropathy Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,Significantly increased,"Sensory	41 (12%)	0	&lt;0·0001	6 (2%)	0	0·031",94313:94483,5840256,29449189,Unavailable
5840256,Any pain Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Any pain	31 (9%)	32 (10%)	0·54	3 (1%)	7 (2%)	0·34",94526:94701,5840256,29449189,Unavailable
5840256,Joint problems Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Joint	8 (2%)	6 (2%)	1·00	0	1 (&lt;1%)	1·00",94741:94909,5840256,29449189,Unavailable
5840256,Muscle problems Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Muscle 5 (2%) 1 (&lt;1%) 0·22 0 0 1·00,94741:94909,5840256,29449189,Unavailable
5840256,"Pelvic, back, or limb problems Grade 3 or worse (6 months)",Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,"Pelvic, back, or limb 10 (3%) 9 (3%) 0·33 0 3 (1%) 0·25",94741:94909,5840256,29449189,Unavailable
5840256,Dyspnoea Grade 3 or worse (6 months),Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Pulmonary: dyspnoea 1 (&lt;1%) 0 1·00 1 (&lt;1%) 1 (&lt;1%) 1·00,94741:94909,5840256,29449189,Unavailable
5840256,"Thrombosis or embolism	Grade 3 or worse (6 months)",Chemotherapy + Radiotherapy ,Radiotherapy alone,No significant difference,Thrombosis or embolism 3 (1%) 0 0·37 1 (&lt;1%) 1 (&lt;1%) 1·00,94741:94909,5840256,29449189,Unavailable
3566922,Adequate clinical and parasitological response (28 days) PCR corrected,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,pyronaridine-artesunate PCR-corrected day-28 ACPR was statistically significantly &gt;90% (P &lt; .0001). Pyronaridine-artesunate was non-inferior to artemether-lumefantrine: treatment difference -1.8% (95% CI -4.3 to 1.6).,8813:9051,3566922,23113947,Unavailable
3566922,Drug-related AEs,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"The incidence of drug-related adverse events was 37.2% (132/355) with pyronaridine-artesunate, 44.4% (80/180) with artemether-lumefantrine.",9052:9191,3566922,23113947,Unavailable
3566922,Clinical biochemistry ,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Clinical biochemistry results showed similar mean changes versus baseline in the two treatment groups.,9192:9295,3566922,23113947,Unavailable
3566922,Adequate clinical and parasitological response (28 days) PCR corrected,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"Day-28 PCR-corrected ACPR,b n/N329/339165/167&nbsp;  % (95% CI)97.1 (94.6–98.6)98.8 (95.7–99.9)–1.8 (–4.3 to 1.6); P = .22",31411:31906,3566922,23113947,Unavailable
3566922,Adequate clinical and parasitological response (28 days) crude,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"Day-28 crude ACPR, n/N305/341149/172&nbsp;  % (95% CI)89.4 (85.7–92.5)86.6 (80.6–91.3)2.8 (–2.9 to 9.4); P = .35",33167:33641,3566922,23113947,Unavailable
3566922,Adequate clinical and parasitological response (42 days) PCR corrected,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"Day-42 PCR-corrected ACPR,b n/N257/275133/139&nbsp;  % (95% CI)93.5 (89.9–96.1)95.7 (90.8–98.4)–2.2 (–6.5 to 3.1); P = .36",49152:49578,3566922,23113947,Unavailable
3566922,Adequate clinical and parasitological response (42 days) crude,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"Day-42 crude ACPR, n/N249/325130/166&nbsp;  % (95% CI)76.6 (71.6–81.1)78.3 (71.3–84.3)–1.7 (–9.1 to 6.4); P = .67",36177:36652,3566922,23113947,Unavailable
3566922,Adequate clinical and parasitological response (28 days) PCR corrected,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Non-inferiority of pyronaridine-artesunate to artemether-lumefantrine was concluded for day-28 PCR-corrected ACPR in the per-protocol population,49152:49296,3566922,23113947,Unavailable
3566922,Adequate clinical and parasitological response (28 days) crude,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Non-inferiority was also demonstrated for day-28 crude ACPR and day-42 PCR-corrected and crude ACPR in the per-protocol population (Table 2) and for outcomes in the intent-to-treat population,49347:49578,3566922,23113947,Unavailable
3566922,Adequate clinical and parasitological response (42 days) PCR corrected,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Non-inferiority was also demonstrated for day-28 crude ACPR and day-42 PCR-corrected and crude ACPR in the per-protocol population (Table 2) and for outcomes in the intent-to-treat population,49347:49577,3566922,23113947,Unavailable
3566922,Adequate clinical and parasitological response (42 days) crude,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Non-inferiority was also demonstrated for day-28 crude ACPR and day-42 PCR-corrected and crude ACPR in the per-protocol population (Table 2) and for outcomes in the intent-to-treat population,49347:49577,3566922,23113947,Unavailable
3566922,Recrudescence rate,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"Kaplan–Meier analysis (intent-to-treat population) showed no difference between the two treatment groups for recrudescence rate (P = .53, log rank test; Figure 2a), or re-infection rate (P = .77, log rank test; Figure 2b).",50771:51101,3566922,23113947,Unavailable
3566922,Re-infection rate,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"Kaplan–Meier analysis (intent-to-treat population) showed no difference between the two treatment groups for recrudescence rate (P = .53, log rank test; Figure 2a), or re-infection rate (P = .77, log rank test; Figure 2b).",50771:51101,3566922,23113947,Unavailable
3566922,Recrudescence rate,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"Kaplan–Meier analysis (intent-to-treat population) showed no difference between pyronaridine-artesunate granules and artemether-lumefantrine crushed tablets for (a) recrudescence rate (P = .53, log-rank test) or (b) re-infection rate (P = .77, log-rank test).",51177:51522,3566922,23113947,Unavailable
3566922,Re-infection rate,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"Kaplan–Meier analysis (intent-to-treat population) showed no difference between pyronaridine-artesunate granules and artemether-lumefantrine crushed tablets for (a) recrudescence rate (P = .53, log-rank test) or (b) re-infection rate (P = .77, log-rank test).",51177:51522,3566922,23113947,Unavailable
3566922,Time to parasite clearance ,Pyronaridine-artesunate,Artemether-lumefantrine,Significantly decreased,"Median time to parasite clearance was shorter with pyronaridine-artesunate (24.1 h; 95% CI 24.0, 24.1) versus artemether-lumefantrine (24.2 h; 95% CI 24.1, 32.0; P = .02, log-rank test; Figure 3a).",52063:52221,3566922,23113947,Unavailable
3566922,Anti-pyretic medication use,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Anti-pyretic medication was taken by 220/355 (62.0%) patients in the pyronaridine-artesunate group and 118/180 (65.6%) in the artemether-lumefantrine group.,52063:52221,3566922,23113947,Unavailable
3566922,Fever clearance time,Pyronaridine-artesunate,Artemether-lumefantrine,Significantly decreased,"Median fever clearance time was marginally shorter with pyronaridine-artesunate (8.1 h; 95% CI 8.0, 8.1) versus artemether-lumefantrine (8.1 h; 95% CI 8.0, 15.8; P = .049, log rank test; Figure 3b).",52221:52473,3566922,23113947,Unavailable
3566922,Gametocyte clearance time,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"For those patients who had gametocyte clearance by day 3, median gametocyte clearance time was similar between the treatment groups (P = .48, log-rank test).",52531:52706,3566922,23113947,Unavailable
3566922,Occurrence of post-baseline gametocytes,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,In the pyronaridine-artesunate group a total 26.8% (95/354) patients had post-baseline gametocytes versus 24.7% (44/178) with artemether-lumefantrine.,52877:53028,3566922,23113947,Unavailable
3566922,New occurrences of gametocytes,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,New occurrences of gametocytes in patients that had none at baseline occurred in 15.0% (53/354) of patients in the pyronaridine-artesunate group and 11.2% (20/178) in the artemether-lumefantrine group.,53028:53229,3566922,23113947,Unavailable
3566922,Time to parasite clearance ,Pyronaridine-artesunate,Artemether-lumefantrine,Significantly decreased,"Kaplan–Meier analysis (intent-to-treat population) showed significantly faster (a) parasite clearance time (P = .02, log-rank test) and (b) fever clearance time (P = .049, log-rank test) with pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets.",53305:53663,3566922,23113947,Unavailable
3566922,Fever clearance time,Pyronaridine-artesunate,Artemether-lumefantrine,Significantly decreased,"Kaplan–Meier analysis (intent-to-treat population) showed significantly faster (a) parasite clearance time (P = .02, log-rank test) and (b) fever clearance time (P = .049, log-rank test) with pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets.",53305:53663,3566922,23113947,Unavailable
3566922,AEs of any cause,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"Adverse events of any cause were experienced by 285/355 (80.3%) patients in the pyronaridine-artesunate, and 143/180 (79.4%) patients in the artemether-lumefantrine group",54613:54976,3566922,23113947,Unavailable
3566922,Drug-related AEs,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Adverse events thought by the investigator to be drug related occurred in 132/355 (37.2%) patients in the pyronaridine-artesunate group and 80/180 (44.4%) in the artemether-lumefantrine group. There were no clinically important differences in the nature or incidence of adverse events between the two study groups (Table 4).,54613:54976,3566922,23113947,Unavailable
3566922,AEs of any cause,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Adverse event of any causea285 (80.3)143 (79.4),55779:NaN,3566922,23113947,Unavailable
3566922,Cough,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Cough44 (12.4)28 (15.6),55993:NaN,3566922,23113947,Unavailable
3566922,Upper respiratory tract infection,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Upper respiratory tract infection42 (11.8)19 (10.6),56379:NaN,3566922,23113947,Unavailable
3566922,Anemia,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Anemia34 (9.6)14 (7.8),56379:NaN,3566922,23113947,Unavailable
3566922,Platelets increased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Platelets increased33 (9.3)19 (10.6),56557:56691,3566922,23113947,Unavailable
3566922,Blood glucose decreased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Blood glucose decreased32 (9.0)19 (10.6),56749:NaN,3566922,23113947,Unavailable
3566922,Bronchitis,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Bronchitis28 (7.9)10 (5.6),56945:NaN,3566922,23113947,Unavailable
3566922,Vomiting,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Vomiting25 (7.0)8 (4.4),57127:NaN,3566922,23113947,Unavailable
3566922,Pyrexia,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Pyrexia23 (6.5)8 (4.4),57306:NaN,3566922,23113947,Unavailable
3566922,Blood albumin decreased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Blood albumin decreased21 (5.9)16 (8.9),57484:57621,3566922,23113947,Unavailable
3566922,Influenza-like illness,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Influenza-like illness19 (5.4)8 (4.4),57678:NaN,3566922,23113947,Unavailable
3566922,Drug-related AEs,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Drug-related adverse eventsb132 (37.2)80 (44.4),57870:NaN,3566922,23113947,Unavailable
3566922,Blood glucose decreased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Drug-related adverse eventsb132 (37.2)80 (44.4),57870:NaN,3566922,23113947,Unavailable
3566922,Platelet count increased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Drug-related adverse eventsb132 (37.2)80 (44.4),57870:NaN,3566922,23113947,Unavailable
3566922,Blood albumin decreased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Drug-related adverse eventsb132 (37.2)80 (44.4),57870:NaN,3566922,23113947,Unavailable
3566922,Anemia,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Anemia15 (4.2)11 (6.1),58670:NaN,3566922,23113947,Unavailable
3566922,Blood potassium increased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Blood potassium increased15 (4.2)6 (3.3),58848:NaN,3566922,23113947,Unavailable
3566922,Hemoglobin decreased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Hemoglobin decreased15 (4.2)5 (2.8),59044:59177,3566922,23113947,Unavailable
3566922,Upper respiratory tract infection,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Upper respiratory tract infection14 (3.9)5 (2.8),59235:NaN,3566922,23113947,Unavailable
3566922,AST increased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,AST increased14 (3.9)7 (3.9),59439:NaN,3566922,23113947,Unavailable
3566922,Hematocrit decreased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Hematocrit decreased14 (3.9)5 (2.8),59623:NaN,3566922,23113947,Unavailable
3566922,Vomiting,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,Vomiting7 (2.0)6 (3.3),59814:59934,3566922,23113947,Unavailable
3566922,Blood creatinine decreased,Pyronaridine-artesunate,Artemether-lumefantrine,No significant difference,"Blood creatinine decreased	7 (2.0)	7 (3.9)",59976:60064,3566922,23113947,Unavailable
5435070,Posture score improvement,NaHCO3,NaCl,No significant difference,"Clinical scores for posture, behavior, and degree of enophthalmos improved in all treatment groups, with no difference between treatment groups at the end of the study period",44170:44344,5435070,28407322,Unavailable
5435070,Posture score improvement,NaHCO3,Glucose,No significant difference,"Clinical scores for posture, behavior, and degree of enophthalmos improved in all treatment groups, with no difference between treatment groups at the end of the study period",47522:47725,5435070,28407322,Unavailable
5435070,Posture score improvement,NaCl,Glucose,No significant difference,"Clinical scores for posture, behavior, and degree of enophthalmos improved in all treatment groups, with no difference between treatment groups at the end of the study period",47522:47725,5435070,28407322,Unavailable
5435070,Behavior score improvement,NaHCO3,NaCl,No significant difference,"Clinical scores for posture, behavior, and degree of enophthalmos improved in all treatment groups, with no difference between treatment groups at the end of the study period",47522:47725,5435070,28407322,Unavailable
5435070,Behavior score improvement,NaHCO3,Glucose,No significant difference,"Clinical scores for posture, behavior, and degree of enophthalmos improved in all treatment groups, with no difference between treatment groups at the end of the study period",47522:47725,5435070,28407322,Unavailable
5435070,Behavior score improvement,NaCl,Glucose,No significant difference,"Clinical scores for posture, behavior, and degree of enophthalmos improved in all treatment groups, with no difference between treatment groups at the end of the study period",47522:47725,5435070,28407322,Unavailable
5435070,Degree of enophthalmos improvement,NaHCO3,NaCl,No significant difference,"Clinical scores for posture, behavior, and degree of enophthalmos improved in all treatment groups, with no difference between treatment groups at the end of the study period",47522:47725,5435070,28407322,Unavailable
5435070,Degree of enophthalmos improvement,NaHCO3,Glucose,No significant difference,"Clinical scores for posture, behavior, and degree of enophthalmos improved in all treatment groups, with no difference between treatment groups at the end of the study period",47522:47725,5435070,28407322,Unavailable
5435070,Degree of enophthalmos improvement,NaCl,Glucose,No significant difference,"Clinical scores for posture, behavior, and degree of enophthalmos improved in all treatment groups, with no difference between treatment groups at the end of the study period",47522:47725,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (10m),NaHCO3,NaCl,No significant difference,"Similar decrements of cK were observed in groups NaCl and NaBic between 10 and 20 minutes, which were significantly higher than in calves of group Gluc during the same period of time.",47522:47725,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (10m),NaHCO3,Glucose,Significantly increased,"Similar decrements of cK were observed in groups NaCl and NaBic between 10 and 20 minutes, which were significantly higher than in calves of group Gluc during the same period of time.",47522:47725,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (10m),NaCl,Glucose,Significantly increased,"Similar decrements of cK were observed in groups NaCl and NaBic between 10 and 20 minutes, which were significantly higher than in calves of group Gluc during the same period of time.",47522:47725,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (20m),NaHCO3,NaCl,No significant difference,"Similar decrements of cK were observed in groups NaCl and NaBic between 10 and 20 minutes, which were significantly higher than in calves of group Gluc during the same period of time.",47522:47725,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (20m),NaHCO3,Glucose,Significantly increased,"Similar decrements of cK were observed in groups NaCl and NaBic between 10 and 20 minutes, which were significantly higher than in calves of group Gluc during the same period of time.",47522:47725,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (20m),NaCl,Glucose,Significantly increased,"Similar decrements of cK were observed in groups NaCl and NaBic between 10 and 20 minutes, which were significantly higher than in calves of group Gluc during the same period of time.",47522:47725,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (30-120m),NaHCO3,NaCl,Significantly increased,"Between 30 minutes and 120 minutes, the most marked decrement of cK was observed in calves group NaBic, which was reflected by Diff K values that differed significantly from calves of group NaCl, but not from calves of group Gluc.",47895:48142,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (30-120m),NaHCO3,Glucose,No significant difference,"Between 30 minutes and 120 minutes, the most marked decrement of cK was observed in calves group NaBic, which was reflected by Diff K values that differed significantly from calves of group NaCl, but not from calves of group Gluc.",47895:48142,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (120m),NaHCO3,NaCl,Significantly increased,"At 120 minutes, the observed decrements were equivalent to −26.0 ± 10.4%, −9.1 ± 8.3%, and −21.6 ± 6.4% of baseline cK in groups NaBic, NaCl, and Gluc, respectively. Those values differed significantly between groups NaCl and NaBic (P = .003), NaCl and Gluc (P = .032), but not between NaBic and Gluc (P = 1.00).",48143:48523,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (20m),NaHCO3,Glucose,No significant difference,"At 120 minutes, the observed decrements were equivalent to −26.0 ± 10.4%, −9.1 ± 8.3%, and −21.6 ± 6.4% of baseline cK in groups NaBic, NaCl, and Gluc, respectively. Those values differed significantly between groups NaCl and NaBic (P = .003), NaCl and Gluc (P = .032), but not between NaBic and Gluc (P = 1.00).",48143:48523,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (20m),NaCl,Glucose,Significantly decreased,"At 120 minutes, the observed decrements were equivalent to −26.0 ± 10.4%, −9.1 ± 8.3%, and −21.6 ± 6.4% of baseline cK in groups NaBic, NaCl, and Gluc, respectively. Those values differed significantly between groups NaCl and NaBic (P = .003), NaCl and Gluc (P = .032), but not between NaBic and Gluc (P = 1.00).",48143:48523,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (AUC),NaHCO3,NaCl,Significantly increased,"The AUCDiff K values also differed significantly between groups NaBic and NaCl (P = .008), but not between NaBic and Gluc (P = .28), and NaCl and Gluc (P = .35).",48703:48926,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (AUC),NaHCO3,Glucose,No significant difference,"The AUCDiff K values also differed significantly between groups NaBic and NaCl (P = .008), but not between NaBic and Gluc (P = .28), and NaCl and Gluc (P = .35).",48703:48926,5435070,28407322,Unavailable
5435070,Reduction in potassium concentration (AUC),NaCl,Glucose,No significant difference,"The AUCDiff K values also differed significantly between groups NaBic and NaCl (P = .008), but not between NaBic and Gluc (P = .28), and NaCl and Gluc (P = .35).",48703:48926,5435070,28407322,Unavailable
5435070,Increase in sodium concentration ,NaHCO3,NaCl,No significant difference,"A similar increase in plasma cNa was observed after treatment in groups NaBic and NaCl, with values that differed significantly from baseline throughout the study period",85121:85343,5435070,28407322,Unavailable
5435070,Increase in sodium concentration (7-20m),NaHCO3,Glucose,Significantly increased,IV administration of a sodium‐free glucose solution resulted in a significant decrease in cNa with values that differed significantly from calves of groups NaBic and NaCl between 7 minutes and 20 minutes.,85121:85343,5435070,28407322,Unavailable
5435070,Increase in sodium concentration (7-20m),NaCl,Glucose,Significantly increased,IV administration of a sodium‐free glucose solution resulted in a significant decrease in cNa with values that differed significantly from calves of groups NaBic and NaCl between 7 minutes and 20 minutes.,85121:85343,5435070,28407322,Unavailable
5435070,Change in plasma volume (7-20m),NaHCO3,Glucose,Significantly decreased,The changes in plasma volume relative to baseline were significantly higher in calves of group Gluc between 7 and 20 minutes than for calves of groups NaCl and NaBic.,87251:87417,5435070,28407322,Unavailable
5435070,Change in plasma volume (7-20m),NaCl,Glucose,Significantly decreased,The changes in plasma volume relative to baseline were significantly higher in calves of group Gluc between 7 and 20 minutes than for calves of groups NaCl and NaBic.,87251:87417,5435070,28407322,Unavailable
5435070,Plasma glucose concentration ,NaHCO3,Glucose,Significantly decreased,Infusions of the 46.2% glucose solution resulted in a large increase in plasma glucose and insulin concentration that differed significantly from baseline and from calves of groups NaCl and NaBic throughout the study period,88656:88879,5435070,28407322,Unavailable
5435070,Plasma glucose concentration ,NaCl,Glucose,Significantly decreased,Infusions of the 46.2% glucose solution resulted in a large increase in plasma glucose and insulin concentration that differed significantly from baseline and from calves of groups NaCl and NaBic throughout the study period,88656:88880,5435070,28407322,Unavailable
5435070, D‐lactate concentrations ,NaHCO3,NaCl,No significant difference,D‐lactate concentrations did not change significantly from baseline values in all treatment groups.,90261:90360,5435070,28407322,Unavailable
5435070, D‐lactate concentrations ,NaHCO3,Glucose,Significantly increased,D‐lactate concentrations did not change significantly from baseline values in all treatment groups.,90261:90360,5435070,28407322,Unavailable
5435070, D‐lactate concentrations ,NaCl,Glucose,Significantly increased,D‐lactate concentrations did not change significantly from baseline values in all treatment groups.,90260:90360,5435070,28407322,Unavailable
5435070,Plasma urea concentration ,NaHCO3,NaCl ,No significant difference,"A significant group and time, but no time × group effect was detectable for plasma urea concentrations.",90260:90360,5435070,28407322,Unavailable
5435070,Plasma urea concentration ,NaHCO3,Glucose,No significant difference,"A significant group and time, but no time × group effect was detectable for plasma urea concentrations.",90260:90360,5435070,28407322,Unavailable
5435070,Plasma urea concentration ,NaCl,Glucose,No significant difference,"A significant group and time, but no time × group effect was detectable for plasma urea concentrations.",90260:90360,5435070,28407322,Unavailable
3636659,Recovery time,Web-based stress-reduction intervention,Control,Significantly decreased,"A growth curve analysis showed that participants in the stress intervention (unstandardized beta coefficient [B]=–3.45, P=.008) recovered more quickly compared to the control group (B=–0.81, P=.34)",73749:74032,3636659,23607962,Unavailable
3636659,Dropout rates at 1-month,Web-based stress-reduction intervention,Control,Significantly increased,"Between-group differences in dropout rates at 1-month (χ2 1=8.4, P=.004), 2-month (χ2 1=5.7, P=.017), and 6-month (χ2 1=7.8, P=.005) follow-up, were significant.",45716:45995,3636659,23607962,Unavailable
3636659,Dropout rates at 2-months,Web-based stress-reduction intervention,Control,Significantly increased,"Between-group differences in dropout rates at 1-month (χ2 1=8.4, P=.004), 2-month (χ2 1=5.7, P=.017), and 6-month (χ2 1=7.8, P=.005) follow-up, were significant.",45716:45995,3636659,23607962,Unavailable
3636659,Dropout rates at 6-months,Web-based stress-reduction intervention,Control,Significantly increased,"Between-group differences in dropout rates at 1-month (χ2 1=8.4, P=.004), 2-month (χ2 1=5.7, P=.017), and 6-month (χ2 1=7.8, P=.005) follow-up, were significant.",45716:45995,3636659,23607962,Unavailable
3636659,Stress,Web-based stress-reduction intervention,Control,Significantly decreased,"participants experienced reductions in their stress levels, but that participants in the LS group experienced a different developmental trajectory over and above the natural variation in stress over time (model 6 vs model 5: Δχ2 3=8.0, P=.046).",73749:74032,3636659,23607962,Unavailable
5815470,Analgesic effect (10m),Acupuncture ,Morphine,Significantly increased,"From the 10th minute until the end of the intervention, acupuncture was associated with a deeper analgesic effect than titrated morphine (P&lt;0.05 from the 10th minute and over).",5981:6175,5815470,29483783,Unavailable
5815470,Analgesic effect (20m),Acupuncture ,Morphine,Significantly increased,"From the 10th minute until the end of the intervention, acupuncture was associated with a deeper analgesic effect than titrated morphine (P&lt;0.05 from the 10th minute and over).",5981:6175,5815470,29483783,Unavailable
5815470,Analgesic effect (30m),Acupuncture ,Morphine,Significantly increased,"From the 10th minute until the end of the intervention, acupuncture was associated with a deeper analgesic effect than titrated morphine (P&lt;0.05 from the 10th minute and over).",5981:6175,5815470,29483783,Unavailable
5815470,Analgesic effect (45m),Acupuncture ,Morphine,Significantly increased,"From the 10th minute until the end of the intervention, acupuncture was associated with a deeper analgesic effect than titrated morphine (P&lt;0.05 from the 10th minute and over).",5981:6175,5815470,29483783,Unavailable
5815470,Analgesic effect (60m),Acupuncture ,Morphine,Significantly increased,"From the 10th minute until the end of the intervention, acupuncture was associated with a deeper analgesic effect than titrated morphine (P&lt;0.05 from the 10th minute and over).",5981:6175,5815470,29483783,Unavailable
5815470,Time to obtain 50% pain reduction,Acupuncture ,Morphine,Significantly decreased,"Analgesia was also faster in the acupuncture group, with time to obtain 50% reduction of baseline VAS of 14 minutes in the acupuncture group versus 28 minutes in the IV titrated-morphine group (P&lt;0.001).",6175:6398,5815470,29483783,Unavailable
5815470,Minor side effects ,Acupuncture ,Morphine,Significantly decreased,Only three patients in the acupuncture group experienced minor side effects versus 42 in the morphine group (P&lt;0.001).,6399:6537,5815470,29483783,Unavailable
5815470,Analgesic effect (10m),Acupuncture ,Morphine,Significantly increased,Mean pain scores were significantly lower in the acupuncture group than in the morphine group from the 10th minute of the protocol start until the 60th minute (P&lt;0.005 at all-time points).,15673:15878,5815470,29483783,Unavailable
5815470,Analgesic effect (20m),Acupuncture ,Morphine,Significantly increased,Mean pain scores were significantly lower in the acupuncture group than in the morphine group from the 10th minute of the protocol start until the 60th minute (P&lt;0.005 at all-time points).,15673:15879,5815470,29483783,Unavailable
5815470,Analgesic effect (30m),Acupuncture ,Morphine,Significantly increased,Mean pain scores were significantly lower in the acupuncture group than in the morphine group from the 10th minute of the protocol start until the 60th minute (P&lt;0.005 at all-time points).,15672:15878,5815470,29483783,Unavailable
5815470,Analgesic effect (45m),Acupuncture ,Morphine,Significantly increased,Mean pain scores were significantly lower in the acupuncture group than in the morphine group from the 10th minute of the protocol start until the 60th minute (P&lt;0.005 at all-time points).,15673:15879,5815470,29483783,Unavailable
5815470,Analgesic effect (60m),Acupuncture ,Morphine,Significantly increased,Mean pain scores were significantly lower in the acupuncture group than in the morphine group from the 10th minute of the protocol start until the 60th minute (P&lt;0.005 at all-time points).,15673:15879,5815470,29483783,Unavailable
5815470,Success ,Acupuncture ,Morphine,No significant difference,"Success rates were similar between the groups, with 87% of participants achieving the main goal in the acupuncture group and 83% in the morphine group (P=0.6).",15493:15672,5815470,29483783,Unavailable
5815470,Time to obtain 50% pain reduction,Acupuncture ,Morphine,Significantly decreased,"In fact, with acupuncture, a 50% reduction in baseline pain score was achieved in half the time taken by morphine (14 versus 28 minutes, P&lt;0.001)",16060:16227,5815470,29483783,Unavailable
5815470,Minor side effects ,Acupuncture ,Morphine,Significantly decreased,"Side effects were observed more frequently in the morphine group than in the acupuncture group (42 versus three, P&lt;0.001).",16565:16704,5815470,29483783,Unavailable
5735554,Mortality ,Xience stent,Catania stent,No significant difference,there was no statistically difference in mortality (4.7% vs. 2.5%; P = 0.527) and stent thrombosis (2.3% vs. 2.5%; P = 0.735).,4701:4864,5735554,29285484,Unavailable
5735554,Stent thrombosis,Xience stent,Catania stent,No significant difference,there was no statistically difference in mortality (4.7% vs. 2.5%; P = 0.527) and stent thrombosis (2.3% vs. 2.5%; P = 0.735).,4701:4864,5735554,29285484,Unavailable
5735554,Mortality ,Xience stent,Catania stent,No significant difference,"Furthermore, there was no statistically significant difference in mortality (4.7% vs. 2.5%; P = 0.527) and stent thrombosis (2.3% vs. 2.5%; P = 0.735) [Table 2].",15200:15437,5735554,29285484,Unavailable
5735554,Stent thrombosis,Xience stent,Catania stent,No significant difference,"Furthermore, there was no statistically significant difference in mortality (4.7% vs. 2.5%; P = 0.527) and stent thrombosis (2.3% vs. 2.5%; P = 0.735) [Table 2].",15200:15437,5735554,29285484,Unavailable
3641457,Moderate/severe exacerbations (overall),Fluticasone propionate + salmeterol,Salmeterol,Significantly decreased,"Overall, SFC significantly reduced the annual rate of moderate/severe exacerbations as compared with SAL alone (rate ratio (RR)=0.701, p&lt;0.001).",5559:5703,3641457,23613569,Unavailable
3641457,Moderate/severe exacerbations (when receiving diuretics) ,Fluticasone propionate + salmeterol,Salmeterol,Significantly decreased,"Three-patient clusters were identified: COPD patients receiving diuretics (RR=0.56, p&lt;0.001); patients not receiving diuretics but with forced expiratory volume in 1 s (FEV1) reversibility ≥12% (RR=0.67, p&lt;0.001) exhibited a substantial reduction in the annual rate of moderate/severe exacerbations relative to SAL.",5704:6036,3641457,23613569,Unavailable
3641457,Moderate/severe exacerbations (when FEV1 reversibility ≥12%) ,Fluticasone propionate + salmeterol,Salmeterol,Significantly decreased,"Three-patient clusters were identified: COPD patients receiving diuretics (RR=0.56, p&lt;0.001); patients not receiving diuretics but with forced expiratory volume in 1 s (FEV1) reversibility ≥12% (RR=0.67, p&lt;0.001) exhibited a substantial reduction in the annual rate of moderate/severe exacerbations relative to SAL.",5704:6036,3641457,23613569,Unavailable
3641457,Moderate/severe exacerbations (no diuretics nor FEV1 reversibility) ,Fluticasone propionate + salmeterol,Salmeterol,No significant difference,"A third cluster, consisting of patients not receiving diuretics and without FEV1 reversibility, demonstrated no difference for SFC versus SAL.",6037:6193,3641457,23613569,Unavailable
3641457,Moderate/severe exacerbations (overall),Fluticasone propionate + salmeterol,Salmeterol,Significantly decreased,"The risk of a moderate or severe exacerbation among SFC users in the pooled study population was decreased by 30% as compared with those using SAL alone (RR=0.701, p&lt;0.001).",28387:28560,3641457,23613569,Unavailable
3757792,Perfusion index,Hypercapnia,Control,Significantly increased,Hypercapnia significantly increased PI and decreased PVI with significant negative correlation.,10604:10760,3757792,24015122,Unavailable
3757792,Pleth variability index,Hypercapnia,Control,Significantly decreased,Hypercapnia significantly increased PI and decreased PVI with significant negative correlation.,10604:10760,3757792,24015122,Unavailable
3757792,Perfusion index,Hypercapnia,Control,Significantly increased,"During hypercapnia, the PI was significantly increased while PVI was significantly decreased compared with normocapnia (P=0.000 for each).",10604:10760,3757792,24015122,Unavailable
3757792,Pleth variability index,Hypercapnia,Control,Significantly decreased,"During hypercapnia, the PI was significantly increased while PVI was significantly decreased compared with normocapnia (P=0.000 for each).",10604:10760,3757792,24015122,Unavailable
5916649,SBP 5 min after ISB,Dexmedetomidine 1  μg/kg,Control,Significantly increased,"Systolic BP was significantly higher in groups D1 and D3 than in group R at 5 min after ISB (P = .004 and P = .012, respectively).",23813:23978,5916649,29668608,Unavailable
5916649,SBP 5 min after ISB,Dexmedetomidine 2  μg/kg,Control,Significantly increased,"Systolic BP was significantly higher in groups D1 and D3 than in group R at 5 min after ISB (P = .004 and P = .012, respectively).",23813:23978,5916649,29668608,Unavailable
5916649,SBP 30min after start,Dexmedetomidine 1  μg/kg,Control,Significantly decreased,"Thirty minutes after the start of surgery, systolic BP was significantly lower in the dexmedetomidine groups than in group R (P = .04 for group D1, P &lt; .001 for group D2 and P = .008 for group D3).",23979:24230,5916649,29668608,Unavailable
5916649,SBP 30min after start,"Dexmedetomidine 1,5  μg/kg",Control,Significantly decreased,"Thirty minutes after the start of surgery, systolic BP was significantly lower in the dexmedetomidine groups than in group R (P = .04 for group D1, P &lt; .001 for group D2 and P = .008 for group D3).",23979:24230,5916649,29668608,Unavailable
5916649,SBP 30min after start,Dexmedetomidine 2  μg/kg,Control,Significantly decreased,"Thirty minutes after the start of surgery, systolic BP was significantly lower in the dexmedetomidine groups than in group R (P = .04 for group D1, P &lt; .001 for group D2 and P = .008 for group D3).",23979:24230,5916649,29668608,Unavailable
5916649,SBP 60min after start,"Dexmedetomidine 1,5  μg/kg",Control,Significantly decreased,"In group D2, systolic BP was significantly lower than in group R at 60 min after the start of surgery (P = 0.01).",24230:24362,5916649,29668608,Unavailable
5916649,SBP at recovery room,Dexmedetomidine 1  μg/kg,Control,Significantly decreased,"In the recovery room, systolic BP was significantly lower in the dexmedetomidine groups than in group R (P = .007 for group D1, P &lt; .001 for groups D2 and D3).",24362:24555,5916649,29668608,Unavailable
5916649,SBP at recovery room,"Dexmedetomidine 1,5  μg/kg",Control,Significantly decreased,"In the recovery room, systolic BP was significantly lower in the dexmedetomidine groups than in group R (P = .007 for group D1, P &lt; .001 for groups D2 and D3).",24362:24555,5916649,29668608,Unavailable
5916649,SBP at recovery room,Dexmedetomidine 2  μg/kg,Control,Significantly decreased,"In the recovery room, systolic BP was significantly lower in the dexmedetomidine groups than in group R (P = .007 for group D1, P &lt; .001 for groups D2 and D3).",24362:24555,5916649,29668608,Unavailable
5916649,DBP 30min after start,Dexmedetomidine 1  μg/kg,Control,Significantly decreased,"The diastolic BP was significantly lower in the dexmedetomidine groups than in group R at 30 min after the start of surgery (P &lt; .001 for groups D1 and D2, P = .001 for group D3).",24556:24776,5916649,29668608,Unavailable
5916649,DBP 30min after start,"Dexmedetomidine 1,5  μg/kg",Control,Significantly decreased,"The diastolic BP was significantly lower in the dexmedetomidine groups than in group R at 30 min after the start of surgery (P &lt; .001 for groups D1 and D2, P = .001 for group D3).",24556:24776,5916649,29668608,Unavailable
5916649,DBP 30min after start,Dexmedetomidine 2  μg/kg,Control,Significantly decreased,"The diastolic BP was significantly lower in the dexmedetomidine groups than in group R at 30 min after the start of surgery (P &lt; .001 for groups D1 and D2, P = .001 for group D3).",24556:24776,5916649,29668608,Unavailable
5916649,DBP 60min after start,"Dexmedetomidine 1,5  μg/kg",Control,Significantly decreased,"Sixty minutes after the start of surgery, diastolic BP was significantly lower in group D2 than in group R (P = .006).",24776:24911,5916649,29668608,Unavailable
5916649,HR at recovery room,Dexmedetomidine 1  μg/kg,Control,Significantly decreased,"HR and SpO2 were significantly lower in the dexmedetomidine groups when compared with the values in group R in the recovery room (P = .016, .005, and .004 for HR and P = .036, .001 and .006 for SpO2 in groups D1, D2, and D3, respectively).",24912:25207,5916649,29668608,Unavailable
5916649,HR at recovery room,"Dexmedetomidine 1,5  μg/kg",Control,Significantly decreased,"HR and SpO2 were significantly lower in the dexmedetomidine groups when compared with the values in group R in the recovery room (P = .016, .005, and .004 for HR and P = .036, .001 and .006 for SpO2 in groups D1, D2, and D3, respectively).",24912:25207,5916649,29668608,Unavailable
5916649,HR at recovery room,Dexmedetomidine 2  μg/kg,Control,Significantly decreased,"HR and SpO2 were significantly lower in the dexmedetomidine groups when compared with the values in group R in the recovery room (P = .016, .005, and .004 for HR and P = .036, .001 and .006 for SpO2 in groups D1, D2, and D3, respectively).",24912:25207,5916649,29668608,Unavailable
5916649,SpO2 at recovery room,Dexmedetomidine 1  μg/kg,Control,Significantly decreased,"HR and SpO2 were significantly lower in the dexmedetomidine groups when compared with the values in group R in the recovery room (P = .016, .005, and .004 for HR and P = .036, .001 and .006 for SpO2 in groups D1, D2, and D3, respectively).",24912:25207,5916649,29668608,Unavailable
5916649,SpO2 at recovery room,"Dexmedetomidine 1,5  μg/kg",Control,Significantly decreased,"HR and SpO2 were significantly lower in the dexmedetomidine groups when compared with the values in group R in the recovery room (P = .016, .005, and .004 for HR and P = .036, .001 and .006 for SpO2 in groups D1, D2, and D3, respectively).",24912:25207,5916649,29668608,Unavailable
5916649,SpO2 at recovery room,Dexmedetomidine 2  μg/kg,Control,Significantly decreased,"HR and SpO2 were significantly lower in the dexmedetomidine groups when compared with the values in group R in the recovery room (P = .016, .005, and .004 for HR and P = .036, .001 and .006 for SpO2 in groups D1, D2, and D3, respectively).",24912:25207,5916649,29668608,Unavailable
5916649,SBP 5 min after ISB,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP 5 min after ISB,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP 5 min after ISB,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP 30min after start,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP 30min after start,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP 30min after start,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP 60min after start,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP 60min after start,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP 60min after start,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP at recovery,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP at recovery,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SBP at recovery,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP 5 min after ISB,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP 5 min after ISB,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP 5 min after ISB,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP 30min after start,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP 30min after start,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP 30min after start,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP 60min after start,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP 60min after start,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP 60min after start,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP at recovery,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP at recovery,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,DBP at recovery,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR 5 min after ISB,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR 5 min after ISB,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR 5 min after ISB,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR 30min after start,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR 30min after start,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR 30min after start,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR 60min after start,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR 60min after start,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR 60min after start,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR at recovery,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR at recovery,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,HR at recovery,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 5 min after ISB,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 5 min after ISB,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 5 min after ISB,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 30min after start,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 30min after start,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 30min after start,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 60min after start,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 60min after start,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 60min after start,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 at recovery,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 at recovery,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,SpO2 at recovery,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in hemodynamic variables between the dexmedetomidine groups.,25208:25304,5916649,29668608,Unavailable
5916649,Hypotension during perioperative period,"Dexmedetomidine 1,5  μg/kg",Control,Significantly increased,"The incidence of hypotension was significantly greater in groups D2 and D3 than in group R (P = .008 and .011 for group D2 and D3, respectively, Table 1) during the perioperative period.",26009:26251,5916649,29668608,Unavailable
5916649,Hypotension during perioperative period,Dexmedetomidine 2  μg/kg,Control,Significantly increased,"The incidence of hypotension was significantly greater in groups D2 and D3 than in group R (P = .008 and .011 for group D2 and D3, respectively, Table 1) during the perioperative period.",26009:26251,5916649,29668608,Unavailable
5916649,Bradicardia,Dexmedetomidine 1  μg/kg,Control,No significant difference,The incidence of bradycardia during the perioperative period was comparable between the 4 groups (Table 1).,26252:26398,5916649,29668608,Unavailable
5916649,Bradicardia,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,The incidence of bradycardia during the perioperative period was comparable between the 4 groups (Table 1).,26252:26398,5916649,29668608,Unavailable
5916649,Bradicardia,Dexmedetomidine 2  μg/kg,Control,No significant difference,The incidence of bradycardia during the perioperative period was comparable between the 4 groups (Table 1).,26252:26398,5916649,29668608,Unavailable
5916649,Bradicardia,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,The incidence of bradycardia during the perioperative period was comparable between the 4 groups (Table 1).,26252:26398,5916649,29668608,Unavailable
5916649,Bradicardia,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,The incidence of bradycardia during the perioperative period was comparable between the 4 groups (Table 1).,26252:26398,5916649,29668608,Unavailable
5916649,Bradicardia,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,The incidence of bradycardia during the perioperative period was comparable between the 4 groups (Table 1).,26252:26398,5916649,29668608,Unavailable
5916649,Sedation score at recovery room,Dexmedetomidine 1  μg/kg,Control,No significant difference,There was no significant difference in sedation score in the recovery room,26496:26571,5916649,29668608,Unavailable
5916649,Sedation score at recovery room,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,There was no significant difference in sedation score in the recovery room,26496:26571,5916649,29668608,Unavailable
5916649,Sedation score at recovery room,Dexmedetomidine 2  μg/kg,Control,No significant difference,There was no significant difference in sedation score in the recovery room,26496:26571,5916649,29668608,Unavailable
5916649,Sedation score at recovery room,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in sedation score in the recovery room,26496:26570,5916649,29668608,Unavailable
5916649,Sedation score at recovery room,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in sedation score in the recovery room,26496:26571,5916649,29668608,Unavailable
5916649,Sedation score at recovery room,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in sedation score in the recovery room,26496:26571,5916649,29668608,Unavailable
5916649,Dyspnea,Dexmedetomidine 1  μg/kg,Control,No significant difference,The incidence of dyspnea was highest in group D2 but there was no significant difference between 4 groups,27311:27417,5916649,29668608,Unavailable
5916649,Dyspnea,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,The incidence of dyspnea was highest in group D2 but there was no significant difference between 4 groups,27311:27416,5916649,29668608,Unavailable
5916649,Dyspnea,Dexmedetomidine 2  μg/kg,Control,No significant difference,The incidence of dyspnea was highest in group D2 but there was no significant difference between 4 groups,27311:27416,5916649,29668608,Unavailable
5916649,Dyspnea,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,The incidence of dyspnea was highest in group D2 but there was no significant difference between 4 groups,27311:27416,5916649,29668608,Unavailable
5916649,Dyspnea,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,The incidence of dyspnea was highest in group D2 but there was no significant difference between 4 groups,27311:27417,5916649,29668608,Unavailable
5916649,Dyspnea,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,The incidence of dyspnea was highest in group D2 but there was no significant difference between 4 groups,27311:27416,5916649,29668608,Unavailable
5916649,Motor nerve block 12h after ISB,Dexmedetomidine 1  μg/kg,Control,Significantly increased,"The modified Bromage scale score was used to assess motor nerve block, and was found to be significantly higher in groups D1 and D3 than in group R 12 h after ISB (P = .003 for group D1 and P &lt; .001 for group D3, Table 3).",28048:28346,5916649,29668608,Unavailable
5916649,Motor nerve block 12h after ISB,Dexmedetomidine 2  μg/kg,Control,Significantly increased,"The modified Bromage scale score was used to assess motor nerve block, and was found to be significantly higher in groups D1 and D3 than in group R 12 h after ISB (P = .003 for group D1 and P &lt; .001 for group D3, Table 3).",28048:28346,5916649,29668608,Unavailable
5916649,Motor nerve block 18h after ISB,Dexmedetomidine 2  μg/kg,Control,Significantly increased,"Eighteen hours after ISB, the modified Bromage scale score was significantly higher in group D3 than in group R (P = .003, Table 3).",28347:28535,5916649,29668608,Unavailable
5916649,Motor nerve block 6h after ISB,Dexmedetomidine 1  μg/kg,Control,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 6h after ISB,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 6h after ISB,Dexmedetomidine 2  μg/kg,Control,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 6h after ISB,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 6h after ISB,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 6h after ISB,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 24h after ISB,Dexmedetomidine 1  μg/kg,Control,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 24h after ISB,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 24h after ISB,Dexmedetomidine 2  μg/kg,Control,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 24h after ISB,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 24h after ISB,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 24h after ISB,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 36h after ISB,Dexmedetomidine 1  μg/kg,Control,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 36h after ISB,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 36h after ISB,Dexmedetomidine 2  μg/kg,Control,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 36h after ISB,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 36h after ISB,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Motor nerve block 36h after ISB,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in motor nerve block between the groups at the other time points.,28536:28639,5916649,29668608,Unavailable
5916649,Duration of sensory block,Dexmedetomidine 1  μg/kg,Control,Significantly increased,"The DOS, DOM, and DOA were significantly longer in the dexmedetomidine groups than in group R",30409:30636,5916649,29668608,Unavailable
5916649,Duration of sensory block,"Dexmedetomidine 1,5  μg/kg",Control,Significantly increased,"The DOS, DOM, and DOA were significantly longer in the dexmedetomidine groups than in group R",30409:30636,5916649,29668608,Unavailable
5916649,Duration of sensory block,Dexmedetomidine 2  μg/kg,Control,Significantly increased,"The DOS, DOM, and DOA were significantly longer in the dexmedetomidine groups than in group R",30409:30636,5916649,29668608,Unavailable
5916649,Duration of motor block,Dexmedetomidine 1  μg/kg,Control,Significantly increased,"The DOS, DOM, and DOA were significantly longer in the dexmedetomidine groups than in group R",30409:30636,5916649,29668608,Unavailable
5916649,Duration of motor block,"Dexmedetomidine 1,5  μg/kg",Control,Significantly increased,"The DOS, DOM, and DOA were significantly longer in the dexmedetomidine groups than in group R",30409:30636,5916649,29668608,Unavailable
5916649,Duration of motor block,Dexmedetomidine 2  μg/kg,Control,Significantly increased,"The DOS, DOM, and DOA were significantly longer in the dexmedetomidine groups than in group R",30409:30636,5916649,29668608,Unavailable
5916649,Duration of analgesia ,Dexmedetomidine 1  μg/kg,Control,Significantly increased,"The DOS, DOM, and DOA were significantly longer in the dexmedetomidine groups than in group R",30409:30636,5916649,29668608,Unavailable
5916649,Duration of analgesia ,"Dexmedetomidine 1,5  μg/kg",Control,Significantly increased,"The DOS, DOM, and DOA were significantly longer in the dexmedetomidine groups than in group R",30409:30636,5916649,29668608,Unavailable
5916649,Duration of analgesia ,Dexmedetomidine 2  μg/kg,Control,Significantly increased,"The DOS, DOM, and DOA were significantly longer in the dexmedetomidine groups than in group R",30409:30636,5916649,29668608,Unavailable
5916649,Duration of sensory block,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,"There were no significant differences in DOS, DOM, and DOA between groups D1 and D2.",29259:29343,5916649,29668608,Unavailable
5916649,Duration of motor block,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,"There were no significant differences in DOS, DOM, and DOA between groups D1 and D2.",29259:29343,5916649,29668608,Unavailable
5916649,Duration of analgesia ,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,"There were no significant differences in DOS, DOM, and DOA between groups D1 and D2.",29259:29343,5916649,29668608,Unavailable
5916649,Duration of sensory block,Dexmedetomidine 2  μg/kg,Dexmedetomidine 1  μg/kg,No significant difference,"When the dexmedetomidine groups were compared, group D3 was associated with the longest DOS, DOM, and DOA (Table 4, Fig. 3), but only DOA was significantly different from that in groups D1 and D2.",28986:29258,5916649,29668608,Unavailable
5916649,Duration of motor block,Dexmedetomidine 2  μg/kg,Dexmedetomidine 1  μg/kg,No significant difference,"When the dexmedetomidine groups were compared, group D3 was associated with the longest DOS, DOM, and DOA (Table 4, Fig. 3), but only DOA was significantly different from that in groups D1 and D2.",28986:29258,5916649,29668608,Unavailable
5916649,Duration of analgesia ,Dexmedetomidine 2  μg/kg,Dexmedetomidine 1  μg/kg,Significantly increased,"When the dexmedetomidine groups were compared, group D3 was associated with the longest DOS, DOM, and DOA (Table 4, Fig. 3), but only DOA was significantly different from that in groups D1 and D2.",28986:29258,5916649,29668608,Unavailable
5916649,Duration of sensory block,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,"When the dexmedetomidine groups were compared, group D3 was associated with the longest DOS, DOM, and DOA (Table 4, Fig. 3), but only DOA was significantly different from that in groups D1 and D2.",28986:29258,5916649,29668608,Unavailable
5916649,Duration of motor block,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,"When the dexmedetomidine groups were compared, group D3 was associated with the longest DOS, DOM, and DOA (Table 4, Fig. 3), but only DOA was significantly different from that in groups D1 and D2.",28986:29258,5916649,29668608,Unavailable
5916649,Duration of analgesia ,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",Significantly increased,"When the dexmedetomidine groups were compared, group D3 was associated with the longest DOS, DOM, and DOA (Table 4, Fig. 3), but only DOA was significantly different from that in groups D1 and D2.",28986:29258,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 12 h after ISB,Dexmedetomidine 1  μg/kg,Control,Significantly decreased,"As shown in Fig. 4, the NRS score was significantly lower in the dexmedetomidine groups than in group R 12 h after ISB (P &lt; .001 for groups D1, D2, and D3) and was also significantly lower in group D3 than in the other groups 18 h after ISB (P = .002, .042, and .013 when compared with groups R, D1, and D2, respectively).",29791:30187,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 12 h after ISB,"Dexmedetomidine 1,5  μg/kg",Control,Significantly decreased,"As shown in Fig. 4, the NRS score was significantly lower in the dexmedetomidine groups than in group R 12 h after ISB (P &lt; .001 for groups D1, D2, and D3) and was also significantly lower in group D3 than in the other groups 18 h after ISB (P = .002, .042, and .013 when compared with groups R, D1, and D2, respectively).",29791:30187,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 12 h after ISB,Dexmedetomidine 2  μg/kg,Control,Significantly decreased,"As shown in Fig. 4, the NRS score was significantly lower in the dexmedetomidine groups than in group R 12 h after ISB (P &lt; .001 for groups D1, D2, and D3) and was also significantly lower in group D3 than in the other groups 18 h after ISB (P = .002, .042, and .013 when compared with groups R, D1, and D2, respectively).",29791:30187,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 18 h after ISB,Dexmedetomidine 2  μg/kg,Dexmedetomidine 1  μg/kg,Significantly decreased,"As shown in Fig. 4, the NRS score was significantly lower in the dexmedetomidine groups than in group R 12 h after ISB (P &lt; .001 for groups D1, D2, and D3) and was also significantly lower in group D3 than in the other groups 18 h after ISB (P = .002, .042, and .013 when compared with groups R, D1, and D2, respectively).",29791:30187,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 18 h after ISB,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",Significantly decreased,"As shown in Fig. 4, the NRS score was significantly lower in the dexmedetomidine groups than in group R 12 h after ISB (P &lt; .001 for groups D1, D2, and D3) and was also significantly lower in group D3 than in the other groups 18 h after ISB (P = .002, .042, and .013 when compared with groups R, D1, and D2, respectively).",29791:30187,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 24h after ISB,Dexmedetomidine 1  μg/kg,Control,No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 24h after ISB,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30409,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 24h after ISB,Dexmedetomidine 2  μg/kg,Control,No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 24h after ISB,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 24h after ISB,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 24h after ISB,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 36h after ISB,Dexmedetomidine 1  μg/kg,Control,No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 36h after ISB,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 36h after ISB,Dexmedetomidine 2  μg/kg,Control,No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 36h after ISB,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 36h after ISB,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Numeric pain rating scale 36h after ISB,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There was no significant difference in pain scores assessed 24 and 36 h after ISB in any of the groups.,30305:30408,5916649,29668608,Unavailable
5916649,Total dose of tramadol,Dexmedetomidine 1  μg/kg,Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of tramadol,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of tramadol,Dexmedetomidine 2  μg/kg,Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of diclofenac ,Dexmedetomidine 1  μg/kg,Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of diclofenac ,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of diclofenac ,Dexmedetomidine 2  μg/kg,Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with tramadol,Dexmedetomidine 1  μg/kg,Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with tramadol,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with tramadol,Dexmedetomidine 2  μg/kg,Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with diclofenac ,Dexmedetomidine 1  μg/kg,Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with diclofenac ,"Dexmedetomidine 1,5  μg/kg",Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with diclofenac ,Dexmedetomidine 2  μg/kg,Control,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of tramadol,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of tramadol,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of tramadol,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of diclofenac ,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of diclofenac ,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Total dose of diclofenac ,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with tramadol,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with tramadol,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with tramadol,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with diclofenac,Dexmedetomidine 1  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with diclofenac,Dexmedetomidine 1  μg/kg,Dexmedetomidine 2  μg/kg,No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5916649,Number of patients with diclofenac,Dexmedetomidine 2  μg/kg,"Dexmedetomidine 1,5  μg/kg",No significant difference,There were no significant differences in the total dose of rescue analgesics or number of patients in whom rescue analgesics were administered between any of the groups for 36 h (Table 5).,30409:30636,5916649,29668608,Unavailable
5815423,Pain-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,Significantly increased,"Of patients treated with ADAM zolmitriptan 3.8 mg or placebo, 41.5% and 14.2%, respectively were pain-free 2 hours post-dose (p = 0.0001) and 68.3% and 42.9% were free from their most bothersome other symptom (p = 0.0009).",6097:6353,5815423,29022755,Unavailable
5815423,Disappearance of other symptoms after 2h (%),3.8 mg ADAM zolmitriptan ,Control,Significantly increased,"Of patients treated with ADAM zolmitriptan 3.8 mg or placebo, 41.5% and 14.2%, respectively were pain-free 2 hours post-dose (p = 0.0001) and 68.3% and 42.9% were free from their most bothersome other symptom (p = 0.0009).",6097:6353,5815423,29022755,Unavailable
5815423,Photophobia-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"Due to the fixed sequential testing methodology, formal statistical significance was not established for secondary endpoints. However, the proportion of patients who were photophobia-free, phonophobia-free, and nausea-free at 2 hours post-dose was higher in the ADAM zolmitriptan 3.8 mg group compared with placebo",6354:6668,5815423,29022755,Unavailable
5815423,Phonophobia-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"Due to the fixed sequential testing methodology, formal statistical significance was not established for secondary endpoints. However, the proportion of patients who were photophobia-free, phonophobia-free, and nausea-free at 2 hours post-dose was higher in the ADAM zolmitriptan 3.8 mg group compared with placebo",6354:6668,5815423,29022755,Unavailable
5815423,Nausea-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"Due to the fixed sequential testing methodology, formal statistical significance was not established for secondary endpoints. However, the proportion of patients who were photophobia-free, phonophobia-free, and nausea-free at 2 hours post-dose was higher in the ADAM zolmitriptan 3.8 mg group compared with placebo",6354:6668,5815423,29022755,Unavailable
5815423,Patients with pain relief after 15m (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose.",28533:28710,5815423,29022755,Unavailable
5815423,Patients with pain relief after 30m (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose.",28533:28710,5815423,29022755,Unavailable
5815423,Patients with pain relief after 3h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose.",28533:28710,5815423,29022755,Unavailable
5815423,Patients with pain relief after 4h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose.",28533:28710,5815423,29022755,Unavailable
5815423,Pain-free patients after 30m (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose.",28533:28710,5815423,29022755,Unavailable
5815423,Pain-free patients after 24h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose.",28533:28710,5815423,29022755,Unavailable
5815423,Pain-free patients after 48h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose.",28533:28710,5815423,29022755,Unavailable
5815423,Pain-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,Significantly increased,ADAM zolmitriptan 3.8 mg was superior to the pooled placebo group for the co-primary endpoints of proportion of patients who were pain-free at 2 hours (41.5% vs. 14.3%; p = 0.0001) and the proportion who were MBS-free at 2 hours (68.3% vs. 42.9%; p = 0.0009),28533:28710,5815423,29022755,Unavailable
5815423,Disappearance of other symptoms after 2h (%),3.8 mg ADAM zolmitriptan ,Control,Significantly increased,ADAM zolmitriptan 3.8 mg was superior to the pooled placebo group for the co-primary endpoints of proportion of patients who were pain-free at 2 hours (41.5% vs. 14.3%; p = 0.0001) and the proportion who were MBS-free at 2 hours (68.3% vs. 42.9%; p = 0.0009),28533:28710,5815423,29022755,Unavailable
5815423,Pain-free patients after 2h (%),1.9 mg ADAM zolmitriptan ,Control,Significantly increased,"ADAM zolmitriptan 1.9 mg was also superior to placebo for pain freedom (27.7% vs. 14.3%; p = 0.0351), but the comparison for MBS at 2 hours was not significant.",28533:28710,5815423,29022755,Unavailable
5815423,Disappearance of other symptoms after 2h (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"ADAM zolmitriptan 1.9 mg was also superior to placebo for pain freedom (27.7% vs. 14.3%; p = 0.0351), but the comparison for MBS at 2 hours was not significant.",28533:28710,5815423,29022755,Unavailable
5815423,Patients with pain relief after 15m (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28905:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 30m (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28905:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 3h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28905:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 4h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28905:29036,5815423,29022755,Unavailable
5815423,Pain-free patients after 30m (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Pain-free patients after 24h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Pain-free patients after 48h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Photophobia-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28905:29036,5815423,29022755,Unavailable
5815423,Phonophobia-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28905:29036,5815423,29022755,Unavailable
5815423,Nausea-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Need of rescue medication for 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 15m (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 30m (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 3h (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 4h (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Pain-free patients after 30m (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Pain-free patients after 24h (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Pain-free patients after 48h (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Photophobia-free patients after 2h (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Phonophobia-free patients after 2h (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Nausea-free patients after 2h (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Need of rescue medication for 2h (%),1.9 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 15m (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 30m (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 3h (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Patients with pain relief after 4h (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Pain-free patients after 30m (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Pain-free patients after 24h (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Pain-free patients after 48h (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Photophobia-free patients after 2h (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Phonophobia-free patients after 2h (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Nausea-free patients after 2h (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Need of rescue medication for 2h (%),1 mg ADAM zolmitriptan ,Control,No significant difference,"In addition, all subsequent significance tests (including secondary endpoints) were not considered to be statistically significant",28906:29036,5815423,29022755,Unavailable
5815423,Photophobia-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In the ADAM zolmitriptan 3.8 mg group, 69.5% were photophobia-free versus 41.6% in the placebo group (nominal p = 0.0003). Corresponding values for phonophobia-free were 69.5% and 55.8% (nominal p = 0.0060). For nausea-free, the corresponding values were 81.7% versus 63.6% (nominal p = 0.0106).",29979:30326,5815423,29022755,Unavailable
5815423,Phonophobia-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In the ADAM zolmitriptan 3.8 mg group, 69.5% were photophobia-free versus 41.6% in the placebo group (nominal p = 0.0003). Corresponding values for phonophobia-free were 69.5% and 55.8% (nominal p = 0.0060). For nausea-free, the corresponding values were 81.7% versus 63.6% (nominal p = 0.0106).",29980:30326,5815423,29022755,Unavailable
5815423,Nausea-free patients after 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"In the ADAM zolmitriptan 3.8 mg group, 69.5% were photophobia-free versus 41.6% in the placebo group (nominal p = 0.0003). Corresponding values for phonophobia-free were 69.5% and 55.8% (nominal p = 0.0060). For nausea-free, the corresponding values were 81.7% versus 63.6% (nominal p = 0.0106).",29979:30326,5815423,29022755,Unavailable
5815423,Need of rescue medication for 2h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,The percentage of patients who took rescue medication within 2 hours post-dose was small in all groups (2.4–7.8%) with no discernable differences among them (Figure 3(d)).,30327:30554,5815423,29022755,Unavailable
5815423,Pain-free patients after 30m (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"The percentages of patients who were pain-free at the pre-specified time points of 30 minutes, 24 hours and 48 hours post-dose were 7.3%, 69.5% and 64.6%, respectively, for the ADAM zolmitriptan 3.8 mg group, and 2.6%, 39.0%, and 39.0% for the placebo group (nominal p = 0.1768 at 30 minutes and p &lt; 0.01 for both 24 and 48 hours).",30562:30927,5815423,29022755,Unavailable
5815423,Pain-free patients after 24h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"The percentages of patients who were pain-free at the pre-specified time points of 30 minutes, 24 hours and 48 hours post-dose were 7.3%, 69.5% and 64.6%, respectively, for the ADAM zolmitriptan 3.8 mg group, and 2.6%, 39.0%, and 39.0% for the placebo group (nominal p = 0.1768 at 30 minutes and p &lt; 0.01 for both 24 and 48 hours).",30562:30927,5815423,29022755,Unavailable
5815423,Pain-free patients after 48h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"The percentages of patients who were pain-free at the pre-specified time points of 30 minutes, 24 hours and 48 hours post-dose were 7.3%, 69.5% and 64.6%, respectively, for the ADAM zolmitriptan 3.8 mg group, and 2.6%, 39.0%, and 39.0% for the placebo group (nominal p = 0.1768 at 30 minutes and p &lt; 0.01 for both 24 and 48 hours).",30562:30928,5815423,29022755,Unavailable
5815423,Patients with pain relief after 15m (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"The percentages of patients who experienced pain relief (improvement to mild or none), was also higher for the zolmitriptan 3.8 mg group than the placebo group at all time points (Figure 2). However, among the pre-specified time points of 15 minutes, 30 minutes, and 4 hours, nominal significance was only achieved at 4 hours (nominal p &lt; 0.0001).",31069:31489,5815423,29022755,Unavailable
5815423,Patients with pain relief after 30m (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"The percentages of patients who experienced pain relief (improvement to mild or none), was also higher for the zolmitriptan 3.8 mg group than the placebo group at all time points (Figure 2). However, among the pre-specified time points of 15 minutes, 30 minutes, and 4 hours, nominal significance was only achieved at 4 hours (nominal p &lt; 0.0001).",31069:31490,5815423,29022755,Unavailable
5815423,Patients with pain relief after 3h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"The percentages of patients who experienced pain relief (improvement to mild or none), was also higher for the zolmitriptan 3.8 mg group than the placebo group at all time points (Figure 2). However, among the pre-specified time points of 15 minutes, 30 minutes, and 4 hours, nominal significance was only achieved at 4 hours (nominal p &lt; 0.0001).",31069:31490,5815423,29022755,Unavailable
5815423,Patients with pain relief after 4h (%),3.8 mg ADAM zolmitriptan ,Control,No significant difference,"The percentages of patients who experienced pain relief (improvement to mild or none), was also higher for the zolmitriptan 3.8 mg group than the placebo group at all time points (Figure 2). However, among the pre-specified time points of 15 minutes, 30 minutes, and 4 hours, nominal significance was only achieved at 4 hours (nominal p &lt; 0.0001).",31069:31489,5815423,29022755,Unavailable
4973800,Morning peak SBP reduction,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,Our results indicated no obvious difference in blood pressure control between the 2 groups.,5520:5713,4973800,27459306,Unavailable
4973800,Morning peak DBP reduction,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,Our results indicated no obvious difference in blood pressure control between the 2 groups.,5520:5713,4973800,27459306,Unavailable
4973800,Morning peak SBP reduction,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"In Group I, the morning peak BP reduction in SBP and DBP at week 8 was markedly less than in Group II",5520:5713,4973800,27459306,Unavailable
4973800,Morning peak DBP reduction,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"In Group I, the morning peak BP reduction in SBP and DBP at week 8 was markedly less than in Group II",5520:5713,4973800,27459306,Unavailable
4973800,Total cholesterol control,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Hypercholesterolemia control in the 2 groups was also not significantly different, taking atorvastatin in the morning was as effective as dosing at night in patients with hypercholesterolemia.",5520:5713,4973800,27459306,Unavailable
4973800,LDL,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Hypercholesterolemia control in the 2 groups was also not significantly different, taking atorvastatin in the morning was as effective as dosing at night in patients with hypercholesterolemia.",5520:5713,4973800,27459306,Unavailable
4973800,Triglycerides ,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Hypercholesterolemia control in the 2 groups was also not significantly different, taking atorvastatin in the morning was as effective as dosing at night in patients with hypercholesterolemia.",5520:5713,4973800,27459306,Unavailable
4973800,Carotid intima-media thickness,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"While the carotid IMT, hs-CRP, and LVMI were significantly lower after treatment, no differences were found between the 2 groups.",5714:5843,4973800,27459306,Unavailable
4973800,hs-CRP,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"While the carotid IMT, hs-CRP, and LVMI were significantly lower after treatment, no differences were found between the 2 groups.",5714:5843,4973800,27459306,Unavailable
4973800,Left ventricular mass index,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"While the carotid IMT, hs-CRP, and LVMI were significantly lower after treatment, no differences were found between the 2 groups.",5714:5843,4973800,27459306,Unavailable
4973800,Carotid intima-media thickness,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Also, there were no significant differences between before and after 8-week treatment in either group with regard to the hs-CRP, LVMI, and carotid -IMT (P&gt;0.05) (see Table 4, Figure 4).",19144:19465,4973800,27459306,Unavailable
4973800,Left ventricular mass index,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Also, there were no significant differences between before and after 8-week treatment in either group with regard to the hs-CRP, LVMI, and carotid -IMT (P&gt;0.05) (see Table 4, Figure 4).",19143:19465,4973800,27459306,Unavailable
4973800,hs-CRP,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Also, there were no significant differences between before and after 8-week treatment in either group with regard to the hs-CRP, LVMI, and carotid -IMT (P&gt;0.05) (see Table 4, Figure 4).",19939:20122,4973800,27459306,Unavailable
4973800,Ankle edema,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Although no obvious difference was found in adverse drug reactions between the 2 groups, compliance was much better in the single-pill group than in patients taking the 2 medications separately.",5844:6038,4973800,27459306,Unavailable
4973800,Headache,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Although no obvious difference was found in adverse drug reactions between the 2 groups, compliance was much better in the single-pill group than in patients taking the 2 medications separately.",5844:6038,4973800,27459306,Unavailable
4973800,Facial flushing,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Although no obvious difference was found in adverse drug reactions between the 2 groups, compliance was much better in the single-pill group than in patients taking the 2 medications separately.",5844:6038,4973800,27459306,Unavailable
4973800,Compliance ,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Although no obvious difference was found in adverse drug reactions between the 2 groups, compliance was much better in the single-pill group than in patients taking the 2 medications separately.",5844:6038,4973800,27459306,Unavailable
4973800,Ankle edema,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,"Ankle edema, the most frequent adverse event, was experienced by 7% (7/100) in Group I and 8% (8/100) in Group II.",19589:19703,4973800,27459306,Unavailable
4973800,Headache,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,The incidence of headache was 1% (1/100) in Group I and 2% (2/100) in Group II.,19704:19784,4973800,27459306,Unavailable
4973800,Facial flushing,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,Facial flushing (1% in Group II) and palpitations (1% in Group I) had the lowest incidences.,19784:19876,4973800,27459306,Unavailable
4973800,Compliance ,Amlodipine/atorvastatin at night,Amlodipine/atorvastatin at daytime ,No significant difference,The number of pills missing was much higher in Group II (Once: 29; Twice: 16; 3 times: 10; More than 3 times: 7) than in Group I (Once: 7; Twice: 5; 3 times: 2; More than 3 times: 1).,19939:20122,4973800,27459306,Unavailable
3169982,Progression-free survival,Bevacizumab + interferon-α-2a,Sunitinib,No significant difference,The indirect efficacy comparison resulted in a statistically nonsignificant PFS difference of BEV+IFN vs SUN (HR: 1.06; 95% CI: 0.78–1.45; P = 0.73) and of BEV+IFN vs PAZ (range based on different connector trials; HR: 0.74–1.03; P = 0.34–0.92).,5958:6237,3169982,21935329,Unavailable
3169982,Progression-free survival,Bevacizumab + interferon-α-2a,Pazopanib ,No significant difference,The indirect efficacy comparison resulted in a statistically nonsignificant PFS difference of BEV+IFN vs SUN (HR: 1.06; 95% CI: 0.78–1.45; P = 0.73) and of BEV+IFN vs PAZ (range based on different connector trials; HR: 0.74–1.03; P = 0.34–0.92).,5958:6237,3169982,21935329,Unavailable
3169982,Compliance ,Bevacizumab + interferon-α-2a,Sunitinib,No significant difference,Simulating real-life patient compliance and its effectiveness impact showed an increased tendency towards BEV+IFN without reaching statistical significance.,6238:6394,3169982,21935329,Unavailable
3169982,Effectiveness ,Bevacizumab + interferon-α-2a,Sunitinib,No significant difference,Simulating real-life patient compliance and its effectiveness impact showed an increased tendency towards BEV+IFN without reaching statistical significance.,6238:6394,3169982,21935329,Unavailable
3169982,Compliance ,Bevacizumab + interferon-α-2a,Pazopanib ,No significant difference,Simulating real-life patient compliance and its effectiveness impact showed an increased tendency towards BEV+IFN without reaching statistical significance.,6238:6394,3169982,21935329,Unavailable
3169982,Effectiveness ,Bevacizumab + interferon-α-2a,Pazopanib ,No significant difference,Simulating real-life patient compliance and its effectiveness impact showed an increased tendency towards BEV+IFN without reaching statistical significance.,6238:6394,3169982,21935329,Unavailable
3169982,Progression-free survival,Bevacizumab + interferon-α-2a,Sunitinib,No significant difference,"ResultsThe indirect efficacy comparison, shown in Figure 5, resulted in a statistically nonsignificant PFS difference of BEV+IFN vs SUN (ITC HR: 1.06; 95% CI: 0.78–1.45; P = 0.73) and of BEV+IFN vs PAZ (range based on different connector trials; ITC HR: 0.74–1.03; P = 0.34–0.92).",NaN:17707,3169982,21935329,Unavailable
3169982,Progression-free survival,Bevacizumab + interferon-α-2a,Pazopanib ,No significant difference,"ResultsThe indirect efficacy comparison, shown in Figure 5, resulted in a statistically nonsignificant PFS difference of BEV+IFN vs SUN (ITC HR: 1.06; 95% CI: 0.78–1.45; P = 0.73) and of BEV+IFN vs PAZ (range based on different connector trials; ITC HR: 0.74–1.03; P = 0.34–0.92).",NaN:17707,3169982,21935329,Unavailable
3169982,Compliance ,Bevacizumab + interferon-α-2a,Sunitinib,No significant difference,"Simulating real-life patient compliance and its effectiveness impact on PFS showed an increased tendency towards BEV+IFN without reaching statistical significance, as shown in Figure 6.",18043:18276,3169982,21935329,Unavailable
3169982,Effectiveness ,Bevacizumab + interferon-α-2a,Sunitinib,No significant difference,"Simulating real-life patient compliance and its effectiveness impact on PFS showed an increased tendency towards BEV+IFN without reaching statistical significance, as shown in Figure 6.",18043:18276,3169982,21935329,Unavailable
3169982,Compliance ,Bevacizumab + interferon-α-2a,Pazopanib ,No significant difference,"Simulating real-life patient compliance and its effectiveness impact on PFS showed an increased tendency towards BEV+IFN without reaching statistical significance, as shown in Figure 6.",18043:18276,3169982,21935329,Unavailable
3169982,Effectiveness ,Bevacizumab + interferon-α-2a,Pazopanib ,No significant difference,"Simulating real-life patient compliance and its effectiveness impact on PFS showed an increased tendency towards BEV+IFN without reaching statistical significance, as shown in Figure 6.",18043:18276,3169982,21935329,Unavailable
4920565,Pain score ,Tamsulosin,Oxybutynin,No significant difference,No significant difference was noted between pain and general health scores,17000:17075,4920565,27286111,Unavailable
4920565,Pain score ,Tamsulosin,Tamsulosin + Oxybutynin,No significant difference,No significant difference was noted between pain and general health scores,17000:17075,4920565,27286111,Unavailable
4920565,Pain score ,Oxybutynin,Tamsulosin + Oxybutynin,No significant difference,No significant difference was noted between pain and general health scores,17000:17075,4920565,27286111,Unavailable
4920565,"General health score	",Tamsulosin,Oxybutynin,No significant difference,No significant difference was noted between pain and general health scores,17000:17075,4920565,27286111,Unavailable
4920565,"General health score	",Tamsulosin,Tamsulosin + Oxybutynin,No significant difference,No significant difference was noted between pain and general health scores,17000:17075,4920565,27286111,Unavailable
4920565,"General health score	",Oxybutynin,Tamsulosin + Oxybutynin,No significant difference,No significant difference was noted between pain and general health scores,17000:17075,4920565,27286111,Unavailable
4920565,Analgesic consumption,Tamsulosin,Oxybutynin,No significant difference,No side effects were reported and there were no differences in analgesic consumption between groups.,17125:17225,4920565,27286111,Unavailable
4920565,Analgesic consumption,Tamsulosin,Tamsulosin + Oxybutynin,No significant difference,No side effects were reported and there were no differences in analgesic consumption between groups.,17124:17225,4920565,27286111,Unavailable
4920565,Analgesic consumption,Oxybutynin,Tamsulosin + Oxybutynin,No significant difference,No side effects were reported and there were no differences in analgesic consumption between groups.,17125:17225,4920565,27286111,Unavailable
4920565,Pain score ,Tamsulosin,Oxybutynin,No significant difference,"Pain score	Day 7	13.4±2.2	11.2±2.7	13.8±5.0	0.207Day 21	14.2±4.3	10.9±3.1	11.2±5.8",18966:19489,4920565,27286111,Unavailable
4920565,Pain score ,Tamsulosin,Tamsulosin + Oxybutynin,No significant difference,"Pain score	Day 7	13.4±2.2	11.2±2.7	13.8±5.0	0.207Day 21	14.2±4.3	10.9±3.1	11.2±5.8",18966:19489,4920565,27286111,Unavailable
4920565,Pain score ,Oxybutynin,Tamsulosin + Oxybutynin,No significant difference,"Pain score	Day 7	13.4±2.2	11.2±2.7	13.8±5.0	0.207Day 21	14.2±4.3	10.9±3.1	11.2±5.8",18966:19489,4920565,27286111,Unavailable
4920565,"General health score	",Tamsulosin,Oxybutynin,No significant difference,"General health score	Day 7	11.7±1.4	11.0±1.4	11.5±1.5	0.699Day 21	11.6±1.2	11.7±1.3	11.2±2.5",19538:20071,4920565,27286111,Unavailable
4920565,"General health score	",Tamsulosin,Tamsulosin + Oxybutynin,No significant difference,"General health score	Day 7	11.7±1.4	11.0±1.4	11.5±1.5	0.699Day 21	11.6±1.2	11.7±1.3	11.2±2.5",19538:20071,4920565,27286111,Unavailable
4920565,"General health score	",Oxybutynin,Tamsulosin + Oxybutynin,No significant difference,"General health score	Day 7	11.7±1.4	11.0±1.4	11.5±1.5	0.699Day 21	11.6±1.2	11.7±1.3	11.2±2.5",19538:20071,4920565,27286111,Unavailable
5791464,Stone clearance rate ,Tamsulosin,Tadalafil,No significant difference,"A statistically insignificant difference was found for stone clearance rate between both groups as a whole (Group A-73.77%, Group B-69.35%, P = 0.690)",12665:NaN,5791464,29416281,Unavailable
5791464,Stone clearance rate (+8 mm),Tamsulosin,Tadalafil,No significant difference,"as well as when we considered both subgroups (A1-78.05%, B1-75.0%, P = 0.802; A2-65.0%, B2-55.6%, P = 0.741).",11528:11620,5791464,29416281,Unavailable
5791464,Stone clearance rate (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"as well as when we considered both subgroups (A1-78.05%, B1-75.0%, P = 0.802; A2-65.0%, B2-55.6%, P = 0.741).",11841:12061,5791464,29416281,Unavailable
5791464,Stone clearance rate ,Tamsulosin,Tadalafil,No significant difference,"The stone expulsion rate was 73.77% in Group A and 69.35% in Group B. Although this was on the higher side in Group A, but the difference was not significant (P = 0.69).",12665:NaN,5791464,29416281,Unavailable
5791464,Mean expulsion time,Tamsulosin,Tadalafil,No significant difference,"The mean expulsion time from the starting of MET was lower for tamsulosin group (9.38 ± 6.66 days) than for tadalafil group (9.61 ± 7.47 days), but this difference was also not significant (P = 0.78).",12207:12444,5791464,29416281,Unavailable
5791464,Number of colic episodes,Tamsulosin,Tadalafil,Significantly decreased,"A number of colic episodes and analgesic use (NSAIDs) were significantly higher in tadalafil group than in tamsulosin group (0.96 ± 0.74, 0.62 ± 0.83, 0.010; 11.82 ± 3.34, 9.15 ± 3.80, 0.020), but the number of hospital visits was higher in tadalafil group (P = 0.15).",11335:11620,5791464,29416281,Unavailable
5791464,Analgesic use,Tamsulosin,Tadalafil,Significantly decreased,"A number of colic episodes and analgesic use (NSAIDs) were significantly higher in tadalafil group than in tamsulosin group (0.96 ± 0.74, 0.62 ± 0.83, 0.010; 11.82 ± 3.34, 9.15 ± 3.80, 0.020), but the number of hospital visits was higher in tadalafil group (P = 0.15).",11335:11620,5791464,29416281,Unavailable
5791464,Number of hospital visits,Tamsulosin,Tadalafil,No significant difference,but the number of hospital visits was higher in tadalafil group (P = 0.15).,12207:12444,5791464,29416281,Unavailable
5791464,Number of colic episodes (+8 mm),Tamsulosin,Tadalafil,Significantly decreased,"Patients in tadalafil group with stone size &gt;8 mm had more colic episodes and they also required significantly more analgesics than patients in tamsulosin group (P = 0.010 and 0.032, respectively).",11841:12062,5791464,29416281,Unavailable
5791464,Analgesic use (+8 mm),Tamsulosin,Tadalafil,Significantly decreased,"Patients in tadalafil group with stone size &gt;8 mm had more colic episodes and they also required significantly more analgesics than patients in tamsulosin group (P = 0.010 and 0.032, respectively).",11841:12061,5791464,29416281,Unavailable
5791464,Number of colic episodes (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Patients with stone size ≤8 mm, more colic episodes, and analgesic requirements were in tadalafil group, but the difference was not significant.",12062:12207,5791464,29416281,Unavailable
5791464,Analgesic use (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Patients with stone size ≤8 mm, more colic episodes, and analgesic requirements were in tadalafil group, but the difference was not significant.",12062:12206,5791464,29416281,Unavailable
5791464,Stone clearance rate (+8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Stone clearance rate (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Mean expulsion time (+8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Mean expulsion time (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Number of hospital visits (+8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Number of hospital visits (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Endoscopic treatment (+8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Endoscopic treatment (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Headache (+8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Headache (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Dizziness (+8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Dizziness (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12207:12444,5791464,29416281,Unavailable
5791464,Orthostatic hypotension (+8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12665:12778,5791464,29416281,Unavailable
5791464,Orthostatic hypotension (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12665:12778,5791464,29416281,Unavailable
5791464,Backache (+8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12665:12778,5791464,29416281,Unavailable
5791464,Backache (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12665:12778,5791464,29416281,Unavailable
5791464,Abnormal ejaculation (+8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12665:12778,5791464,29416281,Unavailable
5791464,Abnormal ejaculation (≤8 mm),Tamsulosin,Tadalafil,No significant difference,"Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [Table 2].",12665:12778,5791464,29416281,Unavailable
5791464,Headache,Tamsulosin,Tadalafil,No significant difference,"No statistical difference was found for adverse drug effects except for retrograde ejaculation, which was significantly high in tamsulosin group (P &lt; 0.001).",5182:5359,5791464,29416281,Unavailable
5791464,Dizziness,Tamsulosin,Tadalafil,No significant difference,"No statistical difference was found for adverse drug effects except for retrograde ejaculation, which was significantly high in tamsulosin group (P &lt; 0.001).",5182:5359,5791464,29416281,Unavailable
5791464,Orthostatic hypotension,Tamsulosin,Tadalafil,No significant difference,"No statistical difference was found for adverse drug effects except for retrograde ejaculation, which was significantly high in tamsulosin group (P &lt; 0.001).",5182:5359,5791464,29416281,Unavailable
5791464,Backache,Tamsulosin,Tadalafil,No significant difference,"No statistical difference was found for adverse drug effects except for retrograde ejaculation, which was significantly high in tamsulosin group (P &lt; 0.001).",5182:5359,5791464,29416281,Unavailable
5791464,Abnormal ejaculation,Tamsulosin,Tadalafil,Significantly increased,"No statistical difference was found for adverse drug effects except for retrograde ejaculation, which was significantly high in tamsulosin group (P &lt; 0.001).",5182:5359,5791464,29416281,Unavailable
5791464,Headache,Tamsulosin,Tadalafil,No significant difference,"Adverse effects such as headache and dizziness occurred more often in tadalafil group (P &gt; 0.05), these were not significant enough to exclude the patients from the study. Incidence of orthostatic hypotension and backache was almost equal in both groups. Abnormal ejaculation was observed in 9.8% of patients in tamsulosin group and 1.6% of patients in tadalafil group with a highly significant difference (P &lt; 0.001) [Table 3].",12665:13172,5791464,29416281,Unavailable
5791464,Dizziness,Tamsulosin,Tadalafil,No significant difference,"Adverse effects such as headache and dizziness occurred more often in tadalafil group (P &gt; 0.05), these were not significant enough to exclude the patients from the study. Incidence of orthostatic hypotension and backache was almost equal in both groups. Abnormal ejaculation was observed in 9.8% of patients in tamsulosin group and 1.6% of patients in tadalafil group with a highly significant difference (P &lt; 0.001) [Table 3].",12665:13172,5791464,29416281,Unavailable
5791464,Orthostatic hypotension,Tamsulosin,Tadalafil,No significant difference,"Adverse effects such as headache and dizziness occurred more often in tadalafil group (P &gt; 0.05), these were not significant enough to exclude the patients from the study. Incidence of orthostatic hypotension and backache was almost equal in both groups. Abnormal ejaculation was observed in 9.8% of patients in tamsulosin group and 1.6% of patients in tadalafil group with a highly significant difference (P &lt; 0.001) [Table 3].",12665:NaN,5791464,29416281,Unavailable
5791464,Backache,Tamsulosin,Tadalafil,No significant difference,"Adverse effects such as headache and dizziness occurred more often in tadalafil group (P &gt; 0.05), these were not significant enough to exclude the patients from the study. Incidence of orthostatic hypotension and backache was almost equal in both groups. Abnormal ejaculation was observed in 9.8% of patients in tamsulosin group and 1.6% of patients in tadalafil group with a highly significant difference (P &lt; 0.001) [Table 3].",12665:NaN,5791464,29416281,Unavailable
5791464,Abnormal ejaculation,Tamsulosin,Tadalafil,Significantly increased,"Adverse effects such as headache and dizziness occurred more often in tadalafil group (P &gt; 0.05), these were not significant enough to exclude the patients from the study. Incidence of orthostatic hypotension and backache was almost equal in both groups. Abnormal ejaculation was observed in 9.8% of patients in tamsulosin group and 1.6% of patients in tadalafil group with a highly significant difference (P &lt; 0.001) [Table 3].",12665:NaN,5791464,29416281,Unavailable
3656393,Sickness absence benefits (overall),Weight-gain restriction programme,Control,No significant difference,The percentage of women in the intervention group who received registered sickness absence benefits was 29.0% compared with 34.7% in the control group (p = 0.26).,19253:19358,3656393,23301596,Unavailable
3656393,Pregnancy benefits (overall),Weight-gain restriction programme,Control,No significant difference,Pregnancy benefits were 31.6% and 34.2% for the intervention and control groups respectively (p = 0.61).,19253:19358,3656393,23301596,Unavailable
3656393,Sickness absence benefits (25%),Weight-gain restriction programme,Control,No significant difference,"25%	1.90 (13.45)	1.03 (8.00)	0.46",20460:20634,3656393,23301596,Unavailable
3656393,Sickness absence benefits (50%),Weight-gain restriction programme,Control,No significant difference,"50%	4.08 (18.09)	5.03 (20.03)	0.65",20689:20864,3656393,23301596,Unavailable
3656393,Sickness absence benefits (75%),Weight-gain restriction programme,Control,No significant difference,"75%	0.37 (3.34)	1.36 (7.76)	0.11",20919:21092,3656393,23301596,Unavailable
3656393,Sickness absence benefits (100%),Weight-gain restriction programme,Control,No significant difference,75% 0.37 (3.34) 1.36 (7.76) 0.11,20919:21092,3656393,23301596,Unavailable
3656393,Sickness absence benefits (total full days),Weight-gain restriction programme,Control,No significant difference,"Total full days of sickness absence benefit	22.26 (56.00)	18.53 (42.09)	0.48",21380:21597,3656393,23301596,Unavailable
3656393,Sickness absence benefits (total full days) when employed at start,Weight-gain restriction programme,Control,No significant difference,"Total full days of sickness absence benefit†	76.68 (81.89)	53.09 (57.36)	0.1",21652:21869,3656393,23301596,Unavailable
3656393,Pregnancy benefits (50%),Weight-gain restriction programme,Control,No significant difference,"50%	2.24 (9.53)	1.54 (7.63)	0.45",22366:22539,3656393,23301596,Unavailable
3656393,Pregnancy benefits (75%),Weight-gain restriction programme,Control,Significantly decreased,75% 0.00 (0.00) 1.14 (7.75) 0.04,22594:22767,3656393,23301596,Unavailable
3656393,Pregnancy benefits (100%),Weight-gain restriction programme,Control,No significant difference,"100%	11.42 (20.16)	12.53 (20.85)	0.62",22822:23000,3656393,23301596,Unavailable
3656393,Pregnancy benefits (total full days),Weight-gain restriction programme,Control,No significant difference,"Total full days of pregnancy benefit	12.54 (20.08)	14.16 (21.72)	0.48",23055:23265,3656393,23301596,Unavailable
3656393,Pregnancy benefits (total full days) when employed at start,Weight-gain restriction programme,Control,No significant difference,"Total full days of pregnancy benefit†	39.66(13.99)	41.41(15.73)	0.54",23320:23529,3656393,23301596,Unavailable
3656393,Sickness absence benefits (total full days) when employed at start,Weight-gain restriction programme,Control,No significant difference,"Furthermore, no differences were found when considering sickness absence and pregnancy benefits for only those women who were employed at the beginning of the programme.",19357:19528,3656393,23301596,Unavailable
3656393,Pregnancy benefits (total full days) when employed at start,Weight-gain restriction programme,Control,No significant difference,"Furthermore, no differences were found when considering sickness absence and pregnancy benefits for only those women who were employed at the beginning of the programme.",19358:19527,3656393,23301596,Unavailable
3701849,ALT normalization (3 months),Entecavir + carnitine,Entecavir ,Significantly increased,The ALT normalization at 3 months was 58.9% for the monotherapy and 95.2% for the combination therapy (P&lt;0.0001).,9711:9841,3701849,23837141,Unavailable
3701849,ALT normalization (12 months),Entecavir + carnitine,Entecavir ,Significantly increased,ALT normalization rate at 12 months was 85.7% for the monotherapy and 100% for the combination group (P=0.0019).,9842:9974,3701849,23837141,Unavailable
3701849,Less than HBV DNA 300 copies/mL (12 months),Entecavir + carnitine,Entecavir ,No significant difference,"The rate of less than HBV DNA 300 copies/mL at 12 months was not statistically significant (P=0.5318) 75.9% for the monotherapy, 70.7% for the combination and it was.",9975:10158,3701849,23837141,Unavailable
3701849,HBsAg level (12 months),Entecavir + carnitine,Entecavir ,No significant difference,Quantification of HBsAg level was not different from the monotherapy to combination at 12 months.,10159:10256,3701849,23837141,Unavailable
3701849,NF-γ secretion by HBsAg,Entecavir + carnitine,Entecavir ,No significant difference,Changes of ELISPOT value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to mono-treatment.,10257:10400,3701849,23837141,Unavailable
3701849,ALT normalization (3 months),Entecavir + carnitine,Entecavir ,Significantly increased,"Normalization rates of subjects' serum ALT were 58.9% and 87.5% in 3-month dosing and 6-month dosing for the monotherapy group, and 95.2% and 100% for the combination therapy group, which showed that the figure was statistically higher in the combination therapy group (P&lt;0.0001 vs. P=0.0038).",21884:22214,3701849,23837141,Unavailable
3701849,ALT normalization (6 months),Entecavir + carnitine,Entecavir ,Significantly increased,"Normalization rates of subjects' serum ALT were 58.9% and 87.5% in 3-month dosing and 6-month dosing for the monotherapy group, and 95.2% and 100% for the combination therapy group, which showed that the figure was statistically higher in the combination therapy group (P&lt;0.0001 vs. P=0.0038).",21884:22214,3701849,23837141,Unavailable
3701849,ALT normalization (9 months),Entecavir + carnitine,Entecavir ,No significant difference,"After 9-month dosing, the figures showed no significant difference between the monotherapy group and the combination therapy group (P=0.1011).",22214:22374,3701849,23837141,Unavailable
3701849,ALT normalization (12 months),Entecavir + carnitine,Entecavir ,Significantly increased,"At the time of 12-month dosing, the figures showed statistically significant difference between two groups with 85.7% and 100% (P=0.0019)",22375:22529,3701849,23837141,Unavailable
3701849,ALT value (12 months),Entecavir + carnitine,Entecavir ,Significantly decreased,"At the time of 12-month dosing, the average values of serum ALT were 25.2±15.0 in the monotherapy group and 13.6±5.1 in the combination therapy group, which showed lower in the combination therapy group (P&lt;0.0001).",23109:23340,3701849,23837141,Unavailable
3701849,ALT normalization (3 months) when +200 U/L,Entecavir + carnitine,Entecavir ,Significantly increased,"When pretreatment ALT was over 200 U/L, the serum ALT normalization rates after 3-month dosing were 53.9% and 88.2% in the monotherapy group and the combination therapy group, respectively (P=0.0348).",23340:23561,3701849,23837141,Unavailable
3701849,ALT normalization (12 months) when +200 U/L,Entecavir + carnitine,Entecavir ,Significantly increased,"At the time of 12-month dosing when the study is completed, the ALT normalization rates were 69.2% and 100% in the monotherapy group and the combination therapy group, respectively, which showed statistically significant difference between two groups (P=0.014).",23562:23840,3701849,23837141,Unavailable
3701849,AST normalization (3 months),Entecavir + carnitine,Entecavir ,No significant difference,"Normalization rates of subjects' serum AST were 73.2% and 79.4% in 3-month dosing and 12-month dosing for the monotherapy group, and 92.6% and 88.9% for the combination therapy group, which showed no significant difference between the monotherapy group and the combination therapy group.",23841:24128,3701849,23837141,Unavailable
3701849,AST normalization (12 months),Entecavir + carnitine,Entecavir ,No significant difference,"Normalization rates of subjects' serum AST were 73.2% and 79.4% in 3-month dosing and 12-month dosing for the monotherapy group, and 92.6% and 88.9% for the combination therapy group, which showed no significant difference between the monotherapy group and the combination therapy group.",23841:24128,3701849,23837141,Unavailable
3701849,Less than HBV DNA 300 copies/mL (3 months),Entecavir + carnitine,Entecavir ,No significant difference,"The rates of ALT normalization and HBV DNA of less than 300 copies/mL after 3, 6, 9, 12-month dosing were 43.6%, 50.9%, 69.1%, 75.9% in the monotherapy group and 54.8%, 50.0%, 64.4%, 70.7% in the combination therapy group, respectively, which showed the increasing trend of serum virus negative conversion rate in both groups according to treatment period, but no difference in HBV DNA negative conversion rate between two groups.",24215:24645,3701849,23837141,Unavailable
3701849,Less than HBV DNA 300 copies/mL (6 months),Entecavir + carnitine,Entecavir ,No significant difference,"The rates of ALT normalization and HBV DNA of less than 300 copies/mL after 3, 6, 9, 12-month dosing were 43.6%, 50.9%, 69.1%, 75.9% in the monotherapy group and 54.8%, 50.0%, 64.4%, 70.7% in the combination therapy group, respectively, which showed the increasing trend of serum virus negative conversion rate in both groups according to treatment period, but no difference in HBV DNA negative conversion rate between two groups.",24215:24645,3701849,23837141,Unavailable
3701849,Less than HBV DNA 300 copies/mL (9 months),Entecavir + carnitine,Entecavir ,No significant difference,"The rates of ALT normalization and HBV DNA of less than 300 copies/mL after 3, 6, 9, 12-month dosing were 43.6%, 50.9%, 69.1%, 75.9% in the monotherapy group and 54.8%, 50.0%, 64.4%, 70.7% in the combination therapy group, respectively, which showed the increasing trend of serum virus negative conversion rate in both groups according to treatment period, but no difference in HBV DNA negative conversion rate between two groups.",24215:24645,3701849,23837141,Unavailable
3701849,Less than HBV DNA 300 copies/mL (12 months),Entecavir + carnitine,Entecavir ,No significant difference,"The rates of ALT normalization and HBV DNA of less than 300 copies/mL after 3, 6, 9, 12-month dosing were 43.6%, 50.9%, 69.1%, 75.9% in the monotherapy group and 54.8%, 50.0%, 64.4%, 70.7% in the combination therapy group, respectively, which showed the increasing trend of serum virus negative conversion rate in both groups according to treatment period, but no difference in HBV DNA negative conversion rate between two groups.",24215:24645,3701849,23837141,Unavailable
3701849, HBV DNA negative conversion (3 months),Entecavir + carnitine,Entecavir ,No significant difference,"The rates of ALT normalization and HBV DNA of less than 300 copies/mL after 3, 6, 9, 12-month dosing were 43.6%, 50.9%, 69.1%, 75.9% in the monotherapy group and 54.8%, 50.0%, 64.4%, 70.7% in the combination therapy group, respectively, which showed the increasing trend of serum virus negative conversion rate in both groups according to treatment period, but no difference in HBV DNA negative conversion rate between two groups.",24215:24645,3701849,23837141,Unavailable
3701849, HBV DNA negative conversion (6 months),Entecavir + carnitine,Entecavir ,No significant difference,"The rates of ALT normalization and HBV DNA of less than 300 copies/mL after 3, 6, 9, 12-month dosing were 43.6%, 50.9%, 69.1%, 75.9% in the monotherapy group and 54.8%, 50.0%, 64.4%, 70.7% in the combination therapy group, respectively, which showed the increasing trend of serum virus negative conversion rate in both groups according to treatment period, but no difference in HBV DNA negative conversion rate between two groups.",24215:24645,3701849,23837141,Unavailable
3701849, HBV DNA negative conversion (9 months),Entecavir + carnitine,Entecavir ,No significant difference,"The rates of ALT normalization and HBV DNA of less than 300 copies/mL after 3, 6, 9, 12-month dosing were 43.6%, 50.9%, 69.1%, 75.9% in the monotherapy group and 54.8%, 50.0%, 64.4%, 70.7% in the combination therapy group, respectively, which showed the increasing trend of serum virus negative conversion rate in both groups according to treatment period, but no difference in HBV DNA negative conversion rate between two groups.",24215:24645,3701849,23837141,Unavailable
3701849, HBV DNA negative conversion (12 months),Entecavir + carnitine,Entecavir ,No significant difference,"The rates of ALT normalization and HBV DNA of less than 300 copies/mL after 3, 6, 9, 12-month dosing were 43.6%, 50.9%, 69.1%, 75.9% in the monotherapy group and 54.8%, 50.0%, 64.4%, 70.7% in the combination therapy group, respectively, which showed the increasing trend of serum virus negative conversion rate in both groups according to treatment period, but no difference in HBV DNA negative conversion rate between two groups.",24215:24645,3701849,23837141,Unavailable
3701849,HBsAg seroclearance (12 months),Entecavir + carnitine,Entecavir ,No significant difference,"HBeAg seroclearance rates at the time of therapeutic termination were 14.3% and 5.6% in the monotherapy group and the combination therapy group, respectively while HBeAg seroconversion rates were 10.2% and 5.6% in the monotherapy group and the combination therapy group, respectively, which showed no difference between two groups.",24984:25316,3701849,23837141,Unavailable
3701849,HBsAg seroconversion (12 months),Entecavir + carnitine,Entecavir ,No significant difference,"HBeAg seroclearance rates at the time of therapeutic termination were 14.3% and 5.6% in the monotherapy group and the combination therapy group, respectively while HBeAg seroconversion rates were 10.2% and 5.6% in the monotherapy group and the combination therapy group, respectively, which showed no difference between two groups.",24984:25316,3701849,23837141,Unavailable
3701849,HBsAg level (12 months),Entecavir + carnitine,Entecavir ,No significant difference,"In the monotherapy group, quantitative HBsAg level declined from 42,810 IU/mL to 10,433 IU/mL at the time of 12-month dosing on average, while in the combination therapy group, quantitative HBsAg level reduced from 44,037 IU/mL to 8,621 IU/mL at the time of 12-month dosing on average, which showed no difference between two groups.",24984:25316,3701849,23837141,Unavailable
3701849,Peripheral blood mitochondria copy numbers (12 months),Entecavir + carnitine,Entecavir ,No significant difference,"At the baseline and end of treatment, peripheral blood mitochondria copy numbers were 1,298.3 copies/mL and 2,944.1 copies/mL in the monotherapy group and 1,437.2 copies/mL and 2,320.8 copies/mL in the combination therapy group, respectively, but no statistical significance was found in both groups (P=0.7351).",26246:26574,3701849,23837141,Unavailable
3701849,Indigestion,Entecavir + carnitine,Entecavir ,No significant difference,"Indigestion, skin rash, and drowsiness were the frequent adverse events of the medication. However, the prevalence of each symptom was not statistically significant",26974:27139,3701849,23837141,Unavailable
3701849,Skin rash,Entecavir + carnitine,Entecavir ,No significant difference,"Indigestion, skin rash, and drowsiness were the frequent adverse events of the medication. However, the prevalence of each symptom was not statistically significant",26974:27139,3701849,23837141,Unavailable
3701849,Drowsiness ,Entecavir + carnitine,Entecavir ,No significant difference,"Indigestion, skin rash, and drowsiness were the frequent adverse events of the medication. However, the prevalence of each symptom was not statistically significant",26974:27139,3701849,23837141,Unavailable
3701849,Fatigue,Entecavir + carnitine,Entecavir ,No significant difference,"The prevalence of fatigue, general weakness, chronic gastritis, and upper respiratory infection, has not related with treatment (P=0.2573).",27260:27416,3701849,23837141,Unavailable
3701849,General weakness,Entecavir + carnitine,Entecavir ,No significant difference,"The prevalence of fatigue, general weakness, chronic gastritis, and upper respiratory infection, has not related with treatment (P=0.2573).",27260:27416,3701849,23837141,Unavailable
3701849,Chronic gastritis,Entecavir + carnitine,Entecavir ,No significant difference,"The prevalence of fatigue, general weakness, chronic gastritis, and upper respiratory infection, has not related with treatment (P=0.2573).",27260:27416,3701849,23837141,Unavailable
3701849,Upper respiratory infection,Entecavir + carnitine,Entecavir ,No significant difference,"The prevalence of fatigue, general weakness, chronic gastritis, and upper respiratory infection, has not related with treatment (P=0.2573).",27260:27416,3701849,23837141,Unavailable
4711001,Free testosterone level,Pramipexole,Control,Significantly increased,"The free testosterone level increased in both the levodopa group (change of 5.41 ± 16.18) and pramipexole group (8.95 ± 13.15), but decreased in the untreated group (−13.92 ± 23.12) from baseline to 12-week post-treatment. The between group difference reached a statistical significance of 0.019 with the use of an ANOVA test on the changes.",9641:9983,4711001,26788334,Unavailable
4711001,Free testosterone level,Levodopa,Control,Significantly increased,"The free testosterone level increased in both the levodopa group (change of 5.41 ± 16.18) and pramipexole group (8.95 ± 13.15), but decreased in the untreated group (−13.92 ± 23.12) from baseline to 12-week post-treatment. The between group difference reached a statistical significance of 0.019 with the use of an ANOVA test on the changes.",9641:9983,4711001,26788334,Unavailable
4711001,UPDRS,Pramipexole,Control,No significant difference,There were no significant changes in UPDRS total or motor scores although there was a trend toward improvement in motor scores in both treatment groups compared to placebo.,9983:10156,4711001,26788334,Unavailable
4711001,UPDRS,Levodopa ,Control,No significant difference,There were no significant changes in UPDRS total or motor scores although there was a trend toward improvement in motor scores in both treatment groups compared to placebo.,9983:10156,4711001,26788334,Unavailable
4711001,UPDRS,Pramipexole,Levodopa ,No significant difference,There were no significant changes in UPDRS total or motor scores although there was a trend toward improvement in motor scores in both treatment groups compared to placebo.,9983:10156,4711001,26788334,Unavailable
4711001,Motor scores,Pramipexole,Control,No significant difference,There were no significant changes in UPDRS total or motor scores although there was a trend toward improvement in motor scores in both treatment groups compared to placebo.,9983:10156,4711001,26788334,Unavailable
4711001,Motor scores,Levodopa ,Control,No significant difference,There were no significant changes in UPDRS total or motor scores although there was a trend toward improvement in motor scores in both treatment groups compared to placebo.,9983:10156,4711001,26788334,Unavailable
4711001,Motor scores,Pramipexole,Levodopa ,No significant difference,There were no significant changes in UPDRS total or motor scores although there was a trend toward improvement in motor scores in both treatment groups compared to placebo.,9983:10156,4711001,26788334,Unavailable
4711001,Free testosterone level,Pramipexole,Control,Significantly increased,"There were statistically significant differences in the change in free testosterone level, increased in both the levodopa group and pramipexole group but decreased in the untreated group at 12-weeks post-treatment.",5305:5519,4711001,26788334,Unavailable
4711001,Free testosterone level,Levodopa,Control,Significantly increased,"There were statistically significant differences in the change in free testosterone level, increased in both the levodopa group and pramipexole group but decreased in the untreated group at 12-weeks post-treatment.",5305:5519,4711001,26788334,Unavailable
4711001,UPDRS,Pramipexole,Control,No significant difference,There were no significant differences in the changes of UPDRS total or motor scores,5520:5603,4711001,26788334,Unavailable
4711001,UPDRS,Levodopa ,Control,No significant difference,There were no significant differences in the changes of UPDRS total or motor scores,5519:5603,4711001,26788334,Unavailable
4711001,UPDRS,Pramipexole,Levodopa ,No significant difference,There were no significant differences in the changes of UPDRS total or motor scores,5520:5603,4711001,26788334,Unavailable
4711001,Motor scores,Pramipexole,Control,No significant difference,There were no significant differences in the changes of UPDRS total or motor scores,5520:5603,4711001,26788334,Unavailable
4711001,Motor scores,Levodopa ,Control,No significant difference,There were no significant differences in the changes of UPDRS total or motor scores,5520:5603,4711001,26788334,Unavailable
4711001,Motor scores,Pramipexole,Levodopa ,No significant difference,There were no significant differences in the changes of UPDRS total or motor scores,5520:5603,4711001,26788334,Unavailable
3828218,Mitochondrial H2O22O2 production rate,Aerobic + resistance training,Control,Significantly increased,"Mitochondrial H2O22O2 production rate was observed in the placental mitochondria of exercised women, compared with control subjects (p&lt;0.05) (Fig. 4).",31607:31856,3828218,24244656,Unavailable
3828218,Fetal weight ,Aerobic + resistance training,Control,No significant difference,Fetal weight (3013.2±493.8 vs. 3133.3±406.5 g) was not altered in the exercise trained compared to the non-exercise group.,32447:32570,3828218,24244656,Unavailable
3828218,Placental weight ,Aerobic + resistance training,Control,Significantly decreased,"In contrast, placental (Figure 5A; p&lt;0.05) weight decreased in the exercise trained compared to the non-exercised.",32570:32736,3828218,24244656,Unavailable
3828218,Placental efficiency ,Aerobic + resistance training,Control,Significantly increased,"Furthermore, placental efficiency was increased (Figure 5B; p&lt;0.05) in the exercise trained.",32737:32885,3828218,24244656,Unavailable
3828218,Number of cotyledons,Aerobic + resistance training,Control,No significant difference,There was no difference in the number of cotyledons (12.5±0.5 vs. 12±1.0) between the exercise and non-exercise groups.,32885:33004,3828218,24244656,Unavailable
3828218,Placental weight ,Aerobic + resistance training,Control,Significantly decreased,A. Placental weight was decreased in the exercise trained compared to the non-exercised.,33275:33370,3828218,24244656,Unavailable
3828218,Placental efficiency ,Aerobic + resistance training,Control,Significantly increased,The placental efficiency was increased in the exercise group compared to the control group.,33387:33478,3828218,24244656,Unavailable
3828218,eNOS expresion,Aerobic + resistance training,Control,Significantly increased,Combined aerobic and resistance exercise training during pregnancy leads to a 2-fold increase in eNOS expression and 4-fold increase in NO production in placental cytosol (p = 0.05).,5775:5957,3828218,24244656,Unavailable
3828218,NO production,Aerobic + resistance training,Control,Significantly increased,Combined aerobic and resistance exercise training during pregnancy leads to a 2-fold increase in eNOS expression and 4-fold increase in NO production in placental cytosol (p = 0.05).,5775:5957,3828218,24244656,Unavailable
3828218,eNOS expresion,Aerobic + resistance training,Control,Significantly increased,pregnant women 12 weeks of exercise training resulted in a 4-fold increase in eNOS/β-actin expression in cytosolic samples (p&lt;0.05).,28664:28796,3828218,24244656,Unavailable
3828218,NO production,Aerobic + resistance training,Control,Significantly increased,A 2-fold increase in NO production was also observed in their cytosolic samples (p&lt;0.05) (Fig 2).,28796:28952,3828218,24244656,Unavailable
1660570,Withdrawal symptoms reduction (day 2),Buprenorphine + Valproate,Control,Significantly increased,"The difference between the two groups was significantly in favour of the BPN/VPA group for days 2 (p &lt; 0.001), 3 (p &lt; 0.05), 4 (p &lt; 0.001), 5 (p &lt; 0.01), 7 (p &lt; 0.01) and 8 (p &lt; 0.05).",4541:4726,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 3),Buprenorphine + Valproate,Control,Significantly increased,"The difference between the two groups was significantly in favour of the BPN/VPA group for days 2 (p &lt; 0.001), 3 (p &lt; 0.05), 4 (p &lt; 0.001), 5 (p &lt; 0.01), 7 (p &lt; 0.01) and 8 (p &lt; 0.05).",4541:4726,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 4),Buprenorphine + Valproate,Control,Significantly increased,"The difference between the two groups was significantly in favour of the BPN/VPA group for days 2 (p &lt; 0.001), 3 (p &lt; 0.05), 4 (p &lt; 0.001), 5 (p &lt; 0.01), 7 (p &lt; 0.01) and 8 (p &lt; 0.05).",4541:4726,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 5),Buprenorphine + Valproate,Control,Significantly increased,"The difference between the two groups was significantly in favour of the BPN/VPA group for days 2 (p &lt; 0.001), 3 (p &lt; 0.05), 4 (p &lt; 0.001), 5 (p &lt; 0.01), 7 (p &lt; 0.01) and 8 (p &lt; 0.05).",4541:4726,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 7),Buprenorphine + Valproate,Control,Significantly increased,"The difference between the two groups was significantly in favour of the BPN/VPA group for days 2 (p &lt; 0.001), 3 (p &lt; 0.05), 4 (p &lt; 0.001), 5 (p &lt; 0.01), 7 (p &lt; 0.01) and 8 (p &lt; 0.05).",4541:4726,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 8),Buprenorphine + Valproate,Control,Significantly increased,"The difference between the two groups was significantly in favour of the BPN/VPA group for days 2 (p &lt; 0.001), 3 (p &lt; 0.05), 4 (p &lt; 0.001), 5 (p &lt; 0.01), 7 (p &lt; 0.01) and 8 (p &lt; 0.05).",4541:4726,1660570,17107609,Unavailable
1660570,Completing the medical phase of detoxification,Buprenorphine + Valproate,Control,No significant difference,Patients in the CLN/CBZ-group were less likely to complete the medical phase of detoxification than those in the BPN/VPA-group; retentions at the end were 67% (8 of 12 patients) in the BPN/VPA-group and 50% (25 of 50 patients) in the control group. The difference was not significant (p = 0.15,18128:18421,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 2),Buprenorphine + Valproate,Control,Significantly increased,"The difference was significant in favour of BPN/VPA for the first four days and days seven and eight (Mann-Whitney U-test, p &lt; 0.05).",19506:19639,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 3),Buprenorphine + Valproate,Control,Significantly increased,"The difference was significant in favour of BPN/VPA for the first four days and days seven and eight (Mann-Whitney U-test, p &lt; 0.05).",19506:19639,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 4),Buprenorphine + Valproate,Control,Significantly increased,"The difference was significant in favour of BPN/VPA for the first four days and days seven and eight (Mann-Whitney U-test, p &lt; 0.05).",19506:19639,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 5),Buprenorphine + Valproate,Control,Significantly increased,"The difference was significant in favour of BPN/VPA for the first four days and days seven and eight (Mann-Whitney U-test, p &lt; 0.05).",19506:19639,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 7),Buprenorphine + Valproate,Control,Significantly increased,"The difference was significant in favour of BPN/VPA for the first four days and days seven and eight (Mann-Whitney U-test, p &lt; 0.05).",19506:19639,1660570,17107609,Unavailable
1660570,Withdrawal symptoms reduction (day 8),Buprenorphine + Valproate,Control,Significantly increased,"The difference was significant in favour of BPN/VPA for the first four days and days seven and eight (Mann-Whitney U-test, p &lt; 0.05).",19506:19639,1660570,17107609,Unavailable
4489334,≥50%max Total relief of pain,Ibuprofen sodium,Paracetamol,Significantly increased,"Using categorical pain relief scores, for the outcome of ≥50%maxTOTPAR, both ibuprofen formulations were significantly better than paracetamol 1000 mg (Table 1).",14629:14831,4489334,24848990,Unavailable
4489334,≥50%max Total relief of pain,"Ibuprofen-poloxamer	",Paracetamol,Significantly increased,"Using categorical pain relief scores, for the outcome of ≥50%maxTOTPAR, both ibuprofen formulations were significantly better than paracetamol 1000 mg (Table 1).",14629:14831,4489334,24848990,Unavailable
4489334,≥50%max Total relief of pain,Ibuprofen sodium,Paracetamol,Significantly increased,"Paracetamol	1000	36	11	4.1 (2.7–8.2)Ibuprofen sodium	400	69	11	1.7 (1.4–2.2)Ibuprofen-poloxamer	400	74	11	1.6 (1.3–2.0)",16147:NaN,4489334,24848990,Unavailable
4489334,≥50%max Total relief of pain,"Ibuprofen-poloxamer	",Paracetamol,Significantly increased,"Paracetamol	1000	36	11	4.1 (2.7–8.2)Ibuprofen sodium	400	69	11	1.7 (1.4–2.2)Ibuprofen-poloxamer	400	74	11	1.6 (1.3–2.0)",16147:NaN,4489334,24848990,Unavailable
4489334,≥50%max Total relief of pain,Ibuprofen sodium,Paracetamol,Significantly increased,"Each ibuprofen formulation significantly better than paracetamol, p &lt; 0.001, z-test.",16966:17087,4489334,24848990,Unavailable
4489334,≥50%max Total relief of pain,"Ibuprofen-poloxamer	",Paracetamol,Significantly increased,"Each ibuprofen formulation significantly better than paracetamol, p &lt; 0.001, z-test.",16966:17087,4489334,24848990,Unavailable
3702243,Fibroid volume,Mifepristone ,Placebo,Significantly decreased,"Three months into treatment, fibroid volume was reduced by 28.5% in the mifepristone group with an increase of 1.8% in the placebo group (P = 0.031).",4364:4531,3702243,23843709,Unavailable
3702243,Pelvic pain,Mifepristone ,Placebo,Significantly decreased,"There were significant differences between the groups with respect to pelvic pain prevalence (P = 0.006), pelvic pressure (P = 0.027), rectal pain (P = 0.013), hypermenorrhea (P &lt; 0.001), and metrorrhagia (P = 0.002) at the end of treatment.",4531:4861,3702243,23843709,Unavailable
3702243,Pelvic pressure,Mifepristone ,Placebo,Significantly decreased,"There were significant differences between the groups with respect to pelvic pain prevalence (P = 0.006), pelvic pressure (P = 0.027), rectal pain (P = 0.013), hypermenorrhea (P &lt; 0.001), and metrorrhagia (P = 0.002) at the end of treatment.",4531:4861,3702243,23843709,Unavailable
3702243,Rectal pain,Mifepristone ,Placebo,Significantly decreased,"There were significant differences between the groups with respect to pelvic pain prevalence (P = 0.006), pelvic pressure (P = 0.027), rectal pain (P = 0.013), hypermenorrhea (P &lt; 0.001), and metrorrhagia (P = 0.002) at the end of treatment.",4531:4861,3702243,23843709,Unavailable
3702243,Hypermenorrhea ,Mifepristone ,Placebo,Significantly decreased,"There were significant differences between the groups with respect to pelvic pain prevalence (P = 0.006), pelvic pressure (P = 0.027), rectal pain (P = 0.013), hypermenorrhea (P &lt; 0.001), and metrorrhagia (P = 0.002) at the end of treatment.",4531:4861,3702243,23843709,Unavailable
3702243,Metrorrhagia ,Mifepristone ,Placebo,Significantly decreased,"There were significant differences between the groups with respect to pelvic pain prevalence (P = 0.006), pelvic pressure (P = 0.027), rectal pain (P = 0.013), hypermenorrhea (P &lt; 0.001), and metrorrhagia (P = 0.002) at the end of treatment.",4531:4861,3702243,23843709,Unavailable
3702243,Amenorrhea ,Mifepristone ,Placebo,Significantly increased,"Amenorrhea was 93.1% and 4.3% in the mifepristone and placebo groups, respectively (P &lt; 0.001).",4861:4973,3702243,23843709,Unavailable
3702243,Hot flushes,Mifepristone ,Placebo,Significantly increased,Treatment side effects were significantly greater in the mifepristone group.,4974:5050,3702243,23843709,Unavailable
3702243,Hot flush episode duration,Mifepristone ,Placebo,Significantly increased,Treatment side effects were significantly greater in the mifepristone group.,4974:5050,3702243,23843709,Unavailable
3702243,Nausea,Mifepristone ,Placebo,Significantly increased,Treatment side effects were significantly greater in the mifepristone group.,4974:5050,3702243,23843709,Unavailable
3702243,Feeling of fatigue,Mifepristone ,Placebo,Significantly increased,Treatment side effects were significantly greater in the mifepristone group.,4974:5050,3702243,23843709,Unavailable
3702243,Estradiol levels,Mifepristone ,Placebo,No significant difference,Estradiol levels did not differ significantly between the placebo and mifepristone groups at the end of treatment.,5051:5165,3702243,23843709,Unavailable
3702243,Quality of life (symptoms),Mifepristone ,Placebo,Significantly increased,Improvement in quality of life was significantly greater in the categories of “symptoms” (P = 0.004) and “activity” (P = 0.045) in the mifepristone group.,5166:5357,3702243,23843709,Unavailable
3702243,Quality of life (activity),Mifepristone ,Placebo,Significantly increased,Improvement in quality of life was significantly greater in the categories of “symptoms” (P = 0.004) and “activity” (P = 0.045) in the mifepristone group.,5166:5357,3702243,23843709,Unavailable
3702243,Completion of 3 months,Mifepristone ,Placebo,Significantly increased,"The 3-month treatment was completed by 47/62 (75.8%) and 58/62 (93.5%) subjects in the placebo and 5 mg groups, respectively (P = 0.003).",17984:18138,3702243,23843709,Unavailable
3702243,Absence of fibroid reduction ,Mifepristone ,Placebo,Significantly decreased,"There was no reduction in fibroid volume in 31/47 (66.0%) and 11/58 (19.0%) subjects in the placebo and mifepristone groups, respectively (P &lt; 0.001).",20767:20935,3702243,23843709,Unavailable
3702243,Absence of uterine size reduction  ,Mifepristone ,Placebo,Significantly decreased,"There was no reduction in uterine size in 34/47 (72.3%) and 13/58 (22.4%) subjects in the placebo and mifepristone groups, respectively (P &lt; 0.001).",20767:20935,3702243,23843709,Unavailable
3702243,Hemoglobin ,Mifepristone ,Placebo,No significant difference,there were no significant differences between the treatment groups in final hemoglobin values.,21416:21511,3702243,23843709,Unavailable
3702243,Amenorrhea ,Mifepristone ,Placebo,Significantly increased,"Amenorrhea was present 3 months into treatment in 2/47 (4.3%) and 54/58 (93.1%) subjects in the placebo and mifepristone groups, respectively (P &lt; 0.001).",21550:21721,3702243,23843709,Unavailable
3702243,Hot flushes,Mifepristone ,Placebo,Significantly increased,"Hot flushes were reported at some point during treatment by 4/47 (8.5%) and 14/58 (24.1%) subjects in the placebo and mifepristone groups, respectively (P = 0.017).",21416:21511,3702243,23843709,Unavailable
3702243,Hot flushes (at night),Mifepristone ,Placebo,No significant difference,"In total, 5/18 (27.8%) subjects reported hot flushes at night, 9/18 (50.0%) subjects during the day, and 4/18 (22.2%) subjects at any time, the differences being asymptotically significant between the groups (P = 0.052)",21907:22143,3702243,23843709,Unavailable
3702243,Average hot flushes in 24 hours,Mifepristone ,Placebo,No significant difference,"the average number of hot flush episodes over 24 hours were 2.0 ± 2.0 times a day and 2.2 ± 1.2 times a day, respectively (P = 0.851)",22325:22476,3702243,23843709,Unavailable
3702243,Average hot flushes per week,Mifepristone ,Placebo,No significant difference,"over a week was 3.2 ± 2.1 days with episodes and 4.1 ± 2.0 days with episodes (P = 0.451), respectively.",22478:22600,3702243,23843709,Unavailable
3702243,Hot flush episode duration,Mifepristone ,Placebo,Significantly increased,"The hot flush episode duration was significantly greater in the mifepristone group than in the placebo group, at 3.6 ± 3.2 minutes versus 1.2 ± 0.5 minutes (P = 0.019), respectively.",22478:22600,3702243,23843709,Unavailable
3702243,Intensity of hot flush ,Mifepristone ,Placebo,No significant difference,"The intensity of the hot flushes in the mifepristone group was similar to that in the placebo group, 4.5 ± 1.3 and 5.8 ± 2.5 (P = 0.210), respectively.",22800:22969,3702243,23843709,Unavailable
3702243,Nausea,Mifepristone ,Placebo,Significantly increased,"Nausea was significantly more frequent in the mifepristone group than in the placebo group, with 13/58 (2.4%) and 3/47 (6.4%) cases (P = 0.011), respectively.",22800:22969,3702243,23843709,Unavailable
3702243,Feeling of fatigue,Mifepristone ,Placebo,Significantly increased,"The feeling of fatigue was also significantly more frequent in the mifepristone group than in the placebo group, with 10/58 (17.2%) and 3/47 (6.4%) cases (P = 0.047), respectively.",22800:22969,3702243,23843709,Unavailable
3702243,Any irregular bleeding,Mifepristone ,Placebo,Significantly decreased,"Between the beginning and end of treatment, 45/47 (95.7%) and 12/58 (20.7%) subjects in the placebo and mifepristone groups, respectively, reported some irregular bleeding (P &lt; 0.001); the average number of days for such bleeding was: 25.1 ± 4.9 days and 9.0 ± 7.9 days in the placebo and mifepristone groups, respectively (P &lt; 0.001).",22800:22969,3702243,23843709,Unavailable
3702243,Days with any irregular bleeding,Mifepristone ,Placebo,Significantly decreased,"Between the beginning and end of treatment, 45/47 (95.7%) and 12/58 (20.7%) subjects in the placebo and mifepristone groups, respectively, reported some irregular bleeding (P &lt; 0.001); the average number of days for such bleeding was: 25.1 ± 4.9 days and 9.0 ± 7.9 days in the placebo and mifepristone groups, respectively (P &lt; 0.001).",22800:22969,3702243,23843709,Unavailable
3510710,Treatment retention,Cognitive Behavioral Self-Help Program,Control,Significantly increased,Participants in the intervention group showed greater treatment retention compared with the control group (P&nbsp;=&nbsp;.04).,6557:6691,3510710,23192752,Unavailable
3510710,Severity of cocaine dependence,Cognitive Behavioral Self-Help Program,Control,No significant difference,"At the follow-up assessments, the severity of cocaine dependence did not differ between the intervention and control groups (P&nbsp;=&nbsp;.75)",6789:6939,3510710,23192752,Unavailable
3510710,Cocaine craving,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Furthermore, there were no differences in cocaine craving, depression, or alcohol and other substance use.",6941:7047,3510710,23192752,Unavailable
3510710,Depression,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Furthermore, there were no differences in cocaine craving, depression, or alcohol and other substance use.",6941:7047,3510710,23192752,Unavailable
3510710,Alcohol use,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Furthermore, there were no differences in cocaine craving, depression, or alcohol and other substance use.",6941:7047,3510710,23192752,Unavailable
3510710,Cannabis use,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Furthermore, there were no differences in cocaine craving, depression, or alcohol and other substance use.",6941:7047,3510710,23192752,Unavailable
3510710,Cocaine use,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Furthermore, there were no differences in cocaine craving, depression, or alcohol and other substance use.",6941:7047,3510710,23192752,Unavailable
3510710,Quantity of cocaine per week,Cognitive Behavioral Self-Help Program,Control,No significant difference,"the average number of cocaine-free days per week did not change significantly, whereas the weekly quantity of cocaine used decreased equally in both groups (P&nbsp;=&nbsp;.009).",7078:7263,3510710,23192752,Unavailable
3510710,Modules completed,Cognitive Behavioral Self-Help Program,Control,Significantly increased,"Participants in the Snow Control intervention group completed more modules (mean 2.60, SD 2.04) than those in the control group (mean 1.80, SD 1.60; t 194&nbsp;=&nbsp;3.086, P&nbsp;=&nbsp;.002, Cohen’s d [d]&nbsp;=&nbsp;0.438).",40105:40347,3510710,23192752,Unavailable
3510710,Days between first and last log-in,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Overall, the average number of days that elapsed between the first and last log-ins did not differ between the intervention group (mean 32.53, SD 31.52) and the control group (mean 27.44, SD 20.53; t 194&nbsp;=&nbsp;1.335, P&nbsp;=&nbsp;.28, d&nbsp;=&nbsp;0.191).",40526:40804,3510710,23192752,Unavailable
3510710,Treatment retention,Cognitive Behavioral Self-Help Program,Control,Significantly increased,"According to the consumption diary data, retention in the intervention group (see Figure 2) was significantly greater than that of the control group (week 6: χ2 1&nbsp;=&nbsp;2.1, P&nbsp;=&nbsp;.04, w&nbsp;=&nbsp;0.220).",40846:41118,3510710,23192752,Unavailable
3510710,Severity of cocaine dependence,Cognitive Behavioral Self-Help Program,Control,No significant difference,"As seen in Table 4, no significant group&nbsp;×&nbsp;time interactions in the severity of cocaine dependence (P&nbsp;=&nbsp;.75) were seen.",43665:43844,3510710,23192752,Unavailable
3510710,Cocaine craving,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Furthermore, no significant group&nbsp;×&nbsp;time interactions were observed in the secondary outcomes of cocaine craving (P&nbsp;=&nbsp;.90) or depression (P&nbsp;=&nbsp;.57).",43845:44026,3510710,23192752,Unavailable
3510710,Depression,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Furthermore, no significant group&nbsp;×&nbsp;time interactions were observed in the secondary outcomes of cocaine craving (P&nbsp;=&nbsp;.90) or depression (P&nbsp;=&nbsp;.57).",43845:44026,3510710,23192752,Unavailable
3510710,Alcohol use,Cognitive Behavioral Self-Help Program,Control,No significant difference,"As seen in Table 6, no group&nbsp;×&nbsp;time interactions were found between in the consumption of cannabis, cocaine, or alcohol at the follow-up assessments (P&nbsp;≥&nbsp;.05).",44179:44381,3510710,23192752,Unavailable
3510710,Cannabis use,Cognitive Behavioral Self-Help Program,Control,No significant difference,"As seen in Table 6, no group&nbsp;×&nbsp;time interactions were found between in the consumption of cannabis, cocaine, or alcohol at the follow-up assessments (P&nbsp;≥&nbsp;.05).",44179:44381,3510710,23192752,Unavailable
3510710,Cocaine use,Cognitive Behavioral Self-Help Program,Control,No significant difference,"As seen in Table 6, no group&nbsp;×&nbsp;time interactions were found between in the consumption of cannabis, cocaine, or alcohol at the follow-up assessments (P&nbsp;≥&nbsp;.05).",44179:44381,3510710,23192752,Unavailable
3510710,Severity of cocaine dependence,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Severity of Dependence Scale (SDS)a (degrees of freedom [df]&nbsp;=&nbsp;8.4)				Study group (control vs intervention)	–0.36	0.74	–0.49	.63Time	–1.45	0.23	–6.25	.000Study group&nbsp;×&nbsp;time	0.07	0.22	0.33	.75",48951:50057,3510710,23192752,Unavailable
3510710,Cocaine craving,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Cocaine Craving Questionnaire-Brief (CCQ-Brief)a (df&nbsp;=&nbsp;7.3)				Study group (control vs intervention)	0.67	1.92	0.35	.73Time	1.07	0.78	1.37	.21Study group&nbsp;×&nbsp;time	0.07	0.60	0.12	.90",50119:51212,3510710,23192752,Unavailable
3510710,Depression,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Beck Depression Inventory (BDI)b (df&nbsp;=&nbsp;6.5)				Study group (control vs intervention)	–2.86	2.69	–1.06	.29Time	–4.45	1.09	–4.08	.006Study group&nbsp;×&nbsp;time	0.43	0.76	0.57	.57",51274:52356,3510710,23192752,Unavailable
3510710,Alcohol use,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Alcohol consumption within previous month (df&nbsp;=&nbsp;10.0)				Study group (control vs intervention)	0.95 (0.42&nbsp;-&nbsp;2.15)	0.39	–0.13	.89Time	1.42 (1.06&nbsp;-&nbsp;1.90)	0.19	2.61	.02Study group&nbsp;×&nbsp;time	1.01 (0.74&nbsp;-&nbsp;1.37)	0.15	0.07	.95",60131:61242,3510710,23192752,Unavailable
3510710,Cannabis use,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Cannabis consumption within previous month (df&nbsp;=&nbsp;9.4)				Study group (control vs intervention)	0.73 (0.30&nbsp;-&nbsp;1.79)	0.33	–0.69	.49Time	1.92 (1.32&nbsp;-&nbsp;2.79)	0.32	3.93	.003Study group&nbsp;×&nbsp;time	1.03 (0.72&nbsp;-&nbsp;1.47)	0.18	0.18	.86",57798:58910,3510710,23192752,Unavailable
3510710,Cocaine use,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Cocaine consumption within previous month (df&nbsp;=&nbsp;4.0)				Study group (control vs intervention)	0.78 (0.17&nbsp;-&nbsp;3.55)	0.22	–0.07	.95Time	0.42 (0.07&nbsp;-&nbsp;2.50)	0.45	–0.58	.59Study group&nbsp;×&nbsp;time	1.08 (0.70&nbsp;-&nbsp;1.67)	0.24	0.36	.72",58965:60076,3510710,23192752,Unavailable
3510710,Binge drinking,Cognitive Behavioral Self-Help Program,Control,No significant difference,"Binge drinking within previous month (df&nbsp;=&nbsp;5.0)				Study group (control vs intervention)	1.13 (0.45&nbsp;-&nbsp;2.84)	0.52	0.28	.78Time	1.57 (0.77&nbsp;-&nbsp;3.21)	0.44	1.64	.16Study group&nbsp;×&nbsp;time	0.94 (0.66&nbsp;-&nbsp;1.34)	0.16	–0.35	.73",61297:62402,3510710,23192752,Unavailable
3510710,Cocaine use (week 4),Cognitive Behavioral Self-Help Program,Control,No significant difference,"According to the consumption diaries (see Figure 3), there were no differences in the reduction of the average weekly use of cocaine (in milligrams) between the intervention and control groups at week 4 (t 37&nbsp;=&nbsp;0.077, P&nbsp;=.94, d&nbsp;=&nbsp;0.010) or week 6 (t 24&nbsp;=&nbsp;0.544, P&nbsp;=&nbsp;.59, d&nbsp;=&nbsp;0.245).",62712:63126,3510710,23192752,Unavailable
3510710,Cocaine use (week 6),Cognitive Behavioral Self-Help Program,Control,No significant difference,"According to the consumption diaries (see Figure 3), there were no differences in the reduction of the average weekly use of cocaine (in milligrams) between the intervention and control groups at week 4 (t 37&nbsp;=&nbsp;0.077, P&nbsp;=.94, d&nbsp;=&nbsp;0.010) or week 6 (t 24&nbsp;=&nbsp;0.544, P&nbsp;=&nbsp;.59, d&nbsp;=&nbsp;0.245).",62712:63126,3510710,23192752,Unavailable
3510710,Cocaine-free days (week 4),Cognitive Behavioral Self-Help Program,Control,No significant difference,"the average number of cocaine-free days per week did not change significantly, whereas the weekly quantity of cocaine used decreased equally in both groups (P&nbsp;=&nbsp;.009).",62712:63126,3510710,23192752,Unavailable
3510710,Cocaine-free days (week 6),Cognitive Behavioral Self-Help Program,Control,No significant difference,"the average number of cocaine-free days per week did not change significantly, whereas the weekly quantity of cocaine used decreased equally in both groups (P&nbsp;=&nbsp;.009).",62712:63126,3510710,23192752,Unavailable
3510710,Cocaine-free days (week 4),Cognitive Behavioral Self-Help Program,Control,No significant difference,"Similarly, the mean number of cocaine-free days per week recorded in the consumption diaries did not differ between groups at week 4 (t 46&nbsp;=&nbsp;2.225, P&nbsp;=&nbsp;.31, d&nbsp;=&nbsp;0.512) or week 6 (t 30&nbsp;=&nbsp;0.841, P&nbsp;=&nbsp;.94, d&nbsp;=&nbsp;0.079).",63127:63430,3510710,23192752,Unavailable
3510710,Cocaine-free days (week 6),Cognitive Behavioral Self-Help Program,Control,No significant difference,"Similarly, the mean number of cocaine-free days per week recorded in the consumption diaries did not differ between groups at week 4 (t 46&nbsp;=&nbsp;2.225, P&nbsp;=&nbsp;.31, d&nbsp;=&nbsp;0.512) or week 6 (t 30&nbsp;=&nbsp;0.841, P&nbsp;=&nbsp;.94, d&nbsp;=&nbsp;0.079).",63127:63430,3510710,23192752,Unavailable
3510710,Quantity of cocaine per week,Cognitive Behavioral Self-Help Program,Control,No significant difference,"the weekly quantity of cocaine used decreased equally in both groups between week 1 and 6 (t 25&nbsp;=&nbsp;3.188, P&nbsp;=&nbsp;.004, d&nbsp;=&nbsp;0.761, imputed data set: t 195&nbsp;=&nbsp;2.63, P&nbsp;=&nbsp;.009) as seen in Figure 4.",63715:64035,3510710,23192752,Unavailable
3770019,≥5% weight loss,Taeeumjowi-tang,Control ,No significant difference,"The subject response rate of ≥5% weight loss compared to baseline was similar in both groups, and no statistically significant difference was observed (P = 0.87).",6073:6252,3770019,24062784,Unavailable
3770019,Total cholesterol ,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes in both within groups and between groups for lipid profile and body fat composition.,6382:6501,3770019,24062784,Unavailable
3770019,HDL,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes in both within groups and between groups for lipid profile and body fat composition.,6382:6501,3770019,24062784,Unavailable
3770019,Triglycerides ,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes in both within groups and between groups for lipid profile and body fat composition.,6382:6501,3770019,24062784,Unavailable
3770019,Total fat area,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes in both within groups and between groups for lipid profile and body fat composition.,6382:6501,3770019,24062784,Unavailable
3770019,Visceral fat area ,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes in both within groups and between groups for lipid profile and body fat composition.,6382:6501,3770019,24062784,Unavailable
3770019,Subcutaneous fat area ,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes in both within groups and between groups for lipid profile and body fat composition.,6382:6501,3770019,24062784,Unavailable
3770019,≥5% weight loss,Taeeumjowi-tang,Control ,No significant difference,"After the 12-week treatment period, the rate of subjects who lost at least 5% of baseline was similar in both groups with no statistically significant difference (TJ001 group and placebo group, 21.1% and 18.2%, resp., P = 0.87",21012:21255,3770019,24062784,Unavailable
3770019,≥3% weight loss,Taeeumjowi-tang,Control ,Significantly increased,"However, the subject rates of at least 3% weight loss were significantly higher in the treatment group compared with the placebo group (P = 0.01, Figure 2).",21307:21519,3770019,24062784,Unavailable
3770019,Weight ,Taeeumjowi-tang,Control ,No significant difference,"A significant decrease in weight was observed in both groups but was greater in the treatment group (−1.95 ± 3.35 kg, P &lt; 0.0001); however, it was not significant between groups",22196:22390,3770019,24062784,Unavailable
3770019,BMI,Taeeumjowi-tang,Control ,No significant difference,"The within-group changes in BMI, WC, and HC were also significant in each group but not significant for the between-group comparison.",22446:22579,3770019,24062784,Unavailable
3770019,Waist circumference,Taeeumjowi-tang,Control ,No significant difference,"The within-group changes in BMI, WC, and HC were also significant in each group but not significant for the between-group comparison.",22446:22579,3770019,24062784,Unavailable
3770019,Hip circumference,Taeeumjowi-tang,Control ,No significant difference,"The within-group changes in BMI, WC, and HC were also significant in each group but not significant for the between-group comparison.",22446:22579,3770019,24062784,Unavailable
3770019,Total cholesterol ,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes both within groups and between groups in regards to lipid profile and body fat composition (Table 3).,22977:23154,3770019,24062784,Unavailable
3770019,HDL,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes both within groups and between groups in regards to lipid profile and body fat composition (Table 3).,22977:23154,3770019,24062784,Unavailable
3770019,Triglycerides ,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes both within groups and between groups in regards to lipid profile and body fat composition (Table 3).,22977:23153,3770019,24062784,Unavailable
3770019,Total fat area,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes both within groups and between groups in regards to lipid profile and body fat composition (Table 3).,22977:23154,3770019,24062784,Unavailable
3770019,Visceral fat area ,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes both within groups and between groups in regards to lipid profile and body fat composition (Table 3).,22977:23153,3770019,24062784,Unavailable
3770019,Subcutaneous fat area ,Taeeumjowi-tang,Control ,No significant difference,There were no significant changes both within groups and between groups in regards to lipid profile and body fat composition (Table 3).,22977:23153,3770019,24062784,Unavailable
3770019,Questionnaire scores,Taeeumjowi-tang,Control ,No significant difference,Questionnaire scores were also not statistically significant for both the within-group and between-group assessments,23154:23270,3770019,24062784,Unavailable
3770019,SBP (week 4),Taeeumjowi-tang,Control ,No significant difference,Mean systolic and diastolic blood pressure and creatinine were not different between groups at any week nor were they different from the baseline measurements within each group at the final visit of the study (Table 4).,23612:23872,3770019,24062784,Unavailable
3770019,SBP (week 8),Taeeumjowi-tang,Control ,No significant difference,Mean systolic and diastolic blood pressure and creatinine were not different between groups at any week nor were they different from the baseline measurements within each group at the final visit of the study (Table 4).,23612:23872,3770019,24062784,Unavailable
3770019,SBP (week 12),Taeeumjowi-tang,Control ,No significant difference,Mean systolic and diastolic blood pressure and creatinine were not different between groups at any week nor were they different from the baseline measurements within each group at the final visit of the study (Table 4).,23612:23872,3770019,24062784,Unavailable
3770019,DBP (week 4),Taeeumjowi-tang,Control ,No significant difference,Mean systolic and diastolic blood pressure and creatinine were not different between groups at any week nor were they different from the baseline measurements within each group at the final visit of the study (Table 4).,23612:23872,3770019,24062784,Unavailable
3770019,DBP (week 8),Taeeumjowi-tang,Control ,No significant difference,Mean systolic and diastolic blood pressure and creatinine were not different between groups at any week nor were they different from the baseline measurements within each group at the final visit of the study (Table 4).,23612:23872,3770019,24062784,Unavailable
3770019,DBP (week 12),Taeeumjowi-tang,Control ,No significant difference,Mean systolic and diastolic blood pressure and creatinine were not different between groups at any week nor were they different from the baseline measurements within each group at the final visit of the study (Table 4).,23612:23872,3770019,24062784,Unavailable
3770019,Creatinine ,Taeeumjowi-tang,Control ,No significant difference,Mean systolic and diastolic blood pressure and creatinine were not different between groups at any week nor were they different from the baseline measurements within each group at the final visit of the study (Table 4).,23612:23872,3770019,24062784,Unavailable
3770019,Pulse,Taeeumjowi-tang,Control ,Significantly increased,"There was a significant change in pulse observed in the placebo group and in the between-group comparison (P = 0.0058 and P = 0.018, resp.).",24074:24248,3770019,24062784,Unavailable
1557723,Risk of bone metastases over 5 years,Clodronate addition ,Standard treatment ,Significantly decreased,"Oral clodronate significantly reduced the risk of bone metastases in all patients over the 5 year study period (51 patients versus 73 patients with placebo; HR = 0.692, P = 0.043)",6294:6464,1557723,16542503,Unavailable
1557723,Risk of bone metastases over 2 years,Clodronate addition ,Standard treatment ,Significantly decreased,"the difference was also statistically significant over the 2 year medication period (19 patients versus 35 patients with placebo; HR = 0.546, P = 0.031).",6294:6464,1557723,16542503,Unavailable
1557723, Risk of bone metastases over 5 years (II/III disease),Clodronate addition ,Standard treatment ,Significantly decreased,"These differences were most pronounced in patients with stage II/III disease (39 patients versus 64 patients with placebo, HR = 0.592, P = 0.009 over 5 years; 16 patients versus 32 patients with placebo, HR= 0.496, P = 0.020 over 2 years).",6465:6738,1557723,16542503,Unavailable
1557723,Risk of bone metastases over 2 years (II/III disease),Clodronate addition ,Standard treatment ,Significantly decreased,"These differences were most pronounced in patients with stage II/III disease (39 patients versus 64 patients with placebo, HR = 0.592, P = 0.009 over 5 years; 16 patients versus 32 patients with placebo, HR= 0.496, P = 0.020 over 2 years).",6464:6738,1557723,16542503,Unavailable
1557723,Survival ,Clodronate addition ,Standard treatment ,No significant difference,"Survival data also favoured the clodronate arm (HR for all patients = 0.768, P = 0.048; HR for stage II/III disease = 0.743, P = 0.041), although this was not significant due to multiple analyses.",6738:6970,1557723,16542503,Unavailable
1557723,Survival (II/III disease),Clodronate addition ,Standard treatment ,No significant difference,"Survival data also favoured the clodronate arm (HR for all patients = 0.768, P = 0.048; HR for stage II/III disease = 0.743, P = 0.041), although this was not significant due to multiple analyses.",6738:6970,1557723,16542503,Unavailable
1557723,Risk of bone metastases over 5 years,Clodronate addition ,Standard treatment ,Significantly decreased,"The addition of oral clodronate to adjuvant therapy for breast cancer significantly reduced the risk of bone metastases by 31% over the 5 year study period (51 patients versus 73 patients receiving placebo, HR = 0.692; P = 0.043; Figure 1 and Table 2).",16078:16423,1557723,16542503,Unavailable
1557723,Risk of bone metastases over 2 years,Clodronate addition ,Standard treatment ,Significantly decreased,During the 2-year treatment period patients in the clodronate arm had a 45% reduction in the risk of bone metastases (P = 0.031; Table 2).,16424:16618,1557723,16542503,Unavailable
1557723, Risk of bone metastases over 5 years (II/III disease),Clodronate addition ,Standard treatment ,Significantly decreased,"For stage II/III disease, over the 5 year study period, the clodronate treated patients had a 41% decrease in the risk of developing bone metastases (P = 0.009); during the 2 year medication period, the risk was decreased by 50% (P = 0.020; Figure 3).",17216:17538,1557723,16542503,Unavailable
1557723,Risk of bone metastases over 2 years (II/III disease),Clodronate addition ,Standard treatment ,Significantly decreased,"For stage II/III disease, over the 5 year study period, the clodronate treated patients had a 41% decrease in the risk of developing bone metastases (P = 0.009); during the 2 year medication period, the risk was decreased by 50% (P = 0.020; Figure 3).",17215:17538,1557723,16542503,Unavailable
1557723,Bone metastases-related bone events,Clodronate addition ,Standard treatment ,Significantly decreased,there was evidence of a reduction in the number of bone metastases-related bone events in clodronate patients (29/530; 5.5%) compared with placebo patients (53/539; 9.8%) (P &lt; 0.01; Table 3).,17649:17899,1557723,16542503,Unavailable
1557723,Occurrence of visceral metastases,Clodronate addition ,Standard treatment ,No significant difference,"With regard to non-osseous metastases arising during the 5 year study period, there was no significant difference in the occurrence of visceral metastases for patients randomized to clodronate: 79 patients versus 94 placebo patients (HR = 0.84, 95% CI 0.62–1.13; P = 0.24).",18365:18656,1557723,16542503,Unavailable
1557723,Occurrence of visceral metastases (II/III disease),Clodronate addition ,Standard treatment ,No significant difference,"For patients with stage II/III disease, there was a similar non-significant reduction in visceral metastases for women randomized to clodronate: 64 patients versus 81 placebo patients (HR = 0.77, 95% CI 0.56–1.07; P = 0.12; Table 2).",18656:18945,1557723,16542503,Unavailable
1557723,Survival ,Clodronate addition ,Standard treatment ,No significant difference,"atients who received oral clodronate had an overall survival advantage as reported previously [18], although this is no longer statistically significant due to multiple analyses.",18953:19171,1557723,16542503,Unavailable
1557723,Survival (II/III disease),Clodronate addition ,Standard treatment ,No significant difference,"Patients who received oral clodronate had an overall survival advantage as reported previously [18], although this is no longer statistically significant due to multiple analyses. This was observed for all patients (Figure 4) and for patients with stage II/III disease (Figure 5).",18952:19345,1557723,16542503,Unavailable
1557723,Diarrhoea ,Clodronate addition ,Standard treatment ,Significantly increased,Diarrhoea occurred in 19.9% of the clodronate-treated patients versus 10% of the placebo-treated patients (P &lt; 0.05),20255:20389,1557723,16542503,Unavailable
5426500,Remission speed,Escitalopram ,Placebo,Significantly increased,"Remission in the escitalopram group occurred significantly earlier versus placebo after adjustment for baseline HADS-A scores (HR, 1.89; 95% CI, 1.20–2.99)",14177:14332,5426500,28449559,Unavailable
5426500,Anxiety symptoms,Escitalopram ,Placebo,Significantly decreased,"However, the groups did significantly differ in changes in HADS-A scores (mean±SD: escitalopram group, −3.0±2.1; placebo group, −1.3±1.8) in that escitalopram significantly reduced anxiety symptoms compared with placebo.",14805:15025,5426500,28449559,Unavailable
5426500,Dose,Escitalopram ,Placebo,No significant difference,"There were no significant differences in drug treatment between the two groups regarding dose, duration, concomitant medications, discontinuation, or adverse events (Supplementary Table 2).",15311:15567,5426500,28449559,Unavailable
5426500,Duration,Escitalopram ,Placebo,No significant difference,"There were no significant differences in drug treatment between the two groups regarding dose, duration, concomitant medications, discontinuation, or adverse events (Supplementary Table 2).",15311:15567,5426500,28449559,Unavailable
5426500,Concomitant medications,Escitalopram ,Placebo,No significant difference,"There were no significant differences in drug treatment between the two groups regarding dose, duration, concomitant medications, discontinuation, or adverse events (Supplementary Table 2).",15311:15567,5426500,28449559,Unavailable
5426500,Discontinuation,Escitalopram ,Placebo,No significant difference,"There were no significant differences in drug treatment between the two groups regarding dose, duration, concomitant medications, discontinuation, or adverse events (Supplementary Table 2).",15311:15567,5426500,28449559,Unavailable
5426500,Adverse events,Escitalopram ,Placebo,No significant difference,"There were no significant differences in drug treatment between the two groups regarding dose, duration, concomitant medications, discontinuation, or adverse events (Supplementary Table 2).",15311:15567,5426500,28449559,Unavailable
4444307,Beck Depression Inventory-II,Smartphone application,Full behavioural treatment,No significant difference,"No significant interaction of group and time was found between groups on the BDI-II, neither between pre- and post-treatment (BDI-II: (F 1, 91.13 = 0.09, p = .76)) nor between pre- and follow-up treatment (BDI-II: (F 1, 171.81 = 0.13, p = .72)).",48939:49274,4444307,26010890,Unavailable
4444307,PHQ-9,Smartphone application,Full behavioural treatment,No significant difference,No significant interaction effects for group and time were found on the secondary measures,50956:51046,4444307,26010890,Unavailable
4444307,Beck Anxiety Inventory,Smartphone application,Full behavioural treatment,No significant difference,No significant interaction effects for group and time were found on the secondary measures,50956:51046,4444307,26010890,Unavailable
4444307,Quality of Life Inventory,Smartphone application,Full behavioural treatment,No significant difference,No significant interaction effects for group and time were found on the secondary measures,50956:51046,4444307,26010890,Unavailable
4444307,Acceptance and Action Questionnaire,Smartphone application,Full behavioural treatment,No significant difference,No significant interaction effects for group and time were found on the secondary measures,50956:51046,4444307,26010890,Unavailable
4444307,Recovery rates,Smartphone application,Full behavioural treatment,No significant difference,"As seen in Table 3, there were no significant differences in recovery rates between both treatment groups",52491:52650,4444307,26010890,Unavailable
4444307,Credibility ratings,Smartphone application,Full behavioural treatment,No significant difference,"Independent t-tests showed no significant differences between both groups at the C-scale (t 84 = −0.30, p = 0.76).",56279:56438,4444307,26010890,Unavailable
4444307, Working Alliance Inventory,Smartphone application,Full behavioural treatment,No significant difference,"The results of the Working Alliance Inventory showed no significant differences between both groups (t 91 = −0.32 to t 77 = 0.89, p = .75 to .37)",56445:56663,4444307,26010890,Unavailable
5892002,EQ-VAS,Therapie-Aktiv,Usual care,No significant difference,"There was no significant difference in EQ-VAS between groups (mean difference 1.00, p = 0.339).",7759:7855,5892002,29643940,Unavailable
5892002,EQ-VAS,Therapie-Aktiv,Usual care,No significant difference,The mean difference (1.00) between intervention and control group was not significant (p = 0.339).,35914:36013,5892002,29643940,Unavailable
5435072,Mean gastric pH,Omeprazole,Placebo,Significantly increased,"Mean gastric pH in the cats that received omeprazole was 7.2 ± 0.4 (range, 6.6–7.8) and was significantly higher than the pH in cats that received the placebo 2.8 ± 1.0 (range, 1.3–4.1; P &lt; .001).",10508:10825,5435072,28425145,Unavailable
5435072,Gastrin concentrations,Omeprazole,Placebo,No significant difference,"Serum gastrin concentrations were measured in all 27 cats enrolled in the study. Gastrin concentrations in the placebo group (34.3 ± 10.8 ng/L; range, 22–64 ng/L) and omeprazole group (45.7 mean ± 37.2 ng/L; range, 16–135 ng/L) were not significantly different (P = .62).",36239:36527,5435072,28425145,Unavailable
5435072,Mean gastric pH,Omeprazole,Placebo,Significantly increased,"Mean gastric pH in the cats that received omeprazole was 7.2 ± 0.4 (range, 6.6–7.8) and was significantly higher than the pH in cats that received the placebo 2.8 ± 1.0 (range, 1.3–4.1; P &lt; .001; Fig 3).",37064:37340,5435072,28425145,Unavailable
5435072,Esophageal pH,Omeprazole,Placebo,Significantly increased,"Mean esophageal pH for the omeprazole group was 6.8 ± 0.4 (range, 6.3–7.6) and was significantly higher (P &lt; .001) than mean pH for the placebo group 5.3 ± 0.9 (range, 3.8–6.6).",38620:38815,5435072,28425145,Unavailable
5435072,Gastroesophageal Reflux Events,Omeprazole,Placebo,No significant difference,The administration of omeprazole did not significantly decrease the number of RE in comparison with the placebo group (P = .057).,40321:40467,5435072,28425145,Unavailable
3691733,Receiving any blood transfusions overall,INVOS modality ,Control,Significantly decreased,"When protocol was strictly followed (“per protocol analysis”), compared to the control group, significantly fewer patients monitored with INVOS received any blood transfusions (46 of 70 patients in INVOS group vs. 55 of 67 patients in the control group, p = 0.029).",52890:NaN,3691733,23758929,Unavailable
3691733,Receiving red blood cell transfusions intra-operatively ,INVOS modality ,Control,Significantly decreased,"Similarly, patients monitored with INVOS received significantly fewer units of red blood cell transfusions intraoperatively (0.20 ± 0.50 vs. 0.52 ± 0.88, p = 0.008) and overall during hospital stay (1.31 ± 1.20 vs. 1.82 ± 1.46, p = 0.024).",5997:6236,3691733,23758929,Unavailable
3691733,Receiving red blood cell transfusions during hospital stay,INVOS modality ,Control,Significantly decreased,"Similarly, patients monitored with INVOS received significantly fewer units of red blood cell transfusions intraoperatively (0.20 ± 0.50 vs. 0.52 ± 0.88, p = 0.008) and overall during hospital stay (1.31 ± 1.20 vs. 1.82 ± 1.46, p = 0.024).",5997:6236,3691733,23758929,Unavailable
3691733,Hematocrit after arterial line placement,INVOS modality ,Control,No significant difference,After arterial line placement38.45 ± 4.3238.68 ± 4.400.765,35494:35718,3691733,23758929,Unavailable
3691733,Hematocrit after anesthesia induction,INVOS modality ,Control,No significant difference,After anesthesia induction38.19 ± 4.6137.84 ± 4.530.655,35783:36004,3691733,23758929,Unavailable
3691733,Hematocrit after first cardioplegia,INVOS modality ,Control,No significant difference,After first cardioplegia20.20 ± 3.6020.16 ± 3.830.947,36069:36288,3691733,23758929,Unavailable
3691733,Hematocrit at end of CPB,INVOS modality ,Control,No significant difference,End of CPB23.07 ± 3.4523.26 ± 3.030.721,36353:36558,3691733,23758929,Unavailable
3691733,Hematocrit at end of operation,INVOS modality ,Control,No significant difference,End of operation27.55 ± 4.1827.50 ± 4.150.943,36623:36834,3691733,23758929,Unavailable
3691733,Hematocrit at 6 hours in the ICU,INVOS modality ,Control,No significant difference,6&nbsp;hours in the ICU28.15 ± 3.3828.79 ± 3.320.263,36899:NaN,3691733,23758929,Unavailable
3691733,Hematocrit at 12 hours in the ICU,INVOS modality ,Control,No significant difference,12&nbsp;hours in the ICU28.61 ± 3.7729.29 ± 3.580.254,37177:37391,3691733,23758929,Unavailable
3691733,Hematocrit at  day of discharge ,INVOS modality ,Control,No significant difference,Day of discharge30.67 ± 3.0731.28 ± 2.580.193,37456:37667,3691733,23758929,Unavailable
3691733,IV fluids to initiation of CPB,INVOS modality ,Control,No significant difference,IV fluids to initiation of CPB368.5 ± 177.0416.4 ± 184.60.101,37963:38165,3691733,23758929,Unavailable
3691733,Urine to initiation of CPB,INVOS modality ,Control,No significant difference,Urine to initiation of CPB110.8 ± 95.9135.7 ± 127.60.164,38221:38418,3691733,23758929,Unavailable
3691733,Urine output during CPB,INVOS modality ,Control,No significant difference,Urine output during CPB666.2 ± 594.0694.0 ± 423.00.743,38939:39134,3691733,23758929,Unavailable
3691733,Total urine output,INVOS modality ,Control,No significant difference,Total urine output1326.2 ± 842.21419.3 ± 690.70.452,39190:39382,3691733,23758929,Unavailable
3691733,Use of filter,INVOS modality ,Control,No significant difference,"Use of filter, n (%)8 (10.6%)9 (12.0%)0.796",39438:39622,3691733,23758929,Unavailable
3691733,"Overall fluid balance	",INVOS modality ,Control,No significant difference,"Overall fluid balance	685.4 ± 784.1	809.9 ± 651.1	0.290",39662:NaN,3691733,23758929,Unavailable
3691733,Receiving red blood cell transfusions intra-operatively ,INVOS modality ,Control,Significantly decreased,"Intraoperatively, fewer group A (INVOS) patients received fewer RBC units, and the difference was statistically significant (p = 0.04).",40039:40174,3691733,23758929,Unavailable
3691733,Hematocrit indication for transfusion,INVOS modality ,Control,No significant difference,the proportion of patients who met the hematocrit indication for transfusion did not differ significantly between the two groups (p = 0.854).,40958:41099,3691733,23758929,Unavailable
3691733,Receiving red blood cell transfusions intra-operatively ,INVOS modality ,Control,Significantly decreased,"compared to the control group, the total number of RBCs transfused per patient was significantly lower in the INVOS group intraoperatively (0.20 ± 0.50 units per patient in the INVOS group vs. 0.52 ± 0.88 units per patient in the control group, p = 0.008), and during the entire hospitalization (1.31 ± 1.20 units per patient in the INVOS group vs. 1.82 ± 1.46 units per patient in the control group, p = 0.024).",48877:49289,3691733,23758929,Unavailable
3691733,Receiving red blood cell transfusions during hospital stay,INVOS modality ,Control,Significantly decreased,"compared to the control group, the total number of RBCs transfused per patient was significantly lower in the INVOS group intraoperatively (0.20 ± 0.50 units per patient in the INVOS group vs. 0.52 ± 0.88 units per patient in the control group, p = 0.008), and during the entire hospitalization (1.31 ± 1.20 units per patient in the INVOS group vs. 1.82 ± 1.46 units per patient in the control group, p = 0.024).",48877:49289,3691733,23758929,Unavailable
3691733,Receiving red blood cell transfusions intra-operatively ,INVOS modality ,Control,Significantly decreased,RBC/pt overall0.20 ± 0.500.52 ± 0.880.008,51332:51539,3691733,23758929,Unavailable
3691733,RBC per transfused patient in OR,INVOS modality ,Control,Significantly decreased,RBC per transfused pt1.27 ± 0.471.75 ± 0.550.021,51053:NaN,3691733,23758929,Unavailable
3691733,Patients transfused in OR,INVOS modality ,Control,Significantly decreased,Patients transfused11 (15.7%)20 (29.8%)0.048,50778:50988,3691733,23758929,Unavailable
3691733,Receiving red blood cell transfusions in ICU,INVOS modality ,Control,No significant difference,RBC/pt overall1.11 ± 1.071.30 ± 1.250.344,52058:52268,3691733,23758929,Unavailable
3691733,RBC per transfused patient in ICU,INVOS modality ,Control,No significant difference,RBC per transfused pt1.86 ± 0.721.78 ± 1.040.670,52333:52547,3691733,23758929,Unavailable
3691733,Patients transfused in ICU,INVOS modality ,Control,No significant difference,Patients transfused42 (60.0%)49 (74.2%)0.103,52058:52268,3691733,23758929,Unavailable
3691733,Receiving any blood transfusions overall,INVOS modality ,Control,Significantly decreased,"RBC/pt overall	1.31 ± 1.20	1.82 ± 1.46	0.024",53865:NaN,3691733,23758929,Unavailable
3691733,RBC per transfused patient overall,INVOS modality ,Control,No significant difference,RBC per transfused pt2.00 ± 0.892.22 ± 1.210.314,53602:NaN,3691733,23758929,Unavailable
3691733,Patients transfused overall,INVOS modality ,Control,Significantly decreased,Patients transfused46 (65.7%)55 (82.1%)0.029,53327:53537,3691733,23758929,Unavailable
5752785,Successful CVC ,Seldinger technique with body manoeuvres,Control,Significantly increased,CVC was achieved in 98% (49/50) of patients in study group and 80% (40/50) of patients in control group (P = 0.008).,4843:4933,5752785,29307904,Unavailable
5752785,Catheterisation time,Seldinger technique with body manoeuvres,Control,Significantly decreased,Mean catheterisation time was significantly lower in the study group (151.06 ± 40.50 s) compared to control group (173.50 ± 50.66 s) (P = 0.023).,4548:4711,5752785,29307904,Unavailable
5752785,Catheter misplacement,Seldinger technique with body manoeuvres,Control,Significantly decreased,"The incidence of catheter misplacement and failure to cannulate were lower in the study group (0%, 2% vs. 20%, 12.5%, respectively).",4711:4843,5752785,29307904,Unavailable
5752785,Failure to cannulate,Seldinger technique with body manoeuvres,Control,Significantly decreased,"The incidence of catheter misplacement and failure to cannulate were lower in the study group (0%, 2% vs. 20%, 12.5%, respectively).",4711:4843,5752785,29307904,Unavailable
5752785,Catheterisation attempts,Seldinger technique with body manoeuvres,Control,No significant difference,Groups did not differ in a number of catheterisation attempts and incidence of haematoma.,4843:4933,5752785,29307904,Unavailable
5752785,Haematomas,Seldinger technique with body manoeuvres,Control,No significant difference,Groups did not differ in a number of catheterisation attempts and incidence of haematoma.,4843:4933,5752785,29307904,Unavailable
5752785,Successful CVC ,Seldinger technique with body manoeuvres,Control,Significantly increased,"Out of total 100 patients, 89 had successful catheterisation. CVC was achieved in 98% (49/50) patients in study group and 80% (40/50) of patients in control group, significantly higher in the study group (P = 0.008).",11496:11729,5752785,29307904,Unavailable
5752785,Catheterisation attempts,Seldinger technique with body manoeuvres,Control,No significant difference,"The mean number of catheterisation attempts (mean ± standard deviation [SD]) was 1.42 ± 0.61 in the study group and was 1.70 ± 0.81 in the control group, statistically insignificant with a P = 0.096.",11736:11952,5752785,29307904,Unavailable
5752785,Needing 3 attempts,Seldinger technique with body manoeuvres,Control,Significantly decreased,"Out of the 50 cases in each group, three attempts were required in a significantly lower number of patients in the study group as compared to the control group (3/50; 11/50, respectively, P = 0.041).",11953:12169,5752785,29307904,Unavailable
5752785,Catheterisation time,Seldinger technique with body manoeuvres,Control,Significantly decreased,The total time taken to CVC in seconds was significantly lower in the study group (151.06 ± 40.49) as compared to control group (173.50 ± 50.66) (P = 0.023).,12871:13046,5752785,29307904,Unavailable
5752785,Satisfactory CVP trace,Seldinger technique with body manoeuvres,Control,No significant difference,"Out of the 40 successful catheterisations in the control group, 37 had satisfactory CVP trace, i.e. 92.5%, whereas 100% (49/49) of patients with successful catheterisations in the study group had satisfactory CVP trace (P = 0.087)",13046:13293,5752785,29307904,Unavailable
5752785,Catheter misplacement,Seldinger technique with body manoeuvres,Control,Significantly decreased,The incidence of catheter misplacement and failure to cannulate was significantly lower in the study group compared to the control group (P = 0.016 and 0.008).,13841:14017,5752785,29307904,Unavailable
5752785,Failure to cannulate,Seldinger technique with body manoeuvres,Control,Significantly decreased,The incidence of catheter misplacement and failure to cannulate was significantly lower in the study group compared to the control group (P = 0.016 and 0.008).,13840:14017,5752785,29307904,Unavailable
3621886,Flow-mediated dilation (week 8),Pentoxifylline ,Control,No significant difference,The difference in mean absolute change (SD) in FMD after 8 weeks between the placebo [−1.06 (1.45)%] and PTX [−1.93 (3.03)%] groups was not significant (P = 0.44).,9525:9759,3621886,23593327,Unavailable
3621886,Soluble tumor necrosis factor receptor-1 (week 4),Pentoxifylline ,Control,Significantly increased,The only significant between-group difference in the changes in biomarkers from baseline to week 8 was in soluble tumor necrosis factor receptor-1 (sTNFRI) [−83.2 pg/mL in the placebo group vs. +65.9 pg/mL in the PTX group; P = 0.03].,49269:50096,3621886,23593327,Unavailable
3621886,Flow-mediated dilation (week 8),Pentoxifylline ,Control,No significant difference,The mean (SD) difference in absolute change in FMD at 8 weeks between the placebo [−1.06 (1.45)%] and PTX [−1.93 (3.03)%] groups was not significant (P = 0.44).,29897:30057,3621886,23593327,Unavailable
3621886,Resting brachial artery diameter (week 4),Pentoxifylline ,Control,No significant difference,"Resting brachial artery diameter, cm			Baseline	0.44 (0.05)	0.42 (0.08)	0.60Week 4	0.44 (0.05)	0.43 (0.08)	0.72",31950:32597,3621886,23593327,Unavailable
3621886,Resting brachial artery diameter (week 8),Pentoxifylline ,Control,No significant difference,"Resting brachial artery diameter, cm			Baseline	0.44 (0.05)	0.42 (0.08)	0.60Week 4	0.44 (0.05)	0.43 (0.08)	0.72Week 8	0.44 (0.04)	0.43 (0.07)	0.68",31950:32822,3621886,23593327,Unavailable
3621886,Flow-mediated dilation (week 4),Pentoxifylline ,Control,No significant difference,"Flow-mediated dilation (%)			Baseline	3.46 (2.32)	4.09 (2.87)	0.54Week 4	3.36 (2.78)	2.35 (1.53)	0.27",32884:33508,3621886,23593327,Unavailable
3621886,Flow-mediated dilation (week 8),Pentoxifylline ,Control,No significant difference,"Flow-mediated dilation (%)			Baseline	3.46 (2.32)	4.09 (2.87)	0.54Week 4	3.36 (2.78)	2.35 (1.53)	0.27Week 8	2.40 (1.58)2	2.80 (1.69)2	0.58",32884:33827,3621886,23593327,Unavailable
3621886,Nitroglycerin-mediated dilation (week 4),Pentoxifylline ,Control,No significant difference,No differences in NTGMD were observed.,32884:33827,3621886,23593327,Unavailable
3621886,Nitroglycerin-mediated dilation (week 8),Pentoxifylline ,Control,No significant difference,No differences in NTGMD were observed.,32884:33827,3621886,23593327,Unavailable
3621886,Nitroglycerin-mediated dilation (week 4),Pentoxifylline ,Control,No significant difference,"Nitroglycerin-mediated dilation (%)			Baseline	13.66 (7.02)	15.88 (6.59)	0.42Week 4	16.68 (7.11)	13.91 (6.51)	0.34",33889:34539,3621886,23593327,Unavailable
3621886,Nitroglycerin-mediated dilation (week 8),Pentoxifylline ,Control,No significant difference,"Nitroglycerin-mediated dilation (%)			Baseline	13.66 (7.02)	15.88 (6.59)	0.42Week 4	16.68 (7.11)	13.91 (6.51)	0.34Week 8	15.28 (5.76)	17.16 (8.16)	0.57",33889:34766,3621886,23593327,Unavailable
3621886,Soluble tumor necrosis factor receptor-1 (week 4),Pentoxifylline ,Control,Significantly increased,"As shown in Figure 2B, the only significant difference in the changes in these biomarkers from baseline to week 8 was in sTNFRI [−83.2 pg/mL in the placebo group vs. 65.9 pg/mL in the PTX group; P = 0.03].",49269:50096,3621886,23593327,Unavailable
3621886,CD4 cell count (week 4),Pentoxifylline ,Control,No significant difference,"CD4 cell count/µL			Baseline	583 (175)	524 (165)	0.39Week 4	534 (206)	601 (269)	0.52",43225:43832,3621886,23593327,Unavailable
3621886,CD4 cell count (week 8),Pentoxifylline ,Control,No significant difference,"CD4 cell count/µL			Baseline	583 (175)	524 (165)	0.39Week 4	534 (206)	601 (269)	0.52Week 8	526 (165)	494 (208)	0.72",43225:44053,3621886,23593327,Unavailable
3621886,CD3+CD8+CD38+HLA-DR+proportions (week 8),Pentoxifylline ,Control,No significant difference,"CD3+CD8+CD38+HLA-DR+proportions (%)			Baseline	36 (19)	39 (15)	0.69Week 8	36 (19)	41 (17)	0.52",44115:44732,3621886,23593327,Unavailable
3621886,"HIV-1 RNA, log10copies/mL (week 4)",Pentoxifylline ,Control,No significant difference,"HIV-1 RNA, log10copies/mL			Baseline	4.0 (1.2)	4.0 (0.7)	0.88Week 4	3.9 (1.1)	4.0 (4.5)	0.72",44794:45409,3621886,23593327,Unavailable
3621886,"HIV-1 RNA, log10copies/mL (week 8)",Pentoxifylline ,Control,No significant difference,"HIV-1 RNA, log10copies/mL			Baseline	4.0 (1.2)	4.0 (0.7)	0.88Week 4	3.9 (1.1)	4.0 (4.5)	0.72Week 8	4.0 (1.0)	4.0 (0.8)	0.87",44794:45630,3621886,23593327,Unavailable
3621886,hsCRP (week 4),Pentoxifylline ,Control,No significant difference,"hsCRP, log10mg/L			Baseline	0.27 (0.41)	0.25 (0.57)	0.95Week 4	0.36 (0.57)	0.37 (0.80)	0.74",45692:46317,3621886,23593327,Unavailable
3621886,hsCRP (week 8),Pentoxifylline ,Control,No significant difference,"hsCRP, log10mg/L			Baseline	0.27 (0.41)	0.25 (0.57)	0.95Week 4	0.36 (0.57)	0.37 (0.80)	0.74Week 8	−0.01 (0.45)	0.15 (0.81)	0.58",45692:46543,3621886,23593327,Unavailable
3621886,IL-6 (week 4),Pentoxifylline ,Control,No significant difference,"IL-6, pg/ml			Baseline	1.91 (1.53)	2.61 (2.59)	0.41Week 4	3.44 (6.52)	2.91 (2.45)	0.79",46605:47214,3621886,23593327,Unavailable
3621886,IL-6 (week 8),Pentoxifylline ,Control,No significant difference,"IL-6, pg/ml			Baseline	1.91 (1.53)	2.61 (2.59)	0.41Week 4	3.44 (6.52)	2.91 (2.45)	0.79Week 8	1.7 (1.55)	5.26 (10.2)	0.30",46605:47438,3621886,23593327,Unavailable
3621886,TIMP-1 (week 4),Pentoxifylline ,Control,No significant difference,"TIMP-1, ng/ml			Baseline	99 (17)	117 (35)	0.12Week 4	98 (20)	112 (31)	0.21",47500:48097,3621886,23593327,Unavailable
3621886,TIMP-1 (week 8),Pentoxifylline ,Control,No significant difference,"TIMP-1, ng/ml			Baseline	99 (17)	117 (35)	0.12Week 4	98 (20)	112 (31)	0.21Week 8	91 (14)	109 (25)	0.06",47500:48315,3621886,23593327,Unavailable
3621886,sVCAM-1 (week 4),Pentoxifylline ,Control,No significant difference,"sVCAM-1, ng/mL			Baseline	1037 (399)	1108 (273)	0.60Week 4	1081 (419)	1156 (283)	0.6",48377:48984,3621886,23593327,Unavailable
3621886,sVCAM-1 (week 8),Pentoxifylline ,Control,No significant difference,"sVCAM-1, ng/mL			Baseline	1037 (399)	1108 (273)	0.60Week 4	1081 (419)	1156 (283)	0.6Week 8	1098 (462)	1130 (281)	0.84",48377:49207,3621886,23593327,Unavailable
3621886,Soluble tumor necrosis factor receptor-1 (week 4),Pentoxifylline ,Control,Significantly increased,"sTNFRI, pg/mL Baseline 1125 (249) 851 (379) 0.04Week 4 1047 (244) 805 (298) 0.04",49269:50096,3621886,23593327,Unavailable
3621886,Soluble tumor necrosis factor receptor-1 (week 8),Pentoxifylline ,Control,No significant difference,"sTNFRI, pg/mL Baseline 1125 (249) 851 (379) 0.04Week 4 1047 (244) 805 (298) 0.04Week 8 1042 (205) 805 (298) 0.12",49269:50096,3621886,23593327,Unavailable
3621886,Soluble tumor necrosis factor receptor-2 (week 4),Pentoxifylline ,Control,No significant difference,"sTNFRII, pg/mL			Baseline	7239 (2606)	7736 (2141)	0.60Week 4	7163 (2106)	7762 (2562)	0.54",50158:50770,3621886,23593327,Unavailable
3621886,Soluble tumor necrosis factor receptor-2 (week 8),Pentoxifylline ,Control,No significant difference,"sTNFRII, pg/mL			Baseline	7239 (2606)	7736 (2141)	0.60Week 4	7163 (2106)	7762 (2562)	0.54Week 8	7455 (2405)	7549 (1945)	0.92",50158:50995,3621886,23593327,Unavailable
3621886,MCP-1 (week 4),Pentoxifylline ,Control,No significant difference,"MCP-1, pg/mL			Baseline	237 (75)	202 (76)	0.24Week 4	193 (55)	205 (100)	0.71",51057:51656,3621886,23593327,Unavailable
3621886,MCP-1 (week 8),Pentoxifylline ,Control,No significant difference,"MCP-1, pg/mL			Baseline	237 (75)	202 (76)	0.24Week 4	193 (55)	205 (100)	0.71Week 8	217 (55)	207 (106)	0.80",51057:51876,3621886,23593327,Unavailable
3621886,IP-10 (week 4),Pentoxifylline ,Control,No significant difference,"IP-10, pg/mL			Baseline	432 (330)	552 (331)	0.36Week 4	386 (283)	528 (324)	0.27",51938:52540,3621886,23593327,Unavailable
3621886,IP-10 (week 8),Pentoxifylline ,Control,No significant difference,"IP-10, pg/mL			Baseline	432 (330)	552 (331)	0.36Week 4	386 (283)	528 (324)	0.27Week 8	377 (295)	440 (182)	0.53",51938:52761,3621886,23593327,Unavailable
3621886,Plasminogen activating inhibitor antigen-1 (week 4),Pentoxifylline ,Control,No significant difference,"PAI-1 Ag, ng/ml			Baseline	17.3 (6.9)	43.3 (27.5)	0.01Week 4	20.3 (13.0)	22.4 (14.5)	0.72",52823:53435,3621886,23593327,Unavailable
3621886,Plasminogen activating inhibitor antigen-1 (week 8),Pentoxifylline ,Control,Significantly increased,"PAI-1 Ag, ng/ml Baseline 17.3 (6.9) 43.3 (27.5) 0.01Week 4 20.3 (13.0) 22.4 (14.5) 0.72Week 8 18.6 (8.6) 29.4 (10.6) 0.02",52823:53659,3621886,23593327,Unavailable
3621886,Total cholesterol (week 4),Pentoxifylline ,Control,No significant difference,"Total cholesterol, mg/dL			Baseline	150 (34)	149 (27)	0.92Week 4	145 (38)	152 (31)	0.67",53721:54331,3621886,23593327,Unavailable
3621886,Total cholesterol (week 8),Pentoxifylline ,Control,No significant difference,"Total cholesterol, mg/dL			Baseline	150 (34)	149 (27)	0.92Week 4	145 (38)	152 (31)	0.67Week 8	146 (26)	142 (34)	0.78",53721:54550,3621886,23593327,Unavailable
3621886,HDL-C (week 4),Pentoxifylline ,Control,No significant difference,"HDL-C, mg/dL			Baseline	39 (11)	38 (11)	0.68Week 4	38 (10)	39 (12)	0.85",54612:55206,3621886,23593327,Unavailable
3621886,HDL-C (week 8),Pentoxifylline ,Control,No significant difference,"HDL-C, mg/dL			Baseline	39 (11)	38 (11)	0.68Week 4	38 (10)	39 (12)	0.85Week 8	39 (11)	35 (10)	0.33",54612:55423,3621886,23593327,Unavailable
3621886,LDL-C (week 4),Pentoxifylline ,Control,No significant difference,"LDL-C, mg/dL			Baseline	95 (29)	90 (28)	0.65Week 4	92 (31)	95 (31)	0.83",55485:56079,3621886,23593327,Unavailable
3621886,LDL-C (week 8),Pentoxifylline ,Control,No significant difference,"LDL-C, mg/dL			Baseline	95 (29)	90 (28)	0.65Week 4	92 (31)	95 (31)	0.83Week 8	90 (21)	86 (28)	0.73",55485:56296,3621886,23593327,Unavailable
3621886,Triglycerides (week 4),Pentoxifylline ,Control,No significant difference,"Triglycerides, mg/dL			Baseline	81 (29)	108 (45)	0.08Week 4	77 (30)	89 (41)	0.43",56358:56961,3621886,23593327,Unavailable
3621886,Triglycerides (week 8),Pentoxifylline ,Control,No significant difference,"Triglycerides, mg/dL			Baseline	81 (29)	108 (45)	0.08Week 4	77 (30)	89 (41)	0.43Week 8	84 (33)	112 (78)	0.31",56358:57179,3621886,23593327,Unavailable
3621886,HOMA-IR (week 4),Pentoxifylline ,Control,No significant difference,"HOMA-IR			Baseline	2.04 (2.19)	2.96 (3.97)	0.48Week 4	1.97 (1.82)	2.28 (2.99)	0.78",57241:57846,3621886,23593327,Unavailable
3621886,HOMA-IR (week 8),Pentoxifylline ,Control,No significant difference,"HOMA-IR			Baseline	2.04 (2.19)	2.96 (3.97)	0.48Week 4	1.97 (1.82)	2.28 (2.99)	0.78Week 8	2.19 (1.72)	2.85 (2.92)	0.54",57241:58071,3621886,23593327,Unavailable
3621886,Reported symptoms,Pentoxifylline ,Control,No significant difference,There were no significant differences between the number of total reported symptoms or laboratory abnormalities in the placebo group compared to the PTX group.,60018:60177,3621886,23593327,Unavailable
3621886,Laboratory abnormalities,Pentoxifylline ,Control,No significant difference,There were no significant differences between the number of total reported symptoms or laboratory abnormalities in the placebo group compared to the PTX group.,60018:60177,3621886,23593327,Unavailable
3621886,Reported symptoms,Pentoxifylline ,Control,No significant difference,"Symptoms			Total	21	14	0.73",61234:61594,3621886,23593327,Unavailable
3621886,Laboratory abnormalities,Pentoxifylline ,Control,No significant difference,"Laboratory Abnormalities			Total	2	6	0.86",62872:63246,3621886,23593327,Unavailable
3493833,Live birth rate,GnRH long agonist,Flexible GnRH antagonist,No significant difference,There was no significant difference in live birth rate and clinical pregnancy rate.,4244:4328,3493833,23162357,Unavailable
3493833,Clinical pregnancy rate,GnRH long agonist,Flexible GnRH antagonist,No significant difference,There was no significant difference in live birth rate and clinical pregnancy rate.,4244:4328,3493833,23162357,Unavailable
3493833,Ovarian hyperstimulation,GnRH long agonist,Flexible GnRH antagonist,Significantly increased,Rate of ovarian hyperstimulation syndrome was significantly higher in the agonist group.,4328:4416,3493833,23162357,Unavailable
3493833,Number of oocytes retrieved,GnRH long agonist,Flexible GnRH antagonist,Significantly increased,"Number of oocytes retrieved, number of follicles and peak estradiol levels were significantly more in the agonist group.",4417:4537,3493833,23162357,Unavailable
3493833,Number of follicles,GnRH long agonist,Flexible GnRH antagonist,Significantly increased,"Number of oocytes retrieved, number of follicles and peak estradiol levels were significantly more in the agonist group.",4417:4537,3493833,23162357,Unavailable
3493833,Peak estradiol levels,GnRH long agonist,Flexible GnRH antagonist,Significantly increased,"Number of oocytes retrieved, number of follicles and peak estradiol levels were significantly more in the agonist group.",4417:4537,3493833,23162357,Unavailable
4563922,Glycated hemoglobin,Pediatrician visit  + nurse visit +phone calls,Control,No significant difference,the evolution of A1C and participants satisfaction over the follow-up period was not significantly influenced by the nurse intervention.,9764:9901,4563922,26350209,Unavailable
4563922,Participants satisfaction,Pediatrician visit  + nurse visit +phone calls,Control,No significant difference,the evolution of A1C and participants satisfaction over the follow-up period was not significantly influenced by the nurse intervention.,9765:9901,4563922,26350209,Unavailable
4563922,Glycated hemoglobin,Pediatrician visit  + nurse visit +phone calls,Control,No significant difference,"The primary analysis was in intention-to-treat and involved all patients who were randomly assigned. The decrease of the A1C rate in the control group was estimated at −0.03&nbsp;% per month but this decrease was not statistically significant (95&nbsp;% CI: (−0.14&nbsp;%; 0.07&nbsp;%), p = 0.54). The supplementary decrease of the A1C rate in the intervention group was estimated at −0.04&nbsp;% (Fig.&nbsp;2). However, this difference of slope was not statistically significant (95&nbsp;% CI: (−0.19&nbsp;%; 0.11&nbsp;%), p = 0.61).",20943:21505,4563922,26350209,Unavailable
